1	A	O
2	subset	O
3	of	O
4	mutations	O
5	in	O
6	the	O
7	Psi	B
8	synthase	I
9	domain	I
10	impairs	O
11	association	O
12	of	O
13	the	O
14	altered	O
15	Cbf5p	B
16	proteins	I
17	with	O
18	selected	O
19	box	O
20	H	B
21	/	I
22	ACA	I
23	snoRNAs	I
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	functional	O
29	catalytic	O
30	domain	O
31	is	O
32	essential	O
33	for	O
34	that	O
35	interaction	O
36	.	O

1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	B
25	-	I
26	domain	I
27	/	I
28	leucine	I
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	B
48	Tax	I
49	-	I
50	responsive	I
51	element	I
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O

1	RBP56	B
2	protein	I
3	turned	O
4	out	O
5	to	O
6	be	O
7	hTAFII68	B
8	which	O
9	was	O
10	isolated	O
11	as	O
12	a	O
13	TATA	B
14	-	I
15	binding	I
16	protein	I
17	associated	I
18	factor	I
19	(	O
20	TAF	B
21	)	O
22	from	O
23	a	O
24	sub	O
25	-	O
26	population	O
27	of	O
28	TFIID	B
29	complexes	I
30	(	O
31	Bertolotti	O
32	A	O
33	.,	O
34	Lutz	O
35	,	O
36	Y	O
37	.,	O
38	Heard	O
39	,	O
40	D	O
41	.	O
42	J	O
43	.,	O
44	Chambon	O
45	,	O
46	P	O
47	.,	O
48	Tora	O
49	,	O
50	L	O
51	.,	O
52	1996	O
53	.	O
54	hTAFII68	B
55	,	O
56	a	O
57	novel	O
58	RNA	O
59	/	O
60	ssDNA	O
61	-	O
62	binding	O
63	protein	O
64	with	O
65	homology	O
66	to	O
67	the	O
68	proto	O
69	-	O
70	oncoproteins	O
71	TLS	B
72	/	O
73	FUS	B
74	and	O
75	EWS	B
76	is	O
77	associated	O
78	with	O
79	both	O
80	TFIID	B
81	and	O
82	RNA	B
83	polymerase	I
84	II	I
85	.	O

1	Thus	O
2	,	O
3	both	O
4	YY1	B
5	and	O
6	CDP	B
7	appear	O
8	to	O
9	be	O
10	negative	O
11	regulators	O
12	of	O
13	the	O
14	differentiation	O
15	-	O
16	induced	O
17	HPV	B
18	-	I
19	6	I
20	E1	I
21	promoter	I
22	and	O
23	thereby	O
24	the	O
25	HPV	O
26	life	O
27	cycle	O
28	.	O

1	Of	O
2	these	O
3	patients	O
4	,	O
5	46	O
6	,	O
7	164	O
8	were	O
9	placed	O
10	on	O
11	a	O
12	waiting	O
13	list	O
14	for	O
15	transplantation	O
16	,	O
17	23	O
18	,	O
19	275	O
20	of	O
21	whom	O
22	received	O
23	a	O
24	first	O
25	cadaveric	O
26	transplant	O
27	between	O
28	1991	O
29	and	O
30	1997	O
31	.	O

1	Although	O
2	most	O
3	SFV	O
4	genes	O
5	have	O
6	homologs	O
7	encoded	O
8	by	O
9	other	O
10	Chordopoxvirinae	O
11	,	O
12	the	O
13	SFV	O
14	genome	O
15	lacks	O
16	a	O
17	key	O
18	gene	O
19	required	O
20	for	O
21	the	O
22	production	O
23	of	O
24	extracellular	O
25	enveloped	O
26	virus	O
27	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	B
7	-	O
8	related	O
9	sequences	O
10	and	O
11	a	O
12	small	B
13	Ig	I
14	-	I
15	related	I
16	sequence	I
17	.	O

1	The	O
2	opioid	O
3	antagonist	O
4	naltrexone	O
5	(	O
6	0	O
7	.	O
8	01	O
9	-	O
10	1	O
11	.	O
12	0	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	antagonized	O
18	the	O
19	discriminative	O
20	stimulus	O
21	effects	O
22	of	O
23	heroin	O
24	,	O
25	but	O
26	naltrexone	O
27	at	O
28	doses	O
29	up	O
30	to	O
31	10	O
32	mg	O
33	/	O
34	kg	O
35	had	O
36	no	O
37	effect	O
38	on	O
39	the	O
40	discriminative	O
41	stimulus	O
42	effects	O
43	of	O
44	cocaine	O
45	.	O

1	Precipitating	O
2	antibodies	O
3	for	O
4	Thermophilic	O
5	actinomycetes	O
6	and	O
7	M	O
8	.	O
9	f	O
10	.	O
11	were	O
12	negative	O
13	.	O

1	The	O
2	microcirculatory	O
3	dynamics	O
4	of	O
5	prostaglandin	O
6	E1	O
7	and	O
8	/	O
9	or	O
10	nicardipine	O
11	and	O
12	their	O
13	different	O
14	reactions	O
15	in	O
16	the	O
17	hyper	O
18	-	O
19	and	O
20	hypodynamic	O
21	state	O
22	of	O
23	septic	O
24	shock	O
25	in	O
26	a	O
27	rat	O
28	model	O

1	The	O
2	pathophysiology	O
3	and	O
4	clinical	O
5	management	O
6	of	O
7	acute	O
8	brain	O
9	injury	O
10	in	O
11	infancy	O
12	and	O
13	childhood	O
14	are	O
15	presented	O
16	using	O
17	acute	O
18	traumatic	O
19	brain	O
20	injury	O
21	as	O
22	a	O
23	model	O
24	.	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	As	O
2	a	O
3	part	O
4	of	O
5	a	O
6	large	O
7	examination	O
8	,	O
9	total	O
10	and	O
11	free	O
12	serum	O
13	cholesterol	O
14	,	O
15	total	O
16	lipid	O
17	and	O
18	triglyceride	O
19	levels	O
20	were	O
21	determined	O
22	.	O

1	447	O
2	microns	O
3	for	O
4	A	O
5	.	O
6	microcephalum	O
7	and	O
8	350	O
9	microns	O
10	for	O
11	A	O
12	.	O
13	wedli	O
14	),	O
15	and	O
16	fewer	O
17	testes	O
18	per	O
19	proglottis	O
20	(	O
21	44	O
22	-	O
23	73	O
24	vs	O
25	.	O

1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O

1	Whereas	O
2	both	O
3	MAP	O
4	and	O
5	MSNA	O
6	increase	O
7	during	O
8	SHG	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	SHG	O
14	to	O
15	PHI	O
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	O
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	MSNA	O
29	,	O
30	facilitating	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O

1	Serum	B
2	alkaline	I
3	phosphatase	I
4	activity	O
5	,	O
6	bone	O
7	mass	O
8	measurements	O
9	,	O
10	dual	O
11	energy	O
12	x	O
13	-	O
14	ray	O
15	absortiometric	O
16	analysis	O
17	of	O
18	mineral	O
19	density	O
20	,	O
21	and	O
22	mechanical	O
23	testing	O
24	values	O
25	in	O
26	vertebrae	O
27	and	O
28	femora	O
29	of	O
30	the	O
31	-	O
32	D	O
33	Sal	O
34	animals	O
35	did	O
36	not	O
37	significantly	O
38	differ	O
39	from	O
40	those	O
41	in	O
42	+	O
43	D	O
44	Sal	O
45	animals	O
46	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	other	O
6	Ras	B
7	effectors	I
8	can	O
9	collaborate	O
10	with	O
11	PI	B
12	3	I
13	-	I
14	kinase	I
15	and	O
16	with	O
17	each	O
18	other	O
19	to	O
20	activate	O
21	Pak	B
22	.	O

1	Skn	B
2	-	I
3	1a	I
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O

1	The	O
2	FFA	O
3	levels	O
4	were	O
5	not	O
6	affected	O
7	(	O
8	P	O
9	greater	O
10	than	O
11	.	O
12	1	O
13	)	O
14	by	O
15	meal	O
16	interval	O
17	.	O

1	Gel	O
2	shift	O
3	analysis	O
4	indicates	O
5	that	O
6	the	O
7	full	B
8	-	I
9	length	I
10	ERM	I
11	protein	I
12	is	O
13	able	O
14	to	O
15	bind	O
16	specifically	O
17	to	O
18	an	O
19	oligonucleotide	O
20	containing	O
21	the	O
22	consensus	O
23	nucleotide	O
24	core	O
25	sequence	O
26	GGAA	O
27	recognized	O
28	by	O
29	the	O
30	Ets	B
31	proteins	O
32	.	O

1	Experimental	O
2	data	O
3	showed	O
4	that	O
5	these	O
6	abnormal	O
7	proteins	O
8	are	O
9	constitutively	O
10	localized	O
11	in	O
12	the	O
13	nucleus	O
14	,	O
15	have	O
16	lost	O
17	the	O
18	transcriptional	O
19	repressor	O
20	functions	O
21	typical	O
22	of	O
23	normal	O
24	NF	B
25	-	I
26	kappa	I
27	B2p52	I
28	and	O
29	may	O
30	be	O
31	capable	O
32	of	O
33	transactivation	O
34	activity	O
35	.	O

1	Germ	O
2	-	O
3	free	O
4	rabbits	O
5	given	O
6	mouse	O
7	CRF	O
8	-	O
9	flora	O
10	showed	O
11	values	O
12	quite	O
13	different	O
14	from	O
15	control	O
16	animals	O
17	for	O
18	most	O
19	parameters	O
20	,	O
21	indicating	O
22	unsuitability	O
23	of	O
24	mouse	O
25	CRF	O
26	flora	O
27	to	O
28	'	O
29	normalize	O
30	'	O
31	rabbits	O
32	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	The	O
2	experimental	O
3	end	O
4	points	O
5	were	O
6	the	O
7	time	O
8	required	O
9	for	O
10	treated	O
11	tumors	O
12	to	O
13	reach	O
14	3	O
15	times	O
16	their	O
17	treatment	O
18	size	O
19	,	O
20	the	O
21	survival	O
22	of	O
23	stem	O
24	cells	O
25	in	O
26	the	O
27	duodenal	O
28	crypts	O
29	,	O
30	and	O
31	the	O
32	breathing	O
33	rate	O
34	measured	O
35	early	O
36	(	O
37	19	O
38	-	O
39	23	O
40	weeks	O
41	)	O
42	and	O
43	late	O
44	(	O
45	41	O
46	-	O
47	46	O
48	weeks	O
49	)	O
50	after	O
51	treatment	O
52	.	O

1	Cytoplasmic	B
2	dynein	I
3	is	O
4	a	O
5	multisubunit	O
6	,	O
7	microtubule	O
8	-	O
9	dependent	O
10	mechanochemical	O
11	enzyme	O
12	that	O
13	has	O
14	been	O
15	proposed	O
16	to	O
17	function	O
18	in	O
19	a	O
20	variety	O
21	of	O
22	intracellular	O
23	movements	O
24	,	O
25	including	O
26	minus	O
27	-	O
28	end	O
29	-	O
30	directed	O
31	transport	O
32	of	O
33	organelles	O
34	.	O

1	A	O
2	direct	O
3	role	O
4	for	O
5	sterol	B
6	regulatory	I
7	element	I
8	binding	I
9	protein	I
10	in	O
11	activation	O
12	of	O
13	3	B
14	-	I
15	hydroxy	I
16	-	I
17	3	I
18	-	I
19	methylglutaryl	I
20	coenzyme	I
21	A	I
22	reductase	I
23	gene	I
24	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	B
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O

1	Such	O
2	marked	O
3	differences	O
4	are	O
5	found	O
6	occasionally	O
7	in	O
8	the	O
9	literature	O
10	:	O
11	heterophile	O
12	antibodies	O
13	against	O
14	bovine	B
15	gammaglobulin	I
16	are	O
17	regarded	O
18	as	O
19	responsible	O
20	for	O
21	the	O
22	interference	O
23	in	O
24	the	O
25	Sephadex	O
26	system	O
27	of	O
28	RIST	O
29	.	O

1	Truncated	B
2	ICSBP	I
3	lacking	O
4	the	O
5	first	O
6	33	O
7	amino	O
8	-	O
9	terminal	O
10	amino	O
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	B
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	REM	O
2	dream	O
3	content	O
4	was	O
5	scored	O
6	for	O
7	categories	O
8	suggesting	O
9	the	O
10	predominant	O
11	influence	O
12	of	O
13	the	O
14	left	O
15	hemisphere	O
16	,	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	good	O
22	ego	O
23	functioning	O
24	,	O
25	verbalization	O
26	,	O
27	or	O
28	the	O
29	right	O
30	hemisphere	O
31	,	O
32	e	O
33	.	O
34	g	O
35	.,	O
36	music	O
37	,	O
38	spatial	O
39	salience	O
40	,	O
41	bizarreness	O
42	.	O

1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O

1	Its	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	shows	O
7	extensive	O
8	homology	O
9	to	O
10	those	O
11	of	O
12	Drosophila	B
13	hsp70	I
14	,	O
15	trout	B
16	hsp70	I
17	,	O
18	Xenopus	B
19	hsp70	I
20	,	O
21	yeast	B
22	hsp70	I
23	,	O
24	and	O
25	some	O
26	homology	O
27	to	O
28	the	O
29	heat	B
30	-	I
31	inducible	I
32	dnaK	I
33	gene	I
34	product	I
35	of	O
36	Escherichia	O
37	coli	O
38	.	O

1	The	O
2	cycle	O
3	length	O
4	of	O
5	induced	O
6	VT	O
7	(	O
8	n	O
9	=	O
10	10	O
11	VTs	O
12	)	O
13	was	O
14	380	O
15	+/-	O
16	41	O
17	msec	O
18	.	O

1	Nitrogen	O
2	balance	O
3	was	O
4	compared	O
5	,	O
6	and	O
7	metabolic	O
8	complications	O
9	were	O
10	monitored	O
11	by	O
12	evaluating	O
13	BUN	O
14	,	O
15	serum	O
16	creatinine	O
17	,	O
18	creatinine	O
19	clearance	O
20	,	O
21	serum	O
22	CO2	O
23	,	O
24	SGOT	B
25	,	O
26	SGPT	B
27	,	O
28	serum	B
29	LDH	I
30	,	O
31	and	O
32	serum	B
33	alkaline	I
34	phosphatase	I
35	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	recombinant	B
7	CREB	I
8	and	O
9	activating	B
10	transcription	I
11	factor	I
12	proteins	I
13	bound	O
14	the	O
15	junB	B
16	CRE	O
17	-	O
18	like	O
19	site	O
20	,	O
21	but	O
22	did	O
23	not	O
24	interact	O
25	with	O
26	a	O
27	mutant	O
28	CRE	O
29	-	O
30	like	O
31	site	O
32	.	O

1	C	O
2	.	O
3	elegans	O
4	KLP	B
5	-	I
6	11	I
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	O
12	KAP	B
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	B
20	urchin	I
21	kinesin	I
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	B
28	/	O
29	KIFB	B
30	/	O
31	KAP3	B
32	kinesin	I
33	complexes	O
34	.	O

1	The	O
2	TIMP	B
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	O
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	Overexpression	O
2	of	O
3	c	B
4	-	I
5	Myc	I
6	in	O
7	serum	O
8	-	O
9	starved	O
10	human	O
11	or	O
12	mouse	O
13	embryonic	O
14	cells	O
15	leads	O
16	to	O
17	apoptosis	O
18	which	O
19	is	O
20	significantly	O
21	reduced	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	growth	O
27	factor	O
28	-	O
29	containing	O
30	serum	O
31	.	O
32	c	B
33	-	I
34	Myc	I
35	-	O
36	induced	O
37	apoptosis	O
38	appears	O
39	to	O
40	be	O
41	deficient	O
42	in	O
43	bax	B
44	-	O
45	null	O
46	as	O
47	compared	O
48	with	O
49	bax	B
50	-	O
51	wild	O
52	-	O
53	type	O
54	mouse	O
55	embryonic	O
56	fibroblasts	O
57	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	In	O
2	one	O
3	mechanism	O
4	,	O
5	a	O
6	specialized	O
7	ubiquitin	B
8	-	O
9	dependent	O
10	proteolytic	O
11	system	O
12	(	O
13	called	O
14	the	O
15	APC	O
16	-	O
17	dependent	O
18	proteolysis	O
19	machinery	O
20	)	O
21	degrades	O
22	the	O
23	mitotic	O
24	(	O
25	Clb	B
26	)	O
27	cyclin	B
28	subunit	I
29	.	O

1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	B
9	RNA	I
10	differed	O
11	from	O
12	FinP	B
13	,	O
14	and	O
15	GST	B
16	-	O
17	FinO	B
18	did	O
19	not	O
20	protect	O
21	finP305	B
22	RNA	I
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O

1	When	O
2	excluding	O
3	children	O
4	with	O
5	ocular	O
6	and	O
7	cerebral	O
8	pathology	O
9	,	O
10	32	O
11	matched	O
12	pairs	O
13	of	O
14	premature	O
15	and	O
16	control	O
17	children	O
18	remained	O
19	.	O

1	This	O
2	complex	O
3	interacts	O
4	at	O
5	the	O
6	GTPase	B
7	domain	I
8	in	O
9	the	O
10	large	O
11	subunit	O
12	rRNA	O
13	,	O
14	overlapping	O
15	the	O
16	binding	O
17	site	O
18	of	O
19	the	O
20	protein	B
21	L11	I
22	-	I
23	like	I
24	eukaryotic	I
25	counterpart	I
26	(	O
27	Saccharomyces	B
28	cerevisiae	I
29	protein	I
30	L15	I
31	and	O
32	mammalian	B
33	protein	I
34	L12	I
35	).	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	B
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O

1	In	O
2	previous	O
3	work	O
4	(	O
5	E	O
6	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	B
13	expression	O
14	.	O

1	While	O
2	the	O
3	examiner	O
4	observed	O
5	the	O
6	interior	O
7	of	O
8	the	O
9	eye	O
10	with	O
11	indirect	O
12	ophthalmoscopy	O
13	,	O
14	the	O
15	point	O
16	source	O
17	of	O
18	light	O
19	from	O
20	the	O
21	fiberoptic	O
22	light	O
23	pipe	O
24	was	O
25	moved	O
26	along	O
27	the	O
28	margins	O
29	of	O
30	the	O
31	episcleral	O
32	plaque	O
33	.	O

1	Vivid	O
2	visual	O
3	hallucinations	O
4	without	O
5	other	O
6	psychopathology	O
7	have	O
8	been	O
9	reported	O
10	for	O
11	several	O
12	hundred	O
13	years	O
14	.	O

1	Results	O
2	of	O
3	the	O
4	long	O
5	-	O
6	term	O
7	observation	O
8	and	O
9	treatment	O
10	of	O
11	patients	O
12	with	O
13	arterial	O
14	hypertension	O

1	Cyclosporine	O
2	treatment	O
3	for	O
4	intractable	O
5	polymyositis	O
6	.	O

1	In	O
2	vitro	O
3	precipitation	O
4	with	O
5	a	O
6	glutathione	B
7	-	I
8	S	I
9	-	I
10	transferase	I
11	-	I
12	fusion	I
13	protein	I
14	containing	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	transactivation	O
20	domain	O
21	of	O
22	STAT5a	B
23	showed	O
24	GH	B
25	-	O
26	regulated	O
27	association	O
28	of	O
29	ERK1	B
30	/	I
31	2	I
32	with	O
33	the	O
34	fusion	O
35	protein	O
36	,	O
37	while	O
38	this	O
39	was	O
40	not	O
41	seen	O
42	when	O
43	serine	O
44	780	O
45	in	O
46	STAT5a	B
47	was	O
48	changed	O
49	to	O
50	alanine	O
51	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	O
43	were	O
44	observed	O
45	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	Novel	O
2	multigene	O
3	families	O
4	encoding	O
5	highly	O
6	repetitive	O
7	peptide	O
8	sequences	O
9	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	requirements	O
6	of	O
7	the	O
8	CH	B
9	gene	I
10	switch	O
11	by	O
12	characterizing	O
13	two	O
14	rearranged	B
15	gamma	I
16	2b	I
17	genes	I
18	from	O
19	a	O
20	gamma	B
21	2b	I
22	producing	O
23	mouse	O
24	myeloma	O
25	(	O
26	MPC	O
27	-	O
28	11	O
29	).	O

1	Self	O
2	-	O
3	emasculation	O
4	is	O
5	the	O
6	end	O
7	result	O
8	of	O
9	an	O
10	unusual	O
11	psychiatric	O
12	disorder	O
13	,	O
14	which	O
15	initially	O
16	requires	O
17	surgical	O
18	treatment	O
19	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	O
11	induced	O
12	Waf1	B
13	/	O
14	Cip1	B
15	-	O
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	Resources	O
2	for	O
3	helping	O
4	patients	O
5	to	O
6	quit	O
7	smoking	O
8	.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	O
17	MDV2	B
18	UL10	I
19	protein	I
20	.	O

1	Cicatricial	O
2	pemphigoid	O
3	is	O
4	an	O
5	autoimmune	O
6	systemic	O
7	disease	O
8	characterized	O
9	by	O
10	chronic	O
11	conjunctival	O
12	cicatrization	O
13	.	O

1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O

1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O

1	All	O
2	samples	O
3	exhibited	O
4	a	O
5	decline	O
6	in	O
7	ethanol	O
8	concentration	O
9	,	O
10	with	O
11	most	O
12	losses	O
13	falling	O
14	within	O
15	the	O
16	expected	O
17	20	O
18	to	O
19	40	O
20	mg	O
21	%	O
22	range	O
23	.	O

1	RNase	B
2	protection	O
3	assays	O
4	reveal	O
5	that	O
6	this	O
7	gene	O
8	,	O
9	unr	B
10	,	O
11	is	O
12	transcribed	O
13	in	O
14	the	O
15	same	O
16	direction	O
17	as	O
18	N	B
19	-	I
20	ras	I
21	and	O
22	that	O
23	its	O
24	3	O
25	'	O
26	end	O
27	is	O
28	located	O
29	just	O
30	130	O
31	base	O
32	pairs	O
33	away	O
34	from	O
35	the	O
36	point	O
37	at	O
38	which	O
39	N	B
40	-	I
41	ras	I
42	transcription	O
43	begins	O
44	.	O

1	LMP2A	B
2	enhances	O
3	Lyn	B
4	and	O
5	Syk	B
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	B
28	tyrosine	I
29	kinase	I
30	.	O

1	1	O
2	,	O
3	3	O
4	-	O
5	bis	O
6	(	O
7	2	O
8	-	O
9	chloroethyl	O
10	)-	O
11	1	O
12	-	O
13	nitrosourea	O
14	(	O
15	bcnu	O
16	)	O
17	and	O
18	other	O
19	nitrosoureas	O
20	in	O
21	cancer	O
22	treatment	O
23	:	O
24	a	O
25	review	O
26	.	O

1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O

1	Serum	O
2	IgG	B
3	was	O
4	initially	O
5	elevated	O
6	in	O
7	6	O
8	patients	O
9	.	O

1	The	O
2	highly	O
3	amyloidogenic	O
4	42	O
5	-	O
6	residue	O
7	form	O
8	of	O
9	Abeta	B
10	(	O
11	Abeta42	B
12	)	O
13	is	O
14	the	O
15	first	O
16	species	O
17	to	O
18	be	O
19	deposited	O
20	in	O
21	both	O
22	sporadic	O
23	and	O
24	familial	O
25	AD	O
26	.	O

1	However	O
2	,	O
3	tyrA	B
4	can	O
5	be	O
6	expressed	O
7	efficiently	O
8	from	O
9	an	O
10	internal	O
11	promoter	O
12	which	O
13	appears	O
14	to	O
15	lie	O
16	within	O
17	the	O
18	3	O
19	'	O
20	portion	O
21	of	O
22	aroF	B
23	.	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O

1	The	O
2	14	B
3	.	I
4	1	I
5	(	I
6	IGLL1	I
7	)	I
8	gene	I
9	is	O
10	expressed	O
11	in	O
12	a	O
13	lineage	O
14	-	O
15	and	O
16	stage	O
17	-	O
18	restricted	O
19	manner	O
20	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O

1	The	O
2	gene	O
3	was	O
4	expressed	O
5	as	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	5	O
11	-	O
12	kb	O
13	mRNA	O
14	in	O
15	most	O
16	nonlymphoid	O
17	human	O
18	cells	O
19	/	O
20	tissues	O
21	including	O
22	prostate	O
23	,	O
24	lung	O
25	,	O
26	liver	O
27	,	O
28	and	O
29	colon	O
30	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	in	O
6	all	O
7	studies	O
8	favouring	O
9	PVI	O
10	.	O

1	Molecular	O
2	cloning	O
3	,	O
4	expression	O
5	pattern	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	human	O
12	CDKN2D	B
13	/	O
14	INK4d	B
15	,	O
16	an	O
17	inhibitor	O
18	of	O
19	cyclin	B
20	D	I
21	-	I
22	dependent	I
23	kinases	I
24	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	,	O
9	the	O
10	oncoprotein	O
11	of	O
12	the	O
13	avian	O
14	retrovirus	O
15	Rev	O
16	-	O
17	T	O
18	,	O
19	can	O
20	increase	O
21	expression	O
22	from	O
23	promoters	O
24	containing	O
25	binding	O
26	sites	O
27	for	O
28	the	O
29	cellular	O
30	transcription	O
31	factor	O
32	Sp1	B
33	in	O
34	chicken	O
35	embryo	O
36	fibroblasts	O
37	(	O
38	S	O
39	.	O

1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	elongation	O
6	activity	O
7	,	O
8	ELL	B
9	contains	O
10	a	O
11	novel	O
12	type	O
13	of	O
14	RNA	B
15	polymerase	I
16	II	I
17	interaction	I
18	domain	I
19	that	O
20	is	O
21	capable	O
22	of	O
23	repressing	O
24	polymerase	O
25	activity	O
26	in	O
27	promoter	O
28	-	O
29	specific	O
30	transcription	O
31	.	O

1	A	O
2	coiled	B
3	-	I
4	coil	I
5	related	I
6	protein	I
7	specific	O
8	for	O
9	synapsed	O
10	regions	O
11	of	O
12	meiotic	O
13	prophase	O
14	chromosomes	O
15	.	O

1	Immuno	O
2	-	O
3	cytochemistry	O
4	,	O
5	using	O
6	antisera	O
7	against	O
8	Campylobacter	O
9	jejuni	O
10	,	O
11	showed	O
12	that	O
13	the	O
14	positive	O
15	staining	O
16	in	O
17	altered	O
18	epithelial	O
19	cells	O
20	were	O
21	restricted	O
22	to	O
23	intracellular	O
24	organisms	O
25	having	O
26	a	O
27	structure	O
28	resembling	O
29	Campylobacter	O
30	spp	O
31	.	O

1	The	O
2	plasmid	O
3	shuffle	O
4	technique	O
5	was	O
6	used	O
7	to	O
8	replace	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	gene	O
14	with	O
15	the	O
16	mutant	O
17	form	O
18	,	O
19	resulting	O
20	in	O
21	failure	O
22	of	O
23	the	O
24	yeast	O
25	cells	O
26	to	O
27	grow	O
28	.	O

1	Ventral	O
2	rhinotomy	O
3	is	O
4	no	O
5	more	O
6	difficult	O
7	than	O
8	dorsal	O
9	rhinotomy	O
10	,	O
11	has	O
12	less	O
13	patient	O
14	morbidity	O
15	and	O
16	fewer	O
17	postoperative	O
18	complications	O
19	,	O
20	and	O
21	is	O
22	more	O
23	cosmetically	O
24	acceptable	O
25	.	O

1	The	O
2	underlying	O
3	cirrhosis	O
4	was	O
5	alcoholic	O
6	in	O
7	11	O
8	(	O
9	53	O
10	.	O
11	3	O
12	%),	O
13	cryptogenic	O
14	in	O
15	5	O
16	(	O
17	23	O
18	.	O
19	8	O
20	%),	O
21	and	O
22	hepatitis	O
23	B	O
24	chronic	O
25	infection	O
26	related	O
27	in	O
28	5	O
29	(	O
30	23	O
31	.	O
32	8	O
33	%).	O

1	Pancreaticoduodenal	O
2	lymph	O
3	node	O
4	enlargement	O
5	,	O
6	regardless	O
7	of	O
8	cause	O
9	,	O
10	has	O
11	been	O
12	a	O
13	source	O
14	of	O
15	imaging	O
16	confusion	O
17	because	O
18	of	O
19	its	O
20	propensity	O
21	to	O
22	mimic	O
23	pancreatic	O
24	malignancy	O
25	yet	O
26	not	O
27	cause	O
28	biliary	O
29	obstruction	O
30	.	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	I
8	16	I
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	B
23	Zn	I
24	-	I
25	15	I
26	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	B
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	B
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	The	O
2	DSF	O
3	regimen	O
4	appears	O
5	to	O
6	have	O
7	significant	O
8	activity	O
9	in	O
10	patients	O
11	who	O
12	have	O
13	metastatic	O
14	pancreatic	O
15	islet	O
16	-	O
17	cell	O
18	carcinoma	O
19	,	O
20	and	O
21	patient	O
22	tolerance	O
23	of	O
24	the	O
25	regimen	O
26	is	O
27	excellent	O
28	,	O
29	thus	O
30	warranting	O
31	further	O
32	investigation	O
33	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	O
45	.	O

1	The	O
2	granules	O
3	grew	O
4	as	O
5	the	O
6	melted	O
7	material	O
8	immersed	O
9	into	O
10	the	O
11	void	O
12	space	O
13	among	O
14	the	O
15	adhered	O
16	particles	O
17	.	O

1	To	O
2	define	O
3	transcriptional	O
4	control	O
5	elements	O
6	responsible	O
7	for	O
8	muscle	O
9	-	O
10	specific	O
11	expression	O
12	of	O
13	the	O
14	human	B
15	myoglobin	I
16	gene	I
17	,	O
18	we	O
19	performed	O
20	mutational	O
21	analysis	O
22	of	O
23	upstream	O
24	sequences	O
25	(	O
26	nucleotide	O
27	positions	O
28	-	O
29	373	O
30	to	O
31	+	O
32	7	O
33	relative	O
34	to	O
35	the	O
36	transcriptional	O
37	start	O
38	site	O
39	)	O
40	linked	O
41	to	O
42	a	O
43	firefly	B
44	luciferase	I
45	gene	I
46	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	Sci	O
2	.	O

1	The	O
2	authors	O
3	have	O
4	tested	O
5	the	O
6	interference	O
7	of	O
8	the	O
9	hemoglobin	B
10	by	O
11	two	O
12	routine	O
13	methods	O
14	(	O
15	Berthelot	O
16	classic	O
17	and	O
18	Berthelot	O
19	modified	O
20	)	O
21	for	O
22	the	O
23	determination	O
24	of	O
25	plasmatic	O
26	urea	O
27	.	O

1	The	O
2	introduction	O
3	of	O
4	an	O
5	acidic	O
6	residue	O
7	at	O
8	the	O
9	second	O
10	site	O
11	was	O
12	essential	O
13	for	O
14	suppression	O
15	of	O
16	the	O
17	Asn	O
18	-	O
19	285	O
20	mutation	O
21	because	O
22	Lys	O
23	-	O
24	220	O
25	and	O
26	Gln	O
27	-	O
28	220	O
29	second	O
30	-	O
31	site	O
32	mutants	O
33	of	O
34	the	O
35	Asn	O
36	-	O
37	285	O
38	mutant	O
39	showed	O
40	very	O
41	low	O
42	tetracycline	O
43	resistance	O
44	.(	O
45	ABSTRACT	O
46	TRUNCATED	O
47	AT	O
48	250	O
49	WORDS	O
50	)	O

1	The	O
2	genes	O
3	encoding	O
4	the	O
5	transcription	B
6	factor	I
7	yTAFII60	I
8	,	O
9	the	O
10	G4p1	B
11	protein	I
12	and	O
13	a	O
14	putative	O
15	glucose	O
16	transporter	O
17	are	O
18	contained	O
19	in	O
20	a	O
21	12	O
22	.	O
23	3	O
24	kb	O
25	DNA	O
26	fragment	O
27	on	O
28	the	O
29	left	O
30	arm	O
31	of	O
32	Saccharomyces	O
33	cerevisiae	O
34	chromosome	O
35	VII	O
36	.	O

1	There	O
2	is	O
3	general	O
4	agreement	O
5	that	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	is	O
11	efficiently	O
12	transmitted	O
13	parenterally	O
14	,	O
15	while	O
16	data	O
17	on	O
18	viral	O
19	transmission	O
20	from	O
21	mothers	O
22	to	O
23	babies	O
24	or	O
25	by	O
26	sexual	O
27	or	O
28	non	O
29	-	O
30	sexual	O
31	household	O
32	contact	O
33	are	O
34	conflicting	O
35	.	O

1	Amiodarone	O
2	,	O
3	seldom	O
4	used	O
5	as	O
6	first	O
7	-	O
8	line	O
9	treatment	O
10	,	O
11	appears	O
12	to	O
13	be	O
14	the	O
15	most	O
16	effective	O
17	drug	O
18	.	O

1	Proctoscopy	O
2	and	O
3	roentgenographic	O
4	studies	O
5	may	O
6	be	O
7	an	O
8	important	O
9	part	O
10	of	O
11	evaluation	O
12	,	O
13	especially	O
14	in	O
15	patients	O
16	who	O
17	present	O
18	with	O
19	perianal	O
20	suppuration	O
21	,	O
22	masses	O
23	,	O
24	or	O
25	anal	O
26	fissures	O
27	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	efficacies	O
6	of	O
7	adjuvant	O
8	carboplatin	O
9	and	O
10	of	O
11	abdominal	O
12	radiotherapy	O
13	seem	O
14	to	O
15	be	O
16	identical	O
17	.	O

1	Failure	O
2	of	O
3	stapedius	O
4	reflexometry	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	myasthenia	O
10	gravis	O
11	.	O

1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	B
6	nucleic	I
7	acid	I
8	-	I
9	binding	I
10	protein	I
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	a	O
6	major	O
7	part	O
8	of	O
9	the	O
10	reduction	O
11	in	O
12	food	O
13	intake	O
14	in	O
15	hyperphagic	O
16	rats	O
17	eating	O
18	a	O
19	quinine	O
20	-	O
21	adulterated	O
22	diet	O
23	is	O
24	due	O
25	to	O
26	postingestional	O
27	events	O
28	.	O

1	The	O
2	PC2	B
3	protein	I
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	B
18	furin	I
19	gene	I
20	product	I
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	O
28	-	O
29	like	O
30	molecule	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Dbf8p	B
9	plays	O
10	an	O
11	essential	O
12	role	O
13	in	O
14	chromosome	O
15	segregation	O
16	.	O

1	We	O
2	have	O
3	identified	O
4	in	O
5	the	O
6	5	O
7	'	O
8	untranslated	O
9	region	O
10	of	O
11	the	O
12	Drosophila	B
13	copia	I
14	retrotransposon	I
15	,	O
16	3	O
17	'	O
18	to	O
19	the	O
20	left	O
21	LTR	O
22	,	O
23	a	O
24	sequence	O
25	for	O
26	transcriptional	O
27	regulation	O
28	by	O
29	homeoproteins	O
30	.	O

1	The	O
2	relatively	O
3	high	O
4	level	O
5	transcription	O
6	from	O
7	this	O
8	gene	O
9	shows	O
10	that	O
11	the	O
12	polymorphic	O
13	chromosome	O
14	ends	O
15	of	O
16	P	O
17	.	O
18	falciparum	O
19	,	O
20	which	O
21	have	O
22	been	O
23	proposed	O
24	to	O
25	be	O
26	transcriptionally	O
27	silent	O
28	,	O
29	can	O
30	be	O
31	active	O
32	expression	O
33	sites	O
34	for	O
35	var	B
36	genes	I
37	.	O

1	All	O
2	patients	O
3	in	O
4	the	O
5	control	O
6	group	O
7	showed	O
8	a	O
9	significant	O
10	improvement	O
11	in	O
12	their	O
13	PEFR	O
14	while	O
15	only	O
16	3	O
17	patients	O
18	in	O
19	the	O
20	treated	O
21	group	O
22	showed	O
23	an	O
24	improvement	O
25	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	named	O
6	this	O
7	gene	O
8	UBP43	B
9	.	O

1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O

1	16	O
2	subjects	O
3	were	O
4	repatch	O
5	tested	O
6	to	O
7	ethylmercury	O
8	chloride	O
9	(	O
10	EtHgCl	O
11	)	O
12	and	O
13	to	O
14	solutions	O
15	containing	O
16	EtHgCl	O
17	mixed	O
18	with	O
19	L	O
20	-	O
21	cysteine	O
22	and	O
23	glutathione	O
24	,	O
25	respectively	O
26	.	O

1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O

1	The	O
2	Schizosaccharomyces	B
3	pombe	I
4	rad1	I
5	+	I
6	cell	I
7	cycle	I
8	checkpoint	I
9	control	I
10	gene	I
11	is	O
12	required	O
13	for	O
14	S	O
15	-	O
16	phase	O
17	and	O
18	G2	O
19	/	O
20	M	O
21	arrest	O
22	in	O
23	response	O
24	to	O
25	both	O
26	DNA	O
27	damage	O
28	and	O
29	incomplete	O
30	DNA	O
31	replication	O
32	.	O

1	Cam	B
2	kinase	I
3	II	I
4	induces	O
5	in	O
6	vivo	O
7	phosphorylation	O
8	of	O
9	Smad2	B
10	and	O
11	Smad4	B
12	and	O
13	,	O
14	to	O
15	a	O
16	lesser	O
17	extent	O
18	,	O
19	Smad3	B
20	.	O

1	The	O
2	site	O
3	-	O
4	specific	O
5	DNA	O
6	inversion	O
7	system	O
8	Cin	B
9	encoded	O
10	by	O
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	B
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O

1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O

1	Heterozygous	O
2	mutation	O
3	in	O
4	the	O
5	G	O
6	+	O
7	5	O
8	position	O
9	of	O
10	intron	O
11	33	O
12	of	O
13	the	O
14	pro	B
15	-	I
16	alpha	I
17	2	I
18	(	I
19	I	I
20	)	I
21	gene	I
22	(	O
23	COL1A2	B
24	)	O
25	that	O
26	causes	O
27	aberrant	O
28	RNA	O
29	splicing	O
30	and	O
31	lethal	O
32	osteogenesis	O
33	imperfecta	O
34	.	O

1	Tolerance	O
2	to	O
3	fenfluramine	O
4	anorexia	O
5	:	O
6	fact	O
7	or	O
8	fiction	O
9	?	O
10	Recent	O
11	findings	O
12	in	O
13	this	O
14	laboratory	O
15	with	O
16	regard	O
17	to	O
18	tolerance	O
19	to	O
20	fenfluramine	O
21	anorexia	O
22	are	O
23	reviewed	O
24	with	O
25	respect	O
26	to	O
27	generality	O
28	of	O
29	the	O
30	behavioural	O
31	phenomenon	O
32	.	O

1	Ti	O
2	exhibited	O
3	a	O
4	feather	O
5	-	O
6	like	O
7	morphology	O
8	.	O

1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	follow	O
5	-	O
6	up	O
7	prospectively	O
8	patients	O
9	with	O
10	arthritis	O
11	after	O
12	infection	O
13	with	O
14	beta	O
15	-	O
16	haemolytic	O
17	streptococci	O
18	of	O
19	Lancefield	O
20	group	O
21	A	O
22	(	O
23	beta	O
24	HSA	O
25	),	O
26	with	O
27	emphasis	O
28	on	O
29	clinical	O
30	characteristics	O
31	and	O
32	serological	O
33	features	O
34	.	O

1	Perhaps	O
2	in	O
3	addition	O
4	to	O
5	,	O
6	or	O
7	as	O
8	part	O
9	of	O
10	,	O
11	its	O
12	essential	O
13	function	O
14	in	O
15	late	O
16	mitosis	O
17	,	O
18	MOB1	B
19	is	O
20	required	O
21	for	O
22	a	O
23	cell	O
24	cycle	O
25	reset	O
26	function	O
27	necessary	O
28	for	O
29	the	O
30	initiation	O
31	of	O
32	the	O
33	spindle	O
34	pole	O
35	body	O
36	duplication	O
37	.	O

1	Because	O
2	the	O
3	CAP	O
4	measures	O
5	variables	O
6	predictive	O
7	of	O
8	abusive	O
9	behavior	O
10	,	O
11	a	O
12	substantial	O
13	relationship	O
14	was	O
15	expected	O
16	between	O
17	the	O
18	CAP	O
19	and	O
20	the	O
21	MHI	O
22	Loss	O
23	of	O
24	Behavioral	O
25	/	O
26	Emotional	O
27	Control	O
28	scale	O
29	.	O

1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	B
16	retrotransposon	I
17	Tto1	I
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O

1	Serum	O
2	ascorbic	O
3	acid	O
4	had	O
5	an	O
6	inverse	O
7	and	O
8	the	O
9	strongest	O
10	association	O
11	with	O
12	systolic	O
13	blood	O
14	pressure	O
15	among	O
16	the	O
17	risk	O
18	factors	O
19	including	O
20	blood	O
21	pressure	O
22	,	O
23	total	O
24	cholesterol	O
25	,	O
26	triglyceride	O
27	,	O
28	gamma	B
29	-	I
30	GTP	I
31	and	O
32	obesity	O
33	.	O

1	The	O
2	expression	O
3	analysis	O
4	of	O
5	the	O
6	KlHIS4	B
7	gene	I
8	under	O
9	phosphate	O
10	starvation	O
11	or	O
12	high	O
13	adenine	O
14	supply	O
15	shows	O
16	that	O
17	factors	O
18	,	O
19	such	O
20	as	O
21	Bas1	B
22	or	O
23	Bas2	B
24	,	O
25	involved	O
26	in	O
27	the	O
28	basal	O
29	control	O
30	may	O
31	also	O
32	operate	O
33	in	O
34	a	O
35	different	O
36	way	O
37	in	O
38	K	O
39	.	O
40	lactis	O
41	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	B
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	B
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	When	O
2	vascular	O
3	pressure	O
4	(	O
5	Pvas	O
6	)	O
7	was	O
8	raised	O
9	abruptly	O
10	from	O
11	-	O
12	5	O
13	to	O
14	+	O
15	25	O
16	cmH2O	O
17	by	O
18	air	O
19	inflation	O
20	for	O
21	60	O
22	min	O
23	,	O
24	Px	O
25	(	O
26	f	O
27	)	O
28	became	O
29	abruptly	O
30	less	O
31	negative	O
32	,	O
33	then	O
34	remained	O
35	stable	O
36	.	O

1	CONCLUSIONS	O
2	:	O
3	Fission	B
4	yeast	I
5	SCF	I
6	is	O
7	composed	O
8	of	O
9	Pop1	B
10	and	O
11	Pop2	B
12	,	O
13	two	O
14	structurally	O
15	related	O
16	but	O
17	functionally	O
18	independent	O
19	F	B
20	-	I
21	box	I
22	/	I
23	WD	I
24	-	I
25	repeat	I
26	proteins	I
27	.	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	cyclin	B
14	D2	I
15	suggested	O
16	that	O
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	B
28	/	I
29	EBP	I
30	,	O
31	PEA3	B
32	,	O
33	AP2	B
34	,	O
35	NF	B
36	-	I
37	Y	I
38	,	O
39	c	B
40	-	I
41	Myc	I
42	,	O
43	and	O
44	Sp1	B
45	may	O
46	have	O
47	a	O
48	major	O
49	positive	O
50	regulatory	O
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	O
7	-	O
8	Barr	O
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	Quantitation	O
2	of	O
3	exocrine	B
4	IgA	I
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O

1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	B
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	B
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	B
17	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	O
8	-	O
9	1	O
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	B
21	length	I
22	UGT2B7	I
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	Oligonucleotide	O
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	I
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	The	O
2	nm23	B
3	-	I
4	H1	I
5	/	O
6	nm23	B
7	-	I
8	H2	I
9	gene	O
10	transcriptional	O
11	activity	O
12	ratio	O
13	varied	O
14	depending	O
15	on	O
16	the	O
17	cell	O
18	line	O
19	.	O

1	Thus	O
2	,	O
3	dpp	B
4	and	O
5	omb	B
6	promote	O
7	both	O
8	dorsal	O
9	leg	O
10	cell	O
11	fate	O
12	as	O
13	well	O
14	as	O
15	transdetermination	O
16	-	O
17	competent	O
18	leg	O
19	disc	O
20	cells	O
21	.	O

1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O

1	The	O
2	mature	O
3	chromosome	O
4	4	O
5	FRG1	B
6	transcript	I
7	is	O
8	1042	O
9	bp	O
10	in	O
11	length	O
12	and	O
13	contains	O
14	nine	O
15	exons	O
16	which	O
17	encode	O
18	a	O
19	putative	O
20	protein	O
21	of	O
22	258	O
23	amino	O
24	acid	O
25	residues	O
26	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	The	O
2	elevation	O
3	of	O
4	cyclic	O
5	AMP	O
6	(	O
7	cAMP	O
8	)	O
9	levels	O
10	in	O
11	the	O
12	cell	O
13	downregulates	O
14	the	O
15	activity	O
16	of	O
17	the	O
18	Raf	B
19	-	I
20	1	I
21	kinase	I
22	.	O

1	A	O
2	p21	B
3	peptide	I
4	spanning	O
5	amino	O
6	acids	O
7	139	O
8	-	O
9	164	O
10	was	O
11	found	O
12	to	O
13	bind	O
14	PCNA	B
15	in	O
16	a	O
17	filter	O
18	binding	O
19	assay	O
20	and	O
21	this	O
22	peptide	O
23	suppressed	O
24	recombinant	O
25	p21	B
26	-	O
27	PCNA	B
28	interaction	O
29	.	O

1	Bepridil	O
2	,	O
3	a	O
4	calcium	O
5	antagonist	O
6	with	O
7	a	O
8	half	O
9	-	O
10	life	O
11	of	O
12	approximately	O
13	42	O
14	hours	O
15	,	O
16	was	O
17	compared	O
18	with	O
19	placebo	O
20	in	O
21	a	O
22	double	O
23	-	O
24	blind	O
25	,	O
26	randomized	O
27	,	O
28	crossover	O
29	trial	O
30	.	O

1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O

1	Three	O
2	high	B
3	mobility	I
4	group	I
5	-	I
6	like	I
7	sequences	I
8	within	O
9	a	O
10	48	O
11	-	O
12	base	O
13	pair	O
14	enhancer	O
15	of	O
16	the	O
17	Col2a1	B
18	gene	I
19	are	O
20	required	O
21	for	O
22	cartilage	O
23	-	O
24	specific	O
25	expression	O
26	in	O
27	vivo	O
28	.	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	found	O
6	between	O
7	the	O
8	TS	O
9	and	O
10	the	O
11	PTS	O
12	.	O

1	These	O
2	and	O
3	other	O
4	comparisons	O
5	suggest	O
6	that	O
7	,	O
8	during	O
9	evolution	O
10	,	O
11	both	O
12	the	O
13	RNA	B
14	-	I
15	polymerase	I
16	specificity	O
17	of	O
18	telomerase	B
19	RNA	I
20	-	I
21	gene	I
22	promoters	I
23	and	O
24	,	O
25	more	O
26	recently	O
27	,	O
28	the	O
29	position	O
30	of	O
31	the	O
32	template	O
33	sequence	O
34	in	O
35	the	O
36	telomerase	B
37	RNA	I
38	changed	O
39	.	O

1	This	O
2	study	O
3	compared	O
4	the	O
5	gross	O
6	and	O
7	fine	O
8	motor	O
9	performance	O
10	of	O
11	14	O
12	traumatically	O
13	brain	O
14	-	O
15	injured	O
16	children	O
17	(	O
18	five	O
19	to	O
20	15	O
21	years	O
22	old	O
23	,	O
24	with	O
25	loss	O
26	of	O
27	consciousness	O
28	for	O
29	at	O
30	least	O
31	24	O
32	hours	O
33	)	O
34	to	O
35	14	O
36	normal	O
37	children	O
38	group	O
39	matched	O
40	for	O
41	age	O
42	and	O
43	sex	O
44	.	O

1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	SGPT	B
2	,	O
3	SGOT	B
4	,	O
5	and	O
6	alkaline	B
7	phosphatase	I
8	concentrations	O
9	were	O
10	essentially	O
11	normal	O
12	in	O
13	all	O
14	subjects	O
15	.	O

1	In	O
2	the	O
3	10	O
4	patients	O
5	with	O
6	a	O
7	more	O
8	severe	O
9	degree	O
10	of	O
11	steatorrhea	O
12	the	O
13	decrease	O
14	in	O
15	fat	O
16	loss	O
17	approached	O
18	20	O
19	%	O
20	and	O
21	a	O
22	close	O
23	relationship	O
24	was	O
25	found	O
26	(	O
27	r	O
28	=	O
29	0	O
30	.	O
31	84	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	)	O
40	between	O
41	the	O
42	extent	O
43	of	O
44	the	O
45	fatty	O
46	acid	O
47	loss	O
48	on	O
49	placebo	O
50	and	O
51	the	O
52	decrease	O
53	of	O
54	this	O
55	loss	O
56	on	O
57	taurine	O
58	.	O

1	The	O
2	clinical	O
3	relevance	O
4	of	O
5	these	O
6	findings	O
7	is	O
8	strengthened	O
9	by	O
10	the	O
11	observation	O
12	that	O
13	similar	O
14	results	O
15	were	O
16	obtained	O
17	when	O
18	P	O
19	.	O
20	HCl	O
21	was	O
22	given	O
23	by	O
24	the	O
25	intravenous	O
26	route	O
27	.	O

1	A	O
2	major	O
3	task	O
4	for	O
5	sports	O
6	scientists	O
7	may	O
8	be	O
9	to	O
10	verify	O
11	empirically	O
12	the	O
13	nature	O
14	of	O
15	an	O
16	integrated	O
17	model	O
18	of	O
19	the	O
20	sport	O
21	performer	O
22	.	O

1	Uracil	B
2	DNA	I
3	glycosylase	I
4	catalyzes	O
5	the	O
6	initial	O
7	step	O
8	in	O
9	the	O
10	repair	O
11	pathway	O
12	that	O
13	removes	O
14	potentially	O
15	mutagenic	O
16	uracil	O
17	from	O
18	duplex	O
19	DNA	O
20	.	O

1	The	O
2	effect	O
3	of	O
4	CBZ	O
5	and	O
6	DPH	O
7	can	O
8	be	O
9	explained	O
10	by	O
11	interference	O
12	with	O
13	thyroid	O
14	hormone	O
15	binding	O
16	to	O
17	TBG	B
18	combined	O
19	with	O
20	enzyme	O
21	-	O
22	induced	O
23	increased	O
24	metabolic	O
25	clearance	O
26	rate	O
27	of	O
28	thyroid	O
29	hormones	O
30	without	O
31	homeostatic	O
32	maintenance	O
33	of	O
34	premedication	O
35	levels	O
36	of	O
37	FT4	O
38	and	O
39	FT3	O
40	.	O

1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	B
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	O
42	.	O

1	The	O
2	selective	O
3	5	B
4	-	I
5	HT3	I
6	receptor	I
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	O
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	B
28	-	I
29	HT4	I
30	receptor	I
31	agonist	O
32	/	O
33	5	B
34	-	I
35	HT3	I
36	receptor	I
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O

1	However	O
2	,	O
3	a	O
4	strongly	O
5	increased	O
6	frequency	O
7	of	O
8	CpG	O
9	dinucleotides	O
10	was	O
11	found	O
12	.	O

1	Imaging	O
2	of	O
3	D2	B
4	dopamine	I
5	receptor	I

1	Urinary	O
2	urate	O
3	excretion	O
4	,	O
5	urate	O
6	clearance	O
7	,	O
8	and	O
9	fractional	O
10	excretion	O
11	of	O
12	urate	O
13	all	O
14	increased	O
15	significantly	O
16	during	O
17	water	O
18	immersion	O
19	,	O
20	and	O
21	decreased	O
22	in	O
23	the	O
24	hour	O
25	following	O
26	water	O
27	immersion	O
28	.	O

1	Another	O
2	tentative	O
3	hotspot	O
4	mutation	O
5	in	O
6	the	O
7	third	O
8	patient	O
9	,	O
10	a	O
11	frame	O
12	shift	O
13	caused	O
14	by	O
15	a	O
16	G	O
17	nucleotide	O
18	insertion	O
19	in	O
20	a	O
21	monotonous	O
22	repeat	O
23	of	O
24	six	O
25	Gs	O
26	in	O
27	HPRT	B
28	exon	I
29	3	I
30	,	O
31	has	O
32	been	O
33	reported	O
34	previously	O
35	in	O
36	three	O
37	other	O
38	LN	O
39	patients	O
40	.	O

1	Analysis	O
2	of	O
3	this	O
4	sequence	O
5	combined	O
6	with	O
7	that	O
8	previously	O
9	reported	O
10	for	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	directly	O
17	proximal	O
18	to	O
19	the	O
20	start	O
21	of	O
22	transcription	O
23	revealed	O
24	several	O
25	putative	O
26	regulatory	O
27	sequences	O
28	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O

1	CDDP	O
2	is	O
3	active	O
4	as	O
5	a	O
6	single	O
7	agent	O
8	in	O
9	non	O
10	-	O
11	Hodgkin	O
12	'	O
13	s	O
14	lymphoma	O
15	.	O

1	This	O
2	paper	O
3	brings	O
4	together	O
5	data	O
6	,	O
7	obtained	O
8	from	O
9	a	O
10	variety	O
11	of	O
12	sources	O
13	,	O
14	on	O
15	the	O
16	extent	O
17	of	O
18	prescription	O
19	and	O
20	use	O
21	of	O
22	psychotropic	O
23	drugs	O
24	in	O
25	the	O
26	late	O
27	1960s	O
28	and	O
29	early	O
30	1970s	O
31	.	O

1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O

1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	B
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O

1	Newcastle	O
2	disease	O
3	virus	O
4	surveillance	O
5	in	O
6	Hong	O
7	Kong	O
8	on	O
9	local	O
10	and	O
11	imported	O
12	poultry	O
13	.	O

1	We	O
2	suggest	O
3	that	O
4	such	O
5	occlusions	O
6	occurred	O
7	at	O
8	the	O
9	time	O
10	of	O
11	the	O
12	infarction	O
13	.	O

1	Joys	O
2	and	O
3	F	O
4	.	O

1	Finally	O
2	,	O
3	antibody	O
4	binding	O
5	to	O
6	site	O
7	IIIa	O
8	on	O
9	the	O
10	hCG	B
11	-	I
12	ectodomain	I
13	complex	I
14	was	O
15	also	O
16	hindered	O
17	by	O
18	an	O
19	anti	O
20	-	O
21	peptide	O
22	mAb	O
23	directed	O
24	against	O
25	a	O
26	peptide	O
27	encoded	O
28	by	O
29	the	O
30	eighth	O
31	exon	O
32	(	O
33	pE	O
34	x	O
35	8	O
36	)	O
37	of	O
38	the	O
39	LHR	B
40	.	O

1	The	O
2	uncomplicated	O
3	cases	O
4	of	O
5	typhoid	O
6	fever	O
7	were	O
8	found	O
9	to	O
10	have	O
11	an	O
12	intact	O
13	CMIR	O
14	as	O
15	compared	O
16	to	O
17	the	O
18	complicated	O
19	cases	O
20	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	a	O
8	mildly	O
9	-	O
10	atypical	O
11	(	O
12	inflammatory	O
13	)	O
14	cytological	O
15	result	O
16	(	O
17	class	O
18	2	O
19	)	O
20	and	O
21	a	O
22	benign	O
23	histological	O
24	diagnosis	O
25	:	O
26	48	O
27	%	O
28	of	O
29	class	O
30	-	O
31	2	O
32	smears	O
33	were	O
34	diagnosed	O
35	histologically	O
36	as	O
37	dysplasia	O
38	or	O
39	worse	O
40	.	O

1	In	O
2	30	O
3	dogs	O
4	the	O
5	left	O
6	limb	O
7	(	O
8	tail	O
9	)	O
10	of	O
11	the	O
12	pancreas	O
13	was	O
14	removed	O
15	but	O
16	left	O
17	in	O
18	the	O
19	abdominal	O
20	cavity	O
21	after	O
22	cessation	O
23	of	O
24	blood	O
25	flow	O
26	to	O
27	produce	O
28	warm	O
29	ischemia	O
30	for	O
31	30	O
32	,	O
33	60	O
34	,	O
35	and	O
36	120	O
37	min	O
38	(	O
39	10	O
40	dogs	O
41	at	O
42	each	O
43	time	O
44	point	O
45	),	O
46	and	O
47	then	O
48	was	O
49	flushed	O
50	with	O
51	cold	O
52	Ringers	O
53	'	O
54	lactate	O
55	and	O
56	transplanted	O
57	to	O
58	the	O
59	iliac	O
60	vessels	O
61	.	O

1	DNA	O
2	sequencing	O
3	and	O
4	Southern	O
5	blot	O
6	analyses	O
7	established	O
8	that	O
9	the	O
10	cDNA	O
11	clones	O
12	are	O
13	derived	O
14	from	O
15	two	O
16	different	O
17	genes	O
18	.	O

1	To	O
2	further	O
3	investigate	O
4	the	O
5	nature	O
6	of	O
7	the	O
8	site	O
9	specificity	O
10	a	O
11	set	O
12	of	O
13	deletion	O
14	mutants	O
15	of	O
16	the	O
17	160	O
18	bp	O
19	sequence	O
20	were	O
21	analysed	O
22	.	O

1	The	O
2	molecular	O
3	associations	O
4	dictating	O
5	INCENP	B
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	HL	B
2	-	I
3	A	I
4	antibodies	I
5	in	O
6	polytransfused	O
7	patients	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	B
10	MAP	I
11	kinase	I
12	(	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	1	I
19	)	O
20	gene	O
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	B
26	.	O

1	The	O
2	author	O
3	provides	O
4	a	O
5	rationale	O
6	for	O
7	an	O
8	interactional	O
9	view	O
10	and	O
11	presents	O
12	a	O
13	case	O
14	in	O
15	which	O
16	post	O
17	-	O
18	surgical	O
19	hiccups	O
20	were	O
21	successfully	O
22	treated	O
23	,	O
24	using	O
25	principles	O
26	developed	O
27	by	O
28	the	O
29	Mental	O
30	Research	O
31	Institute	O
32	.	O

1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	find	O
6	that	O
7	E2F	B
8	-	I
9	1	I
10	can	O
11	cause	O
12	apoptosis	O
13	in	O
14	p53	B
15	-/-	I
16	tumour	O
17	cells	O
18	and	O
19	further	O
20	p300	B
21	,	O
22	which	O
23	also	O
24	functions	O
25	as	O
26	a	O
27	co	O
28	-	O
29	activator	O
30	for	O
31	the	O
32	E2F	B
33	/	O
34	DP	B
35	heterodimer	O
36	,	O
37	enhances	O
38	the	O
39	apoptotic	O
40	activity	O
41	of	O
42	E2F	B
43	-	I
44	1	I
45	.	O

1	While	O
2	Pt	B
3	;	I
4	cycH	I
5	;	I
6	1	I
7	and	O
8	Os	B
9	;	I
10	cycH	I
11	;	I
12	1	I
13	were	O
14	expressed	O
15	in	O
16	all	O
17	tissues	O
18	examined	O
19	,	O
20	the	O
21	transcripts	O
22	accumulated	O
23	abundantly	O
24	in	O
25	dividing	O
26	cells	O
27	.	O

1	The	O
2	stability	O
3	of	O
4	isoniazid	O
5	solutions	O
6	increases	O
7	markedly	O
8	with	O
9	increasing	O
10	NTA	O
11	or	O
12	EDTA	O
13	concentration	O
14	up	O
15	to	O
16	1	O
17	mmol	O
18	/	O
19	l	O
20	.	O

1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	These	O
2	changes	O
3	at	O
4	the	O
5	site	O
6	of	O
7	injection	O
8	consist	O
9	of	O
10	a	O
11	focal	O
12	abnormality	O
13	characterized	O
14	by	O
15	a	O
16	slight	O
17	increase	O
18	in	O
19	signal	O
20	intensity	O
21	on	O
22	T1	O
23	weighted	O
24	images	O
25	and	O
26	markedly	O
27	increased	O
28	signal	O
29	intensity	O
30	on	O
31	T2	O
32	weighted	O
33	images	O
34	.	O

1	In	O
2	order	O
3	to	O
4	delineate	O
5	structural	O
6	motifs	O
7	regulating	O
8	substrate	O
9	affinity	O
10	and	O
11	recognition	O
12	for	O
13	the	O
14	human	B
15	dopamine	I
16	transporter	I
17	(	O
18	DAT	B
19	),	O
20	we	O
21	assessed	O
22	[	O
23	3H	O
24	]	O
25	dopamine	O
26	uptake	O
27	kinetics	O
28	and	O
29	[	O
30	3H	O
31	]	O
32	CFT	O
33	binding	O
34	characteristics	O
35	of	O
36	COS	O
37	-	O
38	7	O
39	cells	O
40	transiently	O
41	expressing	O
42	mutant	B
43	DATs	I
44	in	O
45	which	O
46	the	O
47	COOH	O
48	terminus	O
49	was	O
50	truncated	O
51	or	O
52	substituted	O
53	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	cooperative	O
6	effects	O
7	of	O
8	a	O
9	human	O
10	estrogen	B
11	receptor	I
12	-	I
13	alpha	I
14	(	O
15	ERalpha	B
16	)	O
17	isoform	O
18	on	O
19	estrogen	O
20	(	O
21	E2	O
22	)-	O
23	mediated	O
24	gene	O
25	activation	O
26	in	O
27	U2	O
28	-	O
29	OS	O
30	osteosarcoma	O
31	cells	O
32	.	O

1	Purification	O
2	of	O
3	MvaT	B
4	enriched	O
5	for	O
6	two	O
7	polypeptides	O
8	of	O
9	approximate	O
10	molecular	O
11	mass	O
12	15	O
13	kDa	O
14	and	O
15	16	O
16	kDa	O
17	,	O
18	designated	O
19	P15	B
20	and	O
21	P16	B
22	.	O

1	The	O
2	P13	O
3	and	O
4	N22	O
5	of	O
6	ppSEPs	O
7	had	O
8	phase	O
9	reversal	O
10	relationship	O
11	with	O
12	the	O
13	P2	O
14	and	O
15	N2	O
16	recorded	O
17	from	O
18	the	O
19	PES	O
20	,	O
21	respectively	O
22	.	O

1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O

1	Endurance	O
2	training	O
3	resulted	O
4	in	O
5	an	O
6	increase	O
7	of	O
8	stiffness	O
9	associated	O
10	with	O
11	a	O
12	decrease	O
13	of	O
14	type	O
15	II	O
16	fibers	O
17	.	O

1	RESULTS	O
2	:	O
3	Average	O
4	age	O
5	at	O
6	symptom	O
7	onset	O
8	was	O
9	41	O
10	.	O
11	2	O
12	years	O
13	.	O

1	The	O
2	promoter	O
3	and	O
4	upstream	O
5	region	O
6	of	O
7	the	O
8	Brassica	B
9	napus	I
10	2S	I
11	storage	I
12	protein	I
13	napA	I
14	gene	I
15	were	O
16	studied	O
17	to	O
18	identify	O
19	cis	O
20	-	O
21	acting	O
22	sequences	O
23	involved	O
24	in	O
25	developmental	O
26	seed	O
27	-	O
28	specific	O
29	expression	O
30	.	O

1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O

1	The	O
2	plexiform	O
3	neurofibroma	O
4	and	O
5	multiple	O
6	localized	O
7	neurofibromas	O
8	are	O
9	characteristic	O
10	of	O
11	NF1	B
12	.	O

1	Single	O
2	-	O
3	alanine	O
4	-	O
5	substitution	O
6	mutations	O
7	had	O
8	minimal	O
9	,	O
10	if	O
11	any	O
12	,	O
13	effects	O
14	on	O
15	S	O
16	-	O
17	induced	O
18	cell	O
19	-	O
20	to	O
21	-	O
22	cell	O
23	fusion	O
24	.	O

1	The	O
2	problem	O
3	of	O
4	disablement	O
5	due	O
6	to	O
7	pulmonary	O
8	tuberculosis	O
9	,	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	an	O
15	analysis	O
16	of	O
17	the	O
18	history	O
19	of	O
20	395	O
21	cases	O
22	as	O
23	observed	O
24	in	O
25	Gdansk	O
26	in	O
27	the	O
28	years	O
29	1946	O
30	-	O
31	1965	O

1	Hyperthyroidism	O
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O

1	Of	O
2	7	O
3	patients	O
4	treated	O
5	with	O
6	cyclophosphamide	O
7	,	O
8	hexamethylmelamine	O
9	,	O
10	adriamycin	O
11	and	O
12	cisplatin	O
13	(	O
14	CHAP	O
15	-	O
16	5	O
17	),	O
18	6	O
19	had	O
20	measurable	O
21	disease	O
22	,	O
23	of	O
24	whom	O
25	5	O
26	yielded	O
27	a	O
28	response	O
29	(	O
30	2	O
31	complete	O
32	responses	O
33	for	O
34	19	O
35	+	O
36	and	O
37	40	O
38	months	O
39	and	O
40	3	O
41	partial	O
42	responses	O
43	for	O
44	4	O
45	,	O
46	7	O
47	and	O
48	8	O
49	months	O
50	).	O

1	Diagnosis	O
2	of	O
3	primary	O
4	sclerosing	O
5	cholangitis	O
6	in	O
7	a	O
8	blood	O
9	donor	O
10	with	O
11	elevated	O
12	serum	B
13	alanine	I
14	aminotransferase	I
15	.	O

1	To	O
2	assess	O
3	the	O
4	function	O
5	(	O
6	s	O
7	)	O
8	of	O
9	E74	B
10	during	O
11	metamorphosis	O
12	,	O
13	we	O
14	have	O
15	isolated	O
16	and	O
17	characterized	O
18	recessive	O
19	loss	O
20	-	O
21	of	O
22	-	O
23	function	O
24	mutations	O
25	specific	O
26	to	O
27	each	O
28	transcription	O
29	unit	O
30	.	O

1	Hematopoietic	O
2	system	O
3	in	O
4	streptococcal	O
5	allergy	O
6	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	putative	O
10	cytokine	O
11	which	O
12	is	O
13	induced	O
14	by	O
15	stimulation	O
16	via	O
17	the	O
18	CD2	B
19	structure	I
20	on	O
21	human	O
22	T	O
23	lymphocytes	O
24	.	O

1	Tryptic	O
2	cleavage	O
3	and	O
4	peptide	O
5	sequence	O
6	analysis	O
7	demonstrated	O
8	that	O
9	the	O
10	98	O
11	-	O
12	kD	O
13	protein	O
14	is	O
15	identical	O
16	to	O
17	a	O
18	recently	O
19	cloned	O
20	protein	O
21	,	O
22	special	B
23	A	I
24	-	I
25	T	I
26	-	I
27	rich	I
28	binding	I
29	protein	I
30	1	I
31	(	O
32	SATB1	B
33	),	O
34	that	O
35	binds	O
36	selectively	O
37	to	O
38	nuclear	O
39	matrix	O
40	/	O
41	scaffold	O
42	-	O
43	associated	O
44	regions	O
45	of	O
46	DNA	O
47	(	O
48	MARs	O
49	/	O
50	SARs	O
51	).	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	fatty	B
6	acid	I
7	cyclo	I
8	-	I
9	oxygenase	I
10	inhibitor	O
11	indomethacin	O
12	on	O
13	cerebral	O
14	blood	O
15	flow	O
16	(	O
17	CBF	O
18	)	O
19	and	O
20	the	O
21	metabolic	O
22	rate	O
23	for	O
24	oxygen	O
25	(	O
26	CMRO2	O
27	)	O
28	was	O
29	studied	O
30	in	O
31	paralyzed	O
32	and	O
33	artificially	O
34	ventilated	O
35	rats	O
36	.	O

1	The	O
2	ultrastructure	O
3	of	O
4	retinal	O
5	vessels	O
6	was	O
7	examined	O
8	in	O
9	three	O
10	eyes	O
11	from	O
12	diabetic	O
13	patients	O
14	and	O
15	two	O
16	eyes	O
17	from	O
18	control	O
19	subjects	O
20	.	O

1	Recombinant	B
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Analysis	O
2	of	O
3	corticosteroids	O
4	.	O

1	The	O
2	ligand	O
3	for	O
4	RXR	B
5	,	O
6	9	O
7	-	O
8	cis	O
9	retinoic	O
10	acid	O
11	,	O
12	has	O
13	the	O
14	opposite	O
15	effect	O
16	of	O
17	destabilizing	O
18	the	O
19	heterodimeric	O
20	-	O
21	DNA	O
22	complex	O
23	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	human	B
7	UDP	I
8	-	I
9	d	I
10	-	I
11	Xylose	I
12	:	I
13	proteoglycan	I
14	core	I
15	protein	I
16	beta	I
17	-	I
18	d	I
19	-	I
20	xylosyltransferase	I
21	and	O
22	its	O
23	first	O
24	isoform	B
25	XT	I
26	-	I
27	II	I
28	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	Bazett	O
5	-	O
6	corrected	O
7	QT	O
8	(	O
9	QTc	O
10	)	O
11	interval	O
12	during	O
13	exercise	O
14	has	O
15	been	O
16	used	O
17	as	O
18	a	O
19	marker	O
20	for	O
21	ischemic	O
22	disease	O
23	,	O
24	arrhythmogenic	O
25	substrate	O
26	and	O
27	the	O
28	long	O
29	QT	O
30	syndrome	O
31	.	O

1	Mutually	O
2	exclusive	O
3	interaction	O
4	of	O
5	the	O
6	adenovirus	B
7	E4	I
8	-	I
9	6	I
10	/	I
11	7	I
12	protein	I
13	and	O
14	the	O
15	retinoblastoma	B
16	gene	I
17	product	I
18	with	O
19	internal	O
20	domains	O
21	of	O
22	E2F	B
23	-	I
24	1	I
25	and	O
26	DP	B
27	-	I
28	1	I
29	.	O

1	Cloning	O
2	and	O
3	sequence	O
4	analyses	O
5	revealed	O
6	a	O
7	second	O
8	cDNA	O
9	with	O
10	a	O
11	95	O
12	-	O
13	nt	O
14	deletion	O
15	in	O
16	the	O
17	region	O
18	coding	O
19	for	O
20	the	O
21	putative	O
22	second	O
23	intracellular	O
24	loop	O
25	and	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	of	O
31	the	O
32	5	B
33	-	I
34	HT2C	I
35	-	I
36	R	I
37	.	O

1	Most	O
2	of	O
3	the	O
4	prepeptide	O
5	portion	O
6	of	O
7	the	O
8	precursor	O
9	polypeptide	O
10	is	O
11	encoded	O
12	by	O
13	the	O
14	next	O
15	three	O
16	exons	O
17	,	O
18	and	O
19	the	O
20	mature	O
21	form	O
22	of	O
23	IL	B
24	-	I
25	1	I
26	alpha	I
27	is	O
28	encoded	O
29	by	O
30	the	O
31	remaining	O
32	three	O
33	exons	O
34	.	O

1	The	O
2	nuclear	O
3	proteins	O
4	encoded	O
5	by	O
6	the	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	c	B
12	-	I
13	jun	I
14	protooncogenes	I
15	are	O
16	expressed	O
17	during	O
18	the	O
19	proliferation	O
20	period	O
21	of	O
22	osteoblast	O
23	phenotype	O
24	development	O
25	.	O

1	Kinetic	O
2	coupling	O
3	and	O
4	requirement	O
5	for	O
6	ATP	O
7	hydrolysis	O
8	.	O

1	Ent	B
2	-	I
3	kaurene	I
4	synthase	I
5	from	I
6	the	I
7	fungus	I
8	Phaeosphaeria	I
9	sp	O
10	.	O

1	Immediately	O
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	From	O
2	this	O
3	library	O
4	,	O
5	LEU2	B
6	and	O
7	HIS3	B
8	cDNAs	O
9	were	O
10	recovered	O
11	at	O
12	a	O
13	frequency	O
14	of	O
15	about	O
16	1	O
17	in	O
18	10	O
19	(	O
20	4	O
21	)	O
22	and	O
23	in	O
24	12	O
25	out	O
26	of	O
27	13	O
28	cases	O
29	these	O
30	were	O
31	expressed	O
32	in	O
33	a	O
34	galactose	O
35	-	O
36	dependent	O
37	manner	O
38	.	O

1	Ras	B
2	-	O
3	GRF1	B
4	transiently	O
5	expressed	O
6	with	O
7	v	B
8	-	I
9	Src	I
10	was	O
11	tyrosine	O
12	-	O
13	phosphorylated	O
14	and	O
15	showed	O
16	significant	O
17	GEF	B
18	activity	O
19	toward	O
20	Rac	B
21	,	O
22	but	O
23	not	O
24	Rho	B
25	and	O
26	Cdc42	B
27	,	O
28	which	O
29	was	O
30	comparable	O
31	with	O
32	that	O
33	induced	O
34	by	O
35	Gbetagamma	B
36	.	O

1	Dermatology	O
2	is	O
3	no	O
4	exception	O
5	.	O

1	The	O
2	functional	O
3	homology	O
4	of	O
5	Cwg2	B
6	with	O
7	Cdc43	B
8	,	O
9	which	O
10	has	O
11	been	O
12	implicated	O
13	in	O
14	the	O
15	control	O
16	of	O
17	cell	O
18	polarity	O
19	,	O
20	suggests	O
21	a	O
22	link	O
23	between	O
24	two	O
25	morphogenetic	O
26	events	O
27	such	O
28	as	O
29	establishment	O
30	of	O
31	cell	O
32	polarity	O
33	and	O
34	cell	O
35	wall	O
36	biosynthesis	O
37	.	O

1	Proteinuria	O
2	--	O
3	selected	O
4	physiopathological	O
5	and	O
6	clinical	O
7	problems	O

1	The	O
2	survival	O
3	in	O
4	the	O
5	case	O
6	of	O
7	these	O
8	patients	O
9	was	O
10	studied	O
11	five	O
12	years	O
13	later	O
14	.	O

1	Human	B
2	acid	I
3	ceramidase	I
4	((	O
5	AC	O
6	)	O
7	N	O
8	-	O
9	acylsphingosine	O
10	amidohydrolase	O
11	,	O
12	EC	B
13	3	I
14	.	I
15	5	I
16	.	O

1	Treatment	O
2	of	O
3	Graves	O
4	'	O
5	disease	O
6	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	The	O
2	association	O
3	of	O
4	p255	B
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	B
15	CC3	I
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	O
23	pre	O
24	-	O
25	messenger	O
26	RNA	O
27	and	O
28	splicing	O
29	products	O
30	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	Statement	O
2	of	O
3	the	O
4	American	O
5	Academy	O
6	of	O
7	Implant	O
8	Dentistry	O
9	.	O

1	Current	O
2	status	O
3	and	O
4	future	O
5	perspectives	O

1	Anesthesia	O
2	with	O
3	M	O
4	/	O
5	K	O
6	was	O
7	reversed	O
8	after	O
9	41	O
10	.	O
11	6	O
12	min	O
13	of	O
14	immobilization	O
15	with	O
16	atipamezole	O
17	.	O

1	We	O
2	studied	O
3	the	O
4	functional	O
5	interaction	O
6	between	O
7	human	O
8	embryonic	O
9	zeta	B
10	2	I
11	globin	I
12	promoter	O
13	and	O
14	the	O
15	alpha	B
16	globin	I
17	regulatory	I
18	element	I
19	(	O
20	HS	B
21	-	I
22	40	I
23	)	O
24	located	O
25	40	O
26	kb	O
27	upstream	O
28	of	O
29	the	O
30	zeta	B
31	2	I
32	globin	I
33	gene	I
34	.	O

1	Hypertonic	O
2	glucose	O
3	administered	O
4	intrajejunally	O
5	in	O
6	Heidenhain	O
7	pouch	O
8	dogs	O
9	resulted	O
10	in	O
11	an	O
12	equal	O
13	inhibition	O
14	of	O
15	pentagastrin	O
16	-	O
17	induced	O
18	acid	O
19	secretion	O
20	from	O
21	the	O
22	pouch	O
23	and	O
24	the	O
25	main	O
26	stomach	O
27	,	O
28	whereas	O
29	hypertonic	O
30	saline	O
31	had	O
32	no	O
33	effect	O
34	.	O

1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O

1	Correlation	O
2	between	O
3	intraocular	O
4	involvement	O
5	and	O
6	systemic	O
7	outcome	O
8	was	O
9	poor	O
10	.	O

1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	layers	O
8	were	O
9	tested	O
10	concerning	O
11	the	O
12	valuation	O
13	of	O
14	the	O
15	haemocompatibility	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	polymers	O
21	polyurethane	O
22	(	O
23	PUR	O
24	),	O
25	polyvinylchloride	O
26	(	O
27	PVC	O
28	),	O
29	and	O
30	polystyrene	O
31	(	O
32	PS	O
33	)	O
34	in	O
35	two	O
36	different	O
37	worked	O
38	test	O
39	chambers	O
40	.	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	In	O
2	mice	O
3	,	O
4	three	O
5	major	O
6	families	O
7	of	O
8	L1	O
9	elements	O
10	,	O
11	termed	O
12	"	O
13	A	O
14	,"	O
15	"	O
16	F	O
17	,"	O
18	and	O
19	"	O
20	V	O
21	,"	O
22	have	O
23	been	O
24	defined	O
25	on	O
26	the	O
27	basis	O
28	of	O
29	the	O
30	sequence	O
31	found	O
32	at	O
33	the	O
34	5	O
35	'	O
36	terminus	O
37	.	O

1	Restriction	O
2	analysis	O
3	and	O
4	Southern	O
5	hybridization	O
6	revealed	O
7	the	O
8	presence	O
9	of	O
10	Tn5422	B
11	in	O
12	all	O
13	the	O
14	plasmid	O
15	-	O
16	mediated	O
17	cadmium	O
18	-	O
19	resistant	O
20	L	O
21	.	O
22	monocytogenes	O
23	strains	O
24	tested	O
25	but	O
26	not	O
27	in	O
28	strains	O
29	encoding	O
30	cadmium	O
31	resistance	O
32	on	O
33	the	O
34	chromosome	O
35	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O

1	After	O
2	description	O
3	of	O
4	his	O
5	short	O
6	life	O
7	and	O
8	an	O
9	explanation	O
10	of	O
11	the	O
12	light	O
13	conductor	O
14	Bozzini	O
15	'	O
16	s	O
17	merit	O
18	is	O
19	emphasized	O
20	,	O
21	by	O
22	his	O
23	invention	O
24	as	O
25	first	O
26	physician	O
27	to	O
28	have	O
29	made	O
30	accessible	O
31	to	O
32	medicine	O
33	endoscopic	O
34	diagnostic	O
35	possibilities	O
36	.	O

1	Rare	O
2	neurogenic	O
3	tumor	O
4	with	O
5	metastasis	O
6	to	O
7	mouth	O
8	,	O
9	jaw	O
10	and	O
11	face	O
12	regions	O

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	Asthmatic	O
2	patients	O
3	showed	O
4	greater	O
5	responses	O
6	of	O
7	both	O
8	parameters	O
9	to	O
10	adrenaline	O
11	than	O
12	controls	O
13	indicating	O
14	that	O
15	long	O
16	-	O
17	term	O
18	corticosteroid	O
19	treatment	O
20	enhances	O
21	the	O
22	acute	O
23	responses	O
24	of	O
25	plasminogen	B
26	activator	I
27	and	O
28	clotting	B
29	factor	I
30	VIII	I
31	to	O
32	adrenaline	O
33	infusion	O
34	.	O

1	A	O
2	constitutive	O
3	allele	O
4	of	O
5	GPA2	B
6	could	O
7	stimulate	O
8	growth	O
9	of	O
10	a	O
11	strain	O
12	lacking	O
13	both	O
14	RAS	B
15	genes	I
16	.	O

1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	I
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	A	O
2	comparison	O
3	among	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	regions	O
9	encompassing	O
10	the	O
11	presumptive	O
12	HS	B
13	promoter	I
14	of	O
15	the	O
16	soybean	B
17	HS	I
18	-	I
19	protein	I
20	genes	I
21	demonstrated	O
22	this	O
23	region	O
24	to	O
25	be	O
26	extremely	O
27	homologous	O
28	.	O

1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Expression	O
2	of	O
3	thiamin	O
4	biosynthetic	O
5	genes	O
6	(	O
7	thiCOGE	B
8	)	O
9	and	O
10	production	O
11	of	O
12	symbiotic	B
13	terminal	I
14	oxidase	I
15	cbb3	I
16	in	O
17	Rhizobium	O
18	etli	O
19	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	B
38	locus	I
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O

1	The	O
2	slower	O
3	-	O
4	electrophoretic	O
5	-	O
6	mobility	O
7	form	O
8	of	O
9	p68	B
10	was	O
11	absent	O
12	in	O
13	human	O
14	cells	O
15	in	O
16	G1	O
17	/	O
18	S	O
19	and	O
20	appeared	O
21	as	O
22	the	O
23	cells	O
24	entered	O
25	G2	O
26	/	O
27	M	O
28	.	O

1	Functional	O
2	flow	O
3	was	O
4	evaluated	O
5	using	O
6	laser	O
7	Doppler	O
8	flowmetry	O
9	(	O
10	LDF	O
11	),	O
12	for	O
13	which	O
14	the	O
15	output	O
16	signal	O
17	,	O
18	blood	O
19	cell	O
20	flux	O
21	(	O
22	BCF	O
23	),	O
24	is	O
25	expressed	O
26	in	O
27	terms	O
28	of	O
29	volts	O
30	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	similar	O
6	fragment	O
7	lacking	O
8	the	O
9	38	O
10	-	O
11	base	O
12	-	O
13	pair	O
14	region	O
15	had	O
16	no	O
17	such	O
18	stabilizing	O
19	effect	O
20	.	O

1	A	O
2	portion	O
3	of	O
4	p193	B
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O

1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	neuron	B
11	-	I
12	specific	I
13	SCG10	I
14	gene	I
15	evolved	O
16	by	O
17	duplication	O
18	and	O
19	modification	O
20	of	O
21	the	O
22	more	O
23	broadly	O
24	expressed	O
25	stathmin	B
26	/	O
27	Lap18	B
28	gene	O
29	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	O
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	B
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	Basal	O
2	plasma	O
3	renin	B
4	activity	O
5	(	O
6	PRA	O
7	)	O
8	was	O
9	slightly	O
10	raised	O
11	prior	O
12	to	O
13	training	O
14	(	O
15	P	O
16	<	O
17	0	O
18	.	O
19	07	O
20	)	O
21	compared	O
22	to	O
23	the	O
24	controls	O
25	and	O
26	post	O
27	-	O
28	training	O
29	.	O

1	We	O
2	conclude	O
3	that	O
4	administration	O
5	of	O
6	the	O
7	calcium	O
8	antagonist	O
9	Verapamil	O
10	is	O
11	of	O
12	no	O
13	additional	O
14	value	O
15	in	O
16	tocolytic	O
17	treatment	O
18	with	O
19	beta	O
20	-	O
21	mimetics	O
22	.	O

1	The	O
2	members	O
3	of	O
4	the	O
5	Myb	B
6	family	I
7	of	I
8	transcription	I
9	factors	I
10	are	O
11	defined	O
12	by	O
13	homology	O
14	in	O
15	the	O
16	DNA	O
17	-	O
18	binding	O
19	domain	O
20	;	O
21	all	O
22	bind	O
23	the	O
24	Myb	B
25	-	I
26	binding	I
27	site	I
28	(	O
29	MBS	B
30	)	O
31	sequence	O
32	(	O
33	YG	O
34	(	O
35	A	O
36	/	O
37	G	O
38	)	O
39	C	O
40	(	O
41	A	O
42	/	O
43	C	O
44	/	O
45	G	O
46	)	O
47	GTT	O
48	(	O
49	G	O
50	/	O
51	A	O
52	)).	O

1	McCann	O
2	III	O
3	,	O
4	F	O
5	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	I
56	121	I
57	-	I
58	476	I
59	)	I
60	p	I
61	.	O

1	CONCLUSION	O
2	:	O
3	This	O
4	retrospective	O
5	analysis	O
6	does	O
7	not	O
8	confirm	O
9	the	O
10	efficacy	O
11	of	O
12	one	O
13	course	O
14	of	O
15	simultaneous	O
16	Mitomycin	O
17	-	O
18	C	O
19	and	O
20	5	O
21	-	O
22	fluorouracil	O
23	,	O
24	at	O
25	least	O
26	in	O
27	association	O
28	with	O
29	full	O
30	-	O
31	dose	O
32	radiotherapy	O
33	incorporating	O
34	Iridium	O
35	-	O
36	192	O
37	boost	O
38	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	O
16	and	O
17	serum	B
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	gene	O
9	has	O
10	significant	O
11	homology	O
12	to	O
13	the	O
14	interferon	B
15	regulatory	I
16	factors	I
17	(	O
18	IRFs	B
19	).	O

1	The	O
2	predicted	O
3	protein	O
4	,	O
5	Seb1p	B
6	,	O
7	consists	O
8	of	O
9	82	O
10	amino	O
11	acids	O
12	and	O
13	contains	O
14	one	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	region	O
20	at	O
21	the	O
22	C	O
23	-	O
24	terminus	O
25	but	O
26	no	O
27	N	O
28	-	O
29	terminal	O
30	signal	O
31	sequence	O
32	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	B
6	constitutively	O
7	increases	O
8	ras	B
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O

1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O

1	Biochemical	O
2	analysis	O
3	reveals	O
4	that	O
5	KS1	B
6	is	O
7	a	O
8	nuclear	O
9	protein	O
10	containing	O
11	two	O
12	transcriptional	O
13	repressor	O
14	domains	O
15	,	O
16	R1	O
17	and	O
18	R2	O
19	.	O

1	A	O
2	724	O
3	-	O
4	bp	O
5	segment	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	consisting	O
13	of	O
14	the	O
15	proximal	O
16	E	O
17	-	O
18	box	O
19	flanked	O
20	upstream	O
21	by	O
22	a	O
23	mammalian	O
24	-	O
25	specific	O
26	352	O
27	-	O
28	bp	O
29	region	O
30	was	O
31	sufficient	O
32	for	O
33	maximal	O
34	transcriptional	O
35	activation	O
36	in	O
37	postconfluent	O
38	BC3H1	O
39	myoblasts	O
40	.	O

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	B
9	response	I
10	factor	I
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	Altogether	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O

1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	B
14	cleavage	I
15	-	I
16	activating	I
17	protein	I
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O

1	The	O
2	duration	O
3	and	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	negative	O
9	potential	O
10	were	O
11	greatest	O
12	for	O
13	completely	O
14	regenerating	O
15	ears	O
16	with	O
17	overgrowth	O
18	,	O
19	smaller	O
20	for	O
21	partially	O
22	regenerating	O
23	ears	O
24	,	O
25	and	O
26	smallest	O
27	for	O
28	the	O
29	nonregenerating	O
30	ears	O
31	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	The	O
2	differential	O
3	diagnosis	O
4	of	O
5	both	O
6	affections	O
7	is	O
8	based	O
9	on	O
10	the	O
11	clinical	O
12	course	O
13	,	O
14	sialography	O
15	and	O
16	CT	O
17	examination	O
18	which	O
19	along	O
20	with	O
21	modern	O
22	ATB	O
23	treatment	O
24	significantly	O
25	modify	O
26	hitherto	O
27	used	O
28	surgical	O
29	therapy	O
30	.	O

1	In	O
2	all	O
3	cells	O
4	,	O
5	the	O
6	accumulation	O
7	of	O
8	high	O
9	Dsg	B
10	protein	I
11	levels	O
12	required	O
13	calcium	O
14	and	O
15	was	O
16	not	O
17	observed	O
18	in	O
19	low	O
20	calcium	O
21	(	O
22	0	O
23	.	O
24	05	O
25	-	O
26	0	O
27	.	O
28	07	O
29	mM	O
30	)	O
31	media	O
32	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O

1	The	O
2	study	O
3	goals	O
4	were	O
5	to	O
6	isolate	O
7	a	O
8	full	O
9	-	O
10	length	O
11	clone	O
12	encoding	O
13	CO	B
14	-	I
15	Ag	I
16	from	O
17	a	O
18	bovine	O
19	corneal	O
20	cDNA	O
21	library	O
22	and	O
23	to	O
24	express	O
25	this	O
26	clone	O
27	in	O
28	Escherichia	O
29	coli	O
30	(	O
31	E	O
32	.	O
33	coli	O
34	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAPE	O
6	-	O
7	S	O
8	-	O
9	S	O
10	are	O
11	prone	O
12	to	O
13	irregular	O
14	nocturnal	O
15	breathing	O
16	patterns	O
17	at	O
18	high	O
19	altitude	O
20	,	O
21	which	O
22	is	O
23	associated	O
24	with	O
25	the	O
26	development	O
27	of	O
28	AMS	O
29	,	O
30	but	O
31	it	O
32	was	O
33	not	O
34	possible	O
35	to	O
36	determine	O
37	whether	O
38	these	O
39	abnormal	O
40	breathing	O
41	patterns	O
42	are	O
43	a	O
44	cause	O
45	or	O
46	an	O
47	effect	O
48	of	O
49	AMS	O
50	.	O

1	5	O
2	(	O
3	Sunset	O
4	Yellow	O
5	FCF	O
6	)	O
7	were	O
8	determined	O
9	using	O
10	liquid	O
11	chromatography	O
12	/	O
13	mass	O
14	spectrometry	O
15	(	O
16	LC	O
17	/	O
18	MS	O
19	)	O
20	with	O
21	electrospray	O
22	ionization	O
23	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	protection	O
6	assay	O
7	and	O
8	specific	O
9	blocking	O
10	oligonucleotides	O
11	,	O
12	we	O
13	find	O
14	that	O
15	recognition	O
16	of	O
17	the	O
18	5	O
19	'	O
20	splice	O
21	-	O
22	site	O
23	(	O
24	5	O
25	'	O
26	ss	O
27	)	O
28	and	O
29	branchpoint	O
30	sequence	O
31	(	O
32	BPS	O
33	)	O
34	elements	O
35	by	O
36	U11	B
37	and	O
38	U12	B
39	snRNPs	I
40	,	O
41	respectively	O
42	,	O
43	displays	O
44	strong	O
45	cooperativity	O
46	,	O
47	requiring	O
48	both	O
49	sites	O
50	in	O
51	the	O
52	pre	O
53	-	O
54	mRNA	O
55	substrate	O
56	for	O
57	efficient	O
58	complex	O
59	formation	O
60	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	I
7	2	I
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	I
15	beta	I
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	Smad	B
27	and	O
28	TAK1	B
29	pathways	O
30	.	O

1	The	O
2	maximum	O
3	stress	O
4	due	O
5	to	O
6	the	O
7	hygroscopic	O
8	examination	O
9	of	O
10	the	O
11	composite	O
12	was	O
13	0	O
14	.	O
15	74	O
16	kg	O
17	/	O
18	mm2	O
19	at	O
20	equilibrium	O
21	of	O
22	the	O
23	water	O
24	absorbed	O
25	of	O
26	the	O
27	composite	O
28	.	O

1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	B
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O

1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	I
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	B
35	and	O
36	urf209	B
37	processing	O
38	activities	O
39	.	O

1	In	O
2	Experiments	O
3	1	O
4	and	O
5	2	O
6	,	O
7	infants	O
8	,	O
9	like	O
10	adults	O
11	,	O
12	initially	O
13	categorized	O
14	novel	O
15	objects	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	physical	O
21	appearance	O
22	,	O
23	but	O
24	only	O
25	if	O
26	trained	O
27	with	O
28	multiple	O
29	exemplars	O
30	,	O
31	after	O
32	delays	O
33	of	O
34	1	O
35	and	O
36	7	O
37	days	O
38	.	O

1	The	O
2	mysteries	O
3	of	O
4	geographic	O
5	variability	O
6	in	O
7	nonmelanoma	O
8	skin	O
9	cancer	O
10	incidence	O
11	.	O

1	We	O
2	have	O
3	mapped	O
4	the	O
5	human	B
6	STAG3	I
7	gene	I
8	to	O
9	the	O
10	7q22	O
11	region	O
12	of	O
13	chromosome	O
14	7	O
15	;	O
16	six	O
17	human	B
18	STAG3	I
19	-	I
20	related	I
21	genes	I
22	have	O
23	also	O
24	been	O
25	mapped	O
26	:	O
27	two	O
28	at	O
29	7q22	O
30	near	O
31	the	O
32	functional	O
33	gene	O
34	,	O
35	one	O
36	at	O
37	7q11	O
38	.	O
39	22	O
40	,	O
41	and	O
42	three	O
43	at	O
44	7q11	O
45	.	O
46	23	O
47	,	O
48	two	O
49	of	O
50	them	O
51	flanking	O
52	the	O
53	breakpoints	O
54	commonly	O
55	associated	O
56	with	O
57	the	O
58	Williams	B
59	-	I
60	Beuren	I
61	syndrome	I
62	(	I
63	WBS	I
64	)	I
65	deletion	I
66	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	(	O
8	snRNP	O
9	)	O
10	to	O
11	the	O
12	pre	O
13	-	O
14	mRNA	O
15	is	O
16	an	O
17	early	O
18	and	O
19	important	O
20	step	O
21	in	O
22	spliceosome	O
23	assembly	O
24	.	O

1	X2	O
2	test	O
3	,	O
4	with	O
5	Yates	O
6	correction	O
7	if	O
8	need	O
9	,	O
10	was	O
11	used	O
12	as	O
13	statistical	O
14	.	O
15	method	O
16	.	O

1	Plasma	B
2	lactoferrin	I
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	RA	O
6	-	O
7	mediated	O
8	repression	O
9	of	O
10	the	O
11	hMGP	B
12	gene	I
13	is	O
14	due	O
15	to	O
16	binding	O
17	of	O
18	liganded	O
19	RAR	B
20	/	O
21	RXR	B
22	to	O
23	a	O
24	novel	O
25	negative	O
26	RA	O
27	response	O
28	element	O
29	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	O
18	Cdks	B
19	.	O

1	Spontaneous	O
2	recovery	O
3	occurs	O
4	within	O
5	30	O
6	min	O
7	to	O
8	2	O
9	hrs	O
10	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	B
14	leukemia	I
15	factor	I
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	O
28	DBP	B
29	fusion	O
30	proteins	O
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	However	O
2	,	O
3	by	O
4	immobilized	O
5	metal	O
6	affinity	O
7	chromatography	O
8	assay	O
9	,	O
10	self	O
11	-	O
12	association	O
13	of	O
14	PR	B
15	-	I
16	A	I
17	was	O
18	3	O
19	.	O
20	5	O
21	-	O
22	fold	O
23	more	O
24	efficient	O
25	than	O
26	that	O
27	of	O
28	either	O
29	the	O
30	DhLBD	O
31	or	O
32	hLBD	O
33	constructs	O
34	.	O

1	The	O
2	psychologic	O
3	factors	O
4	associated	O
5	wth	O
6	serious	O
7	illness	O
8	,	O
9	terminal	O
10	prognoses	O
11	,	O
12	and	O
13	dying	O
14	complicate	O
15	the	O
16	scenario	O
17	even	O
18	more	O
19	as	O
20	compared	O
21	with	O
22	that	O
23	of	O
24	nonmalignant	O
25	pain	O
26	.	O

1	The	O
2	ESEG	O
3	'	O
4	s	O
5	are	O
6	a	O
7	direct	O
8	result	O
9	of	O
10	the	O
11	NEXT	O
12	study	O
13	.	O

1	Common	O
2	history	O
3	and	O
4	prospects	O
5	in	O
6	surgical	O
7	gynecology	O
8	of	O
9	the	O
10	Charite	O
11	and	O
12	the	O
13	Vienna	O
14	University	O
15	Clinic	O

1	Although	O
2	the	O
3	extracellular	O
4	domain	O
5	of	O
6	the	O
7	TSH	B
8	-	I
9	R	I
10	is	O
11	sufficient	O
12	for	O
13	high	O
14	affinity	O
15	binding	O
16	of	O
17	TSH	B
18	,	O
19	we	O
20	conclude	O
21	that	O
22	the	O
23	hyt	O
24	mutation	O
25	in	O
26	the	O
27	fourth	O
28	transmembrane	O
29	domain	O
30	eliminates	O
31	TSH	B
32	binding	O
33	.	O

1	Coexpression	O
2	studies	O
3	indicate	O
4	that	O
5	insulin	B
6	and	O
7	PKB	B
8	suppress	O
9	transactivation	O
10	by	O
11	C	B
12	/	I
13	EBPbeta	I
14	,	O
15	but	O
16	not	O
17	C	B
18	/	I
19	EBPalpha	I
20	,	O
21	and	O
22	that	O
23	N	O
24	-	O
25	terminal	O
26	transactivation	O
27	domains	O
28	in	O
29	C	B
30	/	I
31	EBPbeta	I
32	are	O
33	required	O
34	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Whereas	O
2	a	O
3	PR55	B
4	beta	I
5	transcript	I
6	of	O
7	about	O
8	2	O
9	.	O
10	3	O
11	kb	O
12	was	O
13	detected	O
14	at	O
15	high	O
16	levels	O
17	in	O
18	the	O
19	neuroblastoma	O
20	derived	O
21	cell	O
22	line	O
23	LA	O
24	-	O
25	N	O
26	-	O
27	1	O
28	,	O
29	the	O
30	level	O
31	of	O
32	the	O
33	mRNA	O
34	was	O
35	very	O
36	low	O
37	in	O
38	the	O
39	other	O
40	human	O
41	cell	O
42	lines	O
43	analyzed	O
44	.	O

1	The	O
2	second	O
3	transcriptional	O
4	unit	O
5	,	O
6	designated	O
7	UL26	B
8	.	I
9	5	I
10	,	O
11	predicted	O
12	to	O
13	specify	O
14	a	O
15	protein	O
16	of	O
17	329	O
18	amino	O
19	acids	O
20	,	O
21	encodes	O
22	the	O
23	family	B
24	35	I
25	proteins	I
26	;	O
27	it	O
28	is	O
29	transcribed	O
30	by	O
31	an	O
32	mRNA	O
33	which	O
34	initiates	O
35	at	O
36	approximately	O
37	nucleotide	O
38	+	O
39	1000	O
40	of	O
41	the	O
42	UL26	B
43	transcription	O
44	initiation	O
45	site	O
46	and	O
47	is	O
48	translated	O
49	from	O
50	the	O
51	methionine	O
52	initiation	O
53	codon	O
54	located	O
55	at	O
56	position	O
57	+	O
58	1099	O
59	of	O
60	the	O
61	UL26	B
62	transcriptional	I
63	unit	I
64	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	pooling	O
7	requirements	O
8	are	O
9	task	O
10	dependent	O
11	.	O

1	In	O
2	wandering	O
3	stage	O
4	larvae	O
5	,	O
6	the	O
7	OBP	B
8	transcript	I
9	appeared	O
10	to	O
11	be	O
12	at	O
13	least	O
14	250	O
15	-	O
16	fold	O
17	less	O
18	abundant	O
19	than	O
20	ribosomal	O
21	RNA	O
22	.	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	B
6	desmin	I
7	in	O
8	SW13	O
9	(	O
10	vim	B
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	B
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Folded	O
2	tissue	O
3	and	O
4	crimped	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	tunica	O
10	albuginea	O
11	permit	O
12	its	O
13	expansion	O
14	during	O
15	erection	O
16	.	O

1	Also	O
2	,	O
3	the	O
4	BALB	B
5	/	I
6	c	I
7	gene	I
8	contains	O
9	a	O
10	single	O
11	substitution	O
12	in	O
13	a	O
14	conserved	O
15	octamer	O
16	sequence	O
17	approximately	O
18	equal	O
19	to	O
20	100	O
21	nucleotides	O
22	upstream	O
23	of	O
24	the	O
25	coding	O
26	region	O
27	,	O
28	which	O
29	could	O
30	affect	O
31	its	O
32	expression	O
33	.	O

1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	B
17	/	O
18	twy	B
19	)	O
20	in	O
21	vivo	O
22	.	O

1	Salient	O
2	applications	O
3	of	O
4	PB	O
5	-	O
6	PK	O
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	Constitutive	O
2	activation	O
3	of	O
4	Rac1	B
5	and	O
6	RhoA	B
7	causes	O
8	tumorigenic	O
9	transformation	O
10	of	O
11	NIH	O
12	3T3	O
13	cells	O
14	,	O
15	and	O
16	their	O
17	functions	O
18	may	O
19	be	O
20	required	O
21	for	O
22	full	O
23	Ras	B
24	transformation	O
25	.	O

1	Estrogen	O
2	replacement	O
3	therapy	O
4	and	O
5	risk	O
6	of	O
7	breast	O
8	cancer	O
9	:	O
10	results	O
11	of	O
12	two	O
13	meta	O
14	-	O
15	analyses	O
16	.	O

1	Role	O
2	of	O
3	estrogen	B
4	receptor	I
5	ligand	O
6	and	O
7	estrogen	O
8	response	O
9	element	O
10	sequence	O
11	on	O
12	interaction	O
13	with	O
14	chicken	B
15	ovalbumin	I
16	upstream	I
17	promoter	I
18	transcription	I
19	factor	I
20	(	O
21	COUP	B
22	-	I
23	TF	I
24	).	O

1	Weak	O
2	promoter	O
3	activity	O
4	was	O
5	observed	O
6	for	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	C1	B
12	and	O
13	C2	B
14	ORFs	O
15	(	O
16	C1	B
17	-	O
18	C2	B
19	gene	O
20	)	O
21	and	O
22	for	O
23	the	O
24	promoter	O
25	of	O
26	the	O
27	V1	B
28	ORF	I
29	.	O

1	Human	B
2	thyroid	I
3	stimulator	I
4	(	O
5	HTS	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O

1	PNRC	B
2	:	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	nuclear	O
8	receptor	O
9	coregulatory	O
10	protein	O
11	that	O
12	modulates	O
13	transcriptional	O
14	activation	O
15	of	O
16	multiple	O
17	nuclear	O
18	receptors	O
19	including	O
20	orphan	O
21	receptors	O
22	SF1	B
23	(	O
24	steroidogenic	B
25	factor	I
26	1	I
27	)	O
28	and	O
29	ERRalpha1	B
30	(	O
31	estrogen	B
32	related	I
33	receptor	I
34	alpha	I
35	-	I
36	1	I
37	).	O

1	2	O
2	cases	O
3	of	O
4	type	O
5	II	O
6	tyrosinosis	O
7	(	O
8	Richner	O
9	-	O
10	Hanhart	O
11	syndrome	O
12	)	O

1	We	O
2	also	O
3	identified	O
4	Sp1	B
5	,	O
6	Sp3	B
7	,	O
8	and	O
9	NGFI	B
10	-	I
11	A	I
12	/	O
13	Egr	B
14	-	I
15	1	I
16	as	O
17	the	O
18	primary	O
19	nuclear	O
20	transcription	O
21	factors	O
22	binding	O
23	to	O
24	TRE1	B
25	which	O
26	mediate	O
27	Tax	B
28	responsiveness	O
29	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	the	O
6	mTRF1	B
7	cDNA	I
8	resulted	O
9	in	O
10	a	O
11	56	O
12	kDa	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	TTAGGG	O
18	repeat	O
19	arrays	O
20	.	O
21	mTRF1	B
22	displayed	O
23	the	O
24	same	O
25	sequence	O
26	specificity	O
27	as	O
28	hTRF1	B
29	,	O
30	preferring	O
31	arrays	O
32	of	O
33	TTAGGG	O
34	repeats	O
35	as	O
36	a	O
37	binding	O
38	substrate	O
39	over	O
40	TTAGGC	O
41	and	O
42	TTGGGG	O
43	repeats	O
44	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	low	O
6	concentrations	O
7	of	O
8	IL	B
9	-	I
10	1	I
11	beta	I
12	may	O
13	be	O
14	useful	O
15	for	O
16	nonsurgical	O
17	treatment	O
18	of	O
19	human	O
20	vitreous	O
21	hemorrhage	O
22	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	B
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O

1	Only	O
2	fully	O
3	processed	O
4	Pra	B
5	(	O
6	N0	O
7	and	O
8	Nb	O
9	)	O
10	and	O
11	ICP35	B
12	(	O
13	ICP35	B
14	e	I
15	,	I
16	f	I
17	)	O
18	are	O
19	present	O
20	in	O
21	B	O
22	capsids	O
23	,	O
24	which	O
25	are	O
26	believed	O
27	to	O
28	be	O
29	precursors	O
30	of	O
31	mature	O
32	virions	O
33	.	O

1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	B
19	cytoplasmic	I
20	TyrRS	I
21	activity	O
22	was	O
23	produced	O
24	.	O

1	Although	O
2	differences	O
3	were	O
4	not	O
5	significant	O
6	,	O
7	infants	O
8	in	O
9	the	O
10	experimental	O
11	group	O
12	had	O
13	more	O
14	changes	O
15	in	O
16	the	O
17	intermittent	O
18	mandatory	O
19	ventilation	O
20	(	O
21	IMV	O
22	)	O
23	settings	O
24	during	O
25	transport	O
26	,	O
27	and	O
28	more	O
29	such	O
30	infants	O
31	arrived	O
32	at	O
33	the	O
34	receiving	O
35	hospital	O
36	with	O
37	acceptable	O
38	pH	O
39	and	O
40	PCO2	O
41	values	O
42	.	O

1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O

1	Cloning	O
2	by	O
3	complementation	O
4	and	O
5	subsequent	O
6	physical	O
7	and	O
8	genetic	O
9	analysis	O
10	revealed	O
11	that	O
12	it	O
13	maps	O
14	to	O
15	RAF1	B
16	.	O

1	J	O
2	.	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	O
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O

1	The	O
2	study	O
3	made	O
4	to	O
5	define	O
6	the	O
7	ability	O
8	of	O
9	lipid	B
10	A	I
11	monoclonal	I
12	antibodies	I
13	to	O
14	correct	O
15	hemodynamic	O
16	disturbances	O
17	due	O
18	to	O
19	endotoxemia	O
20	in	O
21	dog	O
22	experiments	O
23	showed	O
24	the	O
25	efficacy	O
26	of	O
27	the	O
28	antibodies	O
29	administration	O
30	.	O

1	Clinical	O
2	chemistry	O
3	.	O

1	Tyrosine	B
2	kinase	I
3	oncogenes	O
4	abrogate	O
5	interleukin	B
6	-	I
7	3	I
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	B
18	-	I
19	myc	I
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	B
25	-	I
26	myc	I
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	B
33	-	I
34	abl	I
35	.	O

1	Ongoing	O
2	and	O
3	future	O
4	investigations	O
5	may	O
6	better	O
7	define	O
8	the	O
9	optimal	O
10	approach	O
11	for	O
12	local	O
13	control	O
14	,	O
15	the	O
16	optimal	O
17	duration	O
18	of	O
19	maintenance	O
20	chemotherapy	O
21	,	O
22	and	O
23	the	O
24	possible	O
25	role	O
26	of	O
27	biologic	O
28	response	O
29	modifiers	O
30	and	O
31	growth	O
32	factors	O
33	in	O
34	further	O
35	improving	O
36	the	O
37	outcome	O
38	for	O
39	patients	O
40	with	O
41	this	O
42	disease	O
43	.	O

1	Instead	O
2	,	O
3	the	O
4	results	O
5	support	O
6	the	O
7	idea	O
8	that	O
9	Pc	B
10	group	I
11	products	I
12	provide	O
13	stable	O
14	memory	O
15	or	O
16	imprinting	O
17	of	O
18	boundaries	O
19	which	O
20	are	O
21	initially	O
22	specified	O
23	by	O
24	gap	O
25	and	O
26	pair	O
27	-	O
28	rule	O
29	regulators	O
30	.	O

1	Most	O
2	pituitary	O
3	hormone	O
4	-	O
5	coding	O
6	gene	O
7	promoters	O
8	are	O
9	activated	O
10	by	O
11	Ptx1	B
12	.	O

1	The	O
2	Twentieth	O
3	Anniversary	O
4	of	O
5	the	O
6	Pomeranian	O
7	Medical	O
8	Academy	O
9	.	O

1	The	O
2	HBP	B
3	gene	I
4	is	O
5	composed	O
6	of	O
7	eight	O
8	exons	O
9	covering	O
10	19	O
11	.	O
12	5	O
13	kb	O
14	on	O
15	the	O
16	short	O
17	arm	O
18	of	O
19	chromosome	O
20	4	O
21	.	O

1	Evaluation	O
2	of	O
3	desmopressin	O
4	for	O
5	dental	O
6	extractions	O
7	in	O
8	patients	O
9	with	O
10	hemostatic	O
11	disorders	O
12	.	O

1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	B
7	-	I
8	nucleotidase	I
9	.	O

1	Different	O
2	sequence	O
3	elements	O
4	of	O
5	both	O
6	the	O
7	retroviral	O
8	vectors	O
9	and	O
10	the	O
11	c	B
12	-	I
13	myc	I
14	gene	I
15	recombined	O
16	during	O
17	genesis	O
18	of	O
19	highly	O
20	oncogenic	O
21	retroviruses	O
22	CMII	O
23	,	O
24	MC29	O
25	,	O
26	or	O
27	MH2	O
28	.	O

1	nos	B
2	-	I
3	1	I
4	and	O
5	nos	B
6	-	I
7	2	I
8	,	O
9	two	O
10	genes	O
11	related	O
12	to	O
13	Drosophila	B
14	nanos	I
15	,	O
16	regulate	O
17	primordial	O
18	germ	O
19	cell	O
20	development	O
21	and	O
22	survival	O
23	in	O
24	Caenorhabditis	O
25	elegans	O
26	.	O

1	We	O
2	conducted	O
3	a	O
4	prospective	O
5	,	O
6	randomized	O
7	controlled	O
8	trial	O
9	of	O
10	metoprolol	O
11	,	O
12	a	O
13	selective	O
14	beta	O
15	-	O
16	blocker	O
17	for	O
18	prevention	O
19	of	O
20	gastrointestinal	O
21	bleeding	O
22	from	O
23	portal	O
24	hypertension	O
25	in	O
26	29	O
27	non	O
28	-	O
29	selected	O
30	patients	O
31	with	O
32	liver	O
33	disease	O
34	and	O
35	previous	O
36	gastrointestinal	O
37	bleeding	O
38	.	O

1	Complexes	O
2	of	O
3	qTBP42	B
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	leukemia	I
6	/	I
7	lymphotropic	I
8	virus	I
9	type	I
10	1	I
11	Tax	I
12	protein	I
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	B
26	domain	I
27	of	O
28	p300	B
29	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterized	O
6	the	O
7	GCD6	B
8	and	O
9	GCD7	B
10	genes	I
11	and	O
12	shown	O
13	that	O
14	their	O
15	products	O
16	are	O
17	required	O
18	to	O
19	repress	O
20	GCN4	B
21	translation	O
22	under	O
23	nonstarvation	O
24	conditions	O
25	.	O

1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O

1	An	O
2	InlC	B
3	deletion	I
4	mutant	I
5	shows	O
6	reduced	O
7	virulence	O
8	when	O
9	tested	O
10	in	O
11	an	O
12	intravenous	O
13	mouse	O
14	model	O
15	,	O
16	but	O
17	intracellular	O
18	replication	O
19	of	O
20	the	O
21	mutant	O
22	in	O
23	Caco	O
24	-	O
25	2	O
26	and	O
27	J774	O
28	cells	O
29	appears	O
30	to	O
31	be	O
32	comparable	O
33	with	O
34	that	O
35	of	O
36	the	O
37	wild	O
38	-	O
39	type	O
40	strain	O
41	.	O

1	Competition	O
2	with	O
3	a	O
4	putative	O
5	MADS	B
6	box	I
7	consensus	O
8	binding	O
9	site	O
10	from	O
11	the	O
12	promoter	O
13	of	O
14	the	O
15	coordinately	O
16	regulated	O
17	opaque	B
18	-	I
19	phase	I
20	-	I
21	specific	I
22	gene	I
23	PEP1	I
24	(	O
25	SAP1	B
26	)	O
27	and	O
28	the	O
29	human	B
30	MADS	I
31	box	I
32	consensus	I
33	binding	I
34	site	I
35	for	O
36	serum	B
37	response	I
38	factor	I
39	demonstrated	O
40	that	O
41	one	O
42	of	O
43	the	O
44	three	O
45	complexes	O
46	formed	O
47	was	O
48	specific	O
49	to	O
50	the	O
51	OP4	B
52	sequence	I
53	.	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	I
23	amino	I
24	acids	I
25	)	I
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	The	O
2	interaction	O
3	of	O
4	caffeine	O
5	,	O
6	theophylline	O
7	and	O
8	theobromine	O
9	with	O
10	monoamine	B
11	oxidase	I
12	inhibitors	O
13	.	O

1	The	O
2	intrapancreatic	O
3	spread	O
4	of	O
5	the	O
6	carcinoma	O
7	correlated	O
8	with	O
9	portal	O
10	invasion	O
11	of	O
12	carcinoma	O
13	,	O
14	hardness	O
15	of	O
16	the	O
17	body	O
18	and	O
19	tail	O
20	,	O
21	obstruction	O
22	of	O
23	main	O
24	pancreatic	O
25	duct	O
26	and	O
27	irregular	O
28	pancreaticogram	O
29	.	O

1	In	O
2	calves	O
3	receiving	O
4	milk	O
5	-	O
6	substitute	O
7	diets	O
8	containing	O
9	80	O
10	-	O
11	260	O
12	g	O
13	DM	O
14	/	O
15	kg	O
16	,	O
17	milk	O
18	intakes	O
19	were	O
20	reduced	O
21	by	O
22	up	O
23	to	O
24	30	O
25	%	O
26	on	O
27	the	O
28	1st	O
29	day	O
30	that	O
31	calves	O
32	were	O
33	fed	O
34	once	O
35	daily	O
36	instead	O
37	of	O
38	twice	O
39	daily	O
40	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	Non	O
2	-	O
3	complement	O
4	-	O
5	dependent	O
6	sperm	O
7	-	O
8	immobilizing	O
9	activity	O
10	was	O
11	also	O
12	detected	O
13	in	O
14	the	O
15	cervical	O
16	mucus	O
17	of	O
18	several	O
19	patients	O
20	.	O

1	Furthermore	O
2	,	O
3	the	O
4	insertion	O
5	of	O
6	the	O
7	ColE1	B
8	cer	I
9	site	I
10	into	O
11	the	O
12	RK2	O
13	plasmid	O
14	deleted	O
15	for	O
16	the	O
17	par	O
18	region	O
19	failed	O
20	to	O
21	stabilize	O
22	the	O
23	plasmid	O
24	in	O
25	the	O
26	MC1061K	O
27	strain	O
28	,	O
29	indicating	O
30	that	O
31	the	O
32	multimer	O
33	resolution	O
34	activity	O
35	encoded	O
36	by	O
37	parCBA	B
38	is	O
39	not	O
40	by	O
41	itself	O
42	responsible	O
43	for	O
44	the	O
45	stabilization	O
46	activity	O
47	observed	O
48	for	O
49	this	O
50	operon	O
51	.	O

1	Occupational	O
2	asthma	O
3	and	O
4	rhinoconjunctivitis	O
5	from	O
6	inhalation	O
7	of	O
8	crystalline	O
9	bovine	B
10	serum	I
11	albumin	I
12	powder	O
13	.	O

1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	In	O
2	the	O
3	control	O
4	preparation	O
5	before	O
6	weight	O
7	was	O
8	allowed	O
9	to	O
10	increase	O
11	,	O
12	isogravimetric	O
13	capillary	O
14	pressure	O
15	(	O
16	Pci	O
17	)	O
18	averaged	O
19	8	O
20	mmHg	O
21	lower	O
22	than	O
23	colloid	O
24	osmotic	O
25	pressure	O
26	of	O
27	the	O
28	plasma	O
29	(	O
30	IIp	O
31	).	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	B
11	TrxR2	I
12	gene	I
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O

1	Prevention	O
2	of	O
3	transfusion	O
4	reactions	O
5	by	O
6	the	O
7	use	O
8	of	O
9	saline	O
10	washed	O
11	red	O
12	blood	O
13	cells	O
14	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Proteinuria	O
2	in	O
3	a	O
4	young	O
5	man	O
6	.	O

1	Protein	B
2	kinase	I
3	A	I
4	-	I
5	Ialpha	I
6	subunit	O
7	-	O
8	directed	O
9	antisense	O
10	inhibition	O
11	of	O
12	ovarian	O
13	cancer	O
14	cell	O
15	growth	O
16	:	O
17	crosstalk	O
18	with	O
19	tyrosine	B
20	kinase	I
21	signaling	O
22	pathway	O
23	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O

1	These	O
2	genetic	O
3	alterations	O
4	do	O
5	not	O
6	affect	O
7	synthesis	O
8	of	O
9	the	O
10	major	O
11	c	B
12	-	I
13	myc	I
14	protein	I
15	,	O
16	p64	B
17	,	O
18	which	O
19	is	O
20	initiated	O
21	from	O
22	the	O
23	first	O
24	AUG	O
25	codon	O
26	in	O
27	exon	O
28	2	O
29	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	A	O
2	rabbit	O
3	antiserum	O
4	was	O
5	raised	O
6	against	O
7	a	O
8	synthetic	O
9	peptide	O
10	corresponding	O
11	to	O
12	a	O
13	hydrophilic	O
14	portion	O
15	of	O
16	the	O
17	translated	O
18	murine	O
19	cDNA	O
20	sequence	O
21	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	MBF	O
6	on	O
7	incisors	O
8	and	O
9	its	O
10	direction	O
11	in	O
12	three	O
13	dimensions	O
14	for	O
15	different	O
16	jaw	O
17	openings	O
18	in	O
19	ten	O
20	subjects	O
21	.	O

1	The	O
2	gene	B
3	ccpA	I
4	encoding	O
5	the	O
6	catabolite	B
7	control	I
8	protein	I
9	CcpA	I
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O

1	It	O
2	is	O
3	impossible	O
4	to	O
5	define	O
6	only	O
7	one	O
8	clinical	O
9	outline	O
10	because	O
11	both	O
12	symptomatic	O
13	and	O
14	asymptomatic	O
15	infected	O
16	NB	O
17	may	O
18	be	O
19	found	O
20	with	O
21	gestational	O
22	age	O
23	at	O
24	term	O
25	and	O
26	pre	O
27	-	O
28	term	O
29	and	O
30	when	O
31	born	O
32	with	O
33	a	O
34	weight	O
35	above	O
36	or	O
37	below	O
38	2000	O
39	g	O
40	.	O

1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O

1	Co	O
2	-	O
3	existence	O
4	of	O
5	these	O
6	regulatory	O
7	elements	O
8	with	O
9	other	O
10	elements	O
11	,	O
12	such	O
13	as	O
14	the	O
15	AP	B
16	-	I
17	2	I
18	element	I
19	or	O
20	CCAAT	O
21	box	O
22	,	O
23	was	O
24	also	O
25	found	O
26	.	O

1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	Identification	O
2	of	O
3	a	O
4	new	O
5	gene	O
6	in	O
7	the	O
8	streptococcal	O
9	plasmid	O
10	pLS1	O
11	:	O
12	the	O
13	rnaI	B
14	gene	I
15	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	a	O
6	comparison	O
7	between	O
8	the	O
9	number	O
10	and	O
11	shape	O
12	of	O
13	corneal	O
14	endothelial	O
15	cells	O
16	has	O
17	been	O
18	performed	O
19	in	O
20	25	O
21	patients	O
22	before	O
23	and	O
24	6	O
25	months	O
26	after	O
27	PRK	O
28	.	O

1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	B
10	of	I
11	Hh	I
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	Choice	O
2	of	O
3	vessel	O
4	.	O

1	Recently	O
2	,	O
3	an	O
4	electrical	O
5	-	O
6	mechanical	O
7	analog	O
8	model	O
9	of	O
10	heat	O
11	flow	O
12	within	O
13	the	O
14	brain	O
15	has	O
16	been	O
17	developed	O
18	from	O
19	which	O
20	an	O
21	expression	O
22	for	O
23	CBF	O
24	has	O
25	been	O
26	derived	O
27	:	O
28	CBF	O
29	=	O
30	Cb	O
31	/(	O
32	tau	O
33	rho	O
34	c	O
35	)	O
36	where	O
37	tau	O
38	is	O
39	the	O
40	thermal	O
41	decay	O
42	constant	O
43	,	O
44	rho	O
45	is	O
46	the	O
47	density	O
48	of	O
49	blood	O
50	,	O
51	and	O
52	c	O
53	is	O
54	its	O
55	specific	O
56	heat	O
57	.	O

1	1	O
2	,	O
3	among	O
4	which	O
5	nine	O
6	have	O
7	been	O
8	cloned	O
9	and	O
10	two	O
11	(	O
12	potentially	O
13	functional	O
14	)	O
15	sequenced	O
16	.	O

1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O

1	Maximum	O
2	number	O
3	of	O
4	strains	O
5	(	O
6	39	O
7	.	O
8	1	O
9	%)	O
10	were	O
11	resistant	O
12	in	O
13	S	O
14	.	O
15	bareilly	O
16	serotype	O
17	,	O
18	followed	O
19	by	O
20	S	O
21	.	O
22	typhimurium	O
23	(	O
24	21	O
25	.	O
26	7	O
27	%)	O
28	and	O
29	least	O
30	in	O
31	S	O
32	.	O
33	typhi	O
34	(	O
35	17	O
36	.	O
37	4	O
38	%).	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	tissue	O
6	emulsion	O
7	,	O
8	vitamin	O
9	A	O
10	and	O
11	nonspecific	O
12	gamma	B
13	-	I
14	globulin	I
15	on	O
16	the	O
17	blood	O
18	clearance	O
19	in	O
20	rabbits	O

1	Plasma	O
2	and	O
3	erthrocyte	O
4	lipid	O
5	profile	O
6	and	O
7	lipoprotein	B
8	lipase	I
9	activity	O
10	in	O
11	postheparin	O
12	plasma	O
13	on	O
14	vasectomized	O
15	rabbits	O
16	were	O
17	studied	O
18	and	O
19	also	O
20	the	O
21	incidence	O
22	of	O
23	atherosclerosis	O
24	in	O
25	different	O
26	arterial	O
27	beds	O
28	.	O

1	Sequence	O
2	comparison	O
3	between	O
4	the	O
5	translated	O
6	ORF	O
7	and	O
8	a	O
9	protein	O
10	database	O
11	reveal	O
12	between	O
13	26	O
14	.	O
15	5	O
16	and	O
17	23	O
18	.	O
19	4	O
20	%	O
21	aa	O
22	sequence	O
23	homology	O
24	to	O
25	bacterial	B
26	transmembrane	I
27	(	I
28	TM	I
29	)	I
30	proteins	I
31	including	O
32	those	O
33	mediating	O
34	chloramphenicol	O
35	(	O
36	Cm	O
37	)	O
38	and	O
39	tetracycline	O
40	(	O
41	Tc	O
42	)	O
43	resistance	O
44	and	O
45	an	O
46	arabinose	O
47	-	O
48	proton	O
49	symport	O
50	protein	O
51	.	O

1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O

1	Hepatitis	B
2	B	I
3	surface	I
4	antigen	I
5	was	O
6	detected	O
7	in	O
8	2	O
9	patients	O
10	,	O
11	with	O
12	negative	O
13	hepatitis	B
14	C	I
15	virus	I
16	antibody	I
17	.	O

1	The	O
2	most	O
3	common	O
4	grade	O
5	3	O
6	toxicity	O
7	was	O
8	neutropenia	O
9	,	O
10	thrombocytopenia	O
11	,	O
12	and	O
13	parasthesias	O
14	(	O
15	observed	O
16	in	O
17	<	O
18	10	O
19	%	O
20	of	O
21	cycles	O
22	).	O

1	Expression	O
2	of	O
3	the	O
4	CYP11A1	B
5	gene	I
6	is	O
7	increased	O
8	by	O
9	hormones	O
10	,	O
11	such	O
12	as	O
13	adrenocorticotropin	B
14	and	O
15	luteinizing	B
16	hormone	I
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	number	O
24	of	O
25	growth	O
26	factors	O
27	,	O
28	suggesting	O
29	that	O
30	its	O
31	promoter	O
32	may	O
33	contain	O
34	regulatory	O
35	elements	O
36	that	O
37	respond	O
38	to	O
39	multiple	O
40	signal	O
41	transduction	O
42	pathways	O
43	.	O

1	Regulation	O
2	of	O
3	irgA	B
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	O
12	the	O
13	transcriptional	O
14	level	O
15	,	O
16	and	O
17	there	O
18	is	O
19	an	O
20	interrupted	O
21	dyad	O
22	symmetric	O
23	sequence	O
24	in	O
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	O
34	Fur	B
35	binding	I
36	sites	I
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	B
39	-	I
40	complex	I
41	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	indoramin	O
6	may	O
7	have	O
8	Class	O
9	III	O
10	antiarrhythmic	O
11	activity	O
12	.	O

1	Although	O
2	IL	B
3	-	I
4	2	I
5	and	O
6	IFN	B
7	-	I
8	alpha	I
9	activated	O
10	STAT1	B
11	alpha	I
12	and	O
13	STAT5	B
14	,	O
15	IL	B
16	-	I
17	2	I
18	predominantly	O
19	activated	O
20	STAT5	B
21	,	O
22	while	O
23	IFN	B
24	-	I
25	alpha	I
26	predominantly	O
27	activated	O
28	STAT1	B
29	alpha	I
30	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	B
10	molecule	O
11	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	B
6	inhibits	O
7	tyrosine	B
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	O

1	Glomerular	O
2	lesions	O
3	in	O
4	renal	O
5	allografts	O
6	.	O

1	Mechanisms	O
2	of	O
3	visible	O
4	-	O
5	light	O
6	emission	O
7	from	O
8	electro	O
9	-	O
10	oxidized	O
11	porous	O
12	silicon	O
13	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	the	O
6	first	O
7	three	O
8	components	O
9	were	O
10	not	O
11	significantly	O
12	different	O
13	in	O
14	ARVD	O
15	patients	O
16	and	O
17	control	O
18	subjects	O
19	.	O

1	Caries	O
2	and	O
3	parodontitis	O
4	have	O
5	been	O
6	one	O
7	of	O
8	the	O
9	most	O
10	spread	O
11	diseases	O
12	of	O
13	mankind	O
14	.	O

1	Selective	O
2	effect	O
3	of	O
4	pulmonary	O
5	oedema	O
6	on	O
7	prostaglandin	O
8	E2	O
9	pharmacokinetics	O
10	in	O
11	rat	O
12	lung	O
13	.	O

1	Differentiation	O
2	was	O
3	not	O
4	observed	O
5	after	O
6	cellular	O
7	expression	O
8	of	O
9	GTPase	B
10	-	O
11	deficient	O
12	forms	O
13	of	O
14	alpha	B
15	i2	I
16	or	O
17	alpha	B
18	0	I
19	,	O
20	indicating	O
21	selectivity	O
22	for	O
23	the	O
24	Gq	B
25	family	I
26	of	O
27	G	B
28	proteins	I
29	.	O

1	Percent	O
2	identities	O
3	of	O
4	the	O
5	mouse	B
6	PP2	I
7	to	O
8	mouse	B
9	Y1	I
10	,	O
11	mouse	O
12	Y4	B
13	/	O
14	PP1	B
15	and	O
16	human	B
17	Y2	I
18	receptors	I
19	are	O
20	53	O
21	,	O
22	42	O
23	,	O
24	and	O
25	31	O
26	,	O
27	respectively	O
28	.	O

1	Intracavitary	O
2	irradiation	O
3	was	O
4	carried	O
5	out	O
6	with	O
7	a	O
8	microSelectron	O
9	HDR	O
10	afterloading	O
11	device	O
12	and	O
13	usually	O
14	22	O
15	.	O
16	5	O
17	Gy	O
18	was	O
19	given	O
20	in	O
21	three	O
22	fractions	O
23	repeated	O
24	weekly	O
25	.	O

1	The	O
2	core	B
3	enzyme	I
4	is	O
5	homologous	O
6	to	O
7	those	O
8	of	O
9	bacteriophages	O
10	T3	O
11	,	O
12	T7	O
13	and	O
14	SP6	O
15	whereas	O
16	the	O
17	specificity	O
18	factor	O
19	shows	O
20	similarities	O
21	with	O
22	bacterial	B
23	sigma	I
24	factors	I
25	.	O

1	Thus	O
2	,	O
3	SOX8	B
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O

1	In	O
2	one	O
3	acromegalic	O
4	patient	O
5	visual	O
6	improvement	O
7	was	O
8	obtained	O
9	while	O
10	the	O
11	abnormal	O
12	GH	B
13	secretion	O
14	remained	O
15	unaltered	O
16	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	B
5	gene	I
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	O
16	-	O
17	terminal	O
18	GAL4	B
19	-	O
20	like	O
21	Zn	O
22	(	O
23	II	O
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	O
29	zinc	O
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	O
40	like	O
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	O
48	-	O
49	terminal	O
50	acidic	O
51	alpha	O
52	-	O
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	B
5	homologue	I
6	(	O
7	BarX	B
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	HIV	O
13	-	O
14	1	O
15	transcript	O
16	.	O

1	Neonatal	O
2	lupus	O
3	erythematosus	O
4	is	O
5	most	O
6	often	O
7	associated	O
8	with	O
9	autoantibodies	O
10	against	O
11	Ro	B
12	and	O
13	La	B
14	antigens	O
15	.	O

1	Thus	O
2	,	O
3	Fis	B
4	acts	O
5	as	O
6	an	O
7	accessory	O
8	transcriptional	O
9	activator	O
10	at	O
11	the	O
12	mar	B
13	promoter	I
14	.	O

1	METHODS	O
2	:	O
3	TBN	O
4	measurements	O
5	were	O
6	performed	O
7	in	O
8	31	O
9	female	O
10	outpatients	O
11	with	O
12	breast	O
13	carcinoma	O
14	who	O
15	were	O
16	undergoing	O
17	standard	O
18	cyclophosphamide	O
19	,	O
20	methotrexate	O
21	,	O
22	and	O
23	5	O
24	-	O
25	fluorouracil	O
26	(	O
27	CMF	O
28	)-	O
29	based	O
30	chemotherapy	O
31	(	O
32	median	O
33	age	O
34	,	O
35	48	O
36	years	O
37	;	O
38	range	O
39	,	O
40	26	O
41	-	O
42	77	O
43	years	O
44	).	O

1	The	O
2	Dax	B
3	-	I
4	1	I
5	gene	I
6	encodes	O
7	a	O
8	protein	O
9	that	O
10	is	O
11	structurally	O
12	related	O
13	to	O
14	members	O
15	of	O
16	the	O
17	orphan	B
18	nuclear	I
19	receptor	I
20	superfamily	I
21	.	O

1	We	O
2	found	O
3	the	O
4	following	O
5	:	O
6	Specific	O
7	mutations	O
8	affected	O
9	the	O
10	precise	O
11	carbohydrate	O
12	structure	O
13	and	O
14	folding	O
15	of	O
16	the	O
17	HA	B
18	trimer	I
19	.	O

1	Although	O
2	human	O
3	infections	O
4	with	O
5	bacteraemia	O
6	due	O
7	to	O
8	Pasteurella	O
9	multocida	O
10	are	O
11	not	O
12	uncommon	O
13	,	O
14	endocarditis	O
15	associated	O
16	with	O
17	P	O
18	.	O
19	haemolytica	O
20	is	O
21	rare	O
22	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	O
7	,	O
8	birds	O
9	were	O
10	given	O
11	a	O
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	O
21	9	O
22	)	O
23	or	O
24	a	O
25	kappa	O
26	-	O
27	opioid	O
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	The	O
2	IE13	O
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	I
31	gene	I
32	.	O

1	An	O
2	anchored	O
3	AFLP	O
4	-	O
5	and	O
6	retrotransposon	O
7	-	O
8	based	O
9	map	O
10	of	O
11	diploid	O
12	Avena	O
13	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequences	O
6	of	O
7	each	O
8	of	O
9	the	O
10	W3A1	B
11	ETF	I
12	subunits	I
13	exhibit	O
14	only	O
15	approximately	O
16	30	O
17	%	O
18	identity	O
19	with	O
20	the	O
21	corresponding	O
22	subunits	O
23	of	O
24	the	O
25	ETF	B
26	from	O
27	human	O
28	,	O
29	rat	O
30	,	O
31	and	O
32	Paracoccus	O
33	denitrificans	O
34	,	O
35	which	O
36	as	O
37	a	O
38	group	O
39	are	O
40	greater	O
41	than	O
42	50	O
43	%	O
44	identical	O
45	.	O

1	Yeast	O
2	mutants	O
3	assigned	O
4	to	O
5	the	O
6	pet	B
7	complementation	O
8	group	O
9	G104	O
10	were	O
11	found	O
12	to	O
13	lack	O
14	alpha	B
15	-	I
16	ketoglutarate	I
17	dehydrogenase	I
18	activity	O
19	as	O
20	a	O
21	result	O
22	of	O
23	mutations	O
24	in	O
25	the	O
26	dihydrolipoyl	B
27	transsuccinylase	I
28	(	O
29	KE2	B
30	)	O
31	component	O
32	of	O
33	the	O
34	complex	O
35	.	O

1	In	O
2	summary	O
3	,	O
4	at	O
5	equianesthetic	O
6	concentrations	O
7	,	O
8	desflurane	O
9	and	O
10	isoflurane	O
11	produced	O
12	similar	O
13	hemodynamic	O
14	effects	O
15	;	O
16	however	O
17	,	O
18	in	O
19	the	O
20	absence	O
21	of	O
22	drugs	O
23	that	O
24	inhibit	O
25	autonomic	O
26	reflexes	O
27	,	O
28	desflurane	O
29	had	O
30	less	O
31	negative	O
32	inotropic	O
33	activity	O
34	and	O
35	produced	O
36	less	O
37	decrease	O
38	in	O
39	arterial	O
40	pressure	O
41	.	O

1	We	O
2	studied	O
3	the	O
4	GR	B
5	in	O
6	DMS	O
7	-	O
8	79	O
9	cells	O
10	derived	O
11	from	O
12	a	O
13	human	O
14	ACTH	B
15	-	O
16	secreting	O
17	small	O
18	cell	O
19	lung	O
20	cancer	O
21	.	O

1	V	O
2	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	B
6	PHO8	I
7	promoter	I
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	B
14	promoter	I
15	.	O

1	Evaluation	O
2	of	O
3	thyroid	O
4	function	O
5	.	O

1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O

1	IL	B
2	-	I
3	1beta	I
4	(	O
5	10	O
6	ng	O
7	/	O
8	ml	O
9	)	O
10	drastically	O
11	increased	O
12	both	O
13	PDGFalphaR	B
14	and	O
15	CCAAT	B
16	/	I
17	enhancer	I
18	-	I
19	binding	I
20	protein	I
21	delta	I
22	(	O
23	C	B
24	/	I
25	EBPdelta	I
26	)	O
27	mRNA	O
28	levels	O
29	in	O
30	a	O
31	time	O
32	dependent	O
33	manner	O
34	.	O

1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	The	O
2	ZNF274	B
3	gene	I
4	is	O
5	mapped	O
6	distal	O
7	to	O
8	marker	O
9	RP	O
10	S28	O
11	1	O
12	in	O
13	the	O
14	human	O
15	chromosome	O
16	19qter	O
17	region	O
18	,	O
19	by	O
20	RH	O
21	mapping	O
22	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	Interestingly	O
2	,	O
3	the	O
4	activated	O
5	PDGF	B
6	beta	I
7	-	I
8	receptor	I
9	was	O
10	found	O
11	not	O
12	to	O
13	bind	O
14	Crk	B
15	proteins	I
16	.	O

1	III	O
2	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	telomeres	O
7	of	O
8	the	O
9	two	O
10	nuclei	O
11	have	O
12	different	O
13	functions	O
14	.	O

1	Third	O
2	-	O
3	and	O
4	later	O
5	-	O
6	parity	O
7	cows	O
8	were	O
9	randomly	O
10	assigned	O
11	after	O
12	each	O
13	parturition	O
14	to	O
15	Charolais	O
16	and	O
17	Red	O
18	Poll	O
19	bulls	O
20	in	O
21	multiple	O
22	-	O
23	sire	O
24	pastures	O
25	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	roles	O
8	that	O
9	CCK	B
10	and	O
11	trypsin	B
12	inhibitors	O
13	are	O
14	believed	O
15	to	O
16	play	O
17	in	O
18	the	O
19	negative	O
20	feedback	O
21	control	O
22	of	O
23	pancreatic	O
24	exocrine	O
25	function	O
26	.	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	B
6	acetyltransferase	I
7	activity	O
8	of	O
9	p300	B
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	B
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	The	O
2	German	O
3	Society	O
4	of	O
5	Pediatric	O
6	Oncology	O
7	in	O
8	1981	O
9	initiated	O
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O

1	In	O
2	Group	O
3	IV	O
4	dogs	O
5	that	O
6	received	O
7	alpha	B
8	-	I
9	MSH	I
10	only	O
11	during	O
12	reperfusion	O
13	,	O
14	BAEPs	O
15	were	O
16	increased	O
17	approximately	O
18	10	O
19	to	O
20	14	O
21	%	O
22	more	O
23	than	O
24	in	O
25	Group	O
26	II	O
27	during	O
28	the	O
29	late	O
30	reperfusion	O
31	period	O
32	.	O

1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	B
7	transporters	I
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	also	O
6	observed	O
7	between	O
8	PbB	O
9	and	O
10	ALAD	B
11	activity	O
12	of	O
13	the	O
14	stearate	O
15	workers	O
16	.	O

1	Measurements	O
2	included	O
3	bone	O
4	mineral	O
5	density	O
6	of	O
7	the	O
8	lumbar	O
9	spine	O
10	and	O
11	proximal	O
12	femur	O
13	(	O
14	by	O
15	dual	O
16	-	O
17	energy	O
18	X	O
19	-	O
20	ray	O
21	absorptiometry	O
22	)	O
23	and	O
24	biochemical	O
25	markers	O
26	of	O
27	bone	O
28	remodeling	O
29	(	O
30	serum	O
31	bone	O
32	-	O
33	specific	O
34	alkaline	B
35	phosphatase	I
36	by	O
37	immunoassay	O
38	and	O
39	urine	O
40	deoxypyridinoline	O
41	by	O
42	high	O
43	-	O
44	pressure	O
45	liquid	O
46	chromatography	O
47	).	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Modulation	O
2	of	O
3	25	B
4	-	I
5	hydroxyvitamin	I
6	D3	I
7	-	I
8	24	I
9	-	I
10	hydroxylase	I
11	by	O
12	aminophylline	O
13	:	O
14	a	O
15	cytochrome	B
16	P	I
17	-	I
18	450	I
19	monooxygenase	I
20	system	O
21	.	O

1	Present	O
2	results	O
3	reveal	O
4	a	O
5	frequency	O
6	-	O
7	dependent	O
8	inhibition	O
9	of	O
10	ganglionic	O
11	transmission	O
12	by	O
13	diltiazem	O
14	,	O
15	and	O
16	suggest	O
17	that	O
18	diltiazem	O
19	may	O
20	depress	O
21	excessive	O
22	sympathetic	O
23	activity	O
24	without	O
25	affecting	O
26	normal	O
27	ganglionic	O
28	transmission	O
29	.	O

1	Conversely	O
2	,	O
3	the	O
4	central	O
5	regions	O
6	are	O
7	highly	O
8	variable	O
9	.	O

1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	CX	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	tubulin	B
14	mRNA	I
15	in	O
16	vivo	O
17	is	O
18	not	O
19	simply	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	Analysis	O
2	of	O
3	mig	B
4	/	O
5	CAT	B
6	chimeric	O
7	constructs	O
8	transiently	O
9	transfected	O
10	into	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	mouse	O
17	monocytic	O
18	cell	O
19	line	O
20	revealed	O
21	a	O
22	unique	O
23	IFN	B
24	-	I
25	gamma	I
26	-	I
27	responsive	I
28	element	I
29	(	O
30	gamma	B
31	RE	I
32	-	I
33	1	I
34	).	O

1	Angiography	O
2	was	O
3	performed	O
4	following	O
5	the	O
6	rCBF	O
7	study	O
8	and	O
9	the	O
10	degree	O
11	of	O
12	vasospasm	O
13	was	O
14	measured	O
15	on	O
16	the	O
17	angiograms	O
18	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	novel	O
9	beta1	B
10	,	I
11	6	I
12	-	I
13	N	I
14	-	I
15	acetylglucosaminyltransferase	I
16	forming	O
17	core	O
18	2	O
19	and	O
20	core	O
21	4	O
22	.	O

1	1	O
2	.	O

1	Expression	O
2	of	O
3	thymidine	B
4	kinase	I
5	gene	I
6	in	O
7	normal	O
8	human	O
9	diploid	O
10	cells	O
11	is	O
12	both	O
13	cell	O
14	cycle	O
15	-	O
16	and	O
17	age	O
18	-	O
19	dependent	O
20	and	O
21	appears	O
22	to	O
23	be	O
24	transcriptionally	O
25	regulated	O
26	.	O

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	B
25	promoter	I
26	.	O

1	No	O
2	significant	O
3	differences	O
4	were	O
5	identified	O
6	between	O
7	groups	O
8	for	O
9	pH	O
10	,	O
11	PaCO2	O
12	,	O
13	intracranial	O
14	pressure	O
15	,	O
16	heart	O
17	rate	O
18	,	O
19	brain	O
20	temperature	O
21	,	O
22	or	O
23	glucose	O
24	levels	O
25	.	O

1	Examination	O
2	of	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	Punta	B
8	Toro	I
9	M	I
10	gene	I
11	product	I
12	reveals	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	hydrophobic	O
18	sequences	O
19	including	O
20	a	O
21	19	O
22	-	O
23	amino	O
24	acid	O
25	,	O
26	carboxy	O
27	-	O
28	proximal	O
29	,	O
30	hydrophobic	O
31	region	O
32	(	O
33	G2	O
34	).	O

1	Deleting	O
2	SNF1	B
3	repressed	O
4	meiosis	O
5	at	O
6	the	O
7	same	O
8	three	O
9	steps	O
10	that	O
11	were	O
12	inhibited	O
13	by	O
14	glucose	O
15	,	O
16	suggesting	O
17	that	O
18	glucose	O
19	blocks	O
20	meiosis	O
21	by	O
22	inhibiting	O
23	Snf1	B
24	.	O

1	Inhibition	O
2	of	O
3	the	O
4	apolipoprotein	B
5	B	I
6	mRNA	I
7	editing	O
8	enzyme	O
9	-	O
10	complex	O
11	by	O
12	hnRNP	B
13	C1	I
14	protein	I
15	and	O
16	40S	B
17	hnRNP	I
18	complexes	I
19	.	O

1	Removal	O
2	of	O
3	the	O
4	carboxyl	O
5	region	O
6	severely	O
7	reduced	O
8	transcriptional	O
9	activation	O
10	.	O

1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	B
5	-	I
6	1	I
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	B
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	B
26	-	I
27	1	I
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	B
36	-	I
37	selectin	I
38	.	O

1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O

1	Flavonoids	O
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	B
12	dimers	I
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	On	O
2	a	O
3	separate	O
4	occasion	O
5	the	O
6	T1	O
7	weighted	O
8	and	O
9	T2	O
10	weighted	O
11	sagittal	O
12	and	O
13	T2	O
14	weighted	O
15	axial	O
16	sequences	O
17	were	O
18	reported	O
19	blind	O
20	in	O
21	relation	O
22	to	O
23	the	O
24	initial	O
25	assessment	O
26	.	O

1	In	O
2	viral	O
3	infections	O
4	,	O
5	G	B
6	-	I
7	CSF	I
8	was	O
9	correlated	O
10	with	O
11	mononuclear	O
12	cells	O
13	(	O
14	rs	O
15	=	O
16	0	O
17	.	O
18	41	O
19	,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	05	O
25	),	O
26	white	O
27	blood	O
28	cell	O
29	counts	O
30	(	O
31	rs	O
32	=	O
33	0	O
34	.	O
35	56	O
36	,	O
37	P	O
38	<	O
39	0	O
40	.	O
41	01	O
42	),	O
43	neutrophils	O
44	(	O
45	rs	O
46	=	O
47	0	O
48	.	O
49	41	O
50	,	O
51	P	O
52	<	O
53	0	O
54	.	O
55	05	O
56	)	O
57	and	O
58	CRP	B
59	(	O
60	rs	O
61	=	O
62	0	O
63	.	O
64	47	O
65	,	O
66	P	O
67	<	O
68	0	O
69	.	O
70	05	O
71	).	O

1	The	O
2	ratio	O
3	of	O
4	the	O
5	activity	O
6	of	O
7	arogenate	B
8	dehydrogenase	I
9	to	O
10	that	O
11	of	O
12	prephenate	B
13	dehydrogenase	I
14	(	O
15	approximately	O
16	3	O
17	:	O
18	1	O
19	)	O
20	remained	O
21	constant	O
22	throughout	O
23	purification	O
24	,	O
25	and	O
26	the	O
27	two	O
28	activities	O
29	were	O
30	therefore	O
31	inseparable	O
32	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O

1	Estrus	O
2	and	O
3	copulative	O
4	abilities	O
5	of	O
6	androgen	O
7	-	O
8	sterilized	O
9	rats	O

1	Xenopus	B
2	Ran	I
3	-	I
4	binding	I
5	protein	I
6	1	I
7	:	O
8	molecular	O
9	interactions	O
10	and	O
11	effects	O
12	on	O
13	nuclear	O
14	assembly	O
15	in	O
16	Xenopus	O
17	egg	O
18	extracts	O
19	.	O

1	Sci	O
2	.	O

1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	B
8	-	I
9	1	I
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	B
21	EFP	I
22	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	Therefore	O
2	,	O
3	high	O
4	set	O
5	-	O
6	up	O
7	accuracy	O
8	and	O
9	reproducibility	O
10	are	O
11	mandatory	O
12	.	O

1	We	O
2	speculate	O
3	that	O
4	the	O
5	human	O
6	papillomavirus	O
7	late	O
8	mRNAs	O
9	,	O
10	produced	O
11	from	O
12	several	O
13	hundred	O
14	copies	O
15	of	O
16	the	O
17	virus	O
18	genome	O
19	present	O
20	in	O
21	infected	O
22	cells	O
23	,	O
24	compete	O
25	with	O
26	the	O
27	c	B
28	-	I
29	fos	I
30	mRNAs	I
31	for	O
32	destabilizing	O
33	cellular	O
34	factors	O
35	and	O
36	that	O
37	this	O
38	may	O
39	lead	O
40	to	O
41	elevated	O
42	Fos	B
43	protein	I
44	levels	O
45	in	O
46	human	O
47	papillomavirus	O
48	infected	O
49	cells	O
50	.	O

1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	O
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	O
40	replicon	O
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	O
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O

1	This	O
2	compares	O
3	favorably	O
4	to	O
5	results	O
6	of	O
7	similarly	O
8	sized	O
9	melanomas	O
10	treated	O
11	by	O
12	enucleation	O
13	.	O

1	BACKGROUND	O
2	:	O
3	It	O
4	is	O
5	generally	O
6	accepted	O
7	that	O
8	smoking	O
9	increases	O
10	blood	O
11	pressure	O
12	and	O
13	inhibits	O
14	muscle	O
15	sympathetic	O
16	nerve	O
17	activity	O
18	(	O
19	SNA	O
20	).	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	sequence	O
6	identity	O
7	(	O
8	96	O
9	%)	O
10	between	O
11	hydrolase	B
12	B	I
13	and	I
14	C	I
15	,	O
16	particularly	O
17	in	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	,	O
24	suggests	O
25	that	O
26	the	O
27	genes	O
28	encoding	O
29	these	O
30	two	O
31	carboxylesterases	B
32	evolved	O
33	by	O
34	duplication	O
35	and	O
36	divergence	O
37	of	O
38	a	O
39	common	O
40	ancestral	O
41	gene	O
42	.	O

1	When	O
2	expressed	O
3	per	O
4	kilogram	O
5	body	O
6	weight	O
7	,	O
8	mean	O
9	GIT	O
10	increased	O
11	in	O
12	the	O
13	dF	O
14	group	O
15	from	O
16	0	O
17	.	O
18	14	O
19	%	O
20	to	O
21	0	O
22	.	O
23	16	O
24	%	O
25	above	O
26	RMR	O
27	,	O
28	with	O
29	a	O
30	significant	O
31	decrease	O
32	from	O
33	0	O
34	.	O
35	15	O
36	%	O
37	to	O
38	0	O
39	.	O
40	13	O
41	%	O
42	in	O
43	the	O
44	P	O
45	group	O
46	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	IS2404	B
6	and	O
7	IS2606	B
8	:	O
9	two	O
10	distinct	O
11	repeated	O
12	sequences	O
13	for	O
14	detection	O
15	of	O
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	Identification	O
2	of	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	sequence	O
8	in	O
9	the	O
10	CD2	B
11	cytoplasmic	I
12	domain	I
13	critical	O
14	for	O
15	regulation	O
16	of	O
17	integrin	B
18	-	O
19	mediated	O
20	adhesion	O
21	and	O
22	activation	O
23	of	O
24	phosphoinositide	B
25	3	I
26	-	I
27	kinase	I
28	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	Such	O
2	an	O
3	interaction	O
4	could	O
5	be	O
6	detected	O
7	using	O
8	a	O
9	GST	B
10	-	O
11	POU	B
12	fusion	O
13	protein	O
14	bound	O
15	to	O
16	glutathione	O
17	-	O
18	agarose	O
19	beads	O
20	.	O

1	Furthermore	O
2	,	O
3	a	O
4	minor	O
5	start	O
6	site	O
7	was	O
8	localized	O
9	179	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	major	O
15	site	O
16	using	O
17	reverse	B
18	transcriptase	I
19	-	O
20	polymerase	O
21	chain	O
22	reaction	O
23	with	O
24	various	O
25	P1	O
26	primers	O
27	(	O
28	primer	O
29	walking	O
30	),	O
31	primer	O
32	extension	O
33	,	O
34	and	O
35	cDNA	O
36	cloning	O
37	.	O

1	Large	O
2	and	O
3	small	O
4	medullary	O
5	lesions	O
6	inhibited	O
7	the	O
8	occurrence	O
9	of	O
10	target	O
11	fibres	O
12	in	O
13	the	O
14	tenotomized	O
15	muscles	O
16	,	O
17	the	O
18	smallest	O
19	one	O
20	being	O
21	neurolysis	O
22	of	O
23	the	O
24	dorsal	O
25	roots	O
26	.	O

1	This	O
2	open	O
3	reading	O
4	frame	O
5	was	O
6	confirmed	O
7	the	O
8	correct	O
9	one	O
10	by	O
11	direct	O
12	amino	O
13	-	O
14	terminal	O
15	sequence	O
16	analysis	O
17	of	O
18	the	O
19	overproduced	O
20	msgB	B
21	gene	I
22	product	I
23	.	O

1	Fifty	O
2	-	O
3	seven	O
4	patients	O
5	aged	O
6	<	O
7	55	O
8	years	O
9	with	O
10	acute	O
11	lymphoblastic	O
12	leukemia	O
13	(	O
14	ALL	O
15	)	O
16	in	O
17	second	O
18	or	O
19	third	O
20	bone	O
21	marrow	O
22	(	O
23	BM	O
24	)	O
25	relapse	O
26	or	O
27	refractory	O
28	to	O
29	first	O
30	-	O
31	line	O
32	therapy	O
33	were	O
34	enrolled	O
35	in	O
36	an	O
37	Italian	O
38	cooperative	O
39	study	O
40	.	O

1	Our	O
2	results	O
3	concluded	O
4	that	O
5	1	O
6	)	O
7	the	O
8	two	O
9	inhibin	B
10	/	O
11	activin	B
12	beta	O
13	B	O
14	-	O
15	subunit	O
16	mRNAs	O
17	were	O
18	transcribed	O
19	from	O
20	different	O
21	initiation	O
22	sites	O
23	;	O
24	2	O
25	)	O
26	both	O
27	promoters	O
28	may	O
29	be	O
30	controlled	O
31	by	O
32	up	O
33	-	O
34	stream	O
35	negative	O
36	regulatory	O
37	elements	O
38	;	O
39	and	O
40	3	O
41	)	O
42	neither	O
43	of	O
44	these	O
45	promoters	O
46	is	O
47	responsive	O
48	to	O
49	cAMP	O
50	and	O
51	/	O
52	or	O
53	phorbol	O
54	esters	O
55	under	O
56	the	O
57	conditions	O
58	employed	O
59	.	O

1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	O
20	activities	O
21	of	O
22	promoters	O
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O

1	The	O
2	serum	B
3	insulin	I
4	response	O
5	cannot	O
6	.	O

1	Radiosensitive	O
2	nature	O
3	of	O
4	paravascular	O
5	infiltrate	O
6	-	O
7	producing	O
8	potential	O
9	of	O
10	parental	O
11	spleen	O
12	cells	O
13	.	O

1	Relations	O
2	between	O
3	adrenergic	O
4	mechanisms	O
5	and	O
6	analgesic	O
7	effects	O

1	Substrates	O
2	for	O
3	p210	B
4	(	O
5	bcr	B
6	-	O
7	abl	B
8	)	O
9	are	O
10	likely	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	the	O
16	pathogenesis	O
17	of	O
18	CML	O
19	.	O

1	RESULTS	O
2	:	O
3	Statistically	O
4	significant	O
5	differences	O
6	were	O
7	obtained	O
8	between	O
9	group	O
10	I	O
11	and	O
12	II	O
13	concerning	O
14	the	O
15	number	O
16	of	O
17	patients	O
18	in	O
19	whom	O
20	induced	O
21	atrial	O
22	fibrillation	O
23	with	O
24	conduction	O
25	by	O
26	the	O
27	accessory	O
28	pathway	O
29	and	O
30	RR	O
31	<	O
32	or	O
33	=	O
34	250	O
35	msec	O
36	was	O
37	found	O
38	(	O
39	0	O
40	vs	O
41	6	O
42	,	O
43	p	O
44	=	O
45	0	O
46	.	O
47	0045	O
48	).	O

1	In	O
2	11	O
3	patients	O
4	with	O
5	Horton	O
6	'	O
7	s	O
8	headache	O
9	morphological	O
10	investigations	O
11	(	O
12	differential	O
13	white	O
14	blood	O
15	cell	O
16	count	O
17	),	O
18	cytoenzymatic	O
19	determinations	O
20	(	O
21	alkaline	B
22	and	I
23	acid	I
24	phosphatase	I
25	,	O
26	non	B
27	-	I
28	specific	I
29	esterase	I
30	)	O
31	and	O
32	cytoimmunological	O
33	tests	O
34	(	O
35	IgM	B
36	and	O
37	IgG	B
38	binding	O
39	)	O
40	were	O
41	carried	O
42	out	O
43	on	O
44	capillary	O
45	blood	O
46	neutrophils	O
47	obtained	O
48	from	O
49	the	O
50	area	O
51	of	O
52	pain	O
53	,	O
54	non	O
55	-	O
56	painful	O
57	area	O
58	of	O
59	the	O
60	skin	O
61	on	O
62	the	O
63	head	O
64	on	O
65	the	O
66	contralateral	O
67	side	O
68	,	O
69	and	O
70	from	O
71	the	O
72	finger	O
73	.	O

1	Progressive	O
2	100	O
3	-	O
4	mmHg	O
5	stepwise	O
6	decreases	O
7	in	O
8	superfusate	O
9	oxygen	O
10	partial	O
11	pressure	O
12	(	O
13	PO2	O
14	)	O
15	from	O
16	control	O
17	(	O
18	95	O
19	%	O
20	O2	O
21	aeration	O
22	,	O
23	PO2	O
24	,	O
25	620	O
26	-	O
27	650	O
28	mmHg	O
29	)	O
30	were	O
31	produced	O
32	,	O
33	and	O
34	subsequent	O
35	changes	O
36	in	O
37	isometric	O
38	active	O
39	and	O
40	resting	O
41	tension	O
42	were	O
43	measured	O
44	.	O

1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	B
6	-	O
7	dependent	O
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	B
13	ligase	I
14	(	O
15	E3	B
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	Diazepam	O
2	(	O
3	3	O
4	mg	O
5	/	O
6	kg	O
7	)	O
8	generalized	O
9	to	O
10	Ro	O
11	11	O
12	-	O
13	6896	O
14	whereas	O
15	the	O
16	structurally	O
17	related	O
18	Ro	O
19	5	O
20	-	O
21	4864	O
22	(	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	and	O
28	30	O
29	mg	O
30	/	O
31	kg	O
32	)	O
33	did	O
34	not	O
35	.	O

1	Biol	O
2	.	O

1	ECP	B
2	and	O
3	tryptase	B
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O

1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O

1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O

1	One	O
2	of	O
3	these	O
4	SEBPs	B
5	,	O
6	SEBP2	B
7	,	O
8	was	O
9	shown	O
10	to	O
11	be	O
12	the	O
13	product	O
14	of	O
15	the	O
16	homeotic	B
17	gene	I
18	fork	I
19	head	I
20	.	O

1	Selected	O
2	topics	O
3	in	O
4	laboratory	O
5	animal	O
6	medicine	O
7	.	O

1	Klebsiella	O
2	oxytoca	O
3	can	O
4	assimilate	O
5	nitrate	O
6	and	O
7	nitrite	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	nasFEDCBA	B
15	operon	I
16	.	O

1	Underestimations	O
2	by	O
3	as	O
4	much	O
5	as	O
6	35	O
7	%	O
8	may	O
9	occur	O
10	due	O
11	to	O
12	the	O
13	problems	O
14	in	O
15	the	O
16	existing	O
17	methodologies	O
18	.	O

1	The	O
2	workup	O
3	included	O
4	skin	O
5	tests	O
6	(	O
7	up	O
8	to	O
9	1	O
10	microgram	O
11	/	O
12	ml	O
13	,	O
14	Pharmacia	O
15	),	O
16	measurement	O
17	of	O
18	specific	O
19	serum	O
20	IgE	B
21	with	O
22	RAST	O
23	-	O
24	CAP	O
25	(	O
26	Pharmacia	O
27	),	O
28	and	O
29	CAST	O
30	with	O
31	three	O
32	concentrations	O
33	of	O
34	bee	O
35	(	O
36	Apis	O
37	mellifera	O
38	)	O
39	and	O
40	wasp	O
41	(	O
42	Vespula	O
43	spec	O
44	.)	O
45	venom	O
46	(	O
47	Aquagen	O
48	ALK	O
49	).	O

1	RT	O
2	-	O
3	PCR	O
4	was	O
5	performed	O
6	using	O
7	previously	O
8	reported	O
9	degenerate	O
10	oligonucleotide	O
11	primers	O
12	to	O
13	the	O
14	ligand	O
15	binding	O
16	domain	O
17	(	O
18	LBD	O
19	)	O
20	of	O
21	known	O
22	beta	B
23	integrin	I
24	subunits	I
25	and	O
26	Bge	B
27	cDNA	I
28	.	O

1	By	O
2	using	O
3	lambda	O
4	gt11	O
5	expression	O
6	cloning	O
7	with	O
8	oligonucleotides	O
9	corresponding	O
10	to	O
11	the	O
12	human	O
13	immunodeficiency	O
14	virus	O
15	1	O
16	TATA	O
17	element	O
18	,	O
19	we	O
20	report	O
21	the	O
22	identification	O
23	of	O
24	a	O
25	cellular	O
26	protein	O
27	with	O
28	a	O
29	calculated	O
30	molecular	O
31	mass	O
32	of	O
33	123	O
34	kDa	O
35	that	O
36	we	O
37	designate	O
38	TATA	B
39	element	I
40	modulatory	I
41	factor	I
42	(	O
43	TMF	B
44	).	O

1	The	O
2	proliferation	B
3	potential	I
4	protein	I
5	-	I
6	related	I
7	(	O
8	P2P	B
9	-	I
10	R	I
11	)	O
12	gene	O
13	with	O
14	domains	O
15	encoding	O
16	heterogeneous	O
17	nuclear	O
18	ribonucleoprotein	O
19	association	O
20	and	O
21	Rb1	B
22	binding	O
23	shows	O
24	repressed	O
25	expression	O
26	during	O
27	terminal	O
28	differentiation	O
29	.	O

1	Of	O
2	600	O
3	mediastinoscopies	O
4	carried	O
5	out	O
6	from	O
7	1966	O
8	to	O
9	1973	O
10	,	O
11	479	O
12	were	O
13	performed	O
14	to	O
15	assess	O
16	the	O
17	operability	O
18	of	O
19	a	O
20	pulmonary	O
21	carcinoma	O
22	.	O

1	Mo	O
2	+	O
3	SV	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	inoculated	O
9	animals	O
10	became	O
11	moribund	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	postinoculation	O
18	,	O
19	whereas	O
20	delta	O
21	Mo	O
22	+	O
23	SV	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	inoculated	O
29	animals	O
30	became	O
31	moribund	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	postinoculation	O
38	.	O

1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O

1	Furthermore	O
2	,	O
3	direct	O
4	association	O
5	with	O
6	D3	O
7	phosphatidylinositides	O
8	seems	O
9	to	O
10	be	O
11	essential	O
12	for	O
13	activation	O
14	of	O
15	PKB	B
16	/	O
17	Akt	B
18	.	O

1	These	O
2	observed	O
3	drug	O
4	interactions	O
5	,	O
6	plus	O
7	the	O
8	known	O
9	effect	O
10	of	O
11	probenecid	O
12	to	O
13	block	O
14	secretion	O
15	of	O
16	PZA	O
17	,	O
18	have	O
19	to	O
20	be	O
21	considered	O
22	in	O
23	evaluating	O
24	the	O
25	effect	O
26	of	O
27	the	O
28	two	O
29	drugs	O
30	given	O
31	together	O
32	,	O
33	compared	O
34	to	O
35	the	O
36	effect	O
37	of	O
38	each	O
39	drug	O
40	given	O
41	separately	O
42	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	A	O
2	case	O
3	of	O
4	manifest	O
5	latent	O
6	nystagmus	O
7	of	O
8	late	O
9	onset	O
10	in	O
11	a	O
12	13	O
13	-	O
14	year	O
15	-	O
16	old	O
17	girl	O
18	is	O
19	reported	O
20	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	The	O
2	coding	O
3	sequence	O
4	for	O
5	a	O
6	260	O
7	-	O
8	amino	O
9	-	O
10	acid	O
11	residue	O
12	polypeptide	O
13	was	O
14	interrupted	O
15	by	O
16	a	O
17	single	O
18	short	O
19	intron	O
20	of	O
21	60	O
22	base	O
23	pairs	O
24	(	O
25	bp	O
26	),	O
27	and	O
28	about	O
29	70	O
30	%	O
31	of	O
32	the	O
33	deduced	O
34	amino	O
35	acid	O
36	sequence	O
37	of	O
38	the	O
39	Drosophila	B
40	PCNA	I
41	was	O
42	identical	O
43	to	O
44	the	O
45	rat	O
46	and	O
47	human	B
48	PCNA	I
49	polypeptides	I
50	,	O
51	with	O
52	conserved	O
53	unique	O
54	repeats	O
55	of	O
56	leucine	O
57	in	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	region	O
63	.	O

1	The	O
2	presence	O
3	of	O
4	an	O
5	unusual	O
6	transcript	O
7	possessing	O
8	IVS2C	B
9	beta	I
10	1	I
11	at	O
12	the	O
13	5	O
14	'	O
15	terminus	O
16	suggests	O
17	that	O
18	cleavage	O
19	of	O
20	its	O
21	splice	O
22	acceptor	O
23	is	O
24	inefficient	O
25	or	O
26	negatively	O
27	regulated	O
28	.	O

1	Antibodies	O
2	raised	O
3	to	O
4	the	O
5	expressed	O
6	NS3	B
7	by	O
8	immunization	O
9	of	O
10	mice	O
11	detected	O
12	both	O
13	NS3	B
14	and	O
15	NS3A	B
16	in	O
17	BTV	O
18	-	O
19	10	O
20	-	O
21	infected	O
22	BHK	O
23	cells	O
24	but	O
25	not	O
26	in	O
27	purified	O
28	BTV	O
29	-	O
30	10	O
31	virus	O
32	particles	O
33	.	O

1	We	O
2	argue	O
3	that	O
4	the	O
5	primary	O
6	role	O
7	of	O
8	hh	B
9	in	O
10	controlling	O
11	polarity	O
12	is	O
13	to	O
14	cause	O
15	anterior	O
16	compartment	O
17	cells	O
18	to	O
19	reverse	O
20	their	O
21	interpretation	O
22	of	O
23	an	O
24	underlying	O
25	symmetric	O
26	polarization	O
27	.	O

1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	B
7	encoding	I
8	Alzheimer	I
9	beta	I
10	-	I
11	amyloid	I
12	precursor	I
13	protein	I
14	(	O
15	APP	B
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O

1	When	O
2	the	O
3	73	O
4	-	O
5	bp	O
6	fragment	O
7	was	O
8	fused	O
9	to	O
10	an	O
11	alpha1	B
12	-	I
13	globin	I
14	promoter	O
15	-	O
16	CAT	B
17	construct	O
18	and	O
19	cotransfected	O
20	with	O
21	CCAAT	B
22	transcription	I
23	factor	I
24	1	I
25	(	O
26	CTF1	B
27	)/	O
28	NF1	B
29	into	O
30	Drosophila	O
31	Schneider	O
32	SL2	O
33	insect	O
34	cells	O
35	(	O
36	which	O
37	lack	O
38	NF1	B
39	-	I
40	like	I
41	proteins	I
42	)	O
43	trans	O
44	-	O
45	activation	O
46	of	O
47	CAT	B
48	activity	O
49	was	O
50	observed	O
51	.	O

1	Hemolytic	O
2	jaundice	O
3	due	O
4	to	O
5	G6PD	B
6	deficiency	O
7	causing	O
8	kernicterus	O
9	in	O
10	a	O
11	female	O
12	newborn	O
13	.	O

1	Induction	O
2	of	O
3	AtP5CS1	B
4	mRNA	I
5	accumulation	O
6	in	O
7	salt	O
8	-	O
9	treated	O
10	seedlings	O
11	involves	O
12	an	O
13	immediate	O
14	early	O
15	transcriptional	O
16	response	O
17	regulated	O
18	by	O
19	ABA	O
20	signalling	O
21	that	O
22	is	O
23	not	O
24	inhibited	O
25	by	O
26	cycloheximide	O
27	,	O
28	but	O
29	abolished	O
30	by	O
31	the	O
32	deficiency	O
33	of	O
34	ABA	O
35	biosynthesis	O
36	in	O
37	the	O
38	aba1	B
39	Arabidopsis	I
40	mutant	I
41	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	O
13	tRNA	O
14	can	O
15	confer	O
16	a	O
17	mutator	O
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	B
29	and	O
30	mutC	B
31	cells	O
32	.	O

1	In	O
2	Denmark	O
3	only	O
4	1	O
5	-	O
6	3	O
7	cases	O
8	of	O
9	transfusion	O
10	-	O
11	associated	O
12	hepatitis	O
13	NANB	O
14	(	O
15	TAH	O
16	-	O
17	NANB	O
18	)	O
19	are	O
20	registered	O
21	annually	O
22	or	O
23	about	O
24	1	O
25	case	O
26	per	O
27	100	O
28	,	O
29	000	O
30	units	O
31	transfused	O
32	.	O

1	3	O
2	-(	O
3	N	O
4	-	O
5	Alkyl	O
6	-	O
7	N	O
8	-	O
9	2	O
10	-	O
11	chloroethylaminomethyl	O
12	)-	O
13	5	O
14	-	O
15	or	O
16	7	O
17	-	O
18	halogenobenzo	O
19	[	O
20	b	O
21	]	O
22	thiophen	O
23	hydrochlorides	O
24	.	O

1	A	O
2	22K	O
3	polypeptide	O
4	was	O
5	detected	O
6	as	O
7	a	O
8	translation	O
9	product	O
10	of	O
11	late	O
12	RNA	O
13	that	O
14	hybridized	O
15	to	O
16	this	O
17	DNA	O
18	fragment	O
19	.	O

1	Genes	O
2	for	O
3	ocs	B
4	element	I
5	binding	I
6	factors	I
7	(	O
8	OBFs	B
9	),	O
10	belonging	O
11	to	O
12	a	O
13	specific	O
14	class	O
15	of	O
16	basic	B
17	-	I
18	region	I
19	leucine	I
20	zipper	I
21	(	I
22	bZIP	I
23	)	I
24	transcription	I
25	factors	I
26	,	O
27	have	O
28	been	O
29	isolated	O
30	in	O
31	a	O
32	number	O
33	of	O
34	plants	O
35	.	O

1	Spectrophotometric	O
2	microanalysis	O
3	of	O
4	ethylenediaminotetracetic	O
5	acid	O
6	in	O
7	pharmaceutical	O
8	preparations	O

1	18F	O
2	and	O
3	85Sr	O
4	scintimetry	O
5	in	O
6	the	O
7	study	O
8	of	O
9	primary	O
10	arthropathies	O
11	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	We	O
2	estimate	O
3	that	O
4	the	O
5	protease	O
6	activity	O
7	is	O
8	at	O
9	least	O
10	35	O
11	-	O
12	fold	O
13	greater	O
14	in	O
15	mature	O
16	B	O
17	cells	O
18	than	O
19	in	O
20	pre	O
21	-	O
22	B	O
23	cells	O
24	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	Although	O
2	eight	O
3	contiguous	O
4	genes	O
5	necessary	O
6	for	O
7	urease	B
8	activity	O
9	have	O
10	been	O
11	cloned	O
12	and	O
13	sequenced	O
14	,	O
15	the	O
16	transcriptional	O
17	organization	O
18	and	O
19	regulation	O
20	of	O
21	specific	O
22	genes	O
23	within	O
24	the	O
25	Proteus	B
26	gene	I
27	cluster	I
28	has	O
29	not	O
30	been	O
31	investigated	O
32	in	O
33	detail	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	H	B
5	-	I
6	NS	I
7	negative	O
8	regulation	O
9	operated	O
10	only	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	Fur	B
16	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	B
16	tetrapeptide	I
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	B
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O

1	A	O
2	rate	O
3	-	O
4	decreasing	O
5	dose	O
6	of	O
7	physostigmine	O
8	,	O
9	an	O
10	acetylcholinesterase	B
11	inhibitor	O
12	,	O
13	was	O
14	studied	O
15	in	O
16	combination	O
17	with	O
18	the	O
19	range	O
20	of	O
21	atropine	O
22	doses	O
23	.	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	In	O
2	memory	O
3	of	O
4	Magdelaine	O
5	Comtesse	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	Serum	O
2	and	O
3	peritoneal	O
4	dialysis	O
5	fluid	O
6	(	O
7	PDF	O
8	)	O
9	were	O
10	collected	O
11	for	O
12	assay	O
13	throughout	O
14	the	O
15	course	O
16	of	O
17	the	O
18	study	O
19	and	O
20	for	O
21	5	O
22	days	O
23	thereafter	O
24	.	O

1	Thus	O
2	,	O
3	cibenzoline	O
4	is	O
5	an	O
6	effective	O
7	antiarrhythmic	O
8	agent	O
9	with	O
10	a	O
11	favourable	O
12	pharmacokinetic	O
13	profile	O
14	that	O
15	may	O
16	be	O
17	considered	O
18	with	O
19	other	O
20	class	O
21	I	O
22	drugs	O
23	in	O
24	patients	O
25	requiring	O
26	therapy	O
27	for	O
28	high	O
29	risk	O
30	arrhythmias	O
31	.	O

1	Improving	O
2	the	O
3	evidence	O
4	base	O
5	for	O
6	anaesthesia	O
7	.	O

1	To	O
2	gain	O
3	insight	O
4	into	O
5	the	O
6	expression	O
7	of	O
8	the	O
9	AtCP1	B
10	gene	I
11	,	O
12	northern	O
13	blot	O
14	analysis	O
15	was	O
16	carried	O
17	out	O
18	.	O

1	For	O
2	monocytes	O
3	,	O
4	as	O
5	measured	O
6	on	O
7	the	O
8	Hematrak	O
9	,	O
10	it	O
11	was	O
12	13	O
13	.	O
14	4	O
15	%.	O

1	Transduction	O
2	of	O
3	the	O
4	human	O
5	leukemic	O
6	cell	O
7	line	O
8	K562	O
9	showed	O
10	that	O
11	viral	O
12	MRP1	B
13	-	O
14	PG13	O
15	supernatants	O
16	routinely	O
17	transfer	O
18	the	O
19	MRP1	B
20	gene	I
21	to	O
22	approximately	O
23	35	O
24	%	O
25	of	O
26	target	O
27	K562	O
28	cells	O
29	,	O
30	of	O
31	which	O
32	at	O
33	least	O
34	one	O
35	third	O
36	are	O
37	capable	O
38	of	O
39	proliferating	O
40	in	O
41	the	O
42	presence	O
43	of	O
44	otherwise	O
45	toxic	O
46	concentrations	O
47	of	O
48	etoposide	O
49	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	cytoplasmic	B
6	tyrosine	I
7	kinase	I
8	,	O
9	termed	O
10	BPK	B
11	(	O
12	B	B
13	cell	I
14	progenitor	I
15	kinase	I
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	all	O
22	stages	O
23	of	O
24	the	O
25	B	O
26	lineage	O
27	and	O
28	in	O
29	myeloid	O
30	cells	O
31	.	O

1	The	O
2	interaction	O
3	between	O
4	DDB	B
5	and	O
6	E2F1	B
7	can	O
8	also	O
9	be	O
10	detected	O
11	by	O
12	coimmunoprecipitation	O
13	experiments	O
14	.	O

1	Characterization	O
2	of	O
3	the	O
4	human	B
5	gene	I
6	encoding	I
7	cytokeratin	I
8	17	I
9	and	O
10	its	O
11	expression	O
12	pattern	O
13	.	O

1	VII	O
2	.	O

1	We	O
2	have	O
3	tested	O
4	this	O
5	proposal	O
6	by	O
7	carrying	O
8	out	O
9	circular	O
10	dichroism	O
11	(	O
12	CD	O
13	)	O
14	and	O
15	NMR	O
16	experiments	O
17	on	O
18	the	O
19	Skn	B
20	domain	I
21	and	O
22	five	O
23	truncated	O
24	proteins	O
25	.	O

1	Am	O
2	.	O

1	"	O
2	Let	O
3	the	O
4	hundred	O
5	flowers	O
6	bloom	O
7	".	O

1	Selective	O
2	macrophage	O
3	inhibition	O
4	abolishes	O
5	warfarin	O
6	-	O
7	induced	O
8	reduction	O
9	of	O
10	metastasis	O
11	.	O

1	GN101	O
2	,	O
3	YC819	O
4	-	O
5	9	O
6	,	O
7	and	O
8	SB3	O
9	.	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	I
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	B
25	gene	I
26	expression	O
27	.	O

1	In	O
2	the	O
3	Arithmetic	O
4	subtest	O
5	one	O
6	of	O
7	the	O
8	items	O
9	would	O
10	not	O
11	meet	O
12	the	O
13	difficulty	O
14	grading	O
15	shown	O
16	while	O
17	the	O
18	last	O
19	two	O
20	items	O
21	offer	O
22	very	O
23	little	O
24	possibility	O
25	of	O
26	success	O
27	for	O
28	all	O
29	subjects	O
30	.(	O
31	ABSTRACT	O
32	TRUNCATED	O
33	AT	O
34	250	O
35	WORDS	O
36	)	O

1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	p40	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O

1	By	O
2	DNase	B
3	I	I
4	footprint	O
5	analysis	O
6	of	O
7	the	O
8	PNR	O
9	element	O
10	,	O
11	a	O
12	palindrome	O
13	of	O
14	two	O
15	high	O
16	-	O
17	affinity	O
18	Ets	B
19	-	I
20	binding	I
21	sites	I
22	(	O
23	CTTCCCTGGAAG	O
24	)	O
25	was	O
26	identified	O
27	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O

1	An	O
2	association	O
3	between	O
4	hSIE	B
5	and	O
6	Stat	B
7	-	I
8	3	I
9	after	O
10	MHC	B
11	-	I
12	I	I
13	ligation	O
14	was	O
15	directly	O
16	demonstrated	O
17	by	O
18	precipitating	O
19	Stat	B
20	-	I
21	3	I
22	from	O
23	nuclear	O
24	extracts	O
25	with	O
26	biotinylated	O
27	hSIE	B
28	probe	O
29	and	O
30	avidin	B
31	-	O
32	coupled	O
33	agarose	O
34	.	O

1	For	O
2	the	O
3	5HT5A	B
4	receptor	I
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O

1	Furthermore	O
2	,	O
3	the	O
4	UvrA	B
5	protein	I
6	interacts	O
7	with	O
8	the	O
9	UvrB	B
10	protein	I
11	to	O
12	modulate	O
13	its	O
14	activities	O
15	,	O
16	both	O
17	in	O
18	solution	O
19	and	O
20	in	O
21	association	O
22	with	O
23	DNA	O
24	,	O
25	where	O
26	the	O
27	UvrAB	B
28	complex	I
29	possesses	O
30	a	O
31	helicase	B
32	activity	O
33	.	O

1	Control	O
2	subjects	O
3	'	O
4	evoked	O
5	potentials	O
6	(	O
7	EPs	O
8	)	O
9	were	O
10	characterized	O
11	by	O
12	an	O
13	initial	O
14	positivity	O
15	in	O
16	the	O
17	90	O
18	-	O
19	140	O
20	ms	O
21	range	O
22	(	O
23	P1	O
24	)	O
25	at	O
26	the	O
27	temporo	O
28	-	O
29	occipital	O
30	site	O
31	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O

1	2	O
2	-	O
3	AP	O
4	induced	O
5	marked	O
6	,	O
7	steady	O
8	rises	O
9	in	O
10	mRNA	O
11	accumulation	O
12	from	O
13	both	O
14	transfected	O
15	and	O
16	chromosomally	O
17	integrated	O
18	HIV	O
19	-	O
20	1	O
21	constructs	O
22	but	O
23	no	O
24	increases	O
25	from	O
26	an	O
27	endogenous	O
28	gene	O
29	encoding	O
30	gamma	B
31	-	I
32	actin	I
33	or	O
34	glucose	B
35	6	I
36	-	I
37	phosphate	I
38	dehydrogenase	I
39	.	O

1	Echocardiography	O
2	revealed	O
3	right	O
4	ventricular	O
5	diastolic	O
6	collapse	O
7	(	O
8	RVDC	O
9	)	O
10	without	O
11	physical	O
12	signs	O
13	of	O
14	cardiac	O
15	tamponade	O
16	.	O

1	Nursing	O
2	home	O
3	discharges	O
4	in	O
5	clinical	O
6	practice	O
7	.	O

1	Morphine	O
2	produced	O
3	a	O
4	dose	O
5	-	O
6	dependent	O
7	bradycardia	O
8	followed	O
9	by	O
10	tachycardia	O
11	.	O

1	Our	O
2	findings	O
3	also	O
4	provide	O
5	the	O
6	basis	O
7	for	O
8	the	O
9	development	O
10	of	O
11	assays	O
12	to	O
13	screen	O
14	for	O
15	the	O
16	ligands	O
17	to	O
18	testis	B
19	receptor	I
20	2	I
21	and	O
22	hERR1	B
23	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	To	O
2	dissect	O
3	these	O
4	mechanisms	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	and	O
10	mutant	B
11	Raf	I
12	-	I
13	1	I
14	proteins	I
15	were	O
16	studied	O
17	in	O
18	an	O
19	in	O
20	vitro	O
21	system	O
22	with	O
23	purified	O
24	plasma	O
25	membranes	O
26	from	O
27	v	B
28	-	I
29	Ras	I
30	-	O
31	and	O
32	v	B
33	-	I
34	Src	I
35	-	O
36	transformed	O
37	cells	O
38	(	O
39	transformed	O
40	membranes	O
41	).	O

1	Similar	O
2	memory	O
3	impairments	O
4	found	O
5	in	O
6	medial	O
7	septal	O
8	-	O
9	vertical	O
10	diagonal	O
11	band	O
12	of	O
13	Broca	O
14	and	O
15	nucleus	O
16	basalis	O
17	lesioned	O
18	rats	O
19	:	O
20	are	O
21	memory	O
22	defects	O
23	induced	O
24	by	O
25	nucleus	O
26	basalis	O
27	lesions	O
28	related	O
29	to	O
30	the	O
31	degree	O
32	of	O
33	non	O
34	-	O
35	specific	O
36	subcortical	O
37	cell	O
38	loss	O
39	?	O
40	The	O
41	function	O
42	of	O
43	nucleus	O
44	basalis	O
45	(	O
46	NB	O
47	)	O
48	and	O
49	medial	O
50	septal	O
51	-	O
52	vertical	O
53	diagonal	O
54	band	O
55	of	O
56	Broca	O
57	(	O
58	MS	O
59	-	O
60	VDBB	O
61	)	O
62	in	O
63	a	O
64	place	O
65	navigation	O
66	task	O
67	requiring	O
68	reference	O
69	memory	O
70	was	O
71	investigated	O
72	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	Unique	O
2	to	O
3	this	O
4	system	O
5	,	O
6	the	O
7	activity	O
8	of	O
9	TraR	B
10	is	O
11	negatively	O
12	modulated	O
13	by	O
14	an	O
15	antiactivator	O
16	called	O
17	TraM	B
18	.	O

1	When	O
2	ligated	O
3	to	O
4	the	O
5	proIL	B
6	-	I
7	1	I
8	beta	I
9	cap	I
10	site	I
11	-	I
12	proximal	I
13	region	I
14	(	O
15	located	O
16	between	O
17	-	O
18	131	O
19	to	O
20	+	O
21	12	O
22	),	O
23	both	O
24	the	O
25	proIL	B
26	-	I
27	1	I
28	beta	I
29	and	O
30	the	O
31	simian	B
32	virus	I
33	40	I
34	enhancer	I
35	elements	I
36	functioned	O
37	more	O
38	efficiently	O
39	in	O
40	monocytes	O
41	than	O
42	in	O
43	HeLa	O
44	cells	O
45	,	O
46	which	O
47	are	O
48	not	O
49	normally	O
50	competent	O
51	for	O
52	IL	B
53	-	I
54	1	I
55	beta	I
56	expression	O
57	.	O

1	Behavioral	O
2	and	O
3	electrographic	O
4	expression	O
5	of	O
6	natural	O
7	sleep	O
8	and	O
9	wakefulness	O
10	in	O
11	reptiles	O

1	The	O
2	CBF1	B
3	site	I
4	within	O
5	HS2	O
6	resides	O
7	near	O
8	sites	O
9	for	O
10	hematopoietic	O
11	regulators	O
12	such	O
13	as	O
14	GATA	B
15	-	I
16	1	I
17	,	O
18	NF	B
19	-	I
20	E2	I
21	,	O
22	and	O
23	TAL1	B
24	.	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	B
11	,	O
12	of	O
13	Neurospora	O
14	crassa	O
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	Drug	O
2	inhibition	O
3	of	O
4	whole	O
5	blood	O
6	aspirin	B
7	esterase	I
8	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	the	O
8	hUBF	B
9	-	I
10	promoter	I
11	interaction	O
12	is	O
13	highly	O
14	sensitive	O
15	to	O
16	the	O
17	antagonistic	O
18	effects	O
19	of	O
20	cisplatin	O
21	-	O
22	DNA	O
23	adducts	O
24	.	O

1	A	O
2	Dictyostelium	O
3	transformant	O
4	overexpressing	O
5	DdPTPa	B
6	does	O
7	not	O
8	develop	O
9	normally	O
10	.	O

1	Mitogen	B
2	-	I
3	activated	I
4	protein	I
5	(	I
6	MAP	I
7	)	I
8	kinase	I
9	phosphatase	I
10	-	I
11	3	I
12	(	O
13	MKP	B
14	-	I
15	3	I
16	)	O
17	is	O
18	a	O
19	dual	O
20	specificity	O
21	phosphatase	O
22	that	O
23	inactivates	O
24	extracellular	B
25	signal	I
26	-	I
27	regulated	I
28	kinase	I
29	(	O
30	ERK	B
31	)	O
32	MAP	B
33	kinases	I
34	.	O

1	Generally	O
2	ILC	O
3	and	O
4	ILVF	O
5	values	O
6	decreased	O
7	with	O
8	increasing	O
9	exposure	O
10	time	O
11	with	O
12	rate	O
13	constants	O
14	ranging	O
15	from	O
16	0	O
17	.	O
18	03	O
19	to	O
20	0	O
21	.	O
22	33	O
23	day	O
24	-	O
25	1	O
26	(	O
27	wet	O
28	and	O
29	lipid	O
30	weight	O
31	)	O
32	for	O
33	ILC	O
34	and	O
35	0	O
36	.	O
37	03	O
38	to	O
39	0	O
40	.	O
41	31	O
42	day	O
43	-	O
44	1	O
45	for	O
46	ILVF	O
47	.	O

1	Recombinant	B
2	soluble	I
3	pMCP	I
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	B
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	B
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	B
32	.	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	B
9	-	I
10	kb	I
11	EcoRI	I
12	fragment	I
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	B
32	gene	I
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequences	O
5	with	O
6	the	O
7	BLAST	O
8	and	O
9	GRAIL	O
10	programs	O
11	provided	O
12	additional	O
13	independent	O
14	evidence	O
15	that	O
16	15	O
17	of	O
18	these	O
19	17	O
20	clones	O
21	contain	O
22	coding	O
23	sequences	O
24	and	O
25	that	O
26	nine	O
27	other	O
28	clones	O
29	are	O
30	likely	O
31	to	O
32	contain	O
33	sequences	O
34	coding	O
35	for	O
36	portions	O
37	of	O
38	new	O
39	genes	O
40	.	O

1	Since	O
2	the	O
3	ETS	B
4	domain	I
5	,	O
6	which	O
7	is	O
8	localized	O
9	in	O
10	the	O
11	carboxy	O
12	terminal	O
13	region	O
14	of	O
15	the	O
16	encoded	O
17	protein	O
18	,	O
19	is	O
20	95	O
21	%	O
22	and	O
23	96	O
24	%	O
25	identical	O
26	to	O
27	that	O
28	of	O
29	PEA3	B
30	and	O
31	ER81	B
32	,	O
33	respectively	O
34	,	O
35	we	O
36	named	O
37	this	O
38	new	O
39	member	O
40	'	B
41	Ets	I
42	Related	I
43	Molecule	I
44	PEA3	I
45	-	I
46	like	I
47	'	I
48	(	O
49	ERM	B
50	).	O

1	Immunohistochemical	O
2	studies	O
3	revealed	O
4	positive	O
5	staining	O
6	for	O
7	S100	B
8	protein	I
9	in	O
10	all	O
11	the	O
12	granular	O
13	cell	O
14	tumors	O
15	of	O
16	the	O
17	adult	O
18	but	O
19	in	O
20	none	O
21	of	O
22	the	O
23	congenital	O
24	granular	O
25	cell	O
26	epulides	O
27	.	O

1	Bioplastique	O
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	Interestingly	O
2	,	O
3	the	O
4	interaction	O
5	of	O
6	ZAP	B
7	-	I
8	70	I
9	with	O
10	the	O
11	motif	O
12	was	O
13	dependent	O
14	on	O
15	the	O
16	presence	O
17	of	O
18	both	O
19	ZAP	B
20	-	I
21	70	I
22	SH2	I
23	domains	I
24	and	O
25	both	O
26	of	O
27	the	O
28	tyrosine	O
29	residues	O
30	in	O
31	the	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	ZAP	B
37	-	I
38	70	I
39	interacts	O
40	with	O
41	two	O
42	phosphotyrosine	O
43	residues	O
44	and	O
45	that	O
46	the	O
47	binding	O
48	of	O
49	the	O
50	two	O
51	SH2	B
52	domains	I
53	is	O
54	cooperative	O
55	.	O

1	With	O
2	both	O
3	wild	O
4	-	O
5	type	O
6	and	O
7	the	O
8	mutant	O
9	enzymes	O
10	,	O
11	ATP	O
12	activates	O
13	both	O
14	[	O
15	14C	O
16	]	O
17	Asp	O
18	in	O
19	equilibrium	O
20	N	O
21	-	O
22	carbamyl	O
23	-	O
24	L	O
25	-	O
26	aspartate	O
27	(	O
28	C	O
29	-	O
30	Asp	O
31	)	O
32	and	O
33	the	O
34	[	O
35	32P	O
36	]	O
37	carbamyl	O
38	phosphate	O
39	(	O
40	C	O
41	-	O
42	P	O
43	)	O
44	in	O
45	equilibrium	O
46	Pi	O
47	exchanges	O
48	.	O

1	We	O
2	have	O
3	carried	O
4	out	O
5	a	O
6	comprehensive	O
7	and	O
8	systematic	O
9	mutagenesis	O
10	of	O
11	the	O
12	Cse4p	B
13	N	I
14	terminus	I
15	to	O
16	analyze	O
17	its	O
18	function	O
19	.	O

1	CONCLUSIONS	O
2	:	O
3	There	O
4	is	O
5	a	O
6	relation	O
7	in	O
8	the	O
9	topography	O
10	of	O
11	some	O
12	visual	O
13	field	O
14	areas	O
15	assessed	O
16	by	O
17	SWAP	O
18	and	O
19	the	O
20	inferotemporal	O
21	neuroretinal	O
22	rim	O
23	area	O
24	,	O
25	which	O
26	may	O
27	play	O
28	a	O
29	role	O
30	in	O
31	the	O
32	diagnosis	O
33	and	O
34	follow	O
35	-	O
36	up	O
37	of	O
38	suspected	O
39	glaucoma	O
40	.	O

1	The	O
2	data	O
3	indicates	O
4	the	O
5	presence	O
6	of	O
7	5	B
8	-	I
9	HT2	I
10	serotonergic	I
11	receptors	I
12	in	O
13	the	O
14	bronchial	O
15	artery	O
16	of	O
17	these	O
18	species	O
19	.	O

1	Given	O
2	its	O
3	relative	O
4	longevity	O
5	on	O
6	the	O
7	Web	O
8	,	O
9	TIE	O
10	researchers	O
11	have	O
12	been	O
13	in	O
14	a	O
15	unique	O
16	position	O
17	to	O
18	observe	O
19	trends	O
20	in	O
21	telemedicine	O
22	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	If	O
2	the	O
3	haemoglobin	B
4	concentration	O
5	(	O
6	Hb	B
7	)	O
8	was	O
9	less	O
10	than	O
11	12	O
12	g	O
13	dL	O
14	-	O
15	1	O
16	they	O
17	were	O
18	given	O
19	a	O
20	four	O
21	week	O
22	course	O
23	of	O
24	ferrous	O
25	sulphate	O
26	.	O

1	Renin	B
2	secretion	O
3	in	O
4	essential	O
5	and	O
6	accelerated	O
7	hypertension	O
8	.	O

1	METHOD	O
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	O
42	serum	B
43	immunoglobulin	I
44	E	I
45	(	O
46	IgE	B
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	O
53	serum	B
54	IgE	I
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O

1	Prostaglandin	O
2	synthesis	O
3	inhibitors	O
4	have	O
5	been	O
6	shown	O
7	to	O
8	delay	O
9	healing	O
10	of	O
11	bone	O
12	and	O
13	this	O
14	has	O
15	led	O
16	to	O
17	limitations	O
18	on	O
19	their	O
20	use	O
21	clinically	O
22	in	O
23	some	O
24	situations	O
25	.	O

1	In	O
2	contrast	O
3	,	O
4	overproduction	O
5	of	O
6	Der3p	B
7	is	O
8	lethal	O
9	in	O
10	a	O
11	sec61	B
12	-	I
13	2	I
14	strain	O
15	at	O
16	the	O
17	permissive	O
18	temperature	O
19	of	O
20	25	O
21	degrees	O
22	C	O
23	.	O

1	Recently	O
2	,	O
3	a	O
4	distantly	O
5	related	O
6	UmuC	B
7	-	I
8	homolog	I
9	,	O
10	DinB	B
11	,	O
12	has	O
13	also	O
14	been	O
15	identified	O
16	in	O
17	E	O
18	.	O
19	coli	O
20	.	O

1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O

1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O

1	A	O
2	polypeptide	O
3	encoded	O
4	by	O
5	the	O
6	NTS	O
7	16	O
8	open	O
9	reading	O
10	frame	O
11	has	O
12	sequence	O
13	similarity	O
14	to	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	several	O
20	receptor	B
21	protein	I
22	kinases	I
23	from	I
24	plants	I
25	including	O
26	the	O
27	S	B
28	-	I
29	receptor	I
30	kinases	I
31	implicated	O
32	in	O
33	the	O
34	rejection	O
35	of	O
36	self	O
37	-	O
38	pollen	O
39	in	O
40	Brassica	O
41	species	O
42	and	O
43	the	O
44	Pto	B
45	gene	I
46	product	I
47	of	I
48	tomato	I
49	which	O
50	confers	O
51	resistance	O
52	to	O
53	a	O
54	bacterial	O
55	pathogen	O
56	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	Some	O
2	of	O
3	the	O
4	mutations	O
5	obtained	O
6	do	O
7	not	O
8	contain	O
9	a	O
10	copy	O
11	of	O
12	the	O
13	Ulysses	B
14	element	I
15	at	O
16	the	O
17	mutant	O
18	locus	O
19	,	O
20	suggesting	O
21	that	O
22	a	O
23	different	O
24	transposable	O
25	element	O
26	may	O
27	be	O
28	responsible	O
29	for	O
30	the	O
31	mutation	O
32	.	O

1	In	O
2	17	O
3	patients	O
4	with	O
5	deletions	O
6	,	O
7	the	O
8	parental	O
9	origin	O
10	of	O
11	deletion	O
12	was	O
13	determined	O
14	.	O

1	EIAV	B
2	LTR	I
3	sequence	I
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O

1	Staining	O
2	with	O
3	IF	O
4	MoAB	O
5	alone	O
6	of	O
7	BAL	O
8	fluid	O
9	only	O
10	seemed	O
11	to	O
12	be	O
13	even	O
14	more	O
15	sensitive	O
16	than	O
17	silver	O
18	methenamine	O
19	staining	O
20	of	O
21	BAL	O
22	,	O
23	TBB	O
24	and	O
25	brushing	O
26	material	O
27	.	O

1	Retinal	O
2	changes	O
3	in	O
4	pigmentary	O
5	retinopathy	O
6	in	O
7	children	O

1	In	O
2	the	O
3	ultramarathon	O
4	runner	O
5	the	O
6	testosterone	O
7	levels	O
8	sharply	O
9	rose	O
10	at	O
11	the	O
12	beginning	O
13	of	O
14	the	O
15	training	O
16	session	O
17	(	O
18	from	O
19	the	O
20	7	O
21	,	O
22	20	O
23	ng	O
24	/	O
25	ml	O
26	to	O
27	11	O
28	,	O
29	50	O
30	ng	O
31	/	O
32	ml	O
33	after	O
34	20	O
35	'	O
36	training	O
37	),	O
38	and	O
39	subsequently	O
40	decrease	O
41	after	O
42	3	O
43	hours	O
44	(	O
45	9	O
46	,	O
47	20	O
48	ng	O
49	/	O
50	ml	O
51	)	O
52	and	O
53	at	O
54	the	O
55	end	O
56	of	O
57	the	O
58	6	O
59	hours	O
60	training	O
61	(	O
62	4	O
63	,	O
64	60	O
65	ng	O
66	/	O
67	ml	O
68	).	O

1	Cold	O
2	cardioplegia	O
3	was	O
4	administered	O
5	at	O
6	45	O
7	mm	O
8	Hg	O
9	every	O
10	20	O
11	minutes	O
12	for	O
13	2	O
14	hours	O
15	.	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	four	O
5	known	O
6	acyl	B
7	-	I
8	CoA	I
9	synthetases	I
10	(	O
11	fatty	B
12	acid	I
13	activation	I
14	proteins	I
15	,	O
16	Faaps	B
17	).	O

1	MZF	B
2	-	I
3	1	I
4	represses	O
5	CAT	B
6	reporter	I
7	gene	I
8	expression	O
9	via	O
10	GAL4	B
11	binding	I
12	sites	I
13	in	O
14	the	O
15	nonhematopoietic	O
16	cell	O
17	lines	O
18	NIH	O
19	3T3	O
20	and	O
21	293	O
22	.	O

1	Tests	O
2	of	O
3	the	O
4	method	O
5	indicate	O
6	(	O
7	1	O
8	)	O
9	the	O
10	Mossbauer	O
11	source	O
12	can	O
13	be	O
14	placed	O
15	on	O
16	the	O
17	basilar	O
18	membrane	O
19	without	O
20	altering	O
21	the	O
22	signal	O
23	-	O
24	transmission	O
25	properties	O
26	of	O
27	the	O
28	cochlea	O
29	,	O
30	and	O
31	(	O
32	2	O
33	)	O
34	the	O
35	source	O
36	adheres	O
37	to	O
38	the	O
39	basilar	O
40	membrane	O
41	.	O

1	Although	O
2	isl	B
3	-	I
4	1	I
5	binds	O
6	to	O
7	both	O
8	the	O
9	insulin	B
10	and	O
11	amylin	B
12	gene	I
13	promoter	I
14	elements	I
15	in	O
16	vitro	O
17	,	O
18	these	O
19	sequences	O
20	display	O
21	marked	O
22	differences	O
23	in	O
24	their	O
25	relative	O
26	transcriptional	O
27	properties	O
28	when	O
29	ligated	O
30	adjacent	O
31	to	O
32	a	O
33	heterologous	O
34	promoter	O
35	and	O
36	transfected	O
37	into	O
38	InR1	O
39	-	O
40	G9	O
41	islet	O
42	cells	O
43	.	O

1	One	O
2	patient	O
3	only	O
4	had	O
5	any	O
6	test	O
7	abnormalities	O
8	.	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	GRE	O
8	sufficient	O
9	to	O
10	account	O
11	for	O
12	full	O
13	glucocorticoid	O
14	inducibility	O
15	and	O
16	an	O
17	HNF	B
18	-	I
19	1	I
20	site	I
21	close	O
22	to	O
23	the	O
24	promoter	O
25	that	O
26	are	O
27	major	O
28	determinants	O
29	of	O
30	transcriptional	O
31	control	O
32	of	O
33	the	O
34	Xenopus	B
35	fibrinogen	I
36	B	I
37	beta	I
38	subunit	I
39	gene	I
40	in	O
41	cells	O
42	from	O
43	normal	O
44	liver	O
45	tissue	O
46	.	O

1	The	O
2	examinations	O
3	were	O
4	performed	O
5	on	O
6	two	O
7	groups	O
8	of	O
9	20	O
10	(	O
11	using	O
12	AmF	O
13	/	O
14	SnF2	O
15	)-,	O
16	resp	O
17	.	O

1	The	O
2	Mauriceville	O
3	and	O
4	Varkud	O
5	mitochondrial	O
6	plasmids	O
7	are	O
8	closely	O
9	related	O
10	,	O
11	closed	O
12	-	O
13	circular	O
14	DNAs	O
15	(	O
16	3	O
17	.	O
18	6	O
19	and	O
20	3	O
21	.	O
22	7	O
23	kb	O
24	,	O
25	respectively	O
26	)	O
27	that	O
28	have	O
29	characteristics	O
30	of	O
31	mtDNA	O
32	introns	O
33	and	O
34	retroid	O
35	elements	O
36	.	O

1	The	O
2	amplification	O
3	was	O
4	achieved	O
5	using	O
6	two	O
7	primers	O
8	which	O
9	correspond	O
10	to	O
11	TRH	B
12	progenitor	I
13	sequence	I
14	(	O
15	Lys	O
16	/	O
17	Arg	O
18	-	O
19	Arg	O
20	-	O
21	Gln	O
22	-	O
23	His	O
24	-	O
25	Pro	O
26	-	O
27	Gly	O
28	-	O
29	Lys	O
30	/	O
31	Arg	O
32	-	O
33	Arg	O
34	).	O

1	Southern	O
2	blotting	O
3	analysis	O
4	implied	O
5	the	O
6	occurrence	O
7	of	O
8	multiple	O
9	COXVb	B
10	genes	I
11	in	O
12	the	O
13	rat	O
14	genome	O
15	.	O

1	Surprisingly	O
2	,	O
3	TFIIIC	B
4	alpha	I
5	has	O
6	no	O
7	homology	O
8	to	O
9	any	O
10	of	O
11	the	O
12	yeast	B
13	TFIIIC	I
14	subunits	I
15	already	O
16	cloned	O
17	,	O
18	suggesting	O
19	a	O
20	significant	O
21	degree	O
22	of	O
23	evolutionary	O
24	divergence	O
25	for	O
26	RNA	B
27	polymerase	I
28	III	I
29	factors	I
30	.	O

1	A	O
2	role	O
3	for	O
4	RalGDS	B
5	and	O
6	a	O
7	novel	O
8	Ras	B
9	effector	O
10	in	O
11	the	O
12	Ras	B
13	-	O
14	mediated	O
15	inhibition	O
16	of	O
17	skeletal	O
18	myogenesis	O
19	.	O

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	B
6	-	I
7	specific	I
8	RNA	I
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	B
27	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	B
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	B
35	were	O
36	constructed	O
37	.	O

1	The	O
2	AL	O
3	-	O
4	R8	O
5	SI	O
6	:	O
7	the	O
8	next	O
9	generation	O
10	staging	O
11	container	O
12	for	O
13	plutonium	O
14	pits	O
15	at	O
16	the	O
17	USDOE	O
18	Pantex	O
19	Plant	O
20	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	of	O
10	the	O
11	CD69	B
12	gene	I
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	a	O
18	potential	O
19	TATA	O
20	element	O
21	30	O
22	base	O
23	pairs	O
24	upstream	O
25	of	O
26	the	O
27	major	O
28	transcription	O
29	initiation	O
30	site	O
31	and	O
32	several	O
33	putative	O
34	binding	O
35	sequences	O
36	for	O
37	inducible	O
38	transcription	O
39	factors	O
40	(	O
41	NF	B
42	-	I
43	kappa	I
44	B	I
45	,	O
46	Egr	B
47	-	I
48	1	I
49	,	O
50	AP	B
51	-	I
52	1	I
53	),	O
54	which	O
55	might	O
56	mediate	O
57	the	O
58	inducible	O
59	expression	O
60	of	O
61	this	O
62	gene	O
63	.	O

1	Members	O
2	of	O
3	the	O
4	myocyte	B
5	-	I
6	specific	I
7	enhancer	I
8	-	I
9	binding	I
10	factor	I
11	2	I
12	(	O
13	MEF2	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O

1	A	O
2	patient	O
3	suffering	O
4	from	O
5	heparin	O
6	-	O
7	associated	O
8	thrombocytopenia	O
9	(	O
10	HAT	O
11	),	O
12	recurrent	O
13	arteriothromboses	O
14	,	O
15	and	O
16	acute	O
17	renal	O
18	failure	O
19	after	O
20	treatment	O
21	with	O
22	standard	O
23	heparin	O
24	is	O
25	described	O
26	.	O

1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	B
12	early	I
13	genes	I
14	.	O

1	In	O
2	addition	O
3	,	O
4	two	O
5	-	O
6	dimensional	O
7	nuclear	O
8	magnetic	O
9	resonance	O
10	studies	O
11	with	O
12	F17A	O
13	,	O
14	K13Q	O
15	,	O
16	F15Y	O
17	and	O
18	F27Y	O
19	revealed	O
20	that	O
21	the	O
22	mutants	O
23	have	O
24	the	O
25	same	O
26	overall	O
27	structure	O
28	as	O
29	the	O
30	wild	B
31	-	I
32	type	I
33	CspB	I
34	protein	I
35	.	O

1	Collagen	B
2	was	O
3	extracted	O
4	from	O
5	the	O
6	skin	O
7	,	O
8	and	O
9	the	O
10	lack	O
11	of	O
12	type	B
13	III	I
14	collagen	I
15	was	O
16	determined	O
17	by	O
18	means	O
19	of	O
20	sodium	O
21	dodecyl	O
22	sulfate	O
23	-	O
24	polyacrylamide	O
25	gel	O
26	electrophoresis	O
27	(	O
28	SDS	O
29	-	O
30	PAGE	O
31	).	O

1	EBNA	B
2	-	I
3	2	I
4	and	O
5	the	O
6	cis	O
7	-	O
8	acting	O
9	CD23	B
10	element	I
11	increased	O
12	TK	B
13	-	O
14	promoted	O
15	mRNA	O
16	and	O
17	did	O
18	not	O
19	alter	O
20	the	O
21	herpes	B
22	simplex	I
23	virus	I
24	TK	I
25	promoter	I
26	transcription	I
27	start	I
28	site	I
29	.	O

1	The	O
2	revertant	O
3	TATA	O
4	boxes	O
5	accelerated	O
6	the	O
7	kinetics	O
8	of	O
9	HIV	O
10	replication	O
11	when	O
12	present	O
13	in	O
14	the	O
15	context	O
16	of	O
17	an	O
18	LTR	O
19	containing	O
20	a	O
21	Sp1	B
22	mutation	O
23	(	O
24	deletion	O
25	or	O
26	site	O
27	specific	O
28	);	O
29	no	O
30	effect	O
31	was	O
32	observed	O
33	on	O
34	the	O
35	infectivity	O
36	of	O
37	wild	O
38	-	O
39	type	O
40	HIV	O
41	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	O
8	splicing	O
9	suppressor	O
10	1	O
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	We	O
2	have	O
3	recently	O
4	shown	O
5	that	O
6	the	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	of	O
12	the	O
13	RAR	B
14	beta	I
15	2	I
16	gene	I
17	in	I
18	mouse	I
19	embryos	I
20	is	O
21	regulated	O
22	at	O
23	the	O
24	translational	O
25	level	O
26	by	O
27	short	O
28	upstream	O
29	open	O
30	reading	O
31	frames	O
32	(	O
33	uORFs	O
34	)	O
35	In	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	Zimmer	O
43	,	O
44	A	O
45	.,	O
46	A	O
47	.	O
48	M	O
49	.	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	Surprisingly	O
2	,	O
3	a	O
4	C	O
5	to	O
6	G	O
7	transversion	O
8	at	O
9	the	O
10	first	O
11	residue	O
12	of	O
13	the	O
14	CAT	B
15	pentanucleotide	I
16	,	O
17	which	O
18	severely	O
19	impairs	O
20	the	O
21	activity	O
22	of	O
23	both	O
24	promoters	O
25	,	O
26	appears	O
27	to	O
28	increase	O
29	affinity	O
30	of	O
31	the	O
32	CAT	B
33	binding	I
34	protein	I
35	.	O

1	The	O
2	present	O
3	data	O
4	also	O
5	indicate	O
6	that	O
7	patients	O
8	with	O
9	TGBM	O
10	nephropathy	O
11	often	O
12	have	O
13	concomitant	O
14	IgA	B
15	nephropathy	O
16	and	O
17	mesangial	O
18	proliferative	O
19	glomerulonephritis	O
20	.	O

1	Plasma	O
2	renin	B
3	activity	O
4	did	O
5	not	O
6	change	O
7	in	O
8	response	O
9	to	O
10	head	O
11	-	O
12	up	O
13	tilt	O
14	or	O
15	isoprenaline	O
16	infusion	O
17	in	O
18	the	O
19	patients	O
20	.	O

1	In	O
2	the	O
3	United	O
4	States	O
5	high	O
6	-	O
7	MW	O
8	HES	O
9	480	O
10	which	O
11	is	O
12	difficult	O
13	to	O
14	degrade	O
15	is	O
16	most	O
17	frequently	O
18	used	O
19	and	O
20	results	O
21	in	O
22	a	O
23	larger	O
24	in	O
25	vivo	O
26	MW	O
27	and	O
28	subsequent	O
29	decrease	O
30	in	O
31	factor	B
32	VIII	I
33	/	O
34	von	B
35	Willebrand	I
36	factor	I
37	levels	O
38	.	O

1	Most	O
2	patients	O
3	preferred	O
4	tablets	O
5	to	O
6	injection	O
7	both	O
8	on	O
9	day	O
10	1	O
11	(	O
12	313	O
13	v	O
14	200	O
15	)	O
16	and	O
17	at	O
18	follow	O
19	up	O
20	(	O
21	373	O
22	v	O
23	104	O
24	).	O

1	Mean	O
2	rCBF	O
3	increased	O
4	in	O
5	some	O
6	patients	O
7	4	O
8	-	O
9	8	O
10	weeks	O
11	after	O
12	surgery	O
13	on	O
14	the	O
15	ipsilateral	O
16	side	O
17	.	O

1	Despite	O
2	the	O
3	high	O
4	frequency	O
5	of	O
6	natural	O
7	infection	O
8	,	O
9	the	O
10	seropositive	O
11	rates	O
12	of	O
13	JEV	O
14	antibody	O
15	still	O
16	correlated	O
17	well	O
18	with	O
19	the	O
20	dose	O
21	of	O
22	vaccine	O
23	received	O
24	,	O
25	i	O
26	.	O
27	e	O
28	.,	O
29	67	O
30	%	O
31	(	O
32	1122	O
33	/	O
34	1664	O
35	),	O
36	66	O
37	%	O
38	(	O
39	65	O
40	/	O
41	97	O
42	),	O
43	33	O
44	%	O
45	(	O
46	4	O
47	/	O
48	12	O
49	)	O
50	and	O
51	40	O
52	%	O
53	(	O
54	19	O
55	/	O
56	47	O
57	)	O
58	for	O
59	children	O
60	receiving	O
61	3	O
62	,	O
63	2	O
64	,	O
65	1	O
66	,	O
67	and	O
68	0	O
69	dose	O
70	of	O
71	JE	O
72	vaccines	O
73	,	O
74	respectively	O
75	(	O
76	P	O
77	<	O
78	0	O
79	.	O
80	0001	O
81	Chi	O
82	-	O
83	square	O
84	for	O
85	trend	O
86	test	O
87	).	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O

1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O

1	CKbeta4GT	B
2	-	I
3	II	I
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	B
10	II	I
11	transmembrane	I
12	glycoprotein	I
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O

1	In	O
2	the	O
3	37	O
4	patients	O
5	without	O
6	lung	O
7	disease	O
8	respiratory	O
9	muscle	O
10	weakness	O
11	was	O
12	accompanied	O
13	by	O
14	significant	O
15	decreases	O
16	in	O
17	vital	O
18	capacity	O
19	,	O
20	total	O
21	lung	O
22	capacity	O
23	,	O
24	and	O
25	maximum	O
26	voluntary	O
27	ventilation	O
28	;	O
29	by	O
30	significant	O
31	increases	O
32	in	O
33	residual	O
34	volume	O
35	and	O
36	arterial	O
37	carbon	O
38	dioxide	O
39	tension	O
40	(	O
41	PaCO2	O
42	);	O
43	and	O
44	greater	O
45	likelihood	O
46	of	O
47	dependence	O
48	on	O
49	ventilators	O
50	,	O
51	atelectasis	O
52	,	O
53	and	O
54	pneumonia	O
55	.	O

1	The	O
2	calcium	O
3	ratio	O
4	(	O
5	mean	O
6	ratio	O
7	of	O
8	the	O
9	predicted	O
10	to	O
11	measured	O
12	TBCa	O
13	)	O
14	in	O
15	men	O
16	was	O
17	1	O
18	.	O
19	000	O
20	+/-	O
21	7	O
22	.	O
23	8	O
24	%	O
25	and	O
26	in	O
27	women	O
28	0	O
29	.	O
30	996	O
31	+/-	O
32	7	O
33	.	O
34	1	O
35	%.	O

1	Ras2p	B
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	B
16	(	O
17	Cdc42p	B
18	/	O
19	Ste20p	B
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	B
33	/	O
34	cAMP	O
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	After	O
2	termination	O
3	of	O
4	medication	O
5	the	O
6	animals	O
7	were	O
8	kindled	O
9	electrically	O
10	in	O
11	the	O
12	nucleus	O
13	amygdala	O
14	.	O

1	Strains	O
2	bearing	O
3	the	O
4	drs2	B
5	mutation	I
6	process	O
7	the	O
8	20S	B
9	precursor	I
10	of	O
11	the	O
12	mature	B
13	18S	I
14	rRNA	I
15	slowly	O
16	and	O
17	are	O
18	deficient	O
19	in	O
20	40S	B
21	ribosomal	I
22	subunits	I
23	.	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	Re	O
2	-	O
3	examination	O
4	of	O
5	the	O
6	ED01	O
7	study	O
8	.	O

1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	O
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O

1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	B
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O

1	Effects	O
2	of	O
3	chronic	O
4	metaraminol	O
5	treatment	O
6	on	O
7	the	O
8	sympathetic	O
9	activity	O
10	of	O
11	intact	O
12	and	O
13	adrenal	O
14	demedullated	O
15	rats	O
16	kept	O
17	in	O
18	warm	O
19	or	O
20	cold	O
21	environments	O
22	.	O

1	The	O
2	unexpected	O
3	presence	O
4	of	O
5	the	O
6	tRNA	B
7	(	I
8	trp	I
9	)(	I
10	CCA	I
11	)-	I
12	gene	I
13	transcript	I
14	in	I
15	mitochondria	I
16	is	O
17	also	O
18	reported	O
19	.	O

1	LPO	O
2	and	O
3	SOD	B
4	levels	O
5	were	O
6	measured	O
7	at	O
8	five	O
9	points	O
10	before	O
11	and	O
12	during	O
13	the	O
14	operation	O
15	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	B
28	protein	I
29	(	O
30	TP	B
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	(	O
2	1991	O
3	).	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	results	O
5	show	O
6	that	O
7	once	O
8	daily	O
9	oral	O
10	valganciclovir	O
11	can	O
12	produce	O
13	exposures	O
14	of	O
15	ganciclovir	O
16	(	O
17	AUC24	O
18	)	O
19	exceeding	O
20	those	O
21	attained	O
22	using	O
23	intravenous	O
24	ganciclovir	O
25	10	O
26	mg	O
27	/	O
28	kg	O
29	.	O

1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O

1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	B
5	/	O
6	Erk	B
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	B
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	B
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	B
23	.	O

1	Using	O
2	Ki	B
3	-	I
4	ras	I
5	-	O
6	transformed	O
7	3T3	O
8	cells	O
9	as	O
10	a	O
11	model	O
12	system	O
13	,	O
14	we	O
15	show	O
16	that	O
17	both	O
18	RA	O
19	and	O
20	the	O
21	'	O
22	dissociating	O
23	'	O
24	retinoids	O
25	inhibit	O
26	anchorage	O
27	-	O
28	independent	O
29	cell	O
30	proliferation	O
31	,	O
32	suggesting	O
33	that	O
34	retinoid	O
35	-	O
36	induced	O
37	growth	O
38	inhibition	O
39	may	O
40	be	O
41	related	O
42	to	O
43	AP1	B
44	transrepression	O
45	.	O

1	Both	O
2	groups	O
3	were	O
4	subjected	O
5	to	O
6	tests	O
7	of	O
8	delayed	O
9	hypersensitivity	O
10	with	O
11	Candidin	B
12	,	O
13	Trycophytin	B
14	and	O
15	Tuberculin	B
16	.	O

1	To	O
2	evaluate	O
3	whether	O
4	the	O
5	human	O
6	gene	O
7	is	O
8	also	O
9	a	O
10	target	O
11	of	O
12	thyroid	O
13	hormone	O
14	we	O
15	have	O
16	searched	O
17	for	O
18	T3	O
19	-	O
20	responsive	O
21	elements	O
22	in	O
23	NRGN	B
24	cloned	O
25	genomic	O
26	fragments	O
27	spanning	O
28	the	O
29	whole	O
30	gene	O
31	.	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	B
10	/	O
11	CIC2B9	B
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	B
21	/	O
22	Ds	B
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	overall	O
7	performance	O
8	of	O
9	a	O
10	new	O
11	oscillometric	O
12	wrist	O
13	blood	O
14	pressure	O
15	monitor	O
16	(	O
17	Braun	O
18	PrecisionSensor	O
19	,	O
20	Braun	O
21	GmbH	O
22	,	O
23	Kronberg	O
24	,	O
25	Germany	O
26	)	O
27	as	O
28	defined	O
29	by	O
30	the	O
31	ANSI	O
32	/	O
33	AAMI	O
34	SP10	O
35	-	O
36	1992	O
37	guidelines	O
38	,	O
39	and	O
40	to	O
41	analyze	O
42	the	O
43	data	O
44	for	O
45	the	O
46	optimized	O
47	selection	O
48	of	O
49	the	O
50	algorithm	O
51	that	O
52	derives	O
53	the	O
54	blood	O
55	pressure	O
56	values	O
57	from	O
58	the	O
59	oscillometric	O
60	blood	O
61	pressure	O
62	curves	O
63	.	O

1	National	O
2	certification	O
3	:	O
4	a	O
5	vital	O
6	component	O
7	of	O
8	quality	O
9	assurance	O
10	.	O

1	In	O
2	order	O
3	to	O
4	identify	O
5	and	O
6	classify	O
7	the	O
8	basic	O
9	CT	O
10	appearances	O
11	of	O
12	interstitial	O
13	pneumonia	O
14	,	O
15	radiologic	O
16	-	O
17	pathologic	O
18	correlative	O
19	study	O
20	was	O
21	performed	O
22	using	O
23	inflated	O
24	and	O
25	fixed	O
26	lungs	O
27	from	O
28	autopsy	O
29	and	O
30	surgery	O
31	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	Replicating	O
2	simian	O
3	virus	O
4	40	O
5	(	O
6	SV40	O
7	)	O
8	chromosomes	O
9	were	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	to	O
15	other	O
16	eukaryotic	O
17	chromosomes	O
18	in	O
19	that	O
20	the	O
21	rate	O
22	and	O
23	extent	O
24	of	O
25	micrococcal	B
26	nuclease	I
27	(	O
28	MNase	B
29	)	O
30	digestion	O
31	were	O
32	greater	O
33	with	O
34	replicating	O
35	than	O
36	with	O
37	nonreplicating	O
38	mature	O
39	SV40	O
40	chromatin	O
41	.	O

1	The	O
2	ERH	B
3	expression	O
4	profile	O
5	is	O
6	similar	O
7	,	O
8	to	O
9	that	O
10	of	O
11	An3	B
12	,	O
13	which	O
14	localizes	O
15	to	O
16	the	O
17	animal	O
18	hemisphere	O
19	of	O
20	oocytes	O
21	and	O
22	is	O
23	abundantly	O
24	expressed	O
25	in	O
26	the	O
27	embryo	O
28	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	patient	O
7	'	O
8	s	O
9	report	O
10	of	O
11	one	O
12	inaccurate	O
13	Clinitemp	O
14	,	O
15	we	O
16	undertook	O
17	to	O
18	investigate	O
19	the	O
20	accuracy	O
21	of	O
22	this	O
23	thermometer	O
24	.	O

1	Serial	O
2	levels	O
3	of	O
4	troponin	B
5	T	I
6	and	O
7	the	O
8	activity	O
9	of	O
10	CK	B
11	-	I
12	MB	I
13	were	O
14	measured	O
15	6	O
16	,	O
17	12	O
18	,	O
19	24	O
20	and	O
21	48	O
22	h	O
23	after	O
24	aortic	O
25	unclamping	O
26	.	O

1	A	O
2	hydrodynamic	O
3	description	O
4	of	O
5	the	O
6	osmotic	O
7	reflection	O
8	coefficient	O
9	with	O
10	application	O
11	to	O
12	the	O
13	pore	O
14	theory	O
15	of	O
16	transcapillary	O
17	exchange	O
18	.	O

1	Isolation	O
2	and	O
3	identification	O
4	of	O
5	genes	O
6	activating	O
7	UAS2	B
8	-	I
9	dependent	I
10	ADH2	I
11	expression	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	Supraventricular	O
2	arrhythmias	O
3	--	O
4	digoxin	O
5	and	O
6	quinidine	O
7	revisited	O
8	.	O

1	The	O
2	corresponding	O
3	gene	O
4	was	O
5	identified	O
6	in	O
7	the	O
8	GenBankTM	O
9	data	O
10	base	O
11	by	O
12	sequence	O
13	alignment	O
14	and	O
15	termed	O
16	RPS30A	B
17	.	O

1	Glutamyl	B
2	-	I
3	tRNA	I
4	synthetase	I
5	and	O
6	prolyl	B
7	-	I
8	tRNA	I
9	synthetase	I
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	B
16	-	I
17	tRNA	I
18	synthetases	I
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O

1	Laboratory	O
2	evaluation	O
3	was	O
4	normal	O
5	,	O
6	and	O
7	neuroimaging	O
8	failed	O
9	to	O
10	confirm	O
11	obstruction	O
12	of	O
13	venous	O
14	or	O
15	lymphatic	O
16	drainage	O
17	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	and	O
6	craniofacial	O
7	dimensions	O
8	following	O
9	administration	O
10	of	O
11	the	O
12	antineoplastic	O
13	agent	O
14	vincristine	O
15	to	O
16	young	O
17	rats	O
18	.	O

1	Thus	O
2	,	O
3	multiple	O
4	myogenic	O
5	factors	O
6	that	O
7	vary	O
8	qualitatively	O
9	and	O
10	quantitatively	O
11	may	O
12	be	O
13	responsible	O
14	for	O
15	the	O
16	different	O
17	and	O
18	complex	O
19	modulatory	O
20	programs	O
21	of	O
22	actin	B
23	gene	I
24	expression	O
25	observed	O
26	during	O
27	in	O
28	vivo	O
29	muscle	O
30	differentiation	O
31	.	O

1	In	O
2	studies	O
3	of	O
4	many	O
5	different	O
6	phenotypically	O
7	distinct	O
8	cells	O
9	,	O
10	the	O
11	CRE	O
12	of	O
13	the	O
14	somatostatin	B
15	gene	I
16	promoter	I
17	is	O
18	a	O
19	prototype	O
20	of	O
21	a	O
22	highly	O
23	cAMP	O
24	-	O
25	responsive	O
26	element	O
27	regulated	O
28	by	O
29	CREB	B
30	.	O

1	Clinical	O
2	value	O
3	of	O
4	the	O
5	estimation	O
6	of	O
7	growth	O
8	kinetics	O
9	of	O
10	primary	O
11	ovarian	O
12	cancer	O
13	recurrences	O
14	by	O
15	CA125	B
16	doubling	O
17	time	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	Thus	O
2	,	O
3	the	O
4	tri	O
5	-	O
6	snRNP	O
7	-	O
8	specific	O
9	27K	O
10	protein	O
11	could	O
12	potentially	O
13	be	O
14	involved	O
15	in	O
16	SR	B
17	protein	O
18	-	O
19	mediated	O
20	protein	O
21	/	O
22	protein	O
23	interactions	O
24	and	O
25	,	O
26	additionally	O
27	,	O
28	its	O
29	phosphorylation	O
30	state	O
31	could	O
32	modulate	O
33	pre	O
34	-	O
35	mRNA	O
36	splicing	O
37	.	O

1	Cell	O
2	.	O

1	A	O
2	region	O
3	of	O
4	the	O
5	deduced	O
6	protein	O
7	shares	O
8	extensive	O
9	homology	O
10	with	O
11	a	O
12	catalytic	O
13	region	O
14	of	O
15	Raf	B
16	kinases	I
17	,	O
18	a	O
19	feature	O
20	shared	O
21	only	O
22	with	O
23	TFIIE	B
24	among	O
25	transcription	O
26	factors	O
27	.	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	The	O
2	overall	O
3	incidence	O
4	of	O
5	SIDS	O
6	was	O
7	1	O
8	.	O
9	43	O
10	per	O
11	1	O
12	,	O
13	000	O
14	live	O
15	births	O
16	.	O

1	Genomic	O
2	clones	O
3	encompassing	O
4	the	O
5	human	B
6	ETS1	I
7	gene	I
8	were	O
9	isolated	O
10	and	O
11	utilized	O
12	to	O
13	define	O
14	its	O
15	molecular	O
16	organization	O
17	.	O

1	PNT	O
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O

1	It	O
2	has	O
3	been	O
4	demonstrated	O
5	previously	O
6	that	O
7	Pax	B
8	-	I
9	6	I
10	,	O
11	a	O
12	paired	B
13	domain	I
14	(	O
15	PD	B
16	)/	O
17	homeodomain	B
18	(	O
19	HD	B
20	)	O
21	transcription	O
22	factor	O
23	critical	O
24	for	O
25	eye	O
26	development	O
27	,	O
28	contributes	O
29	to	O
30	the	O
31	activation	O
32	of	O
33	the	O
34	alphaB	B
35	-,	I
36	alphaA	I
37	-,	I
38	delta1	I
39	-,	I
40	and	I
41	zeta	I
42	-	I
43	crystallin	I
44	genes	O
45	in	O
46	the	O
47	lens	O
48	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	We	O
2	provide	O
3	community	O
4	metabolic	O
5	data	O
6	that	O
7	indicate	O
8	that	O
9	large	O
10	changes	O
11	in	O
12	CO2	O
13	concentration	O
14	can	O
15	occur	O
16	in	O
17	coral	O
18	reef	O
19	waters	O
20	via	O
21	biogeochemical	O
22	processes	O
23	not	O
24	directly	O
25	associated	O
26	with	O
27	photosynthesis	O
28	,	O
29	respiration	O
30	,	O
31	calcification	O
32	,	O
33	and	O
34	CaCO3	O
35	dissolution	O
36	.	O

1	The	O
2	splice	O
3	acceptor	O
4	site	O
5	is	O
6	ca	O
7	.	O

1	Cataract	O
2	extraction	O
3	in	O
4	primary	O
5	glaucoma	O

1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	Following	O
2	chondroitinase	B
3	AC	I
4	and	I
5	ABC	I
6	digestion	O
7	,	O
8	staining	O
9	reactions	O
10	suggested	O
11	that	O
12	the	O
13	highest	O
14	levels	O
15	of	O
16	dermatan	O
17	sulfate	O
18	were	O
19	in	O
20	the	O
21	diabetes	O
22	resistant	O
23	group	O
24	(	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	compared	O
32	to	O
33	diabetic	O
34	,	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	001	O
41	compared	O
42	to	O
43	diabetes	O
44	prone	O
45	)	O
46	and	O
47	the	O
48	highest	O
49	levels	O
50	of	O
51	chondroitin	O
52	sulfates	O
53	were	O
54	in	O
55	the	O
56	diabetes	O
57	prone	O
58	group	O
59	(	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	001	O
66	).	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	Sera	O
2	from	O
3	euthyroid	O
4	post	O
5	-	O
6	menopausal	O
7	or	O
8	pregnant	O
9	women	O
10	yielded	O
11	TSH	B
12	levels	O
13	within	O
14	the	O
15	normal	O
16	range	O
17	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	O
28	GM	B
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	O
39	IL	B
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O

1	In	O
2	summary	O
3	,	O
4	WT1	B
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	B
17	,	O
18	the	O
19	U5	B
20	small	I
21	nuclear	I
22	RNP	I
23	-	I
24	associated	I
25	protein	I
26	p116	I
27	and	O
28	hnRNP	O
29	A1	B
30	.	O

1	Factors	O
2	that	O
3	showed	O
4	significant	O
5	correlation	O
6	to	O
7	elevated	O
8	CIC	O
9	'	O
10	s	O
11	in	O
12	the	O
13	highly	O
14	elevated	O
15	portion	O
16	of	O
17	our	O
18	CIC	O
19	population	O
20	were	O
21	poor	O
22	NIH	O
23	score	O
24	,	O
25	increased	O
26	patient	O
27	age	O
28	,	O
29	low	O
30	peak	O
31	expiratory	O
32	flow	O
33	rate	O
34	,	O
35	and	O
36	elevated	O
37	total	O
38	serum	B
39	IgG	I
40	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	O
22	WAF1	B
23	/	O
24	Cip1	B
25	promoter	O
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Immunofluorescence	O
2	microscopy	O
3	and	O
4	cell	O
5	fractionation	O
6	analyses	O
7	showed	O
8	that	O
9	the	O
10	110	O
11	-	O
12	kDa	O
13	protein	O
14	was	O
15	exclusively	O
16	nuclear	O
17	,	O
18	whereas	O
19	the	O
20	150	O
21	-	O
22	kDa	O
23	protein	O
24	was	O
25	present	O
26	in	O
27	both	O
28	the	O
29	cytoplasm	O
30	and	O
31	nucleus	O
32	of	O
33	human	O
34	cells	O
35	.	O

1	The	O
2	products	O
3	of	O
4	the	O
5	Saccharomyces	B
6	cerevisiae	I
7	CIN1	I
8	,	O
9	CIN2	B
10	and	O
11	CIN4	B
12	genes	I
13	participate	O
14	in	O
15	a	O
16	nonessential	O
17	pathway	O
18	required	O
19	for	O
20	normal	O
21	microtubule	O
22	function	O
23	.	O

1	Beta	O
2	blocking	O
3	agents	O
4	.	O

1	We	O
2	evaluated	O
3	regional	O
4	right	O
5	ventricular	O
6	wall	O
7	motion	O
8	during	O
9	systole	O
10	in	O
11	patients	O
12	with	O
13	surgically	O
14	repaired	O
15	tetralogy	O
16	of	O
17	Fallot	O
18	(	O
19	TOF	O
20	)	O
21	using	O
22	color	O
23	kinesis	O
24	imaging	O
25	.	O

1	Coronary	O
2	arteries	O
3	--	O
4	old	O
5	and	O
6	new	O
7	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	rat	B
5	SH2	I
6	-	I
7	containing	I
8	inositol	I
9	phosphatase	I
10	2	I
11	(	O
12	SHIP2	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	cDNA	O
6	for	O
7	the	O
8	human	B
9	U2	I
10	snRNA	I
11	-	I
12	specific	I
13	A	I
14	'	I
15	protein	I
16	.	O

1	Most	O
2	of	O
3	the	O
4	expressed	O
5	human	B
6	E3	I
7	polypeptides	I
8	(	O
9	five	O
10	bands	O
11	)	O
12	were	O
13	found	O
14	in	O
15	the	O
16	insoluble	O
17	pellet	O
18	while	O
19	primarily	O
20	full	B
21	-	I
22	length	I
23	mature	I
24	E3	I
25	was	O
26	found	O
27	in	O
28	the	O
29	soluble	O
30	fraction	O
31	.	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	Polypeptides	O
2	of	O
3	the	O
4	same	O
5	apparent	O
6	sizes	O
7	are	O
8	detected	O
9	in	O
10	spores	O
11	of	O
12	a	O
13	cotE	B
14	null	O
15	mutant	O
16	,	O
17	on	O
18	which	O
19	basis	O
20	we	O
21	infer	O
22	that	O
23	the	O
24	products	O
25	of	O
26	the	O
27	cotJ	B
28	operon	I
29	are	O
30	required	O
31	for	O
32	the	O
33	normal	O
34	formation	O
35	of	O
36	the	O
37	inner	O
38	layers	O
39	of	O
40	the	O
41	coat	O
42	or	O
43	are	O
44	themselves	O
45	structural	O
46	components	O
47	of	O
48	the	O
49	coat	O
50	.	O

1	DMI	O
2	and	O
3	2	O
4	-	O
5	OH	O
6	-	O
7	DMI	O
8	concentrations	O
9	were	O
10	determined	O
11	in	O
12	a	O
13	similar	O
14	group	O
15	of	O
16	61	O
17	DMI	O
18	-	O
19	treated	O
20	patients	O
21	.	O

1	Translation	O
2	of	O
3	the	O
4	coding	O
5	segment	O
6	,	O
7	which	O
8	was	O
9	designated	O
10	MsPRP2	B
11	,	O
12	suggested	O
13	it	O
14	encodes	O
15	a	O
16	chimeric	O
17	40	O
18	,	O
19	569	O
20	Da	O
21	cell	O
22	wall	O
23	protein	O
24	with	O
25	an	O
26	amino	O
27	-	O
28	terminal	O
29	signal	O
30	sequence	O
31	,	O
32	a	O
33	repetitive	O
34	proline	O
35	-	O
36	rich	O
37	sequence	O
38	,	O
39	and	O
40	a	O
41	cysteine	O
42	-	O
43	rich	O
44	carboxyl	O
45	-	O
46	terminal	O
47	sequence	O
48	homologous	O
49	to	O
50	nonspecific	O
51	lipid	O
52	transfer	O
53	proteins	O
54	.	O

1	If	O
2	facilities	O
3	for	O
4	measurements	O
5	of	O
6	O2	O
7	consumption	O
8	and	O
9	hence	O
10	metabolic	O
11	rate	O
12	are	O
13	available	O
14	,	O
15	these	O
16	should	O
17	be	O
18	utilized	O
19	.	O

1	Studies	O
2	of	O
3	lipogenesis	O
4	by	O
5	labelled	O
6	precursors	O
7	in	O
8	the	O
9	pregnant	O
10	rat	O
11	.	O

1	Repair	O
2	of	O
3	this	O
4	insertion	O
5	by	O
6	homologous	O
7	recombination	O
8	restores	O
9	the	O
10	activity	O
11	of	O
12	the	O
13	hprt	B
14	locus	I
15	,	O
16	thus	O
17	confirming	O
18	the	O
19	site	O
20	of	O
21	mutation	O
22	.	O

1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O

1	Do	O
2	overall	O
3	treatment	O
4	time	O
5	,	O
6	field	O
7	size	O
8	,	O
9	and	O
10	treatment	O
11	energy	O
12	influence	O
13	local	O
14	control	O
15	of	O
16	T1	O
17	-	O
18	T2	O
19	squamous	O
20	cell	O
21	carcinomas	O
22	of	O
23	the	O
24	glottic	O
25	larynx	O
26	?	O
27	PURPOSE	O
28	:	O
29	To	O
30	evaluate	O
31	treatment	O
32	and	O
33	patient	O
34	related	O
35	prognostic	O
36	factors	O
37	that	O
38	may	O
39	influence	O
40	local	O
41	control	O
42	in	O
43	the	O
44	treatment	O
45	of	O
46	T1	O
47	-	O
48	T2	O
49	squamous	O
50	cell	O
51	carcinoma	O
52	of	O
53	the	O
54	glottic	O
55	larynx	O
56	.	O

1	Definite	O
2	JPsA	O
3	(	O
4	24	O
5	patients	O
6	)	O
7	was	O
8	defined	O
9	as	O
10	arthritis	O
11	associated	O
12	,	O
13	but	O
14	not	O
15	necessarily	O
16	coincident	O
17	,	O
18	with	O
19	a	O
20	typical	O
21	psoriatic	O
22	rash	O
23	,	O
24	or	O
25	arthritis	O
26	plus	O
27	at	O
28	least	O
29	3	O
30	of	O
31	4	O
32	minor	O
33	criteria	O
34	:	O
35	dactylitis	O
36	,	O
37	nail	O
38	pitting	O
39	,	O
40	psoriasis	O
41	-	O
42	like	O
43	rash	O
44	,	O
45	or	O
46	family	O
47	history	O
48	of	O
49	psoriasis	O
50	.	O

1	An	O
2	inactive	O
3	analog	O
4	of	O
5	wortmannin	O
6	,	O
7	WM12	O
8	,	O
9	did	O
10	not	O
11	affect	O
12	TCR	B
13	/	O
14	CD3	B
15	-	O
16	induced	O
17	Erk2	B
18	activation	O
19	,	O
20	and	O
21	wortmannin	O
22	had	O
23	no	O
24	effect	O
25	on	O
26	the	O
27	activity	O
28	of	O
29	Erk2	B
30	when	O
31	added	O
32	directly	O
33	to	O
34	the	O
35	in	O
36	vitro	O
37	assays	O
38	.	O

1	Evoked	O
2	electromyographic	O
3	response	O
4	to	O
5	indirect	O
6	supramaximal	O
7	stimulation	O
8	at	O
9	1	O
10	Hz	O
11	was	O
12	monitored	O
13	in	O
14	ten	O
15	adult	O
16	goats	O
17	under	O
18	thiopentone	O
19	-	O
20	halothane	O
21	anaesthesia	O
22	.	O

1	It	O
2	appears	O
3	that	O
4	the	O
5	pulmonary	O
6	gas	O
7	exchange	O
8	parenchyma	O
9	of	O
10	these	O
11	smallest	O
12	mammals	O
13	is	O
14	well	O
15	suited	O
16	to	O
17	supply	O
18	the	O
19	organism	O
20	with	O
21	the	O
22	comparatively	O
23	high	O
24	levels	O
25	of	O
26	O2	O
27	required	O
28	by	O
29	the	O
30	high	O
31	metabolic	O
32	rates	O
33	,	O
34	exhibiting	O
35	a	O
36	structural	O
37	adaptation	O
38	of	O
39	the	O
40	lung	O
41	to	O
42	higher	O
43	VO2	O
44	.	O

1	The	O
2	pathogenesis	O
3	of	O
4	Limited	O
5	Joint	O
6	Mobility	O
7	(	O
8	LJM	O
9	)	O
10	in	O
11	diabetes	O
12	is	O
13	unknown	O
14	,	O
15	but	O
16	the	O
17	abnormality	O
18	is	O
19	said	O
20	to	O
21	be	O
22	associated	O
23	with	O
24	an	O
25	increased	O
26	incidence	O
27	of	O
28	microangiopathy	O
29	.	O

1	In	O
2	view	O
3	of	O
4	the	O
5	short	O
6	t1	O
7	/	O
8	2	O
9	,	O
10	we	O
11	used	O
12	three	O
13	doses	O
14	/	O
15	day	O
16	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	Northern	O
2	analysis	O
3	revealed	O
4	no	O
5	detectable	O
6	expression	O
7	of	O
8	the	O
9	transcript	O
10	in	O
11	diapause	O
12	-	O
13	or	O
14	nondiapause	O
15	-	O
16	programmed	O
17	wandering	O
18	larvae	O
19	,	O
20	and	O
21	only	O
22	trace	O
23	expression	O
24	in	O
25	nondiapausing	O
26	pupae	O
27	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	O
10	,	O
11	d20	O
12	,	O
13	d27	O
14	,	O
15	d31	O
16	,	O
17	d40	O
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	O
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	O
51	-	O
52	SR	O
53	alpha	O
54	-	O
55	296	O
56	)	O
57	in	O
58	CV	O
59	-	O
60	1	O
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	Taking	O
2	into	O
3	consideration	O
4	weight	O
5	and	O
6	seasonal	O
7	changes	O
8	in	O
9	bone	O
10	mass	O
11	,	O
12	total	O
13	(	O
14	TBBMC	O
15	)	O
16	and	O
17	regional	O
18	body	O
19	bone	O
20	mineral	O
21	content	O
22	were	O
23	measured	O
24	in	O
25	38	O
26	women	O
27	treated	O
28	with	O
29	GnRH	B
30	agonists	O
31	for	O
32	6	O
33	months	O
34	for	O
35	endometriosis	O
36	or	O
37	leiomyomata	O
38	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	O
12	(	O
13	Ft	O
14	II	O
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	gcd1	B
6	-	I
7	101	I
8	mutation	I
9	suppressed	O
10	the	O
11	low	O
12	translational	O
13	efficiency	O
14	of	O
15	GCN4	B
16	-	O
17	lacZ	B
18	mRNA	O
19	observed	O
20	in	O
21	gcn2	B
22	-	I
23	and	O
24	gcn3	B
25	-	I
26	cells	O
27	.	O

1	Female	O
2	subjects	O
3	,	O
4	including	O
5	both	O
6	normal	O
7	subjects	O
8	and	O
9	idiopathic	O
10	calcium	O
11	stone	O
12	-	O
13	formers	O
14	,	O
15	have	O
16	higher	O
17	urinary	O
18	cyclic	O
19	AMP	O
20	levels	O
21	than	O
22	their	O
23	male	O
24	counterparts	O
25	,	O
26	and	O
27	this	O
28	difference	O
29	is	O
30	significant	O
31	when	O
32	urinary	O
33	cyclic	O
34	AMP	O
35	is	O
36	expressed	O
37	in	O
38	the	O
39	units	O
40	mumol	O
41	/	O
42	g	O
43	of	O
44	creatinine	O
45	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	Thirty	O
2	Class	O
3	I	O
4	and	O
5	Class	O
6	II	O
7	recessions	O
8	in	O
9	30	O
10	patients	O
11	were	O
12	treated	O
13	with	O
14	a	O
15	modified	O
16	subepithelial	O
17	connective	O
18	tissue	O
19	graft	O
20	procedure	O
21	.	O

1	The	O
2	biochemistry	O
3	of	O
4	amniotic	O
5	fluid	O
6	with	O
7	poor	O
8	fetal	O
9	growth	O
10	.	O

1	The	O
2	alcoholic	O
3	patient	O
4	,	O
5	his	O
6	work	O
7	and	O
8	the	O
9	subjectivity	O
10	of	O
11	the	O
12	period	O

1	Although	O
2	not	O
3	common	O
4	,	O
5	the	O
6	disorder	O
7	is	O
8	the	O
9	most	O
10	frequently	O
11	diagnosed	O
12	disturbance	O
13	of	O
14	porphyrin	O
15	metabolism	O
16	in	O
17	many	O
18	countries	O
19	,	O
20	and	O
21	further	O
22	insight	O
23	into	O
24	its	O
25	unusual	O
26	pathogenesis	O
27	may	O
28	clarify	O
29	the	O
30	hepatotoxic	O
31	effects	O
32	of	O
33	the	O
34	4	O
35	etiologic	O
36	agents	O
37	.	O

1	The	O
2	Authors	O
3	have	O
4	proposed	O
5	to	O
6	develop	O
7	this	O
8	research	O
9	employing	O
10	a	O
11	preparation	O
12	containing	O
13	exclusively	O
14	a	O
15	cortisonic	O
16	,	O
17	the	O
18	desametazone	O
19	,	O
20	in	O
21	order	O
22	to	O
23	evaluate	O
24	the	O
25	alterations	O
26	of	O
27	the	O
28	dentinogenesis	O
29	to	O
30	be	O
31	attributed	O
32	to	O
33	such	O
34	component	O
35	.	O

1	Biol	O
2	.	O

1	Post	O
2	-	O
3	transcriptional	O
4	regulation	O
5	of	O
6	ribosomal	B
7	protein	I
8	gene	I
9	expression	O
10	during	O
11	development	O
12	in	O
13	Dictyostelium	O
14	discoideum	O
15	.	O

1	The	O
2	average	O
3	deviations	O
4	in	O
5	the	O
6	X	O
7	-	O
8	ray	O
9	counts	O
10	of	O
11	the	O
12	constant	O
13	elements	O
14	from	O
15	the	O
16	series	O
17	means	O
18	were	O
19	used	O
20	to	O
21	correct	O
22	the	O
23	recorded	O
24	count	O
25	of	O
26	the	O
27	variable	O
28	element	O
29	in	O
30	each	O
31	block	O
32	.	O

1	Active	O
2	complexes	O
3	eluted	O
4	at	O
5	a	O
6	higher	O
7	molecular	O
8	weight	O
9	than	O
10	inactive	O
11	complexes	O
12	,	O
13	were	O
14	relatively	O
15	deficient	O
16	in	O
17	both	O
18	p21	B
19	and	O
20	p27	B
21	,	O
22	and	O
23	contained	O
24	Cdk2	B
25	with	O
26	increased	O
27	threonine	O
28	160	O
29	phosphorylation	O
30	,	O
31	consistent	O
32	with	O
33	a	O
34	mechanism	O
35	of	O
36	activation	O
37	of	O
38	cyclin	B
39	E	I
40	-	O
41	Cdk2	B
42	involving	O
43	both	O
44	reduced	O
45	CDK	B
46	inhibitor	O
47	association	O
48	and	O
49	CDK	B
50	-	I
51	activating	I
52	kinase	I
53	-	O
54	mediated	O
55	phosphorylation	O
56	of	O
57	Cdk2	B
58	.	O

1	During	O
2	the	O
3	following	O
4	pregnancy	O
5	ultrasonographic	O
6	studies	O
7	of	O
8	the	O
9	male	O
10	fetus	O
11	in	O
12	the	O
13	16th	O
14	week	O
15	of	O
16	gestation	O
17	revealed	O
18	severe	O
19	micrognathia	O
20	,	O
21	short	O
22	and	O
23	wide	O
24	thumbs	O
25	,	O
26	and	O
27	big	O
28	toes	O
29	,	O
30	and	O
31	bowed	O
32	tibiae	O
33	.	O

1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O

1	Labial	O
2	bar	O
3	.	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	B
7	-	I
8	binding	I
9	motif	I
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	B
23	.	O

1	The	O
2	ability	O
3	of	O
4	spt2	B
5	mutations	I
6	to	O
7	suppress	O
8	the	O
9	transcriptional	O
10	interference	O
11	caused	O
12	by	O
13	the	O
14	delta	B
15	promoter	I
16	insertion	I
17	his	I
18	-	I
19	4	I
20	-	I
21	912	I
22	delta	I
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	B
29	-	I
30	type	I
31	HIS4	I
32	mRNA	I
33	levels	O
34	.	O

1	Eukaryotic	B
2	initiation	I
3	factor	I
4	3	I
5	(	O
6	eIF3	B
7	)	O
8	is	O
9	a	O
10	large	O
11	multisubunit	O
12	complex	O
13	that	O
14	stabilizes	O
15	the	O
16	ternary	O
17	complex	O
18	,	O
19	eIF2	B
20	x	O
21	GTP	O
22	x	O
23	tRNA	B
24	(	I
25	Met	I
26	)	I
27	i	I
28	and	O
29	promotes	O
30	mRNA	O
31	binding	O
32	to	O
33	the	O
34	40	B
35	S	I
36	ribosomal	I
37	subunit	I
38	.	O
39	eIF3	B
40	also	O
41	functions	O
42	as	O
43	a	O
44	ribosome	O
45	subunit	O
46	anti	O
47	-	O
48	association	O
49	factor	O
50	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	enhancer	O
6	was	O
7	also	O
8	probed	O
9	by	O
10	inserting	O
11	a	O
12	pair	O
13	of	O
14	complementary	O
15	synthetic	O
16	oligodeoxynucleotides	O
17	which	O
18	represented	O
19	the	O
20	region	O
21	between	O
22	nt	O
23	positions	O
24	-	O
25	235	O
26	and	O
27	-	O
28	215	O
29	into	O
30	a	O
31	truncated	O
32	template	O
33	which	O
34	lacked	O
35	the	O
36	enhancer	O
37	.	O

1	It	O
2	is	O
3	also	O
4	homologous	O
5	to	O
6	other	O
7	sugar	O
8	carriers	O
9	from	O
10	human	O
11	,	O
12	mouse	O
13	and	O
14	Escherichia	O
15	coli	O
16	.	O

1	Thalamotomy	O
2	aiming	O
3	at	O
4	the	O
5	CM	O
6	-	O
7	Pf	O
8	complex	O
9	and	O
10	using	O
11	stereotactic	O
12	gamma	O
13	irradiation	O
14	has	O
15	been	O
16	performed	O
17	in	O
18	a	O
19	series	O
20	of	O
21	52	O
22	patients	O
23	with	O
24	severe	O
25	pain	O
26	due	O
27	to	O
28	malignancy	O
29	.	O

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	The	O
2	ns2	B
3	gene	I
4	comprises	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	(	O
10	ORF	O
11	)	O
12	encoding	O
13	a	O
14	putative	O
15	nonstructural	O
16	(	O
17	ns	O
18	)	O
19	protein	O
20	of	O
21	279	O
22	amino	O
23	acids	O
24	with	O
25	a	O
26	predicted	O
27	molecular	O
28	mass	O
29	of	O
30	32	O
31	-	O
32	kDa	O
33	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	The	O
2	development	O
3	of	O
4	a	O
5	data	O
6	base	O
7	is	O
8	described	O
9	which	O
10	can	O
11	be	O
12	used	O
13	as	O
14	common	O
15	reference	O
16	for	O
17	ECG	O
18	computer	O
19	programs	O
20	analyzing	O
21	12	O
22	or	O
23	15	O
24	simultaneously	O
25	recorded	O
26	leads	O
27	.	O

1	A	O
2	false	O
3	positive	O
4	marker	O
5	screen	O
6	was	O
7	associated	O
8	with	O
9	the	O
10	occurrence	O
11	of	O
12	hand	O
13	-	O
14	foot	O
15	syndrome	O
16	even	O
17	when	O
18	the	O
19	effect	O
20	of	O
21	regimen	O
22	was	O
23	accounted	O
24	for	O
25	by	O
26	stratification	O
27	(	O
28	p	O
29	=	O
30	.	O
31	01	O
32	).	O

1	Those	O
2	dosages	O
3	that	O
4	inhibited	O
5	mean	O
6	NTE	B
7	activity	O
8	in	O
9	spinal	O
10	cord	O
11	greater	O
12	than	O
13	or	O
14	equal	O
15	to	O
16	72	O
17	%	O
18	and	O
19	brain	O
20	greater	O
21	than	O
22	or	O
23	equal	O
24	to	O
25	66	O
26	%	O
27	of	O
28	control	O
29	values	O
30	within	O
31	44	O
32	hr	O
33	postexposure	O
34	produced	O
35	marked	O
36	spinal	O
37	cord	O
38	pathology	O
39	14	O
40	days	O
41	postexposure	O
42	in	O
43	greater	O
44	than	O
45	or	O
46	equal	O
47	to	O
48	90	O
49	%	O
50	of	O
51	similarly	O
52	dosed	O
53	animals	O
54	.	O

1	Consanguinity	O
2	and	O
3	migration	O
4	in	O
5	the	O
6	marriages	O
7	of	O
8	the	O
9	region	O
10	of	O
11	Nunoa	O
12	,	O
13	Santiago	O
14	,	O
15	1850	O
16	-	O
17	1960	O

1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	kinase	O
7	-	O
8	dead	O
9	but	O
10	not	O
11	wild	O
12	-	O
13	type	O
14	forms	O
15	of	O
16	Fyn	B
17	,	O
18	Lck	B
19	,	O
20	and	O
21	ZAP	B
22	-	I
23	70	I
24	block	O
25	70Z	O
26	Cbl	B
27	-	O
28	mediated	O
29	NFAT	B
30	activation	O
31	.	O

1	These	O
2	results	O
3	continue	O
4	to	O
5	support	O
6	the	O
7	hypothesis	O
8	that	O
9	HS2	O
10	,	O
11	HS3	O
12	,	O
13	and	O
14	HS4	O
15	act	O
16	as	O
17	a	O
18	single	O
19	,	O
20	integral	O
21	unit	O
22	to	O
23	regulate	O
24	human	B
25	globin	I
26	gene	I
27	transcription	O
28	as	O
29	a	O
30	holocomplex	O
31	,	O
32	but	O
33	they	O
34	can	O
35	also	O
36	be	O
37	interpreted	O
38	to	O
39	say	O
40	that	O
41	formation	O
42	of	O
43	a	O
44	DNase	B
45	I	I
46	hypersensitive	O
47	holocomplex	O
48	alone	O
49	is	O
50	not	O
51	sufficient	O
52	for	O
53	mediating	O
54	high	O
55	-	O
56	level	O
57	globin	B
58	gene	I
59	transcription	O
60	.	O

1	Sixteen	O
2	patients	O
3	were	O
4	studied	O
5	within	O
6	24	O
7	hours	O
8	of	O
9	resuscitation	O
10	and	O
11	all	O
12	showed	O
13	depressed	O
14	right	O
15	ventricular	O
16	ejection	O
17	(	O
18	RVEF	O
19	)	O
20	and	O
21	/	O
22	or	O
23	an	O
24	increased	O
25	end	O
26	-	O
27	diastolic	O
28	volume	O
29	(	O
30	RVEDVI	O
31	).	O

1	The	O
2	repression	O
3	domain	O
4	,	O
5	and	O
6	indeed	O
7	the	O
8	entire	O
9	Cdc68	B
10	protein	I
11	,	O
12	is	O
13	highly	O
14	conserved	O
15	,	O
16	as	O
17	shown	O
18	by	O
19	the	O
20	sequence	O
21	of	O
22	the	O
23	Cdc68	B
24	functional	I
25	homolog	I
26	from	O
27	the	O
28	yeast	O
29	Kluyveromyces	O
30	lactis	O
31	and	O
32	by	O
33	database	O
34	searches	O
35	.	O

1	During	O
2	an	O
3	8	O
4	-	O
5	wk	O
6	follow	O
7	-	O
8	up	O
9	,	O
10	parasites	O
11	reappeared	O
12	in	O
13	10	O
14	patients	O
15	,	O
16	5	O
17	after	O
18	each	O
19	drug	O
20	,	O
21	between	O
22	1	O
23	and	O
24	7	O
25	wk	O
26	after	O
27	treatment	O
28	.	O

1	Extracellular	B
2	-	I
3	regulated	I
4	kinase	I
5	(	O
6	ERK	B
7	)	O
8	activation	O
9	and	O
10	molecular	O
11	coupling	O
12	of	O
13	the	O
14	adaptor	O
15	proteins	O
16	p130	B
17	Crk	I
18	-	I
19	associated	I
20	substrate	I
21	(	O
22	CAS	B
23	)	O
24	and	O
25	c	B
26	-	I
27	CrkII	I
28	(	O
29	Crk	B
30	)	O
31	represent	O
32	two	O
33	distinct	O
34	pathways	O
35	that	O
36	induce	O
37	cell	O
38	invasion	O
39	and	O
40	protect	O
41	cells	O
42	from	O
43	apoptosis	O
44	in	O
45	a	O
46	three	O
47	-	O
48	dimensional	O
49	collagen	B
50	matrix	O
51	.	O

1	Some	O
2	mutations	O
3	affected	O
4	Dhfr	B
5	in	O
6	a	O
7	qualitative	O
8	manner	O
9	,	O
10	such	O
11	as	O
12	by	O
13	changing	O
14	the	O
15	startpoint	O
16	of	O
17	one	O
18	of	O
19	the	O
20	major	O
21	Dhfr	B
22	transcripts	I
23	or	O
24	changing	O
25	the	O
26	relative	O
27	abundance	O
28	of	O
29	the	O
30	two	O
31	major	O
32	Dhfr	B
33	transcripts	I
34	.	O

1	The	O
2	two	O
3	different	O
4	phosphoforms	O
5	of	O
6	STAT5	B
7	have	O
8	identical	O
9	in	O
10	vitro	O
11	DNA	O
12	binding	O
13	specificity	O
14	and	O
15	reactivity	O
16	with	O
17	tyrosine	O
18	phosphopeptides	O
19	,	O
20	but	O
21	differ	O
22	in	O
23	their	O
24	cellular	O
25	localization	O
26	.	O

1	CTF1alpha	B
2	,	O
3	expressed	O
4	in	O
5	Escherichia	O
6	coli	O
7	,	O
8	showed	O
9	specific	O
10	binding	O
11	to	O
12	the	O
13	palindrome	O
14	2	O
15	DNA	O
16	fragment	O
17	but	O
18	not	O
19	to	O
20	palindrome	O
21	1	O
22	or	O
23	mutant	O
24	palindrome	O
25	2	O
26	DNA	O
27	fragments	O
28	,	O
29	suggesting	O
30	specific	O
31	binding	O
32	of	O
33	CTF1alpha	B
34	to	O
35	palindrome	O
36	2	O
37	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	B
6	),	O
7	and	O
8	Efs	B
9	/	O
10	Sin	B
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	The	O
2	persistent	O
3	fetal	O
4	dispersion	O
5	of	O
6	nodal	O
7	and	O
8	Hiss	O
9	bundle	O
10	fragments	O
11	within	O
12	the	O
13	ventricular	O
14	septum	O
15	is	O
16	proposed	O
17	as	O
18	a	O
19	possible	O
20	explanation	O
21	.	O

1	Plasma	O
2	lecithin	B
3	/	I
4	cholesterol	I
5	acyltransferase	I
6	(	O
7	LCAT	B
8	)	O
9	activity	O
10	in	O
11	multiple	O
12	-	O
13	organ	O
14	donors	O
15	:	O
16	a	O
17	predictor	O
18	of	O
19	allograft	O
20	viability	O
21	in	O
22	clinical	O
23	liver	O
24	transplantation	O
25	.	O

1	Its	O
2	application	O
3	in	O
4	Madagascar	O
5	:	O
6	advantages	O
7	and	O
8	disadvantages	O

1	A	O
2	soap	O
3	and	O
4	water	O
5	(	O
6	1	O
7	:	O
8	1	O
9	,	O
10	v	O
11	/	O
12	v	O
13	)	O
14	solution	O
15	effectively	O
16	decontaminated	O
17	powdered	O
18	stratum	O
19	corneum	O
20	.	O

1	Morphine	O
2	injected	O
3	into	O
4	the	O
5	lateral	O
6	ventricle	O
7	of	O
8	the	O
9	rat	O
10	produced	O
11	unilateral	O
12	analgesia	O
13	in	O
14	the	O
15	formalin	O
16	test	O
17	,	O
18	which	O
19	involves	O
20	continuous	O
21	,	O
22	moderate	O
23	pain	O
24	.	O

1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	Laboratory	O
2	aspects	O
3	with	O
4	particular	O
5	reference	O
6	to	O
7	chemotherapy	O
8	and	O
9	control	O
10	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	Trials	O
2	of	O
3	sevine	O
4	activity	O
5	against	O
6	mosquito	O
7	larvae	O

1	Use	O
2	of	O
3	free	O
4	-	O
5	access	O
6	minerals	O
7	.	O

1	The	O
2	27	O
3	-	O
4	base	O
5	element	O
6	interacts	O
7	with	O
8	a	O
9	PDGF	B
10	-	O
11	activated	O
12	serine	O
13	/	O
14	threonine	O
15	phosphoprotein	O
16	that	O
17	is	O
18	detected	O
19	only	O
20	within	O
21	the	O
22	nucleus	O
23	of	O
24	PDGF	O
25	-	O
26	treated	O
27	3T3	O
28	cells	O
29	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	BL	O
6	cell	O
7	line	O
8	Raji	O
9	with	O
10	constructs	O
11	containing	O
12	core	O
13	promoter	O
14	mutations	O
15	confirmed	O
16	that	O
17	the	O
18	proximal	O
19	Sp1	B
20	site	I
21	and	O
22	the	O
23	TATA	O
24	box	O
25	are	O
26	essential	O
27	for	O
28	the	O
29	activation	O
30	of	O
31	promoter	O
32	P1	O
33	by	O
34	the	O
35	Ig	B
36	kappa	I
37	enhancers	I
38	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	Cdc2	B
2	co	O
3	-	O
4	precipitates	O
5	with	O
6	Pch1	B
7	in	O
8	S	O
9	.	O
10	pombe	O
11	cell	O
12	lysates	O
13	,	O
14	although	O
15	Cdc2	B
16	may	O
17	not	O
18	be	O
19	the	O
20	major	O
21	catalytic	O
22	partner	O
23	of	O
24	a	O
25	Pch1	B
26	kinase	I
27	in	O
28	vivo	O
29	.	O

1	An	O
2	experiment	O
3	examined	O
4	the	O
5	effects	O
6	of	O
7	treatment	O
8	with	O
9	gonadotrophin	B
10	releasing	I
11	hormone	I
12	(	O
13	100	O
14	micrograms	O
15	GnRH	B
16	injected	O
17	24	O
18	h	O
19	after	O
20	progestagen	O
21	sponge	O
22	removal	O
23	),	O
24	season	O
25	of	O
26	treatment	O
27	(	O
28	autumn	O
29	v	O
30	.	O
31	spring	O
32	),	O
33	the	O
34	effect	O
35	of	O
36	supplementary	O
37	feeding	O
38	with	O
39	lupin	O
40	grain	O
41	(	O
42	in	O
43	autumn	O
44	only	O
45	,	O
46	from	O
47	12	O
48	days	O
49	before	O
50	until	O
51	8	O
52	days	O
53	after	O
54	sponge	O
55	removal	O
56	)	O
57	on	O
58	the	O
59	time	O
60	of	O
61	ovulation	O
62	in	O
63	182	O
64	mature	O
65	Merino	O
66	ewes	O
67	superovulated	O
68	with	O
69	a	O
70	combination	O
71	of	O
72	400	O
73	I	O
74	.	O
75	U	O
76	.	O
77	pregnant	B
78	mare	I
79	serum	I
80	gonadotrophin	I
81	(	O
82	PMSG	B
83	)	O
84	and	O
85	12	O
86	mg	O
87	follicle	B
88	stimulating	I
89	hormone	I
90	(	O
91	FSH	B
92	-	I
93	P	I
94	).	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	is	O
7	highly	O
8	GC	O
9	rich	O
10	,	O
11	with	O
12	multiple	O
13	CpG	O
14	doublets	O
15	,	O
16	and	O
17	contains	O
18	multiple	O
19	binding	O
20	sites	O
21	for	O
22	Sp1	B
23	.	O

1	Rapid	O
2	detection	O
3	of	O
4	radioisotopically	O
5	contaminated	O
6	test	O
7	serum	O
8	before	O
9	radioassay	O
10	of	O
11	vitamin	O
12	B12	O
13	.	O

1	We	O
2	analyzed	O
3	serial	O
4	biopsy	O
5	specimens	O
6	from	O
7	eight	O
8	patients	O
9	with	O
10	FL	O
11	for	O
12	secondary	O
13	alterations	O
14	of	O
15	the	O
16	rearranged	B
17	bcl	I
18	-	I
19	2	I
20	gene	I
21	in	O
22	the	O
23	breakpoint	O
24	and	O
25	open	O
26	reading	O
27	frame	O
28	(	O
29	ORF	O
30	)	O
31	regions	O
32	.	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	O
6	the	O
7	genome	O
8	can	O
9	be	O
10	folded	O
11	into	O
12	a	O
13	tRNA	O
14	-	O
15	like	O
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	O
26	-	O
27	like	O
28	structure	O
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	O
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	Eight	O
2	recombinant	O
3	DNA	O
4	clones	O
5	of	O
6	endogenous	O
7	murine	O
8	leukemia	O
9	virus	O
10	(	O
11	MuLV	O
12	)-	O
13	related	O
14	DNA	O
15	sequences	O
16	have	O
17	been	O
18	isolated	O
19	from	O
20	a	O
21	lambdaphage	O
22	genomic	O
23	library	O
24	of	O
25	Balb	O
26	/	O
27	c	O
28	mouse	O
29	DNA	O
30	.	O

1	The	O
2	SH2	O
3	-	O
4	containing	O
5	adapter	O
6	protein	O
7	GRB10	B
8	interacts	O
9	with	O
10	BCR	B
11	-	O
12	ABL	B
13	.	O

1	BCL	B
2	-	I
3	2	I
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O

1	Alveolar	O
2	growth	O
3	,	O
4	contemporary	O
5	with	O
6	dental	O
7	eruption	O
8	,	O
9	is	O
10	sufficient	O
11	to	O
12	compensate	O
13	possible	O
14	hypotrophy	O
15	of	O
16	maxillary	O
17	bone	O
18	bases	O
19	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	B
5	genes	I
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	B
24	coxI	I
25	intron	I
26	aI4	I
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	O
32	-	O
33	amino	O
34	-	O
35	acid	O
36	site	O
37	-	O
38	specific	O
39	DNA	B
40	endonuclease	I
41	.	O

1	2	O
2	.--	O
3	concepts	O
4	of	O
5	higher	O
6	nervous	O
7	function	O
8	in	O
9	the	O
10	USSR	O
11	.	O

1	Additional	O
2	information	O
3	including	O
4	echocardiographic	O
5	sequences	O
6	,	O
7	perioperative	O
8	video	O
9	sequences	O
10	,	O
11	x	O
12	-	O
13	ray	O
14	analysis	O
15	,	O
16	angiograms	O
17	,	O
18	etc	O
19	.	O
20	is	O
21	represented	O
22	in	O
23	the	O
24	program	O
25	.	O

1	Visual	O
2	acuity	O
3	may	O
4	be	O
5	decreased	O
6	by	O
7	transient	O
8	changes	O
9	in	O
10	refractive	O
11	error	O
12	caused	O
13	by	O
14	sulfonamides	O
15	,	O
16	the	O
17	antifungal	O
18	agent	O
19	metronidazole	O
20	,	O
21	thiazide	O
22	diuretics	O
23	,	O
24	and	O
25	carbonic	B
26	anhydrase	I
27	inhibitors	O
28	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	B
10	anemia	I
11	group	I
12	C	I
13	protein	I
14	(	O
15	FANCC	B
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	Sequencing	O
2	of	O
3	the	O
4	three	O
5	pag	B
6	-	I
7	3	I
8	alleles	I
9	showed	O
10	that	O
11	two	O
12	apparent	O
13	null	O
14	alleles	O
15	encode	O
16	a	O
17	nonsense	O
18	mutation	O
19	before	O
20	the	O
21	zinc	O
22	fingers	O
23	and	O
24	a	O
25	missense	O
26	mutation	O
27	in	O
28	the	O
29	fourth	O
30	zinc	O
31	finger	O
32	that	O
33	changes	O
34	a	O
35	coordinating	O
36	histidine	O
37	to	O
38	a	O
39	tyrosine	O
40	.	O

1	An	O
2	experiment	O
3	was	O
4	carried	O
5	on	O
6	133	O
7	grown	O
8	up	O
9	fowls	O
10	and	O
11	broilers	O
12	from	O
13	4	O
14	industrial	O
15	farms	O
16	,	O
17	vaccinated	O
18	with	O
19	spray	O
20	lento	O
21	and	O
22	mesogenic	O
23	vaccines	O
24	for	O
25	straining	O
26	the	O
27	immunity	O
28	against	O
29	pseodopest	O
30	through	O
31	RIHA	O
32	and	O
33	provoking	O
34	pseudoplague	O
35	with	O
36	a	O
37	pathogenic	O
38	virus	O
39	.	O

1	Synthetic	O
2	ligands	O
3	have	O
4	been	O
5	identified	O
6	that	O
7	reset	O
8	and	O
9	amplify	O
10	the	O
11	cycle	O
12	of	O
13	pulsatile	O
14	GH	B
15	secretion	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	orphan	B
21	GH	I
22	-	I
23	secretagogue	I
24	receptor	I
25	(	O
26	GHS	B
27	-	I
28	R	I
29	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	sequence	O
7	of	O
8	the	O
9	p54	B
10	gene	I
11	carried	O
12	by	O
13	two	O
14	virulent	O
15	ASFV	O
16	strains	O
17	(	O
18	E70	O
19	and	O
20	E75	O
21	)	O
22	with	O
23	that	O
24	obtained	O
25	from	O
26	virus	O
27	Ba71V	O
28	showed	O
29	100	O
30	%	O
31	similarity	O
32	.	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	RNP1	B
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O

1	The	O
2	importance	O
3	of	O
4	these	O
5	sites	O
6	for	O
7	transcriptional	O
8	activation	O
9	was	O
10	studied	O
11	by	O
12	site	O
13	-	O
14	directed	O
15	mutagenesis	O
16	followed	O
17	by	O
18	promoter	O
19	function	O
20	analysis	O
21	of	O
22	the	O
23	mutants	O
24	with	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	system	O
30	.	O

1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	B
12	and	O
13	crb2	B
14	mutants	I
15	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	B
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	A	O
2	significant	O
3	association	O
4	between	O
5	a	O
6	family	O
7	history	O
8	and	O
9	a	O
10	higher	O
11	urinary	O
12	pH	O
13	was	O
14	observed	O
15	among	O
16	the	O
17	female	O
18	calcium	O
19	stone	O
20	patients	O
21	.	O

1	Mutations	O
2	in	O
3	three	O
4	loci	O
5	(	O
6	SIC1	B
7	,	O
8	SWI5	B
9	,	O
10	and	O
11	RIC3	B
12	)	O
13	were	O
14	identified	O
15	.	O

1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O

1	Furthermore	O
2	,	O
3	phosphatidylinositol	O
4	(	O
5	3	O
6	,	O
7	4	O
8	,	O
9	5	O
10	)	O
11	trisphosphate	O
12	specifically	O
13	stimulates	O
14	the	O
15	activity	O
16	of	O
17	ILK	B
18	in	O
19	vitro	O
20	,	O
21	and	O
22	in	O
23	addition	O
24	,	O
25	membrane	O
26	targetted	O
27	constitutively	O
28	active	O
29	Pi	B
30	(	I
31	3	I
32	)	I
33	K	I
34	activates	O
35	ILK	B
36	in	O
37	vivo	O
38	.	O

1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O

1	As	O
2	with	O
3	the	O
4	heterologous	O
5	DNA	O
6	binding	O
7	domain	O
8	,	O
9	MZF	B
10	-	I
11	1	I
12	represses	O
13	reporter	O
14	gene	O
15	expression	O
16	in	O
17	nonhematopoietic	O
18	cell	O
19	lines	O
20	and	O
21	activates	O
22	expression	O
23	in	O
24	hematopoietic	O
25	cell	O
26	lines	O
27	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	Of	O
6	the	O
7	17	O
8	men	O
9	and	O
10	17	O
11	women	O
12	,	O
13	who	O
14	were	O
15	21	O
16	to	O
17	80	O
18	years	O
19	of	O
20	age	O
21	,	O
22	27	O
23	had	O
24	hereditary	O
25	motor	O
26	and	O
27	sensory	O
28	neuropathy	O
29	type	O
30	I	O
31	and	O
32	7	O
33	had	O
34	acquired	O
35	demyelinating	O
36	polyneuropathy	O
37	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	O
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	O
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	O
22	myosin	B
23	cytoskeleton	O
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	O
30	kHz	O
31	.	O

1	Seventeen	O
2	of	O
3	the	O
4	35	O
5	patients	O
6	were	O
7	randomly	O
8	chosen	O
9	to	O
10	receive	O
11	a	O
12	training	O
13	program	O
14	(	O
15	lasting	O
16	approximately	O
17	1	O
18	month	O
19	)	O
20	designed	O
21	to	O
22	establish	O
23	a	O
24	systematic	O
25	strategy	O
26	of	O
27	organizing	O
28	complex	O
29	visual	O
30	material	O
31	.	O

1	Intravesical	O
2	chemotherapy	O
3	.	O

1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	O
9	family	O
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O

1	While	O
2	daily	O
3	food	O
4	intake	O
5	was	O
6	almost	O
7	constant	O
8	regardless	O
9	of	O
10	the	O
11	dietary	O
12	protein	O
13	level	O
14	,	O
15	water	O
16	intake	O
17	and	O
18	urine	O
19	volume	O
20	increased	O
21	with	O
22	increasing	O
23	the	O
24	dietary	O
25	protein	O
26	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	I	I
8	induces	O
9	bcl	B
10	-	I
11	2	I
12	promoter	I
13	through	O
14	the	O
15	transcription	O
16	factor	O
17	cAMP	B
18	-	I
19	response	I
20	element	I
21	-	I
22	binding	I
23	protein	I
24	.	O

1	It	O
2	has	O
3	also	O
4	been	O
5	shown	O
6	that	O
7	a	O
8	variety	O
9	of	O
10	extracellular	O
11	factors	O
12	stimulate	O
13	a	O
14	pair	O
15	of	O
16	MAPK	O
17	p44	B
18	and	O
19	MAPK	O
20	p42	B
21	of	O
22	MAPK	B
23	family	I
24	members	I
25	.	O

1	Furthermore	O
2	,	O
3	cpxA	B
4	*	I
5	mutations	O
6	suppress	O
7	the	O
8	toxicity	O
9	conferred	O
10	by	O
11	the	O
12	LamB	B
13	-	O
14	LacZ	B
15	hybrid	O
16	protein	O
17	,	O
18	which	O
19	exerts	O
20	its	O
21	effects	O
22	in	O
23	the	O
24	cytoplasm	O
25	,	O
26	sequestered	O
27	from	O
28	DegP	B
29	.	O

1	Treatment	O
2	was	O
3	well	O
4	-	O
5	tolerated	O
6	.	O

1	The	O
2	incompatibility	O
3	group	O
4	W	O
5	plasmid	O
6	pSa	O
7	suppresses	O
8	Agrobacterium	O
9	tumefaciens	O
10	oncogenicity	O
11	(	O
12	J	O
13	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	demonstrated	O
6	specific	O
7	nuclear	O
8	protein	O
9	binding	O
10	to	O
11	-	O
12	85	O
13	/-	O
14	64	O
15	,	O
16	and	O
17	single	O
18	point	O
19	mutations	O
20	suggested	O
21	important	O
22	binding	O
23	nucleotides	O
24	between	O
25	-	O
26	79	O
27	/-	O
28	68	O
29	with	O
30	five	O
31	critical	O
32	bases	O
33	between	O
34	-	O
35	74	O
36	/-	O
37	70	O
38	(	O
39	5	O
40	'-	O
41	CTCCT	O
42	-	O
43	3	O
44	').	O

1	Multizone	O
2	PRK	O
3	has	O
4	been	O
5	suggested	O
6	to	O
7	increase	O
8	the	O
9	predictability	O
10	of	O
11	higher	O
12	myopic	O
13	corrections	O
14	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	I
11	C	I
12	.,	O
13	HDL	B
14	-	I
15	C	I
16	.,	O
17	HDL2	B
18	-	I
19	C	I
20	.,	O
21	apo	B
22	B	I
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	I
29	B	I
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	I
37	B	I
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O

1	To	O
2	do	O
3	this	O
4	,	O
5	segments	O
6	of	O
7	DNA	O
8	from	O
9	the	O
10	5	O
11	'	O
12	flank	O
13	of	O
14	the	O
15	initiation	O
16	sites	O
17	for	O
18	germline	O
19	epsilon	O
20	RNA	O
21	were	O
22	ligated	O
23	to	O
24	a	O
25	luciferase	B
26	reporter	I
27	gene	I
28	and	O
29	transfected	O
30	into	O
31	two	O
32	mouse	O
33	B	O
34	cell	O
35	lines	O
36	,	O
37	one	O
38	of	O
39	which	O
40	can	O
41	be	O
42	induced	O
43	to	O
44	switch	O
45	to	O
46	IgE	B
47	.	O

1	A	O
2	third	O
3	ORF	O
4	,	O
5	ORF5	O
6	,	O
7	shows	O
8	homology	O
9	with	O
10	gene	B
11	agrB	I
12	from	O
13	Staphylococcus	O
14	aureus	O
15	,	O
16	which	O
17	is	O
18	involved	O
19	in	O
20	the	O
21	mechanism	O
22	of	O
23	regulation	O
24	of	O
25	the	O
26	virulence	O
27	phenotype	O
28	in	O
29	this	O
30	species	O
31	.	O

1	The	O
2	content	O
3	of	O
4	glucosamine	O
5	and	O
6	galactosamine	O
7	in	O
8	tartar	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	O
31	NF	B
32	-	I
33	kappaB	I
34	)	O
35	complex	O
36	Rel	B
37	A	I
38	x	O
39	NF	B
40	-	I
41	kappaB1	I
42	.	O

1	The	O
2	effectiveness	O
3	of	O
4	the	O
5	haemodialysate	O
6	Solcoseryl	O
7	for	O
8	second	O
9	-	O
10	intention	O
11	wound	O
12	healing	O
13	in	O
14	horses	O
15	and	O
16	ponies	O
17	.	O

1	Basal	O
2	promoter	O
3	activity	O
4	is	O
5	enhanced	O
6	by	O
7	a	O
8	functional	O
9	M1	O
10	domain	O
11	in	O
12	LHR	B
13	-	O
14	expressing	O
15	mouse	O
16	Leydig	O
17	tumor	O
18	cells	O
19	(	O
20	MLTC	O
21	)	O
22	but	O
23	not	O
24	in	O
25	non	O
26	-	O
27	expressing	O
28	CHO	O
29	cells	O
30	.	O

1	F	B
2	-	I
3	box	I
4	proteins	I
5	are	O
6	receptors	O
7	that	O
8	recruit	O
9	phosphorylated	O
10	substrates	O
11	to	O
12	the	O
13	SCF	B
14	ubiquitin	I
15	-	O
16	ligase	B
17	complex	O
18	.	O

1	We	O
2	have	O
3	performed	O
4	toeprinting	O
5	analyses	O
6	on	O
7	repA	B
8	mRNA	I
9	of	O
10	plasmid	O
11	R1	O
12	,	O
13	both	O
14	free	O
15	and	O
16	in	O
17	duplex	O
18	with	O
19	the	O
20	antisense	O
21	RNA	O
22	,	O
23	CopA	B
24	.	O

1	A	O
2	3	O
3	-	O
4	yr	O
5	retrospective	O
6	review	O
7	is	O
8	effective	O
9	and	O
10	detects	O
11	94	O
12	%	O
13	of	O
14	the	O
15	undercalls	O
16	.	O

1	After	O
2	6	O
3	months	O
4	,	O
5	definite	O
6	improvement	O
7	in	O
8	strength	O
9	occurred	O
10	in	O
11	4	O
12	of	O
13	7	O
14	carnitine	O
15	-	O
16	treated	O
17	patients	O
18	and	O
19	in	O
20	none	O
21	of	O
22	7	O
23	controls	O
24	.	O

1	The	O
2	protector	O
3	doubled	O
4	the	O
5	estimated	O
6	fall	O
7	distance	O
8	for	O
9	fracture	O
10	of	O
11	the	O
12	trochanter	O
13	.	O

1	The	O
2	ARF	B
3	promoter	I
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	B
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	the	O
6	patch	O
7	determines	O
8	the	O
9	proper	O
10	conformation	O
11	of	O
12	the	O
13	site	O
14	and	O
15	thereby	O
16	contributes	O
17	to	O
18	recognition	O
19	indirectly	O
20	.	O

1	ST	O
2	elevation	O
3	occurs	O
4	in	O
5	5	O
6	patients	O
7	(	O
8	55	O
9	.	O
10	5	O
11	%)	O
12	of	O
13	subgroup	O
14	A	O
15	and	O
16	in	O
17	no	O
18	patient	O
19	of	O
20	the	O
21	subgroup	O
22	B	O
23	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	essential	O
5	IncP	O
6	alpha	O
7	plasmid	O
8	transfer	O
9	genes	O
10	traF	B
11	and	O
12	traG	B
13	and	O
14	involvement	O
15	of	O
16	traF	B
17	in	O
18	phage	O
19	sensitivity	O
20	.	O

1	A	O
2	second	O
3	aim	O
4	was	O
5	to	O
6	determine	O
7	whether	O
8	the	O
9	decrease	O
10	in	O
11	muscle	O
12	-	O
13	tendon	O
14	unit	O
15	rest	O
16	length	O
17	produced	O
18	by	O
19	prolonged	O
20	immobilisation	O
21	in	O
22	a	O
23	shortened	O
24	position	O
25	is	O
26	mediated	O
27	primarily	O
28	by	O
29	adaptations	O
30	of	O
31	the	O
32	muscle	O
33	or	O
34	tendon	O
35	.	O

1	Structure	O
2	-	O
3	function	O
4	analysis	O
5	of	O
6	the	O
7	Z	O
8	-	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	Zalpha	O
14	of	O
15	dsRNA	B
16	adenosine	I
17	deaminase	I
18	type	I
19	I	I
20	reveals	O
21	similarity	O
22	to	O
23	the	O
24	(	B
25	alpha	I
26	+	I
27	beta	I
28	)	I
29	family	I
30	of	O
31	helix	B
32	-	I
33	turn	I
34	-	I
35	helix	I
36	proteins	I
37	.	O

1	The	O
2	immune	O
3	response	O
4	of	O
5	past	O
6	-	O
7	infection	O
8	of	O
9	cytomegalovirus	O
10	in	O
11	the	O
12	patients	O
13	of	O
14	RTID	O
15	is	O
16	rather	O
17	remarkable	O
18	.	O

1	Oligonucleotides	O
2	,	O
3	designed	O
4	on	O
5	the	O
6	basis	O
7	of	O
8	conserved	O
9	flanking	O
10	amino	O
11	acid	O
12	sequence	O
13	segments	O
14	within	O
15	the	O
16	catalytic	O
17	domain	O
18	of	O
19	eukaryotic	B
20	protein	I
21	kinase	I
22	C	I
23	(	O
24	PKC	B
25	)	O
26	proteins	O
27	,	O
28	were	O
29	used	O
30	as	O
31	primers	O
32	for	O
33	polymerase	O
34	chain	O
35	reactions	O
36	to	O
37	amplify	O
38	a	O
39	427	O
40	-	O
41	bp	O
42	chromosomal	O
43	DNA	O
44	fragment	O
45	from	O
46	the	O
47	filamentous	O
48	fungus	O
49	Trichoderma	O
50	reesei	O
51	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	high	O
7	level	O
8	human	B
9	desmin	I
10	expression	O
11	depends	O
12	on	O
13	a	O
14	280	O
15	-	O
16	base	O
17	pair	O
18	muscle	O
19	-	O
20	specific	O
21	enhancer	O
22	which	O
23	can	O
24	function	O
25	not	O
26	only	O
27	in	O
28	myotubes	O
29	,	O
30	but	O
31	can	O
32	also	O
33	activate	O
34	gene	O
35	expression	O
36	in	O
37	myoblasts	O
38	.	O

1	The	O
2	role	O
3	of	O
4	'	O
5	scientific	O
6	psychiatry	O
7	'	O
8	in	O
9	understanding	O
10	patients	O
11	with	O
12	chronic	O
13	schizophrenia	O
14	or	O
15	severe	O
16	personality	O
17	disorder	O
18	.	O

1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	B
15	mRNA	I
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	RESULTS	O
2	:	O
3	An	O
4	herpetic	O
5	seroconversion	O
6	is	O
7	observed	O
8	with	O
9	presence	O
10	of	O
11	type	O
12	I	O
13	herpes	O
14	simplex	O
15	virus	O
16	(	O
17	HSV	O
18	I	O
19	)	O
20	nucleic	O
21	acids	O
22	in	O
23	the	O
24	recipient	O
25	'	O
26	s	O
27	aqueous	O
28	humor	O
29	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	and	O
5	antihypertensive	O
6	treatment	O
7	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	O
20	BTU2	B
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O

1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SGC1	B
9	gene	I
10	product	I
11	includes	O
12	a	O
13	region	O
14	with	O
15	substantial	O
16	similarity	O
17	to	O
18	the	O
19	basic	O
20	-	O
21	helix	O
22	-	O
23	loop	O
24	-	O
25	helix	O
26	domain	O
27	of	O
28	the	O
29	Myc	B
30	family	I
31	of	O
32	DNA	O
33	-	O
34	binding	O
35	proteins	O
36	.	O

1	Patients	O
2	with	O
3	acute	O
4	myocardial	O
5	infarction	O
6	had	O
7	higher	O
8	plasma	O
9	concentrations	O
10	of	O
11	neutrophil	B
12	elastase	I
13	and	O
14	the	O
15	non	O
16	-	O
17	peroxide	O
18	diene	O
19	conjugated	O
20	isomer	O
21	of	O
22	linoleic	O
23	acid	O
24	than	O
25	normal	O
26	volunteers	O
27	or	O
28	patients	O
29	with	O
30	stable	O
31	ischaemic	O
32	heart	O
33	disease	O
34	.	O

1	Blood	O
2	pressure	O
3	also	O
4	was	O
5	increased	O
6	by	O
7	lidocaine	O
8	(	O
9	6	O
10	mg	O
11	kg	O
12	-	O
13	1	O
14	).	O

1	The	O
2	biology	O
3	of	O
4	Hyostrongylus	O
5	ruidus	O
6	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	O
12	Ras	B
13	/	O
14	MAPK	B
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	O
25	TGF	B
26	-	I
27	beta1	I
28	production	O
29	.	O

1	While	O
2	TGF	B
3	-	I
4	beta1	I
5	does	O
6	not	O
7	alter	O
8	the	O
9	mitogen	O
10	-	O
11	induced	O
12	expression	O
13	and	O
14	abundance	O
15	of	O
16	G1	O
17	phase	O
18	cyclin	B
19	D1	I
20	and	O
21	cdks	B
22	4	I
23	and	I
24	2	I
25	in	O
26	MCs	O
27	,	O
28	it	O
29	inhibits	O
30	cyclin	B
31	E	I
32	-	O
33	cdk	B
34	2	I
35	activity	O
36	,	O
37	thus	O
38	preventing	O
39	mitogen	O
40	-	O
41	elicited	O
42	phosphorylation	O
43	and	O
44	inactivation	O
45	of	O
46	pRb	B
47	in	O
48	G1	O
49	phase	O
50	and	O
51	transition	O
52	to	O
53	S	O
54	phase	O
55	.	O

1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O

1	After	O
2	age	O
3	30	O
4	,	O
5	mean	O
6	hemoglobin	B
7	levels	O
8	for	O
9	men	O
10	gradually	O
11	declined	O
12	,	O
13	while	O
14	those	O
15	in	O
16	women	O
17	rose	O
18	,	O
19	so	O
20	that	O
21	the	O
22	sex	O
23	difference	O
24	diminished	O
25	after	O
26	60	O
27	years	O
28	of	O
29	age	O
30	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	B
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O

1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O

1	Biol	O
2	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	CDNA	O
2	cloning	O
3	of	O
4	chick	B
5	brain	I
6	alpha	I
7	-	I
8	amino	I
9	-	I
10	3	I
11	-	I
12	hydroxy	I
13	-	I
14	5	I
15	-	I
16	methyl	I
17	-	I
18	4	I
19	-	I
20	isoxazolepropionic	I
21	acid	I
22	receptors	I
23	reveals	O
24	conservation	O
25	of	O
26	structure	O
27	,	O
28	function	O
29	and	O
30	post	O
31	-	O
32	transcriptional	O
33	processes	O
34	with	O
35	mammalian	O
36	receptors	O
37	.	O

1	Five	O
2	-	O
3	year	O
4	survivals	O
5	amounted	O
6	to	O
7	100	O
8	%,	O
9	86	O
10	.	O
11	2	O
12	%,	O
13	59	O
14	.	O
15	4	O
16	%,	O
17	29	O
18	.	O
19	8	O
20	%,	O
21	and	O
22	20	O
23	%	O
24	for	O
25	stages	O
26	I	O
27	,	O
28	II	O
29	,	O
30	III	O
31	,	O
32	IVA	O
33	and	O
34	IVB	O
35	respectively	O
36	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	kinetics	O
8	of	O
9	MEK	B
10	inhibition	O
11	by	O
12	these	O
13	compounds	O
14	reveals	O
15	that	O
16	U0126	O
17	has	O
18	approximately	O
19	100	O
20	-	O
21	fold	O
22	higher	O
23	affinity	O
24	for	O
25	deltaN3	B
26	-	I
27	S218E	I
28	/	I
29	S222D	I
30	MEK	I
31	than	O
32	does	O
33	PD098059	O
34	.	O

1	Combined	O
2	immunochemotherapy	O
3	with	O
4	cyclophosphamide	O
5	plus	O
6	BCG	O
7	gave	O
8	a	O
9	better	O
10	enhancement	O
11	of	O
12	the	O
13	antitumor	O
14	effect	O
15	of	O
16	the	O
17	cytostatic	O
18	than	O
19	that	O
20	of	O
21	the	O
22	combination	O
23	of	O
24	methotrexate	O
25	plus	O
26	BCG	O
27	and	O
28	cyclophosphamide	O
29	plus	O
30	levamisole	O
31	.	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O

1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	B
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	B
29	/	O
30	Nup214	B
31	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	Hoeben	O
2	,	O
3	F	O
4	.	O
5	J	O
6	.	O

1	Restoration	O
2	of	O
3	opponens	O
4	function	O
5	with	O
6	transplantation	O
7	of	O
8	free	O
9	composites	O
10	dorsal	O
11	pedal	O
12	skin	O
13	flap	O
14	containing	O
15	m	O
16	.	O
17	extensor	O
18	hallucis	O
19	brevis	O

1	A	O
2	randomized	O
3	,	O
4	prospective	O
5	study	O
6	was	O
7	conducted	O
8	to	O
9	compare	O
10	ovarian	O
11	stimulation	O
12	with	O
13	human	B
14	menopausal	I
15	gonadotropin	I
16	(	O
17	hMG	B
18	)	O
19	and	O
20	human	B
21	follicle	I
22	-	I
23	stimulating	I
24	hormone	I
25	(	O
26	hFSH	B
27	)	O
28	in	O
29	an	O
30	in	O
31	vitro	O
32	fertilization	O
33	and	O
34	embryo	O
35	transfer	O
36	(	O
37	IVF	O
38	-	O
39	ET	O
40	)	O
41	program	O
42	.	O

1	Because	O
2	RNase	B
3	III	I
4	host	I
5	mutants	I
6	are	O
7	defective	O
8	in	O
9	sib	B
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	B
16	mRNA	I
17	at	O
18	sib	B
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	B
25	mRNA	I
26	decay	O
27	and	O
28	decrease	O
29	int	B
30	synthesis	O
31	.	O

1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	B
9	hormone	I
10	on	O
11	lymphocytes	O

1	Cortisol	O
2	excretion	O
3	,	O
4	appeared	O
5	to	O
6	be	O
7	markedly	O
8	affected	O
9	by	O
10	the	O
11	season	O
12	although	O
13	other	O
14	factors	O
15	such	O
16	as	O
17	social	O
18	and	O
19	environmental	O
20	stress	O
21	cannot	O
22	be	O
23	discounted	O
24	.	O

1	Bacterial	O
2	metabolism	O
3	of	O
4	4	O
5	-	O
6	chlorophenoxyacetate	O
7	.	O

1	Dopamine	O
2	caused	O
3	a	O
4	prominent	O
5	potassium	O
6	efflux	O
7	measured	O
8	as	O
9	86Rb	O
10	+	O
11	efflux	O
12	from	O
13	control	O
14	glands	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	denervated	O
22	glands	O
23	.	O

1	Paradoxically	O
2	,	O
3	coexpression	O
4	of	O
5	the	O
6	transcriptionally	O
7	inactive	O
8	,	O
9	amino	O
10	-	O
11	terminally	O
12	deleted	O
13	IDX	B
14	-	I
15	1	I
16	mutant	I
17	proteins	I
18	,	O
19	either	O
20	with	O
21	the	O
22	wild	B
23	-	I
24	type	I
25	IDX	I
26	-	I
27	1	I
28	or	O
29	with	O
30	themselves	O
31	,	O
32	results	O
33	in	O
34	a	O
35	marked	O
36	enhancement	O
37	of	O
38	transactivation	O
39	of	O
40	the	O
41	transcriptional	O
42	TAAT	B
43	-	I
44	1	I
45	element	I
46	reporter	I
47	.	O

1	The	O
2	TUP1	B
3	gene	I
4	was	O
5	isolated	O
6	in	O
7	a	O
8	screen	O
9	for	O
10	genes	O
11	that	O
12	regulate	O
13	mating	O
14	type	O
15	(	O
16	V	O
17	.	O
18	L	O
19	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	was	O
8	partially	O
9	inhibited	O
10	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	THOV	B
6	NP	I
7	contains	O
8	a	O
9	motif	O
10	(	O
11	KRxxxxxxxxxKTKK	O
12	)	O
13	at	O
14	amino	O
15	acid	O
16	positions	O
17	179	O
18	-	O
19	193	O
20	that	O
21	represents	O
22	a	O
23	classical	O
24	bipartite	O
25	nuclear	O
26	localization	O
27	signal	O
28	(	O
29	NLS	O
30	).	O

1	Thrombosis	O
2	of	O
3	the	O
4	renal	O
5	vein	O
6	may	O
7	be	O
8	dramatic	O
9	and	O
10	include	O
11	renal	O
12	failure	O
13	.	O

1	Immunodepression	O
2	was	O
3	combined	O
4	with	O
5	the	O
6	increase	O
7	of	O
8	glucocorticoid	O
9	activity	O
10	of	O
11	adrenal	O
12	cortex	O
13	,	O
14	while	O
15	no	O
16	significant	O
17	changes	O
18	in	O
19	thyroid	O
20	hormones	O
21	were	O
22	registered	O
23	.	O

1	Volunteers	O
2	were	O
3	irradiated	O
4	on	O
5	their	O
6	backs	O
7	with	O
8	suberythemal	O
9	UV	O
10	daily	O
11	for	O
12	5	O
13	d	O
14	after	O
15	application	O
16	of	O
17	the	O
18	sunscreens	O
19	and	O
20	their	O
21	base	O
22	lotion	O
23	to	O
24	different	O
25	sites	O
26	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	Granisetron	O
2	,	O
3	but	O
4	not	O
5	saline	O
6	,	O
7	abolished	O
8	vomiting	O
9	and	O
10	nausea	O
11	when	O
12	given	O
13	as	O
14	intervention	O
15	after	O
16	this	O
17	combined	O
18	emetic	O
19	regimen	O
20	.	O

1	These	O
2	analyses	O
3	demonstrate	O
4	that	O
5	the	O
6	dUTPase	B
7	isoforms	O
8	are	O
9	encoded	O
10	by	O
11	the	O
12	same	O
13	gene	O
14	with	O
15	isoform	O
16	-	O
17	specific	O
18	transcripts	O
19	arising	O
20	through	O
21	the	O
22	use	O
23	of	O
24	alternative	O
25	5	O
26	'	O
27	exons	O
28	.	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	Horvath	O
2	,	O
3	I	O
4	.	O

1	Therefore	O
2	,	O
3	the	O
4	positive	O
5	cAMP	O
6	control	O
7	of	O
8	the	O
9	hypoxic	O
10	SRP1	B
11	and	O
12	HEM13	B
13	genes	I
14	was	O
15	uncoupled	O
16	from	O
17	the	O
18	HOG	B
19	pathway	O
20	.	O

1	The	O
2	identity	O
3	between	O
4	hnRNPs	B
5	H	I
6	and	O
7	H	B
8	'	I
9	is	O
10	96	O
11	%,	O
12	between	O
13	H	B
14	and	O
15	F	B
16	78	O
17	%,	O
18	and	O
19	between	O
20	H	B
21	'	I
22	and	O
23	F	B
24	75	O
25	%,	O
26	respectively	O
27	.	O

1	The	O
2	interaction	O
3	of	O
4	U1	B
5	-	I
6	70K	I
7	with	O
8	the	O
9	SRZ	B
10	proteins	I
11	is	O
12	confirmed	O
13	further	O
14	in	O
15	vitro	O
16	using	O
17	a	O
18	blot	O
19	overlay	O
20	assay	O
21	.	O

1	This	O
2	multimodality	O
3	treatment	O
4	for	O
5	locally	O
6	advanced	O
7	gynecologic	O
8	tumors	O
9	appears	O
10	feasible	O
11	with	O
12	modification	O
13	,	O
14	and	O
15	continued	O
16	work	O
17	exploring	O
18	this	O
19	approach	O
20	is	O
21	encouraged	O
22	.	O

1	These	O
2	data	O
3	locate	O
4	the	O
5	aniridia	B
6	gene	I
7	(	O
8	AN2	B
9	)	O
10	and	O
11	a	O
12	recurrent	O
13	T	B
14	-	I
15	cell	I
16	leukemia	I
17	breakpoint	I
18	(	O
19	TCL2	B
20	)	O
21	in	O
22	the	O
23	marker	O
24	sequence	O
25	,	O
26	on	O
27	opposite	O
28	sides	O
29	of	O
30	MIC1	B
31	.	O

1	Three	O
2	cysteine	O
3	and	O
4	four	O
5	tryptophan	O
6	residues	O
7	,	O
8	previously	O
9	identified	O
10	as	O
11	conserved	O
12	amongst	O
13	nitrous	B
14	-	I
15	oxide	I
16	reductases	I
17	,	O
18	are	O
19	found	O
20	in	O
21	the	O
22	Paracoccus	O
23	enzyme	O
24	.	O

1	Thus	O
2	,	O
3	although	O
4	p28	B
5	may	O
6	play	O
7	only	O
8	a	O
9	limited	O
10	role	O
11	during	O
12	the	O
13	early	O
14	embryonic	O
15	cleavages	O
16	,	O
17	it	O
18	may	O
19	function	O
20	later	O
21	in	O
22	development	O
23	to	O
24	establish	O
25	a	O
26	somatic	O
27	type	O
28	of	O
29	cell	O
30	cycle	O
31	.	O

1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O

1	Paf1p	B
2	may	O
3	therefore	O
4	be	O
5	required	O
6	for	O
7	both	O
8	positive	O
9	and	O
10	negative	O
11	regulation	O
12	of	O
13	subsets	O
14	of	O
15	yeast	O
16	genes	O
17	.	O

1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O

1	Incorporation	O
2	of	O
3	the	O
4	polyene	O
5	antibiotic	O
6	amphotericin	O
7	B	O
8	(	O
9	AMB	O
10	)	O
11	in	O
12	liposomes	O
13	results	O
14	in	O
15	a	O
16	marked	O
17	reduction	O
18	in	O
19	drug	O
20	toxicity	O
21	with	O
22	no	O
23	loss	O
24	of	O
25	antifungal	O
26	potency	O
27	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	B
8	(	I
9	2	I
10	)	I
11	sgRNAs	I
12	of	O
13	TMV	B
14	U1	I
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	B
30	(	I
31	MP	I
32	,	I
33	75	I
34	)	I
35	(	I
36	HIRES	I
37	(	I
38	MP	I
39	),	I
40	(	I
41	75	I
42	)(	I
43	CR	I
44	)-	I
45	MP	I
46	-	I
47	CP	I
48	-	I
49	3	I
50	'	I
51	UTR	I
52	;	O
53	HIRES	B
54	(	I
55	MP	I
56	,	I
57	75	I
58	)(	I
59	U1	I
60	)-	I
61	MP	I
62	-	I
63	CP	I
64	-	I
65	3	I
66	'	I
67	UTR	I
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	B
75	gene	I
76	in	O
77	vitro	O
78	.	O

1	Sinusoidal	O
2	oscillations	O
3	of	O
4	a	O
5	gas	O
6	dilution	O
7	indicator	O

1	Concurrent	O
2	with	O
3	ligand	O
4	-	O
5	dependent	O
6	uptake	O
7	,	O
8	we	O
9	now	O
10	show	O
11	that	O
12	the	O
13	receptor	O
14	undergoes	O
15	ligand	O
16	-	O
17	induced	O
18	ubiquitination	O
19	,	O
20	suggesting	O
21	that	O
22	receptor	O
23	ubiquitination	O
24	may	O
25	function	O
26	in	O
27	the	O
28	ligand	O
29	-	O
30	dependent	O
31	endocytosis	O
32	of	O
33	the	O
34	a	B
35	-	I
36	factor	I
37	receptor	I
38	as	O
39	well	O
40	as	O
41	in	O
42	its	O
43	constitutive	O
44	endocytosis	O
45	.	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	BIAcore	O
2	analysis	O
3	gave	O
4	a	O
5	Kaff	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	B
23	-	I
24	A3	I
25	to	O
26	T84	B
27	.	I
28	1	I
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	B
46	-	I
47	A3	I
48	to	O
49	T84	B
50	.	I
51	66	I
52	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	Widening	O
2	of	O
3	the	O
4	abdominal	O
5	aortic	O
6	wall	O
7	on	O
8	an	O
9	ultrasound	O
10	examination	O
11	was	O
12	the	O
13	key	O
14	to	O
15	the	O
16	incidental	O
17	diagnosis	O
18	of	O
19	a	O
20	clinically	O
21	unsuspected	O
22	type	O
23	B	O
24	dissection	O
25	.	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O

1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	O
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	B
33	domains	I
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	O
14	TR2	B
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O

1	Scotchbond	O
2	2	O
3	showed	O
4	the	O
5	least	O
6	dye	O
7	penetration	O
8	but	O
9	not	O
10	statistically	O
11	less	O
12	than	O
13	the	O
14	XR	O
15	bond	O
16	/	O
17	Silus	O
18	Plus	O
19	combination	O
20	.	O

1	These	O
2	widely	O
3	expressed	O
4	proteins	O
5	share	O
6	a	O
7	C	O
8	-	O
9	terminal	O
10	region	O
11	that	O
12	bears	O
13	significant	O
14	sequence	O
15	homology	O
16	to	O
17	a	O
18	group	O
19	of	O
20	GDP	B
21	/	I
22	GTP	I
23	exchange	I
24	proteins	I
25	for	O
26	the	O
27	Rab3	B
28	family	I
29	of	O
30	small	B
31	GTP	I
32	binding	I
33	proteins	I
34	.	O

1	These	O
2	differences	O
3	are	O
4	smaller	O
5	than	O
6	those	O
7	described	O
8	in	O
9	standard	O
10	textbooks	O
11	.	O

1	Increased	O
2	granulocyte	B
3	-	I
4	colony	I
5	stimulating	I
6	factor	I
7	(	O
8	G	B
9	-	I
10	CSF	I
11	)	O
12	levels	O
13	in	O
14	neonates	O
15	with	O
16	perinatal	O
17	complications	O
18	.	O

1	Vocal	O
2	cord	O
3	abduction	O
4	rehabilitation	O
5	by	O
6	nervous	O
7	selective	O
8	anastomosis	O
9	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	B
12	M6P	I
13	/	I
14	IGF	I
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	O
20	IGF	B
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	proteins	O
7	,	O
8	we	O
9	have	O
10	characterized	O
11	domains	O
12	responsible	O
13	for	O
14	activation	O
15	or	O
16	repression	O
17	.	O

1	4	O
2	.	O

1	A	O
2	protein	O
3	footprint	O
4	also	O
5	was	O
6	identified	O
7	for	O
8	a	O
9	GC	O
10	box	O
11	element	O
12	at	O
13	nucleotides	O
14	-	O
15	59	O
16	to	O
17	-	O
18	45	O
19	.	O

1	Thus	O
2	,	O
3	TRAF2	B
4	initiates	O
5	SAPK	B
6	and	O
7	p38	B
8	activation	O
9	by	O
10	binding	O
11	two	O
12	proximal	O
13	protein	O
14	kinases	O
15	:	O
16	GCK	B
17	and	O
18	RIP	B
19	.	O

1	The	O
2	major	O
3	findings	O
4	of	O
5	our	O
6	studies	O
7	are	O
8	as	O
9	follows	O
10	:	O
11	1	O
12	)	O
13	There	O
14	are	O
15	no	O
16	detectable	O
17	signals	O
18	around	O
19	GDF	B
20	-	I
21	9	I
22	-	O
23	deficient	O
24	follicles	O
25	for	O
26	several	O
27	theca	O
28	cell	O
29	layer	O
30	markers	O
31	[	O
32	i	O
33	.	O
34	e	O
35	.	O

1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	O
11	domain	O
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	B
23	domain	O
24	of	O
25	c	B
26	-	I
27	IAP1	I
28	and	O
29	induced	O
30	apoptosis	O
31	.	O

1	The	O
2	immuno	O
3	-	O
4	purified	O
5	mRNA	O
6	in	O
7	the	O
8	polysome	O
9	complex	O
10	was	O
11	used	O
12	to	O
13	prepare	O
14	cDNA	O
15	with	O
16	which	O
17	to	O
18	probe	O
19	a	O
20	D	O
21	.	O
22	melanogaster	O
23	genomic	O
24	library	O
25	.	O

1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O

1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	suggest	O
7	that	O
8	NF	B
9	-	I
10	kappaB	I
11	activity	O
12	may	O
13	be	O
14	regulated	O
15	by	O
16	its	O
17	interaction	O
18	with	O
19	the	O
20	cell	O
21	cycle	O
22	regulatory	O
23	protein	O
24	,	O
25	E2F	B
26	-	I
27	1	I
28	.	O

1	No	O
2	drop	O
3	in	O
4	oxygen	O
5	saturation	O
6	(	O
7	SaO2	O
8	)	O
9	or	O
10	visual	O
11	evidence	O
12	of	O
13	transient	O
14	electroencephalographic	O
15	(	O
16	EEG	O
17	)	O
18	arousals	O
19	can	O
20	be	O
21	found	O
22	at	O
23	repeat	O
24	polysomnography	O
25	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	a	O
6	sequence	O
7	match	O
8	between	O
9	enhancers	O
10	and	O
11	certain	O
12	promoter	O
13	elements	O
14	is	O
15	critical	O
16	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	Surprisingly	O
2	,	O
3	3	O
4	full	B
5	-	I
6	length	I
7	murine	I
8	survivin	I
9	cDNA	I
10	clones	O
11	were	O
12	isolated	O
13	,	O
14	predicting	O
15	the	O
16	existence	O
17	of	O
18	3	O
19	distinct	O
20	survivin	B
21	proteins	I
22	.	O

1	Overall	O
2	,	O
3	these	O
4	findings	O
5	demonstrate	O
6	that	O
7	mutations	O
8	E768D	O
9	and	O
10	V804L	O
11	are	O
12	gain	O
13	-	O
14	of	O
15	-	O
16	function	O
17	mutations	O
18	that	O
19	confer	O
20	to	O
21	the	O
22	long	B
23	RET	I
24	isoform	I
25	the	O
26	capacity	O
27	to	O
28	exert	O
29	a	O
30	biological	O
31	effect	O
32	,	O
33	although	O
34	these	O
35	mutations	O
36	are	O
37	more	O
38	weakly	O
39	activating	O
40	than	O
41	the	O
42	MEN2A	B
43	and	O
44	MEN2B	B
45	mutations	O
46	.	O

1	Transient	O
2	expression	O
3	of	O
4	VSF	B
5	-	I
6	1	I
7	in	O
8	protoplasts	O
9	stimulated	O
10	vs	B
11	-	I
12	1	I
13	dependent	O
14	activation	O
15	of	O
16	the	O
17	-	B
18	76	I
19	/	I
20	grp1	I
21	.	I
22	8	I
23	minimal	I
24	promoter	I
25	.	O

1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	I
22	,	O
23	Bax	B
24	,	O
25	and	O
26	Bad	B
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	B
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O

1	The	O
2	multiple	O
3	factors	O
4	affecting	O
5	plasma	O
6	renin	B
7	activity	O
8	in	O
9	essential	O
10	hypertension	O
11	.	O

1	Another	O
2	common	O
3	mutation	O
4	involved	O
5	amino	O
6	acids	O
7	that	O
8	are	O
9	thought	O
10	to	O
11	make	O
12	specific	O
13	contacts	O
14	with	O
15	DNA	O
16	.	O

1	A	O
2	larger	O
3	region	O
4	upstream	O
5	of	O
6	human	B
7	CMV	I
8	dbp	I
9	also	O
10	mediated	O
11	replication	O
12	in	O
13	transient	O
14	assays	O
15	.	O

1	GAP	B
2	-	I
3	N	I
4	bound	O
5	constitutively	O
6	to	O
7	p190	B
8	in	O
9	both	O
10	serum	O
11	-	O
12	deprived	O
13	and	O
14	growth	O
15	factor	O
16	-	O
17	stimulated	O
18	cells	O
19	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	B
9	goosecoid	I
10	gene	I
11	(	O
12	GSC	B
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O

1	Auditory	O
2	-	O
3	visual	O
4	interaction	O
5	in	O
6	the	O
7	generation	O
8	of	O
9	saccades	O
10	in	O
11	man	O
12	.	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	This	O
2	association	O
3	appears	O
4	to	O
5	be	O
6	mediated	O
7	by	O
8	Src	B
9	-	O
10	SH2	B
11	domain	O
12	,	O
13	because	O
14	PECAM	B
15	-	I
16	1	I
17	can	O
18	be	O
19	precipitated	O
20	by	O
21	a	O
22	GST	B
23	-	O
24	Src	B
25	-	O
26	SH2	B
27	affinity	O
28	matrix	O
29	.	O

1	Pharmacology	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	acetylcholine	O
8	suggest	O
9	that	O
10	raveron	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	influx	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O

1	The	O
2	hemodynamics	O
3	of	O
4	isoproterenol	O
5	-	O
6	induced	O
7	cardiac	O
8	failure	O
9	in	O
10	the	O
11	rat	O
12	.	O

1	The	O
2	requirement	O
3	of	O
4	Tyr	O
5	-	O
6	19	O
7	dephosphorylation	O
8	for	O
9	spindle	O
10	assembly	O
11	is	O
12	also	O
13	observed	O
14	under	O
15	conditions	O
16	in	O
17	which	O
18	spindle	O
19	formation	O
20	is	O
21	independent	O
22	of	O
23	mitosis	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	involvement	O
29	of	O
30	Cdc28	B
31	/	O
32	Clb	B
33	kinase	O
34	in	O
35	SPB	O
36	separation	O
37	is	O
38	direct	O
39	.	O

1	The	O
2	translation	O
3	products	O
4	of	O
5	both	O
6	clones	O
7	are	O
8	highly	O
9	homologous	O
10	to	O
11	APS1	B
12	(	O
13	66	O
14	and	O
15	86	O
16	%	O
17	identity	O
18	,	O
19	respectively	O
20	)	O
21	over	O
22	their	O
23	entire	O
24	lengths	O
25	,	O
26	including	O
27	amino	O
28	terminal	O
29	sequences	O
30	resembling	O
31	transit	O
32	peptides	O
33	for	O
34	plastid	O
35	localization	O
36	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	folate	O
6	compounds	O
7	decrease	O
8	formate	O
9	accumulation	O
10	after	O
11	methanol	O
12	by	O
13	stimulating	O
14	formate	O
15	oxidation	O
16	or	O
17	utilization	O
18	and	O
19	suggest	O
20	a	O
21	possible	O
22	use	O
23	for	O
24	folates	O
25	in	O
26	the	O
27	treatment	O
28	of	O
29	certain	O
30	cases	O
31	of	O
32	human	O
33	methanol	O
34	poisoning	O
35	.	O

1	The	O
2	murine	O
3	Htf9	B
4	-	I
5	a	I
6	/	O
7	RanBP1	B
8	and	O
9	Htf9	B
10	-	I
11	c	I
12	genes	I
13	are	O
14	divergently	O
15	transcribed	O
16	from	O
17	a	O
18	shared	O
19	TATA	O
20	-	O
21	less	O
22	promoter	O
23	.	O

1	Western	O
2	blot	O
3	analyses	O
4	detect	O
5	anti	B
6	-	I
7	E	I
8	-	O
9	specific	O
10	immunoreactivity	O
11	in	O
12	affinity	O
13	-	O
14	purified	O
15	extracts	O
16	derived	O
17	from	O
18	the	O
19	bacterial	O
20	expression	O
21	of	O
22	a	O
23	truncated	B
24	AMPD3	I
25	cDNA	I
26	.	O

1	Significant	O
2	increases	O
3	in	O
4	mean	O
5	serum	O
6	E2	O
7	concentration	O
8	(	O
9	100	O
10	to	O
11	150	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	were	O
17	noted	O
18	at	O
19	6	O
20	and	O
21	8	O
22	hours	O
23	after	O
24	administration	O
25	on	O
26	day	O
27	1	O
28	and	O
29	at	O
30	8	O
31	hours	O
32	on	O
33	day	O
34	4	O
35	.	O

1	The	O
2	two	O
3	mouse	O
4	lines	O
5	carrying	O
6	the	O
7	unfragmented	O
8	Hnf3g	B
9	-	O
10	lacZ	B
11	YAC	O
12	showed	O
13	tissue	O
14	-	O
15	specific	O
16	,	O
17	copy	O
18	number	O
19	-	O
20	dependent	O
21	and	O
22	position	O
23	-	O
24	independent	O
25	expression	O
26	,	O
27	proving	O
28	that	O
29	170	O
30	kb	O
31	of	O
32	the	O
33	Hnf3g	B
34	locus	O
35	contain	O
36	all	O
37	elements	O
38	important	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	Hnf3g	B
44	.	O

1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O

1	For	O
2	smaller	O
3	vessels	O
4	up	O
5	to	O
6	a	O
7	diameter	O
8	of	O
9	0	O
10	.	O
11	5	O
12	mm	O
13	,	O
14	treatments	O
15	at	O
16	16	O
17	and	O
18	18	O
19	J	O
20	/	O
21	cm2	O
22	showed	O
23	good	O
24	results	O
25	in	O
26	60	O
27	and	O
28	82	O
29	%	O
30	respectively	O
31	;	O
32	for	O
33	vessels	O
34	up	O
35	to	O
36	1	O
37	mm	O
38	in	O
39	27	O
40	and	O
41	33	O
42	%.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	O
7	core	O
8	region	O
9	and	O
10	transcription	B
11	factor	I
12	YY1	I
13	in	O
14	Rous	B
15	sarcoma	I
16	virus	I
17	long	I
18	terminal	I
19	repeat	I
20	promoter	I
21	activity	O
22	.	O

1	The	O
2	characteristics	O
3	of	O
4	the	O
5	VirD1	B
6	/	O
7	VirD2	B
8	-	O
9	mediated	O
10	cleavage	O
11	reaction	O
12	strongly	O
13	resemble	O
14	those	O
15	observed	O
16	with	O
17	relaxosomes	O
18	of	O
19	IncP	O
20	plasmids	O
21	involved	O
22	in	O
23	initiation	O
24	of	O
25	transfer	O
26	DNA	O
27	replication	O
28	during	O
29	bacterial	O
30	conjugation	O
31	.	O

1	Also	O
2	in	O
3	the	O
4	spectrum	O
5	of	O
6	mutants	O
7	with	O
8	TGN	O
9	sorting	O
10	defects	O
11	are	O
12	isolates	O
13	with	O
14	mutations	O
15	in	O
16	the	O
17	following	O
18	:	O
19	RIC1	B
20	,	O
21	encoding	O
22	a	O
23	product	O
24	originally	O
25	proposed	O
26	to	O
27	participate	O
28	in	O
29	ribosome	O
30	biogenesis	O
31	;	O
32	LUV1	B
33	,	O
34	encoding	O
35	a	O
36	product	O
37	potentially	O
38	involved	O
39	in	O
40	vacuole	O
41	and	O
42	microtubule	O
43	organization	O
44	;	O
45	and	O
46	INP53	B
47	,	O
48	encoding	O
49	a	O
50	synaptojanin	B
51	-	I
52	like	I
53	inositol	I
54	polyphosphate	I
55	5	I
56	-	I
57	phosphatase	I
58	.	O

1	For	O
2	each	O
3	night	O
4	,	O
5	the	O
6	diary	O
7	allowed	O
8	the	O
9	subjective	O
10	measurement	O
11	of	O
12	bedtime	O
13	,	O
14	wake	O
15	time	O
16	,	O
17	time	O
18	in	O
19	bed	O
20	(	O
21	TIB	O
22	),	O
23	sleep	O
24	efficiency	O
25	,	O
26	number	O
27	of	O
28	minutes	O
29	of	O
30	wake	O
31	after	O
32	sleep	O
33	onset	O
34	(	O
35	WASO	O
36	),	O
37	alertness	O
38	on	O
39	awakening	O
40	,	O
41	and	O
42	percentage	O
43	of	O
44	morning	O
45	needing	O
46	an	O
47	alarm	O
48	(	O
49	or	O
50	a	O
51	person	O
52	functioning	O
53	as	O
54	one	O
55	).	O

1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O

1	The	O
2	promoter	O
3	activity	O
4	was	O
5	measured	O
6	by	O
7	a	O
8	transient	O
9	expression	O
10	of	O
11	a	O
12	chloramphenicol	B
13	acetyltransferase	I
14	(	O
15	CAT	B
16	)	O
17	gene	O
18	connected	O
19	with	O
20	various	O
21	5	O
22	'-	O
23	deletion	O
24	mutants	O
25	of	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	.	O

1	Potscoital	O
2	test	O

1	Induction	O
2	of	O
3	Fas	B
4	ligand	I
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	B
13	with	O
14	the	O
15	T	B
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	O
6	GAL4	B
7	and	O
8	LexA	B
9	-	O
10	Bicoid	B
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O

1	The	O
2	major	O
3	inserted	O
4	DNA	O
5	has	O
6	no	O
7	significant	O
8	homology	O
9	to	O
10	published	O
11	human	O
12	nucleic	O
13	acid	O
14	sequences	O
15	.	O

1	Vam7p	B
2	,	O
3	a	O
4	SNAP	B
5	-	I
6	25	I
7	-	I
8	like	I
9	molecule	I
10	,	O
11	and	O
12	Vam3p	B
13	,	O
14	a	O
15	syntaxin	B
16	homolog	I
17	,	O
18	function	O
19	together	O
20	in	O
21	yeast	O
22	vacuolar	O
23	protein	O
24	trafficking	O
25	.	O

1	The	O
2	distribution	O
3	of	O
4	their	O
5	fibrinogen	B
6	levels	O
7	was	O
8	Gaussian	O
9	,	O
10	but	O
11	more	O
12	wide	O
13	-	O
14	based	O
15	than	O
16	the	O
17	distribution	O
18	of	O
19	our	O
20	normal	O
21	controls	O
22	.	O

1	The	O
2	influence	O
3	of	O
4	patient	O
5	-	O
6	related	O
7	factors	O
8	on	O
9	inter	O
10	-	O
11	observer	O
12	variability	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	neurological	O
18	signs	O
19	was	O
20	investigated	O
21	.	O

1	Short	O
2	-	O
3	course	O
4	amphotericin	O
5	B	O
6	therapy	O
7	for	O
8	candidemia	O
9	in	O
10	pediatric	O
11	patients	O
12	.	O

1	Furthermore	O
2	,	O
3	synergistic	O
4	activation	O
5	of	O
6	ERK2	B
7	occurred	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	changes	O
13	in	O
14	intracellular	O
15	Ca2	O
16	+,	O
17	and	O
18	was	O
19	not	O
20	blocked	O
21	by	O
22	inhibition	O
23	of	O
24	protein	B
25	kinase	I
26	C	I
27	activity	O
28	and	O
29	represents	O
30	a	O
31	separate	O
32	pathway	O
33	by	O
34	which	O
35	CD19	B
36	regulates	O
37	B	O
38	cell	O
39	function	O
40	.	O

1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	I
9	gene	I
10	induction	O
11	is	O
12	mediated	O
13	via	O
14	alternative	O
15	MAP	B
16	kinase	I
17	cascades	I
18	:	O
19	MSK1	B
20	as	O
21	a	O
22	potential	O
23	histone	B
24	H3	I
25	/	O
26	HMG	B
27	-	I
28	14	I
29	kinase	O
30	.	O

1	A	O
2	.	O

1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	O
15	phytochromes	B
16	A	I
17	and	I
18	B	I
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O

1	This	O
2	gene	O
3	encodes	O
4	a	O
5	putative	O
6	transcription	O
7	factor	O
8	with	O
9	regions	O
10	of	O
11	homology	O
12	to	O
13	several	O
14	other	O
15	proteins	O
16	including	O
17	the	O
18	zinc	O
19	fingers	O
20	and	O
21	other	O
22	domains	O
23	of	O
24	the	O
25	Drosophila	B
26	trithorax	I
27	gene	I
28	product	I
29	,	O
30	and	O
31	the	O
32	"	O
33	AT	O
34	-	O
35	hook	O
36	"	O
37	DNA	O
38	-	O
39	binding	O
40	motif	O
41	of	O
42	high	B
43	mobility	I
44	group	I
45	proteins	I
46	.	O

1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	Growth	O
2	curves	O
3	indicated	O
4	that	O
5	proliferation	O
6	of	O
7	clone	O
8	CA9	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	10	O
14	%	O
15	serum	O
16	was	O
17	reduced	O
18	by	O
19	60	O
20	%	O
21	compared	O
22	with	O
23	clone	O
24	ME10	O
25	.	O

1	Photopic	O
2	spectral	O
3	sensitivity	O
4	determined	O
5	electroretinographically	O
6	for	O
7	the	O
8	pigeon	O
9	eye	O
10	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	O
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	B
19	immunodeficiency	I
20	virus	I
21	long	I
22	terminal	I
23	repeat	I
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O

1	Plasma	O
2	vitamin	O
3	E	O
4	,	O
5	total	O
6	lipids	O
7	and	O
8	myeloperoxidase	B
9	levels	O
10	during	O
11	spinal	O
12	surgery	O
13	.	O

1	The	O
2	final	O
3	predicted	O
4	structure	O
5	has	O
6	an	O
7	overall	O
8	backbone	O
9	deviation	O
10	of	O
11	0	O
12	.	O
13	7	O
14	A	O
15	from	O
16	that	O
17	of	O
18	ras	B
19	-	O
20	p21	B
21	.	O

1	The	O
2	first	O
3	gene	O
4	codes	O
5	for	O
6	a	O
7	protein	O
8	containing	O
9	11	O
10	cystein	O
11	residues	O
12	in	O
13	an	O
14	arrangement	O
15	typical	O
16	for	O
17	Fe	B
18	/	I
19	S	I
20	proteins	I
21	.	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	Interleukin	B
2	-	I
3	6	I
4	(	O
5	IL	B
6	-	I
7	6	I
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O

1	The	O
2	number	O
3	of	O
4	crystalline	O
5	deposits	O
6	is	O
7	less	O
8	in	O
9	the	O
10	advanced	O
11	atrophic	O
12	areas	O
13	of	O
14	the	O
15	RPE	O
16	-	O
17	choriocapillaris	O
18	complex	O
19	.	O

1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	O
13	guanyl	O
14	nucleotide	O
15	-	O
16	dependent	O
17	activity	O
18	of	O
19	adenylylcyclase	B
20	in	O
21	vitro	O
22	.	O

1	Expression	O
2	of	O
3	PTPRO	B
4	was	O
5	also	O
6	observed	O
7	in	O
8	human	B
9	CD34	I
10	+	I
11	bone	O
12	marrow	O
13	cells	O
14	and	O
15	5	O
16	-	O
17	FU	O
18	-	O
19	treated	O
20	murine	O
21	primitive	O
22	stem	O
23	cells	O
24	.	O

1	Space	O
2	limitations	O
3	prevent	O
4	an	O
5	exhaustive	O
6	review	O
7	of	O
8	all	O
9	biologic	O
10	pharmaceuticals	O
11	,	O
12	such	O
13	as	O
14	tissue	B
15	plasminogen	I
16	activating	I
17	substance	I
18	,	O
19	hormones	O
20	(	O
21	e	O
22	.	O
23	g	O
24	.,	O
25	thyroid	O
26	,	O
27	insulin	B
28	,	O
29	growth	B
30	hormone	I
31	,	O
32	erythropoietin	B
33	),	O
34	clotting	O
35	factors	O
36	,	O
37	and	O
38	blood	O
39	products	O
40	.	O

1	The	O
2	role	O
3	of	O
4	supercritical	O
5	fluid	O
6	chromatography	O
7	(	O
8	SFC	O
9	)	O
10	as	O
11	a	O
12	viable	O
13	technique	O
14	for	O
15	analyzing	O
16	agricultural	O
17	products	O
18	has	O
19	been	O
20	investigated	O
21	using	O
22	packed	O
23	and	O
24	capillary	O
25	column	O
26	methodology	O
27	.	O

1	We	O
2	discuss	O
3	the	O
4	need	O
5	to	O
6	use	O
7	animals	O
8	older	O
9	than	O
10	3	O
11	months	O
12	for	O
13	the	O
14	study	O
15	of	O
16	'	O
17	adult	O
18	'	O
19	regeneration	O
20	phenomena	O
21	since	O
22	3	O
23	-	O
24	month	O
25	-	O
26	old	O
27	rats	O
28	may	O
29	be	O
30	somewhat	O
31	immature	O
32	.	O

1	Sodium	O
2	restriction	O
3	in	O
4	cardiac	O
5	failure	O
6	.	O

1	Potential	O
2	translational	O
3	start	O
4	signals	O
5	are	O
6	upstream	O
7	of	O
8	ORF1	O
9	and	O
10	ORF2	O
11	.	O

1	The	O
2	95	O
3	%	O
4	confidence	O
5	values	O
6	(	O
7	2SD	O
8	)	O
9	for	O
10	the	O
11	change	O
12	in	O
13	Ros	O
14	required	O
15	to	O
16	exclude	O
17	natural	O
18	variability	O
19	were	O
20	0	O
21	.	O
22	39	O
23	,	O
24	0	O
25	.	O
26	50	O
27	and	O
28	0	O
29	.	O
30	53	O
31	cmH2O	O
32	l	O
33	-	O
34	1	O
35	s	O
36	,	O
37	respectively	O
38	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	-	O
6	profile	O
7	serine	O
8	substitutions	O
9	in	O
10	the	O
11	V3	B
12	loop	O
13	of	O
14	HIV	O
15	-	O
16	1	O
17	gp120	B
18	IIIB	I
19	/	O
20	LAI	B
21	on	O
22	the	O
23	immunogenicity	O
24	of	O
25	the	O
26	envelope	B
27	protein	O
28	.	O

1	Altogether	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	Ypt51p	B
8	,	O
9	Ypt52p	B
10	,	O
11	and	O
12	Ypt53p	B
13	are	O
14	required	O
15	for	O
16	transport	O
17	in	O
18	the	O
19	endocytic	O
20	pathway	O
21	and	O
22	for	O
23	correct	O
24	sorting	O
25	of	O
26	vacuolar	B
27	hydrolases	I
28	suggesting	O
29	a	O
30	possible	O
31	intersection	O
32	of	O
33	the	O
34	endocytic	O
35	with	O
36	the	O
37	vacuolar	O
38	sorting	O
39	pathway	O
40	.	O

1	Identity	O
2	of	O
3	GABP	B
4	with	O
5	NRF	B
6	-	I
7	2	I
8	,	O
9	a	O
10	multisubunit	O
11	activator	O
12	of	O
13	cytochrome	B
14	oxidase	I
15	expression	O
16	,	O
17	reveals	O
18	a	O
19	cellular	O
20	role	O
21	for	O
22	an	O
23	ETS	B
24	domain	I
25	activator	O
26	of	O
27	viral	O
28	promoters	O
29	.	O

1	The	O
2	plasma	O
3	half	O
4	-	O
5	life	O
6	of	O
7	slow	O
8	disposition	O
9	phase	O
10	t1	O
11	/	O
12	2	O
13	beta	O
14	,	O
15	increases	O
16	from	O
17	0	O
18	.	O
19	26	O
20	hour	O
21	in	O
22	rabbits	O
23	with	O
24	normal	O
25	renal	O
26	function	O
27	to	O
28	5	O
29	.	O
30	41	O
31	hours	O
32	in	O
33	rabbits	O
34	with	O
35	severe	O
36	renal	O
37	impairment	O
38	.	O

1	Sibling	O
2	aggregation	O
3	of	O
4	low	B
5	-	I
6	and	I
7	high	I
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	O
13	apolipoproteins	B
14	B	I
15	and	I
16	A	I
17	-	I
18	I	I
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O

1	The	O
2	science	O
3	of	O
4	tissue	O
5	engineering	O
6	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	Signal	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O

1	RA	O
2	-	O
3	treatment	O
4	of	O
5	these	O
6	transfectants	O
7	induced	O
8	morphologic	O
9	and	O
10	immunophenotypic	O
11	maturation	O
12	,	O
13	changes	O
14	in	O
15	RA	O
16	-	O
17	regulated	O
18	genes	O
19	,	O
20	and	O
21	a	O
22	G1	O
23	cell	O
24	cycle	O
25	arrest	O
26	in	O
27	a	O
28	manner	O
29	similar	O
30	to	O
31	parental	O
32	NT2	O
33	/	O
34	D1	O
35	cells	O
36	.	O

1	All	O
2	the	O
3	women	O
4	received	O
5	13	O
6	.	O
7	5	O
8	mg	O
9	plain	O
10	bupivacaine	O
11	via	O
12	subarachnoid	O
13	injection	O
14	at	O
15	the	O
16	L2	O
17	-	O
18	3	O
19	interspace	O
20	.	O

1	SPA	O
2	from	O
3	PAG	O
4	sites	O
5	was	O
6	associated	O
7	with	O
8	aversion	O
9	.	O

1	EGF	B
2	acts	O
3	primarily	O
4	by	O
5	means	O
6	of	O
7	transactivation	O
8	domain	O
9	AF	O
10	-	O
11	1	O
12	,	O
13	whereas	O
14	cAMP	O
15	acts	O
16	via	O
17	transactivation	O
18	domain	O
19	AF	O
20	-	O
21	2	O
22	of	O
23	the	O
24	ER	B
25	.	O

1	The	O
2	discussion	O
3	focuses	O
4	primarily	O
5	on	O
6	the	O
7	newer	O
8	drugs	O
9	like	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	,	O
15	alpha	B
16	-	I
17	adrenergic	I
18	receptor	I
19	blockers	O
20	,	O
21	and	O
22	calcium	O
23	antagonists	O
24	.	O

1	Removal	O
2	of	O
3	thick	O
4	,	O
5	permanently	O
6	altered	O
7	mucoas	O
8	is	O
9	recommended	O
10	even	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	squamous	O
16	epithelium	O
17	.	O

1	Serum	B
2	IgE	I
3	levels	O
4	in	O
5	Tauranga	O
6	children	O
7	.	O

1	In	O
2	contrast	O
3	,	O
4	peak	O
5	filling	O
6	rate	O
7	(	O
8	PFR	O
9	),	O
10	normalized	O
11	to	O
12	end	O
13	diastolic	O
14	volume	O
15	(	O
16	EDV	O
17	),	O
18	or	O
19	stroke	O
20	volume	O
21	(	O
22	SV	O
23	),	O
24	or	O
25	expressed	O
26	as	O
27	the	O
28	ratio	O
29	of	O
30	PFR	O
31	-	O
32	to	O
33	-	O
34	PER	O
35	was	O
36	reduced	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	01	O
43	),	O
44	time	O
45	to	O
46	PFR	O
47	(	O
48	TPFR	O
49	)	O
50	was	O
51	prolonged	O
52	(	O
53	p	O
54	<	O
55	0	O
56	.	O
57	01	O
58	),	O
59	and	O
60	echocardiographic	O
61	left	O
62	ventricular	O
63	mass	O
64	index	O
65	was	O
66	higher	O
67	(	O
68	p	O
69	<	O
70	0	O
71	.	O
72	001	O
73	)	O
74	in	O
75	patients	O
76	with	O
77	acromegaly	O
78	compared	O
79	to	O
80	normals	O
81	.	O

1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	B
9	II	I
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	B
19	.	O

1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O

1	This	O
2	regulation	O
3	requires	O
4	two	O
5	HMG	B
6	-	I
7	box	I
8	proteins	I
9	:	O
10	the	O
11	ubiquitous	O
12	Ste11	B
13	transcription	I
14	factor	I
15	and	O
16	the	O
17	M	O
18	cell	O
19	-	O
20	controlling	O
21	protein	O
22	Mat1	B
23	-	I
24	Mc	I
25	.	O

1	SCA	B
2	was	O
3	resistant	O
4	to	O
5	inhibitors	O
6	of	O
7	serine	O
8	,	O
9	aspartyl	O
10	,	O
11	and	O
12	metalloproteases	B
13	,	O
14	but	O
15	it	O
16	was	O
17	sensitive	O
18	to	O
19	N	O
20	-	O
21	ethylmaleimide	O
22	.	O

1	Paraneoplastic	O
2	rheumatic	O
3	syndromes	O
4	.	O

1	Enhancer	O
2	activity	O
3	requires	O
4	both	O
5	the	O
6	AP	B
7	-	I
8	1	I
9	site	I
10	and	O
11	these	O
12	adjacent	O
13	sequences	O
14	.	O

1	The	O
2	exogenous	O
3	fos	B
4	gene	I
5	was	O
6	rapidly	O
7	induced	O
8	to	O
9	maximal	O
10	levels	O
11	within	O
12	1	O
13	-	O
14	2	O
15	hr	O
16	of	O
17	estrogen	O
18	addition	O
19	.	O

1	The	O
2	requirement	O
3	for	O
4	proteolytic	O
5	activity	O
6	of	O
7	both	O
8	FVIIa	B
9	and	O
10	FXa	B
11	suggests	O
12	that	O
13	protease	O
14	-	O
15	activated	O
16	receptors	O
17	may	O
18	be	O
19	involved	O
20	.	O

1	Construction	O
2	of	O
3	a	O
4	RIP1	B
5	deletion	O
6	strain	O
7	and	O
8	isolation	O
9	of	O
10	temperature	O
11	-	O
12	sensitive	O
13	mutants	O
14	.	O

1	These	O
2	exons	O
3	were	O
4	identified	O
5	by	O
6	cloning	O
7	and	O
8	sequencing	O
9	cDNAs	O
10	obtained	O
11	by	O
12	polymerase	O
13	chain	O
14	reaction	O
15	amplification	O
16	of	O
17	a	O
18	fibroblast	O
19	cDNA	O
20	library	O
21	.	O

1	Reproductive	O
2	period	O
3	affects	O
4	water	O
5	intake	O
6	in	O
7	heat	O
8	-	O
9	stressed	O
10	dehydrated	O
11	goats	O
12	.	O

1	Nuclear	O
2	receptors	O
3	(	O
4	NRs	O
5	)	O
6	can	O
7	function	O
8	as	O
9	ligandinducible	O
10	transregulators	O
11	in	O
12	both	O
13	mammalian	O
14	and	O
15	yeast	O
16	cells	O
17	,	O
18	indicating	O
19	that	O
20	important	O
21	features	O
22	of	O
23	transcriptional	O
24	control	O
25	have	O
26	been	O
27	conserved	O
28	throughout	O
29	evolution	O
30	.	O

1	The	O
2	mammalian	B
3	phosphoinositide	I
4	3	I
5	-	I
6	kinases	I
7	(	O
8	PI3Ks	B
9	)	O
10	p110alpha	B
11	,	I
12	beta	I
13	,	I
14	and	I
15	delta	I
16	form	O
17	heterodimers	O
18	with	O
19	Src	B
20	homology	I
21	2	I
22	(	O
23	SH2	B
24	)	O
25	domain	O
26	-	O
27	containing	O
28	adaptors	O
29	such	O
30	as	O
31	p85alpha	B
32	or	O
33	p55	B
34	(	O
35	PIK	B
36	).	O

1	The	O
2	rate	O
3	-	O
4	decreasing	O
5	effects	O
6	of	O
7	morphine	O
8	and	O
9	U50488	O
10	were	O
11	reversed	O
12	completely	O
13	by	O
14	a	O
15	0	O
16	.	O
17	01	O
18	and	O
19	1	O
20	.	O
21	0	O
22	mg	O
23	/	O
24	kg	O
25	dose	O
26	of	O
27	naloxone	O
28	,	O
29	respectively	O
30	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	Clinical	O
2	accuracy	O
3	of	O
4	updated	O
5	version	O
6	of	O
7	the	O
8	Phadebas	O
9	RAST	O
10	test	O
11	.	O

1	The	O
2	mMIWC1	B
3	promoter	I
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	B
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	B
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	I
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	uncharacterized	O
18	metalloprotease	B
19	of	I
20	Vibrio	I
21	cholerae	I
22	O1	I
23	.	O

1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	B
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O

1	Assuming	O
2	O2	O
3	consumption	O
4	of	O
5	the	O
6	isolated	O
7	skin	O
8	to	O
9	be	O
10	same	O
11	as	O
12	in	O
13	situ	O
14	,	O
15	calculations	O
16	showed	O
17	that	O
18	when	O
19	water	O
20	PO2	O
21	was	O
22	high	O
23	(	O
24	150	O
25	mm	O
26	Hg	O
27	),	O
28	about	O
29	40	O
30	%	O
31	of	O
32	total	O
33	cutaneous	O
34	O2	O
35	uptake	O
36	was	O
37	consumed	O
38	by	O
39	the	O
40	skin	O
41	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O

1	A	O
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	O
16	WWW	O
17	server	O
18	.	O

1	Control	O
2	experiments	O
3	showed	O
4	that	O
5	each	O
6	fusion	O
7	protein	O
8	had	O
9	a	O
10	high	O
11	affinity	O
12	binding	O
13	site	O
14	for	O
15	estradiol	O
16	-	O
17	17	O
18	beta	O
19	and	O
20	could	O
21	transactivate	O
22	an	O
23	ERE	O
24	-	O
25	LacZ	B
26	reporter	O
27	gene	O
28	in	O
29	yeast	O
30	similar	O
31	to	O
32	the	O
33	wild	B
34	type	I
35	ER	I
36	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Recombinant	B
2	human	I
3	erythropoietin	I
4	(	O
5	epoetin	B
6	)	O
7	is	O
8	approved	O
9	to	O
10	be	O
11	administered	O
12	by	O
13	the	O
14	intravenous	O
15	(	O
16	i	O
17	.	O
18	v	O
19	.)	O
20	or	O
21	subcutaneous	O
22	(	O
23	SC	O
24	)	O
25	route	O
26	.	O

1	Then	O
2	we	O
3	correlated	O
4	HRCT	O
5	findings	O
6	with	O
7	the	O
8	clinical	O
9	features	O
10	,	O
11	pulmonary	O
12	functions	O
13	and	O
14	methacholine	O
15	PC20	O
16	(	O
17	PC20M	O
18	)	O
19	and	O
20	studied	O
21	their	O
22	clinical	O
23	significance	O
24	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	O
20	.	O

1	DNA	O
2	sequencing	O
3	of	O
4	the	O
5	DPM1	B
6	gene	I
7	revealed	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	of	O
13	801	O
14	bases	O
15	.	O

1	Its	O
2	clinical	O
3	and	O
4	histopathologic	O
5	characteristics	O
6	.	O

1	The	O
2	Cox	O
3	proportional	O
4	hazards	O
5	model	O
6	was	O
7	applied	O
8	to	O
9	the	O
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	O
23	.	O

1	cDNA	O
2	encoding	O
3	a	O
4	functional	O
5	feline	B
6	liver	I
7	/	I
8	bone	I
9	/	I
10	kidney	I
11	-	I
12	type	I
13	alkaline	I
14	phosphatase	I
15	.	O

1	Diclofenac	O
2	sodium	O
3	-	O
4	chlormezanone	O
5	poisoning	O
6	.	O

1	The	O
2	cDNA	O
3	has	O
4	an	O
5	open	O
6	reading	O
7	frame	O
8	of	O
9	900	O
10	amino	O
11	acids	O
12	capable	O
13	of	O
14	encoding	O
15	a	O
16	97	O
17	-	O
18	kDa	O
19	protein	O
20	.	O

1	The	O
2	sixth	O
3	nucleotide	O
4	was	O
5	bulged	O
6	out	O
7	to	O
8	allow	O
9	stacking	O
10	of	O
11	this	O
12	U	O
13	.	O
14	G	O
15	pair	O
16	on	O
17	the	O
18	adjacent	O
19	helical	O
20	region	O
21	.	O

1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O

1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	B
39	tsp	I
40	).	O

1	ATP	O
2	by	O
3	itself	O
4	also	O
5	reduced	O
6	polypeptide	O
7	binding	O
8	to	O
9	Ssb1	B
10	/	I
11	2p	I
12	to	O
13	a	O
14	level	O
15	that	O
16	was	O
17	intermediate	O
18	between	O
19	that	O
20	observed	O
21	for	O
22	the	O
23	Ssa	B
24	Hsp70	I
25	proteins	I
26	tested	O
27	and	O
28	BiP	B
29	and	O
30	DnaK	B
31	.	O

1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O

1	S6	B
2	kinase	I
3	activation	O
4	requires	O
5	displacement	O
6	of	O
7	this	O
8	inhibitory	O
9	segment	O
10	,	O
11	which	O
12	is	O
13	proposed	O
14	to	O
15	occur	O
16	consequent	O
17	to	O
18	its	O
19	multiple	O
20	phosphorylation	O
21	.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	Evolutionary	O
2	relationships	O
3	among	O
4	putative	O
5	RNA	B
6	-	I
7	dependent	I
8	RNA	I
9	polymerases	I
10	encoded	O
11	by	O
12	a	O
13	mitochondrial	O
14	virus	O
15	-	O
16	like	O
17	RNA	O
18	in	O
19	the	O
20	Dutch	O
21	elm	O
22	disease	O
23	fungus	O
24	,	O
25	Ophiostoma	O
26	novo	O
27	-	O
28	ulmi	O
29	,	O
30	by	O
31	other	O
32	viruses	O
33	and	O
34	virus	O
35	-	O
36	like	O
37	RNAs	O
38	and	O
39	by	O
40	the	O
41	Arabidopsis	O
42	mitochondrial	O
43	genome	O
44	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	RNA	O
6	synthesized	O
7	from	O
8	the	O
9	cloned	O
10	cDNAs	O
11	predicts	O
12	that	O
13	P0	B
14	transcripts	I
15	are	O
16	translated	O
17	into	O
18	a	O
19	novel	O
20	12	O
21	.	O
22	5	O
23	-	O
24	kilodalton	O
25	protein	O
26	corresponding	O
27	to	O
28	the	O
29	first	O
30	open	O
31	reading	O
32	frame	O
33	.	O

1	An	O
2	essential	O
3	role	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	and	O
9	c	B
10	-	I
11	Fos	I
12	in	O
13	basal	O
14	and	O
15	PMA	O
16	-	O
17	stimulated	O
18	transcription	O
19	of	O
20	the	O
21	PAI	B
22	-	I
23	1	I
24	gene	I
25	is	O
26	demonstrated	O
27	by	O
28	our	O
29	finding	O
30	that	O
31	antisense	O
32	c	B
33	-	I
34	jun	I
35	and	O
36	c	B
37	-	I
38	fos	I
39	oligodeoxynucleotides	O
40	both	O
41	strongly	O
42	reduced	O
43	basal	O
44	and	O
45	PMA	O
46	-	O
47	stimulated	O
48	PAI	B
49	-	I
50	1	I
51	synthesis	O
52	.	O

1	Ivermectin	O
2	uptake	O
3	and	O
4	distribution	O
5	in	O
6	the	O
7	plasma	O
8	and	O
9	tissue	O
10	of	O
11	Sudanese	O
12	and	O
13	Mexican	O
14	patients	O
15	infected	O
16	with	O
17	Onchocerca	O
18	volvulus	O
19	.	O

1	The	O
2	prominent	O
3	lesions	O
4	were	O
5	confined	O
6	to	O
7	the	O
8	cerebral	O
9	surface	O
10	layer	O
11	and	O
12	leptomeningeal	O
13	tissue	O
14	including	O
15	the	O
16	arachnoid	O
17	vessels	O
18	,	O
19	which	O
20	were	O
21	all	O
22	bathed	O
23	in	O
24	the	O
25	cerebrospinal	O
26	fluid	O
27	,	O
28	suggesting	O
29	that	O
30	some	O
31	necrotizing	O
32	toxins	O
33	had	O
34	been	O
35	secreted	O
36	into	O
37	the	O
38	fluid	O
39	by	O
40	the	O
41	B	O
42	.	O
43	cereus	O
44	.	O

1	A	O
2	possible	O
3	mechanism	O
4	is	O
5	that	O
6	elevated	O
7	alveolar	O
8	pressure	O
9	and	O
10	decreased	O
11	cardiac	O
12	output	O
13	eliminate	O
14	blood	O
15	flow	O
16	from	O
17	corner	O
18	vessels	O
19	in	O
20	nondependent	O
21	high	O
22	VA	O
23	/	O
24	Q	O
25	regions	O
26	.	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	One	O
2	phage	O
3	clone	O
4	contains	O
5	a	O
6	junction	O
7	between	O
8	alpha	O
9	satellite	O
10	DNA	O
11	and	O
12	a	O
13	novel	O
14	low	O
15	-	O
16	copy	O
17	repeated	O
18	sequence	O
19	.	O

1	Finally	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	that	O
7	fimbrin	B
8	is	O
9	a	O
10	third	O
11	distinct	O
12	plastin	B
13	isoform	I
14	which	O
15	is	O
16	specifically	O
17	expressed	O
18	at	O
19	high	O
20	levels	O
21	in	O
22	the	O
23	small	O
24	intestine	O
25	.	O

1	Eight	O
2	hours	O
3	after	O
4	the	O
5	administration	O
6	of	O
7	colchicine	O
8	,	O
9	the	O
10	serum	B
11	ceruloplasmin	I
12	level	O
13	began	O
14	to	O
15	rise	O
16	again	O
17	in	O
18	female	O
19	rats	O
20	,	O
21	but	O
22	not	O
23	in	O
24	male	O
25	rats	O
26	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	On	O
2	histologic	O
3	examination	O
4	the	O
5	cuboidal	O
6	epithelium	O
7	of	O
8	the	O
9	mucous	O
10	membrane	O
11	was	O
12	found	O
13	to	O
14	be	O
15	changed	O
16	into	O
17	columnar	O
18	epithelium	O
19	,	O
20	with	O
21	uneven	O
22	distribution	O
23	of	O
24	enlarged	O
25	nuclei	O
26	in	O
27	the	O
28	vacuolized	O
29	cytoplasm	O
30	.	O

1	Cell	O
2	lines	O
3	are	O
4	checked	O
5	to	O
6	find	O
7	out	O
8	whether	O
9	they	O
10	develop	O
11	tumors	O
12	in	O
13	nude	O
14	mice	O
15	followed	O
16	by	O
17	an	O
18	analysis	O
19	of	O
20	the	O
21	karyotype	O
22	.	O

1	Through	O
2	transient	O
3	transfection	O
4	of	O
5	NIH3T3	O
6	fibroblast	O
7	cells	O
8	and	O
9	gel	O
10	mobility	O
11	shift	O
12	assays	O
13	,	O
14	the	O
15	functional	O
16	binding	O
17	site	O
18	was	O
19	localized	O
20	to	O
21	a	O
22	short	O
23	region	O
24	(-	O
25	318	O
26	to	O
27	-	O
28	303	O
29	bp	O
30	from	O
31	the	O
32	transcription	O
33	start	O
34	site	O
35	)	O
36	which	O
37	has	O
38	a	O
39	CTCCC	O
40	sequence	O
41	.	O

1	With	O
2	histology	O
3	and	O
4	Evans	O
5	blue	O
6	injections	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	alterations	O
13	were	O
14	seen	O
15	as	O
16	early	O
17	as	O
18	4	O
19	days	O
20	after	O
21	a	O
22	dose	O
23	of	O
24	50	O
25	Gy	O
26	.	O

1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	Brandt	O
6	'	O
7	s	O
8	double	O
9	cuff	O
10	-	O
11	tubes	O
12	(	O
13	G2	O
14	)	O
15	succeed	O
16	in	O
17	avoiding	O
18	uncontrolled	O
19	increase	O
20	of	O
21	cuff	O
22	-	O
23	pressure	O
24	during	O
25	anaesthesia	O
26	with	O
27	N2O	O
28	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	Galpha11	B
7	Q209L	I
8	stimulated	O
9	Src	B
10	family	I
11	kinase	O
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	HEK	O
22	-	O
23	293	O
24	cells	O
25	.	O

1	A	O
2	single	O
3	amino	O
4	acid	O
5	change	O
6	in	O
7	the	O
8	CPY	B
9	vacuolar	I
10	sorting	I
11	signal	I
12	prevents	O
13	this	O
14	interaction	O
15	.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	negative	O
7	inotropic	O
8	action	O
9	of	O
10	nicorandil	O
11	is	O
12	caused	O
13	by	O
14	inhibition	O
15	of	O
16	Ca	O
17	influx	O
18	and	O
19	intracellular	O
20	mobilization	O
21	of	O
22	Ca	O
23	.	O

1	Femoral	O
2	strain	O
3	adaptation	O
4	after	O
5	total	O
6	hip	O
7	replacement	O
8	:	O
9	a	O
10	comparison	O
11	of	O
12	cemented	O
13	and	O
14	porous	O
15	ingrowth	O
16	components	O
17	in	O
18	canines	O
19	.	O

1	Repair	O
2	of	O
3	a	O
4	cosmetic	O
5	defect	O
6	of	O
7	the	O
8	lower	O
9	leg	O
10	with	O
11	a	O
12	myocutaneous	O
13	free	O
14	flap	O
15	.	O

1	AF154055	B
2	.	O

1	SL1	B
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	O
20	elegans	O
21	pre	O
22	-	O
23	mRNA	O
24	.	O

1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O

1	DNA	O
2	strand	O
3	exchange	O
4	catalyzed	O
5	by	O
6	Rad51	B
7	protein	I
8	is	O
9	also	O
10	greatly	O
11	stimulated	O
12	by	O
13	RPA	B
14	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	B
43	/	I
44	pork	I
45	collagen	I
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	A	O
2	conserved	O
3	role	O
4	for	O
5	L1	B
6	as	O
7	a	O
8	transmembrane	O
9	link	O
10	between	O
11	neuronal	O
12	adhesion	O
13	and	O
14	membrane	O
15	cytoskeleton	O
16	assembly	O
17	.	O

1	VP5	B
2	,	O
3	which	O
4	encodes	O
5	the	O
6	major	B
7	capsid	I
8	protein	I
9	,	O
10	each	O
11	fused	O
12	to	O
13	the	O
14	chloramphenicol	B
15	acetyltransferase	I
16	gene	I
17	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	regulation	O
6	in	O
7	the	O
8	budding	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	has	O
13	shown	O
14	that	O
15	a	O
16	central	O
17	regulatory	O
18	protein	O
19	kinase	O
20	,	O
21	Cdc28	B
22	,	O
23	undergoes	O
24	changes	O
25	in	O
26	activity	O
27	through	O
28	the	O
29	cell	O
30	cycle	O
31	by	O
32	associating	O
33	with	O
34	distinct	O
35	groups	O
36	of	O
37	cyclins	B
38	that	O
39	accumulate	O
40	at	O
41	different	O
42	times	O
43	.	O

1	3	O
2	.	O

1	Deletion	O
2	of	O
3	the	O
4	POR2	B
5	gene	I
6	alone	O
7	had	O
8	no	O
9	detectable	O
10	phenotype	O
11	,	O
12	while	O
13	yeasts	O
14	with	O
15	deletions	O
16	of	O
17	both	O
18	the	O
19	POR1	B
20	and	O
21	POR2	B
22	genes	I
23	were	O
24	viable	O
25	and	O
26	able	O
27	to	O
28	grow	O
29	on	O
30	glycerol	O
31	at	O
32	30	O
33	degrees	O
34	C	O
35	,	O
36	albeit	O
37	more	O
38	slowly	O
39	than	O
40	delta	B
41	por1	I
42	single	I
43	mutants	I
44	.	O

1	Antithrombin	B
2	III	I
3	in	O
4	hip	O
5	surgery	O

1	4	O
2	.	O

1	Serum	O
2	concentrations	O
3	of	O
4	E2	O
5	and	O
6	TBOH	O
7	were	O
8	measured	O
9	on	O
10	d	O
11	0	O
12	,	O
13	1	O
14	,	O
15	3	O
16	,	O
17	5	O
18	,	O
19	7	O
20	,	O
21	13	O
22	,	O
23	21	O
24	,	O
25	28	O
26	,	O
27	42	O
28	,	O
29	56	O
30	,	O
31	84	O
32	,	O
33	112	O
34	,	O
35	and	O
36	140	O
37	in	O
38	finishing	O
39	heifers	O
40	administered	O
41	the	O
42	following	O
43	treatments	O
44	:	O
45	1	O
46	)	O
47	control	O
48	;	O
49	2	O
50	)	O
51	MGA	O
52	,	O
53	.	O
54	5	O
55	mg	O
56	per	O
57	heifer	O
58	daily	O
59	;	O
60	3	O
61	)	O
62	Revalor	O
63	-	O
64	H	O
65	(	O
66	140	O
67	mg	O
68	TBA	O
69	+	O
70	14	O
71	mg	O
72	E2	O
73	);	O
74	4	O
75	)	O
76	Revalor	O
77	-	O
78	H	O
79	+	O
80	MGA	O
81	;	O
82	5	O
83	)	O
84	Finaplix	O
85	-	O
86	H	O
87	(	O
88	200	O
89	mg	O
90	TBA	O
91	);	O
92	and	O
93	6	O
94	)	O
95	Finaplix	O
96	-	O
97	H	O
98	+	O
99	MGA	O
100	.	O

1	The	O
2	MPS1	B
3	open	I
4	reading	I
5	frame	I
6	has	O
7	been	O
8	fused	O
9	to	O
10	those	O
11	that	O
12	encode	O
13	the	O
14	LexA	B
15	protein	I
16	or	O
17	the	O
18	GST	B
19	protein	I
20	and	O
21	both	O
22	of	O
23	these	O
24	constructs	O
25	function	O
26	in	O
27	yeast	O
28	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	In	O
6	25	O
7	open	O
8	-	O
9	chest	O
10	,	O
11	anesthetized	O
12	dogs	O
13	,	O
14	progressive	O
15	circumflex	O
16	artery	O
17	stenosis	O
18	led	O
19	to	O
20	a	O
21	concordant	O
22	decrease	O
23	of	O
24	circumflex	O
25	artery	O
26	resting	O
27	and	O
28	hyperemic	O
29	flow	O
30	,	O
31	coronary	O
32	flow	O
33	reserve	O
34	,	O
35	and	O
36	inverse	O
37	angiographic	O
38	mean	O
39	transit	O
40	time	O
41	Tmicro	O
42	-	O
43	1	O
44	(	O
45	P	O
46	<	O
47	.	O
48	01	O
49	).	O

1	A	O
2	case	O
3	report	O
4	with	O
5	angiographic	O
6	follow	O
7	-	O
8	up	O
9	study	O
10	.	O

1	Propranolol	O
2	(	O
3	Inderal	O
4	)	O
5	administered	O
6	in	O
7	a	O
8	dose	O
9	which	O
10	blocks	O
11	the	O
12	beta	O
13	-	O
14	adrenergic	O
15	apparatus	O
16	of	O
17	the	O
18	heart	O
19	prevents	O
20	the	O
21	development	O
22	of	O
23	the	O
24	positive	O
25	inotropic	O
26	effect	O
27	of	O
28	therapeutic	O
29	doses	O
30	of	O
31	strophanthin	O
32	K	O
33	on	O
34	a	O
35	hypodynamic	O
36	left	O
37	ventricular	O
38	myocardium	O
39	.	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Targeted	O
2	disruption	O
3	of	O
4	the	O
5	OGG1	B
6	gene	I
7	in	O
8	yeast	O
9	revealed	O
10	a	O
11	second	O
12	OG	B
13	glycosylase	I
14	/	I
15	lyase	I
16	protein	I
17	,	O
18	tentatively	O
19	named	O
20	Ogg2	B
21	,	O
22	which	O
23	differs	O
24	from	O
25	Ogg1	B
26	in	O
27	that	O
28	it	O
29	preferentially	O
30	acts	O
31	on	O
32	OG	O
33	:	O
34	G	O
35	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	B
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	B
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	O
24	(	O
25	A	O
26	gamma	O
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	O
39	gamma	B
40	-	I
41	globin	I
42	mRNA	O
43	.	O

1	We	O
2	found	O
3	that	O
4	TCR	B
5	signaling	O
6	induces	O
7	AP	B
8	-	I
9	1	I
10	binding	O
11	to	O
12	this	O
13	site	O
14	and	O
15	regulates	O
16	the	O
17	fasl	B
18	promoter	I
19	function	O
20	in	O
21	a	O
22	fashion	O
23	dependent	O
24	on	O
25	NF	B
26	-	I
27	kappaB	I
28	binding	O
29	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O

1	However	O
2	,	O
3	essential	O
4	contrast	O
5	differences	O
6	existing	O
7	between	O
8	the	O
9	FSE	O
10	sequences	O
11	and	O
12	their	O
13	routine	O
14	asymmetric	O
15	dual	O
16	SE	O
17	counterpart	O
18	can	O
19	be	O
20	identified	O
21	.	O

1	A	O
2	32P	O
3	-	O
4	labeled	O
5	LAP	B
6	DNA	O
7	-	O
8	binding	O
9	and	O
10	dimerization	O
11	domain	O
12	"	O
13	zipper	O
14	probe	O
15	"	O
16	was	O
17	used	O
18	to	O
19	isolate	O
20	a	O
21	clone	O
22	that	O
23	encodes	O
24	a	O
25	new	O
26	C	B
27	/	I
28	EBP	I
29	-	I
30	homologous	I
31	protein	I
32	:	O
33	CHOP	B
34	-	I
35	10	I
36	.	O

1	Fenfluramine	O
2	(	O
3	in	O
4	doses	O
5	ranging	O
6	from	O
7	0	O
8	.	O
9	0625	O
10	-	O
11	4	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	infusion	O
19	)	O
20	did	O
21	not	O
22	maintain	O
23	self	O
24	-	O
25	administration	O
26	behavior	O
27	at	O
28	or	O
29	above	O
30	the	O
31	minimum	O
32	requirement	O
33	(	O
34	FR	O
35	30	O
36	).	O

1	A	O
2	hypothesis	O
3	.	O

1	Catheter	O
2	transit	O
3	slows	O
4	the	O
5	response	O
6	to	O
7	a	O
8	step	O
9	increase	O
10	in	O
11	concentration	O
12	by	O
13	about	O
14	0	O
15	.	O
16	13	O
17	s	O
18	(	O
19	from	O
20	10	O
21	per	O
22	cent	O
23	-	O
24	90	O
25	per	O
26	cent	O
27	)	O
28	and	O
29	prolongs	O
30	the	O
31	transit	O
32	time	O
33	through	O
34	the	O
35	catheter	O
36	for	O
37	a	O
38	volatile	O
39	anesthetic	O
40	by	O
41	about	O
42	0	O
43	.	O
44	04	O
45	s	O
46	more	O
47	than	O
48	N2	O
49	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	Association	O
2	of	O
3	human	B
4	Pur	I
5	alpha	I
6	with	O
7	the	O
8	retinoblastoma	B
9	protein	I
10	,	O
11	Rb	B
12	,	O
13	regulates	O
14	binding	O
15	to	O
16	the	O
17	single	O
18	-	O
19	stranded	O
20	DNA	O
21	Pur	B
22	alpha	I
23	recognition	I
24	element	I
25	.	O

1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	B
12	transactivator	I
13	VP16	I
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	B
23	contacts	O
24	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	B
22	associated	I
23	proteins	I
24	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	Treatment	O
2	of	O
3	PCC4	O
4	.	O
5	aza1R	O
6	cells	O
7	with	O
8	an	O
9	RAR	B
10	-	O
11	selective	O
12	agonist	O
13	also	O
14	repressed	O
15	the	O
16	expression	O
17	of	O
18	EC	B
19	-	I
20	1	I
21	mRNA	I
22	while	O
23	treatment	O
24	with	O
25	an	O
26	RXR	B
27	-	O
28	selective	O
29	agonist	O
30	reduced	O
31	EC	B
32	-	I
33	1	I
34	expression	O
35	slightly	O
36	.	O

1	Furthermore	O
2	,	O
3	MOM	B
4	-	I
5	4	I
6	and	O
7	TAK1	B
8	bind	O
9	related	O
10	proteins	O
11	that	O
12	promote	O
13	their	O
14	kinase	O
15	activities	O
16	.	O

1	When	O
2	multiple	O
3	copies	O
4	of	O
5	the	O
6	IL	B
7	-	I
8	1	I
9	beta	I
10	NF	I
11	-	I
12	kappa	I
13	B	I
14	site	I
15	were	O
16	linked	O
17	to	O
18	an	O
19	enhancerless	O
20	simian	B
21	virus	I
22	40	I
23	promoter	I
24	,	O
25	this	O
26	element	O
27	was	O
28	able	O
29	to	O
30	mediate	O
31	phorbol	O
32	ester	O
33	-	O
34	or	O
35	lipopolysaccharide	O
36	-	O
37	inducible	O
38	gene	O
39	expression	O
40	.	O

1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O

1	A	O
2	2	O
3	kb	O
4	transcript	O
5	was	O
6	isolated	O
7	from	O
8	brain	O
9	that	O
10	encodes	O
11	a	O
12	approximately	O
13	57	O
14	kDa	O
15	protein	O
16	;	O
17	the	O
18	predicted	O
19	protein	O
20	contains	O
21	the	O
22	known	O
23	N	B
24	-	I
25	terminal	I
26	Ets	I
27	domain	I
28	of	O
29	PE1	B
30	and	O
31	a	O
32	novel	O
33	C	O
34	-	O
35	terminal	O
36	domain	O
37	with	O
38	signficant	O
39	homology	O
40	to	O
41	murine	B
42	ERF	I
43	.	O

1	40	O
2	patients	O
3	with	O
4	chronic	O
5	osteomyelitis	O
6	were	O
7	treated	O
8	per	O
9	os	O
10	with	O
11	the	O
12	bactericidal	O
13	beta	O
14	-	O
15	lactam	O
16	-	O
17	antibiotic	O
18	cephalexin	O
19	during	O
20	3	O
21	to	O
22	60	O
23	weeks	O
24	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	The	O
2	effect	O
3	of	O
4	L	O
5	-	O
6	methionine	O
7	supplementation	O
8	on	O
9	the	O
10	utilization	O
11	of	O
12	a	O
13	soy	O
14	protein	O
15	isolate	O
16	(	O
17	SPI	O
18	)	O
19	was	O
20	evaluated	O
21	by	O
22	short	O
23	-	O
24	term	O
25	nitrogen	O
26	balance	O
27	studies	O
28	in	O
29	young	O
30	women	O
31	.	O

1	Persistent	O
2	acantholytic	O
3	dermatosis	O
4	with	O
5	increased	O
6	light	O
7	sensitivity	O

1	Kinetics	O
2	of	O
3	the	O
4	inhibition	O
5	indicated	O
6	that	O
7	this	O
8	polymerase	O
9	domain	O
10	can	O
11	inhibit	O
12	viral	O
13	replication	O
14	only	O
15	during	O
16	the	O
17	preinitiation	O
18	stage	O
19	.	O

1	CONCLUSIONS	O
2	:	O
3	Translocation	O
4	of	O
5	bacteria	O
6	or	O
7	endotoxin	O
8	from	O
9	the	O
10	gastrointestinal	O
11	tract	O
12	into	O
13	the	O
14	bloodstream	O
15	has	O
16	been	O
17	noted	O
18	in	O
19	animal	O
20	experiments	O
21	;	O
22	however	O
23	,	O
24	translocation	O
25	was	O
26	not	O
27	detected	O
28	in	O
29	our	O
30	patients	O
31	with	O
32	hemorrhagic	O
33	shock	O
34	.	O

1	Slap	B
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	O
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O

1	Studies	O
2	on	O
3	powdered	O
4	preparations	O
5	.	O

1	The	O
2	muskox	O
3	is	O
4	a	O
5	new	O
6	host	O
7	record	O
8	for	O
9	T	O
10	.	O
11	gondii	O
12	.	O

1	Stimulation	O
2	of	O
3	the	O
4	caudate	O
5	nucleus	O
6	'	O
7	dophamine	O
8	-	O
9	reactive	O
10	system	O
11	in	O
12	dogs	O
13	by	O
14	means	O
15	of	O
16	administration	O
17	of	O
18	dophamine	O
19	(	O
20	60	O
21	micrograms	O
22	)	O
23	and	O
24	phenamine	O
25	led	O
26	to	O
27	deterioration	O
28	of	O
29	conditioned	O
30	and	O
31	unconditioned	O
32	components	O
33	of	O
34	feeding	O
35	behaviour	O
36	.	O

1	Human	O
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O

1	How	O
2	plants	O
3	respond	O
4	to	O
5	attack	O
6	by	O
7	the	O
8	range	O
9	of	O
10	herbivores	O
11	and	O
12	pathogens	O
13	that	O
14	confront	O
15	them	O
16	in	O
17	the	O
18	field	O
19	is	O
20	the	O
21	subject	O
22	of	O
23	considerable	O
24	research	O
25	by	O
26	both	O
27	molecular	O
28	biologists	O
29	and	O
30	ecologists	O
31	.	O

1	The	O
2	resulting	O
3	integrated	O
4	physical	O
5	,	O
6	genetic	O
7	,	O
8	and	O
9	cytogenetic	O
10	map	O
11	constitutes	O
12	a	O
13	resource	O
14	for	O
15	the	O
16	characterization	O
17	of	O
18	genes	O
19	that	O
20	may	O
21	be	O
22	involved	O
23	in	O
24	the	O
25	WAGR	O
26	syndrome	O
27	.	O

1	In	O
2	the	O
3	DNA	O
4	recognition	O
5	helix	O
6	of	O
7	finger	O
8	II	O
9	,	O
10	the	O
11	conserved	O
12	Arg	O
13	at	O
14	position	O
15	62	O
16	(	O
17	N	O
18	-	O
19	terminal	O
20	side	O
21	of	O
22	the	O
23	first	O
24	zinc	O
25	-	O
26	coordinating	O
27	histidine	O
28	)	O
29	was	O
30	changed	O
31	to	O
32	a	O
33	Leu	O
34	or	O
35	Gln	O
36	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	B
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O

1	A	O
2	gapped	O
3	search	O
4	with	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	of	O
11	CDED	B
12	/	O
13	LIOR	B
14	revealed	O
15	a	O
16	36	O
17	-	O
18	41	O
19	%	O
20	similarity	O
21	to	O
22	several	O
23	proteins	O
24	related	O
25	to	O
26	signal	O
27	transduction	O
28	and	O
29	cell	O
30	replication	O
31	,	O
32	such	O
33	as	O
34	ORC1	B
35	and	O
36	KSR	B
37	.	O

1	The	O
2	evaluation	O
3	of	O
4	amniotic	O
5	fluid	O
6	delta	O
7	OD450	O
8	is	O
9	considered	O
10	to	O
11	be	O
12	the	O
13	cornerstone	O
14	of	O
15	clinical	O
16	management	O
17	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	the	O
6	proline	O
7	-	O
8	rich	O
9	region	O
10	of	O
11	CAP	B
12	is	O
13	recognized	O
14	by	O
15	the	O
16	SH3	B
17	domains	I
18	of	O
19	several	O
20	proteins	O
21	,	O
22	including	O
23	the	O
24	yeast	B
25	actin	I
26	-	I
27	associated	I
28	protein	I
29	Abp1p	I
30	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	a	O
6	study	O
7	of	O
8	low	O
9	dose	O
10	X	O
11	-	O
12	rays	O
13	effects	O
14	,	O
15	we	O
16	found	O
17	that	O
18	male	O
19	ICR	O
20	white	O
21	Swiss	O
22	mice	O
23	showed	O
24	remarkable	O
25	suppression	O
26	of	O
27	mounting	O
28	behavior	O
29	after	O
30	whole	O
31	body	O
32	irradiation	O
33	by	O
34	5	O
35	to	O
36	15	O
37	cGy	O
38	X	O
39	-	O
40	rays	O
41	.	O

1	Additional	O
2	studies	O
3	with	O
4	new	O
5	and	O
6	reprocessed	O
7	regenerated	O
8	cellulose	O
9	dialyzers	O
10	comparing	O
11	450	O
12	and	O
13	220	O
14	mL	O
15	/	O
16	min	O
17	blood	O
18	flow	O
19	rates	O
20	at	O
21	10	O
22	minutes	O
23	showed	O
24	no	O
25	change	O
26	in	O
27	BTG	O
28	.	O

1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	intronless	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	B
15	G	I
16	alpha	I
17	q	I
18	cDNA	I
19	.	O

1	Here	O
2	we	O
3	demonstrate	O
4	that	O
5	the	O
6	mechanism	O
7	of	O
8	activation	O
9	of	O
10	HIF	B
11	-	I
12	1alpha	I
13	is	O
14	a	O
15	multi	O
16	-	O
17	step	O
18	process	O
19	which	O
20	includes	O
21	hypoxia	O
22	-	O
23	dependent	O
24	nuclear	O
25	import	O
26	and	O
27	activation	O
28	(	O
29	derepression	O
30	)	O
31	of	O
32	the	O
33	transactivation	O
34	domain	O
35	,	O
36	resulting	O
37	in	O
38	recruitment	O
39	of	O
40	the	O
41	CREB	B
42	-	I
43	binding	I
44	protein	I
45	(	O
46	CBP	B
47	)/	O
48	p300	B
49	coactivator	I
50	.	O

1	Similarly	O
2	,	O
3	overexpression	O
4	of	O
5	increasing	O
6	concentration	O
7	of	O
8	COUP	B
9	-	I
10	TFI	I
11	,	O
12	but	O
13	not	O
14	COUP	B
15	-	I
16	TFI	I
17	delta35	I
18	,	O
19	can	O
20	squelch	O
21	the	O
22	silencing	O
23	activity	O
24	of	O
25	the	O
26	unliganded	O
27	TRbeta	B
28	.	O

1	Time	O
2	shifts	O
3	increase	O
4	growth	B
5	hormone	I
6	release	O
7	.	O

1	Nip7p	B
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	B
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	B
20	precursors	I
21	.	O

1	All	O
2	other	O
3	ejaculate	O
4	parameters	O
5	(	O
6	density	O
7	,	O
8	motility	O
9	,	O
10	swelling	O
11	test	O
12	,	O
13	penetration	O
14	test	O
15	)	O
16	remained	O
17	unchanged	O
18	,	O
19	and	O
20	there	O
21	was	O
22	only	O
23	one	O
24	post	O
25	-	O
26	therapeutic	O
27	pregnancy	O
28	.	O

1	CIITA	B
2	mRNA	I
3	is	O
4	normally	O
5	inducible	O
6	by	O
7	IFN	B
8	-	I
9	gamma	I
10	in	O
11	class	O
12	II	O
13	non	O
14	-	O
15	inducible	O
16	,	O
17	RB	O
18	-	O
19	defective	O
20	lines	O
21	,	O
22	and	O
23	in	O
24	one	O
25	line	O
26	,	O
27	re	O
28	-	O
29	expression	O
30	of	O
31	RB	B
32	has	O
33	no	O
34	effect	O
35	on	O
36	CIITA	B
37	mRNA	I
38	induction	O
39	levels	O
40	.	O

1	In	O
2	transient	O
3	assays	O
4	,	O
5	using	O
6	rice	O
7	suspension	O
8	-	O
9	cultured	O
10	cells	O
11	transformed	O
12	by	O
13	particle	O
14	bombardment	O
15	,	O
16	we	O
17	showed	O
18	previously	O
19	that	O
20	Oshox1	B
21	can	O
22	transcriptionally	O
23	repress	O
24	the	O
25	activity	O
26	of	O
27	reporter	O
28	gene	O
29	constructs	O
30	with	O
31	upstream	O
32	HD	B
33	-	I
34	Zip	I
35	binding	O
36	sites	O
37	.	O

1	A	O
2	centromere	O
3	in	O
4	S	O
5	.	O
6	cerevisiae	O
7	consists	O
8	of	O
9	a	O
10	region	O
11	of	O
12	DNA	O
13	,	O
14	approximately	O
15	150	O
16	bp	O
17	in	O
18	length	O
19	,	O
20	containing	O
21	three	O
22	important	O
23	sequence	O
24	elements	O
25	,	O
26	which	O
27	are	O
28	folded	O
29	with	O
30	proteins	O
31	into	O
32	a	O
33	specific	O
34	conformation	O
35	in	O
36	the	O
37	chromatin	O
38	(	O
39	the	O
40	yeast	O
41	kinetochore	O
42	).	O

1	The	O
2	most	O
3	common	O
4	cause	O
5	of	O
6	renal	O
7	deterioration	O
8	in	O
9	the	O
10	spinal	O
11	cord	O
12	injured	O
13	patient	O
14	is	O
15	irreversible	O
16	vesicoureteral	O
17	reflux	O
18	.	O

1	The	O
2	patients	O
3	undergoing	O
4	VTLB	O
5	had	O
6	significantly	O
7	shorter	O
8	operative	O
9	times	O
10	(	O
11	VTLB	O
12	,	O
13	100	O
14	.	O
15	2	O
16	+/-	O
17	27	O
18	.	O
19	2	O
20	min	O
21	.	O
22	vs	O
23	OLB	O
24	,	O
25	119	O
26	.	O
27	8	O
28	+/-	O
29	42	O
30	.	O
31	6	O
32	min	O
33	;	O
34	p	O
35	<	O
36	0	O
37	.	O
38	01	O
39	)	O
40	and	O
41	less	O
42	blood	O
43	loss	O
44	(	O
45	VTLB	O
46	,	O
47	4	O
48	.	O
49	7	O
50	+/-	O
51	14	O
52	.	O
53	6	O
54	ml	O
55	vs	O
56	OLB	O
57	,	O
58	65	O
59	.	O
60	7	O
61	+/-	O
62	77	O
63	.	O
64	0	O
65	ml	O
66	;	O
67	p	O
68	<	O
69	0	O
70	.	O
71	001	O
72	).	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O

1	No	O
2	significant	O
3	correlations	O
4	of	O
5	peak	O
6	VO2	O
7	were	O
8	observed	O
9	between	O
10	the	O
11	3	O
12	tests	O
13	.	O

1	The	O
2	Epstein	B
3	-	I
4	Barr	I
5	virus	I
6	transactivator	I
7	Zta	I
8	triggers	O
9	lytic	O
10	gene	O
11	expression	O
12	and	O
13	is	O
14	essential	O
15	for	O
16	replication	O
17	of	O
18	the	O
19	lytic	O
20	origin	O
21	,	O
22	oriLyt	O
23	.	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	BACH1t	B
6	recruits	O
7	BACH1	B
8	to	O
9	the	O
10	nucleus	O
11	through	O
12	BTB	B
13	domain	O
14	-	O
15	mediated	O
16	interaction	O
17	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	We	O
5	observed	O
6	a	O
7	congenital	O
8	skin	O
9	defect	O
10	located	O
11	exclusively	O
12	on	O
13	the	O
14	trunk	O
15	.	O

1	The	O
2	NIT2	B
3	protein	I
4	is	O
5	localised	O
6	in	O
7	nuclei	O
8	and	O
9	could	O
10	not	O
11	be	O
12	detected	O
13	in	O
14	the	O
15	cytoplasmic	O
16	fraction	O
17	of	O
18	cells	O
19	subjected	O
20	to	O
21	nitrogen	O
22	derepression	O
23	or	O
24	nitrogen	O
25	repression	O
26	,	O
27	indicating	O
28	that	O
29	the	O
30	nuclear	O
31	import	O
32	of	O
33	NIT2	B
34	is	O
35	not	O
36	regulated	O
37	.	O

1	Using	O
2	in	O
3	organello	O
4	footprint	O
5	analysis	O
6	,	O
7	we	O
8	demonstrate	O
9	that	O
10	within	O
11	human	O
12	placental	O
13	mitochondria	O
14	there	O
15	is	O
16	a	O
17	high	O
18	level	O
19	of	O
20	protein	O
21	-	O
22	DNA	O
23	binding	O
24	at	O
25	regularly	O
26	phased	O
27	intervals	O
28	throughout	O
29	a	O
30	500	O
31	-	O
32	bp	O
33	region	O
34	encompassing	O
35	the	O
36	D	O
37	-	O
38	loop	O
39	DNA	O
40	origins	O
41	and	O
42	two	O
43	promoter	O
44	regions	O
45	.	O

1	Pilot	O
2	study	O
3	of	O
4	blood	O
5	coagulation	O
6	in	O
7	gout	O
8	patients	O
9	.	O

1	Analysis	O
2	for	O
3	DNA	O
4	-	O
5	protein	O
6	interactions	O
7	by	O
8	in	O
9	vitro	O
10	DNase	B
11	-	I
12	I	I
13	footprinting	O
14	identified	O
15	a	O
16	broad	O
17	region	O
18	of	O
19	protection	O
20	extending	O
21	from	O
22	nt	O
23	-	O
24	12	O
25	to	O
26	+	O
27	38	O
28	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	I
11	.	O

1	Mutagenesis	O
2	of	O
3	IM1	B
4	enhances	O
5	the	O
6	ability	O
7	of	O
8	c	B
9	-	I
10	Fos	I
11	to	O
12	activate	O
13	an	O
14	AP1	B
15	bearing	I
16	promoter	I
17	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	Cortisone	O
2	induced	O
3	bone	O
4	changes	O
5	and	O
6	its	O
7	response	O
8	to	O
9	lipid	O
10	clearing	O
11	agents	O
12	.	O

1	The	O
2	fission	B
3	yeast	I
4	dsk1	I
5	+	I
6	gene	I
7	,	O
8	a	O
9	multicopy	O
10	suppressor	O
11	for	O
12	cold	O
13	-	O
14	sensitive	O
15	dis1	B
16	mutants	I
17	,	O
18	encodes	O
19	a	O
20	novel	O
21	61	O
22	-	O
23	kd	O
24	protein	O
25	kinase	O
26	.	O

1	Moreover	O
2	,	O
3	it	O
4	is	O
5	the	O
6	assumptions	O
7	behind	O
8	steady	O
9	-	O
10	state	O
11	O2	O
12	uptake	O
13	that	O
14	do	O
15	not	O
16	permit	O
17	proper	O
18	interpretation	O
19	of	O
20	energy	O
21	expenditure	O
22	during	O
23	EPOC	O
24	;	O
25	1	O
26	l	O
27	O2	O
28	not	O
29	=	O
30	20	O
31	.	O
32	9	O
33	kJ	O
34	.	O

1	The	O
2	git1	B
3	,	O
4	git3	B
5	,	O
6	git5	B
7	,	O
8	git7	B
9	,	O
10	git8	B
11	and	O
12	git10	B
13	genes	I
14	act	O
15	upstream	O
16	of	O
17	adenylate	B
18	cyclase	I
19	,	O
20	presumably	O
21	encoding	O
22	an	O
23	adenylate	B
24	cyclase	I
25	activation	O
26	pathway	O
27	.	O

1	Pol32Delta	B
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	subclones	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	Ctpct	B
23	gene	I
24	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	S	O
2	.,	O
3	K	O
4	.	O

1	The	O
2	decline	O
3	in	O
4	the	O
5	activity	O
6	of	O
7	cytochrome	B
8	oxidase	I
9	,	O
10	peroxidase	B
11	and	O
12	in	O
13	the	O
14	lipid	O
15	content	O
16	of	O
17	peripheral	O
18	neutrophils	O
19	was	O
20	followed	O
21	by	O
22	a	O
23	decrease	O
24	in	O
25	the	O
26	phagocytic	O
27	activity	O
28	.	O

1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O

1	Cloning	O
2	and	O
3	primary	O
4	structure	O
5	of	O
6	neurocan	O
7	,	O
8	a	O
9	developmentally	O
10	regulated	O
11	,	O
12	aggregating	O
13	chondroitin	O
14	sulfate	O
15	proteoglycan	O
16	of	O
17	brain	O
18	.	O

1	Tetrad	O
2	analysis	O
3	and	O
4	mitotic	O
5	recombination	O
6	experiments	O
7	localized	O
8	the	O
9	PEP4	B
10	gene	I
11	proximal	O
12	to	O
13	GAL4	B
14	on	O
15	chromosome	O
16	XVI	O
17	.	O

1	RESULTS	O
2	:	O
3	For	O
4	E1	O
5	,	O
6	itraconazole	O
7	plasma	O
8	drug	O
9	concentration	O
10	extrapolated	O
11	to	O
12	time	O
13	zero	O
14	(	O
15	IV	O
16	dose	O
17	)	O
18	was	O
19	5	O
20	.	O
21	2	O
22	+/-	O
23	1	O
24	.	O
25	4	O
26	micrograms	O
27	/	O
28	ml	O
29	,	O
30	and	O
31	mean	O
32	residence	O
33	time	O
34	(	O
35	MRT	O
36	)	O
37	was	O
38	37	O
39	+/-	O
40	16	O
41	hours	O
42	.	O

1	Dipetalonema	O
2	(	O
3	Alafilaria	O
4	)	O
5	hydrochoerus	O
6	subgen	O
7	.	O
8	et	O
9	sp	O
10	.	O
11	n	O
12	.	O

1	Furthermore	O
2	,	O
3	experiments	O
4	with	O
5	32D	O
6	temperature	O
7	-	O
8	sensitive	O
9	p53	B
10	cells	O
11	indicate	O
12	that	O
13	aberrant	O
14	tal	B
15	-	I
16	1	I
17	expression	O
18	at	O
19	the	O
20	permissive	O
21	temperature	O
22	does	O
23	not	O
24	exert	O
25	a	O
26	proliferative	O
27	effect	O
28	but	O
29	causes	O
30	p53	B
31	-	O
32	mediated	O
33	apoptosis	O
34	,	O
35	i	O
36	.	O
37	e	O
38	.,	O
39	the	O
40	tal	B
41	-	I
42	1	I
43	proliferative	O
44	effect	O
45	depends	O
46	on	O
47	the	O
48	integrity	O
49	of	O
50	the	O
51	cell	O
52	cycle	O
53	checkpoints	O
54	of	O
55	the	O
56	host	O
57	cell	O
58	,	O
59	as	O
60	observed	O
61	for	O
62	c	B
63	-	I
64	myc	I
65	and	O
66	other	O
67	oncogenes	O
68	.	O
69	tal	B
70	-	I
71	1	I
72	mutant	I
73	experiments	O
74	indicate	O
75	that	O
76	ectopic	O
77	tal	B
78	-	I
79	1	I
80	effects	O
81	are	O
82	mediated	O
83	by	O
84	both	O
85	the	O
86	DNA	O
87	-	O
88	binding	O
89	and	O
90	the	O
91	heterodimerization	O
92	domains	O
93	,	O
94	while	O
95	the	O
96	N	B
97	-	I
98	terminally	I
99	truncated	I
100	tal	I
101	-	I
102	1	I
103	variant	I
104	(	O
105	M3	B
106	)	O
107	expressed	O
108	in	O
109	T	O
110	-	O
111	ALL	O
112	malignant	O
113	cells	O
114	mimics	O
115	the	O
116	effects	O
117	of	O
118	the	O
119	wild	O
120	-	O
121	type	O
122	protein	O
123	.	O

1	Effects	O
2	of	O
3	chronic	O
4	descending	O
5	tractotomy	O
6	on	O
7	the	O
8	response	O
9	patterns	O
10	of	O
11	neurons	O
12	in	O
13	the	O
14	trigeminal	O
15	nuclei	O
16	principalis	O
17	and	O
18	oralis	O
19	.	O

1	This	O
2	observation	O
3	cannot	O
4	be	O
5	explained	O
6	by	O
7	the	O
8	scanning	O
9	model	O
10	for	O
11	ribosomal	O
12	initiation	O
13	and	O
14	suggests	O
15	that	O
16	ribosomes	O
17	may	O
18	be	O
19	binding	O
20	directly	O
21	at	O
22	an	O
23	internal	O
24	mRNA	O
25	site	O
26	at	O
27	or	O
28	near	O
29	the	O
30	initiator	O
31	AUG	O
32	codon	O
33	for	O
34	the	O
35	C	B
36	protein	I
37	.	O

1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	"	O
42	classical	O
43	"	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O

1	MDS1	B
2	/	O
3	EVI1	B
4	,	O
5	located	O
6	on	O
7	chromosome	O
8	3	O
9	band	O
10	q26	O
11	,	O
12	encodes	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	DNA	I
18	-	I
19	binding	I
20	transcription	I
21	activator	I
22	not	O
23	detected	O
24	in	O
25	normal	O
26	hematopoietic	O
27	cells	O
28	but	O
29	expressed	O
30	in	O
31	several	O
32	normal	O
33	tissues	O
34	.	O

1	The	O
2	cytosolic	O
3	glutathione	B
4	S	I
5	-	I
6	transferases	I
7	(	O
8	GSTs	B
9	,	O
10	EC	B
11	2	I
12	.	I
13	5	I
14	.	I
15	1	I
16	.	I
17	18	I
18	)	O
19	are	O
20	a	O
21	superfamily	O
22	of	O
23	dimeric	O
24	isoenzymes	O
25	which	O
26	catalyze	O
27	the	O
28	conjugation	O
29	of	O
30	electrophilic	O
31	substrates	O
32	with	O
33	glutathione	O
34	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	TFEC	B
2	,	O
3	a	O
4	basic	B
5	helix	I
6	-	I
7	loop	I
8	-	I
9	helix	I
10	protein	I
11	,	O
12	forms	O
13	heterodimers	O
14	with	O
15	TFE3	B
16	and	O
17	inhibits	O
18	TFE3	B
19	-	O
20	dependent	O
21	transcription	O
22	activation	O
23	.	O

1	Bacteriol	O
2	.	O

1	Delta	O
2	-	O
3	aminolevulinic	O
4	acid	O
5	in	O
6	physiological	O
7	conditions	O
8	and	O
9	some	O
10	diseases	O
11	in	O
12	children	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	In	O
2	Experiment	O
3	2	O
4	,	O
5	we	O
6	again	O
7	used	O
8	classification	O
9	,	O
10	but	O
11	the	O
12	fixed	O
13	standard	O
14	75	O
15	was	O
16	not	O
17	at	O
18	the	O
19	center	O
20	of	O
21	the	O
22	range	O
23	of	O
24	target	O
25	numbers	O
26	(	O
27	20	O
28	,	O
29	21	O
30	,	O
31	...	O

1	Other	O
2	adverse	O
3	events	O
4	with	O
5	incidences	O
6	significantly	O
7	higher	O
8	than	O
9	with	O
10	placebo	O
11	were	O
12	dizziness	O
13	,	O
14	constipation	O
15	,	O
16	sweating	O
17	,	O
18	nervousness	O
19	,	O
20	and	O
21	abnormal	O
22	ejaculation	O
23	.	O

1	The	O
2	S229A	O
3	variant	O
4	can	O
5	better	O
6	flip	O
7	modified	O
8	bases	O
9	but	O
10	does	O
11	not	O
12	tightly	O
13	lock	O
14	the	O
15	flipped	O
16	base	O
17	into	O
18	the	O
19	adenine	O
20	-	O
21	binding	O
22	pocket	O
23	,	O
24	suggesting	O
25	that	O
26	Ser229	O
27	could	O
28	form	O
29	a	O
30	contact	O
31	to	O
32	the	O
33	flipped	O
34	adenine	O
35	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	We	O
2	report	O
3	the	O
4	use	O
5	of	O
6	a	O
7	new	O
8	technetium	O
9	-	O
10	99m	O
11	-	O
12	albumin	B
13	colloid	O
14	white	O
15	blood	O
16	cell	O
17	(	O
18	TAC	O
19	-	O
20	WBC	O
21	)	O
22	scan	O
23	in	O
24	the	O
25	evaluation	O
26	of	O
27	appendicitis	O
28	.	O

1	In	O
2	11	O
3	eyes	O
4	that	O
5	had	O
6	been	O
7	selected	O
8	at	O
9	random	O
10	10	O
11	micrograms	O
12	of	O
13	recombinant	B
14	tissue	I
15	plasminogen	I
16	activator	I
17	were	O
18	injected	O
19	midvitreally	O
20	24	O
21	hrs	O
22	later	O
23	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	beta	B
6	-	I
7	adrenoceptor	I
8	antagonist	O
9	,	O
10	pindolol	O
11	,	O
12	on	O
13	uterine	O
14	smooth	O
15	muscle	O
16	in	O
17	term	O
18	pregnant	O
19	women	O
20	was	O
21	studied	O
22	in	O
23	vitro	O
24	and	O
25	in	O
26	vivo	O
27	(	O
28	in	O
29	hypertensive	O
30	women	O
31	).	O

1	PAO	O
2	blocks	O
3	turnover	O
4	of	O
5	the	O
6	phosphoryl	O
7	group	O
8	of	O
9	pp15	B
10	,	O
11	causing	O
12	its	O
13	accumulation	O
14	,	O
15	and	O
16	thereby	O
17	appears	O
18	to	O
19	interrupt	O
20	signal	O
21	transmission	O
22	from	O
23	the	O
24	receptor	O
25	to	O
26	the	O
27	glucose	O
28	-	O
29	transport	O
30	system	O
31	.	O

1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	I
43	.	O

1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	B
7	-	I
8	1	I
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	B
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O

1	3	O
2	--	O
3	It	O
4	is	O
5	necessary	O
6	to	O
7	think	O
8	about	O
9	cosmetic	O
10	consequences	O
11	of	O
12	the	O
13	chinese	O
14	flap	O
15	and	O
16	consider	O
17	other	O
18	possibilities	O
19	of	O
20	the	O
21	flap	O
22	choice	O
23	.	O

1	A	O
2	transparent	O
3	overlay	O
4	for	O
5	assessing	O
6	amplitude	O
7	of	O
8	ECG	O
9	wave	O
10	forms	O
11	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	B
21	progesterone	I
22	receptor	I
23	(	O
24	hPR	B
25	).	O

1	Five	O
2	concensus	O
3	poly	O
4	A	O
5	addition	O
6	sites	O
7	are	O
8	located	O
9	in	O
10	the	O
11	350	O
12	base	O
13	pairs	O
14	immediately	O
15	following	O
16	the	O
17	protein	B
18	IX	I
19	coding	O
20	region	O
21	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	SAM	O
2	-	O
3	TR	O
4	-	O
5	68	O
6	-	O
7	54	O
8	.	O

1	Sulphur	O
2	amino	O
3	acids	O
4	(	O
5	g	O
6	/	O
7	16	O
8	g	O
9	N	O
10	)	O
11	were	O
12	higher	O
13	in	O
14	the	O
15	isolates	O
16	than	O
17	in	O
18	the	O
19	flours	O
20	.	O

1	Eight	O
2	highly	O
3	trained	O
4	male	O
5	kayakers	O
6	were	O
7	studied	O
8	to	O
9	determine	O
10	the	O
11	relationship	O
12	between	O
13	critical	O
14	power	O
15	(	O
16	CP	O
17	)	O
18	and	O
19	the	O
20	onset	O
21	of	O
22	blood	O
23	lactate	O
24	accumulation	O
25	(	O
26	OBLA	O
27	).	O

1	Topics	O
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	Irradiation	O
2	of	O
3	human	O
4	blood	O
5	platelets	O
6	with	O
7	UV	O
8	-	O
9	A	O
10	in	O
11	vitro	O
12	impairs	O
13	their	O
14	ability	O
15	to	O
16	aggregate	O
17	after	O
18	challenge	O
19	with	O
20	collagen	B
21	.	O

1	Biochemical	O
2	characterization	O
3	of	O
4	valosin	B
5	-	I
6	containing	I
7	protein	I
8	,	O
9	a	O
10	protein	B
11	tyrosine	I
12	kinase	I
13	substrate	O
14	in	O
15	hematopoietic	O
16	cells	O
17	.	O

1	These	O
2	children	O
3	were	O
4	grouped	O
5	into	O
6	four	O
7	diagnostic	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	idiopathic	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	hypopituitarism	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	intrauterine	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	constitutional	O
43	delay	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	familial	O
50	short	O
51	stature	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	pharmacological	O
65	tests	O
66	of	O
67	GH	B
68	reserve	O
69	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	B
24	transcriptosomal	I
25	component	I
26	scaffold	I
27	attachment	I
28	factor	I
29	B	I
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	effect	O
3	of	O
4	echothiophate	O
5	on	O
6	the	O
7	biphasic	O
8	response	O
9	of	O
10	rabbit	O
11	ocular	O
12	pressure	O
13	to	O
14	dipivefrin	O
15	.	O

1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	B
15	-	I
16	1	I
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O

1	Thirty	O
2	of	O
3	the	O
4	clones	O
5	contained	O
6	a	O
7	complete	O
8	340	O
9	base	O
10	-	O
11	pair	O
12	dimer	O
13	unit	O
14	of	O
15	the	O
16	repeat	O
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	potency	O
5	of	O
6	Dacarbacine	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	carcinoid	O
12	tumors	O
13	seems	O
14	to	O
15	be	O
16	underestimated	O
17	up	O
18	to	O
19	now	O
20	.	O

1	Effects	O
2	of	O
3	rhG	B
4	-	I
5	CSF	I
6	on	O
7	neutrophil	O
8	functions	O
9	and	O
10	survival	O
11	in	O
12	sepsis	O
13	induced	O
14	diabetic	O
15	rats	O
16	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	The	O
2	effect	O
3	of	O
4	maternal	O
5	ingestion	O
6	of	O
7	the	O
8	reduced	O
9	energy	O
10	sweetener	O
11	erythritol	O
12	was	O
13	investigated	O
14	in	O
15	KBL	O
16	:	O
17	JW	O
18	strain	O
19	pregnant	O
20	rabbits	O
21	.	O

1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	B
13	BCL	I
14	-	I
15	6	I
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	B
24	-	I
25	6	I
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O

1	Moreover	O
2	,	O
3	xTAK1KN	B
4	could	O
5	block	O
6	the	O
7	expression	O
8	of	O
9	ventral	O
10	mesoderm	O
11	marker	O
12	genes	O
13	induced	O
14	by	O
15	Smad1	B
16	or	I
17	5	I
18	.	O

1	In	O
2	vitro	O
3	expression	O
4	levels	O
5	of	O
6	the	O
7	different	O
8	plasmids	O
9	differed	O
10	by	O
11	as	O
12	much	O
13	as	O
14	tenfold	O
15	.	O

1	The	O
2	potentially	O
3	SLE	O
4	-	O
5	inducing	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O

1	In	O
2	agreement	O
3	with	O
4	previous	O
5	in	O
6	vitro	O
7	data	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	UmuD	B
14	and	O
15	UmuD	B
16	'	I
17	are	O
18	able	O
19	to	O
20	form	O
21	both	O
22	homodimers	O
23	(	O
24	UmuD	B
25	-	O
26	UmuD	B
27	and	O
28	UmuD	O
29	'-	O
30	UmuD	O
31	')	O
32	and	O
33	a	O
34	heterodimer	O
35	(	O
36	UmuD	B
37	-	O
38	UmuD	O
39	').	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	B
9	kinase	I
10	C	I
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O

1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	I
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	O
17	-	O
18	binding	O
19	protein	O
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	B
26	cell	I
27	cycle	I
28	control	I
29	protein	I
30	(	I
31	cdc	I
32	)	I
33	37	O
34	.	O

1	Mature	O
2	mRNA	O
3	for	O
4	cytosolic	B
5	phosphoenolpyruvate	I
6	carboxykinase	I
7	of	I
8	the	I
9	chicken	I
10	is	O
11	2	O
12	.	O
13	8	O
14	kilobases	O
15	in	O
16	length	O
17	,	O
18	similar	O
19	to	O
20	that	O
21	previously	O
22	noted	O
23	for	O
24	mRNA	O
25	coding	O
26	for	O
27	the	O
28	same	O
29	enzyme	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	Mutations	O
2	in	O
3	the	O
4	VPS45	B
5	gene	I
6	,	O
7	a	O
8	SEC1	B
9	homologue	O
10	,	O
11	result	O
12	in	O
13	vacuolar	O
14	protein	O
15	sorting	O
16	defects	O
17	and	O
18	accumulation	O
19	of	O
20	membrane	O
21	vesicles	O
22	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	B
6	and	I
7	human	I
8	cDNAs	I
9	encoding	I
10	UNC	I
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	B
18	).	O

1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	B
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	B
57	.	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	NfxB	B
6	negatively	O
7	autoregulates	O
8	the	O
9	expression	O
10	of	O
11	nfxB	B
12	itself	O
13	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	This	O
2	protein	O
3	,	O
4	designated	O
5	p532	B
6	based	O
7	on	O
8	its	O
9	predicted	O
10	molecular	O
11	weight	O
12	(	O
13	EMBO	O
14	J	O
15	15	O
16	:	O
17	5738	O
18	,	O
19	1996	O
20	),	O
21	contains	O
22	multiple	O
23	structural	O
24	domains	O
25	including	O
26	two	O
27	regions	O
28	of	O
29	seven	O
30	internal	O
31	repeats	O
32	highly	O
33	related	O
34	to	O
35	the	O
36	cell	O
37	cycle	O
38	regulator	O
39	RCC1	B
40	,	O
41	a	O
42	guanine	B
43	nucleotide	I
44	exchange	I
45	factor	I
46	for	O
47	the	O
48	small	B
49	GTP	I
50	-	I
51	binding	I
52	protein	I
53	Ran	I
54	,	O
55	seven	O
56	beta	O
57	-	O
58	repeat	O
59	domains	O
60	characteristic	O
61	of	O
62	the	O
63	beta	O
64	subunit	O
65	of	O
66	heterotrimeric	B
67	G	I
68	proteins	I
69	,	O
70	three	O
71	putative	O
72	SH3	B
73	binding	I
74	sites	I
75	,	O
76	a	O
77	putative	O
78	leucine	O
79	-	O
80	zipper	O
81	and	O
82	a	O
83	carboxy	B
84	-	I
85	terminal	I
86	HECT	I
87	domain	I
88	characteristic	O
89	of	O
90	E3	B
91	ubiquitin	I
92	-	I
93	protein	I
94	ligases	I
95	.	O

1	Five	O
2	of	O
3	the	O
4	patients	O
5	with	O
6	increased	O
7	L	O
8	-	O
9	L	O
10	size	O
11	had	O
12	a	O
13	normal	O
14	A	O
15	-	O
16	P	O
17	diameter	O
18	.	O

1	2	O
2	new	O
3	Algerian	O
4	cases	O

1	The	O
2	intensity	O
3	of	O
4	myocardial	O
5	uptake	O
6	of	O
7	Tc	O
8	-	O
9	99m	O
10	-	O
11	PYP	O
12	in	O
13	patients	O
14	with	O
15	echocardiographic	O
16	left	O
17	ventricular	O
18	hypertrophy	O
19	and	O
20	/	O
21	or	O
22	highly	O
23	refractile	O
24	myocardial	O
25	echoes	O
26	,	O
27	so	O
28	-	O
29	called	O
30	granular	O
31	sparkling	O
32	appearance	O
33	(	O
34	GS	O
35	)	O
36	was	O
37	slightly	O
38	greater	O
39	than	O
40	that	O
41	in	O
42	patients	O
43	with	O
44	neither	O
45	myocardial	O
46	hypertrophy	O
47	nor	O
48	GS	O
49	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	B
8	alpha	I
9	1	I
10	,	I
11	2	I
12	-	I
13	mannosidase	I
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	B
7	gene	I
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	B
15	transcription	I
16	factor	I
17	GATA	I
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O

1	A	O
2	flow	O
3	rate	O
4	of	O
5	at	O
6	least	O
7	5	O
8	mL	O
9	/	O
10	h	O
11	is	O
12	required	O
13	through	O
14	the	O
15	receptor	O
16	(	O
17	volume	O
18	,	O
19	0	O
20	.	O
21	4	O
22	mL	O
23	)	O
24	for	O
25	accurate	O
26	results	O
27	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	csrR	B
20	and	O
21	csrS	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O

1	None	O
2	of	O
3	the	O
4	measured	O
5	parameters	O
6	(	O
7	heart	O
8	contents	O
9	of	O
10	neutral	O
11	lipids	O
12	,	O
13	total	O
14	phospholipids	O
15	,	O
16	phosphatidylcholine	O
17	,	O
18	phosphatidylethanolamine	O
19	,	O
20	diphosphatidylglycerol	O
21	,	O
22	sphingomyelin	O
23	and	O
24	fatty	O
25	acid	O
26	composition	O
27	of	O
28	each	O
29	phospholipid	O
30	class	O
31	)	O
32	appeared	O
33	to	O
34	be	O
35	related	O
36	with	O
37	the	O
38	grading	O
39	of	O
40	the	O
41	lesions	O
42	.	O

1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	Kinase	O
2	-	O
3	deficient	O
4	erbB	B
5	proteins	I
6	reduced	O
7	epidermal	B
8	growth	I
9	factor	I
10	(	O
11	EGF	B
12	)-	O
13	induced	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	endogenous	O
18	Shc	B
19	proteins	I
20	and	O
21	also	O
22	reduced	O
23	immediate	O
24	and	O
25	sustained	O
26	EGF	B
27	-	I
28	induced	I
29	ERK	I
30	MAPK	I
31	activities	O
32	in	O
33	human	O
34	glioblastoma	O
35	cells	O
36	,	O
37	although	O
38	basal	O
39	ERK	B
40	MAPK	I
41	activities	O
42	were	O
43	unaffected	O
44	.	O

1	Insulin	B
2	-	O
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	O
12	insulin	B
13	receptor	I
14	.	O

1	Identical	O
2	c	B
3	-	I
4	erbB3	I
5	transcripts	I
6	are	O
7	expressed	O
8	in	O
9	normal	O
10	human	O
11	placental	O
12	tissues	O
13	.	O

1	A	O
2	catalytic	O
3	domain	O
4	of	O
5	eukaryotic	B
6	DNA	I
7	topoisomerase	I
8	I	I
9	.	O

1	Five	O
2	women	O
3	(	O
4	15	O
5	.	O
6	6	O
7	%)	O
8	met	O
9	criteria	O
10	for	O
11	PMS	O
12	.	O

1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O

1	Reversal	O
2	of	O
3	the	O
4	increase	O
5	in	O
6	apomorphine	O
7	-	O
8	induced	O
9	stereotypy	O
10	and	O
11	aggression	O
12	in	O
13	REM	O
14	sleep	O
15	deprived	O
16	rats	O
17	by	O
18	dopamine	O
19	agonist	O
20	pretreatments	O
21	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	environmental	O
6	conditions	O
7	for	O
8	meiosis	O
9	finely	O
10	regulate	O
11	the	O
12	transcript	O
13	levels	O
14	of	O
15	KIN28	B
16	and	O
17	CCL1	B
18	,	O
19	such	O
20	that	O
21	nitrogen	O
22	starvation	O
23	first	O
24	elevates	O
25	them	O
26	but	O
27	subsequent	O
28	alkalization	O
29	of	O
30	medium	O
31	decreases	O
32	them	O
33	.	O

1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	B
22	.	O

1	None	O
2	of	O
3	the	O
4	cystometrograms	O
5	showed	O
6	uninhibited	O
7	detrusor	O
8	contractions	O
9	.	O

1	By	O
2	Felix	O
3	Lagrange	O
4	,	O
5	1918	O
6	.	O

1	Antimicrobial	O
2	substance	O
3	isolated	O
4	from	O
5	an	O
6	acorn	O
7	extract	O
8	.	O

1	A	O
2	role	O
3	for	O
4	glycogen	B
5	synthase	I
6	kinase	I
7	-	I
8	3	I
9	in	O
10	the	O
11	control	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	The	O
2	induction	O
3	of	O
4	RNKP	B
5	-	I
6	1	I
7	expression	O
8	in	O
9	the	O
10	Con	B
11	A	I
12	-	O
13	cultured	O
14	spleen	O
15	cells	O
16	is	O
17	accompanied	O
18	by	O
19	increases	O
20	in	O
21	both	O
22	NK	O
23	and	O
24	lymphokine	O
25	-	O
26	activated	O
27	killer	O
28	lymphocyte	O
29	activities	O
30	.	O

1	Diagnostic	O
2	value	O
3	of	O
4	serum	B
5	myoglobin	I
6	in	O
7	cases	O
8	of	O
9	neuromuscular	O
10	disease	O

1	The	O
2	Oct	B
3	-	I
4	3	I
5	/	I
6	4	I
7	gene	I
8	product	I
9	,	O
10	which	O
11	belongs	O
12	to	O
13	the	O
14	POU	B
15	family	I
16	of	I
17	transcription	I
18	factors	I
19	,	O
20	is	O
21	a	O
22	good	O
23	candidate	O
24	for	O
25	regulating	O
26	initial	O
27	differentiation	O
28	decisions	O
29	.	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	O
13	function	O
14	and	O
15	substrate	O
16	specificity	O
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	O
29	RNase	B
30	MRP	I
31	RNA	I
32	and	O
33	RNase	B
34	P	I
35	RNA	I
36	of	I
37	S	I
38	.	I
39	cerevisiae	I
40	.	O

1	However	O
2	,	O
3	unlike	O
4	Bcl	B
5	-	I
6	2	I
7	and	O
8	the	O
9	E1B	B
10	19K	I
11	proteins	I
12	,	O
13	which	O
14	completely	O
15	block	O
16	apoptosis	O
17	but	O
18	not	O
19	p53	B
20	-	O
21	dependent	O
22	growth	O
23	arrest	O
24	,	O
25	H	B
26	-	I
27	ras	I
28	expression	O
29	permitted	O
30	DNA	O
31	synthesis	O
32	and	O
33	cell	O
34	proliferation	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	high	O
40	levels	O
41	of	O
42	wild	B
43	-	I
44	type	I
45	p53	I
46	.	O

1	Domain	O
2	II	O
3	is	O
4	highly	O
5	homologous	O
6	to	O
7	the	O
8	LDL	B
9	receptor	I
10	and	O
11	contains	O
12	four	O
13	repeats	O
14	with	O
15	perfect	O
16	conservation	O
17	of	O
18	all	O
19	6	O
20	consecutive	O
21	cysteines	O
22	.	O

1	The	O
2	potential	O
3	impact	O
4	of	O
5	using	O
6	a	O
7	rapid	O
8	diagnostic	O
9	test	O
10	(	O
11	Strep	O
12	A	O
13	OIA	O
14	)	O
15	on	O
16	detection	O
17	and	O
18	treatment	O
19	of	O
20	group	O
21	A	O
22	beta	O
23	-	O
24	hemolytic	O
25	streptococcal	O
26	(	O
27	GABHS	O
28	)	O
29	pharyngitis	O
30	in	O
31	a	O
32	large	O
33	-	O
34	volume	O
35	pediatric	O
36	and	O
37	adolescent	O
38	clinic	O
39	was	O
40	examined	O
41	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Eleven	O
2	patients	O
3	tested	O
4	positive	O
5	for	O
6	the	O
7	hepatitis	B
8	B	I
9	surface	I
10	antigen	I
11	(	O
12	HBsAg	B
13	).	O

1	Penicillin	O
2	-	O
3	G	O
4	degradation	O
5	products	O
6	inhibit	O
7	in	O
8	vitro	O
9	granulopoiesis	O
10	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	B
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	B
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	"	O
7	macro	O
8	"	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O

1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O

1	Moreover	O
2	,	O
3	it	O
4	also	O
5	discusses	O
6	the	O
7	effects	O
8	of	O
9	antihypertensive	O
10	drugs	O
11	currently	O
12	regarded	O
13	as	O
14	first	O
15	-	O
16	choice	O
17	agents	O
18	,	O
19	i	O
20	.	O
21	e	O
22	.	O
23	calcium	O
24	antagonists	O
25	and	O
26	the	O
27	angiotensin	B
28	converting	I
29	enzyme	I
30	inhibitors	O
31	,	O
32	on	O
33	intrarenal	O
34	hemodynamics	O
35	.	O

1	Partial	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	B
8	platelet	I
9	cAMP	I
10	phosphodiesterase	I
11	,	O
12	PDE3A	B
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O

1	HANYS	O
2	criticizes	O
3	laparoscopic	O
4	gall	O
5	bladder	O
6	guidelines	O
7	.	O

1	To	O
2	study	O
3	the	O
4	functional	O
5	differences	O
6	between	O
7	cutaneous	O
8	HPV5	O
9	and	O
10	HPV8	O
11	E7s	B
12	and	O
13	genital	B
14	HPV16	I
15	E7	I
16	,	O
17	we	O
18	cloned	O
19	each	O
20	of	O
21	the	O
22	E7	B
23	open	O
24	reading	O
25	frames	O
26	and	O
27	tested	O
28	their	O
29	immortalizing	O
30	and	O
31	transforming	O
32	activities	O
33	,	O
34	the	O
35	binding	O
36	ability	O
37	of	O
38	their	O
39	products	O
40	with	O
41	retinoblastoma	B
42	protein	I
43	(	O
44	RB	B
45	)	O
46	and	O
47	their	O
48	complementation	O
49	activity	O
50	of	O
51	a	O
52	RB	B
53	-	I
54	nonbinding	I
55	adenovirus	I
56	E1A	I
57	mutant	I
58	.	O

1	Expression	O
2	of	O
3	the	O
4	mouse	B
5	TSH	I
6	beta	I
7	gene	I
8	,	O
9	therefore	O
10	,	O
11	gives	O
12	rise	O
13	to	O
14	multiple	O
15	mRNAs	O
16	,	O
17	each	O
18	with	O
19	a	O
20	unique	O
21	5	O
22	'-	O
23	untranslated	O
24	region	O
25	.	O

1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	HHV	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	I
36	factor	I
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O

1	Latexin	B
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O

1	We	O
2	specially	O
3	devised	O
4	3	O
5	types	O
6	of	O
7	turbo	O
8	pumps	O
9	,	O
10	a	O
11	centrifugal	O
12	pump	O
13	(	O
14	CFP	O
15	),	O
16	a	O
17	mixed	O
18	flow	O
19	pump	O
20	(	O
21	MFP	O
22	),	O
23	and	O
24	an	O
25	axial	O
26	flow	O
27	pump	O
28	(	O
29	AFP	O
30	),	O
31	and	O
32	analyzed	O
33	their	O
34	in	O
35	vitro	O
36	performance	O
37	.	O

1	Lack	O
2	of	O
3	sufficient	O
4	data	O
5	on	O
6	vibration	O
7	measurements	O
8	and	O
9	employment	O
10	durations	O
11	add	O
12	to	O
13	the	O
14	uncertainty	O
15	,	O
16	as	O
17	do	O
18	variations	O
19	in	O
20	tool	O
21	conditions	O
22	(	O
23	grinder	O
24	wheels	O
25	,	O
26	etc	O
27	)	O
28	and	O
29	inherent	O
30	difficulties	O
31	in	O
32	measurement	O
33	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O

1	Imaging	O
2	features	O
3	of	O
4	splenic	O
5	epidermoid	O
6	cyst	O
7	with	O
8	pathologic	O
9	correlation	O
10	.	O

1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O

1	The	O
2	proteins	O
3	encoded	O
4	downstream	O
5	of	O
6	rpoN	B
7	are	O
8	known	O
9	to	O
10	negatively	O
11	regulate	O
12	sigma	B
13	54	I
14	activity	O
15	.	O

1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O

1	D	O
2	.	O

1	A	O
2	phylogenetic	O
3	tree	O
4	of	O
5	members	O
6	of	O
7	the	O
8	T2	B
9	/	I
10	S	I
11	-	I
12	RNase	I
13	superfamily	I
14	in	O
15	plants	O
16	was	O
17	obtained	O
18	.	O

1	Deletion	O
2	or	O
3	inactivation	O
4	of	O
5	CRY1	B
6	leads	O
7	to	O
8	5	O
9	-	O
10	to	O
11	10	O
12	-	O
13	fold	O
14	-	O
15	increased	O
16	levels	O
17	of	O
18	CRY2	B
19	mRNA	I
20	.	O

1	Epitopes	O
2	of	O
3	adhesion	O
4	-	O
5	perturbing	O
6	monoclonal	O
7	antibodies	O
8	map	O
9	within	O
10	a	O
11	predicted	O
12	alpha	O
13	-	O
14	helical	O
15	domain	O
16	of	O
17	the	O
18	integrin	B
19	beta	I
20	1	I
21	subunit	I
22	.	O

1	From	O
2	May	O
3	1985	O
4	to	O
5	May	O
6	1989	O
7	,	O
8	126	O
9	necropsies	O
10	were	O
11	performed	O
12	at	O
13	the	O
14	Sao	O
15	Paulo	O
16	City	O
17	Morgue	O
18	on	O
19	cadavers	O
20	of	O
21	individuals	O
22	AIDS	O
23	victims	O
24	whose	O
25	unnatural	O
26	deaths	O
27	had	O
28	prompted	O
29	police	O
30	investigations	O
31	.	O

1	In	O
2	contrast	O
3	,	O
4	we	O
5	observed	O
6	high	O
7	concentrations	O
8	in	O
9	29	O
10	of	O
11	75	O
12	patients	O
13	with	O
14	tumors	O
15	of	O
16	the	O
17	central	O
18	nervous	O
19	system	O
20	,	O
21	especially	O
22	in	O
23	meningioma	O
24	(	O
25	6	O
26	/	O
27	9	O
28	),	O
29	glioblastoma	O
30	(	O
31	9	O
32	/	O
33	23	O
34	),	O
35	and	O
36	neurinoma	O
37	(	O
38	5	O
39	/	O
40	5	O
41	).	O

1	RESULTS	O
2	:	O
3	Acetabular	O
4	index	O
5	returned	O
6	to	O
7	normal	O
8	gradually	O
9	as	O
10	the	O
11	time	O
12	went	O
13	by	O
14	and	O
15	significantly	O
16	within	O
17	one	O
18	year	O
19	after	O
20	the	O
21	reduction	O
22	of	O
23	developmental	O
24	dislocation	O
25	of	O
26	the	O
27	hip	O
28	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	B
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Thus	O
2	it	O
3	appears	O
4	that	O
5	insertion	O
6	of	O
7	a	O
8	transposable	O
9	element	O
10	near	O
11	the	O
12	5	O
13	'	O
14	terminus	O
15	of	O
16	the	O
17	structural	O
18	gene	O
19	can	O
20	produce	O
21	constitutive	O
22	expression	O
23	of	O
24	a	O
25	normally	O
26	glucose	O
27	-	O
28	repressed	O
29	enzyme	O
30	.	O

1	Diet	O
2	therapy	O
3	with	O
4	soy	O
5	proteins	O
6	for	O
7	chronic	O
8	stomach	O
9	ulcers	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	Prenatal	O
2	exposure	O
3	to	O
4	the	O
5	fungicide	O
6	dinocap	O
7	causes	O
8	behavioral	O
9	torticollis	O
10	,	O
11	ballooning	O
12	and	O
13	cleft	O
14	palate	O
15	in	O
16	mice	O
17	,	O
18	but	O
19	not	O
20	rats	O
21	or	O
22	hamsters	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	TRP1	B
5	RI	O
6	Circle	O
7	DNA	O
8	is	O
9	organized	O
10	into	O
11	nucleosomes	O
12	whose	O
13	size	O
14	and	O
15	spacing	O
16	are	O
17	indistinguishable	O
18	from	O
19	that	O
20	of	O
21	bulk	O
22	yeast	O
23	chromatin	O
24	.	O

1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	The	O
2	second	O
3	goal	O
4	was	O
5	to	O
6	ascertain	O
7	the	O
8	somatotopic	O
9	arrangement	O
10	of	O
11	the	O
12	GPi	O
13	in	O
14	PD	O
15	.	O

1	In	O
2	biopsies	O
3	CK	B
4	-	I
5	MB	I
6	fraction	O
7	of	O
8	total	O
9	myocardial	O
10	CPK	B
11	was	O
12	37	O
13	%,	O
14	the	O
15	total	B
16	-	I
17	CPK	I
18	activity	O
19	of	O
20	human	O
21	skeletal	O
22	muscles	O
23	still	O
24	shows	O
25	a	O
26	5	O
27	%	O
28	fraction	O
29	of	O
30	CK	B
31	-	I
32	MB	I
33	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Other	O
2	assays	O
3	also	O
4	distinguished	O
5	the	O
6	processive	O
7	replication	O
8	of	O
9	pNeo	O
10	.	O
11	Myc	O
12	-	O
13	2	O
14	.	O
15	4	O
16	from	O
17	the	O
18	dispersive	O
19	labeling	O
20	of	O
21	control	O
22	plasmids	O
23	.	O

1	The	O
2	results	O
3	from	O
4	the	O
5	first	O
6	five	O
7	years	O
8	of	O
9	follow	O
10	up	O
11	in	O
12	1972	O
13	showed	O
14	a	O
15	4	O
16	.	O
17	7	O
18	-	O
19	fold	O
20	excess	O
21	mortality	O
22	for	O
23	ischaemic	O
24	and	O
25	other	O
26	heart	O
27	diseases	O
28	(	O
29	ICD	O
30	A83	O
31	-	O
32	A84	O
33	)	O
34	compared	O
35	with	O
36	a	O
37	comparable	O
38	reference	O
39	cohort	O
40	of	O
41	paper	O
42	mill	O
43	workers	O
44	.	O

1	Gains	O
2	increased	O
3	3	O
4	.	O
5	5	O
6	%	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	10	O
13	)	O
14	and	O
15	feed	O
16	conversion	O
17	improved	O
18	5	O
19	.	O
20	9	O
21	%	O
22	(	O
23	P	O
24	less	O
25	than	O
26	.	O
27	07	O
28	)	O
29	in	O
30	steers	O
31	fed	O
32	.	O
33	28	O
34	%	O
35	AS	O
36	-	O
37	VFA	O
38	compared	O
39	with	O
40	gain	O
41	and	O
42	feed	O
43	conversion	O
44	of	O
45	the	O
46	control	O
47	steers	O
48	.	O

1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	XII	O
2	.	O

1	Although	O
2	olfactory	O
3	associative	O
4	conditioning	O
5	in	O
6	newborn	O
7	rats	O
8	produces	O
9	marked	O
10	structural	O
11	and	O
12	functional	O
13	changes	O
14	in	O
15	the	O
16	olfactory	O
17	bulb	O
18	,	O
19	recent	O
20	evidence	O
21	suggests	O
22	that	O
23	extrabulbar	O
24	circuits	O
25	must	O
26	be	O
27	involved	O
28	in	O
29	storing	O
30	these	O
31	early	O
32	memories	O
33	.	O

1	Mitomycin	O
2	-	O
3	C	O
4	can	O
5	cause	O
6	severe	O
7	necrosis	O
8	and	O
9	ulceration	O
10	when	O
11	extravasated	O
12	inadvertently	O
13	into	O
14	skin	O
15	and	O
16	soft	O
17	tissues	O
18	following	O
19	IV	O
20	drug	O
21	administration	O
22	.	O

1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O

1	The	O
2	enhancer	O
3	region	O
4	of	O
5	Akv	O
6	murine	O
7	leukemia	O
8	virus	O
9	contains	O
10	the	O
11	sequence	O
12	motif	O
13	ACAGATGG	O
14	.	O

1	This	O
2	was	O
3	obtained	O
4	with	O
5	the	O
6	thermal	O
7	neutron	O
8	fluency	O
9	2	O
10	.	O
11	0	O
12	x	O
13	10	O
14	(	O
15	10	O
16	)	O
17	n	O
18	/	O
19	cm2	O
20	.	O

1	However	O
2	,	O
3	a	O
4	>	O
5	10	O
6	-	O
7	fold	O
8	increase	O
9	in	O
10	ERK3	B
11	activity	O
12	in	O
13	each	O
14	PKC	B
15	beta	I
16	transfectant	O
17	was	O
18	shown	O
19	by	O
20	immunoprecipitation	O
21	with	O
22	anti	B
23	-	I
24	ERK3	I
25	monoclonal	I
26	antibody	I
27	followed	O
28	by	O
29	either	O
30	immune	O
31	complex	O
32	kinase	O
33	assay	O
34	or	O
35	by	O
36	in	O
37	gel	O
38	kinase	O
39	assay	O
40	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	signaling	O
6	triggered	O
7	by	O
8	surface	O
9	Ig	B
10	engagement	O
11	in	O
12	B	O
13	lymphocytes	O
14	,	O
15	CD38	B
16	ligation	O
17	did	O
18	not	O
19	appear	O
20	to	O
21	induce	O
22	tyrosine	O
23	phosphorylation	O
24	of	O
25	the	O
26	src	B
27	-	I
28	like	I
29	protein	I
30	tyrosine	I
31	kinases	I
32	lyn	I
33	,	O
34	fyn	B
35	,	O
36	and	O
37	btk	B
38	,	O
39	or	O
40	of	O
41	vav	B
42	-	I
43	and	I
44	ras	I
45	-	I
46	GTPase	I
47	-	I
48	activating	I
49	protein	I
50	,	O
51	nor	O
52	did	O
53	it	O
54	induce	O
55	detectable	O
56	changes	O
57	in	O
58	cytosolic	O
59	CA2	O
60	+	O
61	concentrations	O
62	.	O

1	These	O
2	cells	O
3	produced	O
4	P2Y	B
5	(	I
6	11	I
7	)	I
8	mRNA	I
9	during	O
10	culture	O
11	.	O

1	Plots	O
2	of	O
3	RV	O
4	,	O
5	LV	O
6	+	O
7	S	O
8	and	O
9	2A	O
10	weight	O
11	vs	O
12	real	O
13	hematocrit	O
14	showed	O
15	sharp	O
16	upward	O
17	inflections	O
18	at	O
19	real	O
20	hematocrit	O
21	65	O
22	%,	O
23	suggesting	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	increased	O
29	viscosity	O
30	in	O
31	CO	O
32	cardiomegaly	O
33	at	O
34	the	O
35	higher	O
36	hematocrit	O
37	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	The	O
2	activity	O
3	of	O
4	6	O
5	-	O
6	fluoroquinolones	O
7	and	O
8	their	O
9	nonfluorinated	O
10	derivatives	O
11	is	O
12	compared	O
13	in	O
14	general	O
15	.	O

1	The	O
2	ratio	O
3	of	O
4	radioactivity	O
5	in	O
6	tumour	O
7	compared	O
8	with	O
9	normal	O
10	tissue	O
11	(	O
12	T	O
13	:	O
14	N	O
15	ratio	O
16	)	O
17	was	O
18	determined	O
19	after	O
20	simultaneously	O
21	injecting	O
22	microspheres	O
23	into	O
24	the	O
25	portal	O
26	and	O
27	arterial	O
28	circulation	O
29	of	O
30	each	O
31	animal	O
32	.	O

1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	O
6	and	O
7	Zn	O
8	to	O
9	Mg	O
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O

1	Two	O
2	experiments	O
3	were	O
4	conducted	O
5	to	O
6	study	O
7	the	O
8	vacuous	O
9	jaw	O
10	movements	O
11	induced	O
12	in	O
13	rats	O
14	by	O
15	acute	O
16	administration	O
17	of	O
18	the	O
19	monoamine	O
20	-	O
21	depleting	O
22	agent	O
23	reserpine	O
24	.	O

1	This	O
2	phenomenon	O
3	did	O
4	not	O
5	require	O
6	DNA	O
7	binding	O
8	by	O
9	the	O
10	"	O
11	interfering	O
12	"	O
13	receptor	O
14	but	O
15	required	O
16	it	O
17	to	O
18	be	O
19	hormone	O
20	-	O
21	bound	O
22	,	O
23	indicating	O
24	that	O
25	a	O
26	transcriptionally	O
27	active	O
28	form	O
29	of	O
30	the	O
31	interfering	O
32	receptor	O
33	is	O
34	essential	O
35	for	O
36	the	O
37	interfering	O
38	effect	O
39	.	O

1	Serum	O
2	HBV	O
3	-	O
4	DNA	O
5	,	O
6	viral	O
7	serology	O
8	,	O
9	and	O
10	liver	O
11	enzymes	O
12	were	O
13	measured	O
14	sequentially	O
15	;	O
16	liver	O
17	histology	O
18	was	O
19	taken	O
20	before	O
21	and	O
22	during	O
23	treatment	O
24	in	O
25	12	O
26	patients	O
27	.	O

1	CONCLUSION	O
2	:	O
3	More	O
4	than	O
5	50	O
6	%	O
7	of	O
8	patients	O
9	with	O
10	perennial	O
11	rhinitis	O
12	and	O
13	CRS	O
14	do	O
15	not	O
16	improve	O
17	after	O
18	surgery	O
19	,	O
20	a	O
21	response	O
22	that	O
23	may	O
24	be	O
25	predicted	O
26	by	O
27	more	O
28	cells	O
29	expressing	O
30	IL	B
31	-	I
32	5	I
33	mRNA	I
34	in	O
35	the	O
36	ethmoid	O
37	sinuses	O
38	.	O

1	Ime1	B
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	Group	O
2	A	O
3	was	O
4	treated	O
5	with	O
6	three	O
7	or	O
8	four	O
9	doses	O
10	of	O
11	hepatitis	B
12	B	I
13	immune	I
14	globulin	I
15	(	O
16	HBIG	B
17	)	O
18	in	O
19	one	O
20	of	O
21	three	O
22	different	O
23	schedules	O
24	.	O

1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O

1	Estimated	O
2	nucleic	O
3	acid	O
4	N	O
5	absorption	O
6	is	O
7	7	O
8	-	O
9	8	O
10	%	O
11	of	O
12	N	O
13	intake	O
14	.	O

1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	B
13	and	I
14	acid	I
15	phosphatases	I
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O

1	Using	O
2	an	O
3	interspecific	O
4	backcross	O
5	panel	O
6	,	O
7	we	O
8	localized	O
9	both	O
10	Gng3	B
11	and	O
12	Gng3lg	B
13	to	O
14	the	O
15	same	O
16	locus	O
17	on	O
18	chromosome	O
19	19	O
20	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	O
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	MK	O
2	-	O
3	927	O
4	:	O
5	a	O
6	topically	O
7	active	O
8	ocular	O
9	hypotensive	O
10	carbonic	B
11	anhydrase	I
12	inhibitor	O
13	.	O

1	Allagille	O
2	'	O
3	s	O
4	syndrome	O
5	associated	O
6	with	O
7	antenatal	O
8	ascites	O

1	Preferential	O
2	heterodimeric	O
3	parallel	O
4	coiled	O
5	-	O
6	coil	O
7	formation	O
8	by	O
9	synthetic	B
10	Max	I
11	and	O
12	c	B
13	-	I
14	Myc	I
15	leucine	I
16	zippers	I
17	:	O
18	a	O
19	description	O
20	of	O
21	putative	O
22	electrostatic	O
23	interactions	O
24	responsible	O
25	for	O
26	the	O
27	specificity	O
28	of	O
29	heterodimerization	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	SLK	B
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	B
10	and	I
11	nuclear	I
12	associated	I
13	protein	I
14	(	O
15	M	B
16	-	I
17	NAP	I
18	)	O
19	and	O
20	AT1	B
21	-	I
22	46	I
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O

1	The	O
2	differences	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	for	O
8	overall	O
9	response	O
10	rate	O
11	p	O
12	=	O
13	0	O
14	.	O
15	004	O
16	;	O
17	power	O
18	(	O
19	for	O
20	p	O
21	=	O
22	0	O
23	.	O
24	05	O
25	)	O
26	85	O
27	%;	O
28	for	O
29	survival	O
30	p	O
31	=	O
32	0	O
33	.	O
34	09	O
35	;	O
36	for	O
37	grade	O
38	IV	O
39	granulocytopenia	O
40	p	O
41	=	O
42	0	O
43	.	O
44	3	O
45	;	O
46	and	O
47	for	O
48	febrile	O
49	neutropenia	O
50	p	O
51	=	O
52	0	O
53	.	O
54	61	O
55	.	O

1	We	O
2	showed	O
3	that	O
4	Stat3	B
5	and	O
6	Stat3beta	B
7	were	O
8	affinity	O
9	purified	O
10	using	O
11	phosphopeptides	O
12	containing	O
13	Y704	O
14	and	O
15	Y744	O
16	but	O
17	not	O
18	by	O
19	nonphosphorylated	O
20	peptide	O
21	analogues	O
22	or	O
23	by	O
24	phosphopeptides	O
25	containing	O
26	Y729	O
27	and	O
28	Y764	O
29	.	O

1	In	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	the	O
7	upstream	O
8	portion	O
9	of	O
10	the	O
11	delta	O
12	promoter	O
13	led	O
14	to	O
15	a	O
16	10	O
17	fold	O
18	decrease	O
19	in	O
20	expression	O
21	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	to	O
6	what	O
7	extent	O
8	this	O
9	interaction	O
10	might	O
11	contribute	O
12	to	O
13	tumor	O
14	induction	O
15	by	O
16	the	O
17	virus	O
18	,	O
19	we	O
20	have	O
21	introduced	O
22	two	O
23	different	O
24	point	O
25	mutations	O
26	within	O
27	the	O
28	putative	O
29	pRb	B
30	-	I
31	binding	I
32	sequence	I
33	of	O
34	large	B
35	T	I
36	antigen	I
37	,	O
38	and	O
39	as	O
40	a	O
41	preliminary	O
42	to	O
43	in	O
44	vivo	O
45	experiments	O
46	we	O
47	have	O
48	studied	O
49	their	O
50	effects	O
51	in	O
52	vitro	O
53	on	O
54	some	O
55	biological	O
56	activities	O
57	relevant	O
58	to	O
59	tumor	O
60	induction	O
61	.	O

1	Glomerular	O
2	mesangial	O
3	cells	O
4	expressed	O
5	an	O
6	abundant	O
7	1	O
8	.	O
9	1	O
10	kb	O
11	mRNA	O
12	transcript	O
13	for	O
14	Id1	B
15	,	O
16	but	O
17	in	O
18	contrast	O
19	to	O
20	other	O
21	cell	O
22	types	O
23	Id1	B
24	mRNA	I
25	was	O
26	expressed	O
27	in	O
28	both	O
29	randomly	O
30	cycling	O
31	cells	O
32	and	O
33	in	O
34	serum	O
35	-	O
36	deprived	O
37	,	O
38	quiescent	O
39	cultures	O
40	.	O

1	This	O
2	specific	O
3	methylation	O
4	pattern	O
5	caused	O
6	inactivation	O
7	of	O
8	the	O
9	HSV	B
10	tk	I
11	gene	I
12	,	O
13	while	O
14	methylation	O
15	of	O
16	the	O
17	cytosine	O
18	residues	O
19	within	O
20	the	O
21	nucleotide	O
22	sequence	O
23	from	O
24	+	O
25	811	O
26	to	O
27	+	O
28	1309	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	HSV	B
34	tk	I
35	gene	I
36	activity	O
37	.	O

1	He	O
2	was	O
3	administered	O
4	recombinant	B
5	IFN	I
6	alpha	I
7	-	I
8	2b	I
9	under	O
10	the	O
11	diagnosis	O
12	of	O
13	chronic	O
14	hepatitis	O
15	C	O
16	.	O

1	Effects	O
2	of	O
3	a	O
4	new	O
5	antihypertensive	O
6	agent	O
7	,	O
8	SGB	O
9	-	O
10	1534	O
11	,	O
12	on	O
13	rat	O
14	platelet	O
15	aggregation	O
16	.	O

1	During	O
2	this	O
3	period	O
4	,	O
5	administration	O
6	of	O
7	additional	O
8	exogenous	B
9	PRL	I
10	did	O
11	not	O
12	stimulate	O
13	further	O
14	activation	O
15	(	O
16	binding	O
17	)	O
18	of	O
19	the	O
20	Stat	B
21	factors	I
22	.	O

1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O

1	Homozygous	O
2	protein	B
3	C	I
4	(	O
5	PC	B
6	)	O
7	deficiency	O
8	is	O
9	reported	O
10	in	O
11	two	O
12	siblings	O
13	(	O
14	girl	O
15	and	O
16	boy	O
17	)	O
18	who	O
19	received	O
20	their	O
21	proper	O
22	diagnoses	O
23	at	O
24	the	O
25	ages	O
26	of	O
27	7	O
28	4	O
29	/	O
30	12	O
31	and	O
32	1	O
33	3	O
34	/	O
35	12	O
36	years	O
37	respectively	O
38	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	Health	O
2	:	O
3	an	O
4	integrative	O
5	reticulum	O
6	.	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	To	O
2	determine	O
3	what	O
4	role	O
5	eIF4E	B
6	might	O
7	play	O
8	in	O
9	c	B
10	-	I
11	myc	I
12	expression	O
13	,	O
14	the	O
15	c	B
16	-	I
17	myc	I
18	5	I
19	'	I
20	untranslated	I
21	region	I
22	(	I
23	UTR	I
24	)	I
25	was	O
26	fused	O
27	in	O
28	-	O
29	frame	O
30	to	O
31	CAT	B
32	reporters	I
33	,	O
34	and	O
35	several	O
36	more	O
37	derivative	O
38	constructs	O
39	were	O
40	made	O
41	.	O

1	3	O
2	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O

1	Tilmicosin	O
2	is	O
3	a	O
4	novel	O
5	macrolide	O
6	antibiotic	O
7	developed	O
8	for	O
9	exclusive	O
10	use	O
11	in	O
12	veterinary	O
13	medicine	O
14	.	O

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	This	O
2	stimulatory	O
3	effect	O
4	could	O
5	also	O
6	be	O
7	elicited	O
8	by	O
9	c	B
10	-	I
11	Jun	I
12	,	O
13	which	O
14	interacts	O
15	with	O
16	topo	B
17	II	I
18	,	O
19	but	O
20	not	O
21	by	O
22	c	B
23	-	I
24	Fos	I
25	,	O
26	which	O
27	does	O
28	not	O
29	bind	O
30	topo	B
31	II	I
32	in	O
33	our	O
34	in	O
35	vitro	O
36	assay	O
37	.	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	A	O
2	second	O
3	promoter	O
4	activity	O
5	was	O
6	identified	O
7	in	O
8	the	O
9	region	O
10	between	O
11	the	O
12	two	O
13	major	O
14	transcriptional	O
15	start	O
16	sites	O
17	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	The	O
2	RNA	O
3	aptamer	O
4	contains	O
5	three	O
6	stems	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	bulges	O
16	,	O
17	and	O
18	adopts	O
19	an	O
20	unanticipated	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	junctional	O
26	sites	O
27	are	O
28	anchored	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O

1	Here	O
2	the	O
3	cloning	O
4	and	O
5	molecular	O
6	analysis	O
7	of	O
8	the	O
9	Zm	B
10	-	I
11	ERabp1	I
12	,	O
13	Zm	B
14	-	I
15	ERabp4	I
16	,	O
17	and	O
18	Zm	B
19	-	I
20	ERabp5	I
21	genes	I
22	is	O
23	presented	O
24	.	O

1	Structural	O
2	analysis	O
3	and	O
4	characterization	O
5	of	O
6	tissue	O
7	and	O
8	hormonal	O
9	responsive	O
10	expression	O
11	of	O
12	the	O
13	avian	B
14	bone	I
15	sialoprotein	I
16	(	O
17	BSP	B
18	)	O
19	gene	O
20	.	O

1	No	O
2	serious	O
3	side	O
4	effects	O
5	were	O
6	observed	O
7	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	B
11	32	I
12	protein	O
13	.	O

1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	B
16	blocks	O
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	B
24	and	O
25	rut	B
26	sites	I
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	I
25	bodies	I
26	to	O
27	A60	B
28	antigen	I
29	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	O
26	alpha	O
27	-	O
28	helix	O
29	(	O
30	L	O
31	-	O
32	61	O
33	to	O
34	F	O
35	-	O
36	97	O
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	B
49	.	O

1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	O
27	protein	O
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	I
44	(	O
45	hsp27	B
46	).	O

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	This	O
2	hypothesis	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	PEA3	B
10	binding	I
11	sites	I
12	in	O
13	the	O
14	PEA3	B
15	promoter	I
16	and	O
17	with	O
18	the	O
19	ability	O
20	of	O
21	PEA3	B
22	to	O
23	transactivate	O
24	this	O
25	promoter	O
26	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	As	O
2	pleural	O
3	thickening	O
4	is	O
5	seen	O
6	commonly	O
7	in	O
8	asbestosis	O
9	and	O
10	may	O
11	influence	O
12	lung	O
13	volumes	O
14	and	O
15	the	O
16	ratio	O
17	of	O
18	transfer	B
19	factor	I
20	to	O
21	effective	O
22	alveolar	O
23	volume	O
24	,	O
25	the	O
26	results	O
27	of	O
28	these	O
29	measurements	O
30	were	O
31	compared	O
32	only	O
33	in	O
34	the	O
35	cases	O
36	showing	O
37	absent	O
38	or	O
39	minimal	O
40	pleural	O
41	thickening	O
42	.	O

1	This	O
2	promoter	O
3	could	O
4	direct	O
5	the	O
6	constitutive	O
7	expression	O
8	of	O
9	the	O
10	reporter	O
11	beta	B
12	-	I
13	galactosidase	I
14	at	O
15	high	O
16	frequency	O
17	in	O
18	transfected	O
19	colonies	O
20	of	O
21	transformed	O
22	cells	O
23	that	O
24	express	O
25	L	B
26	-	I
27	plastin	I
28	constitutively	O
29	;	O
30	by	O
31	contrast	O
32	,	O
33	this	O
34	promoter	O
35	was	O
36	virtually	O
37	inactive	O
38	in	O
39	transfected	O
40	colonies	O
41	of	O
42	normal	O
43	fibroblasts	O
44	and	O
45	it	O
46	exhibited	O
47	a	O
48	low	O
49	frequency	O
50	of	O
51	constitutive	O
52	activation	O
53	in	O
54	transfected	O
55	colonies	O
56	of	O
57	in	O
58	vitro	O
59	SV40	O
60	-	O
61	transformed	O
62	fibroblasts	O
63	which	O
64	did	O
65	not	O
66	exhibit	O
67	L	B
68	-	I
69	plastin	I
70	expression	O
71	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	identified	O
6	encoding	O
7	a	O
8	second	O
9	GHS	B
10	-	I
11	R	I
12	-	I
13	related	I
14	gene	I
15	(	O
16	GPR39	B
17	).	O

1	Dermoid	O
2	cyst	O
3	in	O
4	a	O
5	free	O
6	skin	O
7	flap	O
8	as	O
9	the	O
10	complication	O
11	after	O
12	treatment	O
13	of	O
14	recurring	O
15	hernia	O

1	Interestingly	O
2	,	O
3	PKA	B
4	activity	O
5	is	O
6	dispensable	O
7	in	O
8	a	O
9	strain	O
10	lacking	O
11	Msn2p	B
12	and	O
13	Msn4p	B
14	activity	O
15	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	B
9	hPRL	I
10	inhibits	O
11	the	O
12	VEGF	B
13	-	O
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	Beyond	O
2	the	O
3	Tower	O
4	of	O
5	Babel	O
6	:	O
7	a	O
8	nomenclature	O
9	for	O
10	suicidology	O
11	.	O

1	YAC	O
2	and	O
3	cosmid	O
4	contigs	O
5	spanning	O
6	the	O
7	Batten	B
8	disease	I
9	(	O
10	CLN3	B
11	)	O
12	region	O
13	at	O
14	16p12	O
15	.	O
16	1	O
17	-	O
18	p11	O
19	.	O
20	2	O
21	.	O

1	A	O
2	recombinant	O
3	with	O
4	a	O
5	5	O
6	'	O
7	end	O
8	from	O
9	src	B
10	and	O
11	a	O
12	3	O
13	'	O
14	end	O
15	from	O
16	ros	B
17	,	O
18	called	O
19	SRC	B
20	x	O
21	ROS	B
22	,	O
23	transformed	O
24	chicken	O
25	embryo	O
26	fibroblasts	O
27	(	O
28	CEF	O
29	)	O
30	to	O
31	a	O
32	spindle	O
33	shape	O
34	morphology	O
35	,	O
36	mimicking	O
37	that	O
38	of	O
39	UR2	B
40	.	O

1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	mRNA	O
15	(	O
16	RRE	B
17	,	O
18	the	O
19	Rev	B
20	response	I
21	element	I
22	)	O
23	and	O
24	the	O
25	virus	B
26	-	I
27	encoded	I
28	protein	I
29	Rev	I
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O

1	Univariate	O
2	statistical	O
3	analysis	O
4	based	O
5	on	O
6	Kaplan	O
7	-	O
8	Meier	O
9	-	O
10	estimates	O
11	and	O
12	Log	O
13	-	O
14	Rank	O
15	-	O
16	Test	O
17	showed	O
18	the	O
19	following	O
20	prognostically	O
21	beneficial	O
22	factors	O
23	:	O
24	Limited	O
25	disease	O
26	stage	O
27	(	O
28	p	O
29	=	O
30	0	O
31	.	O
32	009	O
33	),	O
34	NSE	B
35	serum	O
36	level	O
37	less	O
38	than	O
39	25	O
40	micrograms	O
41	/	O
42	l	O
43	(	O
44	p	O
45	=	O
46	0	O
47	.	O
48	016	O
49	),	O
50	serum	O
51	alkaline	B
52	phosphatase	I
53	less	O
54	than	O
55	200	O
56	U	O
57	/	O
58	l	O
59	(	O
60	p	O
61	=	O
62	0	O
63	.	O
64	035	O
65	),	O
66	normal	O
67	serum	O
68	albumin	B
69	(	O
70	p	O
71	=	O
72	0	O
73	.	O
74	003	O
75	)	O
76	and	O
77	activity	O
78	index	O
79	of	O
80	minimum	O
81	of	O
82	70	O
83	(	O
84	p	O
85	<	O
86	0	O
87	.	O
88	001	O
89	).	O

1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	B
15	fused	O
16	to	O
17	glutathione	B
18	S	I
19	-	I
20	transferase	I
21	(	O
22	GST	B
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	B
28	signaling	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	inhibition	O
9	of	O
10	p27	B
11	(	O
12	KIP1	B
13	)	O
14	transcription	O
15	through	O
16	PI3K	B
17	-	O
18	induced	O
19	FKHR	B
20	-	I
21	L1	I
22	phosphorylation	O
23	provides	O
24	a	O
25	novel	O
26	mechanism	O
27	of	O
28	regulating	O
29	cytokine	O
30	-	O
31	mediated	O
32	survival	O
33	and	O
34	proliferation	O
35	.	O

1	Physical	O
2	analysis	O
3	maps	O
4	SAL6	B
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	B
10	and	O
11	spt14	B
12	.	O

1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	B
10	-	I
11	1	I
12	promoter	I
13	performed	O
14	with	O
15	chloramphenicol	B
16	acetyltransferase	I
17	constructs	I
18	revealed	O
19	that	O
20	Tax	B
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	B
26	-	I
27	1	I
28	promoter	I
29	via	O
30	two	O
31	NF	B
32	-	I
33	kappaB	I
34	sites	I
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	B
46	-	I
47	1	I
48	gene	I
49	promoter	I
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	B
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O

1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O

1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	B
14	genes	I
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	B
27	cDNA	I
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O

1	The	O
2	relation	O
3	between	O
4	VE	O
5	/	O
6	VO2	O
7	and	O
8	Q	O
9	/	O
10	VO2	O
11	showed	O
12	a	O
13	significant	O
14	negative	O
15	correlation	O
16	(	O
17	r	O
18	=	O
19	-	O
20	0	O
21	.	O
22	93	O
23	,	O
24	p	O
25	less	O
26	than	O
27	0	O
28	.	O
29	01	O
30	).	O

1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O

1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O

1	ArgR	B
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O

1	Echinococcus	O
2	granulosus	O
3	was	O
4	diagnosed	O
5	by	O
6	fine	O
7	-	O
8	needle	O
9	aspiration	O
10	cytology	O
11	of	O
12	a	O
13	lung	O
14	cyst	O
15	in	O
16	a	O
17	6	O
18	-	O
19	yr	O
20	-	O
21	old	O
22	white	O
23	female	O
24	in	O
25	central	O
26	Missouri	O
27	.	O

1	Although	O
2	diagnostic	O
3	laparoscopy	O
4	is	O
5	still	O
6	considered	O
7	the	O
8	standard	O
9	reference	O
10	in	O
11	the	O
12	diagnosis	O
13	of	O
14	ectopic	O
15	pregnancy	O
16	(	O
17	EP	O
18	),	O
19	use	O
20	of	O
21	high	O
22	-	O
23	resolution	O
24	endovaginal	O
25	sonography	O
26	,	O
27	in	O
28	conjunction	O
29	with	O
30	qualitative	O
31	serum	O
32	assays	O
33	of	O
34	the	O
35	beta	O
36	subunit	O
37	of	O
38	human	B
39	chorionic	I
40	gonadotropin	I
41	(	O
42	beta	B
43	-	I
44	hCG	I
45	),	O
46	allows	O
47	detection	O
48	of	O
49	earlier	O
50	and	O
51	smaller	O
52	EPs	O
53	.	O

1	ERV1	B
2	is	O
3	involved	O
4	in	O
5	the	O
6	cell	O
7	-	O
8	division	O
9	cycle	O
10	and	O
11	the	O
12	maintenance	O
13	of	O
14	mitochondrial	O
15	genomes	O
16	in	O
17	Saccharomyces	O
18	cerevisiae	O
19	.	O

1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	sought	O
8	to	O
9	investigate	O
10	whether	O
11	constitutive	O
12	NF	B
13	-	I
14	kappaB	I
15	activity	O
16	in	O
17	chronically	O
18	HIV	O
19	-	O
20	1	O
21	-	O
22	infected	O
23	promonocytic	O
24	U937	O
25	(	O
26	U9	O
27	-	O
28	IIIB	O
29	)	O
30	and	O
31	myeloblastic	O
32	PLB	O
33	-	O
34	985	O
35	(	O
36	PLB	O
37	-	O
38	IIIB	O
39	)	O
40	cells	O
41	affects	O
42	apoptotic	O
43	signaling	O
44	.	O

1	New	O
2	techniques	O
3	for	O
4	the	O
5	mass	O
6	spectrometry	O
7	of	O
8	natural	O
9	products	O
10	.	O

1	Such	O
2	studied	O
3	acquired	O
4	with	O
5	low	O
6	energy	O
7	or	O
8	medium	O
9	energy	O
10	collimation	O
11	and	O
12	a	O
13	window	O
14	centered	O
15	on	O
16	the	O
17	159	O
18	keV	O
19	123I	O
20	photopeak	O
21	contain	O
22	appreciable	O
23	septal	O
24	breakthrough	O
25	signals	O
26	originating	O
27	from	O
28	Compton	O
29	scatter	O
30	of	O
31	high	O
32	energy	O
33	photons	O
34	primarily	O
35	from	O
36	124I	O
37	.	O

1	The	O
2	serine	B
3	/	I
4	threonine	I
5	kinase	I
6	Raf	I
7	-	I
8	1	I
9	functions	O
10	downstream	O
11	of	O
12	Rats	B
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	transmits	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O

1	PRL	B
2	-	I
3	1	I
4	is	O
5	able	O
6	to	O
7	dephosphorylate	O
8	phosphotyrosine	O
9	substrates	O
10	,	O
11	and	O
12	mutation	O
13	of	O
14	the	O
15	active	O
16	-	O
17	site	O
18	cysteine	O
19	residue	O
20	abolishes	O
21	this	O
22	activity	O
23	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	role	O
6	of	O
7	two	O
8	recombination	O
9	-	O
10	and	O
11	repair	O
12	-	O
13	defective	O
14	mutations	O
15	,	O
16	rad1	B
17	and	O
18	rad52	B
19	,	O
20	on	O
21	direct	O
22	repeat	O
23	recombination	O
24	in	O
25	transcriptionally	O
26	active	O
27	and	O
28	inactive	O
29	sequences	O
30	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	multivariate	O
6	analysis	O
7	considering	O
8	age	O
9	,	O
10	gender	O
11	,	O
12	and	O
13	a	O
14	previous	O
15	history	O
16	of	O
17	cardiovascular	O
18	diseases	O
19	,	O
20	female	O
21	gender	O
22	was	O
23	not	O
24	independently	O
25	associated	O
26	with	O
27	death	O
28	.	O

1	The	O
2	intranodal	O
3	mesothelial	O
4	cells	O
5	occupied	O
6	the	O
7	sinusoids	O
8	of	O
9	the	O
10	lymph	O
11	nodes	O
12	and	O
13	were	O
14	initially	O
15	suspected	O
16	of	O
17	being	O
18	metastatic	O
19	from	O
20	the	O
21	ovarian	O
22	tumor	O
23	in	O
24	each	O
25	case	O
26	.	O

1	Translation	O
2	of	O
3	specific	O
4	cellular	O
5	genes	O
6	from	O
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	unlikely	O
17	.	O

1	The	O
2	authors	O
3	report	O
4	a	O
5	case	O
6	in	O
7	which	O
8	stereotactic	O
9	irrigation	O
10	of	O
11	a	O
12	brain	O
13	cyst	O
14	was	O
15	temporally	O
16	associated	O
17	with	O
18	respiratory	O
19	distress	O
20	.	O

1	Two	O
2	-	O
3	way	O
4	analysis	O
5	of	O
6	variance	O
7	was	O
8	used	O
9	to	O
10	determine	O
11	whether	O
12	composite	O
13	knowledge	O
14	score	O
15	differed	O
16	among	O
17	patient	O
18	groups	O
19	.	O

1	Toxicities	O
2	included	O
3	:	O
4	nausea	O
5	/	O
6	vomiting	O
7	(	O
8	69	O
9	%),	O
10	headache	O
11	(	O
12	25	O
13	%),	O
14	chills	O
15	(	O
16	69	O
17	%),	O
18	pain	O
19	at	O
20	tumor	O
21	sites	O
22	(	O
23	63	O
24	%),	O
25	hypotension	O
26	(	O
27	31	O
28	%),	O
29	and	O
30	hypertension	O
31	(	O
32	38	O
33	%).	O

1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	I
15	activation	I
16	domain	I
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	L1	B
6	binding	I
7	site	I
8	of	O
9	23S	B
10	rRNA	I
11	in	I
12	Escherichia	I
13	coli	I
14	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	describe	O
7	the	O
8	characterization	O
9	of	O
10	two	O
11	early	O
12	class	B
13	II	I
14	flagellar	I
15	genes	I
16	contained	O
17	in	O
18	the	O
19	orfX	O
20	-	O
21	fliP	B
22	locus	O
23	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	LvUSF2	B
8	is	O
9	nearly	O
10	identical	O
11	to	O
12	LvUSF1	B
13	except	O
14	at	O
15	the	O
16	amino	O
17	end	O
18	,	O
19	where	O
20	they	O
21	are	O
22	sharply	O
23	divergent	O
24	.	O

1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	B
7	and	O
8	tyrosine	B
9	kinases	I
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	B
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	Identification	O
2	of	O
3	the	O
4	plakoglobin	B
5	-	O
6	binding	O
7	domain	O
8	in	O
9	desmoglein	B
10	and	O
11	its	O
12	role	O
13	in	O
14	plaque	O
15	assembly	O
16	and	O
17	intermediate	O
18	filament	O
19	anchorage	O
20	.	O

1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	I
16	amino	I
17	acid	I
18	residues	I
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O

1	The	O
2	RS447	B
3	human	I
4	megasatellite	I
5	tandem	I
6	repetitive	I
7	sequence	I
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	Several	O
2	free	O
3	2nd	O
4	-	O
5	generation	O
6	schizonts	O
7	,	O
8	which	O
9	varied	O
10	in	O
11	diameter	O
12	from	O
13	11	O
14	to	O
15	21	O
16	.	O
17	6	O
18	micrometer	O
19	,	O
20	were	O
21	found	O
22	on	O
23	the	O
24	epithelial	O
25	surface	O
26	of	O
27	the	O
28	cecum	O
29	.	O

1	MutY	B
2	is	O
3	an	O
4	adenine	B
5	-	I
6	DNA	I
7	glycosylase	I
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O

1	Rho	B
2	GDP	I
3	/	I
4	GTP	I
5	exchange	I
6	inhibitor	I
7	,	O
8	Rho	B
9	GDI	I
10	,	O
11	comigrated	O
12	with	O
13	Rac2	B
14	and	O
15	RhoA	B
16	,	O
17	but	O
18	not	O
19	Rac1	B
20	.	O

1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O

1	The	O
2	lymph	O
3	nodes	O
4	from	O
5	two	O
6	of	O
7	the	O
8	patients	O
9	with	O
10	rheumatoid	O
11	arthritis	O
12	contained	O
13	numerous	O
14	sarcoid	O
15	like	O
16	granulomata	O
17	,	O
18	further	O
19	indicating	O
20	a	O
21	possible	O
22	association	O
23	between	O
24	sarcoidosis	O
25	and	O
26	rheumatoid	O
27	arthritis	O
28	.	O

1	The	O
2	5	O
3	'-	O
4	terminus	O
5	of	O
6	the	O
7	p	B
8	-	I
9	gvpF	I
10	-	I
11	M	I
12	mRNA	I
13	was	O
14	located	O
15	169	O
16	nucleotides	O
17	upstream	O
18	of	O
19	p	B
20	-	I
21	gvpF	I
22	within	O
23	p	B
24	-	I
25	gvpE	I
26	.	O

1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	B
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	B
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	By	O
2	sequence	O
3	comparison	O
4	,	O
5	42	O
6	blocks	O
7	of	O
8	homology	O
9	are	O
10	defined	O
11	in	O
12	the	O
13	5	O
14	'-	O
15	terminal	O
16	region	O
17	,	O
18	of	O
19	which	O
20	36	O
21	appear	O
22	in	O
23	the	O
24	CpG	O
25	island	O
26	and	O
27	contain	O
28	numerous	O
29	conserved	O
30	CpG	O
31	dinucleotides	O
32	.	O

1	Also	O
2	,	O
3	the	O
4	amplitude	O
5	of	O
6	the	O
7	oscillatory	O
8	potentials	O
9	(	O
10	O1	O
11	+	O
12	O2	O
13	+	O
14	O3	O
15	+	O
16	O4	O
17	)	O
18	was	O
19	significantly	O
20	reduced	O
21	in	O
22	the	O
23	early	O
24	postoperative	O
25	period	O
26	.	O

1	The	O
2	E6	B
3	/	O
4	E7	B
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	papillomaviruses	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	predicted	O
6	amino	O
7	acid	O
8	sequences	O
9	of	O
10	the	O
11	two	O
12	human	B
13	PKC	I
14	-	I
15	delta	I
16	clones	O
17	with	O
18	the	O
19	rat	O
20	and	O
21	mouse	O
22	homologues	O
23	indicated	O
24	a	O
25	greater	O
26	degree	O
27	of	O
28	sequence	O
29	divergence	O
30	(	O
31	89	O
32	-	O
33	90	O
34	%	O
35	homology	O
36	)	O
37	compared	O
38	to	O
39	the	O
40	high	O
41	degree	O
42	of	O
43	sequence	O
44	conservation	O
45	observed	O
46	with	O
47	other	O
48	human	B
49	PKC	I
50	family	I
51	members	I
52	and	O
53	their	O
54	mammalian	O
55	counterparts	O
56	.	O

1	The	O
2	pheromone	O
3	response	O
4	pathway	O
5	activates	O
6	transcription	O
7	of	O
8	Ty5	B
9	retrotransposons	I
10	located	O
11	within	O
12	silent	O
13	chromatin	O
14	of	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	This	O
2	lack	O
3	of	O
4	correlation	O
5	may	O
6	be	O
7	due	O
8	to	O
9	variations	O
10	in	O
11	the	O
12	metabolic	O
13	activity	O
14	of	O
15	the	O
16	endometriotic	O
17	implants	O
18	present	O
19	at	O
20	different	O
21	stages	O
22	of	O
23	the	O
24	disease	O
25	.	O

1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O

1	The	O
2	LTR	O
3	-	O
4	binding	O
5	activities	O
6	of	O
7	VBP	B
8	,	O
9	a1	B
10	/	I
11	EBP	I
12	,	O
13	and	O
14	B	B
15	-	I
16	cell	I
17	nuclear	I
18	extract	I
19	protein	I
20	were	O
21	compared	O
22	and	O
23	mapped	O
24	by	O
25	gel	O
26	shift	O
27	,	O
28	DNase	B
29	I	I
30	footprinting	O
31	,	O
32	and	O
33	methylation	O
34	interference	O
35	assays	O
36	.	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	Repeated	O
2	administration	O
3	of	O
4	GRg2	O
5	20	O
6	mg	O
7	/	O
8	kg	O
9	i	O
10	.	O
11	p	O
12	.	O
13	significantly	O
14	improved	O
15	the	O
16	CYP	O
17	-	O
18	induced	O
19	recognitional	O
20	deficits	O
21	by	O
22	increasing	O
23	the	O
24	CYP	O
25	-	O
26	decreased	O
27	rate	O
28	from	O
29	55	O
30	.	O
31	8	O
32	+/-	O
33	9	O
34	.	O
35	6	O
36	to	O
37	80	O
38	.	O
39	8	O
40	+/-	O
41	4	O
42	.	O
43	2	O
44	in	O
45	d	O
46	3	O
47	learning	O
48	acquisition	O
49	(	O
50	F	O
51	(	O
52	1	O
53	,	O
54	14	O
55	)	O
56	=	O
57	5	O
58	.	O
59	6	O
60	,	O
61	p	O
62	<	O
63	0	O
64	.	O
65	05	O
66	),	O
67	from	O
68	53	O
69	.	O
70	4	O
71	+/-	O
72	8	O
73	.	O
74	4	O
75	to	O
76	60	O
77	.	O
78	0	O
79	+/-	O
80	8	O
81	.	O
82	2	O
83	in	O
84	48	O
85	h	O
86	memory	O
87	acquisition	O
88	(	O
89	F	O
90	(	O
91	1	O
92	,	O
93	14	O
94	)	O
95	=	O
96	7	O
97	.	O
98	5	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	05	O
105	)	O
106	and	O
107	from	O
108	55	O
109	.	O
110	0	O
111	+/-	O
112	5	O
113	.	O
114	5	O
115	to	O
116	88	O
117	.	O
118	3	O
119	+/-	O
120	2	O
121	.	O
122	5	O
123	in	O
124	24	O
125	h	O
126	memory	O
127	retention	O
128	(	O
129	F	O
130	(	O
131	1	O
132	,	O
133	12	O
134	)	O
135	27	O
136	.	O
137	5	O
138	,	O
139	p	O
140	<	O
141	0	O
142	.	O
143	01	O
144	)	O
145	as	O
146	well	O
147	as	O
148	from	O
149	60	O
150	.	O
151	0	O
152	+/-	O
153	6	O
154	.	O
155	8	O
156	to	O
157	85	O
158	.	O
159	6	O
160	+/-	O
161	6	O
162	.	O
163	9	O
164	in	O
165	48	O
166	h	O
167	memory	O
168	retrieval	O
169	(	O
170	F	O
171	(	O
172	1	O
173	,	O
174	12	O
175	)	O
176	=	O
177	5	O
178	.	O
179	2	O
180	,	O
181	p	O
182	<	O
183	0	O
184	.	O
185	05	O
186	),	O
187	respectively	O
188	.	O

1	The	O
2	present	O
3	investigation	O
4	sought	O
5	to	O
6	identify	O
7	the	O
8	principal	O
9	dimensions	O
10	of	O
11	the	O
12	Framingham	O
13	Type	O
14	A	O
15	scale	O
16	(	O
17	FTAS	O
18	)	O
19	and	O
20	then	O
21	to	O
22	examine	O
23	their	O
24	physiological	O
25	and	O
26	psychological	O
27	correlates	O
28	.	O

1	A	O
2	decrease	O
3	in	O
4	insulin	B
5	-	O
6	induced	O
7	receptor	O
8	kinase	O
9	activity	O
10	was	O
11	observed	O
12	for	O
13	solubilized	O
14	chimeric	O
15	receptors	O
16	.	O

1	Intracellular	O
2	activity	O
3	studies	O
4	indicated	O
5	that	O
6	,	O
7	at	O
8	ten	O
9	times	O
10	MBC	O
11	,	O
12	only	O
13	penicillin	O
14	had	O
15	any	O
16	significant	O
17	activity	O
18	against	O
19	intracellular	O
20	staphylococci	O
21	,	O
22	reducing	O
23	survival	O
24	by	O
25	28	O
26	%.	O

1	Using	O
2	homology	O
3	cloning	O
4	techniques	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	mouse	O
10	homologue	O
11	of	O
12	E	O
13	(	O
14	Pc	O
15	),	O
16	termed	O
17	Epc1	B
18	,	O
19	a	O
20	yeast	O
21	protein	O
22	that	O
23	we	O
24	name	O
25	EPL1	B
26	,	O
27	and	O
28	as	O
29	well	O
30	as	O
31	additional	O
32	ESTs	O
33	from	O
34	Caenorhabditis	O
35	elegans	O
36	,	O
37	mice	O
38	and	O
39	humans	O
40	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	results	O
5	demonstrate	O
6	that	O
7	at	O
8	the	O
9	site	O
10	of	O
11	lumbar	O
12	disc	O
13	herniation	O
14	,	O
15	inflammatory	O
16	cytokines	O
17	such	O
18	as	O
19	interleukin	B
20	-	I
21	1	I
22	alpha	I
23	are	O
24	produced	O
25	,	O
26	which	O
27	increases	O
28	prostaglandin	O
29	E2	O
30	production	O
31	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	B
18	factor	I
19	.	O

1	Plasmids	O
2	for	O
3	the	O
4	cloning	O
5	and	O
6	expression	O
7	of	O
8	full	O
9	-	O
10	length	O
11	double	O
12	-	O
13	stranded	O
14	cDNAs	O
15	under	O
16	control	O
17	of	O
18	the	O
19	SV40	B
20	early	I
21	or	O
22	late	B
23	gene	I
24	promoter	O
25	.	O

1	Histopathologically	O
2	,	O
3	a	O
4	cystic	O
5	lymphangioma	O
6	was	O
7	diagnosed	O
8	because	O
9	of	O
10	the	O
11	morphological	O
12	features	O
13	and	O
14	the	O
15	immunohistochemical	O
16	stainings	O
17	of	O
18	CD34	B
19	and	O
20	Factor	B
21	VIII	I
22	related	I
23	antigen	I
24	which	O
25	were	O
26	observed	O
27	positive	O
28	reactions	O
29	in	O
30	endothelial	O
31	cells	O
32	of	O
33	the	O
34	cysts	O
35	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O

1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O

1	The	O
2	distinguishing	O
3	features	O
4	involved	O
5	eight	O
6	amino	O
7	acid	O
8	changes	O
9	,	O
10	including	O
11	a	O
12	single	O
13	lysine	O
14	deletion	O
15	relative	O
16	to	O
17	a	O
18	primate	O
19	consensus	O
20	sequence	O
21	in	O
22	the	O
23	first	O
24	complementary	O
25	-	O
26	determing	O
27	region	O
28	of	O
29	V1J1	B
30	.	O

1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	O
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O

1	HNF	B
2	-	I
3	3	I
4	beta	I
5	amino	I
6	-	I
7	terminal	I
8	sequences	I
9	defined	O
10	by	O
11	conserved	O
12	region	O
13	IV	O
14	also	O
15	contributed	O
16	to	O
17	transactivation	O
18	,	O
19	but	O
20	region	O
21	IV	O
22	activity	O
23	required	O
24	the	O
25	participation	O
26	of	O
27	the	O
28	region	O
29	II	O
30	-	O
31	III	O
32	domain	O
33	.	O

1	Mouse	B
2	mast	I
3	cell	I
4	protease	I
5	9	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	chromosome	O
13	14	O
14	family	O
15	of	O
16	serine	B
17	proteases	I
18	that	O
19	is	O
20	selectively	O
21	expressed	O
22	in	O
23	uterine	O
24	mast	O
25	cells	O
26	.	O

1	The	O
2	extent	O
3	of	O
4	the	O
5	fbpA	O
6	operator	O
7	sequence	O
8	(	O
9	42	O
10	bp	O
11	),	O
12	as	O
13	defined	O
14	by	O
15	our	O
16	footprinting	O
17	analysis	O
18	,	O
19	would	O
20	suggest	O
21	the	O
22	binding	O
23	of	O
24	two	O
25	Fur	B
26	repressor	I
27	dimers	I
28	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	B
27	products	I
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	Expression	O
2	,	O
3	cellular	O
4	localization	O
5	and	O
6	in	O
7	vitro	O
8	transcription	O
9	studies	O
10	establish	O
11	that	O
12	cloned	B
13	hUBF	I
14	encodes	O
15	a	O
16	nucleolar	O
17	factor	O
18	that	O
19	binds	O
20	specifically	O
21	to	O
22	the	O
23	upstream	O
24	control	O
25	element	O
26	and	O
27	core	O
28	of	O
29	the	O
30	rRNA	O
31	gene	O
32	promoter	O
33	to	O
34	activate	O
35	transcription	O
36	in	O
37	a	O
38	binding	O
39	site	O
40	-	O
41	dependent	O
42	manner	O
43	.	O

1	We	O
2	analyzed	O
3	the	O
4	modular	O
5	organization	O
6	of	O
7	DNA	B
8	polymerase	I
9	beta	I
10	and	O
11	found	O
12	that	O
13	residues	O
14	making	O
15	contact	O
16	with	O
17	DNA	O
18	phosphates	O
19	were	O
20	localized	O
21	to	O
22	five	O
23	modules	O
24	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	Protein	B
2	C	I
3	deficiency	O
4	or	O
5	protein	B
6	S	I
7	deficiency	O
8	was	O
9	the	O
10	only	O
11	identified	O
12	risk	O
13	factor	O
14	for	O
15	5	O
16	.	O
17	4	O
18	%	O
19	(	O
20	2	O
21	patients	O
22	)	O
23	and	O
24	13	O
25	.	O
26	5	O
27	%	O
28	(	O
29	5	O
30	patients	O
31	),	O
32	respectively	O
33	,	O
34	of	O
35	these	O
36	37	O
37	children	O
38	.	O

1	To	O
2	determine	O
3	whether	O
4	mononuclear	O
5	cell	O
6	secretory	O
7	products	O
8	contribute	O
9	to	O
10	the	O
11	changes	O
12	in	O
13	bone	O
14	turnover	O
15	that	O
16	characterize	O
17	the	O
18	development	O
19	of	O
20	postmenopausal	O
21	osteoporosis	O
22	,	O
23	we	O
24	evaluated	O
25	the	O
26	effects	O
27	of	O
28	oophorectomy	O
29	and	O
30	subsequent	O
31	estrogen	O
32	replacement	O
33	on	O
34	the	O
35	spontaneous	O
36	secretion	O
37	of	O
38	interleukin	B
39	1	I
40	(	O
41	IL	B
42	-	I
43	1	I
44	)	O
45	and	O
46	tumor	B
47	necrosis	I
48	factor	I
49	alpha	I
50	(	O
51	TNF	B
52	-	I
53	alpha	I
54	)	O
55	and	O
56	on	O
57	the	O
58	phytohemagglutinin	B
59	A	I
60	-	O
61	induced	O
62	secretion	O
63	of	O
64	granulocyte	B
65	-	I
66	macrophage	I
67	colony	I
68	-	I
69	stimulating	I
70	factor	I
71	(	O
72	GM	B
73	-	I
74	CSF	I
75	)	O
76	from	O
77	peripheral	O
78	blood	O
79	mononuclear	O
80	cells	O
81	.	O

1	Minor	O
2	differences	O
3	were	O
4	noted	O
5	with	O
6	latamoxef	O
7	producing	O
8	mild	O
9	persistant	O
10	elevation	O
11	of	O
12	prothrombin	B
13	time	O
14	(	O
15	0	O
16	.	O
17	7	O
18	second	O
19	)	O
20	associated	O
21	with	O
22	depression	O
23	of	O
24	factor	B
25	II	I
26	and	O
27	factor	B
28	VII	I
29	.	O

1	Our	O
2	study	O
3	was	O
4	addressed	O
5	to	O
6	the	O
7	synthesis	O
8	of	O
9	some	O
10	derivatives	O
11	of	O
12	this	O
13	sequence	O
14	in	O
15	order	O
16	to	O
17	obtain	O
18	both	O
19	peptide	O
20	substrates	O
21	suitable	O
22	for	O
23	the	O
24	detection	O
25	of	O
26	the	O
27	Src	B
28	-	O
29	like	O
30	tyrosine	B
31	kinase	I
32	activity	O
33	and	O
34	active	O
35	site	O
36	-	O
37	directed	O
38	inhibitors	O
39	specific	O
40	for	O
41	this	O
42	class	O
43	of	O
44	enzymes	O
45	.	O

1	Tissue	O
2	necrosis	O
3	was	O
4	evaluated	O
5	using	O
6	triphenyltetrazolium	O
7	staining	O
8	and	O
9	was	O
10	related	O
11	to	O
12	two	O
13	major	O
14	baseline	O
15	predictors	O
16	of	O
17	infarct	O
18	size	O
19	:	O
20	anatomic	O
21	risk	O
22	zone	O
23	size	O
24	and	O
25	coronary	O
26	collateral	O
27	flow	O
28	.	O

1	Left	O
2	atrial	O
3	volumes	O
4	were	O
5	greater	O
6	in	O
7	old	O
8	compared	O
9	with	O
10	young	O
11	subjects	O
12	(	O
13	maximal	O
14	:	O
15	31	O
16	+/-	O
17	10	O
18	cm3	O
19	/	O
20	m2	O
21	vs	O
22	24	O
23	+/-	O
24	8	O
25	cm3	O
26	/	O
27	m2	O
28	,	O
29	p	O
30	=	O
31	0	O
32	.	O
33	02	O
34	;	O
35	at	O
36	onset	O
37	of	O
38	atrial	O
39	systole	O
40	:	O
41	23	O
42	+/-	O
43	8	O
44	cm3	O
45	/	O
46	m2	O
47	vs	O
48	15	O
49	+/-	O
50	5	O
51	cm3	O
52	/	O
53	m2	O
54	,	O
55	p	O
56	=	O
57	0	O
58	.	O
59	0002	O
60	;	O
61	minimal	O
62	:	O
63	13	O
64	+/-	O
65	5	O
66	cm3	O
67	/	O
68	m2	O
69	vs	O
70	9	O
71	+/-	O
72	4	O
73	cm3	O
74	/	O
75	m2	O
76	,	O
77	p	O
78	=	O
79	0	O
80	.	O
81	001	O
82	).	O

1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	HAT	O
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	006	O
14	versus	O
15	group	O
16	1	O
17	).	O

1	When	O
2	transfected	O
3	into	O
4	Drosophila	O
5	SL	O
6	-	O
7	2	O
8	cells	O
9	,	O
10	pCAT	O
11	plasmid	O
12	containing	O
13	2	O
14	,	O
15	090	O
16	bp	O
17	of	O
18	5	O
19	'-	O
20	flanking	O
21	region	O
22	shows	O
23	a	O
24	3	O
25	.	O
26	0	O
27	-	O
28	to	O
29	3	O
30	.	O
31	5	O
32	-	O
33	fold	O
34	increase	O
35	in	O
36	chloramphenicol	B
37	acetyltransferase	I
38	activity	O
39	after	O
40	induction	O
41	with	O
42	retinoic	O
43	acid	O
44	and	O
45	/	O
46	or	O
47	8	O
48	-	O
49	bromo	O
50	-	O
51	cAMP	O
52	.	O

1	In	O
2	contrast	O
3	,	O
4	injection	O
5	of	O
6	a	O
7	plasmid	O
8	encoding	O
9	simian	B
10	virus	I
11	40	I
12	small	I
13	t	I
14	antigen	I
15	,	O
16	which	O
17	interacts	O
18	with	O
19	PP2A	B
20	to	O
21	inhibit	O
22	its	O
23	activity	O
24	towards	O
25	several	O
26	phosphoprotein	O
27	substrates	O
28	,	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	the	O
34	phosphorylation	O
35	state	O
36	of	O
37	CREB	B
38	in	O
39	stimulated	O
40	or	O
41	unstimulated	O
42	NIH	O
43	3T3	O
44	cells	O
45	.	O

1	Peripheral	O
2	vitreochorioretinal	O
3	dystrophies	O
4	in	O
5	myopia	O
6	patients	O

1	Organisms	O
2	were	O
3	recovered	O
4	from	O
5	the	O
6	conjunctiva	O
7	for	O
8	several	O
9	weeks	O
10	,	O
11	and	O
12	persistent	O
13	genital	O
14	and	O
15	gastrointestinal	O
16	infection	O
17	also	O
18	resulted	O
19	from	O
20	the	O
21	ocular	O
22	infection	O
23	in	O
24	some	O
25	cats	O
26	.	O

1	Heterogeneity	O
2	of	O
3	human	B
4	serum	I
5	albumin	I
6	.	O

1	Very	O
2	good	O
3	accuracy	O
4	(	O
5	r	O
6	greater	O
7	than	O
8	0	O
9	.	O
10	9	O
11	)	O
12	was	O
13	found	O
14	when	O
15	except	O
16	comparing	O
17	H	O
18	*	O
19	2	O
20	with	O
21	the	O
22	other	O
23	machine	O
24	and	O
25	the	O
26	reference	O
27	methods	O
28	,	O
29	except	O
30	for	O
31	MCHCH	O
32	and	O
33	basophil	O
34	count	O
35	.	O

1	The	O
2	COOH	O
3	-	O
4	terminus	O
5	of	O
6	this	O
7	new	O
8	isoform	O
9	,	O
10	which	O
11	we	O
12	designate	O
13	beta	B
14	4	I
15	,	O
16	lacks	O
17	a	O
18	22	O
19	amino	O
20	acid	O
21	lysine	O
22	-	O
23	rich	O
24	sequence	O
25	common	O
26	to	O
27	both	O
28	the	O
29	human	B
30	red	I
31	cell	I
32	alpha	I
33	-	I
34	and	I
35	beta	I
36	-	I
37	adducin	I
38	subunits	I
39	and	O
40	homologous	O
41	to	O
42	a	O
43	highly	O
44	conserved	O
45	region	O
46	in	O
47	MARCKS	B
48	,	O
49	a	O
50	filamentous	O
51	actin	B
52	-	O
53	cross	O
54	linking	O
55	protein	O
56	regulated	O
57	by	O
58	protein	B
59	kinase	I
60	C	I
61	and	O
62	calcium	O
63	/	O
64	calmodulin	B
65	.	O
66	beta	B
67	4	I
68	-	I
69	adducin	I
70	preserves	O
71	a	O
72	previously	O
73	identified	O
74	calmodulin	B
75	binding	I
76	domain	I
77	.	O

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	O
16	PWV	O
17	):	O
18	the	O
19	deduced	O
20	CP	B
21	sequence	I
22	is	O
23	only	O
24	distantly	O
25	related	O
26	to	O
27	CPs	B
28	of	O
29	other	O
30	sequenced	O
31	strains	O
32	of	O
33	PWV	O
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	In	O
2	insects	O
3	,	O
4	arylalkylamine	B
5	N	I
6	-	I
7	acetyltransferases	I
8	(	O
9	AANATs	B
10	)	O
11	have	O
12	been	O
13	implicated	O
14	in	O
15	several	O
16	physiological	O
17	processes	O
18	,	O
19	including	O
20	sclerotization	O
21	,	O
22	inactivation	O
23	of	O
24	certain	O
25	neurotransmitters	O
26	,	O
27	and	O
28	,	O
29	similar	O
30	to	O
31	the	O
32	function	O
33	in	O
34	vertebrates	O
35	,	O
36	catalysis	O
37	of	O
38	the	O
39	rate	O
40	-	O
41	limiting	O
42	step	O
43	in	O
44	melatonin	O
45	biosynthesis	O
46	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	instruments	O
6	allows	O
7	occlusion	O
8	of	O
9	the	O
10	ascending	O
11	aorta	O
12	traversed	O
13	by	O
14	the	O
15	perfusion	O
16	cannula	O
17	inserted	O
18	directly	O
19	or	O
20	through	O
21	the	O
22	apex	O
23	of	O
24	the	O
25	heart	O
26	as	O
27	well	O
28	as	O
29	simultaneous	O
30	left	O
31	ventricular	O
32	venting	O
33	.	O

1	Our	O
2	laboratory	O
3	and	O
4	others	O
5	have	O
6	shown	O
7	alternative	O
8	splicing	O
9	of	O
10	up	O
11	to	O
12	ten	O
13	exons	O
14	at	O
15	a	O
16	discrete	O
17	extracellular	O
18	site	O
19	to	O
20	be	O
21	primarily	O
22	responsible	O
23	for	O
24	the	O
25	generation	O
26	of	O
27	CD44	B
28	variant	I
29	(	O
30	CD44v	B
31	)	O
32	isoforms	O
33	.	O

1	The	O
2	order	O
3	of	O
4	the	O
5	helicase	B
6	motif	I
7	and	O
8	the	O
9	nsP3	B
10	homology	I
11	region	I
12	in	O
13	the	O
14	RUB	O
15	genome	O
16	is	O
17	reversed	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	alphavirus	O
23	genome	O
24	indicating	O
25	that	O
26	a	O
27	genetic	O
28	rearrangement	O
29	has	O
30	occurred	O
31	during	O
32	the	O
33	evolution	O
34	of	O
35	these	O
36	viruses	O
37	.	O

1	Thus	O
2	,	O
3	the	O
4	positive	O
5	effect	O
6	of	O
7	NS1	B
8	on	O
9	the	O
10	steady	O
11	-	O
12	state	O
13	levels	O
14	of	O
15	P4	B
16	transcripts	I
17	depends	O
18	on	O
19	the	O
20	amplification	O
21	of	O
22	gene	O
23	copy	O
24	number	O
25	and	O
26	the	O
27	integrity	O
28	of	O
29	the	O
30	terminal	O
31	repeats	O
32	.	O

1	(	O
2	total	O
3	soluble	O
4	solids	O
5	)	O
6	and	O
7	organoleptic	O
8	characteristics	O
9	under	O
10	the	O
11	influence	O
12	of	O
13	different	O
14	treatments	O
15	.	O

1	ATP	O
2	gamma	O
3	S	O
4	inhibition	O
5	can	O
6	be	O
7	overcome	O
8	by	O
9	high	O
10	concentrations	O
11	of	O
12	ATP	O
13	,	O
14	dATP	O
15	,	O
16	araATP	O
17	,	O
18	or	O
19	ddATP	O
20	.	O

1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	B
23	protein	I
24	.	O

1	Family	O
2	planning	O
3	continues	O
4	to	O
5	play	O
6	a	O
7	minor	O
8	role	O
9	,	O
10	and	O
11	only	O
12	25	O
13	.	O
14	3	O
15	per	O
16	cent	O
17	of	O
18	all	O
19	patients	O
20	reviewed	O
21	took	O
22	to	O
23	oral	O
24	contraceptives	O
25	for	O
26	shorter	O
27	or	O
28	longer	O
29	periods	O
30	of	O
31	time	O
32	.	O
33	-	O
34	The	O
35	percentages	O
36	of	O
37	primiparae	O
38	and	O
39	secundiparae	O
40	in	O
41	all	O
42	births	O
43	as	O
44	well	O
45	as	O
46	the	O
47	high	O
48	percentage	O
49	of	O
50	multigravidity	O
51	are	O
52	parameters	O
53	by	O
54	which	O
55	the	O
56	approach	O
57	to	O
58	reproduction	O
59	differs	O
60	substantively	O
61	from	O
62	behaviour	O
63	patterns	O
64	in	O
65	Europe	O
66	.	O

1	Phosphate	B
2	glucose	I
3	dehydrogenase	I
4	deficiency	O
5	causing	O
6	hyperbilirubinemia	O
7	in	O
8	the	O
9	newborn	O

1	Fifteen	O
2	light	O
3	for	O
4	dates	O
5	infants	O
6	and	O
7	their	O
8	placentae	O
9	were	O
10	compared	O
11	to	O
12	15	O
13	well	O
14	-	O
15	grown	O
16	infants	O
17	and	O
18	their	O
19	placentae	O
20	.	O

1	Badcock	O
2	and	O
3	Westheimer	O
4	(	O
5	Spatial	O
6	Vision	O
7	1	O
8	(	O
9	1	O
10	),	O
11	3	O
12	-	O
13	11	O
14	,	O
15	1985	O
16	)	O
17	showed	O
18	that	O
19	a	O
20	thin	O
21	vertical	O
22	line	O
23	induces	O
24	nearby	O
25	zones	O
26	of	O
27	attraction	O
28	and	O
29	repulsion	O
30	;	O
31	this	O
32	study	O
33	extends	O
34	those	O
35	results	O
36	by	O
37	more	O
38	closely	O
39	examining	O
40	the	O
41	horizontal	O
42	and	O
43	vertical	O
44	extents	O
45	of	O
46	the	O
47	repulsion	O
48	zone	O
49	and	O
50	by	O
51	using	O
52	an	O
53	illusory	O
54	contour	O
55	to	O
56	induce	O
57	repulsion	O
58	.	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	Age	O
2	at	O
3	POI	O
4	and	O
5	asymptote	O
6	were	O
7	achieved	O
8	later	O
9	for	O
10	Line	O
11	RBC2	O
12	than	O
13	for	O
14	Line	O
15	F	O
16	.	O

1	The	O
2	recombinant	O
3	purified	O
4	protein	O
5	expressed	O
6	in	O
7	the	O
8	baculovirus	O
9	system	O
10	had	O
11	an	O
12	approximate	O
13	molecular	O
14	size	O
15	20	O
16	kDa	O
17	with	O
18	amino	O
19	-	O
20	terminal	O
21	sequence	O
22	of	O
23	AVQGP	O
24	.	O

1	We	O
2	also	O
3	found	O
4	an	O
5	eIF	B
6	-	I
7	4A	I
8	intronless	O
9	retroposon	O
10	which	O
11	,	O
12	when	O
13	compared	O
14	to	O
15	the	O
16	cDNA	O
17	,	O
18	contains	O
19	a	O
20	single	O
21	nucleotide	O
22	difference	O
23	.	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	B
15	-	I
16	terminally	I
17	truncated	I
18	MIP	I
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	Radiolabeled	O
2	recombinant	B
3	TARC	I
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	I
21	containing	O
22	the	O
23	Ras	B
24	membrane	I
25	localization	I
26	motif	I
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	Recurrent	O
2	arterial	O
3	thrombotic	O
4	disease	O
5	on	O
6	young	O
7	onset	O
8	and	O
9	protein	B
10	S	I
11	deficiency	O
12	.	O

1	Plasmids	O
2	pAMS12	O
3	,	O
4	pAMS13	O
5	and	O
6	pAMS14	O
7	were	O
8	transformed	O
9	into	O
10	a	O
11	laboratory	O
12	strain	O
13	of	O
14	Saccharomyces	O
15	cerevisiae	O
16	,	O
17	whereas	O
18	pAMS15	O
19	was	O
20	stably	O
21	introduced	O
22	into	O
23	two	O
24	commercial	O
25	wine	O
26	yeast	O
27	strains	O
28	.	O

1	Echinostomiasis	O
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	O
22	lack	O
23	of	O
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	Arhythmacanthus	O
2	Yamaguti	O
3	,	O
4	1935	O
5	is	O
6	maintained	O
7	as	O
8	a	O
9	synonym	O
10	of	O
11	Heterosentis	O
12	because	O
13	the	O
14	distinction	O
15	between	O
16	two	O
17	and	O
18	three	O
19	hook	O
20	types	O
21	is	O
22	made	O
23	equivocal	O
24	when	O
25	the	O
26	transition	O
27	between	O
28	the	O
29	apical	O
30	and	O
31	subapical	O
32	hooks	O
33	is	O
34	gradual	O
35	.	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	O
39	epsilon	O
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Sestamibi	O
2	scintigraphy	O
3	,	O
4	performed	O
5	in	O
6	70	O
7	patients	O
8	,	O
9	was	O
10	less	O
11	sensitive	O
12	than	O
13	ultrasonography	O
14	(	O
15	80	O
16	%).	O

1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	mouse	B
6	cytosolic	I
7	chaperonin	I
8	subunit	I
9	gene	I
10	Ccta	I
11	/	I
12	t	I
13	-	I
14	complex	I
15	polypeptide	I
16	1	I
17	by	O
18	selenocysteine	B
19	tRNA	I
20	gene	I
21	transcription	I
22	activating	I
23	factor	I
24	family	I
25	zinc	I
26	finger	I
27	proteins	I
28	.	O

1	Reward	O
2	value	O
3	of	O
4	prosodic	O
5	features	O
6	of	O
7	language	O
8	for	O
9	autistic	O
10	,	O
11	mentally	O
12	retarded	O
13	,	O
14	and	O
15	normal	O
16	children	O
17	.	O

1	Assembly	O
2	of	O
3	a	O
4	complex	O
5	between	O
6	FAK	B
7	and	O
8	Src	B
9	kinases	I
10	may	O
11	serve	O
12	to	O
13	regulate	O
14	the	O
15	subcellular	O
16	localization	O
17	and	O
18	the	O
19	enzymatic	O
20	activity	O
21	of	O
22	members	O
23	of	O
24	the	O
25	Src	B
26	family	I
27	of	O
28	kinases	O
29	.	O

1	The	O
2	3	O
3	'	O
4	UTR	O
5	has	O
6	several	O
7	stable	O
8	hairpins	O
9	that	O
10	are	O
11	flanked	O
12	by	O
13	single	O
14	-	O
15	stranded	O
16	(	O
17	A	O
18	/	O
19	U	O
20	)	O
21	UGC	O
22	sequences	O
23	.	O

1	GRFI	B
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	B
16	mating	I
17	type	I
18	loci	I
19	HML	I
20	E	I
21	and	O
22	HMR	B
23	E	I
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O

1	Tyrosine	O
2	1356	O
3	forms	O
4	a	O
5	multisubstrate	O
6	binding	O
7	site	O
8	for	O
9	the	O
10	Grb2	B
11	and	O
12	Shc	B
13	adaptor	I
14	proteins	I
15	,	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'-	I
23	kinase	I
24	,	O
25	phospholipase	B
26	Cgamma	I
27	,	O
28	and	O
29	a	O
30	phosphatase	O
31	,	O
32	SHP2	B
33	.	O

1	TIP30	B
2	has	O
3	an	O
4	intrinsic	O
5	kinase	O
6	activity	O
7	required	O
8	for	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	a	O
14	subset	O
15	of	O
16	apoptotic	O
17	genes	O
18	.	O

1	In	O
2	the	O
3	rat	B
4	rnu	I
5	allele	I
6	described	O
7	here	O
8	,	O
9	a	O
10	nonsense	O
11	mutation	O
12	in	O
13	exon	O
14	8	O
15	of	O
16	the	O
17	whn	B
18	gene	I
19	was	O
20	identified	O
21	.	O

1	One	O
2	cDNA	O
3	clone	O
4	designated	O
5	NCoA	O
6	-	O
7	62	O
8	,	O
9	encoded	O
10	a	O
11	62	O
12	,	O
13	000	O
14	-	O
15	Da	O
16	protein	O
17	that	O
18	is	O
19	highly	O
20	related	O
21	to	O
22	BX42	B
23	,	O
24	a	O
25	Drosophila	O
26	melanogaster	O
27	nuclear	O
28	protein	O
29	involved	O
30	in	O
31	ecdysone	O
32	-	O
33	stimulated	O
34	gene	O
35	expression	O
36	.	O

1	Insulin	B
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	B
11	hormone	I
12	-	O
13	induced	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	.	O

1	The	O
2	genome	O
3	of	O
4	all	O
5	retroviruses	O
6	consists	O
7	of	O
8	two	O
9	identical	O
10	RNAs	O
11	noncovalently	O
12	linked	O
13	near	O
14	their	O
15	5	O
16	'	O
17	end	O
18	.	O

1	Binding	O
2	of	O
3	SSP	B
4	to	O
5	the	O
6	stage	B
7	selector	I
8	element	I
9	(	O
10	SSE	B
11	)	O
12	in	O
13	the	O
14	proximal	O
15	gamma	B
16	-	I
17	globin	I
18	promoter	I
19	is	O
20	integral	O
21	to	O
22	the	O
23	competitive	O
24	silencing	O
25	of	O
26	a	O
27	linked	O
28	beta	B
29	-	I
30	promoter	I
31	in	O
32	embryonic	O
33	/	O
34	fetal	O
35	stage	O
36	erythroleukemia	O
37	(	O
38	K562	O
39	)	O
40	cells	O
41	.	O

1	Family	O
2	visits	O
3	and	O
4	involvement	O
5	in	O
6	treatment	O
7	of	O
8	patients	O
9	at	O
10	a	O
11	state	O
12	hospital	O
13	.	O

1	Processing	O
2	of	O
3	the	O
4	NS3	O
5	'-	O
6	5B	B
7	polyprotein	O
8	was	O
9	complex	O
10	and	O
11	occurred	O
12	rapidly	O
13	.	O

1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	B
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	B
23	module	I
24	,	O
25	with	O
26	inner	O
27	nuclear	O
28	membrane	O
29	proteins	O
30	lamina	B
31	-	I
32	associated	I
33	polypeptide	I
34	2	I
35	and	O
36	emerin	B
37	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	HIV	O
6	-	O
7	1	O
8	Gag	B
9	sequences	I
10	can	O
11	influence	O
12	the	O
13	viral	B
14	PR	I
15	-	O
16	mediated	O
17	processing	O
18	of	O
19	the	O
20	MuLV	O
21	TM	B
22	Env	I
23	protein	I
24	p15	O
25	(	O
26	E	O
27	).	O

1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O

1	After	O
2	the	O
3	first	O
4	28	O
5	patients	O
6	vincristine	O
7	was	O
8	replaced	O
9	by	O
10	teniposide	O
11	(	O
12	VM	O
13	-	O
14	26	O
15	)	O
16	due	O
17	to	O
18	neurotoxicity	O
19	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	two	O
6	genes	O
7	encoding	O
8	auxin	B
9	-	I
10	binding	I
11	proteins	I
12	from	O
13	tobacco	O
14	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	I
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	signature	O
6	-	O
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	This	O
2	structure	O
3	interconnects	O
4	specific	O
5	triplets	O
6	of	O
7	the	O
8	basal	O
9	bodies	O
10	with	O
11	the	O
12	microtubular	O
13	bundles	O
14	that	O
15	emerge	O
16	from	O
17	the	O
18	basal	O
19	apparatus	O
20	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	a	O
6	25	O
7	-	O
8	bp	O
9	promoter	O
10	element	O
11	previously	O
12	shown	O
13	to	O
14	be	O
15	important	O
16	for	O
17	the	O
18	G1	O
19	-	O
20	S	O
21	activation	O
22	of	O
23	the	O
24	human	B
25	thymidine	I
26	kinase	I
27	(	O
28	htk	B
29	)	O
30	promoter	O
31	in	O
32	growth	O
33	-	O
34	stimulated	O
35	cells	O
36	is	O
37	a	O
38	cellular	O
39	target	O
40	of	O
41	cyclin	B
42	A	I
43	and	O
44	the	O
45	p33cdk2	B
46	complexes	I
47	.	O

1	Diagnosis	O
2	of	O
3	phenylalanine	B
4	hydroxylase	I
5	deficiency	O
6	(	O
7	phenylketonuria	O
8	).	O

1	I	O
2	.	O

1	The	O
2	heterogeneity	O
3	of	O
4	bovine	B
5	IgG2	I
6	--	I
7	VIII	I
8	.	O

1	Petko	O
2	,	O
3	and	O
4	S	O
5	.	O

1	The	O
2	extraction	O
3	recovery	O
4	of	O
5	Amphotericin	O
6	B	O
7	from	O
8	the	O
9	cerebrospinal	O
10	fluid	O
11	is	O
12	higher	O
13	than	O
14	90	O
15	%	O
16	over	O
17	the	O
18	entire	O
19	linear	O
20	range	O
21	.	O

1	Such	O
2	a	O
3	change	O
4	may	O
5	involve	O
6	increased	O
7	mammary	O
8	utilization	O
9	of	O
10	pre	O
11	-	O
12	formed	O
13	long	O
14	-	O
15	chain	O
16	fatty	O
17	acid	O
18	and	O
19	increased	O
20	metabolism	O
21	of	O
22	glucose	O
23	via	O
24	glycolysis	O
25	.	O

1	Endometrial	O
2	biopsies	O
3	and	O
4	plasma	O
5	oestradiol	O
6	(	O
7	E2	O
8	)	O
9	and	O
10	progesterone	O
11	(	O
12	P4	O
13	)	O
14	levels	O
15	in	O
16	23	O
17	patients	O
18	were	O
19	evaluated	O
20	during	O
21	26	O
22	replacement	O
23	therapy	O
24	cycles	O
25	for	O
26	premature	O
27	ovarian	O
28	failure	O
29	.	O

1	Infant	O
2	aged	O
3	3	O
4	.	O
5	5	O
6	years	O
7	presents	O
8	persistence	O
9	of	O
10	primordial	O
11	vitreous	O
12	body	O
13	with	O
14	crystalline	O
15	dislocation	O
16	in	O
17	the	O
18	camera	O
19	aquosa	O
20	and	O
21	secondary	O
22	buphthalmos	O
23	of	O
24	the	O
25	left	O
26	eye	O
27	and	O
28	microphthalmos	O
29	with	O
30	dislocation	O
31	of	O
32	the	O
33	crystalline	O
34	in	O
35	the	O
36	vitreous	O
37	body	O
38	of	O
39	the	O
40	right	O
41	eye	O
42	.	O

1	The	O
2	paper	O
3	is	O
4	concerned	O
5	with	O
6	the	O
7	data	O
8	on	O
9	change	O
10	in	O
11	the	O
12	blood	O
13	level	O
14	of	O
15	ACTH	B
16	,	O
17	STH	B
18	,	O
19	TSH	B
20	,	O
21	cortisol	O
22	,	O
23	T3	O
24	,	O
25	insulin	B
26	,	O
27	C	B
28	-	I
29	peptide	I
30	during	O
31	a	O
32	25	O
33	-	O
34	minute	O
35	session	O
36	of	O
37	respiration	O
38	using	O
39	a	O
40	gaseous	O
41	hypoxic	O
42	mixture	O
43	with	O
44	10	O
45	%	O
46	oxygen	O
47	(	O
48	GHM	O
49	-	O
50	10	O
51	).	O

1	Multiple	O
2	SWI6	B
3	-	O
4	dependent	O
5	cis	O
6	-	O
7	acting	O
8	elements	O
9	control	O
10	SWI4	B
11	transcription	O
12	through	O
13	the	O
14	cell	O
15	cycle	O
16	.	O

1	The	O
2	c	B
3	-	I
4	Ets	I
5	-	I
6	1	I
7	oncoprotein	I
8	is	O
9	a	O
10	transcription	O
11	activator	O
12	that	O
13	specifically	O
14	binds	O
15	to	O
16	DNA	O
17	.	O

1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O

1	She	O
2	was	O
3	able	O
4	to	O
5	stand	O
6	unaided	O
7	by	O
8	3	O
9	years	O
10	of	O
11	age	O
12	with	O
13	then	O
14	progressive	O
15	worsening	O
16	of	O
17	motor	O
18	abilities	O
19	.	O

1	Two	O
2	new	O
3	temperature	O
4	-	O
5	sensitive	O
6	alleles	O
7	of	O
8	SEC3	B
9	,	O
10	1	O
11	of	O
12	10	O
13	late	O
14	-	O
15	acting	O
16	SEC	B
17	genes	I
18	required	O
19	for	O
20	targeting	O
21	or	O
22	fusion	O
23	of	O
24	post	O
25	-	O
26	Golgi	O
27	secretory	O
28	vesicles	O
29	to	O
30	the	O
31	plasma	O
32	membrane	O
33	in	O
34	Saccharomyces	O
35	cerevisiae	O
36	,	O
37	were	O
38	isolated	O
39	in	O
40	a	O
41	screen	O
42	for	O
43	temperature	O
44	-	O
45	sensitive	O
46	secretory	O
47	mutants	O
48	that	O
49	are	O
50	synthetically	O
51	lethal	O
52	with	O
53	sec4	B
54	-	I
55	8	I
56	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	I
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	Analysis	O
2	of	O
3	homologous	O
4	DNA	O
5	sequences	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	mouse	B
13	and	I
14	human	I
15	mts1	I
16	genes	I
17	:	O
18	kB	B
19	-	I
20	like	I
21	site	I
22	and	O
23	microsatellite	O
24	DNA	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	Tendon	O
2	also	O
3	shows	O
4	a	O
5	degree	O
6	of	O
7	extensibility	O
8	.	O

1	Mucosal	O
2	application	O
3	of	O
4	NCX	O
5	-	O
6	4016	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O

1	Their	O
2	mean	O
3	IOP	O
4	was	O
5	15	O
6	.	O
7	3	O
8	(	O
9	SD	O
10	3	O
11	.	O
12	7	O
13	)	O
14	mmHg	O
15	prior	O
16	to	O
17	induction	O
18	of	O
19	anesthesia	O
20	,	O
21	13	O
22	.	O
23	5	O
24	(	O
25	SD	O
26	3	O
27	.	O
28	5	O
29	)	O
30	mmHg	O
31	after	O
32	loss	O
33	of	O
34	eyelash	O
35	reflex	O
36	following	O
37	injection	O
38	of	O
39	methohexitone	O
40	,	O
41	16	O
42	.	O
43	1	O
44	(	O
45	SD	O
46	2	O
47	.	O
48	4	O
49	)	O
50	mmHg	O
51	after	O
52	cessation	O
53	of	O
54	muscle	O
55	fasciculations	O
56	induced	O
57	by	O
58	suxamethonium	O
59	,	O
60	19	O
61	.	O
62	2	O
63	(	O
64	SD	O
65	5	O
66	.	O
67	6	O
68	)	O
69	mmHg	O
70	after	O
71	cessation	O
72	of	O
73	convulsion	O
74	and	O
75	15	O
76	.	O
77	5	O
78	(	O
79	SD	O
80	4	O
81	.	O
82	4	O
83	)	O
84	mmHg	O
85	following	O
86	resumption	O
87	of	O
88	regular	O
89	spontaneous	O
90	respiration	O
91	.	O

1	A	O
2	subset	O
3	of	O
4	these	O
5	DMP1	B
6	recognition	I
7	sequences	I
8	containing	O
9	a	O
10	GGA	O
11	trinucleotide	O
12	core	O
13	can	O
14	also	O
15	function	O
16	as	O
17	Ets	B
18	-	I
19	responsive	I
20	elements	I
21	.	O

1	Once	O
2	NGF	B
3	administration	O
4	is	O
5	proven	O
6	effective	O
7	it	O
8	will	O
9	be	O
10	possible	O
11	to	O
12	develop	O
13	alternative	O
14	ways	O
15	of	O
16	NGF	B
17	administration	O
18	.	O

1	Src	B
2	homology	I
3	(	O
4	SH	B
5	)	O
6	domain	O
7	dependent	O
8	protein	O
9	-	O
10	protein	O
11	interactions	O
12	are	O
13	important	O
14	to	O
15	tyrosine	B
16	kinase	I
17	receptor	I
18	signal	O
19	transduction	O
20	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	Transient	O
2	transfections	O
3	of	O
4	a	O
5	construct	O
6	expressing	O
7	the	O
8	RNA	O
9	transcript	O
10	defined	O
11	by	O
12	clone	O
13	B1	O
14	.	O
15	1	O
16	into	O
17	D17	O
18	cells	O
19	led	O
20	to	O
21	the	O
22	expression	O
23	of	O
24	an	O
25	Env	B
26	/	O
27	Mlvi	B
28	-	I
29	4	I
30	fusion	O
31	protein	O
32	with	O
33	an	O
34	apparent	O
35	molecular	O
36	mass	O
37	of	O
38	33	O
39	kDa	O
40	.	O

1	Recombinant	B
2	human	I
3	TFIID	I
4	supported	O
5	weak	O
6	basal	O
7	transcription	O
8	in	O
9	heat	O
10	-	O
11	treated	O
12	nuclear	O
13	extracts	O
14	whereas	O
15	a	O
16	partially	O
17	purified	O
18	TFIID	B
19	fraction	O
20	from	O
21	HeLa	O
22	cells	O
23	reconstituted	O
24	a	O
25	maximal	O
26	level	O
27	of	O
28	transcription	O
29	.	O

1	Thyroid	O
2	function	O
3	tests	O
4	were	O
5	performed	O
6	on	O
7	300	O
8	admissions	O
9	,	O
10	leaving	O
11	707	O
12	untested	O
13	.	O

1	The	O
2	combination	O
3	of	O
4	F1	O
5	and	O
6	F2	O
7	which	O
8	was	O
9	the	O
10	best	O
11	predictor	O
12	of	O
13	CHD	O
14	in	O
15	this	O
16	population	O
17	(	O
18	G1	O
19	)	O
20	might	O
21	be	O
22	interpreted	O
23	as	O
24	reflecting	O
25	trunk	O
26	adiposity	O
27	mainly	O
28	abdominal	O
29	.	O

1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O

1	Like	O
2	scrotal	O
3	testes	O
4	,	O
5	undescended	O
6	testes	O
7	were	O
8	hypointense	O
9	to	O
10	fat	O
11	on	O
12	sequences	O
13	with	O
14	a	O
15	short	O
16	repetition	O
17	time	O
18	(	O
19	TR	O
20	)	O
21	and	O
22	echo	O
23	time	O
24	(	O
25	TE	O
26	)	O
27	in	O
28	all	O
29	cases	O
30	,	O
31	and	O
32	hyperintense	O
33	or	O
34	isointense	O
35	to	O
36	fat	O
37	on	O
38	long	O
39	TR	O
40	/	O
41	TE	O
42	sequences	O
43	in	O
44	all	O
45	but	O
46	two	O
47	cases	O
48	.	O

1	The	O
2	Laser	O
3	Scanning	O
4	Ophthalmoscope	O
5	enables	O
6	a	O
7	fundus	O
8	-	O
9	based	O
10	examination	O
11	and	O
12	therefore	O
13	allows	O
14	exact	O
15	comparison	O
16	between	O
17	morphologic	O
18	appearance	O
19	and	O
20	corresponding	O
21	function	O
22	.	O

1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O

1	Antibodies	O
2	made	O
3	against	O
4	fusion	O
5	protein	O
6	produced	O
7	by	O
8	the	O
9	DP1A	B
10	clone	O
11	reacted	O
12	specifically	O
13	with	O
14	DP	B
15	-	I
16	I	I
17	and	I
18	-	I
19	II	I
20	on	O
21	immunoblots	O
22	.	O

1	Lipiodol	O
2	was	O
3	covalently	O
4	conjugated	O
5	with	O
6	EDTB	O
7	.	O

1	Lacrimal	O
2	secretion	O
3	in	O
4	hyperthyroidism	O

1	However	O
2	,	O
3	after	O
4	repeated	O
5	infections	O
6	,	O
7	hypobiotic	O
8	larvae	O
9	were	O
10	numerous	O
11	.	O

1	Several	O
2	studies	O
3	have	O
4	characterized	O
5	the	O
6	upstream	O
7	regulatory	O
8	region	O
9	of	O
10	c	B
11	-	I
12	fos	I
13	,	O
14	and	O
15	identified	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	termed	O
21	the	O
22	cyclic	O
23	AMP	O
24	(	O
25	cAMP	O
26	)	O
27	response	O
28	elements	O
29	(	O
30	CREs	O
31	)	O
32	that	O
33	are	O
34	critical	O
35	for	O
36	c	B
37	-	I
38	fos	I
39	transcription	O
40	in	O
41	response	O
42	to	O
43	a	O
44	variety	O
45	of	O
46	extracellular	O
47	stimuli	O
48	.	O

1	In	O
2	Experiment	O
3	II	O
4	,	O
5	as	O
6	performing	O
7	moderate	O
8	supine	O
9	cycling	O
10	(	O
11	55	O
12	%	O
13	VO2	O
14	max	O
15	)	O
16	for	O
17	50	O
18	minutes	O
19	under	O
20	several	O
21	LBNP	O
22	conditions	O
23	in	O
24	5	O
25	sedentary	O
26	women	O
27	,	O
28	there	O
29	were	O
30	correspondingly	O
31	similar	O
32	changing	O
33	manners	O
34	of	O
35	the	O
36	cardiovascular	O
37	adjustments	O
38	to	O
39	each	O
40	of	O
41	the	O
42	phases	O
43	given	O
44	in	O
45	Experiment	O
46	I	O
47	.	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	Marked	O
2	sedative	O
3	activity	O
4	was	O
5	observed	O
6	with	O
7	9	O
8	-	O
9	methoxy	O
10	-	O
11	5	O
12	-	O
13	phenylpyrrolo	O
14	[	O
15	2	O
16	,	O
17	1	O
18	-	O
19	d	O
20	][	O
21	1	O
22	,	O
23	5	O
24	]	O
25	benzothiazepin	O
26	-	O
27	6	O
28	,	O
29	6	O
30	-	O
31	dioxide	O
32	(	O
33	NF19	O
34	)	O
35	and	O
36	9	O
37	-	O
38	chloro	O
39	-	O
40	5	O
41	-	O
42	p	O
43	-	O
44	nitrophenylpyrrolo	O
45	[	O
46	2	O
47	,	O
48	1	O
49	-	O
50	d	O
51	][	O
52	1	O
53	,	O
54	5	O
55	]	O
56	benzothiazepin	O
57	-	O
58	6	O
59	,	O
60	6	O
61	-	O
62	dioxide	O
63	(	O
64	NF20	O
65	).	O

1	The	O
2	ORF	O
3	4	O
4	gene	O
5	was	O
6	minimally	O
7	active	O
8	,	O
9	whereas	O
10	the	O
11	ORF	O
12	62	O
13	gene	O
14	gave	O
15	twofold	O
16	induction	O
17	;	O
18	both	O
19	genes	O
20	,	O
21	acting	O
22	together	O
23	,	O
24	gave	O
25	fivefold	O
26	induction	O
27	.	O

1	Many	O
2	cells	O
3	were	O
4	negative	O
5	for	O
6	endothelial	O
7	-	O
8	cell	O
9	markers	O
10	,	O
11	and	O
12	they	O
13	reacted	O
14	with	O
15	a	O
16	monoclonal	O
17	antibody	O
18	against	O
19	muscle	O
20	actin	B
21	.	O

1	Chenodeoxycholic	O
2	acid	O
3	(	O
4	cheno	O
5	)	O
6	and	O
7	ursodeoxycholic	O
8	acid	O
9	(	O
10	urso	O
11	)	O
12	dissolve	O
13	cholesterol	O
14	gallstones	O
15	in	O
16	man	O
17	.	O

1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O

1	Cloning	O
2	of	O
3	individual	O
4	ZI	O
5	domains	O
6	upstream	O
7	of	O
8	a	O
9	minimal	O
10	promoter	O
11	demonstrated	O
12	that	O
13	the	O
14	ZIA	O
15	,	O
16	ZIC	O
17	,	O
18	and	O
19	ZID	O
20	domains	O
21	,	O
22	but	O
23	not	O
24	the	O
25	ZIB	O
26	domain	O
27	,	O
28	are	O
29	TPA	O
30	responsive	O
31	.	O

1	Two	O
2	distinct	O
3	Salmonella	B
4	fimbrins	I
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	B
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O

1	A	O
2	favourable	O
3	response	O
4	was	O
5	achieved	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	amphotericin	O
11	B	O
12	and	O
13	cotrimoxazole	O
14	.	O

1	When	O
2	phencyclidine	O
3	was	O
4	administered	O
5	alone	O
6	,	O
7	overall	O
8	response	O
9	rate	O
10	decreased	O
11	and	O
12	percent	O
13	errors	O
14	increased	O
15	with	O
16	increasing	O
17	doses	O
18	.	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	Transcriptional	O
2	control	O
3	signals	O
4	of	O
5	a	O
6	herpes	B
7	simplex	I
8	virus	I
9	type	I
10	1	I
11	late	I
12	(	I
13	gamma	I
14	2	I
15	)	I
16	gene	I
17	lie	O
18	within	O
19	bases	O
20	-	O
21	34	O
22	to	O
23	+	O
24	124	O
25	relative	O
26	to	O
27	the	O
28	5	O
29	'	O
30	terminus	O
31	of	O
32	the	O
33	mRNA	O
34	.	O

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	Manifest	O
2	anxiety	O
3	of	O
4	Vietnam	O
5	returnees	O
6	and	O
7	undergraduates	O
8	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O

1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	The	O
2	active	O
3	derivatives	O
4	of	O
5	the	O
6	present	O
7	series	O
8	were	O
9	also	O
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	ORF113	B
6	contains	O
7	a	O
8	transmembrane	O
9	domain	O
10	.	O

1	The	O
2	biosynthesis	O
3	and	O
4	stability	O
5	of	O
6	the	O
7	three	O
8	mutant	O
9	proteins	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	the	O
16	wild	B
17	-	I
18	type	I
19	erbB	I
20	protein	I
21	,	O
22	and	O
23	all	O
24	three	O
25	retained	O
26	the	O
27	ability	O
28	to	O
29	transform	O
30	chicken	O
31	embryo	O
32	fibroblasts	O
33	.	O

1	With	O
2	the	O
3	increasing	O
4	use	O
5	of	O
6	ACE	B
7	inhibitors	O
8	,	O
9	the	O
10	incidence	O
11	of	O
12	rare	O
13	adverse	O
14	effects	O
15	such	O
16	as	O
17	potentially	O
18	lethal	O
19	pancreatitis	O
20	is	O
21	likely	O
22	to	O
23	increase	O
24	.	O

1	The	O
2	26S	B
3	rRNA	I
4	binding	I
5	ribosomal	I
6	protein	I
7	equivalent	O
8	to	O
9	bacterial	B
10	protein	I
11	L11	I
12	is	O
13	encoded	O
14	by	O
15	unspliced	O
16	duplicated	O
17	genes	O
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O

1	DATA	O
2	SYNTHESIS	O
3	:	O
4	Intracoronary	O
5	ultrasound	O
6	has	O
7	been	O
8	shown	O
9	to	O
10	improve	O
11	upon	O
12	demonstrated	O
13	weaknesses	O
14	of	O
15	coronary	O
16	angiography	O
17	.	O

1	Selective	O
2	translation	O
3	initiation	O
4	by	O
5	ribosome	O
6	jumping	O
7	in	O
8	adenovirus	O
9	-	O
10	infected	O
11	and	O
12	heat	O
13	-	O
14	shocked	O
15	cells	O
16	.	O

1	The	O
2	region	O
3	of	O
4	plasmid	O
5	pCM2	O
6	encoding	O
7	the	O
8	pathogenicity	B
9	locus	I
10	pat	I
11	-	I
12	1	I
13	was	O
14	mapped	O
15	by	O
16	deletion	O
17	analysis	O
18	and	O
19	complementation	O
20	studies	O
21	to	O
22	a	O
23	1	O
24	.	O
25	5	O
26	-	O
27	kb	O
28	Bg	B
29	/	I
30	II	I
31	/	O
32	SmaI	B
33	DNA	O
34	fragment	O
35	.	O

1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	findings	O
5	indicate	O
6	a	O
7	physical	O
8	barrier	O
9	of	O
10	oesophageal	O
11	surfactant	O
12	which	O
13	could	O
14	offer	O
15	some	O
16	degree	O
17	of	O
18	protection	O
19	against	O
20	gastro	O
21	-	O
22	oesophageal	O
23	reflux	O
24	but	O
25	one	O
26	which	O
27	is	O
28	particularly	O
29	prone	O
30	to	O
31	attack	O
32	by	O
33	bile	O
34	.	O

1	The	O
2	number	O
3	of	O
4	bacteria	O
5	in	O
6	the	O
7	lung	O
8	,	O
9	peripheral	O
10	white	O
11	blood	O
12	cell	O
13	and	O
14	BAL	O
15	fluid	O
16	cell	O
17	also	O
18	decreased	O
19	by	O
20	the	O
21	administration	O
22	of	O
23	FN	B
24	.	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	The	O
2	predicted	O
3	domain	O
4	structures	O
5	of	O
6	FkbB	B
7	and	O
8	FkbC	B
9	are	O
10	analogous	O
11	to	O
12	that	O
13	of	O
14	FkbA	B
15	and	O
16	comprise	O
17	30	O
18	fatty	B
19	-	I
20	acid	I
21	-	I
22	synthase	I
23	(	O
24	FAS	B
25	)-	O
26	like	O
27	domains	O
28	arranged	O
29	in	O
30	6	O
31	modules	O
32	.	O

1	As	O
2	a	O
3	sequence	O
4	-	O
5	specific	O
6	DNA	O
7	binding	O
8	transcription	O
9	factor	O
10	,	O
11	p53	B
12	specifically	O
13	binds	O
14	to	O
15	a	O
16	20	O
17	-	O
18	bp	O
19	consensus	O
20	motif	O
21	5	O
22	'-	O
23	PuPuPuC	O
24	(	O
25	A	O
26	/	O
27	T	O
28	)	O
29	(	O
30	T	O
31	/	O
32	A	O
33	)	O
34	GPyPyPyPuPuPuC	O
35	(	O
36	A	O
37	/	O
38	T	O
39	)(	O
40	T	O
41	/	O
42	A	O
43	)	O
44	GPyPyPy	O
45	-	O
46	3	O
47	'.	O

1	A	O
2	single	O
3	NMSC	O
4	was	O
5	present	O
6	in	O
7	69	O
8	.	O
9	4	O
10	%,	O
11	two	O
12	in	O
13	16	O
14	%,	O
15	three	O
16	in	O
17	6	O
18	.	O
19	4	O
20	%,	O
21	four	O
22	in	O
23	3	O
24	.	O
25	5	O
26	%,	O
27	five	O
28	to	O
29	nine	O
30	in	O
31	4	O
32	.	O
33	2	O
34	%,	O
35	and	O
36	0	O
37	.	O
38	5	O
39	%	O
40	had	O
41	ten	O
42	or	O
43	more	O
44	.	O

1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O

1	Molecular	O
2	cloning	O
3	and	O
4	sequencing	O
5	of	O
6	a	O
7	cDNA	O
8	encoding	O
9	SR	B
10	beta	I
11	revealed	O
12	that	O
13	SR	B
14	beta	I
15	is	O
16	a	O
17	transmembrane	O
18	protein	O
19	and	O
20	,	O
21	like	O
22	SR	B
23	alpha	I
24	and	O
25	SRP54	B
26	,	O
27	is	O
28	a	O
29	member	O
30	of	O
31	the	O
32	GTPase	B
33	superfamily	I
34	.	O

1	The	O
2	minimum	O
3	inhibitory	O
4	concentrations	O
5	(	O
6	MICs	O
7	)	O
8	of	O
9	ketoconazole	O
10	,	O
11	miconazole	O
12	,	O
13	itraconazole	O
14	,	O
15	fluconazole	O
16	,	O
17	and	O
18	amphotericin	O
19	B	O
20	were	O
21	significantly	O
22	influenced	O
23	by	O
24	the	O
25	inoculum	O
26	size	O
27	,	O
28	regardless	O
29	of	O
30	the	O
31	techniques	O
32	used	O
33	.	O

1	Courses	O
2	were	O
3	repeated	O
4	every	O
5	four	O
6	weeks	O
7	.	O

1	The	O
2	future	O
3	of	O
4	research	O
5	with	O
6	interferon	B
7	may	O
8	be	O
9	divided	O
10	into	O
11	three	O
12	areas	O
13	:	O
14	Efforts	O
15	must	O
16	be	O
17	made	O
18	to	O
19	determine	O
20	how	O
21	best	O
22	to	O
23	translate	O
24	the	O
25	in	O
26	vitro	O
27	synergy	O
28	into	O
29	clinically	O
30	meaningful	O
31	terms	O
32	;	O
33	in	O
34	order	O
35	to	O
36	exploit	O
37	the	O
38	fullest	O
39	potential	O
40	of	O
41	IFN	B
42	,	O
43	research	O
44	is	O
45	moving	O
46	toward	O
47	using	O
48	this	O
49	agent	O
50	earlier	O
51	in	O
52	disease	O
53	either	O
54	as	O
55	an	O
56	adjuvant	O
57	after	O
58	tumor	O
59	debulking	O
60	or	O
61	after	O
62	initial	O
63	diagnosis	O
64	;	O
65	the	O
66	medical	O
67	community	O
68	must	O
69	rethink	O
70	the	O
71	natural	O
72	history	O
73	of	O
74	some	O
75	diseases	O
76	,	O
77	because	O
78	the	O
79	fullest	O
80	potential	O
81	of	O
82	the	O
83	biologic	O
84	agents	O
85	will	O
86	most	O
87	likely	O
88	manifest	O
89	itself	O
90	when	O
91	these	O
92	agents	O
93	are	O
94	used	O
95	together	O
96	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	Finally	O
2	,	O
3	nonphotosynthetic	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	tscA	B
9	-	I
10	lacking	I
11	photosystem	I
12	I	I
13	mutant	I
14	,	O
15	H13	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O

1	PFK	B
2	-	I
3	A	I
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	B
16	-	I
17	B	I
18	and	O
19	PFK	B
20	-	I
21	C	I
22	genes	I
23	.	O

1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O

1	Of	O
2	165	O
3	women	O
4	with	O
5	non	O
6	-	O
7	malignant	O
8	diagnoses	O
9	26	O
10	(	O
11	16	O
12	%)	O
13	had	O
14	CA	B
15	125	I
16	levels	O
17	in	O
18	excess	O
19	of	O
20	35	O
21	U	O
22	/	O
23	ml	O
24	and	O
25	8	O
26	(	O
27	5	O
28	%)	O
29	greater	O
30	than	O
31	65	O
32	U	O
33	/	O
34	ml	O
35	.	O

1	According	O
2	to	O
3	Sugiura	O
4	'	O
5	s	O
6	classification	O
7	,	O
8	they	O
9	consisted	O
10	of	O
11	Type	O
12	Ia	O
13	in	O
14	63	O
15	%,	O
16	Type	O
17	Ib	O
18	in	O
19	11	O
20	%,	O
21	Type	O
22	II	O
23	in	O
24	11	O
25	%,	O
26	and	O
27	Type	O
28	III	O
29	in	O
30	16	O
31	%.	O

1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	B
19	(	O
20	TM	B
21	),	O
22	betathromboglobulin	B
23	(	O
24	beta	B
25	-	I
26	TG	I
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	B
36	activator	I
37	-	I
38	inhibitor	I
39	(	O
40	pAI	B
41	-	I
42	1	I
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O

1	Lys	O
2	(	O
3	193	O
4	)	O
5	and	O
6	Arg	O
7	(	O
8	194	O
9	),	O
10	located	O
11	at	O
12	the	O
13	COOH	O
14	-	O
15	terminal	O
16	end	O
17	of	O
18	HD	B
19	,	O
20	are	O
21	essential	O
22	for	O
23	dimerization	O
24	.	O

1	Both	O
2	TRE	O
3	-	O
4	like	O
5	elements	O
6	were	O
7	capable	O
8	of	O
9	binding	O
10	AP1	B
11	.	O

1	Many	O
2	studies	O
3	have	O
4	pointed	O
5	out	O
6	the	O
7	possibility	O
8	of	O
9	"	O
10	masked	O
11	"	O
12	organic	O
13	factors	O
14	in	O
15	erectile	O
16	impotence	O
17	,	O
18	detectable	O
19	only	O
20	by	O
21	means	O
22	of	O
23	laboratory	O
24	investigations	O
25	:	O
26	mild	O
27	hypogonadism	O
28	,	O
29	hyperprolactinemia	O
30	,	O
31	occlusions	O
32	selectively	O
33	located	O
34	at	O
35	the	O
36	site	O
37	of	O
38	the	O
39	sexual	O
40	arteries	O
41	,	O
42	venous	O
43	incompetence	O
44	,	O
45	subclinical	O
46	neuropathies	O
47	.	O

1	The	O
2	degree	O
3	of	O
4	hypoperfusion	O
5	was	O
6	slightly	O
7	related	O
8	to	O
9	decrease	O
10	in	O
11	FEV1	O
12	.	O
13	0	O
14	%,	O
15	V25	O
16	and	O
17	PaO2	O
18	and	O
19	increase	O
20	in	O
21	circulating	O
22	blood	O
23	volume	O
24	and	O
25	peripheral	O
26	red	O
27	blood	O
28	cell	O
29	counts	O
30	.	O

1	Cleidocranial	O
2	dysostosis	O

1	Detection	O
2	of	O
3	airborne	O
4	Mycobacterium	O
5	tuberculosis	O
6	by	O
7	air	O
8	filtration	O
9	and	O
10	polymerase	O
11	chain	O
12	reaction	O
13	.	O

1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	B
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O

1	12	O
2	healthy	O
3	women	O
4	(	O
5	age	O
6	18	O
7	-	O
8	38	O
9	years	O
10	)	O
11	were	O
12	examined	O
13	using	O
14	the	O
15	2	O
16	-	O
17	hour	O
18	'	O
19	s	O
20	method	O
21	of	O
22	passive	O
23	leg	O
24	rising	O
25	(	O
26	PLR	O
27	)	O
28	in	O
29	follicular	O
30	(	O
31	FP	O
32	)	O
33	and	O
34	luteal	O
35	(	O
36	LP	O
37	)	O
38	phases	O
39	of	O
40	normal	O
41	ovulatory	O
42	cycle	O
43	.	O

1	Mechanism	O
2	of	O
3	the	O
4	t	O
5	(	O
6	14	O
7	;	O
8	18	O
9	)	O
10	chromosomal	O
11	translocation	O
12	:	O
13	structural	O
14	analysis	O
15	of	O
16	both	O
17	derivative	O
18	14	O
19	and	O
20	18	O
21	reciprocal	O
22	partners	O
23	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	Splice	O
2	-	O
3	junction	O
4	elements	O
5	and	O
6	intronic	O
7	sequences	O
8	regulate	O
9	alternative	O
10	splicing	O
11	of	O
12	the	O
13	Drosophila	O
14	myosin	B
15	heavy	I
16	chain	I
17	gene	I
18	transcript	O
19	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	For	O
2	replication	O
3	reporter	O
4	constructs	O
5	where	O
6	E1	B
7	and	O
8	E2	B
9	are	O
10	supplied	O
11	in	O
12	trans	O
13	by	O
14	the	O
15	respective	O
16	expression	O
17	vectors	O
18	,	O
19	distance	O
20	between	O
21	the	O
22	half	O
23	sites	O
24	seems	O
25	to	O
26	play	O
27	a	O
28	major	O
29	role	O
30	,	O
31	yet	O
32	the	O
33	phasing	O
34	relationships	O
35	are	O
36	measurable	O
37	.	O

1	Relationships	O
2	with	O
3	the	O
4	acquired	O
5	immune	O
6	deficiency	O
7	syndrome	O
8	.	O

1	This	O
2	investigation	O
3	was	O
4	undertaken	O
5	to	O
6	determine	O
7	whether	O
8	consuming	O
9	several	O
10	small	O
11	feedings	O
12	of	O
13	preexercise	O
14	carbohydrate	O
15	(	O
16	CHO	O
17	),	O
18	rather	O
19	than	O
20	a	O
21	single	O
22	bolus	O
23	,	O
24	would	O
25	affect	O
26	blood	O
27	glucose	O
28	and	O
29	insulin	B
30	responses	O
31	during	O
32	rest	O
33	and	O
34	exercise	O
35	.	O

1	The	O
2	specificity	O
3	of	O
4	action	O
5	of	O
6	C	B
7	/	I
8	EBP	I
9	family	I
10	members	I
11	may	O
12	be	O
13	derived	O
14	from	O
15	the	O
16	characteristics	O
17	of	O
18	each	O
19	factor	O
20	,	O
21	including	O
22	the	O
23	expression	O
24	profiles	O
25	,	O
26	the	O
27	DNA	O
28	binding	O
29	affinities	O
30	,	O
31	the	O
32	cofactors	O
33	,	O
34	and	O
35	so	O
36	on	O
37	,	O
38	in	O
39	addition	O
40	to	O
41	the	O
42	DNA	O
43	binding	O
44	specificities	O
45	.	O

1	The	O
2	96	O
3	-	O
4	bp	O
5	insert	O
6	contained	O
7	a	O
8	termination	O
9	signal	O
10	which	O
11	caused	O
12	the	O
13	premature	O
14	termination	O
15	of	O
16	the	O
17	protein	O
18	,	O
19	leading	O
20	to	O
21	the	O
22	generation	O
23	of	O
24	a	O
25	p53	B
26	product	I
27	9	O
28	amino	O
29	acids	O
30	shorter	O
31	than	O
32	usual	O
33	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	Here	O
2	we	O
3	present	O
4	genetic	O
5	evidence	O
6	suggesting	O
7	that	O
8	PP2A	B
9	functions	O
10	downstream	O
11	of	O
12	Ras1	B
13	in	O
14	the	O
15	Sevenless	B
16	receptor	I
17	tyrosine	I
18	kinase	I
19	(	O
20	RTK	B
21	)	O
22	signal	O
23	transduction	O
24	pathway	O
25	that	O
26	specifies	O
27	R7	O
28	photoreceptor	O
29	cell	O
30	fate	O
31	in	O
32	the	O
33	developing	O
34	Drosophila	O
35	eye	O
36	.	O

1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	B
18	-	I
19	chimaerin	I
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O

1	In	O
2	the	O
3	control	O
4	group	O
5	,	O
6	platelet	O
7	markers	O
8	increased	O
9	1	O
10	h	O
11	after	O
12	surgery	O
13	.	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	A	O
2	promising	O
3	new	O
4	cement	O
5	,	O
6	4	O
7	-	O
8	META	O
9	/	O
10	MMA	O
11	-	O
12	TBB	O
13	opaque	O
14	resin	O
15	,	O
16	has	O
17	shown	O
18	remarkable	O
19	adhesive	O
20	properties	O
21	as	O
22	a	O
23	bone	O
24	cement	O
25	in	O
26	vivo	O
27	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	demonstrated	O
7	a	O
8	unique	O
9	mechanism	O
10	of	O
11	action	O
12	of	O
13	8	O
14	-	O
15	Cl	O
16	-	O
17	cAMP	O
18	in	O
19	the	O
20	regulation	O
21	of	O
22	these	O
23	kinase	O
24	isozymes	O
25	in	O
26	HL	O
27	-	O
28	60	O
29	human	O
30	promyelocytic	O
31	leukemia	O
32	cells	O
33	.	O

1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O

1	Many	O
2	canonical	O
3	TATA	O
4	sequences	O
5	are	O
6	present	O
7	upstream	O
8	from	O
9	these	O
10	VZV	O
11	transcriptional	O
12	start	O
13	sites	O
14	but	O
15	,	O
16	apparently	O
17	,	O
18	are	O
19	not	O
20	used	O
21	.	O

1	We	O
2	have	O
3	tested	O
4	the	O
5	function	O
6	of	O
7	two	O
8	potential	O
9	NF	B
10	-	I
11	kappaB	I
12	-	I
13	like	I
14	sites	I
15	present	O
16	in	O
17	the	O
18	PAI	B
19	-	I
20	2	I
21	proximal	I
22	promoter	I
23	for	O
24	responsiveness	O
25	to	O
26	TNFalpha	B
27	using	O
28	chloramphenicol	B
29	acetyl	I
30	transferase	I
31	reporter	I
32	gene	I
33	deletion	O
34	and	O
35	mutation	O
36	analyses	O
37	.	O

1	A	O
2	synthetic	O
3	oligonucleotide	O
4	containing	O
5	the	O
6	SRE	O
7	sequence	O
8	from	O
9	the	O
10	mouse	B
11	c	I
12	-	I
13	fos	I
14	gene	I
15	promoter	I
16	(-	O
17	299	O
18	to	O
19	-	O
20	322	O
21	)	O
22	was	O
23	radioactively	O
24	labeled	O
25	,	O
26	used	O
27	as	O
28	a	O
29	probe	O
30	for	O
31	the	O
32	mobility	O
33	shift	O
34	assay	O
35	and	O
36	Southwestern	O
37	(	O
38	DNA	O
39	-	O
40	protein	O
41	)	O
42	blotting	O
43	,	O
44	and	O
45	also	O
46	used	O
47	for	O
48	sequence	O
49	-	O
50	specific	O
51	affinity	O
52	chromatography	O
53	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	The	O
2	structural	O
3	genes	O
4	encoding	O
5	glyceraldehyde	B
6	-	I
7	3	I
8	-	I
9	phosphate	I
10	dehydrogenase	I
11	(	O
12	GAPDH	B
13	),	O
14	3	B
15	-	I
16	phosphoglycerate	I
17	kinase	I
18	(	O
19	PGK	B
20	)	O
21	and	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	part	O
27	of	O
28	triosephosphate	B
29	isomerase	I
30	(	O
31	TIM	B
32	)	O
33	from	O
34	mesophilic	O
35	Bacillus	O
36	megaterium	O
37	DSM319	O
38	have	O
39	been	O
40	cloned	O
41	as	O
42	a	O
43	gene	O
44	cluster	O
45	(	O
46	gap	B
47	operon	I
48	)	O
49	by	O
50	complementation	O
51	of	O
52	an	O
53	Escherichia	O
54	coli	O
55	gap	B
56	amber	I
57	mutant	I
58	.	O

1	T1	O
2	-	O
3	weighted	O
4	MRI	O
5	on	O
6	the	O
7	49th	O
8	postoperative	O
9	day	O
10	demonstrated	O
11	bilateral	O
12	and	O
13	symmetrical	O
14	hyperintense	O
15	lesions	O
16	in	O
17	the	O
18	globus	O
19	pallidus	O
20	.	O

1	The	O
2	zta	B
3	transactivator	I
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	-	O
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	B
24	-	I
25	1	I
26	and	O
27	ZRE	B
28	sites	I
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O

1	Dynamics	O
2	of	O
3	hospital	O
4	stay	O
5	in	O
6	peptic	O
7	ulcer	O
8	patients	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	The	O
2	mobility	O
3	shift	O
4	assay	O
5	of	O
6	the	O
7	65	O
8	bp	O
9	(-	O
10	318	O
11	/	O
12	-	O
13	254	O
14	)	O
15	fragment	O
16	with	O
17	nuclear	O
18	extract	O
19	from	O
20	the	O
21	dark	O
22	-	O
23	adapted	O
24	sample	O
25	showed	O
26	an	O
27	additional	O
28	band	O
29	,	O
30	not	O
31	seen	O
32	with	O
33	the	O
34	light	O
35	-	O
36	grown	O
37	sample	O
38	.	O

1	Pharmacological	O
2	and	O
3	pharmacokinetic	O
4	characteristics	O
5	of	O
6	the	O
7	non	O
8	-	O
9	ionic	O
10	monomeric	O
11	X	O
12	-	O
13	ray	O
14	contrast	O
15	agent	O
16	iopromide	O
17	(	O
18	Ultravist	O
19	,	O
20	CAS	O
21	73334	O
22	-	O
23	07	O
24	-	O
25	3	O
26	)	O
27	were	O
28	evaluated	O
29	in	O
30	preclinical	O
31	studies	O
32	.	O

1	The	O
2	size	O
3	of	O
4	the	O
5	group	O
6	allocated	O
7	to	O
8	the	O
9	good	O
10	compliance	O
11	category	O
12	by	O
13	the	O
14	use	O
15	of	O
16	the	O
17	digoxin	O
18	marker	O
19	was	O
20	equivalent	O
21	in	O
22	size	O
23	to	O
24	a	O
25	group	O
26	of	O
27	patients	O
28	who	O
29	had	O
30	returned	O
31	less	O
32	than	O
33	15	O
34	%	O
35	of	O
36	their	O
37	prescribed	O
38	dose	O
39	or	O
40	reported	O
41	a	O
42	deviation	O
43	of	O
44	less	O
45	than	O
46	6	O
47	%	O
48	from	O
49	their	O
50	prescription	O
51	.	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	These	O
2	same	O
3	regions	O
4	showed	O
5	remarkable	O
6	homology	O
7	to	O
8	two	O
9	invertebrate	O
10	proteins	O
11	,	O
12	CNC	B
13	and	O
14	skin	B
15	-	I
16	1	I
17	,	O
18	postulated	O
19	to	O
20	regulate	O
21	embryonic	O
22	development	O
23	in	O
24	Drosophila	O
25	melanogaster	O
26	and	O
27	Caenorhabditis	O
28	elegans	O
29	,	O
30	respectively	O
31	.	O

1	After	O
2	6	O
3	h	O
4	of	O
5	reperfusion	O
6	,	O
7	PO2	O
8	/	O
9	FlO2	O
10	ratio	O
11	was	O
12	significantly	O
13	better	O
14	after	O
15	Combined	O
16	Therapy	O
17	(	O
18	372	O
19	+/-	O
20	52	O
21	mm	O
22	Hg	O
23	)	O
24	than	O
25	in	O
26	the	O
27	Recipient	O
28	Instilled	O
29	(	O
30	117	O
31	+/-	O
32	47	O
33	mm	O
34	Hg	O
35	)	O
36	and	O
37	Control	O
38	groups	O
39	(	O
40	87	O
41	+/-	O
42	26	O
43	mm	O
44	Hg	O
45	),	O
46	with	O
47	intermediate	O
48	values	O
49	in	O
50	Donor	O
51	Aerosol	O
52	dogs	O
53	(	O
54	232	O
55	+/-	O
56	64	O
57	mm	O
58	Hg	O
59	).	O

1	A	O
2	triple	B
3	-	I
4	mutant	I
5	TBP	I
6	(	O
7	R231E	O
8	+	O
9	R235E	O
10	+	O
11	R239S	O
12	)	O
13	had	O
14	greatly	O
15	reduced	O
16	activity	O
17	for	O
18	yeast	B
19	U6	I
20	snRNA	I
21	gene	I
22	transcription	O
23	while	O
24	remaining	O
25	active	O
26	for	O
27	Pol	B
28	II	I
29	basal	O
30	transcription	O
31	.	O

1	These	O
2	bacteria	O
3	produce	O
4	and	O
5	export	O
6	proteins	O
7	capable	O
8	of	O
9	specific	O
10	interactions	O
11	with	O
12	key	O
13	mammalian	O
14	cell	O
15	regulatory	O
16	molecules	O
17	in	O
18	order	O
19	to	O
20	derail	O
21	the	O
22	normal	O
23	functions	O
24	of	O
25	the	O
26	cells	O
27	.	O

1	Hematopoietic	B
2	growth	I
3	factors	I
4	have	O
5	already	O
6	had	O
7	an	O
8	enormous	O
9	impact	O
10	on	O
11	transfusion	O
12	practice	O
13	by	O
14	eliminating	O
15	or	O
16	reducing	O
17	the	O
18	need	O
19	for	O
20	red	O
21	blood	O
22	cell	O
23	transfusions	O
24	in	O
25	a	O
26	variety	O
27	of	O
28	anemic	O
29	states	O
30	characterized	O
31	by	O
32	an	O
33	absolute	O
34	or	O
35	relative	O
36	decrease	O
37	in	O
38	erythropoietin	B
39	.	O

1	Taken	O
2	together	O
3	,	O
4	we	O
5	provide	O
6	evidence	O
7	for	O
8	the	O
9	existence	O
10	of	O
11	an	O
12	activator	O
13	,	O
14	NFE	B
15	,	O
16	which	O
17	in	O
18	combination	O
19	with	O
20	the	O
21	p50	B
22	and	O
23	c	B
24	-	I
25	Rel	I
26	proteins	I
27	,	O
28	are	O
29	part	O
30	of	O
31	the	O
32	transcription	O
33	factor	O
34	machinery	O
35	that	O
36	regulates	O
37	3	O
38	'	O
39	enhancer	O
40	activity	O
41	,	O
42	and	O
43	thus	O
44	the	O
45	control	O
46	of	O
47	the	O
48	IgH	B
49	locus	I
50	in	O
51	late	O
52	B	O
53	lymphocyte	O
54	development	O
55	.	O

1	Statistics	O
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O

1	Malaria	O
2	,	O
3	anaemia	O
4	,	O
5	and	O
6	HIV	O
7	-	O
8	1	O
9	transmission	O
10	in	O
11	central	O
12	Africa	O
13	.	O

1	At	O
2	cuticular	O
3	positions	O
4	exhibiting	O
5	the	O
6	Brd	B
7	bristle	I
8	loss	I
9	phenotype	I
10	,	O
11	we	O
12	have	O
13	found	O
14	that	O
15	the	O
16	progeny	O
17	of	O
18	the	O
19	multiplied	O
20	SOPs	O
21	develop	O
22	aberrantly	O
23	,	O
24	in	O
25	that	O
26	neurons	O
27	and	O
28	thecogen	O
29	(	O
30	sheath	O
31	)	O
32	cells	O
33	appear	O
34	but	O
35	not	O
36	trichogen	O
37	(	O
38	shaft	O
39	)	O
40	and	O
41	tormogen	O
42	(	O
43	socket	O
44	)	O
45	cells	O
46	.	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	B
20	.	I
21	8Ss	I
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	E2	B
2	point	O
3	mutants	O
4	unable	O
5	to	O
6	inhibit	O
7	cell	O
8	growth	O
9	did	O
10	not	O
11	repress	O
12	cdc25A	B
13	and	O
14	cdc25B	B
15	expression	O
16	,	O
17	nor	O
18	did	O
19	the	O
20	cell	O
21	cycle	O
22	inhibitors	O
23	hydroxyurea	O
24	and	O
25	mimosine	O
26	.	O

1	The	O
2	model	O
3	is	O
4	able	O
5	to	O
6	anticipate	O
7	why	O
8	the	O
9	effect	O
10	of	O
11	water	O
12	fluoridation	O
13	on	O
14	caries	O
15	prevalence	O
16	is	O
17	most	O
18	pronounced	O
19	when	O
20	caries	O
21	is	O
22	diagnosed	O
23	at	O
24	cavity	O
25	level	O
26	.	O

1	The	O
2	major	B
3	49	I
4	-	I
5	kDa	I
6	core	I
7	protein	I
8	in	O
9	the	O
10	liver	O
11	HSPG	B
12	preparation	O
13	was	O
14	found	O
15	to	O
16	be	O
17	reactive	O
18	to	O
19	an	O
20	antibody	O
21	that	O
22	specifically	O
23	recognizes	O
24	the	O
25	cytoplasmic	O
26	domain	O
27	of	O
28	fibroglycan	B
29	.	O

1	All	O
2	subsequent	O
3	patients	O
4	were	O
5	treated	O
6	at	O
7	the	O
8	maximal	O
9	tolerated	O
10	dose	O
11	of	O
12	EDXR	O
13	(	O
14	35	O
15	mg	O
16	/	O
17	m2	O
18	/	O
19	day	O
20	).	O

1	Ectopic	O
2	expression	O
3	of	O
4	Apo	B
5	-	I
6	3	I
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O

1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	B
8	-	I
9	1	I
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	B
26	-	I
27	1	I
28	transcription	I
29	factors	I
30	mediated	O
31	TGF	B
32	-	I
33	beta1	I
34	-	O
35	and	O
36	BMP	B
37	-	I
38	2	I
39	-	O
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	B
45	alpha1	I
46	)	I
47	collagen	I
48	I	I
49	gene	I
50	as	O
51	well	O
52	as	O
53	TGF	B
54	-	I
55	beta1	I
56	-	O
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	B
62	hormone	I
63	(	O
64	PTH	B
65	)/	O
66	PTH	B
67	-	I
68	related	I
69	peptide	I
70	(	I
71	PTHrP	I
72	)	I
73	receptor	I
74	.	O

1	However	O
2	,	O
3	mutations	O
4	in	O
5	the	O
6	HNF	B
7	-	I
8	4	I
9	binding	I
10	site	I
11	on	O
12	element	B
13	CIIB	I
14	and	O
15	inhibition	O
16	of	O
17	HNF	B
18	-	I
19	4	I
20	synthesis	O
21	in	O
22	HepG2	O
23	cells	O
24	by	O
25	antisense	O
26	HNF	B
27	-	I
28	4	I
29	constructs	I
30	decreased	O
31	the	O
32	apoCII	B
33	promoter	I
34	activity	O
35	to	O
36	25	O
37	-	O
38	40	O
39	%	O
40	of	O
41	the	O
42	control	O
43	,	O
44	indicating	O
45	that	O
46	HNF	B
47	-	I
48	4	I
49	is	O
50	a	O
51	positive	O
52	regulator	O
53	of	O
54	the	O
55	apoCII	B
56	gene	I
57	.	O

1	The	O
2	mRNA	O
3	identified	O
4	in	O
5	both	O
6	human	O
7	and	O
8	rat	O
9	cells	O
10	with	O
11	the	O
12	human	B
13	clathrin	I
14	clone	O
15	revealed	O
16	transcripts	O
17	of	O
18	approximately	O
19	6	O
20	.	O
21	5	O
22	kb	O
23	,	O
24	which	O
25	is	O
26	consistent	O
27	with	O
28	the	O
29	predicted	O
30	180	O
31	kDa	O
32	molecular	O
33	weight	O
34	of	O
35	the	O
36	clathrin	B
37	heavy	I
38	chain	I
39	.	O

1	A	O
2	second	O
3	even	O
4	more	O
5	significant	O
6	match	O
7	to	O
8	this	O
9	E	O
10	.	O
11	coli	O
12	region	O
13	was	O
14	found	O
15	in	O
16	the	O
17	retroviral	B
18	ribonuclease	I
19	H	I
20	(	O
21	RNase	B
22	H	I
23	)	O
24	domain	O
25	,	O
26	and	O
27	corresponds	O
28	precisely	O
29	to	O
30	a	O
31	region	O
32	that	O
33	has	O
34	been	O
35	aligned	O
36	by	O
37	previous	O
38	investigators	O
39	with	O
40	the	O
41	E	B
42	.	I
43	coli	I
44	RNase	I
45	H	I
46	,	O
47	suggesting	O
48	that	O
49	Pol	B
50	I	I
51	helices	O
52	O	O
53	and	O
54	P	O
55	are	O
56	homologous	O
57	to	O
58	helices	O
59	A	O
60	and	O
61	D	O
62	of	O
63	the	O
64	RNase	B
65	H	I
66	crystal	O
67	structure	O
68	,	O
69	respectively	O
70	.	O

1	Although	O
2	the	O
3	binding	O
4	of	O
5	IE2	B
6	86	I
7	to	O
8	nonphosphorylated	O
9	full	B
10	-	I
11	length	I
12	CREB	I
13	or	O
14	deltaCREB	B
15	is	O
16	minimal	O
17	,	O
18	IE2	B
19	86	I
20	does	O
21	form	O
22	complexes	O
23	with	O
24	p300	B
25	and	O
26	the	O
27	CREB	B
28	-	I
29	binding	I
30	protein	I
31	(	O
32	CBP	B
33	),	O
34	which	O
35	in	O
36	turn	O
37	bind	O
38	to	O
39	CREB	B
40	and	O
41	can	O
42	serve	O
43	as	O
44	adaptor	O
45	proteins	O
46	for	O
47	CREB	B
48	function	O
49	.	O

1	In	O
2	concept	O
3	II	O
4	62	O
5	patients	O
6	were	O
7	treated	O
8	with	O
9	selective	O
10	vagotomy	O
11	and	O
12	pyloroplasty	O
13	.	O

1	Following	O
2	the	O
3	patients	O
4	during	O
5	a	O
6	course	O
7	of	O
8	therapy	O
9	with	O
10	a	O
11	selective	O
12	vasodilator	O
13	calcium	O
14	antagonist	O
15	,	O
16	the	O
17	beta	O
18	-	O
19	adrenergic	O
20	reflex	O
21	vasodilation	O
22	became	O
23	substantially	O
24	attenuated	O
25	but	O
26	was	O
27	preserved	O
28	during	O
29	a	O
30	placebo	O
31	course	O
32	of	O
33	therapy	O
34	.	O

1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O

1	In	O
2	our	O
3	previous	O
4	studies	O
5	,	O
6	transcriptional	O
7	activation	O
8	was	O
9	shown	O
10	to	O
11	correlate	O
12	with	O
13	IEP86	B
14	binding	O
15	to	O
16	both	O
17	the	O
18	TATA	B
19	-	I
20	box	I
21	binding	I
22	protein	I
23	(	O
24	TBP	B
25	)	O
26	and	O
27	the	O
28	transcription	O
29	factor	O
30	bound	O
31	upstream	O
32	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	EMSA	O
2	competition	O
3	experiments	O
4	showed	O
5	that	O
6	mutations	O
7	within	O
8	the	O
9	direct	O
10	repeats	O
11	failed	O
12	to	O
13	compete	O
14	for	O
15	binding	O
16	of	O
17	the	O
18	nuclear	O
19	proteins	O
20	to	O
21	labeled	O
22	wild	O
23	type	O
24	oligonucleotide	O
25	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	putative	O
10	adhesive	O
11	molecule	O
12	from	O
13	P	O
14	.	O
15	falciparum	O
16	that	O
17	shares	O
18	both	O
19	sequence	O
20	and	O
21	structural	O
22	similarities	O
23	with	O
24	a	O
25	sporozoite	O
26	surface	O
27	molecule	O
28	from	O
29	Plasmodium	O
30	termed	O
31	the	O
32	thrombospondin	B
33	-	I
34	related	I
35	anonymous	I
36	protein	I
37	(	O
38	TRAP	B
39	)	O
40	and	O
41	,	O
42	to	O
43	a	O
44	lesser	O
45	extent	O
46	,	O
47	with	O
48	the	O
49	circumsporozoite	B
50	(	I
51	CS	I
52	)	I
53	protein	I
54	.	O

1	Primary	O
2	amenorrhoea	O
3	in	O
4	a	O
5	phenotypically	O
6	female	O
7	individual	O
8	with	O
9	a	O
10	karyotype	O
11	46	O
12	,	O
13	xy	O
14	and	O
15	bilateral	O
16	gonadoblastoma	O

1	We	O
2	suggest	O
3	that	O
4	MotA	B
5	and	O
6	AsiA	B
7	may	O
8	function	O
9	like	O
10	certain	O
11	eukaryotic	B
12	TAFs	I
13	(	O
14	TATA	B
15	binding	I
16	protein	I
17	(	I
18	TBP	I
19	)	I
20	associated	I
21	factors	I
22	)	O
23	whose	O
24	binding	O
25	to	O
26	TBP	B
27	results	O
28	in	O
29	transcription	O
30	from	O
31	new	O
32	core	O
33	promoter	O
34	sequences	O
35	.	O

1	This	O
2	relatively	O
3	simple	O
4	and	O
5	easily	O
6	performed	O
7	technique	O
8	of	O
9	measuring	O
10	deep	O
11	muscle	O
12	temperature	O
13	appears	O
14	to	O
15	be	O
16	a	O
17	useful	O
18	adjunct	O
19	in	O
20	choosing	O
21	the	O
22	amputation	O
23	level	O
24	.	O

1	The	O
2	cdr1	B
3	sequence	I
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	O
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	B
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	B
12	promoter	I
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	I
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	B
26	E1A	I
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	B
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	For	O
2	colostral	O
3	milk	O
4	there	O
5	was	O
6	a	O
7	significant	O
8	correlation	O
9	of	O
10	vitamin	O
11	K1	O
12	to	O
13	cholesterol	O
14	(	O
15	r	O
16	=	O
17	0	O
18	.	O
19	62	O
20	)	O
21	but	O
22	not	O
23	to	O
24	total	O
25	lipid	O
26	or	O
27	phospholipid	O
28	suggesting	O
29	a	O
30	role	O
31	for	O
32	cholesterol	O
33	in	O
34	the	O
35	secretion	O
36	of	O
37	vitamin	O
38	K1	O
39	into	O
40	colostral	O
41	milk	O
42	.	O

1	The	O
2	sera	O
3	and	O
4	nasal	O
5	secretions	O
6	of	O
7	142	O
8	patients	O
9	,	O
10	who	O
11	were	O
12	positive	O
13	in	O
14	HD	O
15	or	O
16	mites	O
17	skin	O
18	test	O
19	,	O
20	were	O
21	subjected	O
22	to	O
23	a	O
24	radioallergosorbent	O
25	test	O
26	(	O
27	RAST	O
28	)	O
29	for	O
30	estimating	O
31	the	O
32	specific	O
33	IgE	B
34	antibody	I
35	activity	O
36	to	O
37	mites	O
38	.	O

1	Substrates	O
2	include	O
3	the	O
4	p21	B
5	(	O
6	ras	B
7	)	O
8	proteins	O
9	,	O
10	nuclear	B
11	lamins	I
12	,	O
13	and	O
14	a	O
15	series	O
16	of	O
17	retinal	O
18	proteins	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	O
12	/	O
13	H1	O
14	domain	O
15	was	O
16	sufficient	O
17	for	O
18	coactivation	O
19	of	O
20	Zta	B
21	transcription	O
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	B
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	B
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	excess	O
6	prevalence	O
7	of	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	)	O
18	infection	O
19	in	O
20	US	O
21	black	O
22	and	O
23	Hispanic	O
24	homosexual	O
25	men	O
26	relative	O
27	to	O
28	white	O
29	men	O
30	can	O
31	be	O
32	explained	O
33	by	O
34	differences	O
35	in	O
36	sociodemographic	O
37	factors	O
38	,	O
39	history	O
40	of	O
41	sexually	O
42	transmitted	O
43	diseases	O
44	,	O
45	or	O
46	sexual	O
47	and	O
48	drug	O
49	-	O
50	use	O
51	behaviors	O
52	,	O
53	the	O
54	authors	O
55	conducted	O
56	a	O
57	cross	O
58	-	O
59	sectional	O
60	analysis	O
61	of	O
62	baseline	O
63	HIV	O
64	-	O
65	1	O
66	seroprevalence	O
67	and	O
68	HIV	O
69	-	O
70	1	O
71	risk	O
72	factors	O
73	among	O
74	4	O
75	,	O
76	475	O
77	non	O
78	-	O
79	Hispanic	O
80	white	O
81	,	O
82	234	O
83	Hispanic	O
84	white	O
85	,	O
86	and	O
87	194	O
88	black	O
89	homosexual	O
90	men	O
91	from	O
92	four	O
93	centers	O
94	in	O
95	the	O
96	United	O
97	States	O
98	(	O
99	Baltimore	O
100	/	O
101	Washington	O
102	,	O
103	DC	O
104	,	O
105	Pittsburgh	O
106	,	O
107	Chicago	O
108	,	O
109	and	O
110	Los	O
111	Angeles	O
112	).	O

1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O

1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	hybrids	O
7	and	O
8	FISH	O
9	analysis	O
10	,	O
11	the	O
12	PE	B
13	-	I
14	2	I
15	gene	I
16	is	O
17	localized	O
18	to	O
19	human	O
20	chromosome	O
21	19q13	O
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	translocations	O
30	and	O
31	deletions	O
32	in	O
33	leukemias	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	B
44	factor	I
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	carcinogenesis	O
51	.	O

1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	The	O
2	average	O
3	birth	O
4	mass	O
5	of	O
6	these	O
7	newborns	O
8	was	O
9	3491	O
10	.	O
11	9	O
12	+/-	O
13	2	O
14	SD	O
15	780	O
16	.	O
17	5	O
18	g	O
19	and	O
20	that	O
21	in	O
22	the	O
23	control	O
24	group	O
25	3	O
26	,	O
27	767	O
28	.	O
29	5	O
30	+/-	O
31	2	O
32	SD	O
33	824	O
34	.	O
35	2	O
36	g	O
37	(	O
38	P	O
39	less	O
40	than	O
41	0	O
42	.	O
43	05	O
44	).	O

1	To	O
2	study	O
3	the	O
4	structure	O
5	-	O
6	function	O
7	of	O
8	the	O
9	gene	B
10	5	I
11	product	I
12	,	O
13	wild	O
14	-	O
15	type	O
16	and	O
17	mutant	O
18	forms	O
19	of	O
20	NS53	B
21	were	O
22	produced	O
23	by	O
24	using	O
25	a	O
26	recombinant	O
27	baculovirus	O
28	expression	O
29	system	O
30	and	O
31	a	O
32	recombinant	O
33	vaccinia	O
34	virus	O
35	/	O
36	T7	O
37	(	O
38	vTF7	O
39	-	O
40	3	O
41	)	O
42	expression	O
43	system	O
44	.	O

1	FTF	B
2	is	O
3	also	O
4	abundantly	O
5	expressed	O
6	in	O
7	the	O
8	pancreas	O
9	and	O
10	may	O
11	exert	O
12	differentiation	O
13	functions	O
14	in	O
15	endodermal	O
16	sublineages	O
17	,	O
18	similar	O
19	to	O
20	SF	B
21	-	I
22	1	I
23	in	O
24	steroidogenic	O
25	tissues	O
26	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	growth	O
10	-	O
11	regulated	O
12	Syrian	B
13	hamster	I
14	CAD	I
15	gene	I
16	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	protein	O
7	kinase	O
8	MEKK1	B
9	can	O
10	induce	O
11	reporter	O
12	gene	O
13	expression	O
14	from	O
15	the	O
16	atrial	B
17	natriuretic	I
18	factor	I
19	(	O
20	ANF	B
21	)	O
22	promoter	O
23	,	O
24	a	O
25	genetic	O
26	marker	O
27	that	O
28	is	O
29	activated	O
30	during	O
31	in	O
32	vivo	O
33	hypertrophy	O
34	.	O

1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	Mutations	O
2	in	O
3	UPF1	B
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	PRL	B
2	receptor	I
3	also	O
4	activates	O
5	SHP	B
6	-	I
7	2	I
8	,	O
9	a	O
10	cytosolic	B
11	tyrosine	I
12	phosphatase	I
13	.	O

1	In	O
2	contrast	O
3	to	O
4	full	B
5	-	I
6	length	I
7	E2F	I
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	I
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	Their	O
2	conduction	O
3	velocity	O
4	ranged	O
5	from	O
6	0	O
7	.	O
8	23	O
9	to	O
10	0	O
11	.	O
12	98	O
13	m	O
14	/	O
15	sec	O
16	(	O
17	group	O
18	C	O
19	).	O

1	The	O
2	genes	O
3	encoding	O
4	(	B
5	2Fe	I
6	-	I
7	2S	I
8	)	I
9	plant	I
10	-	I
11	like	I
12	ferredoxins	I
13	were	O
14	studied	O
15	in	O
16	the	O
17	widely	O
18	used	O
19	cyanobacterium	O
20	Synechocystis	O
21	PCC6803	O
22	.	O

1	The	O
2	7	O
3	-	O
4	kb	O
5	mRNA	O
6	differs	O
7	by	O
8	alternative	O
9	splicing	O
10	such	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	with	O
17	a	O
18	distinct	O
19	amino	O
20	terminus	O
21	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	calcitonin	B
6	induced	O
7	a	O
8	beta	B
9	-	I
10	endorphin	I
11	increase	O
12	independent	O
13	of	O
14	enhanced	O
15	corticotrophin	B
16	-	O
17	cortisol	O
18	release	O
19	.	O

1	To	O
2	address	O
3	mechanisms	O
4	that	O
5	define	O
6	interactions	O
7	of	O
8	Site	B
9	II	I
10	regulatory	I
11	factors	I
12	with	O
13	this	O
14	cell	O
15	cycle	O
16	control	O
17	element	O
18	,	O
19	we	O
20	have	O
21	investigated	O
22	these	O
23	determinants	O
24	of	O
25	transcriptional	O
26	regulation	O
27	at	O
28	the	O
29	G1	O
30	/	O
31	S	O
32	phase	O
33	transition	O
34	in	O
35	FDC	O
36	-	O
37	P1	O
38	hematopoietic	O
39	progenitor	O
40	cells	O
41	.	O

1	A	O
2	total	O
3	of	O
4	125	O
5	acute	O
6	leukemia	O
7	adult	O
8	patients	O
9	were	O
10	autografted	O
11	with	O
12	bone	O
13	marrow	O
14	(	O
15	BM	O
16	)	O
17	purged	O
18	by	O
19	mafosfamide	O
20	(	O
21	ASTA	O
22	Z	O
23	)	O
24	during	O
25	the	O
26	period	O
27	of	O
28	January	O
29	1983	O
30	to	O
31	January	O
32	1993	O
33	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	investigation	O
6	was	O
7	to	O
8	describe	O
9	a	O
10	new	O
11	formulation	O
12	of	O
13	silver	O
14	sulfadiazine	O
15	in	O
16	a	O
17	water	O
18	soluble	O
19	gel	O
20	,	O
21	poloxamer	O
22	188	O
23	.	O

1	Fructokinase	B
2	activity	O
3	is	O
4	elevated	O
5	up	O
6	to	O
7	twofold	O
8	when	O
9	Z	O
10	.	O
11	mobilis	O
12	was	O
13	grown	O
14	on	O
15	fructose	O
16	instead	O
17	of	O
18	glucose	O
19	,	O
20	and	O
21	there	O
22	was	O
23	a	O
24	parallel	O
25	increase	O
26	in	O
27	frk	B
28	mRNA	I
29	levels	O
30	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	O
6	alpha	B
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	Instead	O
2	,	O
3	it	O
4	contained	O
5	two	O
6	tandem	O
7	kappaB	B
8	elements	I
9	and	O
10	a	O
11	variant	O
12	activating	B
13	transcription	I
14	factor	I
15	/	I
16	cAMP	I
17	response	I
18	element	I
19	site	O
20	,	O
21	which	O
22	closely	O
23	resembled	O
24	sites	O
25	in	O
26	the	O
27	E	B
28	-	I
29	selectin	I
30	gene	I
31	that	O
32	are	O
33	required	O
34	for	O
35	TNF	B
36	-	I
37	alpha	I
38	-	O
39	or	O
40	LPS	O
41	-	O
42	inducible	O
43	expression	O
44	.	O

1	Using	O
2	5	O
3	ng	O
4	/	O
5	mL	O
6	as	O
7	the	O
8	cutoff	O
9	,	O
10	the	O
11	sensitivity	O
12	of	O
13	CEA	B
14	was	O
15	68	O
16	%.	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	The	O
2	biochemical	O
3	and	O
4	molecular	O
5	spectrum	O
6	of	O
7	ornithine	B
8	transcarbamylase	I
9	deficiency	O
10	.	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	patients	O
6	with	O
7	acute	O
8	respiratory	O
9	failure	O
10	requiring	O
11	artificial	O
12	ventilation	O
13	have	O
14	two	O
15	componenents	O
16	of	O
17	the	O
18	pulmonary	O
19	shunt	O
20	,	O
21	one	O
22	parallel	O
23	with	O
24	and	O
25	the	O
26	other	O
27	inversely	O
28	related	O
29	with	O
30	the	O
31	PAO2	O
32	.	O

1	However	O
2	,	O
3	for	O
4	the	O
5	evaluable	O
6	cases	O
7	,	O
8	the	O
9	performances	O
10	of	O
11	the	O
12	CD3500	O
13	and	O
14	the	O
15	STKS	O
16	were	O
17	broadly	O
18	similar	O
19	and	O
20	generally	O
21	correlated	O
22	well	O
23	with	O
24	the	O
25	manual	O
26	reference	O
27	procedure	O
28	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	potential	O
5	activating	O
6	phosphorylation	O
7	sites	O
8	found	O
9	in	O
10	NIMA	B
11	,	O
12	NIM	B
13	-	I
14	1	I
15	,	O
16	and	O
17	related	O
18	protein	O
19	kinases	O
20	was	O
21	performed	O
22	on	O
23	NIMA	B
24	.	O

1	Animal	O
2	age	O
3	and	O
4	sex	O
5	had	O
6	no	O
7	significant	O
8	effects	O
9	on	O
10	CSF	O
11	composition	O
12	,	O
13	but	O
14	serum	O
15	IgG	B
16	concentration	O
17	increased	O
18	with	O
19	age	O
20	.	O

1	The	O
2	homologies	O
3	between	O
4	RAD16	B
5	,	O
6	RAD54	B
7	and	O
8	SNF2	B
9	are	O
10	also	O
11	shared	O
12	by	O
13	several	O
14	additional	O
15	,	O
16	recently	O
17	isolated	O
18	yeast	O
19	and	O
20	Drosophila	O
21	genes	O
22	.	O

1	Deadenylation	O
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	I
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	is	O
7	78	O
8	.	O
9	0	O
10	%	O
11	identical	O
12	to	O
13	the	O
14	cytoplasmic	B
15	dynein	I
16	heavy	I
17	chain	I
18	of	I
19	Neurospora	I
20	crassa	I
21	,	O
22	70	O
23	.	O
24	2	O
25	%	O
26	identical	O
27	to	O
28	that	O
29	of	O
30	Aspergillus	O
31	nidulans	O
32	and	O
33	24	O
34	.	O
35	8	O
36	%	O
37	identical	O
38	to	O
39	that	O
40	of	O
41	Saccharomyces	O
42	cerevisiae	O
43	.	O

1	4	O
2	.	O
3	26	O
4	+/-	O
5	1	O
6	.	O
7	54	O
8	mmol	O
9	/	O
10	l	O
11	,	O
12	P	O
13	<	O
14	0	O
15	.	O
16	01	O
17	),	O
18	and	O
19	systolic	O
20	BP	O
21	responses	O
22	to	O
23	intravenous	O
24	norepinephrine	O
25	and	O
26	angiotensin	B
27	II	I
28	were	O
29	significantly	O
30	higher	O
31	on	O
32	glibenclamide	O
33	than	O
34	on	O
35	metformin	O
36	(	O
37	P	O
38	<	O
39	0	O
40	.	O
41	02	O
42	and	O
43	P	O
44	<	O
45	0	O
46	.	O
47	05	O
48	,	O
49	respectively	O
50	).	O

1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	IgG1	B
26	and	O
27	two	O
28	IgG3	B
29	)	O
30	mAb	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O

1	The	O
2	hIGF	B
3	-	I
4	I	I
5	gene	I
6	has	O
7	two	O
8	promoters	O
9	,	O
10	P1	O
11	and	O
12	P2	O
13	.	O

1	Thus	O
2	,	O
3	the	O
4	B	O
5	-	O
6	S	O
7	mutant	O
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	B
14	GAPDHs	I
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	B
58	GAPDH	I
59	.	O

1	POU	B
2	-	O
3	specific	O
4	and	O
5	POU	B
6	-	O
7	homeo	O
8	domains	O
9	of	O
10	Oct3	B
11	were	O
12	produced	O
13	in	O
14	Echerichia	O
15	coli	O
16	for	O
17	characterization	O
18	of	O
19	DNA	O
20	binding	O
21	to	O
22	the	O
23	octamer	O
24	sequence	O
25	.	O

1	A	O
2	P22	O
3	R17	O
4	derivative	O
5	with	O
6	an	O
7	OcRNA	O
8	site	O
9	(	O
10	P22	O
11	R17	O
12	[	O
13	A	O
14	(-	O
15	10	O
16	)	O
17	U	O
18	])	O
19	develops	O
20	lytically	O
21	following	O
22	infection	O
23	of	O
24	these	O
25	strains	O
26	.	O

1	Foveating	O
2	saccades	O
3	,	O
4	therefore	O
5	,	O
6	can	O
7	be	O
8	distinguished	O
9	from	O
10	other	O
11	FEMs	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	speed	O
17	.	O

1	The	O
2	results	O
3	demonstrate	O
4	(	O
5	i	O
6	)	O
7	that	O
8	the	O
9	selenocysteine	O
10	-	O
11	specific	O
12	UGA	O
13	codon	O
14	is	O
15	readily	O
16	suppressed	O
17	under	O
18	conditions	O
19	where	O
20	the	O
21	homologous	B
22	SelB	I
23	protein	I
24	is	O
25	absent	O
26	and	O
27	(	O
28	ii	O
29	)	O
30	that	O
31	apart	O
32	from	O
33	the	O
34	specificity	O
35	of	O
36	the	O
37	SelB	B
38	-	I
39	mRNA	I
40	interaction	O
41	,	O
42	a	O
43	structural	O
44	compatibility	O
45	of	O
46	the	O
47	quaternary	O
48	complex	O
49	with	O
50	the	O
51	ribosome	O
52	is	O
53	required	O
54	.	O

1	Analysis	O
2	of	O
3	disassociation	O
4	rates	O
5	indicates	O
6	that	O
7	the	O
8	Grf10	B
9	-	O
10	Swi5	B
11	-	O
12	DNA	O
13	complex	O
14	has	O
15	a	O
16	longer	O
17	half	O
18	-	O
19	life	O
20	than	O
21	protein	O
22	-	O
23	DNA	O
24	complexes	O
25	that	O
26	contain	O
27	only	O
28	Swi5	B
29	or	O
30	Grf10	B
31	.	O

1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	Additional	O
2	exonuclease	B
3	III	I
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	B
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Characterization	O
2	of	O
3	fus1	B
4	of	O
5	Schizosaccharomyces	O
6	pombe	O
7	:	O
8	a	O
9	developmentally	O
10	controlled	O
11	function	O
12	needed	O
13	for	O
14	conjugation	O
15	.	O

1	Hypomagnesemia	O
2	was	O
3	due	O
4	to	O
5	magnesium	O
6	wasting	O
7	by	O
8	the	O
9	kidney	O
10	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Our	O
2	analysis	O
3	suggests	O
4	that	O
5	Upf1p	B
6	is	O
7	a	O
8	multifunctional	O
9	protein	O
10	with	O
11	separable	O
12	activities	O
13	that	O
14	can	O
15	affect	O
16	mRNA	O
17	turnover	O
18	and	O
19	nonsense	O
20	suppression	O
21	.	O

1	An	O
2	inverted	O
3	Alu	B
4	repeat	O
5	element	O
6	,	O
7	flanked	O
8	by	O
9	nonamer	O
10	direct	O
11	repeats	O
12	,	O
13	was	O
14	identified	O
15	within	O
16	the	O
17	region	O
18	-	O
19	913	O
20	/-	O
21	620	O
22	,	O
23	relative	O
24	to	O
25	the	O
26	cap	O
27	site	O
28	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	AP	B
6	-	I
7	A	I
8	may	O
9	be	O
10	potentially	O
11	useful	O
12	in	O
13	the	O
14	management	O
15	of	O
16	heart	O
17	failure	O
18	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	To	O
2	understand	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	increased	O
8	cell	O
9	surface	O
10	stability	O
11	compared	O
12	with	O
13	wild	O
14	-	O
15	type	O
16	peptide	O
17	and	O
18	to	O
19	understand	O
20	the	O
21	differences	O
22	in	O
23	T	O
24	cell	O
25	recognition	O
26	between	O
27	I1Y	B
28	and	O
29	I1F	B
30	,	O
31	we	O
32	determined	O
33	the	O
34	x	O
35	-	O
36	ray	O
37	crystal	O
38	structures	O
39	of	O
40	the	O
41	two	O
42	class	B
43	I	I
44	MHC	I
45	-	I
46	peptide	I
47	complexes	I
48	.	O

1	We	O
2	also	O
3	demonstrate	O
4	that	O
5	preformed	O
6	triplexes	O
7	are	O
8	quite	O
9	stable	O
10	when	O
11	precipitated	O
12	with	O
13	ethanol	O
14	and	O
15	resuspended	O
16	in	O
17	water	O
18	.	O

1	Upstream	O
2	of	O
3	the	O
4	dra	B
5	gene	I
6	an	O
7	open	O
8	reading	O
9	frame	O
10	of	O
11	313	O
12	amino	O
13	acids	O
14	was	O
15	identified	O
16	.	O

1	Parodoxical	O
2	rise	O
3	in	O
4	urinary	B
5	albumin	I
6	levels	O
7	after	O
8	treatment	O
9	of	O
10	essential	O
11	hypertension	O
12	.	O

1	Reporter	O
2	gene	O
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	B
9	promoters	I
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O

1	At	O
2	least	O
3	one	O
4	clone	O
5	,	O
6	lambda	O
7	HHG	O
8	41	O
9	,	O
10	contains	O
11	,	O
12	in	O
13	addition	O
14	to	O
15	the	O
16	histone	B
17	genes	I
18	,	O
19	a	O
20	region	O
21	that	O
22	hybridizes	O
23	with	O
24	a	O
25	cytoplasmic	O
26	RNA	O
27	approximately	O
28	330	O
29	nucleotides	O
30	in	O
31	length	O
32	.	O

1	Comparison	O
2	of	O
3	the	O
4	nucleotide	O
5	sequences	O
6	between	O
7	the	O
8	human	O
9	and	O
10	bovine	O
11	DNA	O
12	showed	O
13	that	O
14	the	O
15	sequence	O
16	similarity	O
17	extended	O
18	2400	O
19	bp	O
20	downstream	O
21	from	O
22	the	O
23	coding	O
24	region	O
25	.	O

1	Accordingly	O
2	,	O
3	we	O
4	designated	O
5	this	O
6	gene	B
7	CTL1	I
8	(	O
9	capping	B
10	enzyme	I
11	RNAtriphosphatase	I
12	-	I
13	like	I
14	1	I
15	).	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	Asthma	O
2	was	O
3	significantly	O
4	more	O
5	often	O
6	associated	O
7	with	O
8	ASA	O
9	group	O
10	(	O
11	91	O
12	%)	O
13	vs	O
14	46	O
15	%	O
16	at	O
17	AT	O
18	and	O
19	in	O
20	only	O
21	16	O
22	%	O
23	at	O
24	INTR	O
25	group	O
26	.	O

1	Plasma	B
2	secretin	I
3	,	O
4	pancreozymin	B
5	,	O
6	and	O
7	somatostatin	B
8	-	I
9	like	I
10	hormone	I
11	in	O
12	chronic	O
13	renal	O
14	failure	O
15	patients	O
16	.	O

1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O

1	By	O
2	order	O
3	of	O
4	decreasing	O
5	rate	O
6	,	O
7	finger	O
8	flexors	O
9	,	O
10	jaw	O
11	,	O
12	crossed	O
13	adductors	O
14	,	O
15	and	O
16	triceps	O
17	reflexes	O
18	were	O
19	less	O
20	frequently	O
21	elicited	O
22	in	O
23	both	O
24	groups	O
25	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	O
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	B
19	transcription	I
20	factor	I
21	GATA	I
22	-	I
23	1	I
24	.	O

1	The	O
2	gene	O
3	is	O
4	essential	O
5	for	O
6	yeast	O
7	vegetative	O
8	growth	O
9	.	O

1	We	O
2	have	O
3	studied	O
4	the	O
5	biokinetics	O
6	of	O
7	BLM	O
8	labeled	O
9	with	O
10	indium	O
11	-	O
12	111	O
13	(	O
14	In	O
15	-	O
16	111	O
17	).	O

1	Muscle	B
2	GSH	I
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	The	O
2	lemdr1	B
3	gene	I
4	was	O
5	cloned	O
6	in	O
7	the	O
8	expression	O
9	vector	O
10	pALTNEO	O
11	and	O
12	transfected	O
13	into	O
14	wild	O
15	-	O
16	type	O
17	L	O
18	.	O
19	enriettii	O
20	and	O
21	the	O
22	resulting	O
23	transfected	O
24	cells	O
25	were	O
26	resistant	O
27	to	O
28	vinblastine	O
29	but	O
30	at	O
31	lower	O
32	levels	O
33	than	O
34	in	O
35	the	O
36	selected	O
37	mutant	O
38	cells	O
39	.	O

1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	psoriasis	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O

1	The	O
2	preferential	O
3	serum	B
4	IgA	I
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Drug	O
2	effect	O
3	,	O
4	measured	O
5	as	O
6	postural	O
7	sway	O
8	,	O
9	was	O
10	also	O
11	similar	O
12	in	O
13	the	O
14	patients	O
15	with	O
16	cirrhosis	O
17	and	O
18	control	O
19	subjects	O
20	;	O
21	therefore	O
22	the	O
23	ratio	O
24	of	O
25	effect	O
26	area	O
27	under	O
28	the	O
29	curve	O
30	to	O
31	concentration	O
32	area	O
33	under	O
34	the	O
35	curve	O
36	,	O
37	a	O
38	measure	O
39	of	O
40	sensitivity	O
41	,	O
42	did	O
43	not	O
44	differ	O
45	significantly	O
46	between	O
47	the	O
48	patients	O
49	with	O
50	cirrhosis	O
51	and	O
52	the	O
53	control	O
54	subjects	O
55	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	Leukemia	B
2	-	I
3	inhibitory	I
4	factor	I
5	(	O
6	LIF	B
7	)	O
8	is	O
9	a	O
10	neuropoietin	B
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	Materials	O
2	science	O
3	studies	O
4	on	O
5	the	O
6	soldering	O
7	of	O
8	different	O
9	orthodontic	O
10	wires	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	B
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	Genetic	O
2	and	O
3	biochemical	O
4	evidence	O
5	suggests	O
6	that	O
7	v	B
8	-	I
9	Crk	I
10	can	O
11	induce	O
12	transformation	O
13	of	O
14	chicken	O
15	embryo	O
16	fibroblasts	O
17	by	O
18	influencing	O
19	the	O
20	activity	O
21	of	O
22	cellular	O
23	proteins	O
24	involved	O
25	in	O
26	growth	O
27	regulation	O
28	.	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	The	O
2	microphthalmia	B
3	-	I
4	TFE	I
5	(	O
6	MiT	B
7	)	O
8	subfamily	O
9	of	O
10	basic	B
11	helix	I
12	-	I
13	loop	I
14	-	I
15	helix	I
16	leucine	I
17	zipper	I
18	(	I
19	bHLH	I
20	-	I
21	ZIP	I
22	)	I
23	transcription	I
24	factors	I
25	,	O
26	including	O
27	TFE3	B
28	,	O
29	TFEB	B
30	,	O
31	TFEC	B
32	,	O
33	and	O
34	Mitf	B
35	,	O
36	has	O
37	been	O
38	implicated	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	tissue	O
44	-	O
45	specific	O
46	gene	O
47	expression	O
48	in	O
49	several	O
50	cell	O
51	lineages	O
52	.	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	of	O
6	2862	O
7	bp	O
8	encoding	O
9	a	O
10	954	O
11	amino	O
12	acid	O
13	protein	O
14	was	O
15	identified	O
16	.	O

1	Furthermore	O
2	,	O
3	Zelen	O
4	'	O
5	s	O
6	method	O
7	is	O
8	used	O
9	to	O
10	balance	O
11	the	O
12	number	O
13	of	O
14	patients	O
15	allocated	O
16	to	O
17	the	O
18	two	O
19	groups	O
20	within	O
21	each	O
22	institution	O
23	(	O
24	M	O
25	.	O

1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O

1	These	O
2	changes	O
3	may	O
4	be	O
5	the	O
6	result	O
7	of	O
8	,	O
9	on	O
10	the	O
11	one	O
12	hand	O
13	,	O
14	an	O
15	increased	O
16	sensitivity	O
17	of	O
18	the	O
19	neuromuscular	O
20	transmission	O
21	and	O
22	/	O
23	or	O
24	decreased	O
25	muscle	O
26	contractility	O
27	and	O
28	,	O
29	on	O
30	the	O
31	other	O
32	hand	O
33	,	O
34	the	O
35	result	O
36	of	O
37	a	O
38	reduced	O
39	plasma	O
40	clearance	O
41	during	O
42	hypothermia	O
43	.	O

1	Clinical	O
2	aspects	O
3	of	O
4	early	O
5	increase	O
6	in	O
7	serum	O
8	gamma	B
9	-	I
10	glutamyl	I
11	transferase	I
12	in	O
13	cerebral	O
14	infarction	O
15	.	O

1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	O
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O

1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O

1	A	O
2	progressive	O
3	growth	O
4	of	O
5	blood	O
6	erythrocyte	O
7	membrane	O
8	injury	O
9	has	O
10	been	O
11	demonstrated	O
12	after	O
13	rats	O
14	were	O
15	exposed	O
16	to	O
17	gamma	O
18	-	O
19	irradiaton	O
20	at	O
21	a	O
22	dose	O
23	of	O
24	100	O
25	to	O
26	500	O
27	Gy	O
28	.	O

1	Serum	O
2	-	O
3	ferritin	B
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O

1	Thin	O
2	-	O
3	layer	O
4	chromatographic	O
5	methods	O
6	were	O
7	up	O
8	-	O
9	dated	O
10	for	O
11	pharmacokinetic	O
12	studies	O
13	of	O
14	imipramine	O
15	in	O
16	plasma	O
17	and	O
18	urine	O
19	.	O

1	The	O
2	new	O
3	algorithm	O
4	,	O
5	called	O
6	RBI	O
7	-	O
8	MAP	O
9	,	O
10	is	O
11	based	O
12	on	O
13	the	O
14	rescaled	O
15	block	O
16	iterative	O
17	EM	O
18	(	O
19	RBI	O
20	-	O
21	EM	O
22	)	O
23	algorithm	O
24	.	O

1	Southern	O
2	analysis	O
3	on	O
4	genomic	O
5	DNA	O
6	isolated	O
7	from	O
8	tissues	O
9	and	O
10	cell	O
11	lines	O
12	from	O
13	several	O
14	mouse	O
15	strains	O
16	using	O
17	mCD22	B
18	cDNA	I
19	demonstrated	O
20	that	O
21	the	O
22	Cd22	B
23	locus	I
24	encoding	O
25	mCD22	B
26	is	O
27	a	O
28	single	O
29	copy	O
30	gene	O
31	of	O
32	<	O
33	or	O
34	=	O
35	30	O
36	kb	O
37	.	O

1	A	O
2	portion	O
3	of	O
4	Region	O
5	II	O
6	also	O
7	resembles	O
8	part	O
9	of	O
10	the	O
11	human	O
12	c	B
13	-	I
14	jun	I
15	oncoprotein	O
16	'	O
17	s	O
18	leucine	O
19	zipper	O
20	,	O
21	which	O
22	in	O
23	turn	O
24	,	O
25	has	O
26	been	O
27	demonstrated	O
28	to	O
29	be	O
30	the	O
31	heterodimerization	O
32	site	O
33	between	O
34	the	O
35	jun	B
36	and	O
37	fos	B
38	oncoproteins	I
39	.	O

1	The	O
2	cglIM	B
3	gene	I
4	is	O
5	organized	O
6	in	O
7	an	O
8	unusual	O
9	operon	O
10	which	O
11	contains	O
12	,	O
13	in	O
14	addition	O
15	,	O
16	two	O
17	genes	O
18	encoding	O
19	stress	O
20	-	O
21	sensitive	O
22	restriction	O
23	enzymes	O
24	.	O

1	Suggestive	O
2	evidence	O
3	was	O
4	obtained	O
5	that	O
6	cstA	B
7	is	O
8	involved	O
9	in	O
10	peptide	O
11	utilization	O
12	.	O

1	An	O
2	infectious	O
3	origin	O
4	should	O
5	always	O
6	be	O
7	excluded	O
8	since	O
9	specific	O
10	etiologic	O
11	therapy	O
12	may	O
13	be	O
14	implemented	O
15	.	O

1	On	O
2	an	O
3	antithrombin	B
4	unit	O
5	basis	O
6	,	O
7	CY	O
8	216	O
9	and	O
10	CY	O
11	222	O
12	were	O
13	equivalent	O
14	and	O
15	more	O
16	potent	O
17	than	O
18	UH	O
19	.	O

1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	Although	O
2	Pho85	B
3	is	O
4	not	O
5	essential	O
6	for	O
7	viability	O
8	,	O
9	Pcl1	B
10	,	I
11	2	I
12	-	O
13	Pho85	B
14	kinase	O
15	complexes	O
16	become	O
17	essential	O
18	for	O
19	Start	O
20	in	O
21	the	O
22	absence	O
23	of	O
24	Cln1	B
25	,	I
26	2	I
27	-	O
28	Cdc28	B
29	kinases	O
30	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	B
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	This	O
2	rapid	O
3	and	O
4	extensive	O
5	penetration	O
6	of	O
7	intrathecally	O
8	administered	O
9	chemotherapy	O
10	may	O
11	offer	O
12	insight	O
13	into	O
14	the	O
15	myelopathy	O
16	observed	O
17	with	O
18	these	O
19	treatments	O
20	.	O

1	The	O
2	accumulation	O
3	of	O
4	both	O
5	LHA4	B
6	and	O
7	LHA2	B
8	mRNAs	I
9	is	O
10	induced	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	exogenous	O
16	sugars	O
17	and	O
18	this	O
19	induction	O
20	appears	O
21	to	O
22	be	O
23	dependent	O
24	on	O
25	sugar	O
26	uptake	O
27	and	O
28	metabolism	O
29	,	O
30	because	O
31	mannitol	O
32	and	O
33	3	O
34	-	O
35	O	O
36	-	O
37	methylglucose	O
38	do	O
39	not	O
40	stimulate	O
41	mRNA	O
42	accumulation	O
43	.	O

1	However	O
2	,	O
3	there	O
4	were	O
5	some	O
6	properties	O
7	of	O
8	Rak	B
9	that	O
10	are	O
11	distinct	O
12	from	O
13	Src	B
14	-	I
15	like	I
16	kinases	I
17	:	O
18	(	O
19	a	O
20	)	O
21	expression	O
22	of	O
23	Rak	B
24	was	O
25	predominantly	O
26	in	O
27	epithelial	O
28	-	O
29	derived	O
30	cell	O
31	lines	O
32	and	O
33	tissues	O
34	,	O
35	especially	O
36	normal	O
37	liver	O
38	and	O
39	kidney	O
40	,	O
41	and	O
42	cell	O
43	lines	O
44	of	O
45	breast	O
46	and	O
47	colon	O
48	origin	O
49	;	O
50	(	O
51	b	O
52	)	O
53	Rak	B
54	does	O
55	not	O
56	harbor	O
57	the	O
58	NH2	O
59	-	O
60	terminal	O
61	glycine	O
62	essential	O
63	for	O
64	myristylation	O
65	and	O
66	membrane	O
67	localization	O
68	;	O
69	and	O
70	(	O
71	c	O
72	)	O
73	Rak	B
74	possesses	O
75	a	O
76	putative	O
77	bipartite	O
78	nuclear	O
79	localization	O
80	signal	O
81	in	O
82	the	O
83	SH2	B
84	domain	I
85	,	O
86	and	O
87	subcellular	O
88	fractionation	O
89	studies	O
90	revealed	O
91	that	O
92	p54rak	B
93	resides	O
94	predominantly	O
95	in	O
96	the	O
97	nucleus	O
98	.	O

1	Thus	O
2	adaptation	O
3	to	O
4	continuous	O
5	mild	O
6	stress	O
7	has	O
8	a	O
9	potent	O
10	antiarrhythmic	O
11	effect	O
12	which	O
13	occurs	O
14	due	O
15	to	O
16	the	O
17	increased	O
18	vagal	O
19	tone	O
20	.	O

1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	Avicel	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	patriciarum	O
14	showed	O
15	that	O
16	xynB	B
17	hybridized	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O

1	Transactivation	O
2	of	O
3	the	O
4	HIV	B
5	-	I
6	1	I
7	LTR	I
8	by	O
9	T3R	B
10	alpha	I
11	and	O
12	several	O
13	receptor	O
14	mutants	O
15	revealed	O
16	that	O
17	the	O
18	50	O
19	-	O
20	amino	O
21	-	O
22	acid	O
23	N	O
24	-	O
25	terminal	O
26	A	O
27	/	O
28	B	O
29	region	O
30	of	O
31	T3R	B
32	alpha	I
33	,	O
34	known	O
35	to	O
36	interact	O
37	with	O
38	the	O
39	basal	B
40	transcription	I
41	factor	I
42	TFIIB	I
43	,	O
44	is	O
45	critical	O
46	for	O
47	activation	O
48	of	O
49	both	O
50	Tat	B
51	-	O
52	dependent	O
53	and	O
54	Tat	B
55	-	O
56	independent	O
57	responsive	O
58	sequences	O
59	of	O
60	the	O
61	LTR	O
62	.	O

1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	B
9	C	I
10	terminus	I
11	(	I
12	amino	I
13	acid	I
14	784	I
15	)	I
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	B
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O

1	The	O
2	AD	O
3	components	O
4	were	O
5	markedly	O
6	more	O
7	dependent	O
8	on	O
9	the	O
10	affective	O
11	state	O
12	of	O
13	the	O
14	rat	O
15	then	O
16	was	O
17	the	O
18	V1	O
19	component	O
20	.	O

1	Mutations	O
2	of	O
3	the	O
4	RET	B
5	gene	I
6	,	O
7	encoding	O
8	a	O
9	receptor	B
10	tyrosine	I
11	kinase	I
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	The	O
2	management	O
3	of	O
4	the	O
5	"	O
6	chronic	O
7	"	O
8	patient	O
9	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	O
11	activated	O
12	protein	B
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	O
30	activated	O
31	protein	B
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	The	O
2	structure	O
3	of	O
4	digiprogenin	O
5	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	:	O
6	1	O
7	)	O
8	the	O
9	initial	O
10	response	O
11	to	O
12	tethering	O
13	varies	O
14	according	O
15	to	O
16	previous	O
17	penning	O
18	and	O
19	handling	O
20	experience	O
21	,	O
22	2	O
23	)	O
24	although	O
25	the	O
26	circadian	O
27	rhythm	O
28	of	O
29	cortisol	O
30	was	O
31	either	O
32	altered	O
33	or	O
34	disrupted	O
35	during	O
36	estrus	O
37	,	O
38	such	O
39	disruptions	O
40	were	O
41	not	O
42	influenced	O
43	by	O
44	type	O
45	of	O
46	penning	O
47	and	O
48	3	O
49	)	O
50	tether	O
51	stalls	O
52	may	O
53	chronically	O
54	increase	O
55	cortisol	O
56	concentrations	O
57	in	O
58	gilts	O
59	.	O

1	RESULTS	O
2	:	O
3	Circulating	O
4	leptin	B
5	concentrations	O
6	in	O
7	AN	O
8	were	O
9	3	O
10	.	O
11	5	O
12	+/-	O
13	0	O
14	.	O
15	5	O
16	versus	O
17	7	O
18	.	O
19	6	O
20	+/-	O
21	1	O
22	.	O
23	2	O
24	ng	O
25	/	O
26	ml	O
27	in	O
28	control	O
29	subjects	O
30	.	O

1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	O
21	invasive	O
22	feature	O
23	and	O
24	good	O
25	spatial	O
26	resolution	O
27	.	O

1	The	O
2	promoter	O
3	mutation	O
4	is	O
5	complemented	O
6	in	O
7	trans	O
8	by	O
9	E1A	B
10	products	O
11	of	O
12	the	O
13	heterologous	O
14	helper	O
15	adenovirus	O
16	type	O
17	5	O
18	(	O
19	Ad5	O
20	).	O

1	The	O
2	method	O
3	has	O
4	been	O
5	routinely	O
6	used	O
7	in	O
8	our	O
9	laboratory	O
10	for	O
11	1	O
12	year	O
13	and	O
14	has	O
15	proven	O
16	to	O
17	be	O
18	a	O
19	reliable	O
20	procedure	O
21	for	O
22	the	O
23	biological	O
24	control	O
25	of	O
26	occupational	O
27	exposure	O
28	to	O
29	toluene	O
30	and	O
31	/	O
32	or	O
33	xylene	O
34	.	O

1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	these	O
6	genes	O
7	differ	O
8	at	O
9	only	O
10	nine	O
11	positions	O
12	,	O
13	resulting	O
14	in	O
15	three	O
16	amino	O
17	acid	O
18	differences	O
19	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	Significant	O
2	clinical	O
3	differences	O
4	between	O
5	the	O
6	patients	O
7	treated	O
8	with	O
9	and	O
10	without	O
11	AMB	O
12	were	O
13	longer	O
14	survival	O
15	time	O
16	following	O
17	diagnosis	O
18	of	O
19	illness	O
20	(	O
21	P	O
22	less	O
23	than	O
24	0	O
25	.	O
26	05	O
27	)	O
28	and	O
29	more	O
30	frequent	O
31	cranial	O
32	nerve	O
33	signs	O
34	in	O
35	the	O
36	treated	O
37	patients	O
38	(	O
39	P	O
40	=	O
41	0	O
42	.	O
43	089	O
44	).	O

1	Muscle	O
2	action	O
3	potential	O
4	and	O
5	masticatory	O
6	rhythm	O
7	of	O
8	anterior	O
9	temporal	O
10	and	O
11	masseter	O
12	muscles	O
13	in	O
14	children	O
15	and	O
16	adults	O

1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O

1	The	O
2	results	O
3	presented	O
4	suggest	O
5	that	O
6	TIQ	O
7	reduces	O
8	the	O
9	turnover	O
10	rate	O
11	of	O
12	the	O
13	nigrostriatal	O
14	dopamine	O
15	neurons	O
16	after	O
17	repeated	O
18	administration	O
19	for	O
20	a	O
21	long	O
22	period	O
23	in	O
24	mice	O
25	.	O

1	Therefore	O
2	,	O
3	we	O
4	studied	O
5	ninety	O
6	coagulopathic	O
7	patients	O
8	with	O
9	the	O
10	aim	O
11	of	O
12	determining	O
13	the	O
14	prevalence	O
15	of	O
16	hepatitis	B
17	C	I
18	virus	I
19	(	I
20	HCV	I
21	)	I
22	antibodies	I
23	using	O
24	the	O
25	ELISA	O
26	and	O
27	RIBA	O
28	methods	O
29	.	O

1	The	O
2	mean	O
3	marginal	O
4	discrepancy	O
5	of	O
6	provisional	O
7	restorations	O
8	was	O
9	compared	O
10	for	O
11	restorations	O
12	fabricated	O
13	from	O
14	stone	O
15	,	O
16	low	O
17	-	O
18	viscosity	O
19	poly	O
20	(	O
21	vinyl	O
22	siloxane	O
23	),	O
24	and	O
25	medium	O
26	-	O
27	viscosity	O
28	poly	O
29	(	O
30	vinyl	O
31	siloxane	O
32	).	O

1	It	O
2	was	O
3	concluded	O
4	that	O
5	Scotchbond	O
6	2	O
7	and	O
8	Prisma	O
9	Universal	O
10	Bond	O
11	2	O
12	are	O
13	effective	O
14	and	O
15	are	O
16	the	O
17	dentine	O
18	bonding	O
19	agents	O
20	of	O
21	choice	O
22	.	O

1	Co	O
2	-	O
3	administration	O
4	of	O
5	5FU	O
6	,	O
7	angiotensin	B
8	II	I
9	and	O
10	microspheres	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	compartment	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	5FU	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	The	O
2	use	O
3	of	O
4	this	O
5	model	O
6	for	O
7	investigating	O
8	pathophysiologically	O
9	significant	O
10	issues	O
11	in	O
12	denervating	O
13	diseases	O
14	is	O
15	illustrated	O
16	with	O
17	five	O
18	different	O
19	sets	O
20	of	O
21	parameters	O
22	.	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	Reperfusion	O
2	with	O
3	normal	O
4	blood	O
5	in	O
6	the	O
7	beating	O
8	,	O
9	working	O
10	hearts	O
11	caused	O
12	extensive	O
13	structural	O
14	damage	O
15	,	O
16	reduced	O
17	reflow	O
18	,	O
19	and	O
20	failed	O
21	to	O
22	restore	O
23	contractility	O
24	in	O
25	any	O
26	instance	O
27	(-	O
28	27	O
29	%	O
30	systolic	O
31	shortening	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O

1	These	O
2	two	O
3	contigs	O
4	contain	O
5	a	O
6	total	O
7	of	O
8	163	O
9	open	O
10	reading	O
11	frames	O
12	(	O
13	ORFs	O
14	)	O
15	in	O
16	26	O
17	-	O
18	29	O
19	putative	O
20	operons	O
21	;	O
22	56	O
23	ORFs	O
24	could	O
25	be	O
26	identified	O
27	with	O
28	reasonable	O
29	certainty	O
30	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	I
10	2	I
11	but	O
12	not	O
13	an	O
14	Egr	B
15	-	I
16	1	I
17	expression	O
18	vector	O
19	activated	O
20	VPF	B
21	/	O
22	VEGF	B
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	I
30	2	I
31	protein	I
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	B
37	alpha	I
38	-	O
39	induced	O
40	VPF	B
41	/	O
42	VEGF	B
43	gene	O
44	expression	O
45	.	O

1	Moreover	O
2	,	O
3	the	O
4	mass	O
5	estimated	O
6	with	O
7	the	O
8	QCM	O
9	response	O
10	through	O
11	the	O
12	Sauerbrey	O
13	equation	O
14	and	O
15	the	O
16	mass	O
17	which	O
18	can	O
19	be	O
20	measured	O
21	thanks	O
22	to	O
23	other	O
24	analytical	O
25	techniques	O
26	,	O
27	in	O
28	our	O
29	case	O
30	an	O
31	enzymatic	O
32	assay	O
33	,	O
34	are	O
35	different	O
36	:	O
37	the	O
38	deposited	O
39	mass	O
40	is	O
41	generally	O
42	overestimated	O
43	by	O
44	the	O
45	QCM	O
46	.	O

1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	B
11	-	I
12	1	I
13	BamHI	I
14	-	I
15	D	I
16	DNA	I
17	fragment	I
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O

1	(	O
2	iv	O
3	)	O
4	Although	O
5	UCRBP	B
6	has	O
7	been	O
8	previously	O
9	shown	O
10	to	O
11	act	O
12	as	O
13	a	O
14	transcriptional	O
15	repressor	O
16	,	O
17	we	O
18	show	O
19	here	O
20	that	O
21	UCRBP	B
22	can	O
23	also	O
24	act	O
25	as	O
26	a	O
27	positive	O
28	transactivator	O
29	of	O
30	a	O
31	reporter	O
32	driven	O
33	by	O
34	UCR	O
35	elements	O
36	when	O
37	used	O
38	in	O
39	co	O
40	-	O
41	transfection	O
42	assays	O
43	.	O

1	Experimental	O
2	reproduction	O
3	of	O
4	malignant	O
5	catarrhal	O
6	fever	O
7	in	O
8	Bali	O
9	cattle	O

1	The	O
2	3	O
3	'	O
4	stem	O
5	-	O
6	loop	O
7	is	O
8	highly	O
9	divergent	O
10	in	O
11	structure	O
12	among	O
13	species	O
14	and	O
15	lies	O
16	immediately	O
17	upstream	O
18	of	O
19	the	O
20	binding	O
21	site	O
22	for	O
23	Sm	B
24	proteins	I
25	.	O

1	Although	O
2	a	O
3	wide	O
4	range	O
5	of	O
6	cognitive	O
7	functions	O
8	had	O
9	been	O
10	tested	O
11	,	O
12	all	O
13	but	O
14	one	O
15	seizure	O
16	occurred	O
17	during	O
18	assessment	O
19	of	O
20	memory	O
21	performance	O
22	.	O

1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	O
6	saccharopine	B
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	A	O
2	gene	O
3	in	O
4	Drosophila	O
5	melanogaster	O
6	that	O
7	maps	O
8	cytologically	O
9	to	O
10	2C1	O
11	-	O
12	3	O
13	on	O
14	the	O
15	distal	O
16	portion	O
17	of	O
18	the	O
19	X	O
20	-	O
21	chromosome	O
22	encodes	O
23	a	O
24	member	O
25	of	O
26	the	O
27	steroid	B
28	/	I
29	thyroid	I
30	hormone	I
31	receptor	I
32	superfamily	I
33	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	Pseudomonas	O
2	aeruginosa	O
3	strains	O
4	infecting	O
5	patients	O
6	with	O
7	cystic	O
8	fibrosis	O
9	(	O
10	CF	O
11	)	O
12	acquire	O
13	a	O
14	mucoid	O
15	phenotype	O
16	due	O
17	to	O
18	overproduction	O
19	of	O
20	alginate	O
21	.	O

1	Decreased	O
2	cardiac	O
3	glycogen	O
4	following	O
5	phenformin	O
6	injection	O
7	in	O
8	hyperglycemic	O
9	,	O
10	hyperinsulinemic	O
11	anaesthetized	O
12	rats	O
13	.	O

1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O

1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O

1	The	O
2	major	O
3	phenotypes	O
4	resulting	O
5	from	O
6	Fab1p	B
7	kinase	I
8	inactivation	O
9	include	O
10	temperature	O
11	-	O
12	sensitive	O
13	growth	O
14	,	O
15	vacuolar	O
16	acidification	O
17	defects	O
18	,	O
19	and	O
20	dramatic	O
21	increases	O
22	in	O
23	vacuolar	O
24	size	O
25	.	O

1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O

1	We	O
2	have	O
3	been	O
4	studying	O
5	the	O
6	interaction	O
7	of	O
8	the	O
9	oncogenic	O
10	human	O
11	polyomavirus	O
12	BK	O
13	(	O
14	BKV	O
15	)	O
16	with	O
17	the	O
18	tumor	B
19	-	I
20	suppressor	I
21	protein	I
22	p53	I
23	to	O
24	understand	O
25	the	O
26	biology	O
27	of	O
28	this	O
29	virus	O
30	as	O
31	well	O
32	as	O
33	to	O
34	understand	O
35	the	O
36	basic	O
37	mechanisms	O
38	of	O
39	p53	B
40	transactivation	O
41	.	O

1	Elimination	O
2	of	O
3	gamma	O
4	-	O
5	irradiation	O
6	induced	O
7	oxidation	O
8	in	O
9	aqueous	O
10	drug	O
11	preparations	O

1	The	O
2	roll	O
3	-	O
4	over	O
5	test	O
6	to	O
7	predict	O
8	toxemia	O
9	in	O
10	pregnancy	O
11	.	O

1	Serum	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	I	I
8	(	O
9	IGF	B
10	-	I
11	I	I
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	The	O
2	5	O
3	'	O
4	regions	O
5	of	O
6	these	O
7	two	O
8	soybean	B
9	actin	I
10	genes	I
11	contain	O
12	many	O
13	unusual	O
14	features	O
15	including	O
16	(	O
17	CT	O
18	)	O
19	repeats	O
20	and	O
21	long	O
22	stretches	O
23	of	O
24	pyrimidine	O
25	-	O
26	rich	O
27	DNA	O
28	.	O

1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O

1	Such	O
2	mutations	O
3	are	O
4	thought	O
5	to	O
6	exert	O
7	their	O
8	dominant	O
9	phenotype	O
10	by	O
11	sequestration	O
12	of	O
13	the	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	(	O
19	GNEF	B
20	).	O

1	Marked	O
2	thrombocytopenia	O
3	,	O
4	depletion	O
5	of	O
6	serum	B
7	fibrinogen	I
8	and	O
9	prolonged	O
10	prothrombin	B
11	and	O
12	activated	O
13	partial	O
14	thromboplastin	B
15	time	O
16	,	O
17	were	O
18	recorded	O
19	at	O
20	5	O
21	to	O
22	10	O
23	and	O
24	30	O
25	to	O
26	40	O
27	minutes	O
28	after	O
29	intravenous	O
30	envenomation	O
31	.	O

1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	B
13	E2F	I
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	B
19	E2F	I
20	sites	I
21	as	O
22	competitors	O
23	.	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	Restriction	O
2	mapping	O
3	analysis	O
4	localized	O
5	this	O
6	cDNA	O
7	to	O
8	the	O
9	HHV	B
10	-	I
11	6A	I
12	(	I
13	U1102	I
14	)	I
15	genomic	I
16	BamHI	I
17	G	I
18	fragment	I
19	,	O
20	at	O
21	the	O
22	right	O
23	end	O
24	of	O
25	the	O
26	unique	O
27	long	O
28	segment	O
29	of	O
30	the	O
31	genome	O
32	and	O
33	to	O
34	the	O
35	SalI	B
36	L	I
37	and	O
38	SalI	B
39	O	I
40	fragments	I
41	within	O
42	the	O
43	left	O
44	and	O
45	right	O
46	terminal	O
47	direct	O
48	repeat	O
49	regions	O
50	,	O
51	respectively	O
52	.	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Between	O
6	January	O
7	1992	O
8	and	O
9	June	O
10	1994	O
11	at	O
12	St	O
13	.	O

1	SPP41	B
2	was	O
3	cloned	O
4	and	O
5	sequenced	O
6	and	O
7	found	O
8	to	O
9	be	O
10	essential	O
11	.	O
12	spp43	B
13	is	O
14	allelic	O
15	to	O
16	the	O
17	previously	O
18	identified	O
19	suppressor	B
20	srn1	I
21	,	O
22	which	O
23	encodes	O
24	a	O
25	negative	O
26	regulator	O
27	of	O
28	gene	O
29	expression	O
30	.	O

1	The	O
2	symptoms	O
3	and	O
4	objective	O
5	findings	O
6	were	O
7	caused	O
8	by	O
9	a	O
10	malignant	O
11	lymphoma	O
12	,	O
13	and	O
14	the	O
15	diagnosis	O
16	was	O
17	established	O
18	from	O
19	a	O
20	drill	O
21	biopsy	O
22	.	O

1	Over	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	myoD	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	alleviated	O
21	repression	O
22	by	O
23	COUP	B
24	-	I
25	TF	I
26	II	I
27	.	O

1	In	O
2	addition	O
3	,	O
4	lexical	O
5	priming	O
6	was	O
7	examined	O
8	by	O
9	presenting	O
10	an	O
11	identity	O
12	prime	O
13	earlier	O
14	in	O
15	the	O
16	text	O
17	.	O

1	The	O
2	reconstituted	O
3	RNA	B
4	polymerases	I
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	B
20	-	I
21	CRP	I
22	and	O
23	the	O
24	rrnBP1	B
25	UP	I
26	element	I
27	.	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	PhLP	B
7	complexes	O
8	,	O
9	at	O
10	least	O
11	partially	O
12	,	O
13	with	O
14	Gbetagamma	B
15	in	O
16	vivo	O
17	.	O

1	DNase	B
2	I	I
3	and	O
4	1	O
5	,	O
6	10	O
7	-	O
8	phenanthroline	O
9	-	O
10	copper	O
11	footprinting	O
12	of	O
13	MURA	B
14	-	O
15	Mu1	B
16	TIR	O
17	complexes	O
18	indicate	O
19	that	O
20	MURA	B
21	binds	O
22	to	O
23	a	O
24	conserved	O
25	approximately	O
26	32	O
27	-	O
28	bp	O
29	region	O
30	in	O
31	the	O
32	TIR	O
33	of	O
34	Mu1	B
35	.	O

1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O

1	A	O
2	semiautomatic	O
3	digital	O
4	system	O
5	(	O
6	Videoplan	O
7	2	O
8	)	O
9	was	O
10	used	O
11	.	O

1	Further	O
2	outbreaks	O
3	of	O
4	ocular	O
5	disease	O
6	in	O
7	farmed	O
8	red	O
9	deer	O
10	calves	O
11	caused	O
12	by	O
13	HVC	O
14	-	O
15	1	O
16	were	O
17	investigated	O
18	.	O

1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	B
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	B
31	the	O
32	weakest	O
33	.	O

1	The	O
2	various	O
3	muscles	O
4	of	O
5	the	O
6	pelvic	O
7	floor	O
8	region	O
9	could	O
10	be	O
11	reflexly	O
12	activated	O
13	either	O
14	individually	O
15	or	O
16	as	O
17	a	O
18	mass	O
19	unit	O
20	depending	O
21	on	O
22	the	O
23	intensity	O
24	of	O
25	stimulation	O
26	.	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	OBJECTIVE	O
2	--	O
3	To	O
4	assess	O
5	the	O
6	risk	O
7	of	O
8	hepatitis	O
9	A	O
10	in	O
11	international	O
12	travelers	O
13	and	O
14	to	O
15	recommend	O
16	preventive	O
17	measures	O
18	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	B
14	gene	I
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	B
20	density	I
21	lipoprotein	I
22	free	O
23	cholesterol	O
24	.	O

1	Southern	O
2	blot	O
3	hybridization	O
4	experiments	O
5	suggest	O
6	the	O
7	presence	O
8	of	O
9	one	O
10	copy	O
11	of	O
12	Atcys1	B
13	,	O
14	Athyp1	B
15	and	O
16	AKin10	B
17	per	O
18	haploid	O
19	genome	O
20	,	O
21	and	O
22	Northern	O
23	blot	O
24	analysis	O
25	demonstrates	O
26	that	O
27	the	O
28	three	O
29	genes	O
30	are	O
31	differentially	O
32	expressed	O
33	in	O
34	roots	O
35	,	O
36	shoots	O
37	and	O
38	leaves	O
39	.	O

1	Yeast	O
2	mutants	O
3	lacking	O
4	a	O
5	functional	O
6	NOP1	B
7	gene	I
8	can	O
9	be	O
10	complemented	O
11	by	O
12	human	B
13	fibrillarin	I
14	but	O
15	are	O
16	temperature	O
17	sensitive	O
18	for	O
19	growth	O
20	and	O
21	impaired	O
22	in	O
23	pre	O
24	-	O
25	rRNA	O
26	processing	O
27	.	O

1	The	O
2	side	O
3	-	O
4	to	O
5	-	O
6	side	O
7	difference	O
8	was	O
9	statistically	O
10	significant	O
11	at	O
12	EXT	O
13	30	O
14	degrees	O
15	/	O
16	s	O
17	and	O
18	60	O
19	degrees	O
20	/	O
21	s	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	Precision	O
2	measurement	O
3	of	O
4	the	O
5	pion	O
6	mass	O
7	difference	O
8	m	O
9	pi	O
10	--	O
11	m	O
12	pi	O
13	0	O
14	.	O

1	The	O
2	roxithromycin	O
3	doses	O
4	that	O
5	were	O
6	chosen	O
7	for	O
8	these	O
9	studies	O
10	were	O
11	less	O
12	than	O
13	achievable	O
14	blood	O
15	levels	O
16	.	O

1	Although	O
2	popular	O
3	this	O
4	hypothesis	O
5	is	O
6	far	O
7	from	O
8	explaining	O
9	all	O
10	the	O
11	clinical	O
12	facts	O
13	,	O
14	namely	O
15	that	O
16	rigidity	O
17	is	O
18	equal	O
19	in	O
20	extensor	O
21	and	O
22	flexor	O
23	,	O
24	proximal	O
25	and	O
26	distal	O
27	muscles	O
28	.	O

1	Employing	O
2	fluorescence	O
3	spectroscopy	O
4	and	O
5	circular	O
6	dichroism	O
7	,	O
8	we	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	Ca2	O
15	+	O
16	to	O
17	ALG	B
18	-	I
19	2	I
20	induced	O
21	significant	O
22	conformational	O
23	changes	O
24	in	O
25	both	O
26	the	O
27	N	O
28	-	O
29	terminal	O
30	and	O
31	C	O
32	-	O
33	terminal	O
34	domains	O
35	of	O
36	the	O
37	protein	O
38	.	O

1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O

1	Because	O
2	of	O
3	the	O
4	potential	O
5	implications	O
6	of	O
7	these	O
8	findings	O
9	in	O
10	human	O
11	physiology	O
12	,	O
13	we	O
14	cloned	O
15	the	O
16	hPACAP	B
17	-	I
18	R	I
19	gene	I
20	.	O

1	The	O
2	location	O
3	of	O
4	the	O
5	IBS	O
6	within	O
7	the	O
8	catB	B
9	structural	I
10	gene	I
11	,	O
12	the	O
13	cooperativity	O
14	observed	O
15	in	O
16	footprinting	O
17	studies	O
18	and	O
19	phasing	O
20	studies	O
21	suggest	O
22	that	O
23	the	O
24	IBS	O
25	participates	O
26	in	O
27	the	O
28	interaction	O
29	of	O
30	CatR	B
31	with	O
32	the	O
33	upstream	O
34	binding	O
35	sites	O
36	by	O
37	looping	O
38	out	O
39	the	O
40	intervening	O
41	DNA	O
42	.	O

1	Reverse	O
2	transcription	O
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	B
22	kinases	I
23	.	O

1	Further	O
2	characterization	O
3	of	O
4	these	O
5	putative	O
6	Hoxa	B
7	-	I
8	1	I
9	target	I
10	genes	I
11	will	O
12	aid	O
13	in	O
14	delineating	O
15	the	O
16	functions	O
17	of	O
18	the	O
19	Hoxa	B
20	-	I
21	1	I
22	protein	I
23	in	O
24	the	O
25	differentiation	O
26	processes	O
27	which	O
28	occur	O
29	during	O
30	embryogenesis	O
31	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	assess	O
7	the	O
8	effects	O
9	of	O
10	hypothermia	O
11	and	O
12	chemical	O
13	cardioplegia	O
14	on	O
15	the	O
16	functional	O
17	recovery	O
18	of	O
19	hypertrophied	O
20	non	O
21	-	O
22	failing	O
23	rat	O
24	hearts	O
25	subjected	O
26	to	O
27	an	O
28	extended	O
29	period	O
30	of	O
31	global	O
32	ischaemia	O
33	.	O

1	We	O
2	analysed	O
3	two	O
4	regions	O
5	involved	O
6	in	O
7	preS2	B
8	/	O
9	S	B
10	gene	I
11	transcription	O
12	of	O
13	the	O
14	HBV	O
15	adw	O
16	subtype	O
17	:	O
18	the	O
19	diverged	O
20	TATA	O
21	box	O
22	and	O
23	a	O
24	putative	O
25	initiator	O
26	element	O
27	.	O

1	Radiation	O
2	decreased	O
3	the	O
4	levels	O
5	of	O
6	T4	O
7	and	O
8	T3	O
9	6	O
10	h	O
11	and	O
12	72	O
13	h	O
14	in	O
15	group	O
16	C	O
17	,	O
18	in	O
19	group	O
20	A	O
21	at	O
22	72	O
23	h	O
24	,	O
25	in	O
26	group	O
27	B	O
28	at	O
29	24	O
30	h	O
31	postexposure	O
32	.	O

1	However	O
2	,	O
3	the	O
4	use	O
5	of	O
6	cyclosporin	O
7	A	O
8	is	O
9	associated	O
10	with	O
11	an	O
12	increased	O
13	prevalence	O
14	of	O
15	hypertension	O
16	in	O
17	kidney	O
18	transplant	O
19	recipients	O
20	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	regulation	O
6	of	O
7	flaN	B
8	transcription	O
9	in	O
10	vivo	O
11	depends	O
12	on	O
13	a	O
14	sigma	B
15	54	I
16	promoter	I
17	and	O
18	two	O
19	ftr	O
20	elements	O
21	located	O
22	downstream	O
23	of	O
24	the	O
25	transcription	O
26	start	O
27	site	O
28	at	O
29	+	O
30	86	O
31	(	O
32	ftr2	O
33	)	O
34	and	O
35	+	O
36	120	O
37	(	O
38	ftr3	O
39	).	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	O
6	activity	O
7	of	O
8	p300	B
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	O
15	the	O
16	broadly	O
17	essential	O
18	activation	O
19	function	O
20	of	O
21	the	O
22	CH3	B
23	domain	I
24	/	O
25	E1A	B
26	-	O
27	binding	O
28	region	O
29	.	O

1	Experimental	O
2	cardiotoxicity	O
3	of	O
4	adriamycin	O

1	However	O
2	,	O
3	the	O
4	action	O
5	of	O
6	each	O
7	cognate	O
8	ligand	O
9	and	O
10	the	O
11	accessory	O
12	cellular	O
13	factors	O
14	that	O
15	can	O
16	differentially	O
17	regulate	O
18	the	O
19	transcriptional	O
20	responses	O
21	of	O
22	a	O
23	heterodimer	O
24	-	O
25	DNA	O
26	complex	O
27	are	O
28	not	O
29	well	O
30	understood	O
31	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	However	O
2	,	O
3	study	O
4	of	O
5	the	O
6	productive	O
7	gamma	O
8	gene	O
9	showed	O
10	that	O
11	the	O
12	skipped	O
13	variable	O
14	exon	O
15	was	O
16	bounded	O
17	by	O
18	normal	O
19	splicing	O
20	signals	O
21	and	O
22	that	O
23	the	O
24	adjacent	O
25	intron	O
26	organization	O
27	was	O
28	not	O
29	altered	O
30	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	putative	O
6	RNA	B
7	and	I
8	/	I
9	or	I
10	DNA	I
11	helicase	I
12	has	O
13	been	O
14	isolated	O
15	from	O
16	Arabidopsis	O
17	thaliana	O
18	cDNA	O
19	libraries	O
20	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	Deletion	O
2	mapping	O
3	of	O
4	the	O
5	human	B
6	presenilin	I
7	-	I
8	1	I
9	(	O
10	PS1	B
11	)	O
12	promoter	O
13	delineated	O
14	the	O
15	most	O
16	active	O
17	fragment	O
18	from	O
19	-	O
20	118	O
21	to	O
22	+	O
23	178	O
24	in	O
25	relation	O
26	to	O
27	the	O
28	transcription	O
29	start	O
30	site	O
31	mapped	O
32	in	O
33	this	O
34	study	O
35	,	O
36	in	O
37	both	O
38	human	O
39	neuroblastoma	O
40	SK	O
41	-	O
42	N	O
43	-	O
44	SH	O
45	and	O
46	hepatoma	O
47	HepG2	O
48	cells	O
49	.	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	B
6	-	I
7	specific	I
8	and	I
9	MAP2	I
10	-	I
11	specific	I
12	mRNAs	I
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O

1	There	O
2	were	O
3	9	O
4	patients	O
5	in	O
6	NYHA	O
7	class	O
8	III	O
9	and	O
10	8	O
11	in	O
12	class	O
13	IV	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	Platelet	B
2	activating	I
3	factor	I
4	was	O
5	given	O
6	in	O
7	six	O
8	doses	O
9	at	O
10	15	O
11	minute	O
12	intervals	O
13	and	O
14	airway	O
15	response	O
16	measured	O
17	as	O
18	change	O
19	in	O
20	partial	O
21	expiratory	O
22	flow	O
23	at	O
24	30	O
25	%	O
26	of	O
27	vital	O
28	capacity	O
29	(	O
30	Vp30	O
31	).	O

1	Although	O
2	the	O
3	N13	O
4	-	O
5	N20	O
6	interpeak	O
7	interval	O
8	remained	O
9	stable	O
10	because	O
11	of	O
12	the	O
13	parallel	O
14	shift	O
15	of	O
16	the	O
17	2	O
18	peaks	O
19	,	O
20	the	O
21	central	O
22	conduction	O
23	time	O
24	measured	O
25	from	O
26	onset	O
27	latencies	O
28	of	O
29	N11	O
30	and	O
31	N20	O
32	significantly	O
33	increased	O
34	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	B
25	.	I
26	5S	I
27	RNA	I
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	Alternative	O
2	splicing	O
3	of	O
4	ClC	B
5	-	I
6	6	I
7	(	O
8	a	O
9	member	O
10	of	O
11	the	O
12	CIC	B
13	chloride	I
14	-	I
15	channel	I
16	family	I
17	)	O
18	transcripts	O
19	generates	O
20	three	O
21	truncated	O
22	isoforms	O
23	one	O
24	of	O
25	which	O
26	,	O
27	ClC	B
28	-	I
29	6c	I
30	,	O
31	is	O
32	kidney	O
33	-	O
34	specific	O
35	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	Following	O
2	20	O
3	min	O
4	of	O
5	steady	O
6	state	O
7	anaesthesia	O
8	during	O
9	which	O
10	measurements	O
11	of	O
12	IOP	O
13	,	O
14	arterial	O
15	pressure	O
16	,	O
17	heart	O
18	rate	O
19	,	O
20	FIO2	O
21	,	O
22	FE	O
23	'	O
24	CO2	O
25	and	O
26	CVP	O
27	were	O
28	recorded	O
29	,	O
30	one	O
31	group	O
32	of	O
33	patients	O
34	received	O
35	atracurium	O
36	0	O
37	.	O
38	45	O
39	mg	O
40	kg	O
41	-	O
42	1	O
43	and	O
44	the	O
45	other	O
46	pancuronium	O
47	0	O
48	.	O
49	1	O
50	mg	O
51	kg	O
52	-	O
53	1	O
54	.	O

1	This	O
2	hypothesis	O
3	was	O
4	tested	O
5	by	O
6	introducing	O
7	mutations	O
8	at	O
9	each	O
10	of	O
11	the	O
12	three	O
13	histidine	O
14	pairs	O
15	,	O
16	the	O
17	H382	O
18	-	O
19	X2	O
20	-	O
21	H385	O
22	pair	O
23	,	O
24	the	O
25	H411	O
26	-	O
27	X2	O
28	-	O
29	H414	O
30	pair	O
31	and	O
32	the	O
33	H430	O
34	-	O
35	X5	O
36	-	O
37	H436	O
38	pair	O
39	,	O
40	which	O
41	constitute	O
42	the	O
43	histidine	O
44	-	O
45	rich	O
46	region	O
47	near	O
48	the	O
49	C	O
50	terminus	O
51	of	O
52	gp17	B
53	.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	this	O
6	dose	O
7	-	O
8	intense	O
9	regimen	O
10	can	O
11	be	O
12	safely	O
13	administered	O
14	,	O
15	even	O
16	with	O
17	the	O
18	use	O
19	of	O
20	purged	O
21	marrow	O
22	,	O
23	with	O
24	an	O
25	acceptable	O
26	toxicity	O
27	profile	O
28	.	O

1	Variations	O
2	in	O
3	the	O
4	5	O
5	'	O
6	half	O
7	of	O
8	U3	O
9	were	O
10	primarily	O
11	due	O
12	to	O
13	insertions	O
14	and	O
15	deletions	O
16	.	O

1	Such	O
2	a	O
3	mechanism	O
4	may	O
5	allow	O
6	acceleration	O
7	of	O
8	degenerative	O
9	joint	O
10	conditions	O
11	,	O
12	and	O
13	may	O
14	account	O
15	for	O
16	the	O
17	increased	O
18	prevalence	O
19	of	O
20	such	O
21	conditions	O
22	seen	O
23	with	O
24	HMS	O
25	subjects	O
26	.	O

1	Midge	O
2	control	O
3	in	O
4	flood	O
5	channels	O
6	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	B
24	neuraminidases	I
25	.	O

1	For	O
2	functional	O
3	studies	O
4	,	O
5	two	O
6	promoter	O
7	regions	O
8	were	O
9	cloned	O
10	upstream	O
11	of	O
12	the	O
13	reporter	O
14	gene	O
15	,	O
16	chloramphenicol	B
17	acetyl	I
18	transferase	I
19	(	O
20	CAT	B
21	):	O
22	(	O
23	i	O
24	)	O
25	phbetaE	O
26	-	O
27	B	O
28	-	O
29	the	O
30	plasmid	O
31	that	O
32	contains	O
33	the	O
34	human	O
35	(	O
36	h	O
37	)	O
38	promoter	O
39	region	O
40	(-	O
41	2832	O
42	to	O
43	+	O
44	101	O
45	)	O
46	including	O
47	URE	O
48	,	O
49	and	O
50	(	O
51	ii	O
52	)	O
53	prhbetaE	O
54	-	O
55	B	O
56	-	O
57	the	O
58	plasmid	O
59	that	O
60	contains	O
61	the	O
62	rhesus	O
63	(	O
64	rh	O
65	)	O
66	promoter	O
67	region	O
68	excluding	O
69	URE	O
70	as	O
71	it	O
72	lacks	O
73	a	O
74	270	O
75	bp	O
76	region	O
77	of	O
78	the	O
79	hbetaAPP	B
80	promoter	I
81	(-	O
82	2435	O
83	to	O
84	-	O
85	2165	O
86	).	O

1	Homozygous	O
2	mutant	O
3	mice	O
4	,	O
5	designated	O
6	Cux	B
7	/	O
8	CDPDeltaCR1	B
9	,	O
10	display	O
11	a	O
12	phenotype	O
13	characterized	O
14	by	O
15	curly	O
16	vibrissae	O
17	and	O
18	wavy	O
19	hair	O
20	.	O

1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O

1	Further	O
2	studies	O
3	of	O
4	mandibular	O
5	movement	O
6	at	O
7	initial	O
8	tooth	O
9	contact	O
10	.	O

1	The	O
2	site	O
3	of	O
4	autophosphorylation	O
5	is	O
6	Tyr397	O
7	which	O
8	corresponds	O
9	to	O
10	the	O
11	consensus	O
12	autophosphorylation	O
13	site	O
14	of	O
15	other	O
16	Src	B
17	family	I
18	tyrosine	I
19	kinases	I
20	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	Epidermal	B
2	growth	I
3	factor	I
4	receptor	I
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	B
10	endothelial	I
11	growth	I
12	factor	I
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	B
23	3	I
24	'-	I
25	kinase	I
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O

1	ORFK10	B
2	.	I
3	5	I
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	B
9	-	I
10	associated	I
11	nuclear	I
12	antigen	I
13	2	I
14	(	O
15	LANA2	B
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	In	O
2	addition	O
3	,	O
4	C	B
5	/	I
6	EBP	I
7	beta	I
8	and	O
9	C	B
10	/	I
11	EBP	I
12	gamma	I
13	readily	O
14	heterodimerize	O
15	with	O
16	each	O
17	other	O
18	as	O
19	well	O
20	as	O
21	with	O
22	C	B
23	/	I
24	EBP	I
25	alpha	I
26	.	O

1	The	O
2	p53	B
3	tumor	I
4	suppressor	I
5	gene	I
6	product	I
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O

1	Furthermore	O
2	,	O
3	an	O
4	upstream	O
5	element	O
6	,	O
7	collagen	O
8	element	O
9	I	O
10	(-	O
11	370	O
12	/-	O
13	344	O
14	),	O
15	which	O
16	shares	O
17	homology	O
18	with	O
19	the	O
20	LAP	B
21	binding	O
22	cis	O
23	-	O
24	element	O
25	of	O
26	the	O
27	albumin	B
28	promoter	I
29	(	O
30	9	O
31	of	O
32	13	O
33	bp	O
34	)	O
35	is	O
36	described	O
37	.	O

1	EMBO	O
2	J	O
3	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	surfaces	O
6	of	O
7	tracheal	O
8	cartilage	O
9	matrix	O
10	are	O
11	collagen	B
12	-	O
13	rich	O
14	and	O
15	surround	O
16	a	O
17	proteoglycan	O
18	-	O
19	rich	O
20	core	O
21	.	O

1	A	O
2	high	O
3	efficacy	O
4	of	O
5	the	O
6	combined	O
7	use	O
8	of	O
9	nontoxic	O
10	doses	O
11	of	O
12	two	O
13	pharmaceuticals	O
14	:	O
15	cystamine	O
16	(	O
17	50	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	mexamine	O
24	(	O
25	25	O
26	mg	O
27	/	O
28	kg	O
29	)	O
30	under	O
31	the	O
32	conditions	O
33	of	O
34	short	O
35	-	O
36	term	O
37	exogenous	O
38	hypoxia	O
39	(	O
40	7	O
41	.	O
42	5	O
43	%	O
44	O2	O
45	)	O
46	was	O
47	found	O
48	in	O
49	(	O
50	CBA	O
51	X	O
52	C57Bl	O
53	)	O
54	F1	O
55	mice	O
56	.	O

1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	B
21	'-	I
22	rearranged	I
23	myb	I
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O

1	We	O
2	conclude	O
3	that	O
4	Hansel	O
5	'	O
6	s	O
7	stain	O
8	substantially	O
9	improves	O
10	the	O
11	recognition	O
12	of	O
13	eosinophiluria	O
14	as	O
15	compared	O
16	with	O
17	Wright	O
18	'	O
19	s	O
20	stain	O
21	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	A	O
2	raised	O
3	amplitude	O
4	of	O
5	the	O
6	aggregation	O
7	of	O
8	plates	O
9	and	O
10	a	O
11	decrease	O
12	in	O
13	the	O
14	threshold	O
15	of	O
16	their	O
17	sensitivity	O
18	to	O
19	ADP	O
20	were	O
21	established	O
22	in	O
23	the	O
24	persons	O
25	with	O
26	types	O
27	IIa	O
28	and	O
29	IIb	O
30	HLP	O
31	and	O
32	in	O
33	CHD	O
34	without	O
35	HLP	O
36	.	O

1	Twelve	O
2	patients	O
3	without	O
4	abnormalities	O
5	in	O
6	the	O
7	PTT	O
8	are	O
9	assumed	O
10	to	O
11	harbor	O
12	missense	O
13	mutations	O
14	,	O
15	probably	O
16	in	O
17	TSC2	B
18	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	The	O
2	selenium	O
3	level	O
4	and	O
5	glutathione	B
6	peroxidase	I
7	activity	O
8	in	O
9	the	O
10	blood	O
11	,	O
12	liver	O
13	,	O
14	and	O
15	stomach	O
16	mucosa	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	high	O
23	-	O
24	selenium	O
25	diet	O
26	group	O
27	than	O
28	in	O
29	the	O
30	low	O
31	-	O
32	selenium	O
33	diet	O
34	group	O
35	.	O

1	METHODS	O
2	:	O
3	DSF	O
4	was	O
5	instilled	O
6	in	O
7	one	O
8	eye	O
9	chosen	O
10	at	O
11	random	O
12	and	O
13	CF	O
14	in	O
15	the	O
16	fellow	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	KCS	O
28	.	O

1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O

1	Thus	O
2	,	O
3	ZNF74	B
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	I
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	Pneumothorax	O
2	following	O
3	lung	O
4	abscess	O
5	in	O
6	the	O
7	renal	O
8	transplant	O
9	patient	O
10	.	O

1	This	O
2	protein	O
3	is	O
4	present	O
5	in	O
6	both	O
7	HeLa	O
8	nuclear	O
9	extracts	O
10	and	O
11	S100	B
12	extracts	O
13	but	O
14	absent	O
15	from	O
16	SR	B
17	protein	I
18	preparations	O
19	,	O
20	suggesting	O
21	that	O
22	it	O
23	is	O
24	not	O
25	a	O
26	classical	O
27	SR	B
28	protein	I
29	.	O

1	The	O
2	Ng	B
3	/	I
4	RC3	I
5	and	O
6	PKC	B
7	-	I
8	gamma	I
9	genes	I
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O

1	Enhanced	O
2	period	O
3	-	O
4	peak	O
5	analysis	O
6	of	O
7	electro	O
8	-	O
9	encephalograms	O
10	using	O
11	a	O
12	fast	O
13	sinc	O
14	function	O
15	.	O

1	The	O
2	Og4C3	B
3	enzyme	O
4	-	O
5	linked	O
6	immunosorbent	O
7	assay	O
8	(	O
9	ELISA	O
10	)	O
11	to	O
12	detect	O
13	circulating	O
14	Wuchereria	B
15	bancrofti	I
16	antigen	I
17	uses	O
18	50	O
19	microL	O
20	of	O
21	serum	O
22	.	O

1	Jean	O
2	Klig	O
3	reviews	O
4	recent	O
5	literature	O
6	about	O
7	lower	O
8	respiratory	O
9	tract	O
10	infection	O
11	in	O
12	children	O
13	.	O

1	As	O
2	high	O
3	-	O
4	speed	O
5	,	O
6	volumetric	O
7	imaging	O
8	,	O
9	computed	O
10	tomographic	O
11	scan	O
12	machines	O
13	such	O
14	as	O
15	the	O
16	Dynamic	O
17	Spatial	O
18	Reconstructor	O
19	become	O
20	available	O
21	with	O
22	higher	O
23	density	O
24	resolution	O
25	,	O
26	perhaps	O
27	a	O
28	single	O
29	injection	O
30	of	O
31	contrast	O
32	agent	O
33	into	O
34	the	O
35	right	O
36	atrium	O
37	or	O
38	even	O
39	a	O
40	peripheral	O
41	vein	O
42	may	O
43	be	O
44	adequate	O
45	to	O
46	obtain	O
47	all	O
48	these	O
49	measurements	O
50	.	O

1	Integrin	B
2	adhesion	I
3	receptors	I
4	transduce	O
5	signals	O
6	that	O
7	control	O
8	complex	O
9	cell	O
10	functions	O
11	which	O
12	require	O
13	the	O
14	regulation	O
15	of	O
16	gene	O
17	expression	O
18	,	O
19	such	O
20	as	O
21	proliferation	O
22	,	O
23	differentiation	O
24	and	O
25	survival	O
26	.	O

1	These	O
2	results	O
3	suggested	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	fetus	O
9	played	O
10	some	O
11	role	O
12	in	O
13	the	O
14	production	O
15	of	O
16	E3	O
17	-	O
18	16	O
19	-	O
20	G	O
21	in	O
22	early	O
23	pregnancy	O
24	.	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	Postprandial	O
2	plasma	B
3	enteroglucagon	I
4	concentration	O
5	after	O
6	90	O
7	minutes	O
8	in	O
9	untreated	O
10	patients	O
11	correlated	O
12	positively	O
13	to	O
14	the	O
15	faecal	O
16	fat	O
17	excretion	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	58	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	02	O
31	).	O

1	From	O
2	all	O
3	clinically	O
4	important	O
5	yeasts	O
6	species	O
7	,	O
8	a	O
9	total	O
10	of	O
11	96	O
12	%	O
13	were	O
14	identified	O
15	by	O
16	ATB	O
17	method	O
18	according	O
19	to	O
20	conventional	O
21	methods	O
22	.	O

1	Higher	O
2	fasting	O
3	serum	O
4	gastrin	B
5	concentration	O
6	(	O
7	102	O
8	.	O
9	0	O
10	+/-	O
11	21	O
12	.	O
13	1	O
14	vs	O
15	63	O
16	.	O
17	3	O
18	+/-	O
19	8	O
20	.	O
21	3	O
22	ng	O
23	.	O
24	l	O
25	-	O
26	1	O
27	),	O
28	and	O
29	greater	O
30	postprandial	O
31	gastrin	B
32	release	O
33	(	O
34	AUC0	O
35	-	O
36	120	O
37	:	O
38	16690	O
39	+/-	O
40	2648	O
41	vs	O
42	10654	O
43	+/-	O
44	1283	O
45	ng	O
46	.	O
47	l	O
48	-	O
49	1	O
50	min	O
51	)	O
52	were	O
53	observed	O
54	after	O
55	VTP	O
56	-	O
57	HM	O
58	than	O
59	after	O
60	VTP	O
61	-	O
62	Cas	O
63	.	O

1	In	O
2	addition	O
3	,	O
4	REP21	O
5	plants	O
6	were	O
7	resistant	O
8	to	O
9	an	O
10	unusually	O
11	broad	O
12	range	O
13	of	O
14	tobamoviruses	O
15	including	O
16	tomato	O
17	mosaic	O
18	virus	O
19	,	O
20	tobacco	O
21	mild	O
22	green	O
23	mosaic	O
24	virus	O
25	,	O
26	TMV	O
27	-	O
28	U5	O
29	,	O
30	green	O
31	tomato	O
32	atypical	O
33	mosaic	O
34	virus	O
35	,	O
36	and	O
37	ribgrass	O
38	mosaic	O
39	virus	O
40	.	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	A1	I
5	binds	O
6	to	O
7	the	O
8	transcription	O
9	-	O
10	regulatory	O
11	region	O
12	of	O
13	mouse	O
14	hepatitis	O
15	virus	O
16	RNA	O
17	.	O

1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	PowerBLAST	O
2	analysis	O
3	identified	O
4	six	O
5	clusters	O
6	of	O
7	expressed	O
8	sequence	O
9	tags	O
10	(	O
11	ESTs	O
12	),	O
13	two	O
14	known	O
15	genes	O
16	(	O
17	BIR	B
18	,	O
19	SUR1	B
20	)	O
21	mapped	O
22	previously	O
23	to	O
24	this	O
25	region	O
26	,	O
27	and	O
28	a	O
29	previously	O
30	characterized	O
31	but	O
32	unmapped	O
33	gene	B
34	NEFA	I
35	(	O
36	DNA	B
37	binding	I
38	/	I
39	EF	I
40	hand	I
41	/	I
42	acidic	I
43	amino	I
44	-	I
45	acid	I
46	-	I
47	rich	I
48	).	O

1	In	O
2	14	O
3	cases	O
4	,	O
5	isolates	O
6	were	O
7	biotyped	O
8	yielding	O
9	eight	O
10	with	O
11	biotype	O
12	II	O
13	,	O
14	four	O
15	with	O
16	biotype	O
17	III	O
18	,	O
19	and	O
20	one	O
21	each	O
22	with	O
23	biotypes	O
24	IV	O
25	and	O
26	V	O
27	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	Human	O
2	isoforms	O
3	,	O
4	designated	O
5	1	O
6	to	O
7	4	O
8	,	O
9	differ	O
10	from	O
11	each	O
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	O
17	used	O
18	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	report	O
7	a	O
8	detailed	O
9	study	O
10	of	O
11	the	O
12	structure	O
13	and	O
14	the	O
15	functional	O
16	role	O
17	of	O
18	the	O
19	MalT	B
20	binding	I
21	sites	I
22	located	O
23	in	O
24	the	O
25	adjacent	O
26	and	O
27	divergent	O
28	pulAp	B
29	and	O
30	pulCp	B
31	promoters	I
32	.	O

1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	B
12	,	O
13	encoding	O
14	3	B
15	-	I
16	isopropylmalate	I
17	dehydrogenase	I
18	;	O
19	asd	B
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	B
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	B
41	proteins	I
42	from	I
43	Vibrio	I
44	spp	I
45	.	O

1	Utilizing	O
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	I
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	This	O
2	study	O
3	was	O
4	carried	O
5	out	O
6	to	O
7	analyze	O
8	PRL	B
9	secretion	O
10	in	O
11	metastatic	O
12	prostate	O
13	cancer	O
14	patients	O
15	both	O
16	at	O
17	basal	O
18	conditions	O
19	and	O
20	in	O
21	response	O
22	to	O
23	L	O
24	-	O
25	Dopa	O
26	and	O
27	metoclopramide	O
28	,	O
29	which	O
30	represents	O
31	the	O
32	most	O
33	classical	O
34	inhibitory	O
35	and	O
36	stimulatory	O
37	tests	O
38	for	O
39	PRL	B
40	secretion	O
41	,	O
42	respectively	O
43	.	O

1	Two	O
2	copies	O
3	of	O
4	the	O
5	72	O
6	-	O
7	bp	O
8	repeat	O
9	provided	O
10	efficient	O
11	activation	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O

1	We	O
2	have	O
3	synthesized	O
4	[	O
5	7	O
6	,	O
7	7	O
8	-	O
9	2H2	O
10	]-	O
11	19	O
12	-	O
13	OHA	O
14	with	O
15	high	O
16	deuterium	O
17	content	O
18	and	O
19	,	O
20	together	O
21	with	O
22	[	O
23	7	O
24	,	O
25	7	O
26	-	O
27	2H2	O
28	]	O
29	A	O
30	and	O
31	[	O
32	9	O
33	,	O
34	11	O
35	-	O
36	2H2	O
37	]	O
38	estrone	O
39	(	O
40	E1	O
41	),	O
42	have	O
43	developed	O
44	a	O
45	quantitative	O
46	assay	O
47	of	O
48	serum	O
49	level	O
50	19	O
51	-	O
52	OHA	O
53	,	O
54	A	O
55	,	O
56	and	O
57	E1	O
58	using	O
59	the	O
60	gas	O
61	chromatography	O
62	/	O
63	mass	O
64	spectrometry	O
65	-	O
66	mass	O
67	fragmentography	O
68	method	O
69	to	O
70	monitor	O
71	individual	O
72	subjects	O
73	throughout	O
74	pregnancy	O
75	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	SAGA	I
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	B
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	B
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	3	O
2	)	O
3	and	O
4	one	O
5	distal	O
6	(-	O
7	11	O
8	.	O
9	8	O
10	/-	O
11	10	O
12	.	O
13	9	O
14	),	O
15	presented	O
16	an	O
17	enhancer	O
18	activity	O
19	in	O
20	pituitary	O
21	cells	O
22	when	O
23	placed	O
24	upstream	O
25	of	O
26	the	O
27	SV40	B
28	promoter	I
29	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	role	O
6	of	O
7	cellular	B
8	p21ras	I
9	protein	I
10	in	O
11	insulin	B
12	and	O
13	insulin	B
14	-	I
15	like	I
16	growth	I
17	factor	I
18	-	I
19	I	I
20	(	O
21	IGF	B
22	-	I
23	I	I
24	)	O
25	signaling	O
26	pathways	O
27	.	O

1	Three	O
2	cases	O
3	of	O
4	primary	O
5	signet	O
6	-	O
7	ring	O
8	cell	O
9	carcinoma	O
10	of	O
11	the	O
12	rectum	O
13	are	O
14	described	O
15	.	O

1	METHODS	O
2	:	O
3	A	O
4	population	O
5	survey	O
6	was	O
7	undertaken	O
8	in	O
9	10	O
10	,	O
11	148	O
12	individuals	O
13	to	O
14	measure	O
15	the	O
16	prevalence	O
17	and	O
18	identify	O
19	the	O
20	causes	O
21	of	O
22	blindness	O
23	in	O
24	Lebanon	O
25	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	B
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	The	O
2	pre	O
3	-	O
4	mRNA	O
5	splicing	O
6	factor	O
7	U2AF	B
8	(	O
9	U2	B
10	small	I
11	nuclear	I
12	ribonucleoprotein	I
13	particle	I
14	[	I
15	snRNP	I
16	]	I
17	auxiliary	I
18	factor	I
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O

1	The	O
2	antibody	O
3	titer	O
4	of	O
5	202	O
6	chickens	O
7	to	O
8	SA	O
9	-	O
10	11	O
11	rotavirus	O
12	was	O
13	determined	O
14	by	O
15	enzyme	O
16	-	O
17	linked	O
18	immunosorbent	O
19	blocking	O
20	assay	O
21	.	O

1	Vimentin	B
2	positivity	O
3	was	O
4	noted	O
5	in	O
6	the	O
7	undifferentiated	O
8	and	O
9	fibroblastic	O
10	components	O
11	.	O

1	The	O
2	leader	O
3	sequence	O
4	of	O
5	the	O
6	isolated	O
7	cDNA	O
8	clone	O
9	contains	O
10	several	O
11	small	O
12	open	O
13	reading	O
14	frames	O
15	upstream	O
16	of	O
17	the	O
18	initiation	O
19	codon	O
20	of	O
21	the	O
22	largest	O
23	open	O
24	reading	O
25	frame	O
26	coding	O
27	for	O
28	the	O
29	homeodomain	B
30	protein	I
31	.	O

1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O

1	Administration	O
2	of	O
3	growth	B
4	hormone	I
5	leads	O
6	to	O
7	faster	O
8	growth	O
9	,	O
10	but	O
11	also	O
12	faster	O
13	bone	O
14	maturation	O
15	.	O

1	At	O
2	maximum	O
3	photosensitivity	O
4	the	O
5	inhibitory	O
6	amino	O
7	acids	O
8	gamma	O
9	-	O
10	aminobutyric	O
11	acid	O
12	and	O
13	taurine	O
14	were	O
15	lower	O
16	,	O
17	and	O
18	those	O
19	of	O
20	asparagine	O
21	(	O
22	metabolite	O
23	of	O
24	the	O
25	excitatory	O
26	amino	O
27	acid	O
28	aspartate	O
29	)	O
30	were	O
31	higher	O
32	,	O
33	than	O
34	when	O
35	the	O
36	animals	O
37	were	O
38	not	O
39	photosensitive	O
40	.	O

1	The	O
2	obvious	O
3	functional	O
4	necessity	O
5	for	O
6	editing	O
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	O
12	formation	O
13	of	O
14	translatable	O
15	mRNAs	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	B
4	prolactin	I
5	concentrations	O
6	show	O
7	age	O
8	related	O
9	variations	O
10	in	O
11	presumably	O
12	fertile	O
13	men	O
14	.	O

1	When	O
2	comparing	O
3	the	O
4	barley	B
5	PSI	I
6	-	I
7	K	I
8	and	O
9	PSI	B
10	-	I
11	G	I
12	with	O
13	the	O
14	reported	O
15	PSI	B
16	-	I
17	K	I
18	sequence	I
19	from	I
20	Synechococcus	I
21	vulcanus	I
22	,	O
23	the	O
24	degree	O
25	of	O
26	similarity	O
27	is	O
28	equal	O
29	,	O
30	suggesting	O
31	that	O
32	an	O
33	ancestral	O
34	gene	O
35	has	O
36	been	O
37	duplicated	O
38	in	O
39	a	O
40	chloroplast	O
41	progenitor	O
42	but	O
43	not	O
44	in	O
45	a	O
46	cyanobacterial	O
47	.	O

1	Studies	O
2	on	O
3	Coxsackie	O
4	B	O
5	Type	O
6	5	O
7	virus	O
8	infections	O
9	.	O

1	Most	O
2	apneic	O
3	events	O
4	occurred	O
5	during	O
6	Stages	O
7	I	O
8	and	O
9	II	O
10	,	O
11	and	O
12	REM	O
13	,	O
14	but	O
15	this	O
16	proportion	O
17	was	O
18	less	O
19	during	O
20	the	O
21	gamma	O
22	OH	O
23	study	O
24	(	O
25	77	O
26	.	O
27	9	O
28	+/-	O
29	8	O
30	.	O
31	9	O
32	%)	O
33	than	O
34	during	O
35	the	O
36	control	O
37	studies	O
38	(	O
39	92	O
40	.	O
41	3	O
42	+/-	O
43	1	O
44	.	O
45	9	O
46	and	O
47	95	O
48	.	O
49	9	O
50	+/-	O
51	2	O
52	.	O
53	2	O
54	%),	O
55	apneas	O
56	occurring	O
57	even	O
58	during	O
59	SWS	O
60	with	O
61	gamma	O
62	OH	O
63	.(	O
64	ABSTRACT	O
65	TRUNCATED	O
66	AT	O
67	250	O
68	WORDS	O
69	)	O

1	Cell	O
2	factor	O
3	-	O
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	B
17	major	I
18	immediate	I
19	-	I
20	early	I
21	(	I
22	IE	I
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O

1	Evidence	O
2	for	O
3	such	O
4	peak	O
5	shifts	O
6	has	O
7	been	O
8	found	O
9	in	O
10	the	O
11	responses	O
12	of	O
13	auditory	O
14	nerve	O
15	fibers	O
16	,	O
17	cochlear	O
18	microphonics	O
19	,	O
20	and	O
21	the	O
22	responses	O
23	of	O
24	outer	O
25	hair	O
26	cells	O
27	and	O
28	supporting	O
29	cells	O
30	in	O
31	the	O
32	cochlea	O
33	,	O
34	as	O
35	well	O
36	as	O
37	in	O
38	basilar	O
39	membrane	O
40	vibration	O
41	measurements	O
42	,	O
43	and	O
44	indirectly	O
45	,	O
46	in	O
47	psychophysical	O
48	data	O
49	.	O

1	Both	O
2	tear	O
3	volume	O
4	and	O
5	tear	O
6	flow	O
7	were	O
8	found	O
9	to	O
10	be	O
11	significantly	O
12	(	O
13	P	O
14	less	O
15	than	O
16	0	O
17	.	O
18	001	O
19	)	O
20	decreased	O
21	up	O
22	to	O
23	6	O
24	h	O
25	after	O
26	instillation	O
27	,	O
28	reaching	O
29	a	O
30	minimum	O
31	90	O
32	min	O
33	after	O
34	application	O
35	(	O
36	tear	O
37	volume	O
38	:	O
39	-	O
40	63	O
41	%;	O
42	tear	O
43	flow	O
44	:	O
45	-	O
46	71	O
47	%).	O

1	Oxfendazole	O
2	,	O
3	which	O
4	was	O
5	active	O
6	for	O
7	the	O
8	shortest	O
9	time	O
10	(	O
11	about	O
12	65	O
13	days	O
14	)	O
15	from	O
16	the	O
17	start	O
18	of	O
19	grazing	O
20	(	O
21	May	O
22	1	O
23	),	O
24	produced	O
25	a	O
26	78	O
27	.	O
28	1	O
29	per	O
30	cent	O
31	reduction	O
32	in	O
33	Ostertagia	O
34	species	O
35	and	O
36	an	O
37	84	O
38	.	O
39	4	O
40	per	O
41	cent	O
42	reduction	O
43	in	O
44	D	O
45	viviparus	O
46	.	O

1	Detection	O
2	of	O
3	exercise	O
4	-	O
5	induced	O
6	asynergy	O
7	by	O
8	M	O
9	-	O
10	mode	O
11	echocardiography	O
12	.	O

1	Dopamine	B
2	beta	I
3	-	I
4	hydroxylase	I
5	(	O
6	DBH	B
7	)	O
8	catalyzes	O
9	the	O
10	conversion	O
11	of	O
12	dopamine	O
13	to	O
14	noradrenaline	O
15	and	O
16	is	O
17	selectively	O
18	expressed	O
19	in	O
20	noradrenergic	O
21	and	O
22	adrenergic	O
23	neurons	O
24	and	O
25	neuroendocrine	O
26	cells	O
27	.	O

1	Picture	O
2	the	O
3	smell	O
4	.	O

1	Changes	O
2	in	O
3	dopamine	B
4	receptor	I
5	sensitivity	O
6	in	O
7	humans	O
8	after	O
9	heavy	O
10	alcohol	O
11	intake	O
12	.	O

1	A	O
2	small	O
3	amount	O
4	of	O
5	HSP81	B
6	-	I
7	1	I
8	mRNA	I
9	was	O
10	detected	O
11	only	O
12	in	O
13	roots	O
14	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	contact	O
6	allergy	O
7	to	O
8	K	O
9	-	O
10	CG	O
11	is	O
12	common	O
13	.	O

1	Plasma	O
2	thrombomodulin	B
3	:	O
4	a	O
5	marker	O
6	for	O
7	microvascular	O
8	complications	O
9	in	O
10	diabetes	O
11	mellitus	O
12	.	O

1	Melatonin	O
2	and	O
3	seasonality	O
4	:	O
5	filling	O
6	the	O
7	gap	O
8	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	of	O
7	the	O
8	CD1	B
9	gene	I
10	contained	O
11	the	O
12	binding	O
13	motifs	O
14	for	O
15	two	O
16	cytokine	O
17	-	O
18	inducible	O
19	transcription	O
20	factors	O
21	,	O
22	NF	B
23	-	I
24	IL2	I
25	-	I
26	A	I
27	and	O
28	NF	B
29	-	I
30	IL6	I
31	.	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	This	O
2	two	O
3	-	O
4	helix	O
5	motif	O
6	is	O
7	thought	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	specific	O
13	DNA	O
14	sequence	O
15	recognition	O
16	by	O
17	CAP	B
18	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	B
8	(-)	O
9	CD8	B
10	(-)	O
11	CD3	B
12	(-)	O
13	cells	O
14	with	O
15	rearranged	B
16	TCR	I
17	genes	I
18	developed	O
19	from	O
20	Id3	B
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	O
28	transduced	O
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	peptide	O
6	sequences	O
7	of	O
8	the	O
9	human	B
10	lymphocyte	I
11	-	I
12	specific	I
13	high	I
14	mobility	I
15	group	I
16	(	I
17	HMG	I
18	)-	I
19	box	I
20	transcription	I
21	factor	I
22	TCF	I
23	-	I
24	1	I
25	are	O
26	determined	O
27	by	O
28	alternative	O
29	splice	O
30	mechanisms	O
31	affecting	O
32	the	O
33	exons	O
34	VIII	O
35	to	O
36	X	O
37	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Ras	B
2	-	I
3	and	I
4	ultra	I
5	-	I
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	I
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O

1	Similar	O
2	clinical	O
3	evaluation	O
4	of	O
5	an	O
6	obligate	O
7	carrier	O
8	revealed	O
9	no	O
10	ocular	O
11	abnormalities	O
12	.	O

1	Because	O
2	Trp53	B
3	(	O
4	the	O
5	mouse	B
6	homolog	I
7	of	I
8	human	I
9	TP53	I
10	)	O
11	is	O
12	located	O
13	with	O
14	Tk1	B
15	on	O
16	chromosome	O
17	11	O
18	and	O
19	is	O
20	critical	O
21	in	O
22	regulating	O
23	cellular	O
24	responses	O
25	following	O
26	exposure	O
27	to	O
28	DNA	O
29	damaging	O
30	agents	O
31	,	O
32	we	O
33	wanted	O
34	to	O
35	determine	O
36	if	O
37	these	O
38	mouse	O
39	lymphoma	O
40	cells	O
41	harbor	O
42	mutations	O
43	in	O
44	Trp53	B
45	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	B
6	,	O
7	alpha	B
8	2AP	I
9	,	O
10	and	O
11	C1	B
12	-	I
13	INH	I
14	,	O
15	should	O
16	be	O
17	considered	O
18	equine	O
19	acute	O
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O

1	A	O
2	prerequisite	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	sialylated	O
8	glycoconjugates	O
9	is	O
10	the	O
11	activated	O
12	sugar	O
13	-	O
14	nucleotide	O
15	cytidine	O
16	5	O
17	'-	O
18	monophosphate	O
19	N	O
20	-	O
21	acetylneuraminic	O
22	acid	O
23	(	O
24	CMP	O
25	-	O
26	Neu5Ac	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	B
34	sialyltransferases	I
35	.	O

1	This	O
2	300	O
3	bp	O
4	5	O
5	'-	O
6	upstream	O
7	sequence	O
8	of	O
9	K3	B
10	keratin	I
11	gene	I
12	,	O
13	which	O
14	can	O
15	function	O
16	in	O
17	vitro	O
18	as	O
19	a	O
20	keratinocyte	O
21	-	O
22	specific	O
23	promoter	O
24	,	O
25	contains	O
26	two	O
27	clusters	O
28	of	O
29	partially	O
30	overlapping	O
31	motifs	O
32	,	O
33	one	O
34	with	O
35	an	O
36	NFkB	B
37	consensus	O
38	sequence	O
39	and	O
40	another	O
41	with	O
42	a	O
43	GC	O
44	box	O
45	.	O

1	Is	O
2	desensitization	O
3	'	O
4	for	O
5	ragweed	O
6	hay	O
7	fever	O
8	immunologically	O
9	specific	O
10	?	O

1	The	O
2	GHR	B
3	mRNA	I
4	:	O
5	GHBP	B
6	mRNA	I
7	ratio	O
8	was	O
9	1	O
10	.	O
11	1	O
12	+/-	O
13	0	O
14	.	O
15	12	O
16	and	O
17	remained	O
18	unchanged	O
19	during	O
20	differentiation	O
21	.	O

1	Labile	O
2	LTR	B
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	B
27	-	I
28	binding	I
29	proteins	I
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	The	O
2	effect	O
3	of	O
4	ethanol	O
5	on	O
6	human	O
7	sensorimotor	O
8	reactivity	O
9	was	O
10	assessed	O
11	by	O
12	examining	O
13	the	O
14	acoustic	O
15	startle	O
16	response	O
17	.	O

1	The	O
2	pWP	B
3	-	I
4	19	I
5	also	O
6	encodes	O
7	the	O
8	AAV	O
9	inverted	O
10	terminal	O
11	repeats	O
12	for	O
13	integration	O
14	and	O
15	replication	O
16	and	O
17	the	O
18	herpes	O
19	virus	O
20	thymidine	B
21	kinase	I
22	promoter	O
23	-	O
24	driven	O
25	gene	O
26	for	O
27	neomycin	O
28	resistance	O
29	(	O
30	neoR	B
31	).	O

1	Selenium	O
2	(.	O
3	1	O
4	ppm	O
5	)	O
6	and	O
7	E	O
8	(	O
9	50	O
10	IU	O
11	/	O
12	kg	O
13	)	O
14	supplementation	O
15	of	O
16	the	O
17	diet	O
18	of	O
19	the	O
20	sow	O
21	increased	O
22	plasma	O
23	tocopherol	O
24	and	O
25	Se	O
26	concentrations	O
27	,	O
28	but	O
29	did	O
30	not	O
31	increase	O
32	plasma	B
33	glutathione	I
34	peroxidase	I
35	(	O
36	GSH	B
37	-	I
38	Px	I
39	)	O
40	activity	O
41	.	O

1	Preventive	O
2	effect	O
3	of	O
4	ONO	O
5	-	O
6	3708	O
7	on	O
8	thrombosis	O
9	and	O
10	vasospasms	O
11	in	O
12	vitro	O
13	and	O
14	in	O
15	vivo	O
16	.	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O

1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O

1	[	O
2	Treatment	O
3	of	O
4	early	O
5	T1	O
6	small	O
7	T2N	O
8	breast	O
9	cancers	O
10	.	O

1	This	O
2	led	O
3	to	O
4	the	O
5	conclusion	O
6	that	O
7	the	O
8	metatarsal	O
9	artery	O
10	should	O
11	be	O
12	used	O
13	for	O
14	toe	O
15	MP	O
16	joint	O
17	grafts	O
18	,	O
19	while	O
20	the	O
21	unilateral	O
22	proper	O
23	digital	O
24	artery	O
25	is	O
26	suitable	O
27	for	O
28	toe	O
29	PIP	O
30	joint	O
31	grafts	O
32	,	O
33	together	O
34	with	O
35	concomitant	O
36	or	O
37	dorsal	O
38	cutaneous	O
39	vein	O
40	.	O

1	A	O
2	total	O
3	of	O
4	1459	O
5	men	O
6	aged	O
7	48	O
8	to	O
9	84	O
10	years	O
11	,	O
12	who	O
13	were	O
14	diagnosed	O
15	for	O
16	the	O
17	first	O
18	time	O
19	by	O
20	physicians	O
21	as	O
22	having	O
23	BPH	O
24	in	O
25	1994	O
26	and	O
27	who	O
28	had	O
29	not	O
30	received	O
31	treatment	O
32	,	O
33	participated	O
34	in	O
35	the	O
36	study	O
37	.	O

1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	B
8	-	I
9	2	I
10	protein	I
11	was	O
12	a	O
13	unique	O
14	alpha1	B
15	,	I
16	4	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	O
30	sulfate	O
31	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	human	B
6	Lnk	I
7	,	O
8	an	O
9	adaptor	O
10	protein	O
11	with	O
12	pleckstrin	B
13	homology	O
14	and	O
15	Src	B
16	homology	I
17	2	I
18	domains	I
19	that	O
20	can	O
21	inhibit	O
22	T	O
23	cell	O
24	activation	O
25	.	O

1	An	O
2	ELISA	O
3	procedure	O
4	was	O
5	developed	O
6	for	O
7	monitoring	O
8	the	O
9	specific	O
10	IgE	B
11	response	O
12	in	O
13	dogs	O
14	to	O
15	Dirofilaria	O
16	immitis	O
17	infection	O
18	.	O

1	Chem	O
2	.	O

1	Rainbow	O
2	trout	O
3	were	O
4	obtained	O
5	from	O
6	a	O
7	commercial	O
8	trout	O
9	farm	O
10	,	O
11	kept	O
12	in	O
13	running	O
14	water	O
15	and	O
16	feeding	O
17	in	O
18	experimental	O
19	pellets	O
20	for	O
21	4	O
22	to	O
23	8	O
24	weeks	O
25	.	O

1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O

1	12	O
2	:	O
3	2684	O
4	-	O
5	2697	O
6	,	O
7	1998	O
8	):	O
9	a	O
10	key	O
11	step	O
12	of	O
13	this	O
14	model	O
15	is	O
16	the	O
17	activation	O
18	of	O
19	the	O
20	MAPK	B
21	Fus3p	I
22	through	O
23	the	O
24	G	O
25	(	O
26	betagamma	O
27	)-	O
28	dependent	O
29	relocalization	O
30	of	O
31	the	O
32	Ste5p	B
33	-	O
34	MAPK	B
35	cascade	O
36	to	O
37	the	O
38	plasma	O
39	membrane	O
40	.	O

1	An	O
2	anatomical	O
3	and	O
4	histochemical	O
5	study	O
6	has	O
7	been	O
8	undertaken	O
9	and	O
10	as	O
11	a	O
12	result	O
13	emphasis	O
14	is	O
15	given	O
16	to	O
17	recent	O
18	hypotheses	O
19	that	O
20	suggest	O
21	there	O
22	are	O
23	similarities	O
24	with	O
25	Type	O
26	IV	O
27	glycogen	O
28	storage	O
29	disease	O
30	(	O
31	Andersen	O
32	'	O
33	s	O
34	disease	O
35	)	O
36	which	O
37	,	O
38	although	O
39	clinically	O
40	distinct	O
41	,	O
42	has	O
43	the	O
44	same	O
45	enzyme	O
46	defect	O
47	.	O

1	5	O
2	micrograms	O
3	/	O
4	l	O
5	was	O
6	detected	O
7	in	O
8	urine	O
9	from	O
10	some	O
11	non	O
12	-	O
13	occupationally	O
14	exposed	O
15	persons	O
16	.	O

1	The	O
2	ZnF20	B
3	cDNA	I
4	hybridized	O
5	to	O
6	multiple	O
7	transcripts	O
8	in	O
9	a	O
10	thyroid	O
11	cancer	O
12	cell	O
13	line	O
14	(	O
15	8	O
16	.	O
17	0	O
18	,	O
19	4	O
20	.	O
21	5	O
22	and	O
23	2	O
24	kb	O
25	)	O
26	that	O
27	increased	O
28	after	O
29	cycloheximide	O
30	treatment	O
31	and	O
32	decayed	O
33	<	O
34	2	O
35	h	O
36	after	O
37	addition	O
38	of	O
39	actinomycin	O
40	D	O
41	.	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	The	O
2	isolated	O
3	plasmin	B
4	fragments	O
5	of	O
6	VEGF	B
7	were	O
8	compared	O
9	with	O
10	respect	O
11	to	O
12	heparin	O
13	binding	O
14	,	O
15	interaction	O
16	with	O
17	soluble	O
18	VEGF	B
19	receptors	I
20	,	O
21	and	O
22	ability	O
23	to	O
24	promote	O
25	endothelial	O
26	cell	O
27	mitogenesis	O
28	.	O

1	These	O
2	fusion	O
3	proteins	O
4	also	O
5	allowed	O
6	the	O
7	localization	O
8	of	O
9	the	O
10	transcriptional	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	domains	O
16	of	O
17	the	O
18	ToxR	B
19	protein	I
20	to	O
21	its	O
22	cytoplasmically	O
23	located	O
24	N	O
25	-	O
26	terminal	O
27	portion	O
28	.	O

1	Pigs	O
2	were	O
3	switched	O
4	from	O
5	the	O
6	growing	O
7	to	O
8	the	O
9	finishing	O
10	diet	O
11	at	O
12	57	O
13	and	O
14	61	O
15	kg	O
16	in	O
17	Exp	O
18	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serological	O
6	studies	O
7	,	O
8	the	O
9	highly	O
10	conserved	O
11	A	O
12	domain	O
13	of	O
14	HspA	B
15	was	O
16	found	O
17	to	O
18	be	O
19	the	O
20	immunodominant	O
21	domain	O
22	.	O

1	Recent	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	U1	B
8	snRNP	I
9	is	O
10	recruited	O
11	to	O
12	the	O
13	5	O
14	'	O
15	splice	O
16	site	O
17	by	O
18	protein	O
19	/	O
20	protein	O
21	interactions	O
22	involving	O
23	the	O
24	SR	B
25	domains	O
26	of	O
27	the	O
28	U1	B
29	-	I
30	70K	I
31	protein	I
32	and	O
33	SF2	B
34	/	O
35	ASF	B
36	.	O

1	Slp1	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	B
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	Data	O
2	on	O
3	the	O
4	line	O
5	spread	O
6	function	O
7	(	O
8	LSF	O
9	)	O
10	were	O
11	obtained	O
12	from	O
13	the	O
14	image	O
15	of	O
16	a	O
17	0	O
18	.	O
19	2	O
20	mm	O
21	wide	O
22	slit	O
23	between	O
24	tungsten	O
25	blocks	O
26	that	O
27	were	O
28	positioned	O
29	at	O
30	the	O
31	isocentre	O
32	in	O
33	front	O
34	of	O
35	a	O
36	polystyrene	O
37	phantom	O
38	.	O

1	A	O
2	third	O
3	is	O
4	a	O
5	partial	O
6	element	O
7	terminating	O
8	at	O
9	a	O
10	probable	O
11	internal	O
12	restriction	O
13	site	O
14	used	O
15	for	O
16	cloning	O
17	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	Absorption	O
2	was	O
3	rapid	O
4	,	O
5	with	O
6	a	O
7	mean	O
8	time	O
9	to	O
10	peak	O
11	of	O
12	39	O
13	min	O
14	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	(	O
2	1989	O
3	),	O
4	which	O
5	is	O
6	identical	O
7	to	O
8	the	O
9	SSC1	B
10	gene	I
11	(	O
12	Smith	O
13	et	O
14	al	O
15	.,	O
16	1988	O
17	).	O

1	While	O
2	mutations	O
3	in	O
4	K	B
5	-	I
6	Rev	I
7	that	O
8	inactivate	O
9	any	O
10	one	O
11	of	O
12	these	O
13	properties	O
14	also	O
15	blocked	O
16	K	B
17	-	I
18	Rev	I
19	-	O
20	dependent	O
21	nuclear	O
22	RNA	O
23	export	O
24	,	O
25	several	O
26	K	B
27	-	I
28	Rev	I
29	mutants	I
30	were	O
31	comparable	O
32	to	O
33	wild	O
34	type	O
35	when	O
36	assayed	O
37	for	O
38	any	O
39	of	O
40	these	O
41	individual	O
42	activities	O
43	yet	O
44	nevertheless	O
45	defective	O
46	for	O
47	RNA	O
48	export	O
49	.	O

1	Analysis	O
2	of	O
3	functional	O
4	domains	O
5	of	O
6	Arix	B
7	reveals	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	activation	O
13	domain	O
14	and	O
15	a	O
16	C	O
17	-	O
18	terminal	O
19	repression	O
20	domain	O
21	.	O

1	IST	B
2	is	O
3	not	O
4	the	O
5	RNA	O
6	target	O
7	(	O
8	TAR	O
9	)	O
10	for	O
11	Tat	B
12	trans	O
13	-	O
14	activation	O
15	;	O
16	however	O
17	,	O
18	because	O
19	it	O
20	relies	O
21	entirely	O
22	on	O
23	cellular	O
24	factors	O
25	for	O
26	activity	O
27	,	O
28	IST	B
29	may	O
30	serve	O
31	to	O
32	provide	O
33	abundant	O
34	RNA	O
35	targets	O
36	for	O
37	Tat	B
38	trans	O
39	-	O
40	activation	O
41	without	O
42	a	O
43	requirement	O
44	for	O
45	full	O
46	-	O
47	length	O
48	viral	O
49	mRNA	O
50	expression	O
51	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	B
16	and	I
17	serum	I
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	Congruent	O
2	with	O
3	empirical	O
4	predictions	O
5	,	O
6	the	O
7	most	O
8	homesick	O
9	children	O
10	perceived	O
11	low	O
12	control	O
13	over	O
14	homesickness	O
15	and	O
16	separation	O
17	,	O
18	and	O
19	coped	O
20	by	O
21	relinquishing	O
22	control	O
23	.	O

1	Atrial	O
2	fibrillation	O
3	and	O
4	the	O
5	autonomic	O
6	nervous	O
7	system	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	B
8	-	O
9	p86	B
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	B
26	.	O

1	These	O
2	clones	O
3	were	O
4	found	O
5	to	O
6	share	O
7	a	O
8	common	O
9	domain	O
10	encoded	O
11	by	O
12	p	O
13	(	O
14	CA	O
15	)	O
16	n	O
17	repeats	O
18	;	O
19	a	O
20	simple	O
21	sequence	O
22	length	O
23	polymorphism	O
24	(	O
25	SSLP	O
26	).	O

1	A	O
2	large	O
3	increase	O
4	of	O
5	serum	O
6	ketones	O
7	occurred	O
8	under	O
9	all	O
10	conditions	O
11	,	O
12	and	O
13	the	O
14	exercise	O
15	respiratory	O
16	quotient	O
17	suggested	O
18	some	O
19	increase	O
20	of	O
21	fat	O
22	utilization	O
23	,	O
24	WW	O
25	(	O
26	0	O
27	.	O
28	85	O
29	)	O
30	through	O
31	CW	O
32	(	O
33	0	O
34	.	O
35	84	O
36	)	O
37	to	O
38	CC	O
39	(	O
40	0	O
41	.	O
42	83	O
43	).	O

1	This	O
2	finding	O
3	represents	O
4	both	O
5	a	O
6	potentially	O
7	important	O
8	mechanism	O
9	by	O
10	which	O
11	HPV	O
12	gene	O
13	expression	O
14	can	O
15	be	O
16	regulated	O
17	and	O
18	an	O
19	interesting	O
20	model	O
21	for	O
22	the	O
23	study	O
24	of	O
25	transcriptional	O
26	cooperativity	O
27	.	O

1	Five	O
2	of	O
3	these	O
4	eight	O
5	patients	O
6	in	O
7	group	O
8	II	O
9	also	O
10	received	O
11	8	O
12	-	O
13	in	O
14	-	O
15	1	O
16	chemotherapy	O
17	.	O

1	The	O
2	Drosophila	B
3	suppressor	I
4	of	I
5	sable	I
6	gene	I
7	encodes	O
8	a	O
9	polypeptide	O
10	with	O
11	regions	O
12	similar	O
13	to	O
14	those	O
15	of	O
16	RNA	O
17	-	O
18	binding	O
19	proteins	O
20	.	O

1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O

1	After	O
2	hemodynamic	O
3	stabilization	O
4	,	O
5	the	O
6	goal	O
7	of	O
8	therapy	O
9	is	O
10	to	O
11	diminish	O
12	the	O
13	chance	O
14	that	O
15	an	O
16	ulcer	O
17	will	O
18	continue	O
19	to	O
20	bleed	O
21	or	O
22	will	O
23	rebleed	O
24	.	O

1	Secondary	O
2	pancreatic	O
3	involvement	O
4	of	O
5	mycosis	O
6	fungoides	O
7	detected	O
8	by	O
9	a	O
10	clinically	O
11	palpable	O
12	mass	O
13	.	O

1	Intra	O
2	-	O
3	operative	O
4	ultrasound	O
5	(	O
6	IOUS	O
7	)	O
8	has	O
9	been	O
10	widely	O
11	used	O
12	in	O
13	an	O
14	attempt	O
15	to	O
16	overcome	O
17	these	O
18	difficulties	O
19	,	O
20	but	O
21	is	O
22	limited	O
23	by	O
24	its	O
25	two	O
26	-	O
27	dimensional	O
28	nature	O
29	,	O
30	inter	O
31	-	O
32	user	O
33	variability	O
34	,	O
35	and	O
36	image	O
37	obliteration	O
38	with	O
39	ablative	O
40	or	O
41	resectional	O
42	techniques	O
43	.	O

1	The	O
2	arrangement	O
3	of	O
4	these	O
5	cutoff	O
6	-	O
7	levels	O
8	leads	O
9	to	O
10	a	O
11	sensitivity	O
12	of	O
13	85	O
14	%	O
15	at	O
16	a	O
17	specificity	O
18	of	O
19	55	O
20	%	O
21	for	O
22	Protein	B
23	S100	I
24	when	O
25	measured	O
26	by	O
27	RIA	O
28	,	O
29	and	O
30	to	O
31	a	O
32	sensitivity	O
33	of	O
34	77	O
35	%	O
36	at	O
37	a	O
38	specificity	O
39	of	O
40	61	O
41	%	O
42	when	O
43	measured	O
44	by	O
45	LIA	O
46	.	O

1	The	O
2	cysteine	O
3	-	O
4	rich	O
5	region	O
6	of	O
7	raf	B
8	-	I
9	1	I
10	kinase	I
11	contains	O
12	zinc	O
13	,	O
14	translocates	O
15	to	O
16	liposomes	O
17	,	O
18	and	O
19	is	O
20	adjacent	O
21	to	O
22	a	O
23	segment	O
24	that	O
25	binds	O
26	GTP	B
27	-	I
28	ras	I
29	.	O

1	We	O
2	investigated	O
3	the	O
4	smoking	O
5	habits	O
6	of	O
7	relapsers	O
8	1	O
9	year	O
10	after	O
11	quitting	O
12	in	O
13	a	O
14	smoking	O
15	cessation	O
16	trial	O
17	using	O
18	nicotine	O
19	or	O
20	placebo	O
21	patches	O
22	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	B
6	finger	I
7	protein	I
8	,	O
9	dsRBP	B
10	-	I
11	ZFa	I
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O

1	Ovarian	O
2	tumors	O
3	in	O
4	pregnancy	O
5	.	O

1	The	O
2	sequence	O
3	of	O
4	monkey	B
5	opsin	I
6	closely	O
7	resembles	O
8	the	O
9	human	O
10	sequence	O
11	at	O
12	the	O
13	nucleotide	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	levels	O
19	,	O
20	with	O
21	the	O
22	latter	O
23	having	O
24	only	O
25	7	O
26	differences	O
27	out	O
28	of	O
29	348	O
30	residues	O
31	.	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	O
23	GR	B
24	.	O

1	Identification	O
2	of	O
3	the	O
4	region	O
5	in	O
6	actin	B
7	-	I
8	binding	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	the	O
14	cytoplasmic	O
15	domain	O
16	of	O
17	glycoprotein	B
18	IBalpha	I
19	.	O

1	Possibly	O
2	,	O
3	the	O
4	scr1	B
5	-	I
6	1	I
7	mutation	I
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	B
26	synthesis	O
27	.	O

1	This	O
2	accurate	O
3	and	O
4	rapid	O
5	method	O
6	makes	O
7	the	O
8	MLPA	O
9	test	O
10	logistically	O
11	feasible	O
12	for	O
13	large	O
14	-	O
15	scale	O
16	screening	O
17	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	effect	O
7	of	O
8	the	O
9	isomers	O
10	of	O
11	pentobarbital	O
12	and	O
13	secobarbital	O
14	on	O
15	mult	O
16	FR30	O
17	FI600	O
18	responding	O
19	and	O
20	on	O
21	suppressed	O
22	responding	O
23	are	O
24	qualitatively	O
25	similar	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	O
7	the	O
8	general	O
9	population	O
10	of	O
11	Hisayama	O
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	B
21	B	I
22	surface	I
23	antigen	I
24	in	O
25	general	O
26	population	O
27	.	O

1	Our	O
2	observations	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	HMG	B
9	-	I
10	I	I
11	family	I
12	play	O
13	an	O
14	important	O
15	role	O
16	in	O
17	SRF	B
18	-	O
19	dependent	O
20	transcription	O
21	and	O
22	that	O
23	their	O
24	effect	O
25	is	O
26	mediated	O
27	primarily	O
28	by	O
29	a	O
30	protein	O
31	-	O
32	protein	O
33	interaction	O
34	.	O

1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O

1	However	O
2	,	O
3	Southern	O
4	blot	O
5	and	O
6	karyotype	O
7	analyses	O
8	did	O
9	not	O
10	reveal	O
11	any	O
12	significant	O
13	changes	O
14	in	O
15	copy	O
16	number	O
17	or	O
18	gross	O
19	rearrangements	O
20	of	O
21	the	O
22	p53	B
23	gene	I
24	in	O
25	any	O
26	of	O
27	the	O
28	p53	B
29	-	I
30	cell	O
31	lines	O
32	.	O

1	Effects	O
2	of	O
3	diltiazem	O
4	on	O
5	netilmicin	O
6	-	O
7	induced	O
8	nephrotoxicity	O
9	in	O
10	rabbits	O
11	.	O

1	We	O
2	found	O
3	that	O
4	both	O
5	the	O
6	E26	O
7	virus	O
8	-	O
9	encoded	O
10	v	B
11	-	I
12	ets	I
13	and	O
14	the	O
15	myeloid	B
16	/	I
17	B	I
18	-	I
19	cell	I
20	-	I
21	specific	I
22	factor	I
23	PU	I
24	.	I
25	1	I
26	bind	O
27	efficiently	O
28	to	O
29	this	O
30	site	O
31	in	O
32	vitro	O
33	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	pattern	O
7	of	O
8	blood	O
9	supply	O
10	is	O
11	relevant	O
12	to	O
13	the	O
14	structural	O
15	organisation	O
16	of	O
17	mature	O
18	lamellar	O
19	bone	O
20	around	O
21	the	O
22	implant	O
23	.	O

1	They	O
2	were	O
3	checked	O
4	for	O
5	anti	B
6	-	I
7	HCV	I
8	(	O
9	anti	B
10	-	I
11	C100	I
12	-	I
13	3	I
14	)	O
15	with	O
16	HCV	O
17	EIA	O
18	kit	O
19	(	O
20	Abbott	O
21	Lab	O
22	.,	O
23	North	O
24	Chicago	O
25	,	O
26	IL	O
27	).	O

1	Breitbart	O
2	,	O
3	L	O
4	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	PKC	B
7	alpha	I
8	(	O
9	calcium	O
10	dependent	O
11	)	O
12	and	O
13	PKC	B
14	delta	I
15	(	O
16	calcium	O
17	independent	O
18	)	O
19	may	O
20	mediate	O
21	the	O
22	transcription	O
23	of	O
24	TPA	O
25	-	O
26	inducible	O
27	genes	O
28	through	O
29	both	O
30	AP	B
31	-	I
32	1	I
33	and	O
34	non	O
35	-	O
36	AP	B
37	-	I
38	1	I
39	sequences	O
40	.	O

1	Interestingly	O
2	,	O
3	one	O
4	IRF	B
5	binding	I
6	site	I
7	was	O
8	found	O
9	within	O
10	the	O
11	IRF	B
12	-	I
13	2	I
14	promoter	I
15	,	O
16	and	O
17	expression	O
18	of	O
19	the	O
20	IRF	B
21	-	I
22	2	I
23	gene	I
24	was	O
25	affected	O
26	by	O
27	both	O
28	transient	O
29	and	O
30	stable	O
31	IRF	B
32	-	I
33	1	I
34	expression	O
35	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	the	O
6	E2	B
7	proteins	I
8	present	O
9	in	O
10	various	O
11	cell	O
12	lines	O
13	harboring	O
14	specific	O
15	BPV	O
16	-	O
17	1	O
18	mutants	O
19	,	O
20	including	O
21	the	O
22	2558	O
23	acceptor	O
24	mutant	O
25	,	O
26	proves	O
27	that	O
28	alternate	O
29	modes	O
30	of	O
31	E2	B
32	expression	O
33	exist	O
34	.	O

1	Although	O
2	both	O
3	transfected	O
4	cell	O
5	lines	O
6	contain	O
7	FGF	B
8	-	I
9	1	I
10	cell	I
11	surface	I
12	receptors	I
13	as	O
14	judged	O
15	by	O
16	crosslinking	O
17	studies	O
18	,	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	transfectants	O
24	are	O
25	refractory	O
26	to	O
27	exogenous	O
28	FGF	B
29	-	I
30	1	I
31	,	O
32	whereas	O
33	the	O
34	mutant	O
35	transfectants	O
36	respond	O
37	normally	O
38	.(	O
39	ABSTRACT	O
40	TRUNCATED	O
41	AT	O
42	250	O
43	WORDS	O
44	)	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	Immunophenotyping	O
2	in	O
3	four	O
4	cases	O
5	,	O
6	demonstrated	O
7	non	O
8	-	O
9	B	O
10	,	O
11	non	O
12	-	O
13	T	O
14	cell	O
15	origin	O
16	in	O
17	three	O
18	and	O
19	pre	O
20	-	O
21	B	O
22	cell	O
23	origin	O
24	in	O
25	one	O
26	.	O

1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	B
8	or	O
9	an	O
10	E2F	B
11	-	I
12	related	I
13	transcription	I
14	factor	I
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	B
22	myosin	I
23	expression	O
24	.	O

1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	B
45	phosphatase	I
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O

1	Monotherapy	O
2	with	O
3	ceftazidime	O
4	was	O
5	clinically	O
6	and	O
7	bacteriologically	O
8	as	O
9	effective	O
10	as	O
11	a	O
12	combination	O
13	therapy	O
14	with	O
15	cefazolin	O
16	and	O
17	tobramycin	O
18	.	O

1	The	O
2	presence	O
3	in	O
4	such	O
5	patients	O
6	of	O
7	antibodies	O
8	to	O
9	adrenaline	O
10	and	O
11	noradrenaline	O
12	is	O
13	indicative	O
14	of	O
15	considerable	O
16	disruption	O
17	of	O
18	catecholamine	O
19	biotransformation	O
20	.	O

1	Shoulder	O
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	Chem	O
2	.	O

1	One	O
2	hundred	O
3	fifty	O
4	patients	O
5	were	O
6	reviewed	O
7	at	O
8	1	O
9	year	O
10	after	O
11	arthroplasty	O
12	.	O

1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	O
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O

1	Resistance	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	neurodevelopmental	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	disruptors	O
17	.	O

1	Human	O
2	antitetanus	O
3	serum	O
4	:	O
5	an	O
6	unused	O
7	wealth	O

1	Microwave	O
2	hyperthermia	O
3	-	O
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	B
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	B
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	They	O
2	also	O
3	reported	O
4	that	O
5	E	B
6	mu	I
7	pim	I
8	-	I
9	1	I
10	transgenic	O
11	mice	O
12	show	O
13	greatly	O
14	accelerated	O
15	lymphoma	O
16	development	O
17	when	O
18	infected	O
19	with	O
20	wild	O
21	-	O
22	type	O
23	M	O
24	-	O
25	MuLV	O
26	at	O
27	birth	O
28	.	O

1	The	O
2	alpha	B
3	2A	I
4	-	I
5	adrenergic	I
6	receptor	I
7	(	O
8	alpha	B
9	2AAR	I
10	)	O
11	is	O
12	coupled	O
13	to	O
14	a	O
15	variety	O
16	of	O
17	effectors	O
18	via	O
19	pertussis	B
20	toxin	I
21	-	O
22	sensitive	O
23	GTP	B
24	-	I
25	binding	I
26	proteins	I
27	.	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	The	O
2	CNXA	O
3	domain	O
4	is	O
5	similar	O
6	at	O
7	the	O
8	amino	O
9	acid	O
10	level	O
11	to	O
12	the	O
13	Escherichia	B
14	coli	I
15	moaA	I
16	gene	I
17	product	I
18	,	O
19	while	O
20	CNXC	O
21	is	O
22	similar	O
23	to	O
24	the	O
25	E	B
26	.	I
27	coli	I
28	moaC	I
29	product	I
30	,	O
31	with	O
32	both	O
33	E	O
34	.	O
35	coli	O
36	products	O
37	encoded	O
38	by	O
39	different	O
40	cistrons	O
41	.	O

1	An	O
2	explanation	O
3	explored	O
4	for	O
5	this	O
6	lack	O
7	of	O
8	gene	O
9	expression	O
10	was	O
11	that	O
12	increased	O
13	levels	O
14	of	O
15	RAR	B
16	alpha	I
17	or	O
18	PML	B
19	might	O
20	suppress	O
21	APL	O
22	cell	O
23	growth	O
24	.	O

1	CDK4	B
2	kinase	I
3	activities	O
4	were	O
5	unaffected	O
6	,	O
7	as	O
8	were	O
9	the	O
10	levels	O
11	of	O
12	the	O
13	CDK	B
14	inhibitor	O
15	p21Cip1	B
16	present	O
17	in	O
18	cyclin	B
19	E	I
20	immunocomplexes	I
21	.	O

1	The	O
2	p20	B
3	-	I
4	CGGBP	I
5	gene	I
6	is	O
7	conserved	O
8	among	O
9	mammals	O
10	but	O
11	shows	O
12	no	O
13	homology	O
14	to	O
15	non	O
16	-	O
17	vertebrate	O
18	species	O
19	.	O

1	Nutritional	O
2	cataracts	O
3	in	O
4	timber	O
5	wolves	O
6	.	O

1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	B
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	After	O
2	2	O
3	min	O
4	of	O
5	dobutamine	O
6	injection	O
7	,	O
8	or	O
9	after	O
10	20	O
11	min	O
12	of	O
13	pimobendan	O
14	injection	O
15	,	O
16	the	O
17	myocardium	O
18	was	O
19	removed	O
20	,	O
21	and	O
22	used	O
23	for	O
24	determination	O
25	of	O
26	the	O
27	tissue	O
28	levels	O
29	of	O
30	metabolites	O
31	of	O
32	energy	O
33	and	O
34	carbohydrate	O
35	metabolism	O
36	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	Patients	O
2	at	O
3	risk	O
4	of	O
5	hypothyroidism	O
6	.	O

1	Both	O
2	betaAPP	B
3	mRNA	I
4	and	O
5	Abeta	B
6	levels	O
7	are	O
8	increased	O
9	in	O
10	trisomy	O
11	21	O
12	.	O

1	Critical	O
2	residues	O
3	required	O
4	for	O
5	repression	O
6	are	O
7	located	O
8	within	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	27	O
14	amino	O
15	acids	O
16	of	O
17	c	B
18	-	I
19	Fos	I
20	,	O
21	since	O
22	v	B
23	-	I
24	Fos	I
25	and	O
26	C	O
27	-	O
28	terminal	O
29	truncations	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	did	O
35	not	O
36	down	O
37	regulate	O
38	.	O

1	After	O
2	selection	O
3	and	O
4	conversion	O
5	to	O
6	adipocytes	O
7	,	O
8	the	O
9	level	O
10	of	O
11	EGFR	B
12	expression	O
13	was	O
14	retained	O
15	in	O
16	infectant	O
17	adipocytes	O
18	(	O
19	150	O
20	,	O
21	000	O
22	and	O
23	250	O
24	,	O
25	000	O
26	/	O
27	cell	O
28	,	O
29	respectively	O
30	),	O
31	but	O
32	not	O
33	in	O
34	the	O
35	parental	O
36	3T3	O
37	-	O
38	L1	O
39	adipocytes	O
40	(<	O
41	5000	O
42	/	O
43	cell	O
44	).	O

1	The	O
2	effects	O
3	of	O
4	systemic	O
5	glucose	O
6	concentration	O
7	on	O
8	brain	O
9	metabolism	O
10	following	O
11	repeated	O
12	brain	O
13	ischemia	O
14	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	portion	O
6	of	O
7	UKLF	B
8	contains	O
9	three	O
10	zinc	O
11	fingers	O
12	of	O
13	the	O
14	Cys2	O
15	-	O
16	His2	O
17	type	O
18	and	O
19	binds	O
20	in	O
21	vitro	O
22	to	O
23	the	O
24	CACCC	O
25	motif	O
26	of	O
27	the	O
28	beta	B
29	-	I
30	globin	I
31	promoter	I
32	and	O
33	to	O
34	the	O
35	Sp1	B
36	recognition	I
37	sequence	I
38	.	O

1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	B
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	B
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O

1	The	O
2	lysozyme	B
3	FEF	I
4	site	O
5	is	O
6	immediately	O
7	5	O
8	'	O
9	to	O
10	a	O
11	PU	B
12	.	O

1	Identification	O
2	of	O
3	a	O
4	cis	O
5	-	O
6	acting	O
7	element	O
8	in	O
9	the	O
10	class	B
11	I	I
12	major	I
13	histocompatibility	I
14	complex	I
15	gene	I
16	promoter	I
17	responsive	O
18	to	O
19	activation	O
20	by	O
21	retroviral	O
22	sequences	O
23	.	O

1	E1A	B
2	autoactivation	O
3	mediated	O
4	by	O
5	these	O
6	sites	O
7	was	O
8	about	O
9	twofold	O
10	compared	O
11	with	O
12	a	O
13	ninefold	O
14	activation	O
15	described	O
16	for	O
17	the	O
18	complete	O
19	E1A	B
20	promoter	I
21	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	domain	O
6	by	O
7	in	O
8	vitro	O
9	mutagenesis	O
10	pointed	O
11	to	O
12	a	O
13	core	O
14	of	O
15	hydrophobic	O
16	and	O
17	acidic	O
18	residues	O
19	as	O
20	critical	O
21	for	O
22	the	O
23	activity	O
24	.	O

1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O

1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O

1	An	O
2	important	O
3	mechanism	O
4	by	O
5	which	O
6	the	O
7	tumor	O
8	suppressor	O
9	p53	B
10	maintains	O
11	genomic	O
12	stability	O
13	is	O
14	to	O
15	induce	O
16	cell	O
17	cycle	O
18	arrest	O
19	through	O
20	activation	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	O
28	p21	B
29	(	O
30	WAF1	B
31	/	O
32	Cip1	B
33	)	O
34	gene	O
35	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	P2	B
6	-	I
7	proximal	I
8	CTCF	I
9	binding	I
10	site	I
11	and	O
12	transient	O
13	-	O
14	cotransfection	O
15	experiments	O
16	demonstrate	O
17	that	O
18	CTCF	B
19	is	O
20	a	O
21	transcriptional	O
22	repressor	O
23	of	O
24	the	O
25	human	B
26	c	I
27	-	I
28	myc	I
29	gene	I
30	.	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	The	O
2	response	O
3	properties	O
4	of	O
5	cat	O
6	horizontal	O
7	canal	O
8	afferents	O
9	(	O
10	N	O
11	=	O
12	81	O
13	)	O
14	were	O
15	characterized	O
16	by	O
17	three	O
18	parameters	O
19	:	O
20	their	O
21	long	O
22	time	O
23	constants	O
24	(	O
25	tau	O
26	),	O
27	low	O
28	frequency	O
29	gain	O
30	constants	O
31	(	O
32	G1	O
33	),	O
34	and	O
35	middle	O
36	frequency	O
37	gain	O
38	constants	O
39	(	O
40	Gm	O
41	).	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	matrilysin	B
7	-	I
8	2	I
9	also	O
10	contains	O
11	a	O
12	threonine	O
13	residue	O
14	adjacent	O
15	to	O
16	the	O
17	Zn	O
18	-	O
19	binding	O
20	site	O
21	that	O
22	has	O
23	been	O
24	defined	O
25	as	O
26	a	O
27	specific	O
28	feature	O
29	of	O
30	matrilysin	B
31	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	relationship	O
6	between	O
7	the	O
8	side	O
9	of	O
10	sinusitis	O
11	and	O
12	the	O
13	cleft	O
14	side	O
15	in	O
16	patients	O
17	with	O
18	unilateral	O
19	cleft	O
20	palate	O
21	.	O

1	Lipid	O
2	hydroperoxide	O
3	levels	O
4	in	O
5	plasma	O
6	and	O
7	LDL	B
8	remained	O
9	unchanged	O
10	throughout	O
11	the	O
12	study	O
13	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	B
11	-	I
12	1	I
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	O
24	AP1	B
25	(	O
26	activator	B
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	O
48	protein	O
49	kinase	O
50	C	O
51	pathways	O
52	.	O

1	Hypotension	O
2	was	O
3	produced	O
4	by	O
5	head	O
6	up	O
7	tilt	O
8	.	O

1	In	O
2	the	O
3	p51	B
4	subunit	I
5	,	O
6	the	O
7	Cys181	O
8	side	O
9	-	O
10	chain	O
11	is	O
12	oriented	O
13	in	O
14	a	O
15	similar	O
16	direction	O
17	to	O
18	the	O
19	Tyr181	O
20	side	O
21	-	O
22	chain	O
23	in	O
24	the	O
25	wild	O
26	-	O
27	type	O
28	complex	O
29	.	O

1	ARPIA	O
2	has	O
3	been	O
4	implemented	O
5	by	O
6	using	O
7	a	O
8	relational	O
9	DBMS	O
10	,	O
11	very	O
12	cheap	O
13	and	O
14	highly	O
15	diffused	O
16	on	O
17	personal	O
18	computers	O
19	.	O

1	It	O
2	is	O
3	postulated	O
4	that	O
5	altered	O
6	blood	O
7	flow	O
8	,	O
9	mediated	O
10	through	O
11	the	O
12	well	O
13	-	O
14	known	O
15	prostaglandin	B
16	synthetase	I
17	inhibitory	O
18	effects	O
19	of	O
20	ibuprofen	O
21	,	O
22	resulted	O
23	in	O
24	tubular	O
25	necrosis	O
26	.	O

1	Only	O
2	two	O
3	of	O
4	the	O
5	isoforms	O
6	possess	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	zinc	O
12	finger	O
13	domain	O
14	that	O
15	is	O
16	necessary	O
17	and	O
18	sufficient	O
19	for	O
20	TdT	B
21	promoter	I
22	binding	O
23	.	O

1	Phylogenetic	O
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	B
14	rDNA	I
15	and	O
16	rbcL	B
17	sequences	I
18	.	O

1	12	O
2	-	O
3	O	O
4	-	O
5	Tetradecanoylphorbol	O
6	13	O
7	-	O
8	acetate	O
9	was	O
10	found	O
11	to	O
12	inhibit	O
13	rapidly	O
14	and	O
15	potently	O
16	the	O
17	expression	O
18	of	O
19	mRNAs	O
20	coding	O
21	for	O
22	the	O
23	myogenic	O
24	regulators	O
25	CMD1	B
26	and	O
27	myogenin	B
28	.	O

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	N	O
7	-	O
8	and	O
9	C	O
10	-	O
11	terminal	O
12	mutations	O
13	are	O
14	required	O
15	to	O
16	inhibit	O
17	transrepression	O
18	by	O
19	FBR	B
20	protein	I
21	and	O
22	that	O
23	multiple	O
24	structural	O
25	mutations	O
26	accompanied	O
27	by	O
28	posttranslational	O
29	protein	O
30	modification	O
31	alter	O
32	gene	O
33	regulation	O
34	by	O
35	FBR	B
36	protein	I
37	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	and	O
6	competition	O
7	experiments	O
8	showed	O
9	that	O
10	site	O
11	A	O
12	is	O
13	recognized	O
14	by	O
15	an	O
16	NF1	B
17	protein	I
18	.	O

1	Elevation	O
2	of	O
3	intracellular	O
4	Ca	O
5	(	O
6	2	O
7	+)	O
8	levels	O
9	are	O
10	also	O
11	involved	O
12	because	O
13	treatment	O
14	with	O
15	receptor	O
16	-	O
17	associated	O
18	protein	O
19	,	O
20	nifedipine	O
21	,	O
22	MK801	O
23	,	O
24	removal	O
25	of	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	from	O
31	the	O
32	medium	O
33	and	O
34	dantrolene	O
35	all	O
36	served	O
37	to	O
38	inhibit	O
39	calcium	O
40	elevation	O
41	and	O
42	attenuate	O
43	the	O
44	activation	O
45	of	O
46	CREB	B
47	.	O

1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	O
20	respectively	O
21	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	B
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O

1	Phenobarbital	O
2	-	O
3	induced	O
4	alterations	O
5	in	O
6	the	O
7	metabolism	O
8	of	O
9	[	O
10	3H	O
11	]	O
12	vitamin	O
13	D3	O
14	by	O
15	the	O
16	perfused	O
17	rachitic	O
18	rat	O
19	liver	O
20	in	O
21	vitro	O
22	.	O

1	The	O
2	227	O
3	-	O
4	to	O
5	-	O
6	239	O
7	region	O
8	blocked	O
9	ADR1	B
10	activity	O
11	independently	O
12	of	O
13	the	O
14	TAD	B
15	present	O
16	on	O
17	ADR1	B
18	,	O
19	ADR1	B
20	DNA	O
21	binding	O
22	,	O
23	and	O
24	specific	O
25	ADH2	B
26	promoter	I
27	sequences	I
28	.	O

1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	B
10	mitotic	I
11	regulatory	I
12	protein	I
13	kinase	I
14	in	I
15	budding	I
16	yeast	I
17	.	O

1	The	O
2	patient	O
3	underwent	O
4	two	O
5	intracytoplasmic	O
6	sperm	O
7	injection	O
8	cycles	O
9	with	O
10	thawed	O
11	epididymal	O
12	spermatozoa	O
13	,	O
14	in	O
15	which	O
16	,	O
17	due	O
18	to	O
19	a	O
20	pharmacist	O
21	'	O
22	s	O
23	mistake	O
24	,	O
25	ovarian	O
26	stimulation	O
27	was	O
28	carried	O
29	out	O
30	by	O
31	a	O
32	combination	O
33	of	O
34	long	O
35	-	O
36	acting	O
37	gonadotrophin	B
38	-	I
39	releasing	I
40	hormone	I
41	agonist	O
42	(	O
43	leuprolide	O
44	depot	O
45	)	O
46	and	O
47	gonadotrophins	B
48	.	O

1	Continued	O
2	absorption	O
3	of	O
4	amino	O
5	acids	O
6	by	O
7	the	O
8	NBB	O
9	carrier	O
10	(	O
11	for	O
12	neutral	O
13	amino	O
14	acids	O
15	),	O
16	the	O
17	Y	O
18	+	O
19	system	O
20	(	O
21	for	O
22	dibasic	O
23	amino	O
24	acids	O
25	),	O
26	and	O
27	the	O
28	PHE	O
29	carrier	O
30	were	O
31	operative	O
32	even	O
33	during	O
34	the	O
35	actively	O
36	purging	O
37	stage	O
38	of	O
39	watery	O
40	diarrhoea	O
41	due	O
42	to	O
43	cholera	O
44	.	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	The	O
2	structure	O
3	of	O
4	these	O
5	genes	O
6	suggests	O
7	a	O
8	common	O
9	ancestor	O
10	for	O
11	all	O
12	viperid	B
13	PLA2	I
14	genes	I
15	.	O

1	In	O
2	the	O
3	Rett	O
4	syndrome	O
5	we	O
6	,	O
7	therefore	O
8	,	O
9	suspect	O
10	there	O
11	are	O
12	disturbances	O
13	in	O
14	the	O
15	brain	O
16	stem	O
17	functions	O
18	especially	O
19	in	O
20	the	O
21	ascending	O
22	reticular	O
23	activating	O
24	system	O
25	which	O
26	is	O
27	related	O
28	to	O
29	elevation	O
30	of	O
31	the	O
32	conscious	O
33	level	O
34	.	O

1	These	O
2	data	O
3	should	O
4	be	O
5	useful	O
6	in	O
7	developing	O
8	reagents	O
9	for	O
10	heterozygote	O
11	detection	O
12	and	O
13	prenatal	O
14	diagnosis	O
15	of	O
16	11	B
17	beta	I
18	-	I
19	hydroxylase	I
20	deficiency	O
21	,	O
22	the	O
23	second	O
24	most	O
25	frequent	O
26	cause	O
27	of	O
28	congenital	O
29	adrenal	O
30	hyperplasia	O
31	.	O

1	In	O
2	64	O
3	%	O
4	a	O
5	small	O
6	cardiac	O
7	vein	O
8	does	O
9	not	O
10	exist	O
11	,	O
12	but	O
13	its	O
14	origin	O
15	,	O
16	the	O
17	right	O
18	marginal	O
19	vein	O
20	,	O
21	joins	O
22	the	O
23	system	O
24	of	O
25	anterior	O
26	cardiac	O
27	veins	O
28	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	We	O
2	then	O
3	demonstrated	O
4	that	O
5	1	O
6	)	O
7	GAL4	B
8	-	O
9	REV	B
10	-	O
11	erbA	B
12	alpha	I
13	chimeras	O
14	that	O
15	contain	O
16	the	O
17	'	O
18	AB	O
19	'	O
20	region	O
21	and	O
22	lack	O
23	the	O
24	'	O
25	E	O
26	'	O
27	region	O
28	activated	O
29	transcription	O
30	of	O
31	GAL4	B
32	response	I
33	elements	I
34	in	O
35	the	O
36	presence	O
37	of	O
38	8	O
39	-	O
40	Br	O
41	-	O
42	cAMP	O
43	and	O
44	2	O
45	)	O
46	the	O
47	ligand	O
48	-	O
49	binding	O
50	domain	O
51	(	O
52	LBD	O
53	)	O
54	contains	O
55	an	O
56	active	O
57	transcriptional	O
58	silencer	O
59	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	The	O
2	molecular	O
3	basis	O
4	for	O
5	commitment	O
6	of	O
7	progenitors	O
8	to	O
9	the	O
10	eosinophil	O
11	lineage	O
12	and	O
13	mechanisms	O
14	by	O
15	which	O
16	eosinophil	O
17	-	O
18	specific	O
19	genes	O
20	are	O
21	expressed	O
22	and	O
23	regulated	O
24	during	O
25	differentiation	O
26	is	O
27	unknown	O
28	.	O

1	Until	O
2	now	O
3	,	O
4	each	O
5	of	O
6	these	O
7	loci	O
8	was	O
9	considered	O
10	to	O
11	contain	O
12	three	O
13	genes	O
14	(	O
15	for	O
16	regulator	B
17	,	O
18	permease	B
19	and	O
20	alpha	B
21	-	I
22	glucosidase	I
23	),	O
24	but	O
25	a	O
26	fourth	O
27	gene	O
28	,	O
29	presumably	O
30	an	O
31	extra	O
32	alpha	B
33	-	I
34	glucosidase	I
35	gene	I
36	,	O
37	was	O
38	found	O
39	at	O
40	MAL1	B
41	adjacent	O
42	to	O
43	the	O
44	usual	O
45	cluster	O
46	of	O
47	three	O
48	genes	O
49	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	O
12	G	B
13	-	I
14	CSF	I
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	O
12	/	O
13	HDC	O
14	Ac	O
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O

1	The	O
2	role	O
3	of	O
4	pharmacological	O
5	profiling	O
6	in	O
7	safety	O
8	assessment	O
9	.	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O

1	Preceptorship	O
2	of	O
3	CNS	O
4	students	O
5	:	O
6	an	O
7	exploratory	O
8	study	O
9	.	O

1	While	O
2	all	O
3	deletions	O
4	within	O
5	the	O
6	sequence	O
7	coding	O
8	for	O
9	the	O
10	mature	O
11	tRNA	O
12	led	O
13	to	O
14	inactivity	O
15	of	O
16	the	O
17	mutated	O
18	genes	O
19	,	O
20	substitution	O
21	of	O
22	the	O
23	central	O
24	portion	O
25	by	O
26	concatenated	B
27	Hind	I
28	III	I
29	linkers	I
30	produced	O
31	gene	O
32	units	O
33	active	O
34	in	O
35	transcription	O
36	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	B
30	alpha	I
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	The	O
2	GTPase	B
3	activity	O
4	of	O
5	CDC42Ce	B
6	is	O
7	moderately	O
8	stimulated	O
9	by	O
10	human	B
11	n	I
12	-	I
13	chimaerin	I
14	,	O
15	a	O
16	GTPase	B
17	-	I
18	activating	I
19	protein	I
20	for	O
21	the	O
22	related	O
23	p21	B
24	rac1	I
25	.	O

1	TPBF	B
2	has	O
3	two	O
4	potential	O
5	coiled	O
6	-	O
7	coil	O
8	regions	O
9	,	O
10	a	O
11	basic	O
12	region	O
13	,	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	region	O
19	,	O
20	a	O
21	histidine	O
22	-	O
23	rich	O
24	N	O
25	terminus	O
26	,	O
27	and	O
28	a	O
29	nuclear	O
30	targeting	O
31	sequence	O
32	.	O

1	To	O
2	improve	O
3	test	O
4	efficiency	O
5	,	O
6	we	O
7	modified	O
8	our	O
9	previously	O
10	introduced	O
11	contrast	O
12	/	O
13	color	O
14	card	O
15	test	O
16	by	O
17	including	O
18	a	O
19	patterned	O
20	test	O
21	stimulus	O
22	and	O
23	reducing	O
24	the	O
25	number	O
26	of	O
27	stimuli	O
28	in	O
29	both	O
30	experimental	O
31	phases	O
32	.	O

1	The	O
2	binding	O
3	site	O
4	for	O
5	OxyR	B
6	overlapped	O
7	P1oxyR	B
8	,	O
9	reminiscent	O
10	of	O
11	the	O
12	autoregulatory	O
13	loops	O
14	controlling	O
15	expression	O
16	of	O
17	oxyR	B
18	in	O
19	enteric	O
20	bacteria	O
21	and	O
22	characteristic	O
23	of	O
24	the	O
25	LysR	B
26	superfamily	I
27	in	O
28	general	O
29	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	A	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	compare	O
7	the	O
8	ONLINE	O
9	and	O
10	EMIT	O
11	II	O
12	immunoassays	O
13	with	O
14	gas	O
15	chromatographic	O
16	/	O
17	mass	O
18	spectrometric	O
19	(	O
20	GC	O
21	/	O
22	MS	O
23	)	O
24	analysis	O
25	of	O
26	methaqualone	O
27	metabolites	O
28	on	O
29	urine	O
30	using	O
31	samples	O
32	obtained	O
33	from	O
34	a	O
35	clinical	O
36	study	O
37	.	O

1	Determinants	O
2	of	O
3	recurrent	O
4	ischaemia	O
5	and	O
6	revascularisation	O
7	procedures	O
8	after	O
9	thrombolysis	O
10	with	O
11	recombinant	O
12	tissue	B
13	plasminogen	I
14	activator	I
15	in	O
16	primary	O
17	coronary	O
18	occlusion	O
19	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	B
8	of	I
9	Hairy	I
10	-	I
11	wing	I
12	protein	I
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	A	O
2	haemolytic	O
3	enterotoxigenic	O
4	strain	O
5	of	O
6	E	O
7	.	O
8	coli	O
9	(	O
10	O149	O
11	:	O
12	K88	O
13	:	O
14	H10	O
15	)	O
16	was	O
17	regularly	O
18	recovered	O
19	from	O
20	piglets	O
21	with	O
22	PWD	O
23	while	O
24	rotavirus	O
25	was	O
26	demonstrated	O
27	on	O
28	a	O
29	number	O
30	of	O
31	occasions	O
32	.	O

1	These	O
2	regions	O
3	may	O
4	be	O
5	differentially	O
6	involved	O
7	in	O
8	tissue	O
9	-	O
10	specificity	O
11	,	O
12	and	O
13	/	O
14	or	O
15	circadian	O
16	regulation	O
17	,	O
18	of	O
19	the	O
20	human	B
21	hPer1	I
22	gene	I
23	transcription	O
24	.	O

1	The	O
2	disease	O
3	ran	O
4	an	O
5	atypical	O
6	course	O
7	;	O
8	with	O
9	early	O
10	jaundice	O
11	syndrome	O
12	,	O
13	severe	O
14	enterorrhagia	O
15	and	O
16	late	O
17	appearance	O
18	of	O
19	roseola	O
20	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	the	O
7	isolation	O
8	of	O
9	a	O
10	Fab	B
11	fragment	I
12	(	O
13	Fab	B
14	A8	I
15	)	O
16	showing	O
17	a	O
18	high	O
19	relative	O
20	affinity	O
21	for	O
22	the	O
23	receptor	O
24	(	O
25	0	O
26	.	O
27	5	O
28	nM	O
29	).	O

1	Gag	B
2	protein	O
3	sequence	O
4	motifs	O
5	of	O
6	the	O
7	NC	B
8	domain	I
9	of	O
10	primate	O
11	foamy	O
12	viruses	O
13	assumed	O
14	to	O
15	be	O
16	involved	O
17	in	O
18	genome	O
19	encapsidation	O
20	are	O
21	not	O
22	conserved	O
23	in	O
24	FeFV	O
25	.	O

1	Thus	O
2	in	O
3	this	O
4	region	O
5	of	O
6	the	O
7	vessel	O
8	pyridinoline	O
9	represents	O
10	the	O
11	major	O
12	stabilising	O
13	crosslink	O
14	of	O
15	collagen	B
16	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	In	O
2	18	O
3	%	O
4	lymphography	O
5	was	O
6	clearly	O
7	positive	O
8	and	O
9	CT	O
10	negative	O
11	.	O

1	Previous	O
2	analysis	O
3	of	O
4	the	O
5	98	O
6	-	O
7	bp	O
8	sequence	O
9	has	O
10	delineated	O
11	several	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	that	O
17	are	O
18	recognized	O
19	by	O
20	nuclear	O
21	factors	O
22	present	O
23	in	O
24	human	O
25	brain	O
26	cells	O
27	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	B
5	,	I
6	3GT	I
7	transcripts	I
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	O
23	UTR	O
24	)	O
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	Characterization	O
2	of	O
3	CR1	B
4	repeat	O
5	random	O
6	PCR	O
7	markers	O
8	for	O
9	mapping	O
10	the	O
11	chicken	O
12	genome	O
13	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	Moreover	O
2	,	O
3	an	O
4	in	O
5	vitro	O
6	pull	O
7	-	O
8	down	O
9	assay	O
10	showed	O
11	that	O
12	Os	B
13	;	I
14	CycH	I
15	;	I
16	1	I
17	specifically	O
18	bound	O
19	to	O
20	R2	B
21	but	O
22	not	O
23	to	O
24	other	O
25	rice	B
26	CDKs	I
27	.	O

1	The	O
2	expression	O
3	of	O
4	chloramphenicol	B
5	acetyltransferase	I
6	was	O
7	detected	O
8	within	O
9	1	O
10	h	O
11	after	O
12	infection	O
13	of	O
14	cells	O
15	with	O
16	recombinant	O
17	virus	O
18	,	O
19	reflecting	O
20	the	O
21	early	O
22	nature	O
23	of	O
24	the	O
25	promoters	O
26	used	O
27	.	O

1	A	O
2	comparative	O
3	study	O
4	by	O
5	holographic	O
6	interferometry	O
7	of	O
8	ten	O
9	porcine	O
10	bioprosthetic	O
11	valves	O
12	(	O
13	seven	O
14	Carpentier	O
15	-	O
16	Edwards	O
17	SAV	O
18	,	O
19	two	O
20	BioImplant	O
21	and	O
22	one	O
23	Valcor	O
24	)	O
25	with	O
26	five	O
27	human	O
28	aortic	O
29	valves	O
30	before	O
31	and	O
32	after	O
33	glutaraldehyde	O
34	treatment	O
35	is	O
36	presented	O
37	.	O

1	Endocrine	O
2	cells	O
3	were	O
4	studied	O
5	by	O
6	means	O
7	of	O
8	Grimelius	O
9	'	O
10	silver	O
11	staining	O
12	and	O
13	immunostaining	O
14	for	O
15	chromogranin	B
16	,	O
17	a	O
18	general	O
19	marker	O
20	of	O
21	endocrine	O
22	cells	O
23	.	O

1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	Somatostatin	B
2	gene	I
3	expression	O
4	in	O
5	pancreatic	O
6	islet	O
7	cells	O
8	is	O
9	directed	O
10	by	O
11	cell	O
12	-	O
13	specific	O
14	DNA	O
15	control	O
16	elements	O
17	and	O
18	DNA	O
19	-	O
20	binding	O
21	proteins	O
22	.	O

1	Chick	B
2	brain	I
3	actin	I
4	depolymerizing	I
5	factor	I
6	(	O
7	ADF	B
8	)	O
9	is	O
10	a	O
11	19	O
12	-	O
13	kDa	O
14	protein	O
15	that	O
16	severs	O
17	actin	B
18	filaments	I
19	and	O
20	binds	O
21	actin	B
22	monomers	I
23	.	O

1	The	O
2	csbA	B
3	fusion	I
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O

1	Findings	O
2	of	O
3	positive	O
4	potentials	O
5	showed	O
6	that	O
7	N1	O
8	originated	O
9	in	O
10	the	O
11	area	O
12	of	O
13	ventral	O
14	gray	O
15	matter	O
16	through	O
17	the	O
18	ventro	O
19	-	O
20	lateral	O
21	column	O
22	and	O
23	N2	O
24	through	O
25	the	O
26	dorsal	O
27	column	O
28	.	O

1	Polysorbate	O
2	80	O
3	did	O
4	not	O
5	have	O
6	a	O
7	direct	O
8	stimulant	O
9	or	O
10	relaxant	O
11	effect	O
12	on	O
13	either	O
14	guinea	O
15	pig	O
16	ileum	O
17	or	O
18	rat	O
19	uterus	O
20	,	O
21	however	O
22	,	O
23	it	O
24	antagonised	O
25	the	O
26	contractions	O
27	induced	O
28	by	O
29	acetylcholine	O
30	,	O
31	histamine	O
32	,	O
33	barium	O
34	,	O
35	5	O
36	-	O
37	hydroxytryptamine	O
38	and	O
39	carbachol	O
40	in	O
41	a	O
42	dose	O
43	-	O
44	dependent	O
45	manner	O
46	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	O
19	farther	O
20	upstream	O
21	,	O
22	similar	O
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	Orthop	O
2	.	O

1	Oxygen	O
2	profiles	O
3	calculated	O
4	for	O
5	the	O
6	Krogh	O
7	model	O
8	with	O
9	excentric	O
10	diffusion	O
11	were	O
12	similar	O
13	to	O
14	those	O
15	derived	O
16	for	O
17	the	O
18	two	O
19	models	O
20	of	O
21	concentric	O
22	diffusion	O
23	.	O

1	The	O
2	highest	O
3	doses	O
4	were	O
5	found	O
6	for	O
7	drivers	O
8	who	O
9	transported	O
10	large	O
11	numbers	O
12	of	O
13	99Mo	O
14	generators	O
15	.	O

1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	B
6	factor	I
7	VIII	I
8	:	I
9	coagulant	I
10	(	O
11	F	B
12	.	I
13	VIII	I
14	:	I
15	C	I
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	I
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	B
37	factors	I
38	VII	I
39	(	O
40	F	B
41	.	I
42	VII	I
43	),	O
44	IX	O
45	(	O
46	F	B
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	B
54	.	I
55	X	I
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O

1	The	O
2	cleavage	O
3	dipeptides	O
4	of	O
5	C1YVV	B
6	NIa	I
7	protease	I
8	are	O
9	Q	O
10	(	O
11	E	O
12	)/	O
13	S	O
14	(	O
15	A	O
16	,	O
17	G	O
18	).	O

1	The	O
2	progression	O
3	of	O
4	acute	O
5	bronchitis	O
6	is	O
7	associated	O
8	with	O
9	elevated	O
10	blood	O
11	concentrations	O
12	of	O
13	acute	O
14	-	O
15	phase	O
16	proteins	O
17	,	O
18	KKS	B
19	activation	O
20	in	O
21	the	O
22	blood	O
23	and	O
24	high	O
25	serotonin	O
26	and	O
27	lactic	O
28	acid	O
29	content	O
30	in	O
31	the	O
32	humor	O
33	condensated	O
34	from	O
35	the	O
36	exhaled	O
37	air	O
38	.	O

1	Molecular	O
2	analysis	O
3	of	O
4	a	O
5	novel	O
6	schizosaccharomyces	O
7	pombe	O
8	gene	O
9	containing	O
10	two	O
11	RNP	O
12	consensus	O
13	-	O
14	sequence	O
15	RNA	O
16	-	O
17	binding	O
18	domains	O
19	.	O

1	The	O
2	examination	O
3	must	O
4	include	O
5	T1	O
6	and	O
7	T2	O
8	sequences	O
9	and	O
10	scans	O
11	in	O
12	three	O
13	planes	O
14	.	O

1	Small	O
2	-	O
3	molecule	O
4	control	O
5	of	O
6	insulin	B
7	and	O
8	PDGF	B
9	receptor	I
10	signaling	O
11	and	O
12	the	O
13	role	O
14	of	O
15	membrane	O
16	attachment	O
17	.	O

1	This	O
2	coat	B
3	protein	I
4	consists	O
5	of	O
6	Sar1p	B
7	,	O
8	the	O
9	Sec23p	B
10	protein	I
11	complex	I
12	containing	O
13	Sec23p	B
14	and	O
15	Sec24p	B
16	,	O
17	and	O
18	the	O
19	Sec13p	B
20	protein	I
21	complex	I
22	containing	O
23	Sec13p	B
24	and	O
25	a	O
26	novel	O
27	150	B
28	-	I
29	kDa	I
30	protein	I
31	,	I
32	p150	I
33	.	O

1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Fine	O
5	needle	O
6	aspiration	O
7	cytologic	O
8	smears	O
9	from	O
10	21	O
11	cases	O
12	of	O
13	invasive	O
14	lobular	O
15	carcinoma	O
16	(	O
17	ILC	O
18	)	O
19	of	O
20	breast	O
21	were	O
22	subjected	O
23	to	O
24	detailed	O
25	cytomorphologic	O
26	analysis	O
27	.	O

1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	O
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O

1	We	O
2	previously	O
3	demonstrated	O
4	that	O
5	acute	O
6	expression	O
7	of	O
8	the	O
9	bovine	O
10	papillomavirus	O
11	type	O
12	1	O
13	(	O
14	BPV1	O
15	)	O
16	E2	B
17	protein	I
18	in	O
19	HeLa	O
20	and	O
21	HT	O
22	-	O
23	3	O
24	cervical	O
25	carcinoma	O
26	cell	O
27	lines	O
28	greatly	O
29	reduced	O
30	cellular	O
31	proliferation	O
32	by	O
33	imposing	O
34	a	O
35	specific	O
36	G1	O
37	/	O
38	S	O
39	phase	O
40	growth	O
41	arrest	O
42	.	O

1	Because	O
2	the	O
3	hcf109	B
4	locus	I
5	was	O
6	mapped	O
7	at	O
8	a	O
9	distance	O
10	<	O
11	0	O
12	.	O
13	1	O
14	centimorgans	O
15	from	O
16	the	O
17	phytochrome	B
18	C	I
19	gene	I
20	,	O
21	its	O
22	molecular	O
23	characterization	O
24	by	O
25	positional	O
26	cloning	O
27	is	O
28	possible	O
29	.	O

1	If	O
2	E	O
3	.	O
4	coli	O
5	is	O
6	present	O
7	in	O
8	any	O
9	source	O
10	water	O
11	sample	O
12	,	O
13	the	O
14	borehole	O
15	and	O
16	any	O
17	directly	O
18	connected	O
19	borehole	O
20	should	O
21	be	O
22	embargoed	O
23	.	O

1	Individuals	O
2	attending	O
3	the	O
4	GUM	O
5	Department	O
6	in	O
7	the	O
8	Royal	O
9	Infirmary	O
10	of	O
11	Edinburgh	O
12	between	O
13	1990	O
14	and	O
15	1994	O
16	with	O
17	the	O
18	diagnosis	O
19	of	O
20	HIV	O
21	infection	O
22	,	O
23	genital	O
24	warts	O
25	,	O
26	genital	O
27	herpes	O
28	,	O
29	non	O
30	-	O
31	specific	O
32	genital	O
33	infection	O
34	(	O
35	NSGI	O
36	),	O
37	gonorrhoea	O
38	and	O
39	syphilis	O
40	were	O
41	included	O
42	in	O
43	the	O
44	study	O
45	.	O

1	Dopaminergic	O
2	modulation	O
3	of	O
4	transcallosal	O
5	activity	O
6	of	O
7	cat	O
8	motor	O
9	cortical	O
10	neurons	O
11	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	B
27	(	I
28	Asp	I
29	)	I
30	and	O
31	tRNA	B
32	(	I
33	Phe	I
34	)	I
35	from	O
36	yeast	O
37	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	O
61	-	O
62	2	O
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	B
7	1	I
8	insulin	I
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	Thus	O
2	,	O
3	the	O
4	pol	B
5	alpha	I
6	-	O
7	primase	B
8	complex	O
9	appears	O
10	to	O
11	act	O
12	processively	O
13	for	O
14	only	O
15	a	O
16	short	O
17	distance	O
18	.	O

1	We	O
2	analyzed	O
3	the	O
4	P	O
5	-	O
6	SAECG	O
7	in	O
8	the	O
9	time	O
10	and	O
11	frequency	O
12	domain	O
13	in	O
14	23	O
15	patients	O
16	with	O
17	Paf	O
18	and	O
19	19	O
20	controls	O
21	.	O

1	This	O
2	action	O
3	is	O
4	dependent	O
5	on	O
6	helix	B
7	-	I
8	loop	I
9	-	I
10	helix	I
11	factors	I
12	bound	O
13	to	O
14	the	O
15	E1	B
16	element	O
17	.	O

1	Marked	O
2	racial	O
3	variation	O
4	in	O
5	birthweight	O
6	percentiles	O
7	by	O
8	gestational	O
9	age	O
10	was	O
11	evident	O
12	.	O

1	Cost	O
2	-	O
3	effectiveness	O
4	analysis	O
5	provides	O
6	a	O
7	rational	O
8	means	O
9	of	O
10	allocating	O
11	limited	O
12	health	O
13	care	O
14	resources	O
15	by	O
16	allowing	O
17	the	O
18	comparison	O
19	of	O
20	the	O
21	costs	O
22	of	O
23	lipid	O
24	-	O
25	lowering	O
26	therapy	O
27	,	O
28	in	O
29	particular	O
30	,	O
31	therapy	O
32	with	O
33	beta	B
34	-	I
35	hydroxy	I
36	-	I
37	beta	I
38	-	I
39	methylglutaryl	I
40	-	I
41	CoA	I
42	(	I
43	coenzyme	I
44	A	I
45	)	I
46	reductase	I
47	inhibitors	O
48	(	O
49	statins	O
50	),	O
51	with	O
52	the	O
53	costs	O
54	of	O
55	atherosclerosis	O
56	that	O
57	could	O
58	be	O
59	prevented	O
60	by	O
61	lowering	O
62	cholesterol	O
63	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	zygotically	O
6	activated	O
7	Xretpos	O
8	transcripts	O
9	are	O
10	restricted	O
11	to	O
12	ventro	O
13	-	O
14	posterior	O
15	specific	O
16	regions	O
17	and	O
18	induced	O
19	by	O
20	UV	O
21	-	O
22	irradiation	O
23	and	O
24	BMP	B
25	-	I
26	4	I
27	overexpression	O
28	in	O
29	cycloheximide	O
30	-	O
31	dependent	O
32	way	O
33	.	O
34	genesis	O
35	26	O
36	:	O
37	198	O
38	-	O
39	207	O
40	,	O
41	2000	O
42	.	O

1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	O
9	subjects	O
10	.	O

1	The	O
2	17	O
3	-	O
4	kDa	O
5	protein	O
6	is	O
7	required	O
8	for	O
9	the	O
10	systemic	O
11	infection	O
12	of	O
13	plants	O
14	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	The	O
2	Oct	B
3	-	I
4	2	I
5	glutamine	O
6	-	O
7	rich	O
8	and	O
9	proline	O
10	-	O
11	rich	O
12	activation	O
13	domains	O
14	can	O
15	synergize	O
16	with	O
17	each	O
18	other	O
19	or	O
20	duplicates	O
21	of	O
22	themselves	O
23	to	O
24	activate	O
25	transcription	O
26	.	O

1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	O
9	and	O
10	impaired	O
11	health	O
12	,	O
13	sleep	O
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O

1	RNase	B
2	protection	O
3	assays	O
4	revealed	O
5	a	O
6	correlation	O
7	between	O
8	the	O
9	levels	O
10	of	O
11	dorsal	O
12	and	O
13	ventral	O
14	skin	O
15	expression	O
16	with	O
17	pigmentation	O
18	/	O
19	phaeomelanin	O
20	phenotypes	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	QLMI	O
6	questionnaire	O
7	has	O
8	good	O
9	potential	O
10	as	O
11	an	O
12	instrument	O
13	for	O
14	assessing	O
15	QL	O
16	in	O
17	post	O
18	-	O
19	AMI	O
20	patients	O
21	and	O
22	that	O
23	it	O
24	can	O
25	be	O
26	successfully	O
27	self	O
28	-	O
29	administered	O
30	.	O

1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	B
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O

1	It	O
2	then	O
3	merged	O
4	with	O
5	right	O
6	ventricular	O
7	wavefronts	O
8	ending	O
9	along	O
10	the	O
11	right	O
12	ventricular	O
13	anterior	O
14	atrioventricular	O
15	groove	O
16	and	O
17	outflow	O
18	tract	O
19	.	O

1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	O
14	N	O
15	-	O
16	Pog	O
17	)	O
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	B
11	/	O
12	CIP1	B
13	protein	O
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	B
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	Replacement	O
2	of	O
3	the	O
4	spacer	O
5	sequence	O
6	between	O
7	the	O
8	two	O
9	ARMs	O
10	with	O
11	a	O
12	shorter	O
13	stretch	O
14	of	O
15	sequence	O
16	also	O
17	reduced	O
18	RNA	O
19	binding	O
20	in	O
21	vitro	O
22	.	O

1	Determination	O
2	of	O
3	20	O
4	alpha	O
5	-	O
6	hydroxy	O
7	-	O
8	9	O
9	beta	O
10	,	O
11	10	O
12	alpha	O
13	-	O
14	pregna	O
15	-	O
16	4	O
17	,	O
18	6	O
19	-	O
20	dien	O
21	-	O
22	3	O
23	-	O
24	one	O
25	in	O
26	plasma	O
27	by	O
28	selected	O
29	ion	O
30	monitoring	O
31	.	O

1	Gaucher	O
2	'	O
3	s	O
4	disease	O
5	is	O
6	a	O
7	rare	O
8	metabolic	O
9	disorder	O
10	characterized	O
11	by	O
12	the	O
13	lack	O
14	of	O
15	beta	B
16	-	I
17	glucocerebrosidase	I
18	enzyme	I
19	.	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	RESULTS	O
2	:	O
3	Each	O
4	year	O
5	,	O
6	on	O
7	average	O
8	39	O
9	%	O
10	of	O
11	cases	O
12	seen	O
13	in	O
14	Sardinia	O
15	are	O
16	notified	O
17	;	O
18	646	O
19	(	O
20	40	O
21	%)	O
22	of	O
23	the	O
24	1591	O
25	patients	O
26	notified	O
27	during	O
28	the	O
29	study	O
30	period	O
31	were	O
32	never	O
33	seen	O
34	by	O
35	regional	O
36	medical	O
37	centres	O
38	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	expansion	O
6	of	O
7	the	O
8	dodecamer	O
9	repeat	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	of	O
16	CSTB	B
17	severely	O
18	disrupts	O
19	the	O
20	function	O
21	of	O
22	the	O
23	promoter	O
24	and	O
25	thereby	O
26	reduces	O
27	transcription	O
28	of	O
29	CSTB	B
30	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	B
8	kinase	I
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	B
23	-	I
24	2	I
25	.	O

1	The	O
2	optimal	O
3	care	O
4	of	O
5	CHF	O
6	patient	O
7	includes	O
8	the	O
9	recognition	O
10	and	O
11	management	O
12	of	O
13	these	O
14	electrolyte	O
15	disturbances	O
16	.	O

1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O

1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	The	O
2	adeno	B
3	-	I
4	associated	I
5	virus	I
6	(	I
7	AAV	I
8	)	I
9	rep	I
10	gene	I
11	encodes	O
12	four	O
13	proteins	O
14	(	O
15	Rep78	B
16	,	O
17	Rep68	B
18	,	O
19	Rep52	B
20	,	O
21	and	O
22	Rep40	B
23	)	O
24	required	O
25	for	O
26	AAV	O
27	DNA	O
28	replication	O
29	and	O
30	AAV	O
31	gene	O
32	regulation	O
33	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	was	O
6	then	O
7	used	O
8	to	O
9	clone	O
10	from	O
11	human	O
12	poly	O
13	(	O
14	A	O
15	)+	O
16	RNA	O
17	the	O
18	cDNA	O
19	corresponding	O
20	to	O
21	the	O
22	expressed	O
23	homolog	O
24	of	O
25	psi	B
26	ARF	I
27	4	I
28	,	O
29	referred	O
30	to	O
31	as	O
32	human	B
33	ARF	I
34	4	I
35	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	B
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	region	O
7	upstream	O
8	from	O
9	M	B
10	.	I
11	voltae	I
12	ORFtrpA	I
13	was	O
14	determined	O
15	and	O
16	revealed	O
17	the	O
18	presence	O
19	of	O
20	an	O
21	ORF	O
22	of	O
23	1227	O
24	nucleotides	O
25	(	O
26	ORFtrpB	B
27	)	O
28	encoding	O
29	a	O
30	409	O
31	amino	O
32	acid	O
33	polypeptide	O
34	of	O
35	mol	O
36	.	O
37	wt	O
38	.	O

1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	O
11	for	O
12	electron	O
13	microscopy	O
14	.	O

1	In	O
2	49	O
3	patients	O
4	in	O
5	whom	O
6	gated	O
7	equilibrium	O
8	ventriculography	O
9	and	O
10	cardiac	O
11	catheterization	O
12	were	O
13	performed	O
14	within	O
15	a	O
16	6	O
17	day	O
18	interval	O
19	,	O
20	total	O
21	and	O
22	fractional	O
23	portions	O
24	of	O
25	global	O
26	and	O
27	regional	O
28	right	O
29	ventricular	O
30	ejection	O
31	fraction	O
32	(	O
33	RVEF	O
34	)	O
35	were	O
36	correlated	O
37	with	O
38	pulmonary	O
39	arterial	O
40	systolic	O
41	pressure	O
42	.	O

1	The	O
2	human	B
3	RAD30B	I
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	Two	O
2	domains	O
3	of	O
4	EBNA2	B
5	defined	O
6	by	O
7	deletion	O
8	of	O
9	amino	O
10	acids	O
11	247	O
12	-	O
13	337	O
14	and	O
15	437	O
16	-	O
17	476	O
18	were	O
19	found	O
20	to	O
21	be	O
22	important	O
23	for	O
24	the	O
25	activation	O
26	of	O
27	both	O
28	promoters	O
29	,	O
30	while	O
31	two	O
32	different	O
33	domains	O
34	corresponding	O
35	to	O
36	residues	O
37	4	O
38	-	O
39	18	O
40	and	O
41	118	O
42	-	O
43	198	O
44	were	O
45	required	O
46	solely	O
47	for	O
48	the	O
49	LMP1	B
50	promoter	I
51	.	O

1	Adapromine	O
2	was	O
3	established	O
4	to	O
5	evoke	O
6	a	O
7	decrease	O
8	of	O
9	the	O
10	amplitude	O
11	of	O
12	the	O
13	dominant	O
14	peak	O
15	and	O
16	dominant	O
17	theta	O
18	-	O
19	activity	O
20	in	O
21	power	O
22	spectra	O
23	of	O
24	the	O
25	EEG	O
26	in	O
27	the	O
28	cortex	O
29	and	O
30	hippocamp	O
31	,	O
32	with	O
33	an	O
34	increase	O
35	of	O
36	rapid	O
37	wave	O
38	activity	O
39	in	O
40	the	O
41	beta	O
42	2	O
43	range	O
44	in	O
45	the	O
46	right	O
47	cortex	O
48	and	O
49	hippocamp	O
50	.	O

1	However	O
2	,	O
3	limited	O
4	comparisons	O
5	reveal	O
6	domains	O
7	in	O
8	the	O
9	NH2	O
10	and	O
11	COOH	O
12	termini	O
13	that	O
14	have	O
15	a	O
16	high	O
17	degree	O
18	of	O
19	similarity	O
20	suggesting	O
21	functional	O
22	conservation	O
23	.	O

1	The	O
2	conservation	O
3	of	O
4	both	O
5	the	O
6	G	O
7	-	O
8	box	O
9	and	O
10	H	O
11	-	O
12	box	O
13	in	O
14	different	O
15	CHS	B
16	promoters	I
17	emphasizes	O
18	their	O
19	importance	O
20	as	O
21	regulatory	O
22	motifs	O
23	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	Viruses	O
2	were	O
3	isolated	O
4	from	O
5	9	O
6	lungs	O
7	:	O
8	7	O
9	with	O
10	PI	O
11	-	O
12	3V	O
13	,	O
14	1	O
15	with	O
16	NCP	O
17	BVDV	O
18	type	O
19	1	O
20	,	O
21	and	O
22	1	O
23	with	O
24	both	O
25	BVHV	O
26	-	O
27	1	O
28	and	O
29	BVDV	O
30	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O

1	These	O
2	adverse	O
3	effects	O
4	usually	O
5	abate	O
6	with	O
7	time	O
8	.	O

1	One	O
2	hundred	O
3	twenty	O
4	units	O
5	of	O
6	deglycerolized	O
7	red	O
8	blood	O
9	cells	O
10	,	O
11	some	O
12	with	O
13	glycerol	O
14	added	O
15	so	O
16	as	O
17	to	O
18	exceed	O
19	an	O
20	acceptable	O
21	1	O
22	%	O
23	glycerol	O
24	content	O
25	,	O
26	had	O
27	measurements	O
28	made	O
29	of	O
30	the	O
31	post	O
32	-	O
33	wash	O
34	supernatant	O
35	fluid	O
36	by	O
37	refractive	O
38	index	O
39	and	O
40	osmometry	O
41	.	O

1	Transgenic	O
2	tobacco	O
3	plants	O
4	(	O
5	ppa	B
6	-	I
7	1	I
8	)	O
9	constitutively	O
10	expressing	O
11	Escherichia	B
12	coli	I
13	pyrophosphatase	I
14	behind	O
15	the	O
16	35S	B
17	CaMV	I
18	promoter	I
19	accumulate	O
20	high	O
21	levels	O
22	of	O
23	soluble	O
24	sugars	O
25	in	O
26	their	O
27	leaves	O
28	[	O
29	27	O
30	].	O

1	Ig	B
2	D	I
3	-	O
4	JH	B
5	recombinations	O
6	may	O
7	precede	O
8	TcR	B
9	gene	I
10	recombination	O
11	in	O
12	these	O
13	early	O
14	T	O
15	cell	O
16	lines	O
17	,	O
18	and	O
19	some	O
20	but	O
21	not	O
22	all	O
23	express	O
24	sterile	O
25	Cmu	B
26	transcripts	I
27	.	O

1	For	O
2	symptomatic	O
3	relief	O
4	and	O
5	inhibition	O
6	of	O
7	the	O
8	growth	O
9	of	O
10	the	O
11	metastases	O
12	interferon	B
13	-	I
14	a	I
15	and	O
16	somatostatin	B
17	analogues	O
18	can	O
19	be	O
20	employed	O
21	.	O

1	Low	O
2	NA	O
3	and	O
4	A	O
5	may	O
6	participate	O
7	in	O
8	lowering	O
9	the	O
10	plasma	B
11	renin	I
12	activity	O
13	which	O
14	in	O
15	PA	O
16	in	O
17	suppressed	O
18	,	O
19	sometimes	O
20	disproportionately	O
21	to	O
22	the	O
23	actual	O
24	body	O
25	sodium	O
26	content	O
27	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	cDNA	O
8	,	O
9	CHEMR1	B
10	,	O
11	encoding	O
12	a	O
13	chemokine	O
14	receptor	O
15	with	O
16	a	O
17	homology	O
18	to	O
19	the	O
20	human	B
21	C	I
22	-	I
23	C	I
24	chemokine	I
25	receptor	I
26	,	O
27	CCR	B
28	-	I
29	4	I
30	.	O

1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O

1	There	O
2	were	O
3	35	O
4	boys	O
5	and	O
6	15	O
7	girls	O
8	,	O
9	with	O
10	a	O
11	mean	O
12	age	O
13	of	O
14	five	O
15	and	O
16	a	O
17	half	O
18	years	O
19	.	O

1	The	O
2	homology	O
3	to	O
4	v	B
5	-	I
6	mil	I
7	starts	O
8	within	O
9	the	O
10	coding	O
11	sequence	O
12	of	O
13	exon	O
14	1	O
15	and	O
16	ends	O
17	within	O
18	the	O
19	3	O
20	'	O
21	untranslated	O
22	region	O
23	of	O
24	exon	O
25	11	O
26	,	O
27	12	O
28	nucleotides	O
29	downstream	O
30	from	O
31	the	O
32	nonsense	O
33	codon	O
34	terminating	O
35	the	O
36	large	O
37	open	O
38	reading	O
39	frame	O
40	shared	O
41	between	O
42	c	B
43	-	I
44	mil	I
45	and	O
46	v	B
47	-	I
48	mil	I
49	.	O

1	Identification	O
2	of	O
3	five	O
4	new	O
5	genes	O
6	,	O
7	closely	O
8	related	O
9	to	O
10	the	O
11	interleukin	B
12	-	I
13	1beta	I
14	converting	I
15	enzyme	I
16	gene	I
17	,	O
18	that	O
19	do	O
20	not	O
21	encode	O
22	functional	O
23	proteases	O
24	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	a	O
5	large	O
6	Borrelia	O
7	burgdorferi	O
8	motility	O
9	operon	O
10	which	O
11	is	O
12	initiated	O
13	by	O
14	a	O
15	consensus	O
16	sigma70	B
17	promoter	I
18	.	O

1	Analysis	O
2	with	O
3	additional	O
4	anti	O
5	-	O
6	peptide	O
7	antibodies	O
8	specific	O
9	for	O
10	alpha	B
11	,	I
12	beta	I
13	,	I
14	or	I
15	gamma	I
16	PKC	I
17	indicated	O
18	that	O
19	all	O
20	three	O
21	types	O
22	of	O
23	PKC	B
24	are	O
25	expressed	O
26	in	O
27	JK	O
28	cells	O
29	;	O
30	however	O
31	,	O
32	JKPE	O
33	cells	O
34	lost	O
35	a	O
36	major	O
37	approximately	O
38	82	O
39	kDa	O
40	immunoreactive	O
41	cytosolic	O
42	protein	O
43	detectable	O
44	with	O
45	anti	B
46	-	I
47	PKC	I
48	alpha	I
49	antibody	I
50	.	O

1	The	O
2	yeast	B
3	LPD1	I
4	gene	I
5	encoding	O
6	lipoamide	B
7	dehydrogenase	I
8	is	O
9	subject	O
10	to	O
11	the	O
12	general	O
13	control	O
14	of	O
15	amino	O
16	acid	O
17	biosynthesis	O
18	mediated	O
19	by	O
20	the	O
21	GCN4	B
22	transcription	I
23	factor	I
24	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	B
17	-	I
18	kDa	I
19	SR	I
20	protein	I
21	.	O

1	In	O
2	hemodialyzed	O
3	patients	O
4	(	O
5	Epo	B
6	and	O
7	Non	O
8	-	O
9	Epo	B
10	group	O
11	)	O
12	leptin	B
13	levels	O
14	were	O
15	significantly	O
16	higher	O
17	when	O
18	compared	O
19	to	O
20	CAPD	O
21	patients	O
22	(	O
23	Epo	B
24	and	O
25	Non	O
26	-	O
27	Epo	B
28	group	O
29	,	O
30	respectively	O
31	).	O

1	This	O
2	work	O
3	,	O
4	therefore	O
5	,	O
6	also	O
7	emphasizes	O
8	the	O
9	importance	O
10	of	O
11	careful	O
12	choice	O
13	of	O
14	oligonucleotide	O
15	and	O
16	cDNA	O
17	probes	O
18	to	O
19	study	O
20	PKC	B
21	zeta	I
22	mRNA	I
23	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	B
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	In	O
2	1993	O
3	and	O
4	1994	O
5	and	O
6	infection	O
7	with	O
8	body	O
9	lice	O
10	was	O
11	registered	O
12	41	O
13	times	O
14	in	O
15	31	O
16	patients	O
17	at	O
18	the	O
19	clinic	O
20	for	O
21	homeless	O
22	of	O
23	the	O
24	Community	O
25	Health	O
26	Service	O
27	of	O
28	Utrecht	O
29	.	O

1	MBP	B
2	-	O
3	Rep68	B
4	delta	I
5	-	O
6	mediated	O
7	DNA	O
8	-	O
9	RNA	O
10	helicase	O
11	activity	O
12	required	O
13	ATP	O
14	hydrolysis	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	Mg2	O
20	+	O
21	ions	O
22	and	O
23	was	O
24	inhibited	O
25	by	O
26	high	O
27	ionic	O
28	strength	O
29	.	O

1	Homology	O
2	was	O
3	also	O
4	detected	O
5	between	O
6	the	O
7	putative	O
8	transit	O
9	peptide	O
10	sequence	O
11	of	O
12	cysteine	B
13	synthase	I
14	C	I
15	and	O
16	other	O
17	mitochondrion	O
18	-	O
19	targeting	O
20	leader	O
21	sequences	O
22	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	These	O
2	are	O
3	the	O
4	long	O
5	terminal	O
6	repeat	O
7	(	O
8	LTR	O
9	)	O
10	promoter	O
11	,	O
12	which	O
13	regulates	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	structural	O
19	proteins	O
20	,	O
21	and	O
22	a	O
23	second	O
24	internal	O
25	promoter	O
26	,	O
27	located	O
28	towards	O
29	the	O
30	3	O
31	'	O
32	end	O
33	of	O
34	the	O
35	env	B
36	gene	I
37	,	O
38	that	O
39	directs	O
40	expression	O
41	of	O
42	the	O
43	viral	O
44	auxiliary	O
45	proteins	O
46	.	O

1	I	O
2	.	O

1	The	O
2	determination	O
3	of	O
4	immunoglobulin	B
5	E	I
6	(	O
7	IgE	B
8	)	O
9	antibodies	O
10	by	O
11	one	O
12	of	O
13	several	O
14	laboratory	O
15	tests	O
16	,	O
17	by	O
18	skin	O
19	-	O
20	prick	O
21	tests	O
22	or	O
23	by	O
24	appropriate	O
25	challenge	O
26	procedures	O
27	is	O
28	useful	O
29	either	O
30	to	O
31	identify	O
32	atopic	O
33	individuals	O
34	or	O
35	as	O
36	outcome	O
37	predictors	O
38	in	O
39	wheezy	O
40	children	O
41	.	O

1	Selective	O
2	bronchial	O
3	intubation	O
4	in	O
5	the	O
6	management	O
7	of	O
8	unilateral	O
9	pulmonary	O
10	interstitial	O
11	emphysema	O
12	.	O

1	As	O
2	was	O
3	observed	O
4	previously	O
5	for	O
6	MATa	B
7	cna1	I
8	cna2	I
9	double	O
10	mutants	O
11	,	O
12	MATa	B
13	cnb1	I
14	mutants	I
15	were	O
16	defective	O
17	in	O
18	their	O
19	ability	O
20	to	O
21	recover	O
22	from	O
23	alpha	B
24	-	I
25	factor	I
26	-	O
27	induced	O
28	growth	O
29	arrest	O
30	.	O

1	Monitoring	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	.	O

1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	O
8	gene	O
9	expression	O
10	in	O
11	the	O
12	CNS	O
13	are	O
14	poorly	O
15	understood	O
16	.	O

1	Furthermore	O
2	,	O
3	formation	O
4	of	O
5	foci	O
6	of	O
7	transformed	O
8	RECs	O
9	by	O
10	the	O
11	c	B
12	-	I
13	jun	I
14	/	O
15	ras	B
16	combination	O
17	was	O
18	augmented	O
19	3	O
20	-	O
21	fold	O
22	by	O
23	the	O
24	tumor	O
25	promoter	O
26	phorbol	O
27	12	O
28	-	O
29	tetradecanoate	O
30	13	O
31	-	O
32	acetate	O
33	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	was	O
7	highly	O
8	conserved	O
9	across	O
10	the	O
11	wide	O
12	range	O
13	of	O
14	eukaryotes	O
15	(	O
16	vertebrates	O
17	,	O
18	invertebrates	O
19	,	O
20	fungi	O
21	,	O
22	plants	O
23	and	O
24	protozoa	O
25	)	O
26	in	O
27	which	O
28	this	O
29	gene	O
30	has	O
31	now	O
32	been	O
33	identified	O
34	.	O

1	Reverse	B
2	transcriptase	I
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	B
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	The	O
2	smallest	O
3	active	B
4	FecR	I
5	derivative	I
6	contained	O
7	59	O
8	amino	O
9	acid	O
10	residues	O
11	as	O
12	compared	O
13	to	O
14	the	O
15	317	O
16	residues	O
17	of	O
18	wild	B
19	-	I
20	type	I
21	FecR	I
22	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	Aspirin	O
2	intolerance	O
3	:	O
4	unaltered	O
5	susceptibility	O
6	of	O
7	platelet	B
8	cyclo	I
9	-	I
10	oxygenase	I
11	to	O
12	inhibition	O
13	by	O
14	aspirin	O
15	in	O
16	vitro	O
17	.	O

1	IE2	B
2	-	O
3	IE2	B
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	B
18	cerevisiae	I
19	ADE	I
20	1	I
21	locus	I
22	.	O

1	Endoscopic	O
2	transthoracic	O
3	sympathectomy	O
4	as	O
5	adjuvant	O
6	treatment	O
7	for	O
8	critical	O
9	upper	O
10	-	O
11	limb	O
12	ischaemia	O
13	.	O

1	We	O
2	inserted	O
3	genes	O
4	or	O
5	gene	O
6	segments	O
7	,	O
8	that	O
9	code	O
10	for	O
11	the	O
12	bacterial	B
13	chloramphenicol	I
14	acetyltransferase	I
15	,	O
16	the	O
17	bacterial	O
18	gene	O
19	conferring	O
20	resistance	O
21	against	O
22	hygromycin	O
23	,	O
24	and	O
25	the	O
26	ORF	O
27	E7	B
28	of	O
29	the	O
30	human	O
31	papillomavirus	O
32	type	O
33	18	O
34	into	O
35	these	O
36	vectors	O
37	.	O

1	Sequencing	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	0	O
7	.	O
8	54	O
9	-	O
10	and	O
11	0	O
12	.	O
13	4	O
14	-	O
15	kb	O
16	fragments	O
17	are	O
18	identical	O
19	except	O
20	for	O
21	150	O
22	nucleotides	O
23	missing	O
24	at	O
25	the	O
26	5	O
27	'	O
28	region	O
29	of	O
30	the	O
31	0	O
32	.	O
33	4	O
34	-	O
35	kb	O
36	fragment	O
37	.	O

1	This	O
2	inhibitory	O
3	domain	O
4	has	O
5	been	O
6	deleted	O
7	in	O
8	all	O
9	naturally	O
10	occurring	O
11	AHC	B
12	deletion	I
13	mutants	I
14	described	O
15	to	O
16	date	O
17	.	O

1	Ha	B
2	-	I
3	RasV12	I
4	and	O
5	activated	O
6	proteins	O
7	in	O
8	both	O
9	the	O
10	extra	B
11	-	I
12	cellular	I
13	regulated	I
14	kinase	I
15	(	O
16	ERK	B
17	)	O
18	and	O
19	the	O
20	stress	B
21	-	I
22	activated	I
23	protein	I
24	kinase	I
25	(	O
26	SAPK	B
27	)	O
28	or	O
29	Jun	B
30	N	I
31	-	I
32	terminal	I
33	kinase	I
34	(	O
35	JNK	B
36	)	O
37	cascades	O
38	independently	O
39	stimulated	O
40	PEA3	B
41	-	O
42	mediated	O
43	gene	O
44	expression	O
45	.	O

1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	B
10	Tat	I
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O

1	3	O
2	Significant	O
3	reductions	O
4	in	O
5	lying	O
6	mean	O
7	arterial	O
8	blood	O
9	pressure	O
10	were	O
11	observed	O
12	with	O
13	daily	O
14	doses	O
15	of	O
16	200	O
17	mg	O
18	(-	O
19	9	O
20	%),	O
21	400	O
22	mg	O
23	(-	O
24	10	O
25	%)	O
26	and	O
27	800	O
28	mg	O
29	(-	O
30	14	O
31	%),	O
32	and	O
33	were	O
34	associated	O
35	with	O
36	significant	O
37	decreases	O
38	in	O
39	heart	O
40	rate	O
41	and	O
42	plasma	B
43	renin	I
44	activity	O
45	.	O

1	The	O
2	recognition	O
3	specificity	O
4	of	O
5	the	O
6	p55	B
7	PDZ	I
8	domain	I
9	appears	O
10	to	O
11	be	O
12	unique	O
13	,	O
14	since	O
15	the	O
16	three	O
17	PDZ	B
18	domains	I
19	of	O
20	hDlg	B
21	(	O
22	human	O
23	lymphocyte	O
24	homologue	O
25	of	O
26	the	O
27	Drosophila	B
28	discs	I
29	large	I
30	tumor	I
31	suppressor	I
32	)	O
33	do	O
34	not	O
35	bind	O
36	the	O
37	cytoplasmic	O
38	domain	O
39	of	O
40	glycophorin	B
41	C	I
42	.	O

1	The	O
2	currently	O
3	proposed	O
4	extended	O
5	arch	O
6	repair	O
7	should	O
8	be	O
9	reserved	O
10	for	O
11	the	O
12	small	O
13	group	O
14	of	O
15	infants	O
16	with	O
17	transverse	O
18	aortic	O
19	arch	O
20	to	O
21	ascending	O
22	aorta	O
23	diameter	O
24	ratios	O
25	(	O
26	arch	O
27	indices	O
28	)	O
29	of	O
30	less	O
31	than	O
32	0	O
33	.	O
34	25	O
35	.	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	O
20	.	O

1	Varicella	B
2	-	I
3	zoster	I
4	virus	I
5	(	I
6	VZV	I
7	)	I
8	glycoprotein	I
9	gI	I
10	is	O
11	a	O
12	type	B
13	1	I
14	transmembrane	I
15	glycoprotein	I
16	which	O
17	is	O
18	one	O
19	component	O
20	of	O
21	the	O
22	heterodimeric	O
23	gE	B
24	:	O
25	gI	B
26	Fc	I
27	receptor	I
28	complex	O
29	.	O

1	Nonreturn	O
2	rates	O
3	can	O
4	be	O
5	used	O
6	to	O
7	derive	O
8	more	O
9	elementary	O
10	biological	O
11	measures	O
12	for	O
13	reproductive	O
14	efficiency	O
15	,	O
16	such	O
17	as	O
18	conception	O
19	rate	O
20	and	O
21	calving	O
22	rate	O
23	,	O
24	which	O
25	separately	O
26	might	O
27	be	O
28	more	O
29	reliable	O
30	than	O
31	nonreturn	O
32	rate	O
33	itself	O
34	to	O
35	evaluate	O
36	the	O
37	fertility	O
38	of	O
39	a	O
40	bull	O
41	or	O
42	the	O
43	performance	O
44	of	O
45	an	O
46	AI	O
47	technician	O
48	.	O

1	In	O
2	this	O
3	article	O
4	we	O
5	propose	O
6	to	O
7	find	O
8	out	O
9	the	O
10	percentage	O
11	of	O
12	normal	O
13	occlusion	O
14	and	O
15	the	O
16	distribution	O
17	of	O
18	maloclusions	O
19	,	O
20	according	O
21	to	O
22	the	O
23	anteroposterior	O
24	relationship	O
25	between	O
26	the	O
27	dental	O
28	archs	O
29	(	O
30	following	O
31	the	O
32	ANGLE3	O
33	classification	O
34	).	O

1	Interestingly	O
2	,	O
3	the	O
4	IR5	B
5	ORF	I
6	of	O
7	EHV	O
8	-	O
9	1	O
10	possesses	O
11	a	O
12	sequence	O
13	of	O
14	13	O
15	amino	O
16	acids	O
17	(	O
18	CAYWCCLGHAFAC	O
19	)	O
20	that	O
21	is	O
22	a	O
23	perfect	O
24	match	O
25	to	O
26	the	O
27	consensus	O
28	zinc	O
29	finger	O
30	motif	O
31	(	O
32	C	O
33	-	O
34	X2	O
35	-	O
36	4	O
37	-	O
38	C	O
39	-	O
40	X2	O
41	-	O
42	15	O
43	-	O
44	C	O
45	/	O
46	H	O
47	-	O
48	X2	O
49	-	O
50	4	O
51	-	O
52	C	O
53	/	O
54	H	O
55	).	O

1	We	O
2	now	O
3	describe	O
4	a	O
5	second	O
6	RIM	B
7	protein	I
8	,	O
9	called	O
10	RIM2	B
11	,	O
12	that	O
13	is	O
14	highly	O
15	homologous	O
16	to	O
17	RIM1	B
18	and	O
19	also	O
20	expressed	O
21	primarily	O
22	in	O
23	brain	O
24	.	O

1	With	O
2	this	O
3	bisected	O
4	diastolic	O
5	driving	O
6	,	O
7	the	O
8	abnormal	O
9	echo	O
10	disappeared	O
11	completely	O
12	.	O

1	The	O
2	following	O
3	evidence	O
4	indicates	O
5	that	O
6	the	O
7	69	O
8	-	O
9	kD	O
10	protein	O
11	is	O
12	a	O
13	common	O
14	,	O
15	rather	O
16	than	O
17	a	O
18	U1	B
19	-	O
20	specific	O
21	,	O
22	protein	O
23	,	O
24	possibly	O
25	associating	O
26	with	O
27	the	O
28	snRNP	O
29	core	O
30	particles	O
31	by	O
32	protein	O
33	-	O
34	protein	O
35	interaction	O
36	.	O

1	The	O
2	newly	O
3	devised	O
4	DCT	O
5	method	O
6	yields	O
7	reliable	O
8	data	O
9	in	O
10	measuring	O
11	TBF	O
12	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	O
7	(	O
8	FONICAP	O
9	).	O

1	Use	O
2	of	O
3	Medi	O
4	-	O
5	Jector	O
6	EZ	O
7	dermojet	O
8	for	O
9	anesthesia	O
10	in	O
11	minor	O
12	surgery	O

1	Paroxysmal	O
2	fluctuations	O
3	in	O
4	observed	O
5	parasitemia	O
6	in	O
7	Plasmodium	O
8	falciparum	O
9	malaria	O
10	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	B
9	-	I
10	Pto	I
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	B
16	/	I
17	AB	I
18	genes	I
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	Using	O
2	the	O
3	yeast	O
4	two	O
5	-	O
6	hybrid	O
7	system	O
8	to	O
9	screen	O
10	for	O
11	proteins	O
12	which	O
13	interact	O
14	with	O
15	Tax1	B
16	,	O
17	we	O
18	isolated	O
19	the	O
20	B	O
21	subunit	O
22	of	O
23	the	O
24	CCAAT	O
25	binding	O
26	protein	O
27	NF	B
28	-	I
29	Y	I
30	from	O
31	a	O
32	HeLa	O
33	cDNA	O
34	library	O
35	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	I
19	monooxygenase	I
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	Furthermore	O
2	,	O
3	RING1	B
4	overexpression	O
5	results	O
6	in	O
7	enhanced	O
8	expression	O
9	of	O
10	the	O
11	proto	O
12	-	O
13	oncogenes	O
14	c	B
15	-	I
16	jun	I
17	and	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	Incidences	O
2	of	O
3	nonfatal	O
4	stroke	O
5	,	O
6	myocardial	O
7	infarction	O
8	,	O
9	angina	O
10	pectoris	O
11	und	O
12	left	O
13	ventricular	O
14	hypertrophy	O
15	could	O
16	also	O
17	be	O
18	lowered	O
19	.	O

1	The	O
2	intercistronic	O
3	gene	O
4	junctions	O
5	of	O
6	vesicular	O
7	stomatitis	O
8	virus	O
9	(	O
10	VSV	O
11	)	O
12	contain	O
13	conserved	O
14	sequence	O
15	elements	O
16	that	O
17	are	O
18	important	O
19	for	O
20	polyadenylation	O
21	and	O
22	transcription	O
23	termination	O
24	of	O
25	upstream	O
26	transcript	O
27	as	O
28	well	O
29	as	O
30	reinitiation	O
31	of	O
32	transcription	O
33	of	O
34	downstream	O
35	transcript	O
36	.	O

1	A	O
2	114	O
3	-	O
4	base	O
5	pair	O
6	sequence	O
7	of	O
8	predominantly	O
9	repeating	O
10	purine	O
11	-	O
12	pyrimidine	O
13	nucleotides	O
14	separates	O
15	these	O
16	two	O
17	d	O
18	(	O
19	AC	O
20	)	O
21	repeats	O
22	.	O

1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	I
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	B
45	2m	I
46	.	O

1	Krox	B
2	-	I
3	24	I
4	is	O
5	therefore	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcriptional	O
11	activator	O
12	.	O

1	These	O
2	characteristics	O
3	of	O
4	N22	O
5	/	O
6	P22	O
7	indicate	O
8	that	O
9	it	O
10	is	O
11	a	O
12	localized	O
13	synaptically	O
14	dependent	O
15	event	O
16	conforming	O
17	to	O
18	a	O
19	transverse	O
20	dipole	O
21	with	O
22	dorsal	O
23	negativity	O
24	and	O
25	a	O
26	simultaneous	O
27	anterior	O
28	positivity	O
29	.	O

1	Using	O
2	Southern	O
3	blot	O
4	analysis	O
5	and	O
6	restriction	O
7	mapping	O
8	of	O
9	genomic	O
10	YAC	O
11	(	O
12	yeast	O
13	artificial	O
14	chromosome	O
15	)	O
16	and	O
17	cosmid	O
18	clones	O
19	,	O
20	we	O
21	located	O
22	the	O
23	human	B
24	RIL	I
25	gene	I
26	240	O
27	-	O
28	260	O
29	kb	O
30	telomeric	O
31	to	O
32	the	O
33	IRF1	B
34	gene	I
35	and	O
36	characterized	O
37	its	O
38	genomic	O
39	structure	O
40	.	O

1	Fraction	O
2	2	O
3	contains	O
4	1	O
5	,	O
6	25	O
7	(	O
8	OH	O
9	)	O
10	2	O
11	-	O
12	vitamin	O
13	D3	O
14	,	O
15	vitamin	O
16	D3	O
17	,	O
18	25	O
19	(	O
20	OH	O
21	)-	O
22	vitamin	O
23	D3	O
24	and	O
25	1	O
26	,	O
27	24	O
28	,	O
29	25	O
30	(	O
31	OH	O
32	)	O
33	3	O
34	-	O
35	vitamin	O
36	D3	O
37	.	O

1	The	O
2	single	O
3	site	O
4	of	O
5	glycosylation	O
6	is	O
7	located	O
8	near	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	in	O
14	the	O
15	N	O
16	-	O
17	glycosylation	O
18	sequon	O
19	-	O
20	Asn	O
21	-	O
22	Cys	O
23	-	O
24	Ser	O
25	-	O
26	in	O
27	which	O
28	Cys	O
29	forms	O
30	part	O
31	of	O
32	a	O
33	disulphide	O
34	bridge	O
35	.	O

1	Effects	O
2	of	O
3	dopamine	O
4	and	O
5	of	O
6	a	O
7	dopaminergic	O
8	blocker	O
9	,	O
10	haloperidol	O
11	,	O
12	on	O
13	the	O
14	responses	O
15	of	O
16	carotid	O
17	body	O
18	chemoreceptors	O
19	to	O
20	hypoxia	O
21	and	O
22	hypercapnia	O
23	were	O
24	investigated	O
25	in	O
26	16	O
27	anesthetized	O
28	cats	O
29	.	O

1	The	O
2	human	B
3	papillomavirus	I
4	type	I
5	16	I
6	E7	I
7	protein	I
8	complements	O
9	adenovirus	B
10	type	I
11	5	I
12	E1A	I
13	amino	O
14	-	O
15	terminus	O
16	-	O
17	dependent	O
18	transactivation	O
19	of	O
20	adenovirus	B
21	type	I
22	5	I
23	early	I
24	genes	I
25	and	O
26	increases	O
27	ATF	B
28	and	O
29	Oct	B
30	-	I
31	1	I
32	DNA	O
33	binding	O
34	activity	O
35	.	O

1	From	O
2	day	O
3	30	O
4	after	O
5	turnout	O
6	,	O
7	the	O
8	PFB	O
9	-	O
10	group	O
11	had	O
12	significantly	O
13	lower	O
14	serum	B
15	pepsinogen	I
16	levels	O
17	,	O
18	which	O
19	reflects	O
20	the	O
21	low	O
22	degree	O
23	of	O
24	abomasal	O
25	damage	O
26	in	O
27	these	O
28	animals	O
29	.	O

1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O

1	Salazopyrine	O
2	desensitization	O

1	Luteinizing	B
2	hormone	I
3	-	I
4	releasing	I
5	hormone	I
6	analog	O
7	therapy	O
8	of	O
9	uterine	O
10	fibroid	O
11	:	O
12	analysis	O
13	of	O
14	results	O
15	obtained	O
16	with	O
17	buserelin	O
18	administered	O
19	intranasally	O
20	and	O
21	goserelin	O
22	administered	O
23	subcutaneously	O
24	as	O
25	a	O
26	monthly	O
27	depot	O
28	.	O

1	Dr	O
2	.	O

1	A	O
2	preoperative	O
3	teaching	O
4	booklet	O
5	for	O
6	pediatric	O
7	patients	O
8	.	O

1	Fusion	O
2	of	O
3	ubiquitin	B
4	to	O
5	pADPRP	B
6	increased	O
7	the	O
8	yield	O
9	of	O
10	pADPRP	B
11	approximately	O
12	10	O
13	-	O
14	fold	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	the	O
20	unfused	O
21	enzyme	O
22	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O

1	The	O
2	p73pct1	B
3	/	O
4	p85cdc10	B
5	complex	O
6	binds	O
7	both	O
8	in	O
9	vitro	O
10	and	O
11	in	O
12	vivo	O
13	to	O
14	MCB	B
15	but	O
16	not	O
17	SCB	B
18	or	O
19	E2F	B
20	sites	I
21	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	3	O
6	'-	O
7	end	O
8	-	O
9	adjacent	O
10	sequence	O
11	CA	O
12	(	O
13	N	O
14	)	O
15	3	O
16	-	O
17	10AGTNNAA	O
18	,	O
19	conserved	O
20	in	O
21	plant	O
22	Pol	B
23	II	I
24	-	O
25	specific	O
26	U	B
27	snRNA	I
28	genes	I
29	,	O
30	is	O
31	essential	O
32	for	O
33	the	O
34	3	O
35	'-	O
36	end	O
37	formation	O
38	of	O
39	U2	B
40	transcripts	I
41	and	O
42	,	O
43	similar	O
44	to	O
45	the	O
46	vertebrate	O
47	3	O
48	'	O
49	box	O
50	,	O
51	is	O
52	highly	O
53	tolerant	O
54	to	O
55	mutation	O
56	.	O

1	The	O
2	effects	O
3	on	O
4	reflex	O
5	latencies	O
6	but	O
7	not	O
8	on	O
9	paCO2	O
10	or	O
11	pHa	O
12	were	O
13	blocked	O
14	by	O
15	naloxone	O
16	(	O
17	2	O
18	mg	O
19	/	O
20	kg	O
21	),	O
22	and	O
23	were	O
24	not	O
25	present	O
26	in	O
27	morphine	O
28	-	O
29	tolerant	O
30	animals	O
31	.	O

1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	hrpRS	B
6	and	O
7	hrpL	B
8	are	O
9	part	O
10	of	O
11	a	O
12	regulatory	O
13	cascade	O
14	in	O
15	which	O
16	HrpR	B
17	and	O
18	HrpS	B
19	activate	O
20	expression	O
21	of	O
22	hrpL	B
23	and	O
24	HrpL	B
25	,	O
26	a	O
27	putative	O
28	sigma	B
29	factor	I
30	,	O
31	induces	O
32	expression	O
33	of	O
34	HrpL	B
35	-	I
36	responsive	I
37	genes	I
38	.	O

1	The	O
2	genomic	O
3	fragments	O
4	were	O
5	fused	O
6	upstream	O
7	of	O
8	the	O
9	luciferase	B
10	reporter	I
11	gene	I
12	.	O

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	Inclusion	O
2	in	O
3	this	O
4	family	O
5	of	O
6	proteins	O
7	suggests	O
8	that	O
9	FliQ	B
10	and	O
11	FliR	B
12	may	O
13	participate	O
14	in	O
15	an	O
16	export	O
17	pathway	O
18	required	O
19	for	O
20	flagellum	O
21	assembly	O
22	.	O

1	The	O
2	DNA	O
3	helix	O
4	at	O
5	the	O
6	tandemly	O
7	repeated	O
8	,	O
9	13mer	O
10	sequence	O
11	is	O
12	thermodynamically	O
13	unstable	O
14	,	O
15	as	O
16	evidenced	O
17	by	O
18	hypersensitivity	O
19	to	O
20	single	B
21	-	I
22	strand	I
23	-	I
24	specific	I
25	nuclease	I
26	in	O
27	a	O
28	negatively	O
29	supercoiled	O
30	plasmid	O
31	,	O
32	and	O
33	demonstrated	O
34	by	O
35	stable	O
36	DNA	O
37	unwinding	O
38	seen	O
39	after	O
40	two	O
41	-	O
42	dimensional	O
43	gel	O
44	electrophoresis	O
45	of	O
46	topoisomers	O
47	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	-	I
7	1	I
8	(	I
9	HIV	I
10	-	I
11	1	I
12	)	I
13	Tat	I
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	O
22	.	O

1	This	O
2	study	O
3	proposes	O
4	an	O
5	estimator	O
6	for	O
7	such	O
8	global	O
9	synchronizing	O
10	effects	O
11	upon	O
12	unit	O
13	-	O
14	pair	O
15	correlations	O
16	based	O
17	on	O
18	local	O
19	field	O
20	potentials	O
21	(	O
22	LFPs	O
23	).	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	it	O
6	activated	O
7	transcription	O
8	from	O
9	the	O
10	herpes	B
11	simplex	I
12	virus	I
13	type	I
14	1	I
15	thymidine	I
16	kinase	I
17	promoter	I
18	linked	O
19	to	O
20	the	O
21	chloramphenicol	B
22	acetyltransferase	I
23	gene	I
24	when	O
25	located	O
26	in	O
27	inverted	O
28	orientation	O
29	upstream	O
30	of	O
31	the	O
32	thymidine	B
33	kinase	I
34	promoter	I
35	or	O
36	downstream	O
37	of	O
38	the	O
39	chloramphenicol	B
40	acetyltransferase	I
41	gene	I
42	coding	I
43	sequence	I
44	.	O

1	The	O
2	dorsal	O
3	nerves	O
4	of	O
5	the	O
6	penis	O
7	were	O
8	anesthetized	O
9	bilaterally	O
10	with	O
11	lidocaine	O
12	.	O

1	Oleate	O
2	induced	O
3	steady	O
4	-	O
5	state	O
6	levels	O
7	of	O
8	M	B
9	-	I
10	CPT	I
11	I	I
12	mRNA	I
13	4	O
14	.	O
15	5	O
16	-	O
17	fold	O
18	.	O

1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O

1	These	O
2	mutations	O
3	alter	O
4	two	O
5	regions	O
6	of	O
7	GAL4	B
8	protein	I
9	:	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	,	O
15	and	O
16	the	O
17	transcription	O
18	activation	O
19	domain	O
20	.	O

1	A	O
2	prospective	O
3	observational	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	identify	O
9	early	O
10	indicators	O
11	of	O
12	acute	O
13	dengue	O
14	virus	O
15	infection	O
16	.	O

1	Effects	O
2	of	O
3	methiothepin	O
4	and	O
5	lysergic	O
6	acid	O
7	diethylamide	O
8	on	O
9	serotonin	O
10	release	O
11	in	O
12	vitro	O
13	and	O
14	serotonin	O
15	synthesis	O
16	in	O
17	vivo	O
18	:	O
19	possible	O
20	relation	O
21	to	O
22	serotonin	B
23	autoreceptor	I
24	function	O
25	.	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	Transcription	O
2	initiation	O
3	sites	O
4	of	O
5	the	O
6	rat	O
7	II	B
8	beta	I
9	-,	I
10	III	I
11	beta	I
12	,	I
13	and	I
14	O	I
15	beta	I
16	-	I
17	globin	I
18	genes	O
19	were	O
20	determined	O
21	to	O
22	be	O
23	52	O
24	base	O
25	pairs	O
26	(	O
27	bp	O
28	)	O
29	5	O
30	'-	O
31	upstream	O
32	of	O
33	the	O
34	translation	O
35	initiation	O
36	codon	O
37	(	O
38	ATG	O
39	),	O
40	in	O
41	each	O
42	gene	O
43	by	O
44	primer	O
45	extension	O
46	analysis	O
47	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	neu	B
6	proto	I
7	-	I
8	oncogene	I
9	did	O
10	not	O
11	show	O
12	kinase	O
13	activity	O
14	or	O
15	transforming	O
16	properties	O
17	when	O
18	expressed	O
19	at	O
20	similar	O
21	levels	O
22	in	O
23	NIH	O
24	3T3	O
25	cells	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	However	O
2	,	O
3	changing	O
4	the	O
5	half	O
6	-	O
7	site	O
8	to	O
9	the	O
10	consensus	O
11	sequence	O
12	AGGTCA	O
13	(	O
14	IRper	O
15	-	O
16	1	O
17	)	O
18	increased	O
19	binding	O
20	of	O
21	AaEcR	B
22	.	I
23	AaUSP	I
24	10	O
25	-	O
26	fold	O
27	over	O
28	IRhsp	O
29	-	O
30	1	O
31	and	O
32	,	O
33	at	O
34	the	O
35	same	O
36	time	O
37	,	O
38	reduced	O
39	the	O
40	stringency	O
41	of	O
42	the	O
43	spacer	O
44	length	O
45	requirement	O
46	,	O
47	with	O
48	IRper	O
49	-	O
50	0	O
51	to	O
52	IRper	O
53	-	O
54	5	O
55	showing	O
56	detectable	O
57	binding	O
58	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	B
7	gene	I
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	B
15	-	I
16	phenotype	O
17	.	O

1	RNase	B
2	protection	O
3	analyses	O
4	indicate	O
5	that	O
6	either	O
7	61	B
8	-	I
9	kDa	I
10	CaM	I
11	PDE	I
12	mRNA	I
13	or	O
14	structurally	O
15	related	O
16	transcripts	O
17	encoding	O
18	different	O
19	CaM	B
20	PDE	I
21	isoforms	I
22	are	O
23	expressed	O
24	in	O
25	a	O
26	tissue	O
27	-	O
28	specific	O
29	manner	O
30	.	O

1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O

1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	B
15	alanine	I
16	aminotransferase	I
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O

1	The	O
2	authors	O
3	evaluated	O
4	the	O
5	potential	O
6	for	O
7	thrombotic	O
8	complications	O
9	arising	O
10	from	O
11	implantation	O
12	of	O
13	a	O
14	ventricular	O
15	assist	O
16	device	O
17	(	O
18	Sarns	O
19	/	O
20	3M	O
21	-	O
22	VAD	O
23	)	O
24	in	O
25	four	O
26	calves	O
27	.	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	TMBr	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	striated	B
8	muscle	I
9	alpha	I
10	-	I
11	tropomyosin	I
12	from	O
13	amino	O
14	acids	O
15	1	O
16	through	O
17	258	O
18	but	O
19	contains	O
20	a	O
21	novel	O
22	COOH	O
23	-	O
24	terminal	O
25	region	O
26	from	O
27	amino	O
28	acids	O
29	259	O
30	through	O
31	281	O
32	.	O

1	In	O
2	Experiment	O
3	1	O
4	,	O
5	pups	O
6	that	O
7	had	O
8	received	O
9	an	O
10	injection	O
11	of	O
12	the	O
13	noncompetitive	O
14	N	B
15	-	I
16	methyl	I
17	-	I
18	D	I
19	-	I
20	aspartate	I
21	receptor	I
22	antagonist	O
23	MK	O
24	-	O
25	801	O
26	(	O
27	0	O
28	.	O
29	1	O
30	mg	O
31	/	O
32	kg	O
33	,	O
34	i	O
35	.	O
36	p	O
37	.)	O
38	either	O
39	30	O
40	min	O
41	before	O
42	or	O
43	immediately	O
44	after	O
45	conditioning	O
46	spent	O
47	less	O
48	time	O
49	over	O
50	the	O
51	conditioned	O
52	odor	O
53	than	O
54	saline	O
55	-	O
56	treated	O
57	controls	O
58	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	O
22	,	O
23	the	O
24	leucine	O
25	zipper	O
26	transcription	O
27	factor	O
28	MafB	B
29	/	O
30	Kr	B
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bovine	O
5	cDNA	O
6	insert	O
7	sequence	O
8	was	O
9	273	O
10	nucleotides	O
11	in	O
12	length	O
13	for	O
14	the	O
15	entire	O
16	mRNA	O
17	coding	O
18	region	O
19	,	O
20	212	O
21	nucleotides	O
22	in	O
23	the	O
24	5	O
25	'	O
26	untranslated	O
27	region	O
28	,	O
29	83	O
30	nucleotides	O
31	in	O
32	the	O
33	3	O
34	'	O
35	untranslated	O
36	region	O
37	and	O
38	a	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	tail	O
44	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	3574	O
8	-	O
9	bp	O
10	Bacillus	O
11	subtilis	O
12	(	O
13	Bs	O
14	)	O
15	DNA	O
16	fragment	O
17	located	O
18	between	O
19	the	O
20	nrdA	B
21	and	O
22	citB	B
23	genes	I
24	at	O
25	about	O
26	169	O
27	degrees	O
28	on	O
29	the	O
30	chromosome	O
31	.	O

1	A	O
2	suspected	O
3	new	O
4	storage	O
5	disease	O
6	in	O
7	cattle	O
8	.	O

1	The	O
2	concentrations	O
3	of	O
4	C4	B
5	and	O
6	C1	B
7	-	I
8	INH	I
9	increased	O
10	with	O
11	advancing	O
12	stage	O
13	of	O
14	disease	O
15	and	O
16	were	O
17	above	O
18	normal	O
19	mean	O
20	values	O
21	in	O
22	all	O
23	stages	O
24	.	O

1	A	O
2	polypeptide	O
3	chain	O
4	of	O
5	34	O
6	residues	O
7	of	O
8	the	O
9	deduced	O
10	yeast	O
11	amino	O
12	acid	O
13	sequence	O
14	closely	O
15	resembles	O
16	a	O
17	peptide	O
18	sequence	O
19	at	O
20	the	O
21	ADP	O
22	binding	O
23	site	O
24	of	O
25	bovine	B
26	muscle	I
27	pyruvate	I
28	kinase	I
29	.	O

1	The	O
2	growth	O
3	of	O
4	Aer	O
5	.	O
6	hydrophila	O
7	in	O
8	filter	O
9	-	O
10	sterilized	O
11	lettuce	O
12	extract	O
13	was	O
14	completely	O
15	inhibited	O
16	by	O
17	0	O
18	.	O
19	1	O
20	%	O
21	(	O
22	v	O
23	/	O
24	v	O
25	)	O
26	BMC	O
27	whereas	O
28	that	O
29	of	O
30	Ps	O
31	.	O
32	fluorescens	O
33	was	O
34	not	O
35	significantly	O
36	affected	O
37	by	O
38	1	O
39	%	O
40	(	O
41	v	O
42	/	O
43	v	O
44	)	O
45	BMC	O
46	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	with	O
6	autonomic	O
7	nervous	O
8	system	O
9	activity	O
10	intact	O
11	,	O
12	carotid	O
13	chemoreceptor	O
14	reflex	O
15	activation	O
16	can	O
17	elicit	O
18	an	O
19	absolute	O
20	reflexly	O
21	mediated	O
22	reduction	O
23	in	O
24	coronary	O
25	blood	O
26	flow	O
27	in	O
28	the	O
29	normal	O
30	,	O
31	conscious	O
32	dog	O
33	,	O
34	despite	O
35	an	O
36	increase	O
37	in	O
38	arterial	O
39	pressure	O
40	.	O

1	There	O
2	is	O
3	now	O
4	a	O
5	significative	O
6	difference	O
7	between	O
8	age	O
9	group	O
10	1	O
11	-	O
12	5	O
13	and	O
14	the	O
15	others	O
16	(	O
17	p	O
18	Less	O
19	Than	O
20	0	O
21	,	O
22	02	O
23	).	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	gene	O
7	from	O
8	Arabidopsis	O
9	thaliana	O
10	encoding	O
11	a	O
12	protein	O
13	related	O
14	to	O
15	SNF1	B
16	protein	O
17	kinase	O
18	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	mouse	B
9	HO	I
10	-	I
11	1	I
12	gene	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	of	O
18	p32	B
19	,	O
20	initially	O
21	identified	O
22	as	O
23	a	O
24	stress	O
25	-	O
26	induced	O
27	protein	O
28	in	O
29	mouse	O
30	BALBc	O
31	/	O
32	3T3	O
33	cells	O
34	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	constant	O
6	magnetic	O
7	field	O
8	on	O
9	the	O
10	phagocytic	O
11	activity	O
12	of	O
13	Paramecia	O

1	We	O
2	now	O
3	show	O
4	that	O
5	the	O
6	BAT1	B
7	translation	I
8	product	I
9	is	O
10	the	O
11	homolog	O
12	of	O
13	the	O
14	rat	B
15	p47	I
16	nuclear	I
17	protein	I
18	,	O
19	the	O
20	WM6	B
21	Drosophila	I
22	gene	I
23	product	I
24	,	O
25	and	O
26	probably	O
27	also	O
28	Ce08102	B
29	of	O
30	Caenorhabditis	O
31	elegans	O
32	,	O
33	all	O
34	members	O
35	of	O
36	the	O
37	DEAD	B
38	protein	I
39	family	I
40	of	O
41	ATP	B
42	-	I
43	dependent	I
44	RNA	I
45	helicases	I
46	.	O

1	Structure	O
2	,	O
3	promoter	O
4	analysis	O
5	and	O
6	chromosomal	O
7	assignment	O
8	of	O
9	the	O
10	human	B
11	APEX	I
12	gene	I
13	.	O

1	The	O
2	gene	O
3	is	O
4	contained	O
5	within	O
6	a	O
7	1	O
8	.	O
9	8	O
10	-	O
11	kilobase	O
12	AccI	B
13	-	O
14	EcoRI	B
15	restriction	O
16	fragment	O
17	mapping	O
18	at	O
19	map	O
20	coordinates	O
21	0	O
22	.	O
23	136	O
24	to	O
25	0	O
26	.	O
27	148	O
28	in	O
29	the	O
30	UL	O
31	region	O
32	of	O
33	the	O
34	EHV	O
35	-	O
36	1	O
37	genome	O
38	and	O
39	is	O
40	transcribed	O
41	from	O
42	right	O
43	to	O
44	left	O
45	.	O

1	However	O
2	,	O
3	at	O
4	18	O
5	months	O
6	of	O
7	age	O
8	,	O
9	significantly	O
10	higher	O
11	levels	O
12	of	O
13	IgG1	B
14	(	O
15	P	O
16	less	O
17	than	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	of	O
24	IgG4	B
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	01	O
32	)	O
33	were	O
34	found	O
35	in	O
36	infants	O
37	with	O
38	an	O
39	elevated	O
40	IgE	B
41	(	O
42	greater	O
43	than	O
44	or	O
45	equal	O
46	to	O
47	8	O
48	.	O
49	0	O
50	kU	O
51	/	O
52	l	O
53	)	O
54	than	O
55	in	O
56	those	O
57	with	O
58	a	O
59	lower	O
60	level	O
61	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	Idiopathic	O
2	bilateral	O
3	recurrent	O
4	branch	O
5	retinal	O
6	arterial	O
7	occlusion	O
8	(	O
9	IBRBRAO	O
10	)	O
11	is	O
12	a	O
13	rare	O
14	syndrome	O
15	characterized	O
16	by	O
17	migraine	O
18	headaches	O
19	,	O
20	tinnitus	O
21	,	O
22	vertigo	O
23	,	O
24	hearing	O
25	loss	O
26	,	O
27	and	O
28	recurrent	O
29	branch	O
30	retinal	O
31	artery	O
32	occlusion	O
33	of	O
34	unknown	O
35	etiology	O
36	.	O

1	This	O
2	differential	O
3	sensitivity	O
4	to	O
5	DB	O
6	,	O
7	as	O
8	measured	O
9	by	O
10	a	O
11	lower	O
12	concentration	O
13	of	O
14	DB	O
15	which	O
16	caused	O
17	loss	O
18	of	O
19	righting	O
20	in	O
21	LS	O
22	,	O
23	was	O
24	accompanied	O
25	by	O
26	an	O
27	equal	O
28	rate	O
29	of	O
30	water	O
31	-	O
32	soluble	O
33	barbiturate	O
34	brain	O
35	distribution	O
36	and	O
37	elimination	O
38	in	O
39	the	O
40	two	O
41	lines	O
42	.	O

1	Measurement	O
2	of	O
3	SaO2	O
4	at	O
5	moderate	O
6	altitude	O
7	can	O
8	be	O
9	helpful	O
10	in	O
11	the	O
12	care	O
13	of	O
14	both	O
15	healthy	O
16	and	O
17	ill	O
18	newborns	O
19	or	O
20	infants	O
21	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	SRC	B
2	-	I
3	1	I
4	can	O
5	relieve	O
6	the	O
7	NF	B
8	-	I
9	kappaB	I
10	-	O
11	mediated	O
12	repression	O
13	of	O
14	GR	B
15	activity	O
16	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	O
13	activin	B
14	induces	O
15	the	O
16	gene	B
17	Mix	I
18	.	I
19	2	I
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	O
34	ARF	B
35	).	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	O
26	alpha	B
27	-	I
28	IFN	I
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O

1	Spasmus	O
2	nutans	O
3	:	O
4	a	O
5	syndrome	O
6	of	O
7	auto	O
8	-	O
9	arousal	O
10	.	O

1	Previous	O
2	studies	O
3	demonstrated	O
4	that	O
5	the	O
6	flavin	B
7	-	I
8	containing	I
9	monooxygenases	I
10	(	O
11	FMO	B
12	)	O
13	are	O
14	expressed	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	manner	O
21	.	O

1	The	O
2	previously	O
3	described	O
4	four	O
5	sets	O
6	of	O
7	13	O
8	-	O
9	to	O
10	18	O
11	-	O
12	base	O
13	-	O
14	pair	O
15	interspersed	O
16	repeat	O
17	elements	O
18	between	O
19	-	O
20	55	O
21	and	O
22	-	O
23	580	O
24	provide	O
25	most	O
26	of	O
27	the	O
28	high	O
29	basal	O
30	transcriptional	O
31	strength	O
32	,	O
33	whereas	O
34	the	O
35	arrangement	O
36	of	O
37	further	O
38	upstream	O
39	tandemly	O
40	repeated	O
41	NF1	B
42	-	I
43	binding	I
44	sites	I
45	may	O
46	contribute	O
47	significantly	O
48	to	O
49	the	O
50	expanded	O
51	biological	O
52	host	O
53	range	O
54	for	O
55	expression	O
56	of	O
57	SCMV	B
58	IE94	I
59	compared	O
60	with	O
61	HCMV	B
62	IE68	I
63	.	O

1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O

1	Lack	O
2	of	O
3	controlled	O
4	prospective	O
5	studies	O
6	of	O
7	sleep	O
8	electroencephalograms	O
9	(	O
10	EEG	O
11	),	O
12	and	O
13	the	O
14	use	O
15	of	O
16	medication	O
17	,	O
18	in	O
19	children	O
20	with	O
21	developmental	O
22	dysphasia	O
23	,	O
24	may	O
25	deny	O
26	appropriate	O
27	treatment	O
28	strategies	O
29	to	O
30	children	O
31	with	O
32	severe	O
33	developmental	O
34	speech	O
35	and	O
36	language	O
37	disorders	O
38	.	O

1	A	O
2	genetic	O
3	and	O
4	molecular	O
5	analysis	O
6	of	O
7	non	O
8	-	O
9	inducible	O
10	qutA	B
11	mutants	I
12	showed	O
13	that	O
14	all	O
15	23	O
16	mutations	O
17	analysed	O
18	map	O
19	within	O
20	the	O
21	N	O
22	-	O
23	terminal	O
24	half	O
25	of	O
26	the	O
27	encoded	O
28	QUTA	B
29	protein	I
30	.	O

1	The	O
2	Ras	B
3	guanine	I
4	nucleotide	I
5	-	I
6	binding	I
7	protein	I
8	functions	O
9	as	O
10	a	O
11	molecular	O
12	switch	O
13	in	O
14	signalling	O
15	downstream	O
16	of	O
17	protein	B
18	-	I
19	tyrosine	I
20	kinases	I
21	.	O

1	The	O
2	abluminal	O
3	surface	O
4	is	O
5	often	O
6	almost	O
7	entirely	O
8	encircled	O
9	by	O
10	a	O
11	thick	O
12	layer	O
13	of	O
14	fibrillary	O
15	connective	O
16	tissue	O
17	.	O

1	L3	O
2	-	O
3	L4	O
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	V3	B
6	peptides	O
7	from	O
8	all	O
9	major	O
10	clades	O
11	of	O
12	HIV	O
13	-	O
14	1	O
15	carried	O
16	by	O
17	HIV	B
18	-	I
19	2	I
20	gag	I
21	can	O
22	be	O
23	used	O
24	as	O
25	a	O
26	potential	O
27	HIV	O
28	/	O
29	AIDS	O
30	vaccine	O
31	.	O

1	She	O
2	had	O
3	been	O
4	receiving	O
5	MTX	O
6	7	O
7	.	O
8	5	O
9	mg	O
10	/	O
11	week	O
12	for	O
13	2	O
14	.	O
15	5	O
16	months	O
17	because	O
18	of	O
19	her	O
20	vasculitis	O
21	symptoms	O
22	.	O

1	Since	O
2	the	O
3	regulation	O
4	of	O
5	SWI4	B
6	is	O
7	required	O
8	for	O
9	normal	O
10	cell	O
11	cycle	O
12	progression	O
13	,	O
14	we	O
15	have	O
16	characterized	O
17	cis	O
18	-	O
19	and	O
20	trans	O
21	-	O
22	acting	O
23	regulators	O
24	of	O
25	SWI4	B
26	transcription	O
27	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	B
7	1	I
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	dig1	B
5	dig2	I
6	cells	O
7	constitutively	O
8	invade	O
9	agar	O
10	medium	O
11	,	O
12	whereas	O
13	a	O
14	dig1	B
15	dig2	I
16	ste12	I
17	triple	O
18	mutant	O
19	does	O
20	not	O
21	,	O
22	indicating	O
23	that	O
24	Dig1	B
25	and	O
26	Dig2	B
27	share	O
28	a	O
29	role	O
30	in	O
31	negatively	O
32	regulating	O
33	the	O
34	invasive	O
35	growth	O
36	pathway	O
37	.	O

1	However	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	O
10	TPI	B
11	transcripts	I
12	takes	O
13	place	O
14	prior	O
15	to	O
16	or	O
17	after	O
18	splicing	O
19	remained	O
20	unresolved	O
21	.	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	Acad	O
2	.	O

1	Intra	O
2	-	O
3	articular	O
4	dislocation	O
5	of	O
6	the	O
7	patella	O
8	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O

1	This	O
2	night	O
3	-	O
4	day	O
5	oscillation	O
6	is	O
7	driven	O
8	by	O
9	the	O
10	endogenous	O
11	clock	O
12	(	O
13	located	O
14	in	O
15	the	O
16	suprachiasmatic	O
17	nucleus	O
18	,	O
19	SCN	O
20	).	O

1	Comparable	O
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	O
23	-	O
24	binding	O
25	fragment	O
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O

1	Anastrozole	O
2	is	O
3	the	O
4	first	O
5	aromatase	B
6	inhibitor	O
7	to	O
8	show	O
9	a	O
10	significant	O
11	survival	O
12	advantage	O
13	over	O
14	megestrol	O
15	acetate	O
16	in	O
17	post	O
18	-	O
19	menopausal	O
20	women	O
21	with	O
22	advanced	O
23	breast	O
24	cancer	O
25	.	O

1	In	O
2	all	O
3	other	O
4	cases	O
5	,	O
6	vestibular	O
7	neurectomy	O
8	or	O
9	chemical	O
10	vestibular	O
11	labyrinthectomy	O
12	,	O
13	by	O
14	means	O
15	of	O
16	intratympanic	O
17	low	O
18	concentration	O
19	gentamicin	O
20	(	O
21	20	O
22	mg	O
23	/	O
24	mL	O
25	),	O
26	are	O
27	indicated	O
28	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	Recurrence	O
2	of	O
3	bladder	O
4	tumors	O
5	among	O
6	the	O
7	original	O
8	9	O
9	cases	O
10	has	O
11	occurred	O
12	only	O
13	among	O
14	the	O
15	5	O
16	whose	O
17	properdin	B
18	levels	O
19	remained	O
20	below	O
21	the	O
22	median	O
23	.	O

1	Cardiac	O
2	preservation	O
3	.	O

1	For	O
2	steers	O
3	the	O
4	urinary	O
5	N	O
6	values	O
7	were	O
8	403	O
9	and	O
10	295	O
11	mg	O
12	/	O
13	kg	O
14	W0	O
15	.	O
16	75	O
17	at	O
18	200	O
19	and	O
20	350	O
21	kg	O
22	live	O
23	weight	O
24	respectively	O
25	and	O
26	total	O
27	N	O
28	excretion	O
29	including	O
30	faecal	O
31	N	O
32	was	O
33	408	O
34	and	O
35	320	O
36	mg	O
37	/	O
38	kg	O
39	W0	O
40	.	O
41	75	O
42	.	O

1	Sucrose	O
2	-	O
3	specific	O
4	regulation	O
5	of	O
6	scrB	B
7	was	O
8	also	O
9	lost	O
10	upon	O
11	deletion	O
12	of	O
13	4	O
14	bp	O
15	of	O
16	a	O
17	palindromic	O
18	sequence	O
19	(	O
20	OB	O
21	)	O
22	covering	O
23	positions	O
24	+	O
25	6	O
26	to	O
27	+	O
28	21	O
29	downstream	O
30	of	O
31	the	O
32	scrB	B
33	transcriptional	O
34	start	O
35	site	O
36	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	This	O
2	paper	O
3	summarises	O
4	the	O
5	experimental	O
6	evidence	O
7	upon	O
8	which	O
9	the	O
10	clinical	O
11	trials	O
12	of	O
13	aldose	B
14	reductase	I
15	inhibitors	O
16	in	O
17	diabetic	O
18	patients	O
19	have	O
20	been	O
21	initiated	O
22	and	O
23	the	O
24	results	O
25	of	O
26	published	O
27	drug	O
28	trials	O
29	in	O
30	these	O
31	patients	O
32	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	it	O
6	is	O
7	concluded	O
8	that	O
9	EDLF	O
10	has	O
11	clear	O
12	vasoconstrictor	O
13	properties	O
14	which	O
15	are	O
16	not	O
17	due	O
18	to	O
19	adrenergic	O
20	or	O
21	calcium	O
22	entry	O
23	mechanisms	O
24	and	O
25	that	O
26	there	O
27	are	O
28	differences	O
29	in	O
30	the	O
31	vasoconstrictor	O
32	effects	O
33	of	O
34	EDLFs	O
35	with	O
36	respect	O
37	to	O
38	different	O
39	vascular	O
40	beds	O
41	.	O

1	Not	O
2	even	O
3	extensive	O
4	pancreatic	O
5	resection	O
6	could	O
7	prevent	O
8	pancreatic	O
9	remnant	O
10	infection	O
11	.	O

1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	ethyl	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	Membrane	O
2	-	O
3	bound	O
4	Steel	B
5	factor	I
6	induces	O
7	more	O
8	persistent	O
9	tyrosine	B
10	kinase	I
11	activation	O
12	and	O
13	longer	O
14	life	O
15	span	O
16	of	O
17	c	B
18	-	I
19	kit	I
20	gene	O
21	-	O
22	encoded	O
23	protein	O
24	than	O
25	its	O
26	soluble	O
27	form	O
28	.	O

1	Besides	O
2	the	O
3	characterization	O
4	and	O
5	discussion	O
6	of	O
7	the	O
8	experimental	O
9	setup	O
10	used	O
11	,	O
12	the	O
13	rate	O
14	constants	O
15	obtained	O
16	are	O
17	discussed	O
18	and	O
19	compared	O
20	with	O
21	estimated	O
22	values	O
23	.	O

1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	B
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	B
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	important	O
6	to	O
7	control	O
8	hypertension	O
9	and	O
10	keep	O
11	appropriate	O
12	renal	O
13	blood	O
14	flow	O
15	during	O
16	living	O
17	renal	O
18	transplantation	O
19	surgery	O
20	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	Subunit	O
2	composition	O
3	and	O
4	domain	O
5	structure	O
6	of	O
7	the	O
8	Spo0A	B
9	sporulation	I
10	transcription	I
11	factor	I
12	of	I
13	Bacillus	I
14	subtilis	I
15	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	O
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O

1	TCZ	O
2	provides	O
3	quick	O
4	,	O
5	inexpensive	O
6	,	O
7	noninvasive	O
8	indication	O
9	of	O
10	tissue	O
11	necrosis	O
12	,	O
13	moderate	O
14	-	O
15	to	O
16	-	O
17	severe	O
18	intracranial	O
19	hemorrhage	O
20	,	O
21	and	O
22	delayed	O
23	brain	O
24	maturation	O
25	.	O

1	Electrophoretic	O
2	characteriaztion	O
3	of	O
4	virus	O
5	-	O
6	induced	O
7	interferon	B
8	of	O
9	the	O
10	blood	O
11	and	O
12	urine	O
13	in	O
14	rabbits	O

1	Piroximone	O
2	is	O
3	a	O
4	new	O
5	phosphodiesterase	B
6	III	I
7	inhibitor	O
8	that	O
9	combines	O
10	inotropic	O
11	and	O
12	vasodilator	O
13	properties	O
14	.	O

1	Each	O
2	type	O
3	was	O
4	divided	O
5	into	O
6	two	O
7	subgroups	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	whether	O
13	the	O
14	body	O
15	and	O
16	tail	O
17	of	O
18	the	O
19	pancreas	O
20	showed	O
21	intense	O
22	fatty	O
23	replacement	O
24	(	O
25	type	O
26	a	O
27	=	O
28	negative	O
29	for	O
30	intense	O
31	fatty	O
32	replacement	O
33	,	O
34	type	O
35	b	O
36	=	O
37	positive	O
38	for	O
39	intense	O
40	fatty	O
41	replacement	O
42	).	O

1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	B
6	tat	I
7	,	O
8	rev	B
9	(	O
10	tat	B
11	+	I
12	rev	O
13	+)	O
14	and	O
15	env	B
16	genes	I
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	B
27	SU	I
28	-	I
29	TM	I
30	(	O
31	gp160	B
32	),	O
33	SU	B
34	.	I
35	TM	I
36	(	O
37	gp120	B
38	x	I
39	41	I
40	),	O
41	and	O
42	nucleolar	B
43	rev	I
44	protein	I
45	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	B
6	,	O
7	none	O
8	of	O
9	the	O
10	chimeric	B
11	SefA	I
12	proteins	I
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	After	O
2	giving	O
3	a	O
4	survey	O
5	on	O
6	the	O
7	situation	O
8	of	O
9	antibiotic	O
10	resistance	O
11	in	O
12	the	O
13	region	O
14	of	O
15	Northern	O
16	Bavaria	O
17	during	O
18	1973	O
19	/	O
20	74	O
21	and	O
22	comparing	O
23	the	O
24	activity	O
25	of	O
26	a	O
27	sulfamethoxazole	O
28	(	O
29	SMZ	O
30	)	O
31	trimethoprim	O
32	(	O
33	TMP	O
34	)	O
35	combination	O
36	to	O
37	other	O
38	commonly	O
39	used	O
40	antibiotics	O
41	and	O
42	chemotherapeutic	O
43	agents	O
44	,	O
45	the	O
46	results	O
47	of	O
48	tests	O
49	with	O
50	the	O
51	new	O
52	combination	O
53	of	O
54	N1	O
55	-(	O
56	4	O
57	,	O
58	5	O
59	-	O
60	dimethyl	O
61	-	O
62	2	O
63	-	O
64	oxazolyl	O
65	)-	O
66	sulfanilamide	O
67	)	O
68	(	O
69	sulfamoxole	O
70	)	O
71	and	O
72	2	O
73	,	O
74	4	O
75	-	O
76	diamino	O
77	-	O
78	5	O
79	-(	O
80	3	O
81	,	O
82	4	O
83	,	O
84	5	O
85	-	O
86	trimethoxy	O
87	-	O
88	benzyl	O
89	)-	O
90	pyrimidine	O
91	(	O
92	trimethoprim	O
93	)	O
94	at	O
95	a	O
96	ratio	O
97	of	O
98	5	O
99	:	O
100	1	O
101	(	O
102	CN	O
103	3123	O
104	;	O
105	Nevin	O
106	,	O
107	Supristol	O
108	)	O
109	are	O
110	compared	O
111	to	O
112	those	O
113	of	O
114	tests	O
115	with	O
116	TMP	O
117	/	O
118	SMZ	O
119	.	O

1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O

1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	I
10	a	I
11	and	I
12	b	I
13	,	O
14	but	O
15	not	O
16	c	O
17	and	O
18	d	O
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	B
32	-	I
33	domain	I
34	recognition	I
35	sequence	I
36	.	O

1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O

1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	or	O
9	the	O
10	ets	B
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O

1	G	B
2	-	I
3	CSF	I
4	was	O
5	started	O
6	on	O
7	day	O
8	3	O
9	of	O
10	each	O
11	cycle	O
12	(	O
13	5	O
14	microg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	was	O
22	stopped	O
23	the	O
24	day	O
25	before	O
26	the	O
27	last	O
28	apheresis	O
29	or	O
30	when	O
31	absolute	O
32	neutrophil	O
33	count	O
34	was	O
35	above	O
36	0	O
37	.	O
38	5	O
39	x	O
40	10	O
41	(	O
42	9	O
43	)/	O
44	l	O
45	.	O

1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	panic	O
7	states	O
8	.	O

1	Thomas	O
2	'	O
3	Hospital	O
4	solution	O
5	(	O
6	with	O
7	95	O
8	%	O
9	O2	O
10	:	O
11	5	O
12	%	O
13	CO2	O
14	)	O
15	can	O
16	meet	O
17	the	O
18	metabolic	O
19	demand	O
20	of	O
21	the	O
22	ischaemic	O
23	myocardium	O
24	and	O
25	thus	O
26	increase	O
27	the	O
28	safe	O
29	duration	O
30	of	O
31	cardiac	O
32	arrest	O
33	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	Thirty	O
2	-	O
3	one	O
4	age	O
5	-	O
6	matched	O
7	,	O
8	conscious	O
9	,	O
10	virgin	O
11	,	O
12	male	O
13	Sprague	O
14	-	O
15	Dawley	O
16	rats	O
17	and	O
18	spontaneously	O
19	hypertensive	O
20	rats	O
21	(	O
22	SHRs	O
23	)	O
24	were	O
25	individually	O
26	injected	O
27	with	O
28	a	O
29	single	O
30	subcutaneous	O
31	dose	O
32	of	O
33	85	O
34	mg	O
35	/	O
36	kg	O
37	dl	O
38	-	O
39	isoproterenol	O
40	to	O
41	determine	O
42	the	O
43	degree	O
44	and	O
45	time	O
46	course	O
47	of	O
48	drug	O
49	-	O
50	induced	O
51	cardiac	O
52	failure	O
53	and	O
54	functional	O
55	recovery	O
56	.	O

1	A	O
2	9	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	KpnI	B
8	-	O
9	SalI	B
10	fragment	O
11	,	O
12	where	O
13	all	O
14	the	O
15	DNA	O
16	changes	O
17	associated	O
18	with	O
19	su	B
20	(	I
21	Hw	I
22	)	I
23	mutations	I
24	were	O
25	mapped	O
26	,	O
27	was	O
28	able	O
29	to	O
30	rescue	O
31	the	O
32	su	B
33	(	I
34	Hw	I
35	)	I
36	mutant	I
37	phenotype	O
38	after	O
39	P	O
40	-	O
41	element	O
42	-	O
43	mediated	O
44	germ	O
45	-	O
46	line	O
47	transformation	O
48	.	O

1	M	O
2	.	O
3	M	O
4	.	O
5	C	O
6	.	O
7	was	O
8	used	O
9	for	O
10	2	O
11	.	O
12	5	O
13	minutes	O
14	in	O
15	44	O
16	cases	O
17	(	O
18	20	O
19	HR	O
20	patients	O
21	,	O
22	24	O
23	LR	O
24	patients	O
25	),	O
26	and	O
27	for	O
28	5	O
29	minutes	O
30	in	O
31	66	O
32	cases	O
33	(	O
34	46	O
35	HR	O
36	patients	O
37	,	O
38	20	O
39	LR	O
40	patients	O
41	).	O

1	Clinical	O
2	trials	O
3	with	O
4	1	O
5	,	O
6	3	O
7	-	O
8	bis	O
9	(	O
10	2	O
11	-	O
12	chloroethyl	O
13	)-	O
14	1	O
15	-	O
16	nitrosourea	O
17	,	O
18	NSC	O
19	-	O
20	409962	O
21	.	O

1	As	O
2	authorized	O
3	by	O
4	the	O
5	World	O
6	Health	O
7	Organization	O
8	29th	O
9	Expert	O
10	Committee	O
11	on	O
12	Biological	O
13	Standardization	O
14	,	O
15	the	O
16	preparation	O
17	of	O
18	human	B
19	prolactin	I
20	in	O
21	ampoules	O
22	coded	O
23	75	O
24	/	O
25	504	O
26	has	O
27	been	O
28	established	O
29	as	O
30	the	O
31	International	O
32	Reference	O
33	Preparation	O
34	(	O
35	IRP	O
36	)	O
37	of	O
38	human	B
39	prolactin	I
40	for	O
41	immunoassay	O
42	.	O

1	Experiments	O
2	on	O
3	narcotized	O
4	cats	O
5	demonstrated	O
6	that	O
7	the	O
8	derivatives	O
9	of	O
10	2	O
11	-	O
12	mercaptobenzimidazole	O
13	possessing	O
14	the	O
15	properties	O
16	of	O
17	specific	O
18	bradycardic	O
19	agents	O
20	and	O
21	coded	O
22	as	O
23	CM	O
24	-	O
25	251	O
26	,	O
27	CM	O
28	-	O
29	266	O
30	,	O
31	and	O
32	CM	O
33	-	O
34	345	O
35	,	O
36	reduce	O
37	the	O
38	mean	O
39	rise	O
40	of	O
41	segment	O
42	ST	O
43	on	O
44	numerous	O
45	leads	O
46	of	O
47	the	O
48	epicardial	O
49	electrogram	O
50	during	O
51	5	O
52	-	O
53	min	O
54	occlusion	O
55	of	O
56	the	O
57	anterior	O
58	descending	O
59	branch	O
60	of	O
61	the	O
62	left	O
63	coronary	O
64	artery	O
65	.	O

1	The	O
2	time	O
3	course	O
4	of	O
5	RNA1	B
6	replication	O
7	and	O
8	RNA3	B
9	synthesis	O
10	in	O
11	induced	O
12	yeast	O
13	paralleled	O
14	that	O
15	in	O
16	yeast	O
17	transfected	O
18	with	O
19	natural	O
20	FHV	O
21	virion	O
22	RNA	O
23	.	O

1	The	O
2	yeast	B
3	RER2	I
4	gene	I
5	,	O
6	identified	O
7	by	O
8	endoplasmic	O
9	reticulum	O
10	protein	O
11	localization	O
12	mutations	O
13	,	O
14	encodes	O
15	cis	B
16	-	I
17	prenyltransferase	I
18	,	O
19	a	O
20	key	O
21	enzyme	O
22	in	O
23	dolichol	O
24	synthesis	O
25	.	O

1	Specific	O
2	requirements	O
3	for	O
4	branched	O
5	-	O
6	chain	O
7	amino	O
8	acids	O
9	,	O
10	glutamine	O
11	,	O
12	and	O
13	arginine	O
14	are	O
15	evaluated	O
16	.	O

1	The	O
2	possible	O
3	mechanisms	O
4	underlying	O
5	differences	O
6	in	O
7	post	O
8	-	O
9	tetanic	O
10	effects	O
11	from	O
12	muscle	O
13	and	O
14	cutaneous	O
15	afferents	O
16	in	O
17	adults	O
18	and	O
19	neonates	O
20	are	O
21	discussed	O
22	.	O

1	Among	O
2	82	O
3	superficial	O
4	lesions	O
5	34	O
6	were	O
7	classified	O
8	as	O
9	showing	O
10	CR	O
11	and	O
12	another	O
13	23	O
14	as	O
15	showing	O
16	PR	O
17	,	O
18	with	O
19	a	O
20	response	O
21	rate	O
22	of	O
23	69	O
24	.	O
25	5	O
26	%.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	factor	B
6	IX	I
7	activity	O
8	is	O
9	decreased	O
10	in	O
11	coumarin	O
12	treatment	O
13	with	O
14	factor	B
15	IX	I
16	antigen	O
17	remaining	O
18	normal	O
19	.	O

1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O

1	Abrogation	O
2	of	O
3	p53	B
4	function	O
5	by	O
6	E6	B
7	resulted	O
8	in	O
9	an	O
10	increase	O
11	in	O
12	the	O
13	spontaneous	O
14	mutation	O
15	frequencies	O
16	at	O
17	the	O
18	heterozygous	O
19	thymidine	B
20	kinase	I
21	(	O
22	TK	B
23	)	O
24	locus	O
25	but	O
26	not	O
27	at	O
28	the	O
29	hemizygous	O
30	hypoxanthine	B
31	phosphoribosyl	I
32	transferase	I
33	(	O
34	HPRT	B
35	)	O
36	locus	O
37	.	O

1	Study	O
2	of	O
3	antinuclear	O
4	autoantibodies	O
5	by	O
6	immunofluorescence	O
7	technic	O
8	in	O
9	collagen	B
10	diseases	O

1	Cost	O
2	-	O
3	effectiveness	O
4	of	O
5	interferon	B
6	beta	I
7	-	I
8	1b	I
9	in	O
10	slowing	O
11	multiple	O
12	sclerosis	O
13	disability	O
14	progression	O
15	.	O

1	GGS1	B
2	is	O
3	the	O
4	same	O
5	gene	O
6	as	O
7	TPS1	B
8	which	O
9	was	O
10	identified	O
11	as	O
12	encoding	O
13	a	O
14	subunit	O
15	of	O
16	the	O
17	trehalose	B
18	-	I
19	6	I
20	-	I
21	phosphate	I
22	synthase	I
23	/	I
24	phosphatase	I
25	complex	I
26	and	O
27	it	O
28	is	O
29	allelic	O
30	to	O
31	the	O
32	fdp1	B
33	,	O
34	byp1	B
35	,	O
36	glc6	B
37	and	O
38	cif1	O
39	mutations	O
40	.	O

1	Blood	O
2	sampling	O
3	procedures	O
4	were	O
5	videotaped	O
6	.	O

1	The	O
2	YccA	B
3	protein	I
4	was	O
5	found	O
6	to	O
7	be	O
8	degraded	O
9	in	O
10	an	O
11	FtsH	B
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	vivo	O
17	and	O
18	in	O
19	vitro	O
20	,	O
21	whereas	O
22	the	O
23	YccA11	B
24	mutant	I
25	protein	I
26	,	O
27	lacking	O
28	eight	O
29	amino	O
30	acid	O
31	residues	O
32	within	O
33	the	O
34	amino	O
35	-	O
36	terminal	O
37	cytoplasmic	O
38	domain	O
39	,	O
40	was	O
41	refractory	O
42	to	O
43	the	O
44	degradation	O
45	.	O

1	An	O
2	additional	O
3	advantage	O
4	is	O
5	that	O
6	the	O
7	resin	O
8	can	O
9	be	O
10	removed	O
11	and	O
12	the	O
13	immunoperoxidase	B
14	technique	O
15	carried	O
16	out	O
17	on	O
18	thin	O
19	sections	O
20	.	O

1	When	O
2	combined	O
3	with	O
4	independent	O
5	activating	O
6	mutations	O
7	in	O
8	the	O
9	c	B
10	-	I
11	abl	I
12	kinase	I
13	domain	I
14	or	O
15	NH2	O
16	-	O
17	terminus	O
18	,	O
19	the	O
20	G128R	B
21	mutation	O
22	blocked	O
23	transformation	O
24	by	O
25	the	O
26	double	O
27	mutant	O
28	,	O
29	suggesting	O
30	that	O
31	the	O
32	G128R	B
33	mutant	I
34	was	O
35	unable	O
36	to	O
37	transform	O
38	cells	O
39	for	O
40	trivial	O
41	reasons	O
42	.	O

1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O

1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O

1	Thrombotic	O
2	thrombocytopenic	O
3	purpura	O
4	in	O
5	systemic	O
6	lupus	O
7	erythematosus	O
8	.	O

1	Here	O
2	we	O
3	present	O
4	evidence	O
5	that	O
6	major	B
7	IE	I
8	proteins	I
9	IE86	I
10	,	O
11	IE72	B
12	,	O
13	and	O
14	IE55	B
15	are	O
16	capable	O
17	of	O
18	trans	O
19	-	O
20	activating	O
21	the	O
22	HIV	B
23	LTR	I
24	in	O
25	a	O
26	T	O
27	-	O
28	cell	O
29	line	O
30	,	O
31	HUT	O
32	-	O
33	78	O
34	.	O

1	Most	O
2	strains	O
3	(	O
4	95	O
5	%)	O
6	of	O
7	S	O
8	.	O
9	lugdunensis	O
10	produced	O
11	a	O
12	delta	B
13	hemolysin	I
14	like	O
15	that	O
16	seen	O
17	with	O
18	nine	O
19	other	O
20	species	O
21	of	O
22	CNS	O
23	.	O

1	The	O
2	tumorigenic	O
3	E1A	B
4	+	O
5	cHa	B
6	-	I
7	ras	I
8	cells	O
9	are	O
10	characterized	O
11	by	O
12	high	O
13	and	O
14	constitutive	O
15	DNA	O
16	binding	O
17	activities	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	,	O
23	in	O
24	contrast	O
25	to	O
26	nontransformed	O
27	cells	O
28	and	O
29	the	O
30	E1A	B
31	cells	O
32	.	O

1	Amongst	O
2	other	O
3	qualities	O
4	,	O
5	the	O
6	book	O
7	'	O
8	s	O
9	importance	O
10	lies	O
11	in	O
12	the	O
13	fact	O
14	that	O
15	it	O
16	associates	O
17	an	O
18	elaborate	O
19	theoretical	O
20	construction	O
21	with	O
22	the	O
23	empirical	O
24	data	O
25	,	O
26	working	O
27	within	O
28	the	O
29	possibilities	O
30	provided	O
31	by	O
32	late	O
33	19th	O
34	-	O
35	century	O
36	moral	O
37	statistics	O
38	.	O

1	Serum	B
2	response	I
3	factor	I
4	(	O
5	SRF	B
6	),	O
7	a	O
8	member	O
9	of	O
10	an	O
11	ancient	O
12	family	O
13	of	O
14	DNA	O
15	-	O
16	binding	O
17	proteins	O
18	,	O
19	is	O
20	generally	O
21	assumed	O
22	to	O
23	be	O
24	a	O
25	ubiquitous	O
26	transcription	O
27	factor	O
28	involved	O
29	in	O
30	regulating	O
31	growth	O
32	factor	O
33	-	O
34	responsive	O
35	genes	O
36	.	O

1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	B
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	I
23	II	I
24	)	I
25	s	I
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	B
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	B
43	and	O
44	MBF	B
45	.	O

1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O

1	U73	B
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	Other	O
2	properties	O
3	of	O
4	Hg	O
5	-	O
6	and	O
7	Cd	O
8	-	O
9	spores	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	control	O
16	spores	O
17	.	O

1	The	O
2	development	O
3	and	O
4	distribution	O
5	of	O
6	Trypanosoma	O
7	congolense	O
8	,	O
9	T	O
10	vivax	O
11	and	O
12	T	O
13	brucei	O
14	in	O
15	the	O
16	skin	O
17	of	O
18	goats	O
19	was	O
20	examined	O
21	after	O
22	the	O
23	animals	O
24	were	O
25	bitten	O
26	by	O
27	infected	O
28	Glossina	O
29	morsitans	O
30	centralis	O
31	.	O

1	2	O
2	.	O

1	The	O
2	minus	O
3	-	O
4	end	O
5	-	O
6	directed	O
7	microtubule	O
8	motors	O
9	,	O
10	the	O
11	dyneins	B
12	,	O
13	may	O
14	also	O
15	constitute	O
16	a	O
17	superfamily	O
18	of	O
19	force	O
20	-	O
21	generating	O
22	proteins	O
23	with	O
24	distinct	O
25	attachment	O
26	domains	O
27	.	O

1	As	O
2	pH	O
3	and	O
4	Hb	B
5	can	O
6	also	O
7	affect	O
8	mixed	O
9	venous	O
10	CO2	O
11	content	O
12	,	O
13	the	O
14	effect	O
15	on	O
16	Q	O
17	was	O
18	also	O
19	assessed	O
20	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	A	O
2	new	O
3	UASH	O
4	consensus	O
5	sequence	O
6	derived	O
7	from	O
8	this	O
9	mutational	O
10	analysis	O
11	closely	O
12	matches	O
13	a	O
14	consensus	O
15	Abf1	B
16	binding	I
17	site	I
18	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	A	O
2	segmental	O
3	analysis	O
4	of	O
5	the	O
6	key	O
7	regions	O
8	of	O
9	HLA	B
10	-	I
11	DR1	I
12	that	O
13	control	O
14	T	O
15	cell	O
16	allorecognition	O
17	was	O
18	performed	O
19	by	O
20	using	O
21	a	O
22	series	O
23	of	O
24	transfected	O
25	cell	O
26	lines	O
27	expressing	O
28	the	O
29	products	O
30	of	O
31	recombinant	O
32	DRB	B
33	/	O
34	H	B
35	-	I
36	2Eb	I
37	genes	O
38	,	O
39	paired	O
40	with	O
41	either	O
42	DR	B
43	alpha	I
44	or	O
45	H	B
46	-	I
47	2E	I
48	alpha	I
49	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	B
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	elucidate	O
7	signaling	O
8	pathways	O
9	induced	O
10	by	O
11	photodynamic	O
12	therapy	O
13	(	O
14	PDT	O
15	)	O
16	with	O
17	hypericin	O
18	.	O

1	In	O
2	a	O
3	randomised	O
4	double	O
5	-	O
6	blind	O
7	study	O
8	,	O
9	46	O
10	first	O
11	episode	O
12	schizophrenics	O
13	were	O
14	given	O
15	pimozide	O
16	or	O
17	flupenthixol	O
18	for	O
19	up	O
20	to	O
21	5	O
22	weeks	O
23	;	O
24	the	O
25	mean	O
26	daily	O
27	dose	O
28	at	O
29	the	O
30	end	O
31	was	O
32	18	O
33	.	O
34	8	O
35	mg	O
36	pimozide	O
37	and	O
38	20	O
39	mg	O
40	flupenthixol	O
41	.	O

1	The	O
2	mechanisms	O
3	that	O
4	govern	O
5	the	O
6	activation	O
7	or	O
8	suppression	O
9	of	O
10	the	O
11	CD8	B
12	gene	I
13	are	O
14	likely	O
15	to	O
16	be	O
17	central	O
18	to	O
19	the	O
20	T	O
21	cell	O
22	development	O
23	program	O
24	.	O

1	Gas6	B
2	contains	O
3	an	O
4	NH2	O
5	-	O
6	terminal	O
7	Gla	O
8	domain	O
9	followed	O
10	by	O
11	four	O
12	epidermal	B
13	growth	I
14	factor	I
15	-	I
16	like	I
17	repeats	I
18	and	O
19	tandem	O
20	globular	O
21	(	O
22	G	O
23	)	O
24	domains	O
25	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O

1	Chlamydial	O
2	agents	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	semen	O
8	near	O
9	the	O
10	end	O
11	of	O
12	the	O
13	chlamydemic	O
14	phase	O
15	.	O

1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O

1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	B
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	B
13	gene	I
14	(	O
15	named	O
16	traX	B
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	indicate	O
7	that	O
8	MAP	B
9	kinase	I
10	stimulates	O
11	the	O
12	hPL	B
13	-	I
14	B	I
15	enhancer	I
16	by	O
17	an	O
18	NF	B
19	-	I
20	IL	I
21	-	I
22	6	I
23	-	O
24	dependent	O
25	pathway	O
26	.	O

1	Trypanosoma	O
2	cruzi	O
3	.	O

1	MPO	B
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O

1	The	O
2	substrates	O
3	for	O
4	glycan	O
5	synthesis	O
6	in	O
7	the	O
8	lumen	O
9	of	O
10	the	O
11	Golgi	O
12	are	O
13	nucleotide	O
14	sugars	O
15	that	O
16	must	O
17	be	O
18	transported	O
19	from	O
20	the	O
21	cytosol	O
22	by	O
23	specific	O
24	membrane	O
25	-	O
26	bound	O
27	transporters	O
28	.	O

1	Thus	O
2	,	O
3	the	O
4	L45	O
5	sequence	O
6	between	O
7	kinase	O
8	subdomains	O
9	IV	O
10	and	O
11	V	O
12	specifies	O
13	TGF	B
14	-	I
15	beta	I
16	responsiveness	O
17	of	O
18	the	O
19	type	B
20	I	I
21	receptor	I
22	.	O

1	We	O
2	have	O
3	isolated	O
4	cDNAs	O
5	for	O
6	a	O
7	gene	O
8	coding	O
9	for	O
10	a	O
11	G	B
12	protein	I
13	alpha	I
14	subunit	I
15	from	I
16	tomato	I
17	(	O
18	Lycopersicon	O
19	esculentum	O
20	,	O
21	cv	O
22	.	O

1	Protamine	B
2	and	O
3	heparin	O
4	doses	O
5	,	O
6	their	O
7	sum	O
8	(	O
9	Sigma	O
10	-	O
11	dose	O
12	)	O
13	and	O
14	differential	O
15	(	O
16	Delta	O
17	-	O
18	dose	O
19	)	O
20	doses	O
21	,	O
22	and	O
23	activated	O
24	clotting	O
25	times	O
26	were	O
27	tabulated	O
28	.	O

1	Hemolytic	O
2	disease	O
3	of	O
4	African	O
5	newborn	O
6	.	O

1	Although	O
2	the	O
3	OC	B
4	promoter	I
5	is	O
6	activated	O
7	in	O
8	a	O
9	C	O
10	terminus	O
11	dependent	O
12	manner	O
13	,	O
14	the	O
15	MDR	B
16	,	O
17	LTR	O
18	and	O
19	BSP	B
20	promoters	I
21	are	O
22	repressed	O
23	by	O
24	three	O
25	distinct	O
26	mechanisms	O
27	,	O
28	either	O
29	independent	O
30	of	O
31	or	O
32	involving	O
33	the	O
34	AML	B
35	C	I
36	terminus	I
37	,	O
38	or	O
39	requiring	O
40	only	O
41	the	O
42	conserved	O
43	C	O
44	-	O
45	terminal	O
46	pentapeptide	O
47	VWRPY	O
48	.	O

1	A	O
2	1	O
3	.	O
4	5	O
5	-	O
6	kb	O
7	HindIII	B
8	genomic	O
9	fragment	O
10	carrying	O
11	the	O
12	vspA	B
13	gene	O
14	from	O
15	M	O
16	.	O
17	bovis	O
18	PG45	O
19	was	O
20	cloned	O
21	and	O
22	sequenced	O
23	.	O

1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O

1	USF	B
2	synthesized	O
3	in	O
4	an	O
5	in	O
6	vitro	O
7	transcription	O
8	and	O
9	translation	O
10	system	O
11	also	O
12	binds	O
13	to	O
14	the	O
15	ADH	B
16	promoter	I
17	as	O
18	well	O
19	as	O
20	to	O
21	the	O
22	MLP	O
23	.	O

1	Genotoxic	O
2	activity	O
3	of	O
4	a	O
5	tobacco	O
6	-	O
7	specific	O
8	nitrosamine	O
9	.	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	I
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	The	O
2	acfD	B
3	gene	I
4	encompasses	O
5	254	O
6	nt	O
7	that	O
8	are	O
9	predicted	O
10	to	O
11	encode	O
12	an	O
13	88	O
14	-	O
15	amino	O
16	-	O
17	acid	O
18	(	O
19	aa	O
20	)	O
21	protein	O
22	.	O

1	In	O
2	Salmo	O
3	gairdneri	O
4	,	O
5	no	O
6	specialized	O
7	system	O
8	of	O
9	portal	O
10	vessels	O
11	appears	O
12	to	O
13	exist	O
14	between	O
15	the	O
16	pineal	O
17	organ	O
18	and	O
19	other	O
20	portions	O
21	of	O
22	the	O
23	brain	O
24	.	O

1	Acute	O
2	pancreatitis	O
3	:	O
4	a	O
5	multisystem	O
6	disease	O
7	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	abilities	O
7	of	O
8	constitutive	O
9	and	O
10	conditional	O
11	forms	O
12	of	O
13	the	O
14	three	O
15	Raf	B
16	kinases	I
17	to	O
18	abrogate	O
19	the	O
20	cytokine	O
21	dependency	O
22	of	O
23	FDC	O
24	-	O
25	P1	O
26	cells	O
27	were	O
28	examined	O
29	.	O

1	These	O
2	data	O
3	showed	O
4	:	O
5	that	O
6	progesterone	O
7	secretion	O
8	is	O
9	pulsatile	O
10	throughout	O
11	the	O
12	human	O
13	luteal	O
14	phase	O
15	,	O
16	with	O
17	maximum	O
18	frequency	O
19	in	O
20	the	O
21	mid	O
22	-	O
23	luteal	O
24	phase	O
25	;	O
26	that	O
27	during	O
28	the	O
29	mid	O
30	-	O
31	luteal	O
32	phase	O
33	most	O
34	subjects	O
35	had	O
36	progesterone	O
37	levels	O
38	both	O
39	above	O
40	and	O
41	below	O
42	currently	O
43	accepted	O
44	ovulatory	O
45	thresholds	O
46	;	O
47	the	O
48	use	O
49	of	O
50	a	O
51	single	O
52	measurement	O
53	of	O
54	progesterone	O
55	in	O
56	the	O
57	mid	O
58	-	O
59	luteal	O
60	phase	O
61	is	O
62	not	O
63	always	O
64	a	O
65	reliable	O
66	indicator	O
67	of	O
68	ovulation	O
69	;	O
70	a	O
71	threshold	O
72	greater	O
73	than	O
74	20	O
75	nmol	O
76	/	O
77	l	O
78	may	O
79	yield	O
80	an	O
81	unacceptable	O
82	number	O
83	of	O
84	false	O
85	negative	O
86	results	O
87	.	O

1	Cloning	O
2	,	O
3	expression	O
4	,	O
5	and	O
6	nucleotide	O
7	sequence	O
8	of	O
9	rat	B
10	liver	I
11	sterol	I
12	carrier	I
13	protein	I
14	2	I
15	cDNAs	I
16	.	O

1	The	O
2	RAS	B
3	-	O
4	cyclic	B
5	AMP	I
6	-	I
7	dependent	I
8	protein	I
9	kinase	I
10	cAPK	I
11	pathway	O
12	prevents	O
13	the	O
14	UAS	O
15	activity	O
16	of	O
17	IREu	B
18	in	O
19	the	O
20	presence	O
21	of	O
22	glucose	O
23	as	O
24	the	O
25	sole	O
26	carbon	O
27	source	O
28	,	O
29	while	O
30	the	O
31	transcriptional	O
32	activators	O
33	Msn2p	B
34	and	O
35	Msn4p	B
36	promote	O
37	the	O
38	UAS	O
39	activity	O
40	of	O
41	this	O
42	repeat	O
43	in	O
44	the	O
45	presence	O
46	of	O
47	acetate	O
48	.	O

1	Statement	O
2	on	O
3	the	O
4	development	O
5	of	O
6	guidelines	O
7	for	O
8	the	O
9	prevention	O
10	of	O
11	AIDS	O
12	transmission	O
13	in	O
14	the	O
15	workplace	O
16	.	O

1	Vitiligo	O
2	in	O
3	diabetes	O
4	mellitus	O
5	.	O

1	2	O
2	.	O

1	The	O
2	Wnt	B
3	signaling	O
4	pathway	O
5	functions	O
6	reiteratively	O
7	during	O
8	animal	O
9	development	O
10	to	O
11	control	O
12	cell	O
13	fate	O
14	decisions	O
15	.	O

1	The	O
2	product	O
3	of	O
4	the	O
5	vpr	B
6	open	I
7	reading	I
8	frame	I
9	of	I
10	human	I
11	immunodeficiency	I
12	virus	I
13	type	I
14	1	I
15	(	I
16	HIV	I
17	-	I
18	1	I
19	)	I
20	is	O
21	a	O
22	15	O
23	-	O
24	kDa	O
25	,	O
26	arginine	O
27	-	O
28	rich	O
29	protein	O
30	that	O
31	is	O
32	present	O
33	in	O
34	virions	O
35	in	O
36	molar	O
37	quantities	O
38	equivalent	O
39	to	O
40	that	O
41	of	O
42	Gag	B
43	.	O

1	Implications	O
2	of	O
3	this	O
4	observation	O
5	for	O
6	pediatrics	O
7	are	O
8	discussed	O
9	.	O

1	HBx	B
2	strongly	O
3	elevates	O
4	levels	O
5	of	O
6	GTP	O
7	-	O
8	bound	O
9	Ras	B
10	,	O
11	activated	O
12	and	O
13	phosphorylated	O
14	Raf	B
15	,	O
16	and	O
17	tyrosine	O
18	-	O
19	phosphorylated	O
20	and	O
21	activated	O
22	MAP	B
23	kinase	I
24	.	O

1	Mutational	O
2	studies	O
3	provide	O
4	evidence	O
5	to	O
6	this	O
7	end	O
8	and	O
9	indicate	O
10	that	O
11	the	O
12	side	O
13	chains	O
14	of	O
15	subdomain	O
16	4	O
17	.	O
18	2	O
19	make	O
20	specific	O
21	contacts	O
22	with	O
23	the	O
24	nucleotides	O
25	at	O
26	-	O
27	35	O
28	.	O

1	Chaotic	O
2	electron	O
3	dynamics	O
4	around	O
5	a	O
6	single	O
7	elliptically	O
8	shaped	O
9	antidot	O
10	.	O

1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	B
9	4	I
10	(	O
11	myosin	B
12	from	I
13	rat	I
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	O
28	myosin	B
29	I	I
30	.	O

1	Teratological	O
2	studies	O
3	on	O
4	SF	O
5	-	O
6	837	O
7	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	B
10	gene	I
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O

1	Significant	O
2	alterations	O
3	in	O
4	the	O
5	vasectomized	O
6	rats	O
7	from	O
8	sham	O
9	rats	O
10	included	O
11	:	O
12	testicular	O
13	and	O
14	epididymal	O
15	hypertrophy	O
16	,	O
17	formation	O
18	of	O
19	pathologic	O
20	vas	O
21	deferens	O
22	granulomas	O
23	,	O
24	decreased	O
25	total	O
26	serum	O
27	protein	O
28	,	O
29	lowered	O
30	alpha	B
31	-	I
32	globulin	I
33	levels	O
34	as	O
35	shown	O
36	by	O
37	serum	O
38	electrophoresis	O
39	,	O
40	and	O
41	increased	O
42	sperm	O
43	agglutinin	B
44	antibody	O
45	titers	O
46	.	O

1	S6K2	B
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	B
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	B
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	B
48	.	O

1	The	O
2	pel	B
3	gene	I
4	from	O
5	an	O
6	Amycolata	O
7	sp	O
8	.	O
9	encoding	O
10	a	O
11	pectate	B
12	lyase	I
13	(	O
14	EC	B
15	4	I
16	.	I
17	2	I
18	.	I
19	2	I
20	.	I
21	2	I
22	)	O
23	was	O
24	isolated	O
25	by	O
26	activity	O
27	screening	O
28	a	O
29	genomic	O
30	DNA	O
31	library	O
32	in	O
33	Streptomyces	O
34	lividans	O
35	TK24	O
36	.	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	Sp1	B
6	and	O
7	ETS	B
8	proteins	I
9	are	O
10	required	O
11	to	O
12	bring	O
13	about	O
14	full	O
15	promoter	O
16	activity	O
17	in	O
18	the	O
19	Surf	B
20	-	I
21	1	I
22	direction	O
23	.	O

1	GLRaV	O
2	-	O
3	2	O
4	is	O
5	the	O
6	only	O
7	closterovirus	O
8	,	O
9	so	O
10	far	O
11	,	O
12	that	O
13	matches	O
14	the	O
15	genome	O
16	organization	O
17	of	O
18	the	O
19	type	O
20	member	O
21	of	O
22	the	O
23	group	O
24	,	O
25	BYV	O
26	,	O
27	and	O
28	thus	O
29	can	O
30	be	O
31	unambiguously	O
32	classified	O
33	as	O
34	a	O
35	definitive	O
36	member	O
37	of	O
38	the	O
39	genus	O
40	Closterovirus	O
41	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	B
16	and	O
17	RNR3	B
18	genes	I
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O

1	GCD10	B
2	binds	O
3	RNA	O
4	in	O
5	vitro	O
6	and	O
7	we	O
8	present	O
9	strong	O
10	biochemical	O
11	evidence	O
12	that	O
13	it	O
14	is	O
15	identical	O
16	to	O
17	the	O
18	RNA	O
19	-	O
20	binding	O
21	subunit	O
22	of	O
23	yeast	B
24	initiation	I
25	factor	I
26	-	I
27	3	I
28	(	O
29	eIF	B
30	-	I
31	3	I
32	).	O
33	eIF	B
34	-	I
35	3	I
36	is	O
37	a	O
38	multisubunit	O
39	complex	O
40	that	O
41	stimulates	O
42	translation	O
43	initiation	O
44	in	O
45	vitro	O
46	at	O
47	several	O
48	different	O
49	steps	O
50	.	O

1	These	O
2	include	O
3	the	O
4	CACCC	O
5	and	O
6	CAAT	O
7	motifs	O
8	.	O

1	On	O
2	line	O
3	calculation	O
4	of	O
5	steroid	O
6	concentrations	O
7	by	O
8	radioimmunoassay	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	B
21	in	I
22	Escherichia	I
23	coli	I
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	B
40	(	O
41	Ecc	B
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	B
54	in	I
55	Erwinia	I
56	carotovora	I
57	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	B
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	The	O
2	five	O
3	-	O
4	drug	O
5	combination	O
6	of	O
7	fluorouracil	O
8	imidazole	O
9	carboxamide	O
10	dimethyl	O
11	triazeno	O
12	,	O
13	vincristine	O
14	,	O
15	bis	O
16	-	O
17	chloroethyl	O
18	nitrosourea	O
19	,	O
20	and	O
21	prednisone	O
22	(	O
23	FIVB	O
24	+	O
25	P	O
26	)	O
27	was	O
28	given	O
29	to	O
30	120	O
31	women	O
32	with	O
33	metastatic	O
34	breast	O
35	cancer	O
36	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	in	O
6	cultured	O
7	Jurkat	O
8	T	O
9	cells	O
10	,	O
11	Cbl	B
12	is	O
13	coprecipitated	O
14	with	O
15	antibody	O
16	against	O
17	the	O
18	adapter	B
19	protein	I
20	Grb2	I
21	.	O

1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O

1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	O
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	B
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O

1	MRI	O
2	disclosed	O
3	one	O
4	or	O
5	more	O
6	of	O
7	the	O
8	following	O
9	abnormalities	O
10	in	O
11	24	O
12	(	O
13	63	O
14	%)	O
15	of	O
16	38	O
17	treated	O
18	kidneys	O
19	:	O
20	(	O
21	1	O
22	)	O
23	loss	O
24	of	O
25	corticomedullary	O
26	differentiation	O
27	,	O
28	(	O
29	2	O
30	)	O
31	perirenal	O
32	fluid	O
33	,	O
34	(	O
35	3	O
36	)	O
37	subcapsular	O
38	hematoma	O
39	,	O
40	(	O
41	4	O
42	)	O
43	hemorrhage	O
44	into	O
45	a	O
46	renal	O
47	cyst	O
48	,	O
49	and	O
50	(	O
51	5	O
52	)	O
53	unexplained	O
54	abnormalities	O
55	.	O

1	OBJECTIVE	O
2	:	O
3	The	O
4	purpose	O
5	of	O
6	this	O
7	article	O
8	is	O
9	to	O
10	review	O
11	balance	O
12	instruments	O
13	developed	O
14	within	O
15	the	O
16	past	O
17	10	O
18	years	O
19	that	O
20	can	O
21	be	O
22	used	O
23	in	O
24	the	O
25	clinic	O
26	or	O
27	home	O
28	environment	O
29	.	O

1	The	O
2	transcriptional	O
3	activity	O
4	of	O
5	PPARgamma	B
6	is	O
7	positively	O
8	modulated	O
9	by	O
10	ligand	O
11	binding	O
12	and	O
13	negatively	O
14	regulated	O
15	by	O
16	phosphorylation	O
17	mediated	O
18	by	O
19	the	O
20	MEK	B
21	/	O
22	ERK	B
23	signaling	O
24	pathway	O
25	.	O

1	Moreover	O
2	,	O
3	in	O
4	one	O
5	patient	O
6	with	O
7	a	O
8	sarcoma	O
9	who	O
10	underwent	O
11	a	O
12	leg	O
13	-	O
14	sparing	O
15	procedure	O
16	,	O
17	no	O
18	sciatic	O
19	nerve	O
20	enlargement	O
21	was	O
22	seen	O
23	postoperatively	O
24	.	O

1	The	O
2	alternative	O
3	sigma	B
4	factor	I
5	sigmaB	I
6	in	I
7	Staphylococcus	I
8	aureus	I
9	:	O
10	regulation	O
11	of	O
12	the	O
13	sigB	B
14	operon	I
15	in	O
16	response	O
17	to	O
18	growth	O
19	phase	O
20	and	O
21	heat	O
22	shock	O

1	Cbf3	B
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	Cbf3a	B
7	,	O
8	Cbf3b	B
9	and	O
10	Cbf3c	B
11	.	O

1	Cycles	O
2	were	O
3	repeated	O
4	every	O
5	3	O
6	weeks	O
7	.	O

1	W	O
2	.	O

1	The	O
2	COP	O
3	-	O
4	PAWP	O
5	gradient	O
6	was	O
7	markedly	O
8	decreased	O
9	in	O
10	both	O
11	shock	O
12	and	O
13	non	O
14	-	O
15	shock	O
16	patients	O
17	with	O
18	pulmonary	O
19	edema	O
20	.	O

1	Current	O
2	diagnostic	O
3	uses	O
4	of	O
5	computerized	O
6	tomography	O
7	in	O
8	clinical	O
9	medicine	O
10	.	O

1	In	O
2	this	O
3	case	O
4	the	O
5	degree	O
6	of	O
7	promoter	O
8	methylation	O
9	,	O
10	which	O
11	could	O
12	extend	O
13	beyond	O
14	the	O
15	T	O
16	-	O
17	DNA	O
18	borders	O
19	,	O
20	was	O
21	not	O
22	correlated	O
23	with	O
24	the	O
25	reduction	O
26	in	O
27	steady	O
28	-	O
29	state	O
30	poly	O
31	(	O
32	A	O
33	)+	O
34	mRNA	O
35	levels	O
36	,	O
37	the	O
38	silenced	O
39	state	O
40	was	O
41	transmitted	O
42	through	O
43	meiosis	O
44	and	O
45	reactivation	O
46	lasted	O
47	several	O
48	generations	O
49	.	O

1	We	O
2	found	O
3	that	O
4	lung	O
5	cancer	O
6	tissues	O
7	of	O
8	positive	O
9	67Ga	O
10	scan	O
11	expressed	O
12	TFR	B
13	,	O
14	but	O
15	those	O
16	of	O
17	a	O
18	negative	O
19	scan	O
20	did	O
21	not	O
22	.	O

1	Study	O
2	groups	O
3	were	O
4	control	O
5	,	O
6	and	O
7	those	O
8	treated	O
9	with	O
10	the	O
11	alpha1	B
12	-	I
13	adrenoceptor	I
14	-	I
15	subtype	I
16	blockers	O
17	WB4101	O
18	(	O
19	0	O
20	.	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	i	O
26	.	O
27	v	O
28	.)	O
29	or	O
30	chloroethylclonidine	O
31	(	O
32	1	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	kg	O
38	i	O
39	.	O
40	v	O
41	.).	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	like	O
6	in	O
7	yeast	O
8	,	O
9	in	O
10	plants	O
11	a	O
12	certain	O
13	subfamily	O
14	of	O
15	UBC	B
16	is	O
17	specifically	O
18	involved	O
19	in	O
20	the	O
21	proteolytic	O
22	degradation	O
23	of	O
24	abnormal	O
25	proteins	O
26	as	O
27	result	O
28	of	O
29	stress	O
30	.	O

1	The	O
2	3	O
3	'	O
4	fragment	O
5	was	O
6	shown	O
7	to	O
8	accumulate	O
9	as	O
10	full	O
11	-	O
12	length	O
13	mRNA	O
14	disappeared	O
15	in	O
16	actinomycin	O
17	D	O
18	-	O
19	treated	O
20	cells	O
21	,	O
22	indicating	O
23	a	O
24	precursor	O
25	-	O
26	product	O
27	relationship	O
28	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	O
21	-	O
22	5	O
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	In	O
2	ten	O
3	other	O
4	experiments	O
5	(	O
6	5	O
7	experimental	O
8	and	O
9	5	O
10	control	O
11	rats	O
12	)	O
13	99mTc	O
14	-	O
15	sulfur	O
16	colloid	O
17	was	O
18	injected	O
19	intravenously	O
20	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	B
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	O
19	joins	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	B
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	B
32	heavy	I
33	chain	I
34	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	shows	O
6	strong	O
7	sequence	O
8	similarity	O
9	to	O
10	Escherichia	O
11	coli	O
12	consensus	O
13	promoters	O
14	and	O
15	ribosome	O
16	-	O
17	binding	O
18	sequences	O
19	and	O
20	allows	O
21	high	O
22	levels	O
23	of	O
24	expression	O
25	in	O
26	E	O
27	.	O
28	coli	O
29	.	O

1	Hb	B
2	levels	O
3	remained	O
4	adequate	O
5	(	O
6	Hb	B
7	=	O
8	10	O
9	.	O
10	68	O
11	+/-	O
12	0	O
13	.	O
14	77	O
15	g	O
16	/	O
17	dl	O
18	)	O
19	after	O
20	14	O
21	.	O
22	6	O
23	+/-	O
24	7	O
25	.	O
26	64	O
27	months	O
28	.	O

1	No	O
2	TATA	O
3	or	O
4	Inr	O
5	sequence	O
6	was	O
7	found	O
8	.	O

1	By	O
2	contrast	O
3	,	O
4	PvirE	B
5	or	O
6	Plac	B
7	promoter	I
8	constructs	I
9	yielded	O
10	functional	O
11	VirE2	B
12	only	O
13	if	O
14	virE1	B
15	was	O
16	coexpressed	O
17	with	O
18	virE2	B
19	.	O

1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O

1	This	O
2	last	O
3	region	O
4	contains	O
5	two	O
6	sites	O
7	that	O
8	bind	O
9	Ets	B
10	-	I
11	related	I
12	proteins	I
13	present	O
14	in	O
15	liver	O
16	nuclear	O
17	extracts	O
18	as	O
19	well	O
20	as	O
21	recombinant	B
22	purified	I
23	Ets	I
24	-	I
25	1	I
26	protein	I
27	.	O

1	The	O
2	harpin	B
3	-	O
4	encoding	O
5	hrpZ	B
6	gene	I
7	is	O
8	located	O
9	in	O
10	an	O
11	operon	O
12	that	O
13	also	O
14	encodes	O
15	Hrp	B
16	secretion	I
17	pathway	I
18	components	I
19	and	O
20	is	O
21	part	O
22	of	O
23	the	O
24	functional	O
25	cluster	O
26	of	O
27	hrp	B
28	genes	I
29	carried	O
30	on	O
31	cosmid	O
32	pHIR11	O
33	that	O
34	enables	O
35	saprophytic	O
36	bacteria	O
37	like	O
38	Escherichia	O
39	coli	O
40	and	O
41	Pseudomonas	O
42	fluorescens	O
43	to	O
44	elicit	O
45	the	O
46	HR	O
47	in	O
48	tobacco	O
49	leaves	O
50	.	O

1	Treating	O
2	renal	O
3	anaemia	O
4	with	O
5	recombinant	O
6	human	O
7	erythropoietin	B
8	.	O

1	These	O
2	findings	O
3	were	O
4	reinforced	O
5	by	O
6	an	O
7	analysis	O
8	that	O
9	was	O
10	restricted	O
11	to	O
12	living	O
13	donor	O
14	transplants	O
15	without	O
16	acute	O
17	rejection	O
18	.	O

1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	B
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	B
11	(	O
12	muscle	O
13	),	O
14	L	B
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	Phylogenetic	O
2	analysis	O
3	gave	O
4	evidence	O
5	for	O
6	a	O
7	close	O
8	evolutionary	O
9	relationship	O
10	between	O
11	PhHV	O
12	-	O
13	1	O
14	and	O
15	members	O
16	of	O
17	the	O
18	Varicellovirus	O
19	genus	O
20	of	O
21	the	O
22	alpha	O
23	-	O
24	Herpesvirinae	O
25	and	O
26	canid	O
27	herpesvirus	O
28	in	O
29	particular	O
30	.	O

1	Utilization	O
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	B
13	mRNAs	I
14	of	I
15	1	I
16	.	I
17	9	I
18	and	I
19	4	I
20	.	I
21	3	I
22	kb	I
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	B
13	rbcS	I
14	promoters	I
15	.	O

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O

1	Seven	O
2	out	O
3	of	O
4	34	O
5	patients	O
6	died	O
7	,	O
8	giving	O
9	a	O
10	mortality	O
11	rate	O
12	of	O
13	21	O
14	%.	O

1	The	O
2	antihypertensive	O
3	effect	O
4	of	O
5	Estulic	O
6	has	O
7	been	O
8	examined	O
9	over	O
10	a	O
11	12	O
12	-	O
13	month	O
14	period	O
15	in	O
16	101	O
17	hypertensive	O
18	patients	O
19	.	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	O
8	vs	O
9	80	O
10	%	O
11	for	O
12	the	O
13	NCEP	O
14	I	O
15	.	O

1	Plasma	O
2	ion	O
3	changes	O
4	in	O
5	venous	O
6	blood	O
7	incubated	O
8	with	O
9	beta	B
10	receptor	I
11	blockers	O
12	and	O
13	subjected	O
14	to	O
15	tonometry	O
16	in	O
17	vitro	O
18	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	in	O
6	cultured	O
7	cells	O
8	from	O
9	Drosophila	O
10	melanogaster	O
11	human	B
12	Sp1	I
13	efficiently	O
14	activates	O
15	transcription	O
16	from	O
17	synthetic	O
18	promoters	O
19	containing	O
20	TATA	O
21	boxes	O
22	,	O
23	but	O
24	not	O
25	from	O
26	promoters	O
27	that	O
28	contain	O
29	an	O
30	initiator	O
31	instead	O
32	of	O
33	a	O
34	TATA	O
35	box	O
36	.	O

1	Expression	O
2	is	O
3	exclusively	O
4	limited	O
5	to	O
6	the	O
7	CNS	O
8	at	O
9	this	O
10	and	O
11	later	O
12	stages	O
13	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	DNA	O
6	fragment	O
7	showed	O
8	that	O
9	four	O
10	genes	O
11	are	O
12	present	O
13	encoding	O
14	proteins	O
15	of	O
16	16	O
17	,	O
18	18	O
19	.	O
20	5	O
21	,	O
22	21	O
23	and	O
24	89	O
25	kDal	O
26	.	O

1	Inactivation	O
2	of	O
3	p53	B
4	but	O
5	not	O
6	p73	B
7	by	O
8	adenovirus	B
9	type	I
10	5	I
11	E1B	I
12	55	I
13	-	I
14	kilodalton	I
15	and	I
16	E4	I
17	34	I
18	-	I
19	kilodalton	I
20	oncoproteins	I
21	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O

1	Paradoxically	O
2	,	O
3	however	O
4	,	O
5	the	O
6	GH	B
7	receptor	I
8	cloned	O
9	from	O
10	liver	O
11	exhibits	O
12	no	O
13	sequence	O
14	similarity	O
15	to	O
16	receptors	O
17	with	O
18	known	O
19	signal	O
20	transduction	O
21	mechanisms	O
22	,	O
23	including	O
24	those	O
25	exhibiting	O
26	ligand	O
27	-	O
28	activated	O
29	tyrosine	B
30	kinase	I
31	activity	O
32	.	O

1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	O
15	dependent	O
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	O

1	Downregulation	O
2	of	O
3	FUS	B
4	expression	O
5	in	O
6	BCR	B
7	/	O
8	ABL	B
9	-	O
10	expressing	O
11	32Dcl3	O
12	cells	O
13	was	O
14	associated	O
15	with	O
16	suppression	O
17	of	O
18	growth	O
19	factor	O
20	-	O
21	independent	O
22	colony	O
23	formation	O
24	,	O
25	restoration	O
26	of	O
27	G	B
28	-	I
29	CSF	I
30	-	O
31	induced	O
32	granulocytic	O
33	differentiation	O
34	and	O
35	reduced	O
36	tumorigenic	O
37	potential	O
38	in	O
39	vivo	O
40	.	O

1	Efficacy	O
2	and	O
3	field	O
4	evaluation	O
5	of	O
6	Bacillus	O
7	thuringiensis	O
8	(	O
9	H	O
10	-	O
11	14	O
12	)	O
13	and	O
14	B	O
15	.	O
16	sphaericus	O
17	against	O
18	floodwater	O
19	mosquitoes	O
20	in	O
21	California	O
22	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	B
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	B
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O

1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	B
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	O
22	sex	B
23	hormone	I
24	binding	I
25	globulin	I
26	(	O
27	SHBG	B
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	O
34	SHBG	B
35	-	O
36	bound	O
37	estradiol	O
38	.	O

1	Gene	B
2	1	I
3	has	O
4	been	O
5	completely	O
6	sequenced	O
7	.	O

1	T2	O
2	cancers	O
3	should	O
4	not	O
5	be	O
6	excluded	O
7	from	O
8	the	O
9	benefit	O
10	of	O
11	preoperative	O
12	irradiation	O
13	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	A	O
2	deletion	O
3	series	O
4	of	O
5	the	O
6	5	O
7	'	O
8	flanking	O
9	region	O
10	was	O
11	created	O
12	from	O
13	position	O
14	-	O
15	1329	O
16	to	O
17	-	O
18	74	O
19	relative	O
20	to	O
21	the	O
22	transcriptional	O
23	initiation	O
24	site	O
25	and	O
26	similarly	O
27	examined	O
28	in	O
29	transgenic	O
30	tobacco	O
31	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Two	O
2	new	O
3	artifacts	O
4	in	O
5	automated	O
6	coagulation	O
7	testing	O
8	.	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O

1	Expression	O
2	of	O
3	SREBP	B
4	-	I
5	1a	I
6	stimulated	O
7	StAR	B
8	promoter	I
9	activity	O
10	in	O
11	the	O
12	context	O
13	of	O
14	COS	O
15	-	O
16	1	O
17	cells	O
18	and	O
19	human	O
20	granulosa	O
21	-	O
22	lutein	O
23	cells	O
24	.	O

1	Thus	O
2	the	O
3	present	O
4	data	O
5	also	O
6	suggest	O
7	that	O
8	BP	O
9	and	O
10	HR	O
11	measurements	O
12	are	O
13	influenced	O
14	not	O
15	only	O
16	by	O
17	state	O
18	-	O
19	dependent	O
20	factors	O
21	but	O
22	also	O
23	by	O
24	at	O
25	least	O
26	three	O
27	different	O
28	factors	O
29	that	O
30	are	O
31	each	O
32	independent	O
33	of	O
34	the	O
35	state	O
36	:	O
37	one	O
38	leads	O
39	to	O
40	BP	O
41	and	O
42	HR	O
43	values	O
44	that	O
45	are	O
46	influenced	O
47	by	O
48	the	O
49	cycle	O
50	the	O
51	animal	O
52	is	O
53	in	O
54	and	O
55	the	O
56	other	O
57	two	O
58	influence	O
59	,	O
60	respectively	O
61	,	O
62	the	O
63	ranking	O
64	of	O
65	the	O
66	individual	O
67	'	O
68	s	O
69	BP	O
70	and	O
71	HR	O
72	levels	O
73	within	O
74	the	O
75	population	O
76	.	O

1	Cervicovaginal	O
2	foetal	B
3	fibronectin	I
4	in	O
5	the	O
6	prediction	O
7	of	O
8	preterm	O
9	labour	O
10	in	O
11	a	O
12	low	O
13	-	O
14	risk	O
15	population	O
16	.	O

1	The	O
2	data	O
3	normally	O
4	available	O
5	are	O
6	insufficient	O
7	and	O
8	take	O
9	no	O
10	account	O
11	of	O
12	the	O
13	direction	O
14	of	O
15	recirculation	O
16	,	O
17	which	O
18	may	O
19	be	O
20	a	O
21	determining	O
22	factor	O
23	.	O

1	DNA	O
2	hybridization	O
3	analysis	O
4	revealed	O
5	that	O
6	both	O
7	pigmented	O
8	and	O
9	nonpigmented	O
10	cells	O
11	of	O
12	Y	O
13	.	O
14	pestis	O
15	possess	O
16	a	O
17	DNA	O
18	locus	O
19	homologous	O
20	to	O
21	the	O
22	Escherichia	B
23	coli	I
24	fur	I
25	gene	I
26	.	O

1	The	O
2	Y	O
3	-	O
4	type	O
5	structural	O
6	motif	O
7	is	O
8	also	O
9	conserved	O
10	among	O
11	a	O
12	number	O
13	of	O
14	divergent	O
15	BiP	B
16	mRNAs	I
17	.	O

1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	B
18	gene	I
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	B
31	hydrolases	I
32	.	O

1	In	O
2	cellular	O
3	supernatant	O
4	fraction	O
5	,	O
6	SHRSP	O
7	showed	O
8	a	O
9	decrease	O
10	of	O
11	magnesium	O
12	in	O
13	many	O
14	tissues	O
15	and	O
16	an	O
17	elevation	O
18	of	O
19	the	O
20	calcium	O
21	to	O
22	magnesium	O
23	ratio	O
24	when	O
25	compared	O
26	to	O
27	age	O
28	-	O
29	matched	O
30	WKY	O
31	and	O
32	SHRSR	O
33	.	O

1	However	O
2	,	O
3	cotransfection	O
4	studies	O
5	indicate	O
6	that	O
7	RVR	B
8	does	O
9	not	O
10	activate	O
11	transcription	O
12	when	O
13	this	O
14	hormone	O
15	response	O
16	element	O
17	is	O
18	linked	O
19	to	O
20	a	O
21	reporter	O
22	gene	O
23	but	O
24	rather	O
25	acts	O
26	as	O
27	a	O
28	potent	O
29	competitive	O
30	repressor	O
31	of	O
32	ROR	B
33	alpha	I
34	function	O
35	.	O

1	Thioredoxin	B
2	(	O
3	TR	B
4	)	O
5	is	O
6	a	O
7	small	O
8	ubiquitous	O
9	dithiol	B
10	-	I
11	reductase	I
12	enzyme	I
13	first	O
14	identified	O
15	in	O
16	bacteria	O
17	and	O
18	plants	O
19	.	O

1	Linear	O
2	extrapolation	O
3	is	O
4	used	O
5	below	O
6	the	O
7	experimental	O
8	data	O
9	range	O
10	to	O
11	establish	O
12	an	O
13	upper	O
14	bound	O
15	on	O
16	carcinogenic	O
17	risk	O
18	at	O
19	low	O
20	doses	O
21	.	O

1	The	O
2	unique	O
3	nature	O
4	and	O
5	arrangement	O
6	of	O
7	the	O
8	ANT1	B
9	transcriptional	I
10	control	I
11	elements	I
12	may	O
13	account	O
14	for	O
15	this	O
16	differential	O
17	expression	O
18	.	O

1	Its	O
2	role	O
3	in	O
4	these	O
5	processes	O
6	suggests	O
7	that	O
8	the	O
9	function	O
10	of	O
11	c	B
12	-	I
13	Myb	I
14	may	O
15	be	O
16	important	O
17	early	O
18	in	O
19	the	O
20	establishment	O
21	of	O
22	the	O
23	hematopoietic	O
24	lineage	O
25	.	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O

1	The	O
2	STE20	B
3	gene	I
4	,	O
5	encoding	O
6	a	O
7	protein	O
8	kinase	O
9	required	O
10	for	O
11	pheromone	O
12	signal	O
13	transduction	O
14	,	O
15	has	O
16	recently	O
17	been	O
18	identified	O
19	in	O
20	a	O
21	genetic	O
22	screen	O
23	for	O
24	high	O
25	-	O
26	gene	O
27	-	O
28	dosage	O
29	suppressors	O
30	of	O
31	a	O
32	partly	O
33	defective	O
34	G	B
35	beta	I
36	mutation	O
37	.	O

1	IRF	B
2	-	I
3	1	I
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	O
11	IRF	B
12	-	I
13	2	I
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O

1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O

1	To	O
2	study	O
3	the	O
4	significance	O
5	of	O
6	these	O
7	domains	O
8	and	O
9	the	O
10	overall	O
11	evolutionary	O
12	conservation	O
13	of	O
14	the	O
15	gene	O
16	,	O
17	the	O
18	homolog	O
19	from	O
20	Drosophila	O
21	melanogaster	O
22	was	O
23	isolated	O
24	by	O
25	low	O
26	stringency	O
27	hybridizations	O
28	using	O
29	two	O
30	flanking	O
31	probes	O
32	of	O
33	the	O
34	human	B
35	ERCC3	I
36	cDNA	I
37	.	O

1	Restoration	O
2	of	O
3	impaired	O
4	immune	O
5	functions	O
6	in	O
7	aging	O
8	animals	O
9	.	O

1	However	O
2	,	O
3	neu	B
4	differentiation	O
5	factor	O
6	-	O
7	induced	O
8	heterodimers	O
9	of	O
10	ErbB2	B
11	and	O
12	ErbB4	B
13	activated	O
14	Stat5	B
15	.	O

1	Lithium	O
2	delays	O
3	the	O
4	circadian	O
5	rhythm	O
6	of	O
7	wheel	O
8	-	O
9	running	O
10	in	O
11	Syrian	O
12	hamsters	O
13	at	O
14	plasma	O
15	concentrations	O
16	(	O
17	0	O
18	.	O
19	59	O
20	-	O
21	0	O
22	.	O
23	74	O
24	mM	O
25	)	O
26	that	O
27	also	O
28	cause	O
29	toxic	O
30	weight	O
31	loss	O
32	.	O

1	This	O
2	motif	O
3	is	O
4	similar	O
5	to	O
6	but	O
7	distinct	O
8	from	O
9	the	O
10	LIM	B
11	domain	I
12	and	O
13	the	O
14	RING	B
15	finger	I
16	family	I
17	,	O
18	and	O
19	is	O
20	reminiscent	O
21	of	O
22	known	O
23	metal	O
24	-	O
25	binding	O
26	regions	O
27	.	O

1	Based	O
2	on	O
3	AUC	O
4	infinity	O
5	analyses	O
6	,	O
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	450	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O

1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O

1	Experiment	O
2	3	O
3	showed	O
4	that	O
5	the	O
6	long	O
7	-	O
8	term	O
9	analgesic	O
10	reaction	O
11	could	O
12	also	O
13	be	O
14	reduced	O
15	by	O
16	administration	O
17	of	O
18	naltrexone	O
19	prior	O
20	to	O
21	reexposure	O
22	to	O
23	shock	O
24	.	O

